FN Thomson Reuters Web of Science™ VR 1.0 PT J AU McMillan, PJ Leverenz, JB Bird, TD Schellenberg, GD Craft, S AF McMillan, PJ Leverenz, JB Bird, TD Schellenberg, GD Craft, S TI Insulin degrading enzyme immunostaining is decreased in the hippocampus of familial Alzheimer's disease subjects with presenilin 1 mutations SO NEUROBIOLOGY OF AGING LA English DT Meeting Abstract CT 9th International Conference on Alzheimers Disease and Related Disorders CY JUL 17-22, 2004 CL Philadelphia, PA SP Alzheimers Assoc C1 Univ Washington, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. EM pammcm@u.washington.edu NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD JUL PY 2004 VL 25 SU 2 BP S556 EP S556 DI 10.1016/S0197-4580(04)81843-8 PG 1 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 843EK UT WOS:000223058701839 ER PT J AU Reger, M Watson, GS Cholerton, B Baker, LD Asthana, S Plymate, S Wilkinson, CW Peskind, ER Enstrom, K Hyde, K Belongia, D Craft, S AF Reger, M Watson, GS Cholerton, B Baker, LD Asthana, S Plymate, S Wilkinson, CW Peskind, ER Enstrom, K Hyde, K Belongia, D Craft, S TI Cortisol infusion attenuates insulin's facilitation of verbal memory in patients with Alzheimer's disease SO NEUROBIOLOGY OF AGING LA English DT Meeting Abstract CT 9th International Conference on Alzheimers Disease and Related Disorders CY JUL 17-22, 2004 CL Philadelphia, PA SP Alzheimers Assoc C1 Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. Univ Wisconsin, Sch Med, Madison, WI 53706 USA. VA Puget Sound Hlth Care Syst, Tacoma, WA USA. EM mreger@u.washington.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD JUL PY 2004 VL 25 SU 2 BP S168 EP S169 DI 10.1016/S0197-4580(04)80568-2 PG 2 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 843EK UT WOS:000223058700566 ER PT J AU Rhoads, K Cholerton, B Baker, LD Reger, M Watson, GS Plymate, S Fishel, MA Asthana, S Enstrom, K Keeling, M AF Rhoads, K Cholerton, B Baker, LD Reger, M Watson, GS Plymate, S Fishel, MA Asthana, S Enstrom, K Keeling, M TI The effect of insulin and octreotide on verbal memory and attention in cognitively impaired older adults SO NEUROBIOLOGY OF AGING LA English DT Meeting Abstract CT 9th International Conference on Alzheimers Disease and Related Disorders CY JUL 17-22, 2004 CL Philadelphia, PA SP Alzheimers Assoc C1 Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Tacoma, WA USA. Univ Wisconsin, Sch Med, Madison, WI 53706 USA. EM kristofferrhoads@med.va.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD JUL PY 2004 VL 25 SU 2 BP S169 EP S169 DI 10.1016/S0197-4580(04)80569-4 PG 1 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 843EK UT WOS:000223058700567 ER PT J AU Sager, MA Hermann, BP Gleason, C Johnson, S Cooper, J AF Sager, MA Hermann, BP Gleason, C Johnson, S Cooper, J TI Alzheimer's disease SO NEUROBIOLOGY OF AGING LA English DT Meeting Abstract CT 9th International Conference on Alzheimers Disease and Related Disorders CY JUL 17-22, 2004 CL Philadelphia, PA SP Alzheimers Assoc C1 UW Med Sch, Madison, WI USA. William S Middleton Mem Vet Adm Med Ctr, GRECC, Madison, WI USA. Affin Hlth Syst, Oshkosh, WI USA. EM masager@wisc.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD JUL PY 2004 VL 25 SU 2 BP S115 EP S115 DI 10.1016/S0197-4580(04)80385-3 PG 1 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 843EK UT WOS:000223058700383 ER PT J AU Szot, P White, SS Leverenz, JB Greenup, L Peskind, ER Raskind, MA AF Szot, P White, SS Leverenz, JB Greenup, L Peskind, ER Raskind, MA TI Increased H-3-prazosin binding sites in the dentate gyrus of Alzheimer's disease and dementia with Lewy bodies is due to alpha(1A)-adrenoreceptors SO NEUROBIOLOGY OF AGING LA English DT Meeting Abstract CT 9th International Conference on Alzheimers Disease and Related Disorders CY JUL 17-22, 2004 CL Philadelphia, PA SP Alzheimers Assoc C1 Univ Washington, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. EM szot@u.washington.edu NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD JUL PY 2004 VL 25 SU 2 BP S439 EP S440 DI 10.1016/S0197-4580(04)81448-9 PG 2 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 843EK UT WOS:000223058701445 ER PT J AU Tsuang, D Riekse, R Bird, T Muilenberg, M Steinbart, E McCutcheon, M Purganan, K Leverenz, J AF Tsuang, D Riekse, R Bird, T Muilenberg, M Steinbart, E McCutcheon, M Purganan, K Leverenz, J TI Familial dementia with Lewy bodies SO NEUROBIOLOGY OF AGING LA English DT Meeting Abstract CT 9th International Conference on Alzheimers Disease and Related Disorders CY JUL 17-22, 2004 CL Philadelphia, PA SP Alzheimers Assoc C1 Univ Washington, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. Univ N Dakota, Fargo, ND USA. EM dwt1I@u.washington.edu NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD JUL PY 2004 VL 25 SU 2 BP S86 EP S86 DI 10.1016/S0197-4580(04)80291-4 PG 1 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 843EK UT WOS:000223058700290 ER PT J AU Watson, GS Reger, MA Cholerton, BA Asthana, S Baker, LD Rhoads, KW Plymate, SR Fishel, MA Kahn, SE Craft, S AF Watson, GS Reger, MA Cholerton, BA Asthana, S Baker, LD Rhoads, KW Plymate, SR Fishel, MA Kahn, SE Craft, S TI Rosiglitazone preserves cognitive functions in patients with early Alzheimer's disease SO NEUROBIOLOGY OF AGING LA English DT Meeting Abstract CT 9th International Conference on Alzheimers Disease and Related Disorders CY JUL 17-22, 2004 CL Philadelphia, PA SP Alzheimers Assoc C1 Univ Washington, Seattle, WA 98195 USA. VA Puget Sound HCS, Seattle, WA USA. Univ Wisconsin, Madison, WI USA. William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. EM gswatson@u.washington.edu NR 0 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD JUL PY 2004 VL 25 SU 2 BP S83 EP S83 DI 10.1016/S0197-4580(04)80284-7 PG 1 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 843EK UT WOS:000223058700283 ER PT J AU Roman, GC AF Roman, GC TI Brain hypoperfusion: a critical factor in vascular dementia SO NEUROLOGICAL RESEARCH LA English DT Article DE Binswanger disease; cardiac surgery; cognition; congestive heart failure; hypotension; stroke; vascular dementia ID CORONARY-ARTERY-BYPASS; CEREBRAL WHITE-MATTER; LOW BLOOD-PRESSURE; CONGESTIVE-HEART-FAILURE; COGNITIVE IMPAIRMENT; HIPPOCAMPAL SCLEROSIS; KUNGSHOLMEN PROJECT; ATRIAL-FIBRILLATION; PULSE PRESSURE; OFF-PUMP AB Subcortical ischemic vascular dementia is a relatively common form of dementia. Anatomical changes of ageing in the brain arteries predispose the elderly to the effects of hypotension. Depending on their circulatory pattern, particular regions of the brain are susceptible to ischemic hypoperfusive lesions. These regions include the periventricular white matter, basal ganglia, and hippocampus. Interruption of prefrontal-basal ganglia circuits important for cognition and memory may result from these lesions. Hypotension and hypoperfusion explain the high risk for the development of cognitive impairment and vascular dementia in older patients affected by orthostatic hypotension, congestive heart failure, as well as in those undergoing surgical procedures such as hip and knee replacement and coronary artery bypass graft (CABG). Recognition of the susceptibility of elderly subjects to cerebral lesions induced by hypoperfusion should result in appropriate preventive measures and better treatment. C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX 78229 USA. Audie L Murphy Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78284 USA. RP Roman, GC (reprint author), Univ Texas, Hlth Sci Ctr, MSC 883,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM romang@uthscsa.edu NR 64 TC 100 Z9 110 U1 2 U2 4 PU MANEY PUBLISHING PI LEEDS PA HUDSON RD, LEEDS LS9 7DL, ENGLAND SN 0161-6412 J9 NEUROL RES JI Neurol. Res. PD JUL PY 2004 VL 26 IS 5 BP 454 EP 458 DI 10.1179/016164104225017686 PG 5 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 836GZ UT WOS:000222545100002 PM 15265263 ER PT J AU Erkinjuntti, T Roman, G Gauthier, S AF Erkinjuntti, T Roman, G Gauthier, S TI Treatment of vascular dementia - evidence from clinical trials with cholinesterase inhibitors SO NEUROLOGICAL RESEARCH LA English DT Article DE cerebrovascular disease; dementia; elderly; vascular dementia; cholinesterase inhibitors ID ALZHEIMERS-DISEASE; CEREBROVASCULAR-DISEASE; COGNITIVE DECLINE; EFFICACY; RIVASTIGMINE; GALANTAMINE; DONEPEZIL; TOLERABILITY AB Cerebrovascular disease (CVD), as well as secondary ischemic brain injury from cardiovascular disease, are common causes of dementia and cognitive decline in the elderly. Also, CVD frequently contributes to cognitive loss in patients with Alzheimer's disease (AD). Progress in understanding the pathogenetic mechanism involved in vascular cognitive impairment and vascular dementia (VaD) has resulted in promising treatments of these conditions. Cholinergic deficits in VaD are due to ischemia of basal forebrain nuclei and of cholinergic pathways and can be treated with the use of the cholinesterase inhibitors used in AD. Controlled clinical trials with donepezil, galantamine, and rivastigmine in VaD, as well as in patients with AD plus CVD, have demostrated improvement in cognition, behavior and activites of daily living. C1 Univ Helsinki, Cent Hosp, Helsinki, Finland. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. A Murphy Vet Adm Hosp, San Antonio, TX USA. McGill Ctr Studies Aging, Alzheimers & Relates Disorders Res Unit, Montreal, PQ, Canada. RP Roman, G (reprint author), Dept Med, Div Neurol, MSC 883,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM romang@uthsca.edu NR 21 TC 7 Z9 8 U1 0 U2 0 PU MANEY PUBLISHING PI LEEDS PA HUDSON RD, LEEDS LS9 7DL, ENGLAND SN 0161-6412 J9 NEUROL RES JI Neurol. Res. PD JUL PY 2004 VL 26 IS 5 BP 603 EP 605 DI 10.1179/01610425017631 PG 3 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 836GZ UT WOS:000222545100022 PM 15265282 ER PT J AU Bates-Jensen, BM Alessi, CA Cadogan, M Levy-Storms, L Jorge, J Yoshii, J Al-Samarrai, NR Schnelle, JF AF Bates-Jensen, BM Alessi, CA Cadogan, M Levy-Storms, L Jorge, J Yoshii, J Al-Samarrai, NR Schnelle, JF TI The minimum data set bedfast quality indicator: Differences among nursing homes SO NURSING RESEARCH LA English DT Article DE bedfast; immobility; nursing home quality indicators quality assessment ID ENVIRONMENTAL INTERVENTION; REFLECT DIFFERENCES; CARE; RESIDENTS; OUTCOMES; SLEEP; PREVALENCE AB Background. Excessive time in bed has negative effects on both physical conditioning and functioning. There are no data or practice guidelines relevant to how nurses should manage the in-bed times of nursing home residents, although all nursing homes receive a bedfast prevalence quality indicator report generated from the Minimum Data Set. Objectives: To compare nursing homes that score in the upper and lower quartiles on the Minimum Data Set bedfast prevalence quality indicator for proportion of bedfast residents, activity and mobility nursing care, and amount of time all residents spend in bed, and to evaluate whether residents who spend more time in bed are different from those who spend less time in bed according to functional measures. Methods: A cohort design used medical records, resident interviews, and direct observation data to compare 15 nursing homes (n = 451 residents) on the proportion of bedfast residents, the amount of time residents spent in bed, the frequency of activity, and the scores on six activity and mobility care process indicators. Results: Significant differences were found between upper (i.e., higher prevalence of bedfast residents) and lower quartile nursing homes in the proportion of time residents were observed in bed (43% vs. 34%, respectively; p = .007), and in the proportion of residents who spent more than 22 hours in bed per day (18% vs. 8%, respectively; p = .002). All nursing homes underestimated the number of bedfast residents. The residents of upper quartile homes showed more activity episodes and reported receiving more walking assistance than the residents of lower quartile homes. Discussion: Minimum Data Set bedfast quality indicator identified nursing homes in which residents spent more time in bed, but did not reflect differences in activity and mobility care. In fact, upper quartile homes provided more activity and mobility care than lower quartile homes. Across all the nursing homes, most of the residents spent at least 17 hours a day in bed. Further study of activity and mobility care and bedfast outcomes in nursing homes is needed, and nurses need to note the amount of time nursing home residents spend in bed. C1 Calif State Univ Los Angeles, Borun Ctr Gerontol Res, Jewish Home Aging, Reseda, CA 91335 USA. Univ Calif Los Angeles, Sch Med, Multicampus Program Geriatr Med, Los Angeles, CA USA. Clin Ctr Septulveda, Vet Adm Greater Los Angeles Healthcare Syst, Sepulveda, CA USA. Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA. RP Bates-Jensen, BM (reprint author), Calif State Univ Los Angeles, Borun Ctr Gerontol Res, Jewish Home Aging, 7150 Tampa Ave, Reseda, CA 91335 USA. EM batesjen@ucla.edu FU NIA NIH HHS [AG 10415] NR 39 TC 25 Z9 25 U1 1 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-6562 J9 NURS RES JI Nurs. Res. PD JUL-AUG PY 2004 VL 53 IS 4 BP 260 EP 272 DI 10.1097/00006199-200407000-00009 PG 13 WC Nursing SC Nursing GA 841SB UT WOS:000222950600009 PM 15266165 ER PT J AU Raphael, KG Janal, MN Nayak, S Schwartz, JE Gallagher, RM AF Raphael, KG Janal, MN Nayak, S Schwartz, JE Gallagher, RM TI Familial aggregation of depression in fibromyalgia: a community-based test of alternate hypotheses SO PAIN LA English DT Article DE fibromyalgia; major depressive disorder; first-degree relatives ID POSTTRAUMATIC-STRESS-DISORDER; MYOFASCIAL FACE PAIN; STRUCTURED CLINICAL INTERVIEW; DSM-III-R; MAJOR DEPRESSION; HISTORY METHOD; LIFE EVENTS; SEX-DIFFERENCES; PERSONALITY-DISORDERS; RHEUMATOID-ARTHRITIS AB Numerous studies report that fibromyalgia (FM), a syndrome characterized by widespread pain and generalized tender points, is comorbid with major depressive disorder (MDD). The current study tests two alternate explanations for their comorbidity using a family study methodology. The first is that FM is a depression spectrum disorder. The second is that depression is a consequence of living with FM. We recruited potential probands by initially screening by telephone for FM and MDD among women in the NY/NJ metropolitan area, randomly selecting telephone numbers from a list of households with women. Eligible women were invited for second stage physical examinations for FM diagnosis and psychiatric interviews for MDD diagnosis. All available adult, first-degree relatives received psychiatric interviews. Relatives of probands were divided into four groups on the basis of the probands' FM and MDD diagnoses (FM+/MDD+ (n = 156), FM+/MDD- (n = 51), FM-/MDD+ (n = 351) and FM-/MDD- (n = 101)). Results indicated that rates of MDD in the relatives of probands with FM but without personal histories of MDD were virtually identical to rates of MDD in relatives of probands with MDD themselves. This outcome is consistent with the hypothesis that FM is a depression spectrum disorder, in which FM and MDD are characterized by shared, familially mediated risk factors. The implications of these findings for a stress-vulnerability model of FM are discussed. (C) 2004 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved. C1 Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Psychiat, Newark, NJ 07103 USA. SUNY Stony Brook, Sch Med, Dept Psychiat & Behav Sci, New York, NY USA. Philadelphia Vet Affairs Med Ctr, Pain Management Serv, Philadelphia, PA USA. Univ Penn, Dept Psychiat & Anesthesiol, Philadelphia, PA 19104 USA. RP Raphael, KG (reprint author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Psychiat, BHSB F1512,183 S Orange Ave, Newark, NJ 07103 USA. EM raphaekg@umdnj.edu OI Raphael, Karen/0000-0002-2804-8124 FU NIDCR NIH HHS [R01 DE13486] NR 80 TC 66 Z9 67 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0304-3959 J9 PAIN JI Pain PD JUL PY 2004 VL 110 IS 1-2 BP 449 EP 460 DI 10.1016/j.pain.2004.04.039 PG 12 WC Anesthesiology; Clinical Neurology; Neurosciences SC Anesthesiology; Neurosciences & Neurology GA 845HL UT WOS:000223232800054 PM 15275798 ER PT J AU Grande, LA Loeser, JD Ozuna, J Ashleigh, A Samii, A AF Grande, LA Loeser, JD Ozuna, J Ashleigh, A Samii, A TI Complex regional pain syndrome as a stress response SO PAIN LA English DT Article DE complex regional pain syndrome; reflex sympathetic dystrophy; conversion disorder; post-traumatic stress disorder; encephalomalacia; traumatic brain injury ID REFLEX SYMPATHETIC DYSTROPHY; SYNDROME TYPE-I; DISORDER AB A man in his 50's with a prior traumatic brain injury and multiple psychiatric disorders developed acute pain and swelling in his left leg distal to the mid shin. These symptoms arose during an exacerbation of his post-traumatic stress disorder (PTSD). Among his traumatic memories, he reported having witnessed the combat injury and death of a friend who had lost his left leg distal to the mid shin. A diagnosis of conversion disorder was technically excluded because the findings met criteria for Complex Regional Pain Syndrome (CRPS) type 1. Based on recent research into the neurobiology of CRPS, PTSD and conversion disorder, we propose a supraspinal mechanism which could explain how emotional stress can produce both symptoms and signs. (C) 2004 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved. C1 Vet Affairs Puget Sound Hlth Care Syst, Dept Neurol, Seattle, WA 98108 USA. Vet Affairs Puget Sound Hlth Care Syst, Dept Psychiat, Seattle, WA 98108 USA. Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98195 USA. RP Samii, A (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Dept Neurol, Mailstop 127,1660 S Columbian Way, Seattle, WA 98108 USA. EM asamii@u.washington.edu NR 26 TC 25 Z9 26 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0304-3959 J9 PAIN JI Pain PD JUL PY 2004 VL 110 IS 1-2 BP 495 EP 498 DI 10.1016/j.pain.2004.03.032 PG 4 WC Anesthesiology; Clinical Neurology; Neurosciences SC Anesthesiology; Neurosciences & Neurology GA 845HL UT WOS:000223232800059 PM 15275803 ER PT J AU Castro, P Xia, C Gomez, L Lamb, DJ Ittmann, M AF Castro, P Xia, C Gomez, L Lamb, DJ Ittmann, M TI Interleukin-8 expression is increased in senescent prostatic epithelial cells and promotes the development of benign prostatic hyperplasia SO PROSTATE LA English DT Article DE benign prostatic hyperplasia; cytokines; senescence ID GROWTH-FACTOR; CELLULAR SENESCENCE; HUMAN FIBROBLASTS; PARACRINE INDUCER; CANCER; CULTURE; PATHOGENESIS; GENES; FGF7 AB BACKGROUND. Benign prostatic hyperplasia (BPH) is an extremely common disease of older men characterized by increased growth of prostatic epithelial and stromal cells. Previously we showed that senescent epithelial cells accumulate in the prostate of aging men and secrete interleukin-1alpha (IL-1alpha). IL-8 is also present at increased levels in BPH tissues and induces expression of FGF2, a potent stromal growth factor. Therefore, we sought to determine if IL-8 is also expressed at increased levels by senescent epithelial cells and if this secreted IL-8 plays a robe in the pathogenesis of BPH. METHODS. Expression of IL-8 in human BPH tissue and primary cultures of prostatic epithelial cells was analyzed using an enzyme-linked immunoabsorption assay (ELISA). Tissue senescence was assessed by a quantitative assay for senescence-associated beta galactosidase (SA-beta gal). Proliferation of primary and immortalized prostatic epithelial cells in response to IL-8 was determined by counting of cells at intervals after addition of IL-8. RESULTS. Expression of IL-8 is significantly increased in vitro when cultured prostatic epithelial cells undergo senescence. Quantitative assay of BPH tissue extracts revealed that tissue IL-8 levels are correlated with both SA-beta gal activity and prostate weight. IL-8 promotes proliferation of primary and immortalized prostfatic epithelial cells in culture. CONCLUSIONS. Senescence of prostatic epithelial cells results in increased expression of IL-8, which can promote proliferation of non-senescent epithelial and stromal cells by direct and indirect mechanisms, and in this manner contributes to the increased tissue growth seen in BPH. (C) 2004 Wiley-Liss, Inc. C1 Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA. Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA. Houston Dept Vet Affairs Med Ctr, Houston, TX USA. RP Ittmann, M (reprint author), VAMC, Res Serv, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM mittmann@bcm.tmc.edu FU NIDDK NIH HHS [R01 DK54170, T32 DK07763] NR 27 TC 59 Z9 59 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-4137 J9 PROSTATE JI Prostate PD JUL 1 PY 2004 VL 60 IS 2 BP 153 EP 159 DI 10.1002/pros.20051 PG 7 WC Endocrinology & Metabolism; Urology & Nephrology SC Endocrinology & Metabolism; Urology & Nephrology GA 829UQ UT WOS:000222076100008 PM 15162381 ER PT J AU Sampogna, F Picardi, A Chren, MM Melchi, F Pasquini, P Masini, C Abeni, D AF Sampogna, F Picardi, A Chren, MM Melchi, F Pasquini, P Masini, C Abeni, D TI Association between poorer quality of life and psychiatric morbidity in patients with different Dermatological conditions SO PSYCHOSOMATIC MEDICINE LA English DT Article DE quality of life; psychiatric morbidity; dermatology; Skindex-29; GHQ-12 ID SKIN DISEASES; ATOPIC-DERMATITIS; OUTPATIENTS; RELIABILITY; PSORIASIS; VALIDITY; DEPRESSION; DISORDERS; VITILIGO; VERSION AB Objective: To determine the relationship between skin-related quality of life and psychiatric morbidity in patients with different skin conditions. Methods: We recruited all adults attending the outpatient clinics of the Dermatological Institute IDI-IRCCS, Rome, Italy, during 14 predetermined days. Eligible patients, who gave their informed consent, completed the Skindex-29 and the 12-item General Health Questionnaire (GHQ-12). We used a stringent cut-off threshold (greater than or equal to5 on the GHQ-12) for identification of psychiatric morbidity. Skindex-29 scale scores were computed separately for GHQ noncases and GHQ cases. Results: A total of 2,136 patients were included in the analysis. For all skin conditions, GHQ cases had substantially poorer score in all 3 domains of quality of life, Symptoms, Emotions, and Functioning. Most differences remained significant after adjusting for clinical severity, age, sex, and education in multiple regression models. These differences were not as marked in the Symptoms scale for some conditions known to be nearly asymptomatic (eg, alopecia, vitiligo, nevi), suggesting that, although patients with psychiatric morbidity might be more burdened by their symptoms, nevertheless they do not perceive nonexistent symptoms. Conclusion: In most skin conditions we considered, psychiatric morbidity was strongly associated with poorer quality of life. Although the cross-sectional nature of our study does not allow identification of the direction of this association, care for the psychological condition of patients might have an impact on their quality of life. C1 IRCCS, IDI, Inst Dermatol, I-00167 Rome, Italy. Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. San Francisco Vet Affairs Med Ctr, HSR&D Res Enhancement Award Program, San Francisco, CA USA. RP Abeni, D (reprint author), IRCCS, IDI, Inst Dermatol, Via Monti Creta 104, I-00167 Rome, Italy. EM d.abeni@idi.it RI Picardi, Angelo/B-2181-2013 OI Picardi, Angelo/0000-0003-2392-3011; Abeni, Damiano/0000-0002-0167-7617 FU NIAMS NIH HHS [K02 AR 02203-01] NR 26 TC 74 Z9 76 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0033-3174 J9 PSYCHOSOM MED JI Psychosom. Med. PD JUL-AUG PY 2004 VL 66 IS 4 BP 620 EP 624 DI 10.1097/01.psy.0000132869.96872.b2 PG 5 WC Psychiatry; Psychology; Psychology, Multidisciplinary SC Psychiatry; Psychology GA 840KX UT WOS:000222858600024 PM 15272112 ER PT J AU Blanchard, JJ Sayers, SL Collins, LM Bellack, AS AF Blanchard, JJ Sayers, SL Collins, LM Bellack, AS TI Affectivity in the problem-solving interactions of schizophrenia patients and their family members SO SCHIZOPHRENIA RESEARCH LA English DT Article DE schizophrenia; emotion; negative symptoms; family ID LOW EXPRESSED EMOTION; NEGATIVE SYMPTOMS; GENDER-DIFFERENCES; DEFICIT SCHIZOPHRENIA; TRANSACTIONAL PROCESS; INTERPERSONAL CONTROL; SOCIAL COMPETENCE; NONDEFICIT FORMS; AFFECTIVE STYLE; RELIABILITY AB This study sought to examine the relationship between symptomatology and the affect expressed between individuals with schizophrenia and their family members. It was hypothesized that, because of their impact on patient social behavior and potential burden on relatives, greater negative symptoms would be associated with less emotional expression in patients but would be related to the greater expression of negative emotions in their relatives within a problem-solving discussion. Informed by research on the structure of emotion, a broad assessment of affect, including Negativity, Positivity, and Disengagement, was utilized to examine affect expressed by patients with schizophrenic disorders (N = 91) and their family members during videotaped problem-solving discussions. Although individuals with schizophrenia were comparable to their family members in displays of Negativity, patients displayed less Positivity and greater Disengagement. Greater negative symptoms (in particular blunted or flat affect) were related to a general diminution of affective expression in the schizophrenia group. However, negative symptoms were unrelated to the emotional expression of family members. Other symptoms such as thought disorder and mood symptoms of anxiety, depression, and hostility were not related to displays of affect by either patients or their family members. The findings indicate the importance of examining domains of affect other than negativity and demonstrate that negative symptoms are related to interpersonal displays of affect in schizophrenia. Additionally, these results suggest that schizophrenic symptoms, by themselves, may contribute little to the conflict between patients and their family members. (C) 2003 Elsevier B.V. All rights reserved. C1 Univ Maryland, Dept Psychol, College Pk, MD 20742 USA. Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. Baltimore Vet Affairs Capitol Hlth Care Network, Mental Illness Res Educ & Clin Ctr, Baltimore, MD USA. Univ Maryland, Sch Med, Dept Psychiat, Baltimore, MD 21201 USA. RP Blanchard, JJ (reprint author), Univ Maryland, Dept Psychol, College Pk, MD 20742 USA. EM jblanchard@psyc.umd.edu FU NIMH NIH HHS [MH51240, MH41577, MH39998] NR 67 TC 15 Z9 16 U1 0 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 EI 1573-2509 J9 SCHIZOPHR RES JI Schizophr. Res. PD JUL 1 PY 2004 VL 69 IS 1 BP 105 EP 117 DI 10.1016/j.schres.2003.07.008 PG 13 WC Psychiatry SC Psychiatry GA 826EJ UT WOS:000221811800013 PM 15145476 ER PT J AU Pannu, R Won, JS Khan, M Singh, AK Singh, I AF Pannu, R Won, JS Khan, M Singh, AK Singh, I TI A novel role of lactosylceramide in the regulation of lipopolysaccharide/interferon-gamma-mediated inducible nitric oxide synthase gene expression: Implications for neuroinflammatory diseases SO JOURNAL OF NEUROSCIENCE LA English DT Article DE iNOS; astrocytes; lactosylceramide; lipopolysaccharide; interferon-gamma; spinal cord injury ID TUMOR-NECROSIS-FACTOR; SPINAL-CORD-INJURY; ACTIVATED PROTEIN-KINASE; CENTRAL-NERVOUS-SYSTEM; SMOOTH-MUSCLE-CELLS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; CREUTZFELDT-JAKOB-DISEASE; TRAUMATIC BRAIN-INJURY; C-FOS EXPRESSION; MULTIPLE-SCLEROSIS AB In the present study a possible role of glycosphingolipids (GSLs) in inducible nitric oxide synthase ( iNOS) gene expression and nitric oxide ( NO) production after spinal cord injury (SCI) in rats has been established. In primary rat astrocytes lipopolysaccharide (LPS) and interferon-gamma (IFN-gamma) treatment increased the intracellular levels of lactosylceramide ( LacCer) and induced iNOS gene expression. D-Threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol . HCI ( PDMP), a glucosylceramide synthase and LacCer synthase ( galactosyltransferase, GalT-2) inhibitor, inhibited LPS/IFN-gamma induced iNOS expression, which was reversed by exogenously supplied LacCer, but not by other glycosphingolipids. LPS/IFN-gamma caused a rapid increase in the activity of GalT-2 and synthesis of LacCer. Silencing of GalT-2 gene with the use of antisense oligonucleotides resulted in decreased LPS/IFN-gamma-induced iNOS, TNF-alpha, and IL-1beta gene expression. The PDMP-mediated reduction in LacCer production and inhibition of iNOS expression correlated with decreased Ras and ERK1/2 activation along with decreased IkappaB phosphorylation, NF-kappaB DNA binding activity, and NF-kappaB-luciferase reporter activity. LacCer-mediated Ras activation was redox-mediated and was attenuated by antioxidants N-acetyl cysteine (NAC) and pyrrolidine dithiocarbamate ( PDTC). In vivo administration of PDMP after SCI resulted in improved functional outcome ( Basso, Beattie, Bresnahan score); inhibition of iNOS, TNF-alpha, and IL-1beta expression; decreased neuronal apoptosis; and decreased tissue necrosis and demyelination. The in vivo studies supported the conclusions drawn from cell culture studies and provided evidence for the possible role of GalT-2 and LacCer in SCI-induced inflammation and pathology. To our knowledge this is the first report of a role of LacCer in iNOS expression and the advantage of GSL depletion in attenuating post-SCI inflammation to improve the outcome of SCI. C1 Med Univ S Carolina, Dept Pediat, Div Dev Neurogenet, Charleston, SC 29425 USA. Med Univ S Carolina, Ralph h Johnson Vet Affairs Med Ctr, Dept Pathol, Charleston, SC 29425 USA. RP Singh, I (reprint author), Med Univ S Carolina, Dept Pediat, Div Dev Neurogenet, 316 CSB, Charleston, SC 29425 USA. EM singhi@musc.edu FU NINDS NIH HHS [NS-22576, NS-37766, NS-40144, NS-34741, NS-40810] NR 70 TC 39 Z9 39 U1 0 U2 2 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD JUN 30 PY 2004 VL 24 IS 26 BP 5942 EP 5954 DI 10.1523/JNEUROSCI.1271-04.2004 PG 13 WC Neurosciences SC Neurosciences & Neurology GA 833PZ UT WOS:000222351900011 PM 15229242 ER PT J AU Shin, JM Cho, YM Sachs, G AF Shin, JM Cho, YM Sachs, G TI Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY LA English DT Article ID OMEPRAZOLE ANALOGS; CHEMICAL-REACTIONS; SUBSTITUTED BENZIMIDAZOLES; ACID SECRETION; H+/K+-ATPASE; PANTOPRAZOLE; 2-<(2-PYRIDYLMETHYL)SULFINYL>BENZIMIDAZOLES; 2-MERCAPTOETHANOL; H,K-ATPASE; SYSTEM AB Proton pump inhibitors (PPIs), drugs that are widely used for treatment of acid related diseases, are either substituted pyridylmethylsulfinyl benzimidazole or imidazopyridine derivatives. They are all prodrugs that inhibit the acid-secreting gastric (H+, K+)-ATPase by acid activation to reactive thiophiles that form disulfide bonds with one or more cysteines accessible from the exoplasmic surface of the enzyme. This unique acid-catalysis mechanism had been ascribed to the nucleophilicity of the pyridine ring. However, the data obtained here show that their conversion to the reactive cationic thiophilic sulfenic acid or sulfenamide depends mainly not on pyridine protonation but on a second protonation of the imidazole component that increases the electrophilicity of the C-2 position on the imidazole. This protonation results in reaction of the C-2 with the unprotonated fraction of the pyridine ring to form the reactive derivatives. The relevant PPI pK(a)'s were determined by UV spectroscopy of the benzimidazole or imidazopyridine sulfinylmethyl moieties at different medium pH. Synthesis of a relatively acid stable analogue, M-methyl lansoprazole, (6b), allowed direct determination of both pK(a) values of this intact PPI allowing calculation of the two pK(a) values for all the PPIs. These values predict their relative acid stability and thus the rate of reaction with cysteines of the active proton pump at the pH of the secreting parietal cell. The PPI accumulates in the secretory canaliculus of the parietal cell due to pyridine protonation then binds to the pump and is activated by the second protonation on the surface of the protein to allow disulfide formation. C1 Univ Calif Los Angeles, Dept Physiol & Med, Los Angeles, CA 90073 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Shin, JM (reprint author), Univ Calif Los Angeles, Dept Physiol & Med, Los Angeles, CA 90073 USA. EM jaishin@ucla.edu FU NIDDK NIH HHS [DK46917]; PHS HHS [41301, 53462, 17294] NR 20 TC 150 Z9 152 U1 5 U2 28 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0002-7863 J9 J AM CHEM SOC JI J. Am. Chem. Soc. PD JUN 30 PY 2004 VL 126 IS 25 BP 7800 EP 7811 DI 10.1021/ja049607w PG 12 WC Chemistry, Multidisciplinary SC Chemistry GA 831SY UT WOS:000222217600035 PM 15212527 ER PT J AU Bibbins-Domingo, K Ansari, M Schiller, NB Massie, B Whooley, MA AF Bibbins-Domingo, K Ansari, M Schiller, NB Massie, B Whooley, MA TI Are plasma levels of atrial natriuretic peptide, N-terminal ProANP, and brain natriuretic peptide affected by the presence of coronary artery disease? Response SO CIRCULATION LA English DT Letter ID HEART; SOUL C1 Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Med, San Francisco, CA 94143 USA. Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Epidemiol, San Francisco, CA 94143 USA. RP Bibbins-Domingo, K (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Med, San Francisco, CA 94143 USA. NR 5 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD JUN 29 PY 2004 VL 109 IS 25 BP E331 EP E331 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 833GY UT WOS:000222326300052 ER PT J AU Ahuja, SK Catano, G AF Ahuja, SK Catano, G TI Sharing is caring, except when it comes to HLA-class-I alleles in HIV-1 transmission SO LANCET LA English DT Editorial Material ID HUMAN-IMMUNODEFICIENCY-VIRUS; DISEASE PROGRESSION; TYPE-1 TRANSMISSION; PROTECT MACAQUES; INFECTION; CONCORDANCE; ANTIBODY; ALLOIMMUNIZATION; ALLOANTIBODY; IMMUNIZATION C1 S Texas Vet Hlth Care Syst, Vet Adm Ctr AIDS & HIV 1 Infect, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX 78229 USA. RP Ahuja, SK (reprint author), S Texas Vet Hlth Care Syst, Vet Adm Ctr AIDS & HIV 1 Infect, San Antonio, TX USA. EM ahujas@uthscsa.edu NR 19 TC 4 Z9 4 U1 0 U2 1 PU LANCET LTD PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 0140-6736 J9 LANCET JI Lancet PD JUN 26 PY 2004 VL 363 IS 9427 BP 2103 EP 2104 DI 10.1016/S0140-6736(04)16536-7 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 832LF UT WOS:000222268300005 PM 15220030 ER PT J AU Choudhury, GG AF Choudhury, GG TI A linear signal transduction pathway involving phosphatidylinositol 3-kinase, protein kinase C epsilon, and MAPK in mesangial cells regulates interferon-gamma-induced STAT1 alpha transcriptional activation SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID STAT1 SERINE PHOSPHORYLATION; FOS GENE-TRANSCRIPTION; IFN-GAMMA; PKC-EPSILON; TYROSINE PHOSPHORYLATION; DNA-SYNTHESIS; DIFFERENTIAL REGULATION; INDEPENDENT PATHWAYS; TARGETED DISRUPTION; ENDOTHELIAL-CELLS AB Interferon-gamma (IFN-gamma) exerts an pleiotropic effect in mesangial cells in inflammatory glomerular diseases. The biologic effect of IFN-gamma is mediated by STAT1alpha. The precise mechanism by which IFN-gamma stimulates the transcriptional activity of STAT1alpha is poorly understood. I investigated the role of protein kinase C (PKC) epsilon in regulating the transcriptional activation of STAT1alpha in mesangial cells. IFN-gamma increased PKCepsilon activity in a time-dependent manner with a concomitant increase in STAT1alpha transcriptional activity. Expression of constitutively active PKCepsilon mimicked the effect of IFN-gamma on STAT1alpha-dependent transcription. Expression of dominant negative PKCepsilon inhibited IFN-gamma-induced STAT1alpha-dependent transcription. Ly294002, a pharmacological inhibitor of phosphatidylinositol ( PI) 3-kinase, blocked IFN-gamma-induced PKCepsilon activity and resulted in inhibition of STAT1alpha transcriptional activity but had no effect on STAT1alpha tyrosine phosphorylation and STAT1alpha-DNA complex formation. A PKC inhibitor, H7, also had no effect on STAT1alpha tyrosine phosphorylation and DNA binding. However, Ly294002 and H7 blocked IFN-gamma-induced serine phosphorylation of STAT1alpha. These data indicate that PI 3 kinase-dependent PKCepsilon regulates STAT1alpha transcriptional activity in the absence of any effect on its DNA binding capability. In addition to activating PKCepsilon, IFN-gamma increased MAPK activity, resulting in transcriptional activation of Elk-1, a nuclear target of MAPK. Ly294002 or a dominant negative PI 3-kinase significantly blocked IFN-gamma-induced MAPK activity. On the other hand, ectopic expression of constitutively active PKCepsilon significantly increased MAPK activity. IFN-gamma-stimulated MAPK phosphorylated STAT1alpha in vitro. Inhibition of MAPK activity blocked IFN-gamma-induced serine phosphorylation of STAT1alpha; but its tyrosine phosphorylation and DNA binding were partially inhibited. Finally, expression of dominant negative MAPK significantly inhibited IFN-gamma-induced STAT1alpha-dependent transcription. These data provide the first evidence that IFN-gamma stimulates PKCepsilon in a PI 3-kinase-sensitive manner to activate MAPK, which regulates STAT1alpha transcriptional activity. C1 Univ Texas, Dept Med, Hlth Sci Ctr, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA. RP Choudhury, GG (reprint author), Univ Texas, Dept Med, Hlth Sci Ctr, San Antonio, TX 78229 USA. EM choudhuryg@uthscsa.edu FU NIDDK NIH HHS [P50 DK061597, R01 DK55815] NR 78 TC 54 Z9 55 U1 0 U2 0 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD JUN 25 PY 2004 VL 279 IS 26 BP 27399 EP 27409 DI 10.1074/jbc.M403530200 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 830KH UT WOS:000222120400071 PM 15082710 ER PT J AU Friedman, DI Gordon, LK Egan, RA Jacobson, DM Pomeranz, H Harrison, AR Goldhammer, Y AF Friedman, DI Gordon, LK Egan, RA Jacobson, DM Pomeranz, H Harrison, AR Goldhammer, Y TI Doxycycline and intracranial hypertension SO NEUROLOGY LA English DT Article ID PSEUDOTUMOR CEREBRI; MINOCYCLINE AB The authors report seven patients from six neuro-ophthalmology referral centers who developed pseudo-tumor cerebri during treatment with doxycycline. All four female patients and one of three male patients were obese. Vision was minimally affected in most patients, but two had substantial visual acuity or visual field loss at presentation. Discontinuation of doxycycline, with or without additional intracranial pressure-lowering agents, yielded improvement, but permanent visual acuity or visual field loss occurred in five patients. C1 Univ Rochester, Sch Med & Dent, Dept Ophthalmol, Rochester, NY 14642 USA. Univ Rochester, Sch Med & Dent, Dept Neurol, Rochester, NY 14642 USA. Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90024 USA. Greater Los Angeles Vet Adm Healthcare Syst, Casey Eye Inst, Los Angeles, CA USA. Oregon Hlth Sci Univ, Dept Ophthalmol, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Neurol, Portland, OR 97201 USA. Marshfield Clin Fdn Med Res & Educ, Dept Neurol, Marshfield, WI 54449 USA. Univ Minnesota, Dept Ophthalmol, Minneapolis, MN 55455 USA. Chaim Sheba Med Ctr, Dept Neurol, IL-52621 Tel Hashomer, Israel. RP Friedman, DI (reprint author), Univ Rochester, Sch Med & Dent, Dept Ophthalmol, 601 Elmwood Ave,Box 659, Rochester, NY 14642 USA. EM Deborah_Friedman@urmc.rochester.edu NR 10 TC 25 Z9 27 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD JUN 22 PY 2004 VL 62 IS 12 BP 2297 EP 2299 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA 831FF UT WOS:000222178600029 PM 15210900 ER PT J AU El-Serag, HB Aguirre, T Kuebeler, M Sampliner, RE AF El-Serag, HB Aguirre, T Kuebeler, M Sampliner, RE TI The length of newly diagnosed Barrett's oesophagus and prior use of acid suppressive therapy SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID PROSPECTIVE MULTIVARIATE-ANALYSIS; GASTROESOPHAGEAL REFLUX DISEASE; HIATAL-HERNIA; OMEPRAZOLE; REGRESSION; ADENOCARCINOMA; EXPOSURE; EXTENT; SIZE AB Background: The length of Barrett's oesophagus seems to correlate well with indicators of severe gastro-oesophageal reflux disease. However, it remains unknown whether prior acid suppressive therapy affects the length of newly diagnosed Barrett's oesophagus. Methods: A retrospective analysis of a well-characterized large cohort of patients with Barrett's oesophagus diagnosed between 1981 and 2000. Aim: To compare the length of Barrett's oesophagus between patients who received acid suppressive therapy prior to their diagnosis to those who did not receive such therapy. Pharmacy records were obtained from Department of the Veterans Affairs computerized records and prospectively collected research records. We further examined the association between prior use of acid suppressive therapy and the length of Barrett's oesophagus in correlation analyses, as well as multivariate linear regression analyses while adjusting for differences in year of diagnosis, age, gender, ethnicity, and the presence of intestinal metaplasia of the gastric cardia. Results: There were 340 patients with Barrett's oesophagus first diagnosed between 1981 and 2000. The average length of Barrett's oesophagus at the time of first diagnosis was 4.4 cm (range: 0.5-16). Of all patients, 139 (41%) had prior use of histamine-2 receptor antagonists, or proton-pump inhibitors (41 used both), and 201 (59%) used neither prior to the diagnosis of Barrett's oesophagus. The mean length of Barrett's oesophagus was significantly shorter in patients with prior use of proton-pump inhibitors (3.4 cm) or proton-pump inhibitors and histamine-2 receptor antagonists (3.1 cm) when compared to those with none of these medications (4.8 cm). In the multivariate linear regression model, the prior use of proton-pump inhibitors or either proton-pump inhibitors or histamine-2 receptor antagonists was an independent predictor of shorter length of Barrett's oesophagus (P = 0.0396). Conclusions: The use of acid suppressive therapy among patients is associated with a reduction in the eventual length of newly diagnosed Barrett's oesophagus with gastro-oesophageal reflux disease. This finding is independent of the year of diagnosis or demographic features of patients. Further studies are required to confirm this finding. C1 Houston Vet Affairs Med Ctr, Sect Gastroenterol, Houston, TX USA. Houston Vet Affairs Med Ctr, Hlth Serv Res, Houston, TX USA. Univ Arizona, Hlth Sci Ctr, Tucson, AZ 85721 USA. RP El-Serag, HB (reprint author), 2002 Holcombe Blvd 152, Houston, TX 77030 USA. EM hasheme@bon.unc.edu NR 20 TC 17 Z9 18 U1 0 U2 2 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 0269-2813 J9 ALIMENT PHARM THERAP JI Aliment. Pharmacol. Ther. PD JUN 15 PY 2004 VL 19 IS 12 BP 1255 EP 1260 DI 10.1111/j.1365-2036.2004.02006.x PG 6 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 834QZ UT WOS:000222426900004 PM 15191506 ER PT J AU Graham, DY AF Graham, DY TI 'Guidelines' or marketing for non-steroidal anti-inflammatory drug and proton pump inhibitor use? SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Letter ID HELICOBACTER-PYLORI; OMEPRAZOLE; PREVENTION; ULCERS; MISOPROSTOL; RANITIDINE C1 Baylor Coll Med, VA Med Ctr, Houston, TX 77030 USA. Baylor Coll Med, Dept Med & Mol Virol & Microbiol, Houston, TX 77030 USA. RP Graham, DY (reprint author), Baylor Coll Med, VA Med Ctr, Houston, TX 77030 USA. EM dgraham@bcm.tmc.edu NR 8 TC 1 Z9 1 U1 0 U2 0 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 0269-2813 J9 ALIMENT PHARM THERAP JI Aliment. Pharmacol. Ther. PD JUN 15 PY 2004 VL 19 IS 12 BP 1323 EP 1324 DI 10.1111/j.1365-2036.2004.01950.x PG 2 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 834QZ UT WOS:000222426900013 PM 15191515 ER PT J AU Hayashi, T Boyko, EJ Leonetti, DL McNeely, MJ Newell-Morris, L Kahn, SE Fujimoto, WY AF Hayashi, T Boyko, EJ Leonetti, DL McNeely, MJ Newell-Morris, L Kahn, SE Fujimoto, WY TI Visceral adiposity is an independent predictor of incident hypertension in Japanese Americans SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID BODY-FAT DISTRIBUTION; IMPAIRED GLUCOSE-TOLERANCE; FASTING PLASMA-INSULIN; BLOOD-PRESSURE; ABDOMINAL OBESITY; DIABETES-MELLITUS; VASCULAR-DISEASE; HEART-DISEASE; RISK-FACTORS; OLDER WOMEN AB Background: Visceral adiposity is generally considered to play a key role in the metabolic syndrome. Objective: To examine the relationship between directly measured visceral adiposity and the risk for incident hypertension, independent of other adipose depots and fasting plasma insulin levels. Design: Community-based prospective cohort study with 10- to 11-year follow-up. Setting: King County, Washington. Participants: 300 Japanese Americans with a systolic blood pressure less than 140 mm Hg and a diastolic blood pressure less than 90 mm Hg who were not taking anti hypertensive medications, oral hypoglycemic medications, or insulin at study entry. Measurements: Abdominal, thoracic, and thigh fat areas were measured by using computed tomography. Total subcutaneous fat area was calculated as the sum of these fat areas excluding the intra-abdominal fat area. Hypertension during follow-up was defined as having a systolic blood pressure of 140 mm Hg or greater, having a diastolic blood pressure of 90 mm Hg or greater, or taking anti hypertensive medications. Results: There were 92 incident cases of hypertension during the follow-up period. The intra-abdominal fat area was associated with an increased risk for hypertension. Multiple-adjusted odds ratios of hypertension for quartiles of intra-abdominal fat area (1 = lowest; 4 = highest) were 5.07 (95% CI, 1.75 to 14.73) for quartile 3 and 3.48 (CI, 1.01 to 11.99) for quartile 4 compared with quartile 1 after adjustment for age, sex, fasting plasma insulin level, 2-hour plasma glucose level, body mass index, systolic blood pressure, alcohol consumption, smoking status, and energy expenditure through exercise (P = 0.003 for quadratic trend). The intra-abdominal fat area remained a significant risk factor for hypertension, even after adjustment for total subcutaneous fat area, abdominal subcutaneous fat area, or waist circumference; however, no measure of these fat areas was associated with risk for hypertension in models that contained the intra-abdominal fat area. Limitations: It is not known whether these results pertain to other ethnic groups. Conclusions: Greater visceral adiposity increases the risk for hypertension in Japanese Americans. C1 Vet Affairs Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA 98108 USA. Univ Washington, Seattle, WA 98195 USA. RP Boyko, EJ (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, S-152E,1660 S Columbian Way, Seattle, WA 98108 USA. EM eboyko@u.washington.edu RI Hayashi, Tomoshige/N-8508-2015 OI Boyko, Edward/0000-0002-3695-192X FU NCRR NIH HHS [RR-00037]; NHLBI NIH HHS [HL-49293]; NIDDK NIH HHS [DK-02654, DK-17047, DK-31170, DK-35816] NR 44 TC 149 Z9 158 U1 1 U2 8 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD JUN 15 PY 2004 VL 140 IS 12 BP 992 EP 1000 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 829NK UT WOS:000222055500002 PM 15197016 ER PT J AU Williams, JW Katon, W Lin, EHB Noel, PH Worchel, J Cornell, J Harpole, L Fultz, BA Hunkeler, E Mika, VS Unutzer, J AF Williams, JW Katon, W Lin, EHB Noel, PH Worchel, J Cornell, J Harpole, L Fultz, BA Hunkeler, E Mika, VS Unutzer, J CA IMPACT Investigators TI The effectiveness of depression care management on diabetes-related outcomes in older patients SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID CORONARY-ARTERY-DISEASE; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; OF-THE-LITERATURE; MAJOR DEPRESSION; LATE-LIFE; COLLABORATIVE MANAGEMENT; TREATMENT GUIDELINES; IMPROVE TREATMENT; MENTAL-DISORDERS AB Background: Depression frequently occurs in combination with diabetes mellitus, adversely affecting the course of illness. Objective: To determine whether enhancing care for depression improves affective and diabetic outcomes in older adults with diabetes and depression. Design: Preplanned subgroup analysis of the Improving Mood-Promoting Access to Collaborative Treatment (IMPACT) randomized, controlled trial. Setting: 18 primary care clinics from 8 health care organizations in 5 states. Patients: 1801 patients 60 years of age or older with depression; 417 had coexisting diabetes mellitus. Intervention: A care manager offered education, problem-solving treatment, or support for antidepressant management by the patient's primary care physician; diabetes care was not specifically enhanced. Measurements: Assessments at baseline and at 3, 6, and 12 months for depression, functional impairment, and diabetes self-care behaviors. Hemoglobin A(1c) levels were obtained for 293 patients at baseline and at 6 and 12 months. Results: At 12 months, diabetic patients who were assigned to intervention had less severe depression (range, 0 to 4 on a checklist of 20 depression items; between-group difference, -0.43 [95% CI, -0.57 to -0.29]; P < 0.001) and greater improvement in overall functioning (range, 0 [none] to 10 [unable to perform activities]; between-group difference, -0.89 [CI, -1.46 to -0.32]) than did participants who received usual care. In the intervention group, weekly exercise days increased (between-group difference, 0.50 day [CI, 0.12 to 0.89 day]; P= 0.001); other self-care behaviors were not affected. At baseline, mean (+/-SD) hemoglobin A(1c) levels were 7.28% 1.43%; follow-up values were unaffected by the intervention (P > 0.2). Limitations: Because patients had good glycemic control at baseline, power to detect small but clinically important improvements in glycemic control was limited. Conclusions: Collaborative care improves affective and functional status in older patients with depression and diabetes; however, among patients with good glycemic control, such care minimally affects diabetes-specific outcomes. C1 Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC 27705 USA. Duke Univ, Sch Med, Durham, NC USA. Univ Washington, Sch Med, Seattle, WA USA. Grp Hlth Cooperat Puget Sound, Seattle, WA USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. Cent Texas Vet Hlth Care Syst, Austin, TX USA. Indiana Univ, Ctr Aging Res, Regenstrief Inst, Indianapolis, IN USA. Univ Calif Los Angeles, Los Angeles, CA USA. Kaiser Permanente No Calif, Oakland, CA USA. RP Williams, JW (reprint author), Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, 508 Fulton St, Durham, NC 27705 USA. RI Williams, Jr., John/A-3696-2008 OI Williams, Jr., John/0000-0002-5267-5558 NR 66 TC 168 Z9 173 U1 2 U2 9 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD JUN 15 PY 2004 VL 140 IS 12 BP 1015 EP 1024 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 829NK UT WOS:000222055500005 PM 15197019 ER PT J AU Wong, AL Harker, JO Lau, VP Shatzel, S Port, LH AF Wong, AL Harker, JO Lau, VP Shatzel, S Port, LH TI Spanish arthritis empowerment program: A dissemination and effectiveness study SO ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH LA English DT Article DE empowerment; Spanish language; arthritis; selfmanagement ID RHEUMATOID-ARTHRITIS; SELF-MANAGEMENT; RANDOMIZED-TRIAL; EDUCATION; OUTCOMES AB Objective. To evaluate the effectiveness of the Spanish Arthritis Empowerment Program as presented by the Arthritis Foundation, Southern California Chapter, in Orange County, California. Methods. Participants with arthritis (n = 141) enrolled in the program between October 1999 and May 2001. All materials were in Spanish. Written pretest, 6-week posttest, and 6-month followup tests measured pain rating, self-report joint counts, function (modified Health Assessment Questionnaire [mHAQ]), self efficacy, self-care behavior, and arthritis knowledge. Results. Mean age was 51 years, 92% were female, 84% were born in Mexico, 55% had sixth grade education or less, and 60% had no medical insurance. Of the 141 participants, 118 completed 6-month followup testing. Repeated-measures analysis of variance showed significant improvement from pretest to 6-month followup in pain (6.0 versus 3.4); self efficacy (5.5 versus 8.4), self-care behavior (1.7 versus 4.9), arthritis knowledge (1.6 versus 4.5), and general health (2.1 versus 2.5), all at P < 0.001. Small improvement was reported in mHAQ (0.56 versus 0.50; P = 0.024). Conclusion. The Spanish Arthritis Empowerment Program was successfully disseminated. Significant improvements in self efficacy and in arthritis symptoms were maintained at the, 6-month followup. C1 Olive View UCLA Med Ctr, Sylmar, CA 91342 USA. Calif State Univ Los Angeles, Sch Med, Los Angeles, CA 90032 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda, CA USA. Arthritis Fdn, No Calif Chapter, San Francisco, CA USA. Arthritis Fdn, So Calif Chapter, Los Angeles, CA USA. RP Wong, AL (reprint author), Olive View UCLA Med Ctr, 14445 Olive View Dr,2B182, Sylmar, CA 91342 USA. EM alunwong@ucia.edu NR 15 TC 16 Z9 16 U1 0 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRIT RHEUM-ARTHR JI Arthritis Rheum-Arthritis Care Res. PD JUN 15 PY 2004 VL 51 IS 3 BP 332 EP 336 DI 10.1002/art.20395 PG 5 WC Rheumatology SC Rheumatology GA 827SF UT WOS:000221920200008 PM 15188316 ER PT J AU Escalante, A Del Rincon, I Cornell, JE AF Escalante, A Del Rincon, I Cornell, JE TI Latent variable approach to the measurement of physical disability in rheumatoid arthritis SO ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH LA English DT Article DE physical disability; rheumatoid arthritis; disease-specific health measures; generic health measures; outcome assessment; factor analysis ID QUALITY-OF-LIFE; HEALTH ASSESSMENT QUESTIONNAIRE; DISABLEMENT PROCESS; MODEL SELECTION; INSTRUMENTS; RESPONSIVENESS; IMPROVEMENT; TRIALS; SCALES AB Objective. To measure physical disability in rheumatoid arthritis (RA) using a latent variable derived from a generic and a disease-specific self-reported disability instrument and an observer-assessed functional status scale. Methods. Consecutive patients with RA completed the modified Health Assessment Questionnaire (M-HAQ) and the Short Form 36 (SF-36) physical function scale. An observer assigned a Steinbrocker functional classification. We used principal component factor analysis to extract a latent variable from the 3 scales. We used the "Bayesian Information Criterion to compare how well the new latent variable and the 3 primary scales fit the criterion standards of current work status; vital status at 6 years; grip strength; walking velocity; the timed-button test; pain; and joint tenderness, swelling, and deformity. Results. Complete data were available for 776 RA patients. The extracted latent variable explained 75% of the variance in the 3 primary scales. On a scale of 0-100, higher scores representing less disability, its mean +/- SD was 56.4 +/- 22.5. Correlation between the latent variable and the M-HAQ was -0.87; between the latent variable and SF-36 physical function scale was 0.89, and between the latent variable and Steinbrocker class was -0.85. Mulltivariate models that included the latent variable had superior fit than did models containing the primary scales for the criteria of current working; death by 6 years; pain; joint tenderness, swelling, or deformity; grip strength; walking velocity; and timed button test. Conclusion. A latent variable derived from the M-HAQ, the SF-36 physical function scale, and the Steinbrocker functional class provides a parsimonious scale to measure physical disability in RA. The fit of the latent variable to comparison standards is equivalent or superior to that of the primary scales. C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX 78229 USA. S Texas Vet Adm Hlth Syst, San Antonio, TX USA. RP Escalante, A (reprint author), Univ Texas, Hlth Sci Ctr, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. FU NCRR NIH HHS [M01-RR01346]; NHLBI NIH HHS [K23-HL004481]; NIAMS NIH HHS [K24-AR47530]; NICHD NIH HHS [R01-HD37151] NR 42 TC 10 Z9 10 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRIT RHEUM-ARTHR JI Arthritis Rheum-Arthritis Care Res. PD JUN 15 PY 2004 VL 51 IS 3 BP 399 EP 407 DI 10.1002/art.20404 PG 9 WC Rheumatology SC Rheumatology GA 827SF UT WOS:000221920200017 PM 15188325 ER PT J AU Van Remmen, H Qi, WB Sabia, M Freeman, G Estlack, L Yang, H Guo, ZM Huang, TT Strong, R Lee, S Epstein, CJ Richardson, A AF Van Remmen, H Qi, WB Sabia, M Freeman, G Estlack, L Yang, H Guo, ZM Huang, TT Strong, R Lee, S Epstein, CJ Richardson, A TI Multiple deficiencies in antioxidant enzymes in mice result in a compound increase in sensitivity to oxidative stress SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Article ID MANGANESE SUPEROXIDE-DISMUTASE; CELLULAR GLUTATHIONE-PEROXIDASE; MITOCHONDRIAL-FUNCTION; KNOCKOUT MICE; REPERFUSION INJURY; FREE-RADICALS; DILATED CARDIOMYOPATHY; ISCHEMIA REPERFUSION; NEONATAL LETHALITY; INDUCED APOPTOSIS AB To examine the effect of compound deficiencies in antioxidant defense, we have generated mice (Sod2(+/-)/ Gpx1(-/-)) that are deficient in Mn superoxide dismutase (MnSOD) and glutathione peroxidase 1 (Gpx1) by breeding Sod2(+/-) and Gpx1(-/-) mice together. Although Sod2(+/-)/Gpx(-/-) mice showed a 50% reduction in MnSOD and no detectable Gpx1 activity in either mitochondria or cytosol in all tissues, they were viable and appeared normal. Fibroblasts isolated from Sod2(+/-)/GPx1(-/-) mice were more sensitive (4- to 6-fold) to oxidative stress (t-butyl hydroperoxide or gamma irradiation) than fibroblasts from wild-type mice, and were twice as sensitive as cells from Sod2(+/-) or Gpx1(-/-) mice. Whole-animal studies demonstrated that survival of the Sod2(+/-)/Gpx1(-/-) mice in response to wholebody gamma irradiation or paraquat administration was also reduced compared with that of wild-type, Sod2(+/-), or Gpx1(-/-) mice. Similarly, endogenous oxidative stress induced by cardiac ischemia/reperfusion injury led to greater apoptosis in heart tissue from the Sod2(+/-)/Gpx1(-/-) mice than in that from mice deficient in either MnSOD or Gpx1 alone. These data show that Sod2(+/-)/Gpx1(-/-) mice, deficient in two mitochondrial antioxidant enzymes, have significantly enhanced sensitivity to oxidative stress induced by exogenous insults and to endogenous oxidative stress compared with either wild-type mice or mice deficient in either MnSOD or Gpx1 alone. (C) 2004 Elsevier Inc. All rights reserved. C1 Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Obstet & Gynecol, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Bishop Ctr Longev Studies, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, San Antonio, TX 78284 USA. Meharry Med Coll, Dept Anat & Physiol, Nashville, TN 37208 USA. Meharry Med Coll, Dept Pathol, Nashville, TN 37208 USA. Stanford Univ, Palo Alto, CA 94304 USA. Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA. RP Van Remmen, H (reprint author), Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. EM vanremmen@uthscsa.edu FU NIA NIH HHS [P30 AG013319, P01 AG020591, P03 AG13319, R01 AG16998] NR 41 TC 83 Z9 87 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD JUN 15 PY 2004 VL 36 IS 12 BP 1625 EP 1634 DI 10.1016/j.freeradbiomed.2004.03.016 PG 10 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 831YO UT WOS:000222233000013 PM 15182862 ER PT J AU Reddy, PH McWeeney, S Park, BS Manczak, M Gutala, RV Partovi, D Jung, Y Yau, V Searles, R Mori, M Quinn, J AF Reddy, PH McWeeney, S Park, BS Manczak, M Gutala, RV Partovi, D Jung, Y Yau, V Searles, R Mori, M Quinn, J TI Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease SO HUMAN MOLECULAR GENETICS LA English DT Article ID A-BETA; MOUSE MODEL; OXIDATIVE STRESS; MEMORY DEFICITS; CDNA MICROARRAY; MUTANT PRESENILIN-1; PLAQUE-FORMATION; MESSENGER-RNA; ONTOLOGY GO; BRAIN AB Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by the impairment of cognitive functions and by beta amyloid (Abeta) plaques in the cerebral cortex and the hippocampus. Our objective was to determine genes that are critical for cellular changes in AD progression, with particular emphasis on changes early in disease progression. We investigated an established amyloid precursor protein (APP) transgenic mouse model (the Tg2576 mouse model) for gene expression profiles at three stages of disease progression: long before (2 months of age), immediately before (5 months) and after (18 months) the appearance of Abeta plaques. Using cDNA microarray techniques, we measured mRNA levels in 11 283 cDNA clones from the cerebral cortex of Tg2576 mice and age-matched wild-type (WT) mice at each of the three time points. This gene expression analysis revealed that the genes related to mitochondrial energy metabolism and apoptosis were up-regulated in 2-month-old Tg2576 mice and that the same genes were up-regulated at 5 and 18 months of age. These microarray results were confirmed using northern blot analysis. Results from in situ hybridization of mitochondrial genes-ATPase-6, heat-shock protein 86 and programmed cell death gene 8-suggest that the granule cells of the hippocampal dentate gyrus and the pyramidal neurons in the hippocampus and the cerebral cortex are up-regulated in Tg2576 mice compared with WT mice. Results from double-labeling in situ hybridization suggest that in Tg2576 mice only selective, over-expressed neurons with the mitochondrial gene ATPase-6 undergo oxidative damage. These results, therefore, suggest that mitochondrial energy metabolism is impaired by the expression of mutant APP and/or Abeta, and that the up-regulation of mitochondrial genes is a compensatory response. These findings have important implications for understanding the mechanism of Abeta toxicity in AD and for developing therapeutic strategies for AD. C1 Oregon Hlth & Sci Univ, Inst Neurol Sci, Neurogenet Lab, Beaverton, OR 97006 USA. Oregon Hlth & Sci Univ, Gene Microarray Shared Resource, Spotted Microarray Core, Beaverton, OR 97006 USA. Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Div Biostat, Portland, OR 97239 USA. Portland Vet Affairs Med Ctr, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. RP Reddy, PH (reprint author), Oregon Hlth & Sci Univ, Inst Neurol Sci, Neurogenet Lab, 505 NW 185th Ave, Beaverton, OR 97006 USA. EM reddyh@ohsu.edu OI /0000-0003-3516-7516 FU NCCIH NIH HHS [AT0006]; NIA NIH HHS [AG22643, P30 AG08017] NR 65 TC 185 Z9 195 U1 1 U2 12 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0964-6906 J9 HUM MOL GENET JI Hum. Mol. Genet. PD JUN 15 PY 2004 VL 13 IS 12 BP 1225 EP 1240 DI 10.1093/hmg/ddh140 PG 16 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA 825HZ UT WOS:000221748400004 PM 15115763 ER PT J AU Brooks, SR Kirkham, PM Freeberg, L Carter, RH AF Brooks, SR Kirkham, PM Freeberg, L Carter, RH TI Binding of cytoplasmic proteins to the CD19 intracellular domain is high affinity, competitive, and multimeric SO JOURNAL OF IMMUNOLOGY LA English DT Article ID CELL ANTIGEN RECEPTOR; TANDEM SH2 DOMAINS; TYROSINE KINASE; B-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; LYMPHOCYTES-B; ACTIVATION; VAV; SYK; LYN AB CD19 is required for the development of B1 and marginal zone B cells, for Ab responses, and for B cell memory. CD19 immunoprecipitates contain a complex of cytoplasmic proteins, including Lyn, Vav, phospholipase Cgamma2 (PLCgamma2), Grb2, and the p85 subunit of phosphatidylinositol 3-kinase. Which of these bind directly to CD19 and the strengths of the interactions are unknown. These issues are important in understanding the signaling functions of CD19, which are crucial for normal B cell physiology. Using purified, recombinant proteins, we now show that each of these signaling proteins contains at least one Src homology 2 (SH2) domain that interacts directly with the phosphorylated CD19 cytoplasmic domain. The affinities of binding of the SH2 domains of Vav, p85, and Grb2 to CD19 are each in the nanomolar range by surface plasmon resonance (Biacore) analysis. Binding of Lyn and PLCgamma2 do not fit 1:1 modeling. However, analyses of binding data (Lyn) and competition experiments (PLCgamma2) suggest that these bind with comparable affinity. Competition experiments demonstrate that SH2 domains whose binding is dependent on the same CD19 tyrosine(s) compete for binding, but these SH2 domains do not impede binding of different SH2 domains to other CD19 tyrosines. We conclude that binding to the CD19 cytoplasmic domain is multimeric, high affinity, and competitive. The high affinity of the interactions also suggests that tyrosines that were nonessential in vivo are nevertheless functional. A preliminary structural model suggests that CD19 forms a signaling complex containing multiple cytoplasmic proteins in close proximity to each other and to the plasma membrane. C1 Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA. Univ Alabama, Dept Pharmacol, Birmingham, AL 35294 USA. Univ Alabama, Dept Med, Birmingham, AL 35294 USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL 35233 USA. RP Carter, RH (reprint author), 409 LHRB,701 South 19th St, Birmingham, AL 35294 USA. EM rcarter@uab.edu FU NIAID NIH HHS [AI 07051, AI 42265, T32 AI007051] NR 30 TC 17 Z9 17 U1 0 U2 2 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD JUN 15 PY 2004 VL 172 IS 12 BP 7556 EP 7564 PG 9 WC Immunology SC Immunology GA 828KV UT WOS:000221973100040 PM 15187135 ER PT J AU Pappas, PG Bustamante, B Ticona, E Hamill, RJ Johnson, PC Reboli, A Aberg, J Hasbun, R Hsu, HH AF Pappas, PG Bustamante, B Ticona, E Hamill, RJ Johnson, PC Reboli, A Aberg, J Hasbun, R Hsu, HH TI Recombinant interferon-gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT 41st Interscience Conference on Antimicrobial Agents and Chemotherapy CY DEC 16-19, 2001 CL CHICAGO, IL ID CHRONIC GRANULOMATOUS-DISEASE; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; AMPHOTERICIN-B; CUTANEOUS LEISHMANIASIS; ANTIFUNGAL CHEMOTHERAPY; DISSEMINATED INFECTION; GAMMA-INTERFERON; NEOFORMANS; COMBINATION; FLUCYTOSINE AB We conducted a phase 2, double-blind, placebo-controlled study to evaluate the safety and antifungal activity of adjuvant recombinant interferon (rIFN)-gamma1b in patients with acquired immunodeficiency syndrome and acute cryptococcal meningitis. Patients received 100 or 200 mug of rIFN-gamma1b or placebo, thrice weekly for 10 weeks, plus standard therapy with intravenous amphotericin B, with or without flucytosine, followed by therapy with fluconazole. End points included conversion of cerebrospinal fluid fungal cultures from positive to negative at 2 weeks, resolution of symptoms, and survival. Among 75 patients, 2-week culture conversion occurred in 13% of placebo recipients, 36% of rIFN-gamma1b (100 mug) recipients, and 32% of rIFN-gamma1b (200 mug) recipients. There was a trend toward improved combined mycologic and clinical success in rIFN-gamma1b recipients (26% vs. 8%; P = .078). Therapy with rIFN-gamma1b was well tolerated, and there was no apparent influence on serial CD4 cell counts and human immunodeficiency virus load measurements. Adjunctive therapy with rIFN-gamma1b holds promise for patients with acute cryptococcal meningitis and warrants further study. C1 Univ Alabama, Sch Med, Birmingham, AL 35294 USA. Baylor Univ, Sch Med, Houston, TX 77030 USA. Houston VA Med Ctr, Houston, TX USA. Univ Texas, Houston Med Ctr, Houston, TX USA. Univ Med & Dent New Jersey, Cooper Hosp, Camden, NJ 08103 USA. Washington Univ, Sch Med, St Louis, MO USA. Tulane Univ, Sch Med, New Orleans, LA 70112 USA. InterMune Pharmaceut, Brisbane, CA USA. Univ Peruana Cayetano Heredia, Lima, Peru. Hosp Mayo, Lima, Peru. RP Pappas, PG (reprint author), Univ Alabama, Sch Med, 1900 Univ Blvd,229 Tinsley Harrison Tower, Birmingham, AL 35294 USA. EM pappas@uab.edu NR 25 TC 103 Z9 109 U1 0 U2 4 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD JUN 15 PY 2004 VL 189 IS 12 BP 2185 EP 2191 DI 10.1086/420829 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 824PW UT WOS:000221699500006 PM 15181565 ER PT J AU Polnaszek, N Kwabi-Addo, B Wang, JH Ittmann, M AF Polnaszek, N Kwabi-Addo, B Wang, JH Ittmann, M TI FGFI7 is an autocrine prostatic epithelial growth factor and is upregulated in benign prostatic hyperplasia SO PROSTATE LA English DT Article DE FGF17; fibroblast growth factor; benign prostatic hyperplasia; fibroblast growth factor receptors ID OVER-EXPRESSION; FACTOR FAMILY; CANCER; RECEPTORS; CELLS AB BACKGROUND. Fibroblast growth factors (FGFs) are known to play all important role in the growth of prostatic epithelial cells. Benign prostatic hyperplasia (BPH) is characterized by increased epithelial and stromal proliferation within the transition zone of the prostate. FGF2, FGF7, and FGF9 are expressed in BPH tissue but expression of FGF17 has not been previously characterized in human prostate tissue. METHODS. Expression of FGF17 in human prostate tissue and primary cultures of prostatic epithelial and stromal cells was determined by reverse-transcriptase polymerase chain reaction (RT-PCR). Growth response to FGF17 was assessed by addition of recombinant FGF17 to immortalized normal and neoplastic epithelial. cell lines and primary cultures of prostatic stromal cells in the presence of insulin. Quantitative analysis of expression of FGF17 relative to keratin 18 and/or beta-actin in normal and hyperplastic prostate and prostate carcinoma was carried out by real-time quantitative RT-PCR. RESULTS. FGF17 is expressed by prostatic epithelial cells and can act as an autocrine growth factor for immortalized and neoplastic prostatic epithelial cells. It can also promote stromal proliferation, although only at higher concentrations. Expression of FGH17 per epithelial cell was increased 2-fold in BPH. CONCLUSIONS. FGF17 is expressed by normal, hyperplastic, and neoplastic prostatic epithelial cells and can promote epithelial proliferation in an autocrine manner. FGF17 expression is increased 2-fold in BPH and may contribute to the increased epithelial proliferation seen in this disease. (C) 2003 Wiley-Liss, Inc. C1 Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA. Houston Dept Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Ittmann, M (reprint author), VAMC, Res Serv, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM mittmann@bcm.tmc.edu RI Kwabi-Addo, Bernard/A-6993-2016 OI Kwabi-Addo, Bernard/0000-0003-3692-6350 FU NIDDK NIH HHS [R01 DK54170] NR 20 TC 15 Z9 17 U1 1 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-4137 J9 PROSTATE JI Prostate PD JUN 15 PY 2004 VL 60 IS 1 BP 18 EP 24 DI 10.1002/pros.20026 PG 7 WC Endocrinology & Metabolism; Urology & Nephrology SC Endocrinology & Metabolism; Urology & Nephrology GA 824UE UT WOS:000221711600002 PM 15129425 ER PT J AU Krahl, SE Martin, FC Handforth, A AF Krahl, SE Martin, FC Handforth, A TI Vagus nerve stimulation inhibits harmaline-induced tremor SO BRAIN RESEARCH LA English DT Article DE tremor; hannaline; essential tremor; vagus nerve stimulation; electrical stimulation ID POSITRON EMISSION TOMOGRAPHY; INFERIOR OLIVE; BRAIN-STEM; SOLITARY TRACT; CAT; PROJECTIONS; SYSTEM; NUCLEUS; VAGAL; RATS AB Excessive olivo-cerebellar burst-firing occurs during harmaline-induced tremor. This system receives rich sensory inputs, including visceral. We hypothesized that electrical vagus nerve stimulation (VNS) Would suppress harmaline tremor, as measured with digitized motion power in the rat. Cervical vagus nerve stimulation suppressed power in the 8-12-Hz tremor range by 40%, whereas sham stimulation was ineffective. This study raises the possibility that activation of various sensory modalities, as well as visceral, may reduce tremor. Published by Elsevier B.V. C1 VA Greater Los Angeles Healthcare Syst, Res & Dev Serv, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Div Neurosurg, Los Angeles, CA 90025 USA. VA Greater Los Angeles Healthcare Syst, Neurol Serv, Los Angeles, CA 90073 USA. RP Krahl, SE (reprint author), VA Greater Los Angeles Healthcare Syst, Res & Dev Serv, Bldg 114,Suite 217,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM scott.krahl@med.va.gov NR 26 TC 9 Z9 9 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 J9 BRAIN RES JI Brain Res. PD JUN 11 PY 2004 VL 1011 IS 1 BP 135 EP 138 DI 10.1016/j.brainres.2004.03.021 PG 4 WC Neurosciences SC Neurosciences & Neurology GA 827YI UT WOS:000221939200015 PM 15140653 ER PT J AU Marchesini, N Osta, W Bielawski, J Luberto, C Obeid, LM Hannun, YA AF Marchesini, N Osta, W Bielawski, J Luberto, C Obeid, LM Hannun, YA TI Role for mammalian neutral sphingomyelinase 2 in confluence-induced growth arrest of MCF7 cells SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID TRANS-GOLGI NETWORK; CYCLIN-DEPENDENT KINASES; E-CADHERIN; SACCHAROMYCES-CEREVISIAE; CYTOPLASMIC DOMAIN; INDUCED APOPTOSIS; CONTACT INHIBITION; PHOSPHATIDIC-ACID; CERAMIDE PATHWAY; LEUKEMIC-CELLS AB Recently, we reported that neutral sphingomyelinase 2 (nSMase2) functions as a bona fide neutral sphingomyelinase and that overexpression of nSMase2 in MCF7 breast cancer cells caused a decrease in cell growth (Marchesini, N., Luberto, C., and Hannun, Y. A. (2003) J. Biol. Chem. 278, 13775-13783). In this study, the role of endogenous nSMase2 in regulating growth arrest was investigated. The results show that endogenous nSMase2 mRNA was up-regulated similar to5-fold when MCF7 cells became growth-arrested at confluence, and total neutral SMase activity was increased by 119 +/- 41% with respect to control. Cell cycle analysis showed that up-regulation of endogenous nSMase2 correlated with G(0)/G(1) cell cycle arrest and an increase in total ceramide levels (2.4-fold). Analysis of ceramide species showed that confluence caused selective increases in very long chain ceramide C-24:1 (370 +/- 54%) and C-24:0 (266 +/- 81%) during arrest. The role of endogenous nSMase2 in growth regulation and ceramide metabolism was investigated using short interfering RNA (siRNA)-mediated loss-of-function analysis. Down-regulation of nSMase2 with specific siRNA increased the cell population of cells in S phase of the cell cycle by 59 +/- 14% and selectively reverted the effects of growth arrest on the increase in levels of very long chain ceramides. Mechanistically, confluence arrest also induced hypophosphorylation of the retinoblastoma protein (6-fold) and induction of p21(WAF1) (3-fold). Downregulation of nSMase2 with siRNA largely prevented the dephosphorylation of the retinoblastoma protein and the induction of p21(WAF1), providing a link between the action of nSMase2 and key regulators of cell cycle progression. Moreover, studies on nSMase2 localization in MCF7 cells showed that nSMase2 distributed throughout the cells in subconfluent, proliferating cultures. In contrast, nSMase2 became nearly exclusively located at the plasma membrane in confluent, contact-inhibited cells. Hence, we demonstrate for the first time that nSMase2 functions as a growth suppressor in MCF7 cells, linking confluence to the G(0)/G(1) cell cycle check point. C1 Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. Ralph H Johnson Vet Adm, Charleston, SC 29425 USA. RP Hannun, YA (reprint author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave, Charleston, SC 29425 USA. EM hannun@musc.edu OI obeid, lina/0000-0002-0734-0847 FU NIA NIH HHS [AG16583]; NIGMS NIH HHS [GM 43825] NR 69 TC 94 Z9 99 U1 0 U2 6 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD JUN 11 PY 2004 VL 279 IS 24 BP 25101 EP 25111 DI 10.1074/jbc.M313662200 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 826KL UT WOS:000221827900025 PM 15051724 ER PT J AU Mathur, SK Grodinsky, D AF Mathur, SK Grodinsky, D TI Dislocation of the lenses SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material C1 Loyola Univ, Med Ctr, Maywood, IL 60153 USA. US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. RP Mathur, SK (reprint author), Loyola Univ, Med Ctr, 2160 S 1st Ave, Maywood, IL 60153 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU MASSACHUSETTS MEDICAL SOC/NEJM PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD JUN 10 PY 2004 VL 350 IS 24 BP E22 EP E22 DI 10.1056/NEJMicm030131 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 827GH UT WOS:000221887200010 PM 15190155 ER PT J AU Samaha, FF Rubenstein, RC Yan, WS Ramkumar, M Levy, DI Ahn, YJ Sheng, SH Kleyman, TR AF Samaha, FF Rubenstein, RC Yan, WS Ramkumar, M Levy, DI Ahn, YJ Sheng, SH Kleyman, TR TI Functional polymorphism in the carboxyl terminus of the alpha-subunit of the human epithelial sodium channel SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID CELL-SURFACE EXPRESSION; SENSITIVE NA+ CHANNEL; LIDDLE-SYNDROME; BETA-SUBUNIT; MEMBRANE TOPOLOGY; GAMMA-SUBUNIT; ESSENTIAL-HYPERTENSION; BLACK-PEOPLE; MUTATIONS; AMILORIDE AB A common human epithelial sodium channel ( ENaC) polymorphism, alphaT663A, is present in the cytoplasmic C terminus of the alpha-subunit, although it is unclear whether this polymorphism segregates with blood pressure. We examined whether this polymorphism was associated with differences in functional Na+ channel expression. Whole cell amiloride-sensitive currents in Xenopus oocytes expressing wild type channels (alphaT663betagamma) were significantly similar to1.3-2.0-fold higher than currents measured in oocytes expressing channels with an Ala, Gly or Leu, or Lys at position alpha663. In contrast, differences in functional human ENaC expression were not observed with oocytes expressing channels having Thr (wild type), Ser, or Asp at this position. The surface expression of channels, measured using an epitope-tagged beta-subunit, was significantly reduced in oocytes expressing alphaT663Abetagamma when compared with oocytes expressing alphaT663betagamma. The corresponding polymorphism was generated in the mouse alpha-subunit (malphaA692T) and was not associated with differences in functional alphabetagamma-mouse ENaC expression. The polymorphism is present in a region that is not well conserved between human and mouse. We generated a mouse/human chimera by replacement of the distal C terminus of the mouse alpha-subunit with the distal C terminus of the human alpha-subunit. Co-expression of this m(1-678)/h(650-669)T663A chimera with mouse betagamma led to a significant reduction in whole cell Na+ currents and surface expression when compared with m(1-678)/h( 650-669) T663-mbetagamma. Our results suggest that h alphaT663A is a functional polymorphism that affects human ENaC surface expression. C1 Childrens Hosp Philadelphia, Div Pulm Med, Philadelphia, PA 19104 USA. Univ Penn, Dept Med, Philadelphia, PA 19104 USA. Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. Univ Pittsburgh, Dept Med, Pittsburgh, PA 15261 USA. Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA. RP Rubenstein, RC (reprint author), Childrens Hosp Philadelphia, Div Pulm Med, 34th St & Civ Ctr Blvd,Abramson 410C, Philadelphia, PA 19104 USA. EM rrubenst@mail.med.upenn.edu OI Sheng, Shaohu/0000-0002-7198-1702 FU NIDDK NIH HHS [DK51391, DK54354, DK58046] NR 37 TC 31 Z9 34 U1 0 U2 0 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD JUN 4 PY 2004 VL 279 IS 23 BP 23900 EP 23907 DI 10.1074/jbc.M401941200 PG 8 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 824RA UT WOS:000221702500010 PM 15069064 ER PT J AU Garnovskaya, MN Mukhin, YV Vlasova, TM Grewal, JS Ullian, ME Tholanikunnel, BG Raymond, JR AF Garnovskaya, MN Mukhin, YV Vlasova, TM Grewal, JS Ullian, ME Tholanikunnel, BG Raymond, JR TI Mitogen-induced rapid phosphorylation of serine 795 of the retinoblastoma gene product in vascular smooth muscle cells involves ERK activation SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID E2F TRANSCRIPTION FACTORS; TUMOR-SUPPRESSOR PROTEIN; CYCLIN-DEPENDENT KINASES; ABL TYROSINE KINASE; BREAST-CANCER CELLS; ANGIOTENSIN-II; PHOSPHATIDYLINOSITOL 3-KINASE; MAP KINASE; DIFFERENTIAL REGULATION; NUCLEAR-LOCALIZATION AB We examined the relationship between mitogen-activated MEK (mitogen and extracellular signal-regulated protein kinase kinase) and phosphorylation of the gene product encoded by retinoblastoma ( hereafter referred to as Rb) in vascular smooth muscle cells. Brief treatment of the cells with 100 nM angiotensin II or 1 muM serotonin resulted in serine phosphorylation of Rb that was equal in magnitude to that induced by treating cells for 20 h with 10% fetal bovine serum (approximate to3 x basal). There was no detectable rapid phosphorylation of two close cousins of Rb, p107 and p130. Phosphorylation state-specific antisera demonstrated that the rapid phosphorylation occurred on Ser(795), but not on Ser(249), Thr(252), Thr(373), Ser(780), Ser(807), or Ser(811). Phosphorylation of Rb Ser(795) peaked at 10 min, lagging behind phosphorylation of MEK and ERK (extracellular signal-regulated protein kinase). Rb Ser(795) phosphorylation could be blocked by PD98059, a MEK inhibitor, and greatly attenuated by apigenin, an inhibitor of the Ras --> Raf --> MEK --> ERK pathway. The effect also appears to be mediated by CDK4. Immunoprecipitation/immunoblot studies revealed that serotonin and angiotensin II induced complex formation between CDK4, cyclin D1, and phosphorylated ERK. These studies show a rapid, novel, and selective phosphorylation of Rb Ser(795) by mitogens and demonstrate an unexpected rapid linkage between the actions of the Ras --> Raf --> MEK --> ERK pathway and the phosphorylation state of Rb. C1 Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Med Serv, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29425 USA. RP Garnovskaya, MN (reprint author), Med Univ S Carolina, Dept Med, Div Nephrol, 96 Jonathan Lucas St,Rm 829 CSB,POB 250623, Charleston, SC 29425 USA. EM garnovsk@musc.edu FU NIDDK NIH HHS [R01-DK52448, K01-DK02694]; NIGMS NIH HHS [R01-GM63909] NR 66 TC 28 Z9 28 U1 0 U2 0 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD JUN 4 PY 2004 VL 279 IS 23 BP 24899 EP 24905 DI 10.1074/jbc.M311622200 PG 7 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 824RA UT WOS:000221702500122 PM 15069084 ER PT J AU Chen, HH Nicoletti, MA Hatch, JP Sassi, RB Axelson, D Brambilla, P Monkul, ES Keshavan, MS Ryan, ND Birmaher, B Soares, JC AF Chen, HH Nicoletti, MA Hatch, JP Sassi, RB Axelson, D Brambilla, P Monkul, ES Keshavan, MS Ryan, ND Birmaher, B Soares, JC TI Abnormal left superior temporal gyrus volumes in children and adolescents with bipolar disorder: a magnetic resonance imaging study SO NEUROSCIENCE LETTERS LA English DT Article DE magnetic resonance imaging; bipolar disorder; superior temporal gyrus; adolescents ID GRAY-MATTER VOLUME; 1ST-EPISODE SCHIZOPHRENIA; AGE AB Abnormalities in left superior temporal gyrus (STG) have been reported in adult bipolar patients. However, it is not known whether such abnormalities are already present early in the course of this illness. Magnetic resonance imaging (MRI) morphometric analysis of STG was performed in 16 DSM-IV children and adolescents with bipolar disorder (mean age +/- SD 15.5 +/- 3.4 years) and 21 healthy controls (mean age +/- SD 16.9 +/- 3.8 years). Subjects underwent a 3D spoiled gradient recalled acquisition MRI examination. Using analysis of covariance with age, gender and intra-cranial brain volume as covariates, we found significantly smaller left total STG volumes in bipolar patients (12.5 +/- 1.5 cm(3)) compared with healthy controls (13.6 +/- 2.5 cm(3)) (F = 4.45, d.f. = 1, 32, P = 0.04). This difference was accounted for by significantly smaller left and right STG white matter volumes in bipolar patients. Decreased white matter connections may be the core of abnormalities in STG, which is an important region for speech, language and communication, and could possibly underlie neurocognitive deficits present in bipolar patients. (C) 2004 Elsevier Ireland Ltd. All rights reserved. C1 Univ Texas, Hlth Sci Ctr, Div Mood & Anxiety Disorders, Dept Psychiat, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX 78229 USA. Univ Sao Paulo, Sch Med, Inst Psychiat, Dept Psychiat, Sao Paulo, Brazil. Univ Pittsburgh, Ctr Med, Western Psychiat Inst & Clin, Dept Psychiat, Pittsburgh, PA USA. Univ Verona, Sch Med, Dept Med & Publ Hlth, I-37100 Verona, Italy. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. Dokuz Eylul Univ, Sch Med, Dept Psychiat, Izmir, Turkey. RP Soares, JC (reprint author), Univ Texas, Hlth Sci Ctr, Div Mood & Anxiety Disorders, Dept Psychiat, MC7792,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM soares@uthscsa.edu RI brambilla, paolo/B-4184-2010 OI brambilla, paolo/0000-0002-4021-8456 FU NIMH NIH HHS [MH 30915, MH 01736, MH 55123, MH 59929] NR 20 TC 48 Z9 50 U1 0 U2 4 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0304-3940 J9 NEUROSCI LETT JI Neurosci. Lett. PD JUN 3 PY 2004 VL 363 IS 1 BP 65 EP 68 DI 10.1016/j.neulet.2004.03.042 PG 4 WC Neurosciences SC Neurosciences & Neurology GA 824SR UT WOS:000221707400016 PM 15157998 ER PT J AU Drivdahl, R Haugk, KH Sprenger, CC Nelson, PS Tennant, MK Plymate, SR AF Drivdahl, R Haugk, KH Sprenger, CC Nelson, PS Tennant, MK Plymate, SR TI Suppression of growth and tumorigenicity in the prostate tumor cell line M12 by overexpression of the transcription factor SOX9 SO ONCOGENE LA English DT Article DE SOX9; prostate; androgens; IGF; cancer ID PROTEIN-RELATED PROTEIN-1; MANGANESE SUPEROXIDE-DISMUTASE; CANCER CELLS; ANDROGEN RECEPTOR; EPITHELIAL-CELLS; TESTIS DEVELOPMENT; SEX DETERMINATION; BINDING; EXPRESSION; GENE AB Overexpression of mac25 in the prostate cancer cell line M12 effects a dramatic reversal of the transformed phenotype. cDNA array analysis of RNA from cells overproducing the mac25 protein (M12/mac25) indicated upregulation of the sex determining transcription factor SOX9. In this study, we have confirmed increased expression of SOX9 in M12/mac25 cells and have further investigated the physiological effects of increased SOX9 production. Greatly increased levels of SOX9 RNA and mature protein were demonstrated in cells transfected with a SOX9 cDNA (M12/SOX9), and gel mobility shift assays confirmed binding of nuclear protein from these cells to an oligonucleotide containing the SOX9 consensus binding sequence. M12/SOX9 cells assumed the spindle-shaped morphology characteristic of M12/mac25 cells, suggesting that SOX9 mediates some effects of mac25. Elevated expression of SOX9 resulted in a decreased rate of cellular proliferation, cell cycle arrest in G0/G1, and increased sensitivity to apoptosis. Tumor development in athymic nude mice was inhibited by 80%. Finally, prostate-specific antigen and the androgen receptor, two genes whose expression is characteristic of differentiated cells, were both upregulated in M12/SOX9 cells. These data indicate that SOX9 contributes to growth regulation by mac25 via inhibition of cell growth and promotion of differentiation. C1 Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98105 USA. Univ Washington, Sch Med, Dept Med, Seattle, WA 98105 USA. Univ Washington, Sch Med, Mol & Cell Biol Program, Seattle, WA 98105 USA. Fred Hutchinson Canc Res Ctr, Seattle, WA 98107 USA. RP Plymate, SR (reprint author), Univ Washington, Harborview Med Ctr, Box 359755,325 9th Ave, Seattle, WA 98104 USA. EM splymate@u.washington.edu FU NCI NIH HHS [P01-CA85859, R01-CA56283] NR 55 TC 40 Z9 45 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0950-9232 J9 ONCOGENE JI Oncogene PD JUN 3 PY 2004 VL 23 IS 26 BP 4584 EP 4593 DI 10.1038/sj.onc.1207603 PG 10 WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity GA 825ZV UT WOS:000221799000008 PM 15077158 ER PT J AU Benza, RL Zoghbi, GJ Tallaj, J Brown, R Kirklin, JK Hubbard, M Rayburn, B Foley, B McGiffin, DC Pinderski, LJ Misra, V Bourge, RC AF Benza, RL Zoghbi, GJ Tallaj, J Brown, R Kirklin, JK Hubbard, M Rayburn, B Foley, B McGiffin, DC Pinderski, LJ Misra, V Bourge, RC TI Palliation of allograft vasculopathy with transluminal angioplasty - A decade of experience SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article ID HEART-TRANSPLANT RECIPIENTS; CORONARY-ARTERY-DISEASE; INTRAVASCULAR ULTRASOUND; MYCOPHENOLATE-MOFETIL; BALLOON ANGIOPLASTY; CARDIAC-ANGIOGRAPHY; FOLLOW-UP; IN-VITRO; INTERVENTION; PRAVASTATIN AB OBJECTIVES The goal of this study was to examine the outcomes of percutaneous coronary interventions (PCI) and the predictors for restenosis after cardiac transplantation. BACKGROUND The role of PCI as definitive therapy for allograft coronary disease (ACD) remains contentious. METHODS Between January 1, 1990 and December 31, 2000, 62 patients (1.5 to 15.5 years after transplant) underwent 151 procedures resulting in PCIs of 219 lesions. Follow-up after PCI angiography was usually obtained at three and six months, then yearly. Repeat PCI was routinely done to lesions with >60% restenosis. RESULTS The primary procedural success was 97%. Repeat PCI occurred in 74 of 219 lesions (34%); PCI-related mortality was 2.6% (4 of 151). The freedom from re-PCI (of same vessel site) was 75% at six months, 65% at one year, and 57% at four years. The freedom from restenosis was 95% at one month, 81% at three months, and 57% at six months. Multivariate predictors of freedom from restenosis were the use of stents, higher anti-proliferative immunosuppressant dose, and an era effect. In the setting of one-vessel disease at first PCI, the two-year freedom for ACD death or graft loss was 74%, compared. with 75% for two-vessel and 27% for three-vessel disease (p = 0.009). CONCLUSIONS Despite the increasing effectiveness of PCI for localized ACD, the survival after development of advanced ACD remains poor. Stents appear to increase effectiveness of PCI for ACD, but other factors in the current era contribute to improved outcomes. (C) 2004 by the American College of Cardiology Foundation. C1 Univ Alabama, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA. Birmingham VA Med Ctr, Dept Med, Birmingham, AL USA. Univ Alabama, Dept Surg, Div Cardiovasc Surg, Birmingham, AL 35294 USA. RP Benza, RL (reprint author), Univ Alabama, Dept Med, Div Cardiovasc Dis, 328A THT,1900 Univ Blvd, Birmingham, AL 35294 USA. EM rbenza@uab.edu NR 39 TC 57 Z9 58 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD JUN 2 PY 2004 VL 43 IS 11 BP 1973 EP 1981 DI 10.1016/j.jacc.2004.02.045 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 824VR UT WOS:000221715800008 PM 15172400 ER PT J AU Wong, ML Staszewsky, L Latini, R Barlera, S Glazer, R Aknay, N Hester, A Anand, I Cohn, JN AF Wong, ML Staszewsky, L Latini, R Barlera, S Glazer, R Aknay, N Hester, A Anand, I Cohn, JN TI Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure valsartan - Heart failure trial (Val-HeFT) echocardiographic data SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article ID SURROGATE END-POINTS; ANGIOTENSIN-RECEPTOR BLOCKER; TERM ENALAPRIL THERAPY; INDUCED HYPERTROPHY; EJECTION FRACTION; CARDIAC MYOCYTES; CLINICAL-TRIALS; DYSFUNCTION; PREDICTORS; MORBIDITY AB OBJECTIVES The objective of this study was to test the hypothesis that the severity of left ventricular remodeling predicts the response to treatment and outcomes in chronic heart failure. BACKGROUND Reversal of remodeling should produce the most favorable outcome in patients with the most severe remodeling. METHODS In 5,010 heart failure patients on background therapy and randomized to valsartan and placebo, serial recordings of left ventricular internal diastolic diameter (LVIDd) and ejection fraction (EF) were read at sites that had to meet qualifying standards before participating. Baseline LVIDd and EF were pooled across treatments and retrospectively grouped by quartiles Q1 to Q4, representing best to worst. Kaplan-Meier survival curves were obtained by the log-rank test. Q1 was compared with Q4 for mortality and combined mortality and morbidity (M + M) from Cox regression risk ratios (RRs). Valsartan versus placebo changes from baseline in LVIDd and EF were analyzed by quartiles from analysis of covariance. Valsartan and placebo were compared by RRs for M + M. RESULTS Survival rates were greater in the better quartiles for LVIDd and EF (p < 0.00001). The RR for Q1 versus Q4 in events approached 0.5 for both LVIDd and EF (p < 0.0001). An LVIDd decrease and EF increase were quartile-dependent and greater with valsartan than placebo at virtually all time points. The RR for M + M outcomes favored valsartan in the worse quartiles. CONCLUSIONS Stratification by baseline severity of remodeling showed that patients with worse LVIDd and EF are at highest risk for an event, yet appear to gain the most anti-remodeling effect and clinical benefit with valsartan treatment. (C) 2004 by the American College of Cardiology Foundation. C1 Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90073 USA. Ist Rec Farmacol Mario Negri, Milan, Italy. Nova Pharmaceut Corp, E Hanover, NJ USA. Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA. Vet Affairs Med Ctr, Minneapolis, MN USA. RP Wong, ML (reprint author), Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,500-6641, Los Angeles, CA 90073 USA. EM maylene.wong@med.va.gov NR 24 TC 96 Z9 97 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD JUN 2 PY 2004 VL 43 IS 11 BP 2022 EP 2027 DI 10.1016/j.jacc.2003.12.053 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 824VR UT WOS:000221715800015 PM 15172407 ER PT J AU Masson, CL Barnett, PG Sees, KL Delucchi, KL Rosen, A Wong, W Hall, SM AF Masson, CL Barnett, PG Sees, KL Delucchi, KL Rosen, A Wong, W Hall, SM TI Cost and cost-effectiveness of standard methadone maintenance treatment compared to enriched 180-day methadone detoxification SO ADDICTION LA English DT Article DE cost-effectiveness; health care; injection drug use; methadone detoxification; methadone maintenance; opiate use ID EFFECTIVENESS LEAGUE TABLES; HEALTH-CARE; MULTIPLE IMPUTATION; ADDICTION; SERVICES; MODELS; TRIAL; HIV AB Aims To compare the cost and cost-effectiveness of methadone maintenance treatment and 180-day methadone detoxification enriched with psychosocial services. Design Randomized controlled study conducted from May 1995 to April 1999. Setting Research clinic in an established drug treatment program. Participants One hundred and seventy-nine adults with diagnosed opioid dependence. Intervention Patients were randomized to methadone maintenance (n=91), which required monthly 1 hour/week of psychosocial therapy during the first 6 months or 180-day detoxification (n = 88), which required 3 hours/week of psychosocial therapy and 14 education sessions during the first 6 months. Measurements Total health-care costs and self-reported injection drug use. A two-state Markov model was used to estimate quality-adjusted years of survival. Findings Methadone maintenance produced significantly greater reductions in illicit opioid use than 180-day detoxification during the last 6 months of treatment. Total health-care costs were greater for maintenance than detoxification treatment ($7564 versus $668 7; P < 0.001). Although study costs were significantly higher for methadone maintenance than detoxification patients ($4739 versus $2855, P < 0.001), detoxification patients incurred significantly higher costs for substance abuse and mental health care received outside the study. Methadone maintenance may provide a modest survival advantage compared with detoxification. The cost per life-year gained is $16967. Sensitivity analysis revealed a cost-effectiveness ratio of less than $20000 per quality-adjusted life-year over a wide range of modeling assumptions. Conclusions Compared with enriched detoxification services, methadone maintenance is more effective than enriched detoxification services with a cost-effectiveness ratio within the range of many accepted medical interventions and may provide a survival advantage. Results provide additional support for the use of sustained methadone therapy as opposed to detoxification for treating opioid addiction. C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA. Stanford Univ, Stanford, CA 94305 USA. San Francisco VA Med Ctr, San Francisco, CA USA. RP Masson, CL (reprint author), San Francisco Gen Hosp, Dept Psychiat, 1001 Potrero Ave,Bldg 20,Suite 2100, San Francisco, CA 94110 USA. EM masson@itsa.ucsf.edu NR 32 TC 30 Z9 33 U1 2 U2 4 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 0965-2140 J9 ADDICTION JI Addiction PD JUN PY 2004 VL 99 IS 6 BP 718 EP 726 DI 10.1111/j.1360-0443.2004.00728.x PG 9 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 825NN UT WOS:000221765300008 PM 15139870 ER PT J AU Sanborn, TA Jacobs, AK Frederick, PD Every, NR French, WJ AF Sanborn, TA Jacobs, AK Frederick, PD Every, NR French, WJ CA Natl Registry Mycardial Infraction TI Comparability of quality-of-care indicators for emergency coronary angioplasty in patients with acute myocardial infarction regardless of on-site cardiac surgery (report from the national registry of myocardial infarction) SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID THROMBOLYTIC THERAPY; SURGICAL BACKUP; HOSPITALS; INTERVENTION; ASSOCIATION; EXPERIENCE; TRIAL AB Initial reports have suggested that primary percutaneous coronary intervention (PCI) can be performed safely in selected hospitals without on-site cardiac surgery, however, quality-of-care indicators for primary PCI in these institutions is unknown., Therefore, symptom onset-to-door intervals, door-to-balloon times, compliance with American College of Cardiology/American Heart Association (ACC/AHA) management guidelines, and in-hospital mortality were evaluated in 108,132 patients in 3 hospital settings in the National Registry of Myocardial Infarction: (1) diagnostic laboratories only (n = 47), (2) elective PCI only (n 50), and (3) elective PCI and cardiac surgery (n 562). Mean symptom onset-to-door intervals (127 minutes, 95% confidence interval 118 to 135; 134 minutes, 95% confidence interval 125 to 142; and 140 minutes, 95% confidence intervals 138 to 141; p = 0.01) and door-to-balloon intervals (104 minutes, 95% confidence interval 10 1 to 108; 116 minutes, 95% confidence interval 112 to 119; and 119 minutes, 95% confidence interval 118 to 120; p < 0.0001) were shorter in hospitals without cardiac surgery. Adherence to ACC/AHA guidelines for medications within the first 24 hours'(aspirin, beta blockers, angiotensin-converting enzyme inhibitors) was greater in hospitals without cardiac surgery. There were comparable in-hospital mortality rates (3.2%, 4.2%, and 4.8%, respectively, p 0.07) for patients with similar Thrombolysis In Myocardial Infarction risk scores; however, 4.7% of patients treated with primary PCI,in hospitals without cardiac surgery were transferred to another institution. Thus, hospitals performing primary PCI without on-site cardiac surgery that participated in this registry have quality-of-care indicators and adherence to ACC/AHA management guidelines that are comparable to hospitals with on-site cardiac surgery. The lack of on-site cardiac surgery does not appear to adversely affect quality-of-care indicators in primary PCI. (C)2004 by Excerpta Medica, Inc. C1 Northwestern Univ, Evanston Northwestern Healthcare, Feinberg Sch Med, Evanston, IL 60201 USA. Boston Univ, Med Ctr, Boston, MA 02215 USA. Univ Washington, Ovat Res Grp, Seattle, WA 98195 USA. Univ Washington, VA Puget Sound Healthcare Syst, Seattle, WA 98195 USA. Univ Calif Los Angeles, Harbor Med Ctr, Torrance, CA 90509 USA. RP Sanborn, TA (reprint author), Northwestern Univ, Evanston Northwestern Healthcare, Feinberg Sch Med, Burch 300,2650 Ridge Ave, Evanston, IL 60201 USA. EM tsanborn@enh.org OI Frederick, Paul/0000-0002-7936-5488 NR 13 TC 21 Z9 21 U1 0 U2 1 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD JUN 1 PY 2004 VL 93 IS 11 BP 1335 EP 1339 DI 10.1016/j.amjcard.2004.02.026 PG 5 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 826FQ UT WOS:000221815100001 PM 15165910 ER PT J AU Cook, AF Hoas, H Guttmannova, K Joyner, JC AF Cook, AF Hoas, H Guttmannova, K Joyner, JC TI An error by any other name SO AMERICAN JOURNAL OF NURSING LA English DT Article ID MEDICAL LITERATURE; USERS GUIDES; JOB-SATISFACTION; PATIENT; HOSPITALS; NURSES; CARE; SERVICES; BURNOUT; ARTICLE C1 Univ Montana, Dept Psychol, Missoula, MT 59812 USA. Univ Montana, Natl Rural Bioeth Project, Missoula, MT 59812 USA. US Dept Vet Affairs, Off Gen Counsel, Washington, DC USA. RP Cook, AF (reprint author), Univ Montana, Dept Psychol, Missoula, MT 59812 USA. FU AHRQ HHS [R01 HS11930] NR 33 TC 38 Z9 39 U1 2 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0002-936X J9 AM J NURS JI Am. J. Nurs. PD JUN PY 2004 VL 104 IS 6 BP 32 EP 43 PG 12 WC Nursing SC Nursing GA 828KB UT WOS:000221971100026 PM 15187607 ER PT J AU Nakamura, M Matute-Bello, G Liles, WC Hayashi, S Kajikawa, O Lin, SM Frevert, CW Martin, TR AF Nakamura, M Matute-Bello, G Liles, WC Hayashi, S Kajikawa, O Lin, SM Frevert, CW Martin, TR TI Differential response of human lung epithelial cells to Fas-induced apoptosis SO AMERICAN JOURNAL OF PATHOLOGY LA English DT Article ID RESPIRATORY-DISTRESS SYNDROME; TUMOR-NECROSIS-FACTOR; HYDROSTATIC PULMONARY-EDEMA; INFLAMMATORY CYTOKINES; LIGAND EXPRESSION; INTERFERON-GAMMA; IFN-GAMMA; RABBIT LUNGS; FACTOR-ALPHA; TNF-ALPHA AB The Fas (CD95)/Fas ligand (CD178) system plays an important role in epithelial damage during the acute respiratory distress syndrome. The goal of this study was to determine whether proximal and distal human lung epithelial cells differ in their sensitivity to Fas ligand (rh-sFasL), and whether the response of lung epithelium to Fas ligation is modulated by proinflammatory cytokines. Although the expression of both Fas message and protein was similar in proximal and distal lung epithelial cells, only distal cells became apoptotic when exposed to serial dilutions of rh-sFasL. Stimulation with tumor necrosis factor-alpha, interleukin-1beta, or interferon-gamma significantly increased the sensitivity of proximal cells to rh-sFasL, and exposure to either tumor necrosis factor-alpha or interferon-gamma enhanced the sensitivity of distal cells to Fas ligation. These findings suggest that in normal human lungs, the responses of the epithelium to Fas ligation become more pronounced from proximal to distal locations. Furthermore, proinflammatory cytokines sensitize lung epithelium to Fas-induced death. These findings are relevant for understanding the role of the Fas/FasL system in acute lung injury, in which epithelial damage occurs primarily in distal airway and alveolar epithelium, whereas sFasL is present throughout the airspaces. C1 Vet Affairs Puget Sound Hlth Care Syst, Med Res Serv, Seattle, WA USA. Univ Washington, Sch Med, Dept Med, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Med, Div Allergy & Infect Dis, Seattle, WA 98195 USA. RP Martin, TR (reprint author), Seattle Vet Affairs Med Ctr, 151L,1660 S Columbian Way, Seattle, WA 98108 USA. EM trmartin@u.washington.edu FU NHLBI NIH HHS [K08 HL070840, HL 70840-01, R01 HL062995, HL62995, HL30542] NR 39 TC 44 Z9 52 U1 0 U2 1 PU AMER SOC INVESTIGATIVE PATHOLOGY, INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3993 USA SN 0002-9440 J9 AM J PATHOL JI Am. J. Pathol. PD JUN PY 2004 VL 164 IS 6 BP 1949 EP 1958 DI 10.1016/S0002-9440(10)63755-8 PG 10 WC Pathology SC Pathology GA 823HK UT WOS:000221601000009 PM 15161631 ER PT J AU Figlewicz, DP Zavosh, A Sexton, T Neumaier, JF AF Figlewicz, DP Zavosh, A Sexton, T Neumaier, JF TI Catabolic action of insulin in rat arcuate nucleus is not enhanced by exogenous "tub" expression SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM LA English DT Article DE food intake; body weight; hypothalamus ID HERPES-SIMPLEX-VIRUS; MOLECULAR-CLONING; ADIPOSITY SIGNALS; MESSENGER-RNA; FOOD-INTAKE; GENE; MOUSE; OBESITY; PROTEINS; MUTATION AB The central nervous system (CNS) protein "tub" has been identified from the genetically obese "tubby" mouse. Although the native function of tub in situ is not understood, cell-based studies suggest that one of its roles may be as an intracellular signaling target for insulin. In normal animals, insulin acts at the hypothalamic arcuate nucleus (ARC) to regulate energy balance. Here we used a Herpes Simplex viral expression system to evaluate whether tub overexpression in the ARC of normal rats enhances this action of insulin. In chow-fed rats, tub overexpression had no effect on insulin action. In rats fed a high-fat diet snack in addition to chow, simulating the diet of Westernized societies, the body weight regulatory action of insulin was impaired, and tub overexpression further impaired insulin action. Thus an excess of tub at the ARC does not enhance the in vivo effectiveness of insulin and is not able to compensate for the "downstream" consequences of a high-fat diet to impair CNS body weight regulatory mechanisms. C1 Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Univ Washington, Harborview Med Ctr, Dept Psychiat & Behav Sci, Seattle, WA 98104 USA. RP Figlewicz, DP (reprint author), VA Puget Sound Hlth Care Syst, Metab Endocrinol, 151,1660 So Columbian Way, Seattle, WA 98108 USA. EM latte@u.washington.edu OI Sexton, Timothy/0000-0002-8821-880X FU NIDDK NIH HHS [DK-R01-40963]; NIMH NIH HHS [MH-63303] NR 32 TC 8 Z9 8 U1 0 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1849 J9 AM J PHYSIOL-ENDOC M JI Am. J. Physiol.-Endocrinol. Metab. PD JUN PY 2004 VL 286 IS 6 BP E1004 EP E1010 DI 10.1152/ajpendo.00427.2003 PG 7 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA 823ZU UT WOS:000221653900020 PM 14749205 ER PT J AU Hirokawa, M Furukawa, O Guth, PH Engel, E Kaunitz, JD AF Hirokawa, M Furukawa, O Guth, PH Engel, E Kaunitz, JD TI Low-dose PGE(2) mimics the duodenal secretory response to luminal acid in mice SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY LA English DT Article DE luminal acid exposure; in vivo simulation; intestinal ion transport ID STIMULATED ALKALINE SECRETION; BICARBONATE SECRETION; RABBIT DUODENUM; HCO3-SECRETION; RAT; MUCOSA; PROSTAGLANDIN; TRANSPORT; INJURY; INVIVO AB Luminal exposure to concentrated acid, the most accepted physiological stimulus for duodenal bicarbonate secretion (DBS), cannot be used with in vitro preparations due to potential tissue damage. We thus examined whether exposure to PGE(2), a well-characterized physiological duodenal secretagogue, could mimic the effects of acid perfusion. DBS was measured in C57/BL mice by pH-stat/back-titration and measurement of total dissolved CO2 concentration ([CO2](t)). Anion transport inhibitor DIDS, anion channel inhibitor 5-nitro-2-(3-phenylpropylamino) benzoic acid (NPPB), carbonic anhydrase inhibitor methazolamide, and nonselective cyclooxygenase inhibitor indomethacin were used to inhibit separate components of HCO3- secretory pathway. Baseline DBS was not altered by exposure to methazolamide (0.1 mM) but was slightly reduced by DIDS (0.5 mM). DBS and [CO2](t) increased after acid and PGE(2) exposure. DIDS ( 0.5 mM) and NPPB (0.2 mM) abolished acid-induced DBS increase. Methazolamide ( 0.1 mM) and DIDS inhibited acid-induced [CO2](t) increase. DIDS, NPPB, or methazolamide had little effect on DBS in response to high concentration PGE(2) (100 mug/ml). Low concentration PGE(2) (1 mug/ml) increased DBS that was inhibited by DIDS, NPPB, and methazolamide. Pretreatment with indomethacin (5 mg/kg) inhibited DBS induced by acid exposure but not by PGE(2). High-dose PGE(2) substantially increases DBS by a mechanism that appears to be different than secretory response to luminal acid perfusion. Secretory response to low-dose PGE(2), at least in terms of inhibitor profile, closely resembles secretion in response to perfusion of physiological acid concentrations and may be a useful stimulus for in vitro study of DBS in isolated mouse duodenum. C1 Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA 90073 USA. Ctr Ulcer Res & Educ, Digest Dis Res Ctr, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Biomath, Los Angeles, CA 90024 USA. Brentwood Biomed Res Inst, Los Angeles, CA 90073 USA. RP Kaunitz, JD (reprint author), W Los Angeles Vet Affairs Med Ctr, Bldg 114,Rm 217,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jake@ucla.edu FU NIDDK NIH HHS [R01 DK-54221] NR 22 TC 12 Z9 12 U1 1 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1857 J9 AM J PHYSIOL-GASTR L JI Am. J. Physiol.-Gastroint. Liver Physiol. PD JUN PY 2004 VL 286 IS 6 BP G891 EP G898 DI 10.1152/ajpgi.00458.2003 PG 8 WC Gastroenterology & Hepatology; Physiology SC Gastroenterology & Hepatology; Physiology GA 818UE UT WOS:000221269200003 PM 14764447 ER PT J AU Li, W Knowlton, D Van Winkle, DM Habecker, BA AF Li, W Knowlton, D Van Winkle, DM Habecker, BA TI Infarction alters both the distribution and noradrenergic properties of cardiac sympathetic neurons SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE tyrosine hydroxylase; norepinephrine transporter; myocardial infarction ID TRANSMURAL MYOCARDIAL-INFARCTION; GANGLIONIC TYROSINE-HYDROXYLASE; PREGANGLIONIC NERVE-STIMULATION; VASOACTIVE-INTESTINAL-PEPTIDE; LEUKEMIA INHIBITORY FACTOR; NOREPINEPHRINE TRANSPORTER; RAT-HEART; NEUROPEPTIDE EXPRESSION; CATECHOLAMINE RELEASE; DOWN-REGULATION AB Regional changes occur in the sympathetic innervation of the heart after myocardial infarction (MI), including loss of norepinephrine ( NE) uptake and depletion of neuronal NE. This apparent denervation is accompanied by increased cardiac NE spillover. One potential explanation for these apparently contradictory findings is that the sympathetic neurons innervating the heart are exposed to environmental stimuli that alter neuronal function. To understand the changes that occur in the innervation of the heart after MI, immunohistochemical, biochemical, and molecular analyses were carried out in the heart and stellate ganglia of control and MI rats. Immunohistochemistry with panneuronal markers revealed extensive denervation in the left ventricle (LV) below the infarct, but sympathetic nerve fibers were retained in the base of the heart. Western blot analysis revealed that tyrosine hydroxylase (TH) expression ( normalized to a panneuronal marker) was increased significantly in the base of the heart and in the stellate ganglia but decreased in the LV below the MI. NE transporter ( NET) binding sites, normalized to total protein, were unchanged, except in the LV, where [H-3]nisoxetine binding was decreased. TH mRNA was increased significantly in the left and right stellate ganglia after MI, while NET mRNA was not. In the base of the heart, increased TH coupled with no change in NET may explain the increase in extracellular NE observed after MI. Coupled with substantial denervation in the LV, these changes likely contribute to the onset of cardiac arrhythmias. C1 Portland Vet Affairs Med Ctr, Anesthesiol Serv, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Anesthesiol, Portland, OR 97239 USA. RP Habecker, BA (reprint author), Oregon Hlth Sci Univ, Dept Physiol & Pharmacol, L334,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM habecker@ohsu.edu FU NHLBI NIH HHS [HL 68231, R01 HL068231] NR 43 TC 52 Z9 56 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD JUN PY 2004 VL 286 IS 6 BP H2229 EP H2236 DI 10.1152/ajpheart.00768.2003 PG 8 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA 821QQ UT WOS:000221477600024 PM 14726300 ER PT J AU Rao, VU Shiraishi, H McDermott, PJ AF Rao, VU Shiraishi, H McDermott, PJ TI PKC-epsilon regulation of extracellular signal-regulated kinase: a potential role in phenylephrine-induced cardiocyte growth SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE heart; hypertrophy; cell signaling; mitogen-activated protein kinase ID RAT VENTRICULAR MYOCYTES; ACTIVATED PROTEIN-KINASES; INDUCED CARDIOMYOCYTE HYPERTROPHY; C-EPSILON; CARDIAC-HYPERTROPHY; DIFFERENTIAL ACTIVATION; PRESSURE-OVERLOAD; HEART; TRANSLOCATION; ENDOTHELIN-1 AB Hypertrophic growth of cardiac muscle is dependent on activation of the PKC-epsilon isoform. To define the effectors of PKC-epsilon involved in growth regulation, recombinant adenoviruses were used to overexpress either wild-type PKC-epsilon (PKC-epsilon/WT) or dominant negative PKC-epsilon (PKC-epsilon/DN) in neonatal rat cardiocytes. PKC-epsilon/DN inhibited acute activation of PKC-epsilon produced in response to phorbol ester and reduced ERK1/2 activity as measured by the phosphorylation of p42 and p44 isoforms. The inhibitory effects were specific to PKC-epsilon because PKC-epsilon/DN did not prevent translocation of either PKC-epsilon or PKC-epsilon. Overexpression of PKC-epsilon/DN blunted the acute increase in ERK1/2 phorphorylation induced by the alpha(1)-adrenergic agonist phenylephrine (PE). Inhibition of PKC-delta with rottlerin potentiated the effects of PE on ERK1/2 phosphorylation. PKC-epsilon/DN adenovirus also blocked cardiocyte growth as measured after 48 h of PE treatment, although the multiplicity of infection was lower than that required to block acute ERK1/2 activation. PE activated p38 mitogen-activated protein kinase as measured by its phosphorylation, but the response was not blocked by PKC inhibitors or by overexpression of PKC-epsilon/DN. Taken together, these studies show that the hypertrophic agonist PE regulates ERK1/2 activity in cardiocytes by a pathway dependent on PKC-epsilon and that PE-induced growth is mediated by PKC-epsilon. C1 Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Div Cardiol, Charleston, SC 29425 USA. Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC 29425 USA. RP McDermott, PJ (reprint author), 303 Thurmond Bldg,114 Doughty St, Charleston, SC 29403 USA. EM mcdermp@musc.edu FU NHLBI NIH HHS [P01 HL 48788] NR 43 TC 11 Z9 11 U1 0 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD JUN PY 2004 VL 286 IS 6 BP H2195 EP H2203 DI 10.1152/ajpheart.00475.2003 PG 9 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA 821QQ UT WOS:000221477600020 PM 14975926 ER PT J AU Moriyama, K Ishizaka, A Nakamura, M Kubo, H Kotani, T Yamamoto, S Ogawa, EN Kajikawa, O Frevert, CW Kotake, Y Morisaki, H Koh, H Tasaka, S Martin, TR Takeda, J AF Moriyama, K Ishizaka, A Nakamura, M Kubo, H Kotani, T Yamamoto, S Ogawa, EN Kajikawa, O Frevert, CW Kotake, Y Morisaki, H Koh, H Tasaka, S Martin, TR Takeda, J TI Enhancement of the endotoxin recognition pathway by ventilation with a large tidal volume in rabbits SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY LA English DT Article DE acute lung injury; ventilator-induced lung injury ID INDUCED LUNG INJURY; RESPIRATORY-DISTRESS-SYNDROME; LIPOPOLYSACCHARIDE-BINDING-PROTEIN; NECROSIS-FACTOR-ALPHA; MECHANICAL VENTILATION; ALVEOLAR; CYTOKINES; CD14; MICE; GENE AB Ventilation with a small tidal volume (V-t) is associated with better clinical outcomes than with a large V-t, particularly in critical settings, including acute lung injury. To determine whether Vt influences the lipopolysaccaharide (LPS) recognition pathway, we studied CD14 expression in rabbit lungs and the release of TNF-alpha by cultured alveolar macrophages after 240 min of ventilation with a large ( 20 ml/kg) vs. a small ( 5 ml/kg) V-t. We also applied small or large Vt to lungs instilled with 50 mug/kg of LPS. The alveolar macrophages collected after large V-t ventilation revealed a 20-fold increase in LPS-induced TNF-alpha release compared with those collected after small V-t ventilation, whereas TNF-alpha was undetectable without LPS stimulation. In animals ventilated with a large V-t, the expression of CD14 mRNA in whole lung homogenates and the expression of CD14 protein on alveolar macrophages, assessed by immunohistochemistry, were both significantly increased in the absence of LPS stimulation. A large V-t applied to LPS-instilled lungs increased the pulmonary albumin permeability and TNF-alpha release into the plasma. These results suggest that mechanical stress caused by a large Vt sensitizes the lungs to endotoxin, a phenomenon that may occur partially via the upregulation of CD14. C1 Tokyo Elect Power Co Hosp, Dept Med, Shinjuku Ku, Tokyo 1600016, Japan. Keio Univ, Sch Med, Dept Anesthesiol, Tokyo 1608582, Japan. Keio Univ, Sch Med, Dept Med, Tokyo 1608582, Japan. Va Puget Sound Med Ctr, US Dept Vet Affairs, Med Res Serv, Seattle, WA 98108 USA. Univ Washington, Dept Med, Div Pulm & Crit Care Med, Seattle, WA 98108 USA. Tohoku Univ, Sch Med, Dept Geriatr & Resp Med, Sendai, Miyagi 9808574, Japan. RP Ishizaka, A (reprint author), Tokyo Elect Power Co Hosp, Dept Med, Shinjuku Ku, 9-2 Shinanomachi, Tokyo 1600016, Japan. EM ishiz@attglobal.net RI Morisaki, Hiroshi/J-5960-2013; Kubo, Hiroshi/B-2760-2009 OI Kubo, Hiroshi/0000-0001-6097-4542 FU NHLBI NIH HHS [HL-30542] NR 27 TC 32 Z9 32 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1040-0605 J9 AM J PHYSIOL-LUNG C JI Am. J. Physiol.-Lung Cell. Mol. Physiol. PD JUN PY 2004 VL 286 IS 6 BP L1114 EP L1121 DI 10.1152/ajplung.00296.2003 PG 8 WC Physiology; Respiratory System SC Physiology; Respiratory System GA 819NM UT WOS:000221321700005 PM 14633514 ER PT J AU Mojica, WA Suttorp, MJ Sherman, SE Morton, SC Roth, EA Maglione, MA Rhodes, SL Shekelle, PG AF Mojica, WA Suttorp, MJ Sherman, SE Morton, SC Roth, EA Maglione, MA Rhodes, SL Shekelle, PG TI Smoking-cessation interventions by type of provider - A meta-analysis SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID NICOTINE CHEWING-GUM; ACUTE MYOCARDIAL-INFARCTION; RANDOMIZED CONTROLLED TRIAL; SELF-HELP MATERIALS; GENERAL-PRACTICE; STOP SMOKING; FINANCIAL INCENTIVES; CIGARETTE-SMOKING; HOSPITAL PATIENTS; ADVICE AB Objective: To synthesize the evidence on the effectiveness of smoking-cessation interventions by type of provider. Methods: A random effects meta-regression was estimated to examine the effect of provider and whether the intervention contained nicotine replacement therapy (NRT), on the intervention's relative risk of quitting as compared to placebo or usual care from studies published in databases from inception to 2000. Thirty additional studies not included in the previous 1996 and 2000 U.S. Public Health Service clinical practice guidelines were used to provide the most comprehensive analysis to date of the comparative effectiveness of different types of providers in interventions for smoking cessation that have been published. Results: The effectiveness without NRT follows: psychologist (1.94, 95% confidence interval [Cl]: 1.04-3.62); physician (1.87, CI=1.42-2.45); counselor (1.82, CI=0.84-3.96); nurse (1.76, CI=1.21-2.57); unknown (1.27, CI=0.57-2.82); other (1.18, CI=0.67-2.10); and self-help (1.28, CI=0.89-1.82). Effectiveness of most providers increased by almost twofold with the use of NRT. Conclusions: Smoking-cessation interventions without NRT delivered by psychologists, physicians, or nurses are all effective. NRT increases the effectiveness of most providers. C1 RAND Corp, So Calif Evidence Based Practice Ctr, Hlth Div, Santa Monica, CA 90407 USA. Greater Los Angeles Vet Adam Helathcare Syst, So Calif Avidence Baseed Practice Ctr, Dept Med, Los Angeles, CA USA. RP Mojica, WA (reprint author), RAND Corp, So Calif Evidence Based Practice Ctr, Hlth Div, 1700 Main St,POB 2138, Santa Monica, CA 90407 USA. EM Walter_Mojica@rand.org NR 68 TC 37 Z9 39 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD JUN PY 2004 VL 26 IS 5 BP 391 EP 401 DI 10.1016/j.ampere.2004.02.014 PG 11 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 824IU UT WOS:000221680800003 PM 15165655 ER PT J AU Weiner, M Bock, N Peloquin, CA Burman, WJ Khan, A Vernon, A Zhao, Z Weis, S Sterling, TR Hayden, K Goldberg, S AF Weiner, M Bock, N Peloquin, CA Burman, WJ Khan, A Vernon, A Zhao, Z Weis, S Sterling, TR Hayden, K Goldberg, S CA Tuberculosis Trials Consortium TI Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE pharmacokinetics; rifapentine; treatment; tuberculosis ID MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; CONTINUATION PHASE; RIFAMPICIN; REGIMENS; TRIAL AB The pharmacokinetics of rifapentine at 600, 900, and 1,200 mg were studied during once-weekly continuation phase therapy in 35 patients with tuberculosis. Mean area under the plasma concentration-time curve (AUC(0-infinity)) increased significantly with dose (rifapentine AUC(0-infinity): 296, 410, and 477 mug (.) hour/ml at 600, 900, and 1,200 mg, respectively; p = 0.02 by linear regression). In multivariate stepwise regression analyses, AUC(0-infinity) values for rifapentine and the active 25-desacetyl metabolite were associated with drug dose and plasma albumin concentration, and were lower among men and among white individuals. Fifty-four percent of patients had total (free and protein-bound) plasma concentrations of rifapentine and of desacetyl rifapentine detected for more than 36 hours after clearance of concurrently administered isoniazid. Serious adverse effects of therapy in these study patients were infrequent (11 of 35 cases; 3%) and not linked with higher rifapentine AUC(0-infinity) or peak concentration. The present pharmacokinetic study supports further trials to determine the optimal rifapentine dose for treatment of tuberculosis. C1 S Texas Vet Hlth Care Syst, Dept Med, San Antonio, TX 78229 USA. Univ N Texas, Hlth Sci Ctr, Ft Worth, TX USA. Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. Natl Jewish Med & Res Ctr, Denver, CO USA. Denver Publ Hlth Dept, Denver, CO USA. Johns Hopkins Univ, Sch Med, Baltimore, MD USA. Arkansas Dept Hlth, Little Rock, AR 72205 USA. Seattle King Cty Dept Publ Hlth, Seattle, WA USA. RP Weiner, M (reprint author), S Texas Vet Hlth Care Syst, Dept Med, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM weiner@uthscsa.edu FU NCRR NIH HHS [M01-RR-01346] NR 23 TC 54 Z9 58 U1 0 U2 4 PU AMER THORACIC SOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019-4374 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD JUN 1 PY 2004 VL 169 IS 11 BP 1191 EP 1197 DI 10.1164/rccm.200311-1612OC PG 7 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 824HN UT WOS:000221677400007 PM 14962821 ER PT J AU Song, YL Liu, CX McTeague, M Summanen, P Finegold, SM AF Song, YL Liu, CX McTeague, M Summanen, P Finegold, SM TI Clostridium bartlettii sp nov., isolated from human faeces SO ANAEROBE LA English DT Article DE Clostridium bartlettii sp nov.; faeces; 16S rRNA; phylogery; taxonomy ID 16S RIBOSOMAL-RNA; SEQUENCE-ANALYSIS; COMMUNITIES; BACTERIUM; REVEALS; ACID; GUT AB Seven obligately anaerobic, Gram-positive, rod-shaped, spore-forming organisms isolated from human faecal specimens were characterized using phenotypic and molecular taxonomic methods. Strains of the unidentified bacterium used carbohydrates as fermentable substrates, producing acetic acid, isovaleric acid and phenylacetic acid (PAA) as the major products of glucose metabolism, and possessed a G + C content of approximately 29.8 mol%. Comparative 16S rRNA gene sequencing showed that the 7 strains were genetically highly related to each other (displaying > 99.5% sequence similarity) and represent a previously unknown sub-line within the Clostridium Cluster XL The closest described species to the novel bacterium is Clostridium glycolicum, although a 16S rRNA sequence divergence of 4% demonstrates that they represent different species. Genomic DNA-DNA pairing studies confirmed the separateness of the unknown species and C. glycolicum (30.6% similarity between the proposed type strain of the novel species, WAL 16138, and C. glycolicum ATCC 14880(T)). Based on morphologic, phenotypic and phylogenetic evidence, it is therefore proposed that the unknown bacterium be classified as C bartlettii sp. nov. The type strain of C bartlettii is WAL 16138 T (= ATCCBAA-827(T) = CCUG48940(T)). (C) 2004 Elsevier Ltd. All rights reserved. C1 W Los Angeles Vet Affairs Med Ctr, Res Serv, Los Angeles, CA 90073 USA. W Los Angeles Vet Affairs Med Ctr, Clin Microbiol Lab, Los Angeles, CA 90073 USA. W Los Angeles Vet Affairs Med Ctr, Infect Dis Sect, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90024 USA. RP Song, YL (reprint author), W Los Angeles Vet Affairs Med Ctr, Res Serv, 11301 Wilshire Blvd,Bldg 304,Room E3-227, Los Angeles, CA 90073 USA. EM yulis1@yahoo.com NR 23 TC 16 Z9 16 U1 1 U2 8 PU ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 1075-9964 J9 ANAEROBE JI Anaerobe PD JUN PY 2004 VL 10 IS 3 BP 179 EP 184 DI 10.1016/j.anaerobe.2004.04.004 PG 6 WC Microbiology SC Microbiology GA 837HP UT WOS:000222619900005 PM 16701516 ER PT J AU Mittman, BS AF Mittman, BS TI Creating the evidence base for quality improvement collaboratives SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID HEALTH-CARE; UNITED-STATES; FRAMEWORK; LESSONS AB Intensive efforts are under way to improve health care quality and safety throughout the United States and abroad. Many of these efforts use the quality improvement collaborative method, an approach emphasizing collaborative learning and exchange of insights and support among a set of health care organizations. Unfortunately, the widespread acceptance and reliance on this approach are based not on solid evidence but on shared beliefs and anecdotal affirmations that may overstate the actual effectiveness of the method. More effective use of the collaborative method will require a commitment by users, researchers, and other stakeholders to rigorous, objective evaluation and the creation of a valid, useful knowledge and evidence base. Development of this evidence base will require improved conceptions of the nature of quality problems, quality improvement processes, and the types of research needed to elucidate these processes. Researchers, journal editors, and funding agencies must also cooperate to ensure that published evaluations are relevant, comprehensive, and cumulative. C1 Vet Affairs Greater Los Angeles Healthcare Syst 1, Ctr Study Healthcare Provider Behav, Sepulveda, CA 91343 USA. Vet Affairs Qual Enchancement Res Initiat, Washington, DC USA. RP Mittman, BS (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst 1, Ctr Study Healthcare Provider Behav, 16111 Plummer St, Sepulveda, CA 91343 USA. EM Brian.Mittman@med.va.gov NR 16 TC 154 Z9 155 U1 1 U2 8 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD JUN 1 PY 2004 VL 140 IS 11 BP 897 EP 901 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 824IS UT WOS:000221680600006 PM 15172904 ER PT J AU O'Herrin, JK Fost, N Kudsk, KA AF O'Herrin, JK Fost, N Kudsk, KA TI Health insurance portability accountability act (HIPAA) regulations - Effect on medical record research SO ANNALS OF SURGERY LA English DT Article ID CLINICAL-RESEARCH; PRIVACY RULE; CARE AB Objective: To evaluate the effect of impending HIPAA regulations on Applications for Exemptions from Institutional Review Board (IRB) approval. Summary Background Data: HIPAA was implemented to reduce potential for misuse of personal information and restricts access to medical records by insurers, employers, and clinical researchers. We hypothesized that HIPAA regulations adversely impact medical records research. Methods: The UW-Madison Human Subjects Committee database was accessed to evaluate success and delays in processing Applications for Exemption between September 1999 and March 2003. The number of protocols submitted, number of required revisions, and number considered nonexempt (requiring full IRB review) were determined. Results: Prior to 2000, applications for medical records research were rare (11 applications in 1999-2000). In anticipation of the implementation of HIPAA regulations, a new application process was instituted in 2001. During that year, 92 of 103 were approved by an expedited process with few requiring full IRB approval. In 2002 to 2003, submissions increased to 199 and approval without revision dropped to 59% (P < 0.0001) as the number requiring revision (25%) and full IRB approval (16%) increased significantly (P < 0.0001 and P < 0.05, respectively). Of the 31 requiring full IRB approval, 7 were pursued while 24 (77%) were abandoned. Conclusion: HIPAA appears to inhibit medical record and database research. Ethical considerations in healthcare research are paramount, but current HIPAA implementation strategies increase workload for HSC and researchers, and increase the dropout rate for proposed studies when investigators are unable or unwilling to meet the regulatory requirements. It is unclear whether or to what degree the new requirements add to protection of privacy. Studies designed to investigate the costs and effects on quantity and/or quality of research should be prospectively implemented. C1 Univ Wisconsin, Dept Surg, Madison, WI USA. Univ Wisconsin, Dept Pediat, Madison, WI USA. William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, Madison, WI 53705 USA. RP Kudsk, KA (reprint author), Univ Wisconsin Hosp & Clin, Dept Surg, Clin Sci Ctr H4 736, 600 Highland Ave, Madison, WI 53792 USA. EM Kudsk@surgery.wisc.edu NR 8 TC 34 Z9 35 U1 3 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-4932 J9 ANN SURG JI Ann. Surg. PD JUN PY 2004 VL 239 IS 6 BP 772 EP 776 DI 10.1097/01.sla.0000128307.98274.dc PG 5 WC Surgery SC Surgery GA 823OM UT WOS:000221622600007 PM 15166956 ER PT J AU Reavis, KM Morris, CD Gopal, DV Hunter, JG Jobe, BA AF Reavis, KM Morris, CD Gopal, DV Hunter, JG Jobe, BA TI Laryngopharyngeal reflux symptoms better predict the presence of esophageal adenocarcinoma than typical gastroesophageal reflux symptoms SO ANNALS OF SURGERY LA English DT Article ID PHARYNGEAL ACID REFLUX; BARRETTS-ESOPHAGUS; POSTERIOR LARYNGITIS; RISK-FACTORS; HIATAL-HERNIA; UNITED-STATES; SURVEILLANCE; PREVALENCE; DYSPLASIA; DISEASE AB Objective: To determine whether the presence of laryngopharyngeal reflux symptoms is associated with the presence of esophageal adenocarcinoma (EAC). Background: Most patients diagnosed with EAC have incurable disease at the time of detection. The majority of these patients are unaware of the presence of Barrett's esophagus prior to cancer diagnosis and many do not report typical symptoms of gastroesophageal reflux disease (GERD). This suggests that the current GERD symptom-based screening paradigm may be inadequate. Data support a causal relation between complicated GERD and laryngopharyngeal reflux symptoms. We theorize that laryngopharyngeal reflux symptoms are not recognized expeditiously, resulting in chronic esophageal injury and an unrecognized progression of Barrett's esophagus to EAC. Methods: This is a case-comparison (control) study. Cases were patients diagnosed with EAC (n = 63) between 1997 and 2002. Three comparison groups were selected: 1) Barrett's esophagus patients without dysplasia (n = 50), 2) GERD patients without Barrett's esophagus (n = 50), and 3) patients with no history of GERD symptoms or antisecretory medication use (n = 56). The risk factors evaluated included demographics, medical history, lifestyle variables, and laryngopharyngeal reflux symptoms. Typical GERD symptoms and antisecretory medication use were recorded. Multivariate analysis of demographics, comorbid risk factors, and symptoms was performed with logistic regression to provide odds ratios for the probability of EAC diagnosis. Results: The prevalence of patients with laryngopharyngeal reflux symptoms was significantly greater in the cases than comparison groups (P = 0.0005). The prevalence of laryngopharyngeal reflux symptoms increased as disease severity progressed from the non-GERD comparison group (19.6%) to GERD (26%), Barrett's esophagus (40%), and EAC patients (54%). Symptoms of GERD were less prevalent in cases (43%) when compared with Barrett's esophagus (66%) and GERD (86%) control groups (P < 0.001). Twenty-seven percent (17 of 63) of EAC patients never had GERD or laryngopharyngeal reflux symptoms. Fifty-seven percent of EAC patients presented without ever having typical GERD symptoms. Chronic cough, diabetes, and age emerged as independent risk factors for the development of EAC. Conclusions: Symptoms of laryngopharyngeal reflux are more prevalent in patients with EAC than typical GERD symptoms and may represent the only sign of disease. Chronic cough is an independent risk factor associated with the presence of EAC. Addition of laryngopharyngeal reflux symptoms to the current Barrett's screening guidelines is warranted. C1 Portland VA Med Ctr, Surg Serv, Portland, OR 97207 USA. Oregon Hlth Sci Univ, Dept Surg, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA. Univ Wisconsin, Sect Gastroenterol & Hepatol, Madison, WI 53706 USA. RP Jobe, BA (reprint author), Portland VA Med Ctr, Surg Serv, P3GS,POB 1034, Portland, OR 97207 USA. EM Blair.Jobe@med.va.gov FU NCI NIH HHS [R03 CA105959-01, R03 CA105959]; NIDDK NIH HHS [K23 DK066165-01, K23 DK066165] NR 36 TC 51 Z9 53 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-4932 J9 ANN SURG JI Ann. Surg. PD JUN PY 2004 VL 239 IS 6 BP 849 EP 856 DI 10.1097/01.sla.0000128303.05898.ee PG 8 WC Surgery SC Surgery GA 823OM UT WOS:000221622600022 PM 15166964 ER PT J AU Oberley, TD AF Oberley, TD TI Mitochondria, manganese superoxide dismutase, and cancer SO ANTIOXIDANTS & REDOX SIGNALING LA English DT Editorial Material ID HYDROGEN-PEROXIDE; OXIDATIVE DAMAGE; MUTANT MICE; OVEREXPRESSION; PROLIFERATION; ANTIOXIDANT; MODULATION; ENZYMES; MODEL C1 William S Middleton Mem Vet Adm Med Ctr, Pathol & Lab Med Serv, Madison, WI 53705 USA. Univ Wisconsin, Sch Med, Dept Pathol & Lab Med, Madison, WI 53706 USA. RP William S Middleton Mem Vet Adm Med Ctr, Pathol & Lab Med Serv, Room A35,2500 Overlook Terrace, Madison, WI 53705 USA. EM toberley@facstaff.wisc.edu NR 33 TC 23 Z9 26 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1523-0864 EI 1557-7716 J9 ANTIOXID REDOX SIGN JI Antioxid. Redox Signal. PD JUN PY 2004 VL 6 IS 3 BP 483 EP 487 DI 10.1089/152308604773934242 PG 5 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 825QQ UT WOS:000221773500002 PM 15130275 ER PT J AU Kim, A Zhong, WX Oberley, TD AF Kim, A Zhong, WX Oberley, TD TI Reversible modulation of cell cycle kinetics in NIH/3T3 mouse fibroblasts by inducible overexpression of mitochondrial manganese superoxide dismutase SO ANTIOXIDANTS & REDOX SIGNALING LA English DT Article ID ANTIOXIDANT ENZYME LEVELS; PROSTATE CARCINOMA-CELLS; PARAQUAT RESISTANCE; HYDROGEN-PEROXIDE; GROWTH; INHIBITION; STATE; TUMOR; DNA; REPRESSOR AB To study the mechanism(s) by which manganese-containing superoxide dismutase (MnSOD) mediates cellular growth inhibition, an inducible retroviral vector system regulated by the lac repressor was used to overexpress MnSOD protein in NIH/3T3 cells. Increased MnSOD activity led to decreased cell growth due to prolonged cell cycle transition times in G(1) and S phases without significant changes in G(2)/M phase. Changes in cell cycle transition time were reversible and tightly correlated with MnSOD levels. A transient increase of reactive oxygen species and concomitant decrease in mitochondrial membrane potential were documented following MnSOD induction. N-Acetyl-L-cysteine prevented growth inhibition by MnSOD. Our data suggest that MnSOD may serve a physiological function of regulating cell cycle progression through its prooxidant activity of generating hydrogen peroxide, resulting in coordination of mitochondrial redox state and cellular proliferation. C1 William S Middleton Mem Vet Adm Med Ctr, Pathol & Lab Med Serv, Madison, WI 53705 USA. Univ Wisconsin, Sch Med, Mol & Environm Toxicol Ctr, Madison, WI 53706 USA. Univ Wisconsin, Sch Med, Dept Pathol & Lab Med, Madison, WI 53706 USA. RP William S Middleton Mem Vet Adm Med Ctr, Pathol & Lab Med Serv, Room A35,2500 Overlook Terrace, Madison, WI 53705 USA. EM toberley@facstaff.wisc.edu FU NCI NIH HHS [CA14520-29] NR 32 TC 23 Z9 23 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1523-0864 EI 1557-7716 J9 ANTIOXID REDOX SIGN JI Antioxid. Redox Signal. PD JUN PY 2004 VL 6 IS 3 BP 489 EP 500 DI 10.1089/152308604773934251 PG 12 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 825QQ UT WOS:000221773500003 PM 15130276 ER PT J AU Ridnour, LA Oberley, TD Oberley, LW AF Ridnour, LA Oberley, TD Oberley, LW TI Tumor suppressive effects of MnSOD overexpression may involve imbalance in peroxide generation versus peroxide removal SO ANTIOXIDANTS & REDOX SIGNALING LA English DT Article ID MANGANESE SUPEROXIDE-DISMUTASE; PROSTATE CARCINOMA-CELLS; SYRIAN-HAMSTER TISSUES; GLUTATHIONE-PEROXIDASE; GLIOMA-CELLS; IMMUNOHISTOCHEMICAL LOCALIZATION; DISC ELECTROPHORESIS; MALIGNANT PHENOTYPE; POLYACRYLAMIDE GELS; KIDNEY DEVELOPMENT AB Manganese superoxide dismutase (MnSOD) activity is generally lower in cancer cells when compared with their normal cell counterparts. Many studies have shown that replacing the diminished MnSOD activity leads to inhibition of the malignant phenotype. We sought to overexpress MnSOD in a chemically transformed, malignant rat cell line with low endogenous MnSOD activity to determine the effect on the malignant phenotype. After MnSOD cDNA transfection, clonal populations were characterized at the molecular level for protein, RNA, and DNA, as well as for in vitro and in vivo growth and in vivo lung metastasis. MnSOD transfectants, which both under- and overexpressed MnSOD protein, were identified. These transfectants demonstrated variations in glutathione peroxidase and catalase activity levels, indicating differences in peroxide-generating versus peroxide-metabolizing enzymes (antioxidant imbalance); these differences were suggestive of alterations in their abilities to metabolize peroxide when compared with the parental cell line. In addition, these transfectants demonstrated reductions in both in vitro and in vivo growth, as well as a reduction in metastatic potential, which correlated with antioxidant imbalance. These results suggest that the tumor suppressive effect of MnSOD overexpression is in part mediated by an antioxidant imbalance resulting in the reduced capacity to metabolize increased levels of intracellular peroxides. C1 Univ Iowa, Dept Radiat Oncol, Free Rad & Radiat Biol Program, Iowa City, IA 52242 USA. William S Middleton Mem Vet Adm Med Ctr, Pathol & Lab Med Serv, Madison, WI 53705 USA. RP Univ Iowa, Dept Radiat Oncol, Free Rad & Radiat Biol Program, Iowa City, IA 52242 USA. FU NCI NIH HHS [CA66081] NR 51 TC 49 Z9 53 U1 1 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1523-0864 EI 1557-7716 J9 ANTIOXID REDOX SIGN JI Antioxid. Redox Signal. PD JUN PY 2004 VL 6 IS 3 BP 501 EP 512 DI 10.1089/152308604773934260 PG 12 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 825QQ UT WOS:000221773500004 PM 15130277 ER PT J AU Zhong, WX Yan, T Webber, MM Oberley, TD AF Zhong, WX Yan, T Webber, MM Oberley, TD TI Alteration of cellular phenotype and responses to oxidative stress by manganese superoxide dismutase and a superoxide dismutase mimic in RWPE-2 human prostate adenocarcinoma cells SO ANTIOXIDANTS & REDOX SIGNALING LA English DT Article ID REACTIVE OXYGEN; VITAMIN-C; IN-VITRO; ANTIOXIDANT ENZYMES; HYDROGEN-PEROXIDE; GLUTATHIONE-PEROXIDASE; MALIGNANT PHENOTYPE; CANCER PREVENTION; BINDING-ACTIVITY; REDOX REGULATION AB To study biologic effects of increased manganese superoxide dismutase (MnSOD) on cell behavior, we overexpressed MnSOD in a human prostate cancer cell line RWPE-2 by cDNA transfection. Stable transfectants of MnSOD showed a two- to threefold increase in MnSOD protein and enzymatic activity and a decrease in growth rate with prolonged cell population doubling times. Western blot analysis showed a 1.5- to twofold increase in the cyclin-dependent kinase inhibitor p21(Waf1) in MnSOD transfectants. Overexpression of MnSOD resulted in a seven- to eightfold increase in reduced glutathione (GSH), 18- to 26-fold increase in oxidized glutathione (GSSG), and a two- to threefold decrease in the ratio of GSH to GSSG. MnSOD-overexpressing cells showed an increase in sensitivity to the cytotoxicity of buthionine sulfoximine, a glutathione-depleting agent, and vitamin C, but a decrease in sensitivity to sodium selenite. Treatment with a superoxide dismutase (SOD) mimic MnTMPyP resulted in similar effects of MnSOD overexpression on cell responses to vitamin C and selenium. These data demonstrate that overexpression of MnSOD or treatment with SOD mimics can result in antioxidant or prooxidant effects in cells, depending on the presence of other antioxidants and prooxidants. MnSOD also has redox regulatory effects on cell growth and gene expression. These findings suggest that MnSOD and SOD mimics have the potential for cancer prevention or treatment. C1 Univ Wisconsin, Sch Med, Dept Pathol & Lab Med, Ctr Clin Sci, Madison, WI 53792 USA. William S Middleton Mem Vet Adm Med Ctr, Pathol & Lab Med Serv, Madison, WI 53705 USA. Univ Hosp Cleveland, Ireland Comprehens Canc Ctr, Dept Radiat Oncol, Cleveland, OH 44106 USA. Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA. Michigan State Univ, Dept Zool, E Lansing, MI 48824 USA. Michigan State Univ, Dept Med, E Lansing, MI 48824 USA. RP Univ Wisconsin, Sch Med, Dept Pathol & Lab Med, Ctr Clin Sci, K4-868,Box 8550,600 Highland Ave, Madison, WI 53792 USA. EM wzhong3@wisc.edu NR 50 TC 29 Z9 30 U1 0 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1523-0864 EI 1557-7716 J9 ANTIOXID REDOX SIGN JI Antioxid. Redox Signal. PD JUN PY 2004 VL 6 IS 3 BP 513 EP 522 DI 10.1089/152308604773934279 PG 10 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 825QQ UT WOS:000221773500005 PM 15130278 ER PT J AU Oberley, TD Xue, Y Zhao, YF Kiningham, K Szweda, LI Clair, DKS AF Oberley, TD Xue, Y Zhao, YF Kiningham, K Szweda, LI Clair, DKS TI In situ reduction of oxidative damage, increased cell turnover, and delay of mitochondrial injury by overexpression of manganese superoxide dismutase in a multistage skin carcinogenesis model SO ANTIOXIDANTS & REDOX SIGNALING LA English DT Article ID EPSILON TRANSGENIC MICE; ANTIOXIDANT ENZYMES; NIH/3T3 FIBROBLASTS; PROTEIN; TUMOR; LOCALIZATION; INHIBITION; CARCINOMA; GROWTH; KIDNEY AB To study early subcellular pathologic changes of tumorigenesis in mouse skin and possible modulation by overexpression of the mitochondrial antioxidant enzyme manganese superoxide dismutase (MnSOD), skin keratinocytes from nontransgenic (Ntg) and transgenic (TgH) mice overexpressing MnSOD topically treated with one dose of 7,12-dimethylbenz(a)anthracene (DMBA) and a subsequent dose of 12-O-tetradecanoylphorbol 13-acetate (TPA) were analyzed in situ for levels of MnSOD and the oxidative damage product 4-hydroxy2-nonenal (4HNE)-modified proteins using specific antibodies and immunogold electron microscopy. At all selected time points analyzed after TPA treatment, there was more MnSOD immunoreactive protein in mitochondria of keratinocytes of TgH mice than Ntg mice. Compared with untreated groups, there was a large increase in 4HNE-modified proteins at 6-24 h after TPA treatment, and this increase was larger in Ntg than TgH mice. Indices of mitosis and apoptosis of keratinocytes were greater in DMBA/TPA-treated TgH than Ntg mouse skin. Mitochondrial injury detected by transmission electron microscopy was delayed in keratinocytes of TgH compared with Ntg mice. The present study demonstrated that overexpression of MnSOD not only protected cells from oxidative damage, but also affected cell turnover kinetics. Thus, previously identified reduction in papilloma formation observed in TgH mice is correlated with mitochondrial events. C1 William S Middleton Mem Vet Adm Med Ctr, Pathol & Lab Med Serv, Madison, WI 53705 USA. Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA. Univ Wisconsin, Sch Med, Dept Pathol & Lab Med, Madison, WI 53706 USA. Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA. RP William S Middleton Mem Vet Adm Med Ctr, Pathol & Lab Med Serv, Room A35,2500 Overlook Terrace, Madison, WI 53705 USA. EM toberley@facstaff.wisc.edu; dstc100@pop.uky.edu FU NCI NIH HHS [CA73599-S2, CA73599] NR 41 TC 14 Z9 15 U1 0 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1523-0864 EI 1557-7716 J9 ANTIOXID REDOX SIGN JI Antioxid. Redox Signal. PD JUN PY 2004 VL 6 IS 3 BP 537 EP 548 DI 10.1089/152308604773934297 PG 12 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 825QQ UT WOS:000221773500007 PM 15130280 ER PT J AU Smith, CO Lipe, HP Bird, TD AF Smith, CO Lipe, HP Bird, TD TI Impact of presymptomatic genetic testing for hereditary ataxia and neuromuscular disorders SO ARCHIVES OF NEUROLOGY LA English DT Article ID LATE-ONSET DISORDERS; DISEASE; DISTRESS; SCALE AB Background: With the exception of Huntington disease, the psychological and psychosocial impact of DNA testing for neurogenetic disorders has not been well studied. Objective: To evaluate the psychosocial impact of genetic testing for autosomal dominant forms of hereditary ataxia and neuromuscular disorders. Patients: Fifty subjects at risk for autosomal dominant forms of spinocerebellar ataxia (n=11), muscular dystrophy (n=28), and hereditary neuropathy (n=12). Design and Setting: A prospective, descriptive, observational study in a university setting of individuals who underwent genetic counseling and DNA testing. Participants completed 3 questionnaires before testing and at regular intervals after testing. The questionnaire set included the Revised Impact of Event Scale, the Hospital Anxiety and Depression Scale, demographic information, and an assessment of attitudes and feelings about genetic testing. Results: Thirty-nine subjects (78%) completed 6 months to 5 years of posttest follow-up. Common reasons for pur-suing genetic testing were to provide an explanation for symptoms, emotional relief, and information for future planning. Thirty-four (68%) had positive and 16 (32%) had negative genetic results. In those with a positive result, 26 (76%) had nonspecific signs or symptoms of the relevant disorder. Forty-two participants (84%) felt genetic testing was beneficial. Groups with positive and negative test results coped well with results. However, 13 subjects (10 with positive and 3 with negative results) reported elevated anxiety levels, and 3 (1 with positive and 2 with negative results) expressed feelings of depression during the follow-up period. The test result was not predictive of anxiety or depression. Conclusions: Most individuals find neurogenetic testing to be beneficial, regardless of the result. Anxiety or depression may persist in some persons with positive or negative test results. Testing can have a demonstrable impact on family planning and interpersonal relationships. Further studies are needed to assess the long-term impact of such testing. C1 Vet Affairs Puget Sound Hlth Care Syst, Dept Geriatr 182, Seattle, WA 98108 USA. Univ Washington, Dept Neurol, Seattle, WA 98195 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Seattle, WA 98108 USA. RP Bird, TD (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Dept Geriatr 182, 1660 S Columbian Way, Seattle, WA 98108 USA. EM tomnroz@u.washington.edu NR 14 TC 30 Z9 30 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0003-9942 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD JUN PY 2004 VL 61 IS 6 BP 875 EP 880 DI 10.1001/archneur.61.6.875 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 827XL UT WOS:000221936900007 PM 15210524 ER PT J AU Fay, BT Boninger, ML Fitzgerald, SG Souza, AL Cooper, RA Koontz, AM AF Fay, BT Boninger, ML Fitzgerald, SG Souza, AL Cooper, RA Koontz, AM TI Manual wheelchair pushrim dynamics in people with multiple sclerosis SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE kinematics; kinetics; multiple sclerosis; rehabilitation; wheelchairs ID PROPULSION; FORCES; BIOMECHANICS; INDIVIDUALS; STRENGTH; KINETICS AB Objectives: To define differences in pushrim dynamics during manual wheelchair propulsion by users with multiple sclerosis (MS) relative to 2 control groups of subjects with spinal cord injury (SCI) and no disability (ND) and to investigate changes in propulsion biomechanics at different speeds and with fatigue. Design: Case-control. Setting: Biomechanics laboratory. Participants: A convenience sample of 42 people, 8 women and 6 men per group. Interventions: Not applicable. Main Outcome Measures: The propulsion pattern, mean maximum speed, percentage of time in push and recovery phases, push angle, push frequency, mean maximum resultant pushrim force, mean work and push cycle, and hand-to-pushrim coupling and decoupling effects. Results: The MS groups tended to use an arcing propulsion pattern more than did the control groups (Pmax=.003). The MS group pushed at a lower mean maximum velocity (v) when allowed to choose the speed of propulsion (nu(MS), .67+/-.20m/s; nu(SCI), 1.10+/-0.23m/s: P=.001), when asked to push at 1m/s (nu(MS), .91+/-.26m/s; nu(SCI), 1.12+/-0.11m/s; nu(ND), 1.05+/-0.13m/s; P=.010). and were unable to maintain a self-selected speed during a 5-minute trial (Deltanu(MS), .15+/-.02m/s; Deltanu(ND), .03+/-.06m/s; P<.001). The MS group spent a higher proportion of time in the push phase of propulsion (Pmax=.001). In general, the MS group had smaller push angles, but push frequencies similar to the controls. Statistically adjusted MS group pushrim forces and work per push measures varied depending on context, but in all trials the MS group displayed a braking effect when grasping and releasing the pushrim. The MS group had declines in most measures when pushing at a self-selected speed for 5 minutes. In all trials, the MS group was more likely to display asymmetry between right and left sides in biomechanic parameters. Conclusions: Manual wheelchair users with MS have difficulty grasping and releasing the pushrim and maintaining speed during a fatigue trial. This likely leads to a slow self-selected speed of propulsion that may not be functional. Clinicians should remember these results when prescribing manual wheelchairs for people with MS. C1 A VA Ctr Excellence, Human Engn Res Labs, Highland Dr Med Ctr, Pittsburgh, PA USA. Univ Pittsburgh, Med Ctr, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. Univ Pittsburgh, Med Ctr, Dept Phys Med & Rehabil, Pittsburgh, PA USA. Univ Alberta, Fac Rehabil Med, Edmonton, AB, Canada. RP Boninger, ML (reprint author), VA Pittsburgh Healthcare Syst, 151R-1,7180 Highland Dr, Pittsburgh, PA 15206 USA. EM boninger@pitt.edu OI Boninger, Michael/0000-0001-6966-919X NR 21 TC 13 Z9 13 U1 3 U2 6 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD JUN PY 2004 VL 85 IS 6 BP 935 EP 942 DI 10.1016/j.apmr.2003.08.093 PG 8 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 826NK UT WOS:000221835600011 PM 15179647 ER PT J AU Shen, WT Kebebew, E Duh, QY Clark, OH AF Shen, WT Kebebew, E Duh, QY Clark, OH TI Predictors of airway complications after thyroidectomy for substernal goiter SO ARCHIVES OF SURGERY LA English DT Article; Proceedings Paper CT 74th Annual Meeting of the Pacific-Coast-Surgical-Association CY FEB 16-18, 2003 CL MONTEREY, CA SP Pacific Coast Surg Assoc ID OPERATIVE MANAGEMENT; RETROSTERNAL GOITER; SURGICAL-TREATMENT AB Hypothesis: Airway complications after thyroidectomy for substernal goiter can be predicted by preoperative symptom profiles, radiologic findings, or other factors. Design: Retrospective review. Settings: A university tertiary care center and a veterans' hospital. Patients: Sixty patients with. substernal goiter who underwent thyroidectomy between 1993 and 2002. Main Outcome Measures: Symptoms, preoperative radiologic findings, extent of thyroid resection, tumor size, and postoperative complications. Results: Dysphagia was the most common preoperative symptom (n = 26), followed by dyspnea (n = 21), orthopnea (n = 13), and hoarseness (n = 6); 18 patients (30%) had superior vena caval obstruction. Thirteen patients (22%) were asymptomatic. Preoperative imaging identified tracheal deviation or compression in 45 patients (75%). Substernal goiter was resected via a cervical approach in 59 patients (98%). Of 47 patients with preoperative symptoms, 41 (87%) reported improvement postoperatively. Seven patients (12%) had postoperative airway complications: I developed a neck hematoma requiring reoperation, and 6 could not be immediately extubated; all 6 were successfully extubated after 1 to 10 days. Patients with airway complications were older (mean +/-SEM, 70.3 +/- 3.6 years vs 61.5 +/- 2.2 years), had larger goiters (mean +/- SEM, 210.7 +/- 37.0 g vs 112.2 +/- 7.7 g), and were more likely to have tracheal compression on preoperative imaging than those who did not have complications (P<.05). Conclusions: Most patients with substernal goiters under-went thyroid resection via a cervical approach with an improvement in symptoms. The few patients who developed postoperative airway complications were older, had larger goiters, and were more likely to have tracheal compression on preoperative imaging than those without airway complications. C1 Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. RP Duh, QY (reprint author), San Francisco Vet Affairs Med Ctr, Surg Serv, 4150 Clement St, San Francisco, CA 94121 USA. EM quan-yang.duh@med.va.gov NR 15 TC 43 Z9 48 U1 1 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0004-0010 J9 ARCH SURG-CHICAGO JI Arch. Surg. PD JUN PY 2004 VL 139 IS 6 BP 656 EP 659 DI 10.1001/archsurg.139.6.656 PG 4 WC Surgery SC Surgery GA 828IG UT WOS:000221966400025 PM 15197094 ER PT J AU Liu, WM Szalai, A Zhao, LM Liu, D Martin, F Kimberly, RP Zhou, T Carter, RH AF Liu, WM Szalai, A Zhao, LM Liu, D Martin, F Kimberly, RP Zhou, T Carter, RH TI Control of spontaneous B lymphocyte autoimmunity with adenovirus-encoded soluble TACI SO ARTHRITIS AND RHEUMATISM LA English DT Article ID NECROSIS-FACTOR FAMILY; MRL-LPR MICE; CELL MATURATION; TNF RECEPTOR; T-CELLS; BAFF; SURVIVAL; DISEASE; LIGAND; MEMBER AB Objective. Serum B lymphocyte stimulator (BLyS) is increased in autoimmune diseases, both in animal models and in humans. This study examined the effect of BLyS blockade in 3 animal models of lupus. Methods. Antibodies and lupus-like disease manifestations were examined in mice after administration of a single injection of an adenoviral construct for the transmembrane activator and CAML interactor receptor (AdTACI) that produces high serum levels of TACI-Fc fusion protein. Results. In C57BL/6 (B6) lpr/lpr mice (B6.lpr/lpr), which were used to model autoimmunity in the absence of severe disease, treatment of younger mice with AdTACI prevented the development of hypergammaglobulinemia. In contrast, use of AdTACI for BLyS blockade had only transient effects on the levels of IgG in normal B6 mice. AdTACI blocked the development of autoantibodies in younger B6.lpr/lpr mice and reversed the production of autoantibodies in older B6.lpr/lpr mice, and also reduced the numbers of splenic plasma cells. In MRL.lpr/lpr mice, which were used to examine disease manifestations, AdTACI reduced the extent of glomerulonephritis and proteinuria and improved survival, but had little effect on T cell infiltration and interstitial nephritis. However, in (NZB X NZW)F-1 mice, AdTACI induced neutralizing anti-TACI antibodies and failed to reduce the numbers of B cells. Conclusion. BLyS blockade has little effect on IgG levels in normal mice, but reverses the production of spontaneously produced IgM and IgG autoantibodies in the setting of established autoimmunity. Blockade of BLyS ameliorates B cell-dependent disease manifestations even in the MRL.lpr/lpr model, but its effectiveness on autonomous T cell aspects of the disease is limited. Moreover, its effectiveness is neutralized by anti-TACI antibodies when present. These results provide a basis for understanding the potential effects of BLyS blockade in human disease. C1 Univ Alabama, Birmingham, AL 35294 USA. Birmingham VA Med Ctr, Birmingham, AL USA. RP Carter, RH (reprint author), Univ Alabama, 409 LHRB,701 S 10th St, Birmingham, AL 35294 USA. EM rcarter@uab.edu OI Kimberly, Robert/0000-0002-5330-3086 NR 35 TC 42 Z9 43 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD JUN PY 2004 VL 50 IS 6 BP 1884 EP 1896 DI 10.1002/art.2090 PG 13 WC Rheumatology SC Rheumatology GA 827CL UT WOS:000221876000023 PM 15188365 ER PT J AU Trefler, E Fitzgerald, SG Hobson, DA Bursick, T Joseph, R AF Trefler, E Fitzgerald, SG Hobson, DA Bursick, T Joseph, R TI Outcomes of wheelchair systems intervention with residents of long-term care facilities SO ASSISTIVE TECHNOLOGY LA English DT Article DE elderly; outcomes; wheelchair ID NURSING-HOME RESIDENTS; QUALITY-OF-LIFE; MOBILITY AB This pilot study was designed to measure the effects of individually prescribed wheelchair systems on posture and reach, mobility, quality of life, and satisfaction with technology for residents of long-term care facilities. Thirty persons 60 years of age or older who resided permanently in a long-term care facility and who used seating and mobility systems for 6 hours or more each day were recruited for this project. Outcomes included timed independent mobility, forward and lateral reach, quality of life, and satisfaction with assistive technology. The study used semicrossover design with participants measured three times. Measurements were first made in the existing seating and mobility system and a second time immediately after participants were provided with individually prescribed seating and mobility systems. The final measurement was 3 months after the delivery of the individually prescribed system. Results indicated that individually fitted wheelchair systems for elderly residents of long-term care facilities are beneficial. Participants had less difficulty independently propelling their systems and increased forward reach, quality of life for social function and physical role, and satisfaction with the new wheelchair technology. Persons residing in extended care facilities benefit from receiving individually prescribed wheelchair systems. The individual systems enhance elderly persons' independent mobility, functional reach, feeling of well-being, and satisfaction with their assistive technology. C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15206 USA. Apria Healthcare, Pittsburgh, PA USA. Invacare Corp, Chicago, IL USA. Univ Pittsburgh, SHRS, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. RP Fitzgerald, SG (reprint author), VA Pittsburgh Healthcare Syst, 7180 Highland Dr 151R-1, Pittsburgh, PA 15206 USA. NR 20 TC 29 Z9 29 U1 1 U2 6 PU R E S N A PRESS PI ARLINGTON PA 1700 MOORE ST, STE 1540, ARLINGTON, VA 22209-1903 USA SN 1040-0435 J9 ASSIST TECHNOL JI Assist. Technol. PD SUM PY 2004 VL 16 IS 1 BP 18 EP 27 PG 10 WC Rehabilitation SC Rehabilitation GA 883OP UT WOS:000226022900003 PM 15357146 ER PT J AU Figlewicz, DP Bennett, J Evans, SB Kaiyala, K Sipols, AJ Benoit, SC AF Figlewicz, DP Bennett, J Evans, SB Kaiyala, K Sipols, AJ Benoit, SC TI Intraventricular insulin and leptin reverse place preference conditioned with high-fat diet in rats SO BEHAVIORAL NEUROSCIENCE LA English DT Article ID BRAIN REWARD CIRCUITRY; NUCLEUS-ACCUMBENS; FOOD-INTAKE; BODY-WEIGHT; INSTRUMENTAL PERFORMANCE; INDUCED ANOREXIA; ENERGY-BALANCE; DRUG REWARD; SHORT-TERM; SUCROSE AB The authors hypothesized that insulin and leptin, hormones that convey metabolic and energy balance status to the central nervous system (CNS), decrease the reward value of food, as assessed by conditioned place preference (CPP). CPP to high-fat diet was blocked in ad-lib fed rats given intraventricular insulin or leptin throughout training and test or acutely before the test. Insulin or leptin given only during the training period did not block CPP. Thus, elevated insulin and leptin do not prevent learning a food's reward value, but instead block its retrieval. Food-restricted rats receiving cerebrospinal fluid, insulin, or leptin had comparable CPPs. Results indicate that the CNS roles of insulin and leptin may include processes involving memory and reward. C1 Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Univ Washington, Dept Pediat Dent, Seattle, WA 98195 USA. Latvian State Univ, Dept Med, LV-1063 Riga, Latvia. Univ Cincinnati, Dept Psychiat, Cincinnati, OH 45221 USA. RP Figlewicz, DP (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Metab Endocrinol 151,1660 S Columbian Way, Seattle, WA 98108 USA. EM latte@u.washington.edu FU NIDA NIH HHS [R21 DA 14545]; NIDDK NIH HHS [R01 DK 40963]; NIMH NIH HHS [R03 MH 65353] NR 65 TC 111 Z9 112 U1 2 U2 8 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0735-7044 EI 1939-0084 J9 BEHAV NEUROSCI JI Behav. Neurosci. PD JUN PY 2004 VL 118 IS 3 BP 479 EP 487 DI 10.1037/0735-7044.118.3.479 PG 9 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA 825IO UT WOS:000221750200005 PM 15174925 ER PT J AU Hershman, JM AF Hershman, JM TI Physiological and pathological aspects of the effect of human chorionic gonadotropin on the thyroid SO BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article DE human chorionic gonaclotropin; thyrotropin; pregnancy; hyperemesis gravidarum; hydaticliform mole; choriocarcinoma; mutant thyroid-stimulating hormone receptor ID INTRINSIC THYROTROPIC ACTIVITY; COMPLETE HYDATIDIFORM MOLE; NORMAL PREGNANT-WOMEN; HUMAN TSH RECEPTORS; HYPEREMESIS GRAVIDARUM; GESTATIONAL THYROTOXICOSIS; STIMULATING ACTIVITY; IODIDE UPTAKE; HYPERTHYROIDISM; HCG AB Human chorionic gonadotropin (hCG) is a glycoprotein hormone that has structural similarity to TSH. At the time of the peak hCG levels in normal pregnancy, serum TSH levels fall and bear a mirror image to the hCG peak. This reduction in TSH suggests that hCG causes an increased secretion of T4 and T3. Women with hyperemisis gravidarum often have high hCG levels that cause transient hyperthyroidsm. In the vast majority of such patients, there will be spontaneous remission of the increased thyroid function when the vomiting stops in several weeks. When there are clinical features of hyperthyroidism, it is be reasonable to treat with antithyroid drugs or a beta-adrenergic blocker, but treatment is rarely required beyond 22 weeks of gestation. Hyperthyroidism or increased thyroid function has been reported in many patients with trophoblastic tumors, either hydatiditform mole or choriocarcinoma. The diagnosis of hydatidiform mole is made by ultrasonography that shows a 'snowstorm' appearance without a fetus. Hydatidiform moles secrete large amounts of hCG proportional to the mass of the tumor. The development of hyperthyroidism requires hCG levels of > 200 U/ml that are sustained for several weeks. Removal of the mole cures the hyperthyroidism. There have been many case reports of hyperthyroidism in women with choriocarcinoma and high hCG levels. The principal therapy is chemotherapy, usually given at a specialized center. With effective chemotherapy, long-term survival exceeds 95%. A unique family with recurrent gestational hyperthyroidism associated with hyperemesis gravidarum was found to have a mutation in the extracellular domain of the TSH receptor that made it responsive to normal levels of hCG. C1 VA Greater Los Angeles Healthcare Ctr, Los Angeles, CA 90073 USA. RP Hershman, JM (reprint author), VA Greater Los Angeles Healthcare Ctr, IIID,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jhershmn@ucla.edu NR 71 TC 73 Z9 75 U1 0 U2 1 PU BAILLIERE TINDALL PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 1521-690X J9 BEST PRACT RES CL EN JI Best Pract. Res. Clin. Endoc. Metab. PD JUN PY 2004 VL 18 IS 2 BP 249 EP 265 DI 10.1016/j.beem.2004.03.010 PG 17 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 830XT UT WOS:000222158200010 PM 15157839 ER PT J AU Taha, TA Argraves, KM Obeid, LM AF Taha, TA Argraves, KM Obeid, LM TI Sphingosine-1-phosphate receptors: receptor specificity versus functional redundancy SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS LA English DT Article DE sphingolipid; lysophospholipid; sphingosine-1-phosphate; S1P; edg; GPCR ID SPHINGOSINE 1-PHOSPHATE RECEPTOR; PROTEIN-COUPLED RECEPTOR; SMOOTH-MUSCLE-CELLS; MULTIPLE SIGNALING PATHWAYS; ENDOTHELIAL-CELLS; TRANSPLANTATION DRUG; VASCULAR MATURATION; BARRIER INTEGRITY; FTY720; MIGRATION AB Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid that has recently been shown to bind cell surface SIP receptors (previously called endothelial differentiation gene (Edg) receptors), which are members of the G-protein-coupled family of receptors. Signaling via S1P is a complex process, as cells usually express a number of these receptors on their surfaces. Many of the SIP receptors share common G-proteins, invoking the question of how these receptors are specific in their actions. This review describes the coupling pathways of SIP receptors, and highlights the in vitro and in vivo evidence for the "uniqueness" of each receptor in activating downstream signaling pathways, taking the effect of SIP on migration as an example. (C) 2004 Elsevier B.V. All rights reserved. C1 Med Univ S Carolina, Dept Med, Div Gen Internal Med, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Cell Biol & Anat, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Dept Vet Affairs, Charleston, SC 29401 USA. Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. RP Obeid, LM (reprint author), Med Univ S Carolina, Dept Med, Div Gen Internal Med, 114 Doughty St,POB 250779, Charleston, SC 29425 USA. EM obeidl@musc.edu OI obeid, lina/0000-0002-0734-0847 FU NCI NIH HHS [P01 CA097132-01A1]; NCRR NIH HHS [P20 RR17677-01]; NIA NIH HHS [AG16583]; NIGMS NIH HHS [GM62887] NR 59 TC 132 Z9 136 U1 0 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1388-1981 J9 BBA-MOL CELL BIOL L JI Biochim. Biophys. Acta Mol. Cell Biol. Lipids PD JUN 1 PY 2004 VL 1682 IS 1-3 BP 48 EP 55 DI 10.1016/S1388-1981(04)00023-X PG 8 WC Biochemistry & Molecular Biology; Biophysics; Cell Biology SC Biochemistry & Molecular Biology; Biophysics; Cell Biology GA 831LN UT WOS:000222196000006 PM 15158755 ER PT J AU Boudreau, EA Pelczer, I Borer, PN Heffron, GJ LaPlante, SR AF Boudreau, EA Pelczer, I Borer, PN Heffron, GJ LaPlante, SR TI Changes in drug C-13 NMR chemical shifts as a tool for monitoring interactions with DNA SO BIOPHYSICAL CHEMISTRY LA English DT Article DE netropsin; ligand; nuclear magnetic resonance (NMR); deoxyribo nucleic acid (DNA); drug; chemical shift; carbon; inhibitor ID SEQUENCE-DEPENDENT RECOGNITION; MINOR-GROOVE LIGANDS; G-C-G; OLIGONUCLEOTIDE DUPLEXES; NETROPSIN COMPLEXATION; STRUCTURAL FEATURES; MAGNETIC-RESONANCE; PROTON DETECTION; AQUEOUS-SOLUTION; ASSIGNMENT AB The antibiotic drug, netropsin, was complexed with the DNA oligonucleotide duplex [d(GGTATACC)](2) to monitor drug C-13 NMR chemical shifts changes. The binding mode of netropsin to the minor groove of DNA is well-known, and served as a good model for evaluating the relative sensitivity of 13C chemical shifts to hydrogen bonding. Large downfield shifts were observed for four resonances of carbons that neighbor sites which are known to form hydrogen bond interactions with the DNA minor groove. Many of the remaining resonances of netropsin exhibit shielding or relatively smaller deshielding changes. Based on the model system presented here, large deshielding NMR shift changes of a ligand upon macromolecule binding can likely be attributed to hydrogen bond formation at nearby sites. (C) 2003 Elsevier B.V. All rights reserved. C1 Boehringer Ingelheim Canada Ltd, Res & Dev, Laval, PQ H7S 2G5, Canada. Portland VA Med Ctr, Hlth Sci Res & Dev Program, Portland, OR 97239 USA. Princeton Univ, Dept Chem, Princeton, NJ 08540 USA. Syracuse Univ, Dept Chem, Syracuse, NY 13244 USA. Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. RP LaPlante, SR (reprint author), Boehringer Ingelheim Canada Ltd, Res & Dev, 2100 Cunard St, Laval, PQ H7S 2G5, Canada. EM slaplante@lav.boehringer-ingelheim.com NR 36 TC 15 Z9 15 U1 0 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0301-4622 J9 BIOPHYS CHEM JI Biophys. Chem. PD JUN 1 PY 2004 VL 109 IS 3 BP 333 EP 344 DI 10.1016/j.bpc.2003.12.005 PG 12 WC Biochemistry & Molecular Biology; Biophysics; Chemistry, Physical SC Biochemistry & Molecular Biology; Biophysics; Chemistry GA 820EC UT WOS:000221368900001 PM 15110931 ER PT J AU Vernon, SW Meissner, H Klabunde, C Rimer, BK Ahnen, DJ Bastani, R Mandelson, MT Nadel, MR Sheinfeld-Gorin, S Zapka, J AF Vernon, SW Meissner, H Klabunde, C Rimer, BK Ahnen, DJ Bastani, R Mandelson, MT Nadel, MR Sheinfeld-Gorin, S Zapka, J TI Measures for ascertaining use of colorectal cancer screening in behavioral, health services, and epidemiologic research SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Editorial Material ID FECAL-OCCULT-BLOOD; INCREASE MAMMOGRAPHY USE; SOCIETY GUIDELINES; AVERAGE-RISK; INTERVENTIONS; PREVENTION; SIGMOIDOSCOPY; MORTALITY; UPDATE; QUESTIONNAIRES C1 Univ Texas, Sch Publ Hlth, Houston, TX 77030 USA. Univ Texas, Ctr Hlth Promot & Prevent Res, Houston, TX 77030 USA. Natl Canc Inst, Div Canc Control & Populat Sci, Bethesda, MD USA. Univ N Carolina, Dept Hlth Behav & Hlth Educ, Chapel Hill, NC USA. Univ Colorado, Sch Med, Denver, CO 80202 USA. Denver Vet Affairs Med Ctr, Denver, CO 80202 USA. Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA USA. Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA USA. Grp Hlth Cooperat Ctr Hlth Studies, Seattle, WA USA. Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. Columbia Univ, Joseph L Mailman Sch Publ Hlth, New York, NY USA. Univ Massachusetts, Sch Med, Worcester, MA 01605 USA. Med Univ S Carolina, Charleston, SC 29425 USA. RP Vernon, SW (reprint author), Univ Texas, Sch Publ Hlth, 7000 Fannin,Suite 2650, Houston, TX 77030 USA. EM svernon@sph.uth.tmc.edu FU NCI NIH HHS [U01 CA086322-01] NR 58 TC 76 Z9 76 U1 2 U2 4 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD JUN PY 2004 VL 13 IS 6 BP 898 EP 905 PG 8 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 826ZL UT WOS:000221867900002 PM 15184243 ER PT J AU Olson, AL Gutman, JA Welsh, CH AF Olson, AL Gutman, JA Welsh, CH TI A 50-year-old man with skin lesions and multiple pulmonary nodules SO CHEST LA English DT Article ID SECONDARY SYPHILIS C1 Denver VA Med Ctr, Med Serv, Denver, CO 80220 USA. Eastern Colorado Hlth Care Syst, Denver, CO USA. Univ Colorado, Ctr Hlth Sci, Dept Med, Denver, CO 80202 USA. RP Olson, AL (reprint author), Denver VA Med Ctr, Med Serv, 1055 Clermont St, Denver, CO 80220 USA. EM amy.olson@uchsc.edu NR 10 TC 6 Z9 8 U1 0 U2 0 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD JUN PY 2004 VL 125 IS 6 BP 2322 EP 2327 DI 10.1378/chest.125.6.2322 PG 6 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 832FQ UT WOS:000222253100054 PM 15189957 ER PT J AU Jin, M Tuller, P Wener, MH Black, DA Bankson, DD AF Jin, M Tuller, P Wener, MH Black, DA Bankson, DD TI The evaluation of a sex hormone binding globulin assay and its use in the calculation of free testosterone. SO CLINICAL CHEMISTRY LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Association-for-Clinical-Chemistry CY JUL 25-29, 2004 CL Los Angeles, CA SP Amer Assoc Clin Chem C1 Univ Washington, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CLINICAL CHEMISTRY PI WASHINGTON PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA SN 0009-9147 J9 CLIN CHEM JI Clin. Chem. PD JUN PY 2004 VL 50 IS 6 SU S BP A90 EP A91 PN 2 PG 2 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 828EC UT WOS:000221955200299 ER PT J AU Wigren, C Bankson, DD Eng, W Tuller, P Wener, MH AF Wigren, C Bankson, DD Eng, W Tuller, P Wener, MH TI Measurement of monomeric prolactin following polyethylene glycol precipitation. SO CLINICAL CHEMISTRY LA English DT Meeting Abstract CT 56th Annual Meeting of the American-Association-for-Clinical-Chemistry CY JUL 25-29, 2004 CL Los Angeles, CA SP Amer Assoc Clin Chem C1 Univ Washington, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CLINICAL CHEMISTRY PI WASHINGTON PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA SN 0009-9147 J9 CLIN CHEM JI Clin. Chem. PD JUN PY 2004 VL 50 IS 6 SU S BP A104 EP A105 PN 2 PG 2 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 828EC UT WOS:000221955200348 ER PT J AU Sonnenberg, A AF Sonnenberg, Amnon TI Exploring How to Tell the Truth and Preserve Hope: Can a Balance Between Communication and Empathy Be Calculated? SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article AB Background & Aims: When told the harsh truth about severe disease, a patient might despair and lose all hope. Without knowing the truth, however, the patient cannot participate in decision making and adjust life according to his illness. The present study aims to analyze the relationships between hope and truth in the decision on how much information to disclose to a patient with severe gastrointestinal disease. Methods: The decision analysis is based on the economic concepts of indifference curves and utility function. An inverse linear relationship exists between hope and truth; as more truth becomes revealed, the amount of hope declines. The utility function and the corresponding indifference curve of hope plotted versus truth describe the patient's personal choices among different combinations of hope and truth. The optimal choice among various combinations of hope and truth corresponds with the point at which the inverse hope-truth line meets the indifference curve. Results: In situations in which hope drops steeply as more medical facts are being revealed, the utility to the patient is maximized with less truth being told. With a less pronounced truth-related decline in hope, utility is maximized at higher levels of truth, and, occasionally, utility is maximized only after all medical facts have been disclosed. The lesser the impact of truth on hope, the more truth is being tolerated. Conclusions: A caring gastroenterologist trying to optimize his/her patient's well-being should try to assess the potential influence of truth on the patient's psyche and dispense it accordingly. C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR USA. [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr P3 GI, Gastroenterol Sect, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu RI Girault, Johann/B-2430-2012 NR 26 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD JUN PY 2004 VL 2 IS 6 BP 518 EP 522 DI 10.1016/S1542-3565(04)00172-7 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA V19KR UT WOS:000208071800014 PM 15181622 ER PT J AU Gordon, LK Goldman, M Sandusky, H Ziv, N Hoffman, GS Goodglick, T Goodglick, L AF Gordon, LK Goldman, M Sandusky, H Ziv, N Hoffman, GS Goodglick, T Goodglick, L TI Identification of candidate microbial sequences from inflammatory lesion of giant cell arteritis SO CLINICAL IMMUNOLOGY LA English DT Article DE giant cell arteritis; temporal arteritis; vasculitis; laser capture microdissection; representational difference analysis; granulomatous inflammation; aging ID VARICELLA-ZOSTER-VIRUS; POLYMERASE-CHAIN-REACTION; LARGE-VESSEL ARTERITIS; TEMPORAL ARTERITIS; CHLAMYDIA-PNEUMONIAE; OCULAR MANIFESTATIONS; ULCERATIVE-COLITIS; AORTIC-ANEURYSMS; PANCA ANTIBODIES; PARVOVIRUS B19 AB Giant cell arteritis (GCA) is a granulomatous inflammatory disease of medium and large arteries which is prevalent in the elderly population. The etiology of GCA is unknown, although the immunologic features suggest the possible presence of a microorganism. Our group has examined whether microbial DNA fragments were present at GCA lesions and whether such microbial fragments could be associated with disease pathogenesis. Initial identification of microbial sequences was performed using genomic representational difference analysis (RDA). Laser dissecting microscopy was used to isolate cells from GCA lesions and adjacent uninvolved temporal artery. Using genomic RDA, we isolated 10 gene fragments; three of these sequences had high homology with prokaryotic genes and were considered high-priority candidates for further study. An examination of serum from GCA(+) individuals (in contrast to healthy age-matched controls) showed the presence of IgG which recognized in vitro translated proteins from these clones. (C) 2004 Elsevier Inc. All rights reserved. C1 Univ Calif Los Angeles, Sch Med, Dept Pathol & Lab Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA. Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA. Cleveland Clin Fdn, Cleveland, OH 44195 USA. Georgetown Univ, Washington Hosp Ctr, Dept Ophthalmol, Washington, DC 20007 USA. RP Goodglick, L (reprint author), Univ Calif Los Angeles, Sch Med, Dept Pathol & Lab Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA. EM lgoodglick@mednet.ucla.edu NR 61 TC 11 Z9 11 U1 0 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 J9 CLIN IMMUNOL JI Clin. Immunol. PD JUN PY 2004 VL 111 IS 3 BP 286 EP 296 DI 10.1016/j.clim.2003.12.016 PG 11 WC Immunology SC Immunology GA 830WS UT WOS:000222155500007 PM 15183149 ER PT J AU Nahm, WK Su, TT Rotunda, AM Moy, RL AF Nahm, WK Su, TT Rotunda, AM Moy, RL TI Objective changes in brow position, superior palpebral crease, peak angle of the eyebrow, and jowl surface area after volumetric radiofrequency treatments to half of the face SO DERMATOLOGIC SURGERY LA English DT Article ID NONABLATIVE RADIOFREQUENCY; FOREHEAD LIFT; ABLATION; CATHETER; TISSUE AB Background. Radiofrequency application through a proprietary device has recently been used for facial tissue tightening. Uniform volumetric heating of the dermis is created by passage of electrical current, while protection of the epidermis is maintained by concurrent cryogen cooling. Objective. To objectively quantify the effectiveness of volumetric radiofrequency application on the face, we treated 10 patients on the left side of the face with radiofrequency and evaluated the changes in brow position, superior palpebral crease, angle of the eyebrow, and jowl surface area. Methods. Uniform treatments were applied at 134 J/cm(2) to the left side of the forehead and 1 cm past midline, at 115 J/cm(2) to the left side of temple and cheeks, and at 97 J/cm(2) to the left side of the jaw line and inferior postauricular surface. Patients were evaluated at monthly intervals up to 3 months with digital photography. Morphologic changes were evaluated with the "measuring tool" and "angle tool" of the Mirror Suite imaging system for aligned frontal-view photographs (for eyebrow position, superior palpebral crease elevation, and eyebrow angle changes) and the "outline tool" for aligned oblique-view photographs (for jowl surface area changes). Results. At the end of 3 months on the side that was treated, patients exhibited on average 4.3 mm of brow elevation and 1.9 mm of superior palpebral crease elevation along the midpupillary line and an average of 2.4 mm of brow elevation along the lateral canthal line. There was no significant improvement of brow elevation along the lateral canthal line on the contralateral side. The peak angle of the ipsilateral eyebrow became slightly more acute by an average of 4.5degrees after treatments. Moreover, the jowls on the lower part of the face, displayed a mean decrease of 22.6% in surface area after treatments. The nontreated side displayed a lack of eyebrow angle and jowl surface area changes. Conclusions. The application of radiofrequency to the face provides quantifiable changes. The brow along the midpupillary line is elevated to a greater degree than the lateral brow. This is consistent with acute angle changes seen in the eyebrow. Improvements in the lower part of the face with radiofrequency application can be quantified by demonstrating a decrease jowl surface. Moreover, these measurement techniques can be useful tools for evaluating other treatment parameters with radiofrequency application. . C1 Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA. Vet Affairs Med Ctr, San Diego, CA 92161 USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. RP Moy, RL (reprint author), 100 UCLA Med Plaza,Suite 590, Los Angeles, CA 90024 USA. EM rmoy@ucla.edu NR 25 TC 39 Z9 41 U1 0 U2 2 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 1076-0512 J9 DERMATOL SURG JI Dermatol. Surg. PD JUN PY 2004 VL 30 IS 6 BP 922 EP 928 DI 10.1111/j.1524-4725.2004.30263.x PG 7 WC Dermatology; Surgery SC Dermatology; Surgery GA 824EE UT WOS:000221667200014 PM 15171772 ER PT J AU Spirt, MJ Guth, PH Randall, G Leung, FW AF Spirt, MJ Guth, PH Randall, G Leung, FW TI Gastroduodenal perfusion and mortality in mechanical ventilation-dependent patients with systemic inflammatory response syndrome SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE gastroduodenal perfusion; mechanical ventilation-dependent patients; systemic inflammatory response syndrome; reflectance spectrophotometry; mortality ID INTENSIVE-CARE-UNIT; MUCOSAL BLOOD-FLOW; ENDOSCOPIC REFLECTANCE SPECTROPHOTOMETRY; CRITICALLY-ILL PATIENTS; SEVERE ACUTE-PANCREATITIS; IN-HOSPITAL MORTALITY; APACHE-II; OXYGEN-SATURATION; SEPTIC SHOCK; HEMORRHAGIC-SHOCK AB The role of gastrointestinal blood flow determination in predicting mortality is not known. We tested the hypothesis that when mechanical ventilation-dependent (MVD) patients with systemic inflammatory response syndrome (SIRS) develop a significant reduction in gastroduodenal blood flow, high mortality will ensue. The design was a prospective, observational study at the intensive care unit (study patients) and outpatient endoscopy suite (controls) of a tertiary care Veterans Affairs Hospital. There were 6 study patients and 10 control subjects. Interventions were endoscopic reflectance spectrophotometry recorded indexes of gastroduodenal mucosal oxygen saturation (ISO2) and hemoglobin concentration (IHB). Data for Acute Physiologic and Chronic Health Evaluation (APACHE) II scores were gathered. All study patients had septic SIRS at enrollment. Gastroduodenal blood flow measurements ranged from 32 to 55% (ISO2) and from 42 to 51% (IHB) of those in control subjects. The significant hypoperfusion upgraded diagnosis to severe sepsis. The APACHE II score of 16.8+/-2.8 (mean+/-SE) predicted similar to25% mortality. Observed in-hospital mortality was 83%. Our study confirmed that MVD patients with severe sepsis have a significant impairment of gastroduodenal blood flow. Such a dramatic reduction is associated with a grave prognosis. The impact of these measurements on physicians' predictions of the likelihood of survival in patients receiving intensive care deserves to be assessed. C1 Vet Adm Med Ctr, Sepulveda VA Ambulatory Care Ctr, VA Greater Los Angeles Healthcare Syst, Ctr Ulcer Res & Educ,Div Gastroenterol,Med Serv, Sepulveda, CA 91343 USA. Vet Adm Med Ctr, Sepulveda VA Ambulatory Care Ctr, VA Greater Los Angeles Healthcare Syst, Ctr Ulcer Res & Educ,Res Serv, Sepulveda, CA 91343 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90024 USA. RP Leung, FW (reprint author), Vet Adm Med Ctr, Sepulveda VA Ambulatory Care Ctr, VA Greater Los Angeles Healthcare Syst, Ctr Ulcer Res & Educ,Div Gastroenterol,Med Serv, 111G,16111 Plummer St, Sepulveda, CA 91343 USA. EM felix.leung@med.va.gov NR 49 TC 8 Z9 8 U1 0 U2 0 PU KLUWER ACADEMIC/PLENUM PUBL PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD JUN PY 2004 VL 49 IS 6 BP 906 EP 913 DI 10.1023/B:DDAS.0000034547.87812.74 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 837EB UT WOS:000222610100003 PM 15309876 ER PT J AU Riedl, K Krysan, K Pold, M Dalwadi, H Heuze-Vourc'h, N Dohadwala, M Liu, M Cui, XY Figlin, R Mao, JT Strieter, R Sharma, S Dubinett, SM AF Riedl, K Krysan, K Pold, M Dalwadi, H Heuze-Vourc'h, N Dohadwala, M Liu, M Cui, XY Figlin, R Mao, JT Strieter, R Sharma, S Dubinett, SM TI Multifaceted roles of cyclooxygenase-2 in lung cancer SO DRUG RESISTANCE UPDATES LA English DT Review DE cyclooxygenase; lung cancer; celecoxib; clinical trials ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; GROWTH-FACTOR-RECEPTOR; SQUAMOUS-CELL CARCINOMA; PROSTAGLANDIN H SYNTHASE-2; ACTIVATED PROTEIN-KINASE; MESSENGER-RNA EXPRESSION; LAMININ-5 GAMMA-2 CHAIN; NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; TUMOR ANGIOGENESIS AB Lung cancer is the leading cause of cancer death in the United States. Although the low 5-year survival rate (under 15%) has changed minimally in the last 25 years, new agents and combinations of agents that target tumor proliferation, invasion, and survival may lead to improvement in patient outcomes. There is evidence that cyclooxygenase-2 (COX-2) is overexpressed in lung cancer and promotes tumor proliferation, invasion, angiogenesis, and resistance to apoptosis. COX-2 inhibitors have been found to inhibit tumor growth in animal models and have demonstrated responses when combined with conventional therapy in phase II clinical trials. Further understanding of the mechanisms involved in COX-2-mediated tumorigenesis and its interaction with other molecules in lung cancer may lead to improved therapeutic strategies for this disease. In addition, delineation of how COX-2-dependent genes modulate the malignant phenotype will provide novel insights in lung cancer pathogenesis. (C) 2004 Elsevier Ltd. All fights reserved. C1 Univ Calif Los Angeles, Lung Canc Res Program, Dept Med, David Geffen Sch Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA USA. Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Dubinett, SM (reprint author), Univ Calif Los Angeles, Lung Canc Res Program, Dept Med, David Geffen Sch Med, 10833 LeConte Ave,37-131 CHS, Los Angeles, CA 90095 USA. EM sdubinett@mednet.ucla.edu RI HEUZE-VOURC'H, Nathalie/P-8081-2016 FU NCI NIH HHS [P50 CA90388]; NHLBI NIH HHS [1T32HL6699201] NR 206 TC 70 Z9 77 U1 0 U2 0 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 1368-7646 J9 DRUG RESIST UPDATE JI Drug Resist. Update PD JUN PY 2004 VL 7 IS 3 BP 169 EP 184 DI 10.1016/j.drup.2004.04.003 PG 16 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 850OU UT WOS:000223623100002 PM 15296859 ER PT J AU Mathew, A Sinha, R Burt, R Caan, B Paskett, E Iber, F Kikendall, W Lance, P Shike, M Weissfeld, J Schatzkin, A Lanza, E AF Mathew, A Sinha, R Burt, R Caan, B Paskett, E Iber, F Kikendall, W Lance, P Shike, M Weissfeld, J Schatzkin, A Lanza, E CA Polyp Prevention Study Grp TI Meat intake and the recurrence of colorectal adenomas SO EUROPEAN JOURNAL OF CANCER PREVENTION LA English DT Article DE recurrent colorectal adenomas; red meat; white meat ID COLON-CANCER; PROSPECTIVE COHORT; UNITED-STATES; RISK; CONSUMPTION; WOMEN; FIBER; FAT; DIET; MEN AB A large multicenter randomized controlled trial was reassessed to check whether meat intake and a reduction in its consumption are associated with recurrence of adenomatous polyps of the large bowel, which are precursors of most colorectal malignancies. All subjects (n = 1905; 958 interventions and 947 controls) had one or more histologically confirmed colorectal adenomas removed during a colonoscopy within 6 months before randomization. The subjects were followed-up for approximately 4 years after randomization and a colonoscopy for detecting adenomas was conducted at the 1st and 4th year after randomization. Dietary variables were assessed at baseline (TO) and in conjunction with annual visits at the end of the 1st (T1), 2nd (T2), 3rd (T3) and 4th (T4) years. Odds ratios using logistic regression models for meat variables were estimated based on the average intake at TO, T1, T2, T3 and T4 (prior to the T4 colonoscopy) as well as change (T0-T4) in intake. In the intervention group, the total reduction in median intake of red meat from TO to T4 was observed by the end of 1st year itself (30 and 31% for men and women, respectively). The analysis provide no evidence to suggest that lower intake or reduction in total and in red meat consumption during a period of 4 years reduces the risk of adenoma recurrence (including multiple or advanced adenoma), whereas the data suggest that high intake of fish is associated with lower risk of adenoma recurrence. (C) 2004 Lippincott Williams Wilkins. C1 Reg Canc Ctr, Div Epidemiol & Clin Res, Nutrit Epidemiol Branch, Trivandrum 695011, Kerala, India. Univ Utah, Salt Lake City, UT 84112 USA. Kaiser Fdn Res Inst, Oakland, CA USA. Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA. US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Vet Affairs Med Ctr, Hines, IL 60141 USA. Walter Reed Army Med Ctr, Washington, DC 20307 USA. SUNY Buffalo, Sch Med & Biomed Sci, Buffalo, NY 14260 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Univ Pittsburgh, Pittsburgh, PA 15260 USA. NCI, Canc Prevent Studies Branch, Bethesda, MD 20892 USA. RP Mathew, A (reprint author), Reg Canc Ctr, Div Epidemiol & Clin Res, Nutrit Epidemiol Branch, Trivandrum 695011, Kerala, India. EM amathew@rcctvm.org RI Sinha, Rashmi/G-7446-2015 OI Sinha, Rashmi/0000-0002-2466-7462 NR 22 TC 15 Z9 16 U1 3 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0959-8278 J9 EUR J CANCER PREV JI Eur. J. Cancer Prev. PD JUN PY 2004 VL 13 IS 3 BP 159 EP 164 DI 10.1097/cej.0000130022.23806.7b PG 6 WC Oncology SC Oncology GA 830EA UT WOS:000222103200002 PM 15167213 ER PT J AU Chiba, N Gralnek, IM AF Chiba, N Gralnek, IM TI Health economics as related to gastroenterology SO EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY LA English DT Editorial Material C1 McMaster Univ, Hamilton, ON, Canada. Surrey GI Res Inc, Guelph, ON, Canada. Univ Calif Los Angeles, VA Greater Los Angeles Hlth Care Syst, Daviid Geffen Sch Med, CURE Digest Dis Res Ctr, Los Angeles, CA 90024 USA. Ctr Study Digest Hlth Care Qual & Outcomes, Los Angeles, CA 90024 USA. Ctr neurovisceral Sci & Womens Hlth, Los Angeles, CA 90024 USA. RP Chiba, N (reprint author), McMaster Univ, Hamilton, ON, Canada. EM chiban@on.aibn.com NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0954-691X J9 EUR J GASTROEN HEPAT JI Eur. J. Gastroenterol. Hepatol. PD JUN PY 2004 VL 16 IS 6 BP 511 EP 512 DI 10.1097/01.meg.0000108329.52416.6e PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 827BW UT WOS:000221874300001 ER PT J AU Mazarati, A Lu, XY Kilk, K Langel, U Wasterlain, C Bartfai, T AF Mazarati, A Lu, XY Kilk, K Langel, U Wasterlain, C Bartfai, T TI Galanin type 2 receptors regulate neuronal survival, susceptibility to seizures and seizure-induced neurogenesis in the dentate gyrus SO EUROPEAN JOURNAL OF NEUROSCIENCE LA English DT Article DE hippocampus; peptide nucleic acid antisense; plasticity; rat; status epilepticus ID ELECTROCONVULSIVE SHOCK EXPOSURE; CENTRAL-NERVOUS-SYSTEM; STATUS EPILEPTICUS; MESSENGER-RNA; RAT HIPPOCAMPUS; BASAL FOREBRAIN; CHOLINERGIC NEURONS; PERFORANT PATH; KNOCKOUT MICE; GROWTH-FACTOR AB The neuropeptide galanin has been implicated in inhibiting seizures and protecting hippocampal neurons from excitotoxic injury. In the hippocampus galanin acts through two receptor subtypes, GalR1, expressed in CA1, and GalR2, abundant in dentate gyrus. We developed an approach to induce and to study selective semichronic knockdown of GalR2 in the rat hippocampus. A 50% reduction of GalR2 binding was achieved by continuous infusion of complementary peptide nucleic acid antisense oligonucleotide into the dentate gyrus. This resulted in an increase in the severity of self-sustaining status epilepticus induced by electrical stimulation of the perforant path, induced mild neuronal injury in the dentate hilus, augmented seizure-induced hilar injury and inhibited seizure-induced neurogenesis in the subgranular zone of the dentate gyrus. Our data suggest that in the dentate gyrus, galanin, acting through GalR2, inhibits seizures, promotes viability of hilar interneurons and stimulates seizure-induced neurogenesis. These results are important for understanding the role of galanin and galanin receptor subtypes in the hippocampus both under normal conditions and in excitotoxic injury. C1 W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, D Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. Scripps Res Inst, Dept Neuropharmacol, Harold L Dorris Neurol Res Ctr, La Jolla, CA 92037 USA. Stockholm Univ, Dept Neurochem & Neurotoxicol, SE-10691 Stockholm, Sweden. RP Mazarati, A (reprint author), W Los Angeles Vet Affairs Med Ctr, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM mazarati@ucla.edu FU NINDS NIH HHS [NS 43409] NR 53 TC 86 Z9 91 U1 1 U2 3 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 0953-816X J9 EUR J NEUROSCI JI Eur. J. Neurosci. PD JUN PY 2004 VL 19 IS 12 BP 3235 EP 3244 DI 10.1111/j.1460-9568.2004.03449.x PG 10 WC Neurosciences SC Neurosciences & Neurology GA 832TE UT WOS:000222289300012 PM 15217380 ER PT J AU Finch, CE Weindruch, R AF Finch, CE Weindruch, R TI In praise of Roy - Honouring Roy L. Walford - June 29, 1924-April 27, 2004 - Preface SO EXPERIMENTAL GERONTOLOGY LA English DT Editorial Material C1 Univ So Calif, Dept Sci Biol, Andrus Gerontol Ctr, Los Angeles, CA 90089 USA. Univ Wisconsin, Sch Med, Dept Med,William S Middleton Mem Vet Hosp, Geriatr Res Educ & Clin Ctr, Madison, WI 53705 USA. RP Finch, CE (reprint author), Univ So Calif, Dept Sci Biol, Andrus Gerontol Ctr, Los Angeles, CA 90089 USA. EM cefinch@usc.edu; rhweindr@wisc.edu NR 0 TC 0 Z9 0 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0531-5565 J9 EXP GERONTOL JI Exp. Gerontol. PD JUN PY 2004 VL 39 IS 6 BP 869 EP 869 DI 10.1016/j.exger.2004.03.027 PG 1 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 825TU UT WOS:000221782000002 ER PT J AU Paglia, DE AF Paglia, DE TI Biosphere 2, black swans, and the essence of serendipity SO EXPERIMENTAL GERONTOLOGY LA English DT Article C1 Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, W Los Angeles Vet Affairs Med Ctr, Hematol Res Lab, Los Angeles, CA 90073 USA. Space Biospheres Ventures, Biosphere Project 2, Oracle, AZ USA. RP Paglia, DE (reprint author), Univ Calif Los Angeles, Sch Med, 10833 LeConte Ave, Los Angeles, CA 90095 USA. EM dpaglia@mcn.org NR 2 TC 0 Z9 0 U1 1 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0531-5565 J9 EXP GERONTOL JI Exp. Gerontol. PD JUN PY 2004 VL 39 IS 6 BP 919 EP 922 DI 10.1016/j.exger.2004.03.012 PG 4 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 825TU UT WOS:000221782000018 ER PT J AU Weindruch, R AF Weindruch, R TI Fond memories of my years at UCLA with Roy Walford SO EXPERIMENTAL GERONTOLOGY LA English DT Biographical-Item C1 William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI 53705 USA. Univ Wisconsin, Sch Med, Dept Med, Madison, WI 53706 USA. Univ Wisconsin, Wisconsin Reg Primate Res Ctr, Madison, WI 53715 USA. RP Weindruch, R (reprint author), William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI 53705 USA. EM rhweindr@wisc.edu NR 0 TC 0 Z9 0 U1 0 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0531-5565 J9 EXP GERONTOL JI Exp. Gerontol. PD JUN PY 2004 VL 39 IS 6 BP 943 EP 945 DI 10.1016/j.exger.2004.03.032 PG 3 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 825TU UT WOS:000221782000024 ER PT J AU Avellino, AM Dailey, AT Harlan, JM Sharar, SR Winn, RK McNutt, LD Kliot, M AF Avellino, AM Dailey, AT Harlan, JM Sharar, SR Winn, RK McNutt, LD Kliot, M TI Blocking of up-regulated ICAM-1 does not prevent macrophage infiltration during Wallerian degeneration of peripheral nerve SO EXPERIMENTAL NEUROLOGY LA English DT Article DE Wallerian degeneration; macrophage; ICAM-1; Mac-1; LFA-1; knockout mouse; rat ID INTERCELLULAR-ADHESION MOLECULE-1; IMMUNE-MEDIATED DEMYELINATION; MONOCYTE MIGRATION; MONOCLONAL-ANTIBODY; ENDOTHELIAL-CELLS; SYSTEM; MICE; REGENERATION; RESPONSES; INTEGRIN AB Circulating blood monocytes infiltrate into distal degenerating nerve and differentiate into activated macrophages that remove degenerating axonal and myelin debris and promote axonal regeneration. The cellular and molecular mechanisms responsible for this monocyte-macrophage recruitment remain largely unknown. Cell adhesion molecules which mediate monocyte and endothelial cell interactions, such as the endothelial cell adhesion molecule intercellular adhesion molecule-1 (ICAM-1) interaction with the monocyte adhesion molecules Mac-1 (complement receptor type 3) and LFA-1 (lymphocyte function-associated antigen-1), have been shown to play a critical role in mediating the transendothelial migration of circulating monocytes into nonneural tissues following various types of injury. This study investigated whether these cell adhesion molecules also play a critical role in mediating monocyte-macrophage infiltration during Wallerian degeneration of peripheral nerve. Following sciatic nerve transection, Mac-1- and LFA-1-positive macrophages in distal degenerating nerve increased in number at 2 days and peaked at 14 days before declining. The number of ICAM-1-immunostained blood vessels increased maximally at 1 day before declining to baseline levels by 14 days. Three days following nerve transection, the intensity of ICAM-1 immunostaining on intraneural blood vessels was maximal and then decreased to baseline levels by 14 days. To test the role of ICAM-1 in mediating monocyte-macrophage recruitment, we used two complementary experimental strategies following a sciatic nerve transection: (1) intravenous administration of a rat ICAM-1-blocking monoclonal antibody and (2) ICAM-I knockout mice. In both cases, the number of infiltrating monocytes-macrophages was above controls, which is opposite to what has been shown to occur in other tissues following injury. (C) 2004 Elsevier Inc. All rights reserved. C1 Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Med, Div Hematol, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Anesthesiol, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Surg, Seattle, WA 98195 USA. RP Avellino, AM (reprint author), Childrens Hosp & Med Ctr, Dept Neurol Surg, 4800 Sand Point Way NE,POB 5371-6E-1, Seattle, WA 98105 USA. EM anthony.avellino@seattlechildrens.org FU NHLBI NIH HHS [HL18645]; NINDS NIH HHS [T32NS-07144-15, 1-K08-NS01790-01, 1-F32-NS-10480-01A1] NR 44 TC 15 Z9 15 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4886 J9 EXP NEUROL JI Exp. Neurol. PD JUN PY 2004 VL 187 IS 2 BP 430 EP 444 DI 10.1016/j.expneurol.2004.02.004 PG 15 WC Neurosciences SC Neurosciences & Neurology GA 823HU UT WOS:000221602200022 PM 15144869 ER PT J AU Wen, LK Parchman, ML Shepherd, MD AF Wen, LK Parchman, ML Shepherd, MD TI Family support and diet barriers among older hispanic adults with type 2 diabetes SO FAMILY MEDICINE LA English DT Article ID MEXICAN-AMERICANS; SOCIAL-ENVIRONMENT; SELF-MANAGEMENT; HEALTH BELIEFS; MELLITUS; APGAR; ADHERENCE; VALIDITY; ACCULTURATION; VALIDATION AB Background and Objectives: Diet plays an important role in the management of diabetes, and a suboptimal diet is a commonly identified problem. Family support may be important in overcoming barriers to good diet. We conducted this study to examine the role of the family in overcoming barriers to diet self-care among older Hispanic patients with diabetes. Methods: We performed a cross-sectional survey of 138 older Hispanic adults seeking care at an outpatient university clinic. Patients reported on their perception of family functioning, family support for diet, and barriers to diet self-care. Results: Level of family functioning was related to family support for diet self-care, and family support for diet was related to perceived barriers to diet self-care. Scores for family support were higher for those who perceived their family as functional compared to those who perceived their family as mildly dysfunctional or dysfunctional. As family support for diet increased, perceived barriers to diet self-care decreased. Conclusions: To fully understand difficulties encountered by older Hispanic adults with adherence to a diabetic diet, primary care physicians should explore the role of family support and family functioning. For those with poorly functioning families or low levels of family support, family-level interventions may need to be considered. C1 VERDICT, S Texas Vet Hlth Care Syst, Ambulatory Care 11C6, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Family & Community Med, San Antonio, TX USA. Univ Texas, Coll Pharm, Austin, TX 78712 USA. RP Parchman, ML (reprint author), VERDICT, S Texas Vet Hlth Care Syst, Ambulatory Care 11C6, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM parchman@uthscsa.edu NR 42 TC 46 Z9 47 U1 0 U2 5 PU SOC TEACHERS FAMILY MEDICINE PI LEAWOOD PA 11400 TOMAHAWK CREEK PARKWAY, STE 540, LEAWOOD, KS 66207 USA SN 0742-3225 J9 FAM MED JI Fam. Med. PD JUN PY 2004 VL 36 IS 6 BP 423 EP 430 PG 8 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA 827GW UT WOS:000221888700013 PM 15181555 ER PT J AU Cullen, PA Haake, DA Adler, B AF Cullen, PA Haake, DA Adler, B TI Outer membrane proteins of pathogenic spirochetes SO FEMS MICROBIOLOGY REVIEWS LA English DT Review DE pathogenic spirochetes; outer membrane proteins; lipoproteins; immunity; pathogenesis; surface exposure ID LYME-DISEASE SPIROCHETE; BORRELIA-BURGDORFERI LIPOPROTEINS; DECORIN-BINDING-PROTEIN; MAJOR SURFACE PROTEIN; INACTIVATED TREPONEMA-HYODYSENTERIAE; PEPTIDOGLYCAN-ASSOCIATED LIPOPROTEIN; INTERROGANS SEROVAR HARDJO; RELAPSING FEVER BACTERIUM; VARIABLE ANTIGEN GENES; ESCHERICHIA-COLI AB Pathogenic spirochetes are the causative agents of several important diseases including syphilis, Lyme disease, leptospirosis, swine dysentery, periodontal disease and some forms of relapsing fever. Spirochetal bacteria possess two membranes and the proteins present in the outer membrane are at the site of interaction with host tissue and the immune system. This review describes the current knowledge in the field of spirochetal outer membrane protein (OMP) biology. What is known concerning biogenesis and structure of OMPs, with particular regard to the atypical signal peptide cleavage sites observed amongst the spirochetes, is discussed. We examine the functions that have been determined for several spirochetal OMPs including those that have been demonstrated to function as adhesins, porins or to have roles in complement resistance. A detailed description of the role of spirochetal OMPs in immunity, including those that stimulate protective immunity or that are involved in antigenic variation, is given. A final section is included which covers experimental considerations in spirochetal outer membrane biology. This section covers contentious issues concerning cellular localization of putative OMPs, including determination of surface exposure. A more detailed knowledge of spirochetal OMP biology will hopefully lead to the design of new vaccines and a better understanding of spirochetal pathogenesis. (C) 2003 Federation of European Microbiological Societies. Published by Elsevier B.V. All rights reserved. C1 Monash Univ, Dept Microbiol, Australian Bacterial Pathogenesis Program, Melbourne, Vic 3800, Australia. Monash Univ, Victorian Bioinformat Consortium, Melbourne, Vic 3800, Australia. Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90095 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA 90073 USA. RP Adler, B (reprint author), Monash Univ, Dept Microbiol, Australian Bacterial Pathogenesis Program, Melbourne, Vic 3800, Australia. EM Ben.Adler@med.monash.edu.au FU NIAID NIH HHS [R29 AI034431, AI-34331, R01 AI034431, R01 AI034431-07, R21 AI034431] NR 307 TC 97 Z9 103 U1 2 U2 18 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-6445 J9 FEMS MICROBIOL REV JI Fems Microbiol. Rev. PD JUN PY 2004 VL 28 IS 3 BP 291 EP 318 DI 10.1016/j.femsre.2003.10.004 PG 28 WC Microbiology SC Microbiology GA 830RU UT WOS:000222141400002 PM 15449605 ER PT J AU El-Serag, HB Petersen, NJ Carter, J Graham, DY Richardson, P Genta, RM Rabeneck, L AF El-Serag, HB Petersen, NJ Carter, J Graham, DY Richardson, P Genta, RM Rabeneck, L TI Gastroesophageal reflux among different racial groups in the United States SO GASTROENTEROLOGY LA English DT Article ID HELICOBACTER-PYLORI; BARRETTS-ESOPHAGUS; GASTRIC CARDIA; DISEASE; ADENOCARCINOMA; EPIDEMIOLOGY; POPULATION; PREVALENCE; SYMPTOMS AB Background & Aims: White people in the United States are several-fold more affected by esophageal adenocarcinoma than black people. It remains unknown whether this racial discrepancy reflects a higher prevalence of gastroesophageal reflux disease (GERD) symptoms or a higher degree of esophageal damage. Methods: A cross-sectional survey followed by endoscopy was performed among employees at a VA medical center. The association between race and GERD symptoms and erosive esophagitis was analyzed in logistic regression analyses controlling for demographic, clinical, and histologic variables. Results: A total of 496 of 915 people (54%) returned interpretable questionnaires, and endoscopy was performed in 215 participants. The mean age was 45 years, and 336 (68%) were women. Racial distribution was 43% black, 34% white, and 23% other races. Heartburn occurring at least weekly was reported in 27%, 23%, and 24% of these racial groups, respectively. The age-adjusted prevalence of heartburn or regurgitation was not significantly different among the groups. Erosive esophagitis was found in 50 of 2:15 participants (23%); 31 of these cases were mild. Only one person had Barrett's esophagus (0.4%). For weekly heartburn or regurgitation, black participants had significantly less frequent erosive esophagitis than white participants (24% vs. 50%; P = 0.03). With multiple adjustments, black participants had a persistently lower risk of esophagitis (adjusted odds ratio, 0.22-0.46; P < 0.001). Conclusions: White and black people in the United States have a similarly high prevalence of GERD symptoms. However, black people have a lower prevalence of esophagitis for the same frequency of GERD symptoms. Barrett's esophagus was rare in this study, even among those with frequent symptoms. C1 US Dept Vet Affairs, Med Ctr, Gastroenterol Sect, Houston, TX 77030 USA. US Dept Vet Affairs, Med Ctr, Sect Hlth Serv Res, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. RP US Dept Vet Affairs, Med Ctr, Gastroenterol Sect, 2002 Holcombe Blvd,152, Houston, TX 77030 USA. EM hasheme@bcm.tmc.edu NR 24 TC 132 Z9 140 U1 0 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 EI 1528-0012 J9 GASTROENTEROLOGY JI Gastroenterology PD JUN PY 2004 VL 126 IS 7 BP 1692 EP 1699 DI 10.1053/j.gastro.2004.03.077 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 827GS UT WOS:000221888300013 PM 15188164 ER PT J AU Spiegel, BMR DeRosa, VP Gralnek, IM Wang, V Dulai, GS AF Spiegel, BMR DeRosa, VP Gralnek, IM Wang, V Dulai, GS TI Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: A cost-effectiveness analysis SO GASTROENTEROLOGY LA English DT Article ID ROME CRITERIA; PRIMARY-CARE; DISEASE; PREVALENCE; PROGNOSIS; SYMPTOMS AB Background & Aims: Some patients with diarrhea-predominant irritable bowel syndrome (IBS-D) may have undiagnosed celiac sprue (CS). Because the symptoms of CS respond to a gluten-free diet, testing for CS in IBS may prevent years of morbidity and attendant expense. We sought to determine whether this might be a cost-effective diagnostic strategy in IBS-D. Methods: We used decision analysis to calculate the cost-effectiveness of 2 competing strategies in IBS-D: (1) start empirical IBS treatment and (2) perform serologic test for CS followed by endoscopic biopsy for positive tests. The base-case cohort had a CS prevalence of 3.4%, which was varied between 0% and 100% in sensitivity analysis. The outcome measure was cost per symptomatic improvement. Results: Under base-case conditions, testing for CS instead of starting empiric IBS therapy cost an incremental $11,000 to achieve one additional symptomatic improvement. Testing for CS became the dominant strategy when the prevalence of CS exceeded 8%, the specificity of CS testing exceeded 98%, or the cost of IBS therapy exceeded $130/month. The incremental cost-effectiveness of testing for CS exceeded $50,000 when the prevalence fell below 1%. Conclusions: Testing for CS in patients with IBS-D has an acceptable cost when the prevalence of CS is above 1% and is the dominant strategy when the prevalence exceeds 8%. The decision to test should be based on a consideration of the population prevalence of underlying CS, the operating characteristics of the screening test employed, and the cost of proposed therapy for IBS. C1 VA Greater Los Angeles Healthcare Syst, Div Gastroenterol & Hepatol, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90024 USA. Ctr Neurovisceral Sci & Womens Hlth, Los Angeles, CA USA. Ctr Study Digest Healthcare Qual & Outcomes, Los Angeles, CA USA. RP Spiegel, BMR (reprint author), 11301 Wilshire Blvd,Bldg 115,Room 215B, Los Angeles, CA 90073 USA. EM bspiegel@ucla.edu FU NCRR NIH HHS [K23 RR 16188]; NIDDK NIH HHS [DK 07180] NR 38 TC 86 Z9 91 U1 0 U2 3 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD JUN PY 2004 VL 126 IS 7 BP 1721 EP 1732 DI 10.1053/j.gastro.2004.03.012 PG 12 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 827GS UT WOS:000221888300016 PM 15188167 ER PT J AU Elstein, AS Chapman, GB Chmiel, JS Knight, SJ Chan, C Nadler, RB Kuzel, TM Siston, AK Bennett, CL AF Elstein, AS Chapman, GB Chmiel, JS Knight, SJ Chan, C Nadler, RB Kuzel, TM Siston, AK Bennett, CL TI Agreement between prostate cancer patients and their clinicians about utilities and attribute importance SO HEALTH EXPECTATIONS LA English DT Article DE preferences; substituted judgement; utility assessment; values ID QUALITY-OF-LIFE; SUSTAINING TREATMENT INFLUENCE; PHYSICIANS OWN PREFERENCES; DECISION-ANALYSIS; ADVANCE DIRECTIVES; SUBSTITUTED JUDGMENTS; RADICAL PROSTATECTOMY; HEALTH STATES; PERCEPTIONS; PREDICTIONS AB Purpose To examine the agreement between prostate cancer patients' utilities for selected health states and their rankings of the importance of six attributes of the health states and the clinicians' judgements of what would be in the patients' best interests. Method Patients with newly diagnosed localized prostate cancer individually completed a time trade-off utility assessment shortly after being diagnosed. The health states evaluated were constructed from a multi-attribute utility model that incorporated six aspects of living with the disease and outcomes of treatment. Each patient assessed his current health state and three hypothetical states that might occur in the future, and provided rankings of the importance of the six attributes. The clinicians caring for each patient independently provided their views of what utilities and importance rankings would be in the patient's best interest. Results The across-participant correlations between patients' and clinicians' utilities were very low and not statistically significant. Across-participant correlations between patient and clinician importance rankings for the six attributes were also low. Across-health state and across-attribute correlations between utilities or importance rankings were highly variable across patient-clinician pairs. Conclusion In the clinical settings studied, there is not a strong relationship between valuations of current and possible future health states by patients with newly diagnosed prostate cancer and their clinicians. Implications of these results for substituted judgement, when clinicians advise their patients or recommend a treatment strategy, are discussed. C1 Univ Illinois, Dept Med Educ, Chicago, IL 60680 USA. Rutgers State Univ, Dept Psychol, Piscataway, NJ 08855 USA. Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA. Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. Northwestern Univ, Feinberg Sch Med, Head Sect Endourol Laparoscopy & Stone Dis, Chicago, IL 60611 USA. Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA. Northwestern Univ, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA. VA Chicago Healthcare Syst, Midwest Ctr Hlth Serv Res & Policy Studies, Chicago, IL USA. Northwestern Univ, Feinberg Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA. Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Canc Control Program, Chicago, IL 60611 USA. RP Elstein, AS (reprint author), 338 Brookside Dr, Wilmette, IL 60091 USA. EM aelstein@uic.edu RI Bennett, Charles/C-2050-2008 OI Chapman, Gretchen/0000-0002-1146-480X NR 49 TC 18 Z9 18 U1 1 U2 2 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 1369-6513 J9 HEALTH EXPECT JI Health Expect. PD JUN PY 2004 VL 7 IS 2 BP 115 EP 125 DI 10.1111/j.1369-7625.2004.00267.x PG 11 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 879JY UT WOS:000225715300004 PM 15117386 ER PT J AU Ling, YQ Zhang, JL Luo, B Song, DS Liu, LC Tang, LP Stockard, CR Grizzle, WE Ku, DD Fallon, MB AF Ling, YQ Zhang, JL Luo, B Song, DS Liu, LC Tang, LP Stockard, CR Grizzle, WE Ku, DD Fallon, MB TI The role of endothelin-1 and the endothelin B receptor in the pathogenesis of hepatopulmonary syndrome in the rat SO HEPATOLOGY LA English DT Article ID NITRIC-OXIDE SYNTHASE; PORTAL HYPERTENSIVE-RATS; CIRRHOTIC RATS; PULMONARY DYSFUNCTION; ENHANCED EXPRESSION; BIG ENDOTHELIN-1; HEME OXYGENASE-1; STELLATE CELLS; LIVER-DISEASE; TNF-ALPHA AB Endothelin-1 (ET-1) stimulation of endothelial nitric oxide synthase (eNOS) via pulmonary endothelial endothelin B (ETB) receptors and pulmonary intravascular macrophage accumulation with expression of inducible nitric oxide synthase (iNOS) and heme oxygenase-1 (HO-1) are implicated in experimental hepatopulmonary syndrome (HPS) after common bile duct ligation (CBDL). Our aim was to evaluate the role of ET-1 in the development of experimental HPS. The time course of molecular and physiological changes of HPS and the effects of selective endothelin receptor antagonists in vivo were assessed after CBDL. Effects of ET-1 on intralobar pulmonary vascular segment reactivity and on eNOS expression and activity in rat pulmonary microvascular endothelial cells (RPMVECs) were also evaluated. Hepatic and plasma ET-1 levels increased 1 week after CBDL in association with a subsequent increase in pulmonary microvascular eNOS and ETB receptor levels and the onset of HPS. Selective ETB receptor inhibition in vivo significantly decreased pulmonary eNOS and ETB receptor levels and ameliorated HPS. CBDL pulmonary artery segments had markedly increased ETB receptor mediated, nitric oxide dependent vasodilatory responses to ET-1 compared with controls and ET-1 triggered an ETB receptor dependent stimulation of eNOS in RPMVECs. Pulmonary intravascular macrophages also accumulated after CBDL and expressed HO-1 and iNOS at 3 weeks. Selective ETB receptor blockade also decreased macrophage accumulation and iNOS production. In conclusion, ET-1 plays a central role in modulating pulmonary micovascular tone in experimental HPS. C1 Univ Alabama, Dept Internal Med, Ctr Liver, Birmingham, AL 35294 USA. Univ Alabama, Birmingham VA Med Ctr, Birmingham, AL 35294 USA. Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA. Univ Alabama, Dept Pharmacol, Birmingham, AL 35294 USA. RP Fallon, MB (reprint author), Univ Alabama, Dept Internal Med, Ctr Liver, MCLM 290,1918 Univ Blvd, Birmingham, AL 35294 USA. EM mfallon@uabmc.edu FU NIDDK NIH HHS [DK0203] NR 46 TC 64 Z9 65 U1 0 U2 1 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD JUN PY 2004 VL 39 IS 6 BP 1593 EP 1602 DI 10.1002/hep.20244 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 826SN UT WOS:000221849000016 PM 15185300 ER PT J AU Morilak, DA Frazer, A AF Morilak, DA Frazer, A TI Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders SO INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY LA English DT Review DE antidepressants; anxiety disorders; anxiolytics; depression; norepinephrine; serotonin ID POSTTRAUMATIC-STRESS-DISORDER; SEROTONIN REUPTAKE INHIBITORS; OBSESSIVE-COMPULSIVE DISORDER; VENTRAL TEGMENTAL AREA; COERULEUS NORADRENERGIC NEURONS; CORTICOTROPIN-RELEASING-FACTOR; EXTRACELLULAR DOPAMINE LEVELS; LOCUS-CERULEUS NEURONS; FORCED SWIMMING TEST; PANIC DISORDER AB There is extensive comorbidity between depression and anxiety disorders. Dimensional psychiatric and psychometric approaches have suggested that dysregulation of a limited number of behavioural dimensions that cut across diagnostic categories can account for both the shared and unique symptoms of depression and anxiety disorders. Such an approach recognizes that anxiety, the emotional response to stress, is a key element of depression as well as the defining feature of anxiety disorders, and many antidepressants appear to be effective in the treatment of anxiety disorders as well as depression. Therefore, the pharmacological actions of these drugs must account for their efficacy in both. Brain noradrenergic and serotonergic systems, and perhaps to a more limited extent the dopaminergic system, regulate or modulate many of the same behavioural dimensions (e.g. negative or positive affect) that are affected in depression and anxiety disorders, and that are ameliorated by drug treatment. Whereas much recent research has focused on the regulatory effects of antidepressants on synaptic function and cellular proteins, less emphasis has been placed on monoaminergic regulation at a more global systemic level, or how such systemic alterations in monoaminergic function might alleviate the behavioural, cognitive, emotional and physiological manifestations of depression and anxiety disorders. In this review, we discuss how chronic antidepressant treatment might regulate the tonic activity and/or phasic reactivity of brain monoaminergic systems to account for their ability to effectively modify the behavioural dimensions underlying improvement in both depression and anxiety disorders. C1 Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Ctr Biomed Neurosci, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Morilak, DA (reprint author), Univ Texas, Hlth Sci Ctr, Dept Pharmacol, 7703 Floyd Curl Dr,MC 7764, San Antonio, TX 78229 USA. EM morilak@uthscsa.edu FU NIMH NIH HHS [MH57001, MH58351, MH60118] NR 200 TC 140 Z9 142 U1 1 U2 19 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1461-1457 EI 1469-5111 J9 INT J NEUROPSYCHOPH JI Int. J. Neuropsychopharmacol. PD JUN PY 2004 VL 7 IS 2 BP 193 EP 218 DI 10.1017/S1461145704004080 PG 26 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 828OM UT WOS:000221982600013 PM 15003145 ER PT J AU Jakary, A Davis, K Yucel, K Deicken, R AF Jakary, A Davis, K Yucel, K Deicken, R TI Putamen alterations in familial major depression SO INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY LA English DT Meeting Abstract CT 24th CINP Congress CY JUN 20-24, 2004 CL Paris, FRANCE SP CINP C1 San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA SN 1461-1457 J9 INT J NEUROPSYCHOPH JI Int. J. Neuropsychopharmacol. PD JUN PY 2004 VL 7 SU 1 BP S340 EP S340 PG 1 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 864WF UT WOS:000224663002070 ER PT J AU Marder, S Archibald, D Manos, G Stock, E Jody, D Tourkodimitris, S Marcus, R Iwamoto, T Yamamoto, Y Carson, W AF Marder, S Archibald, D Manos, G Stock, E Jody, D Tourkodimitris, S Marcus, R Iwamoto, T Yamamoto, Y Carson, W TI Long-term effects of aripiprazole therapy on the negative symptoms of schizophrenia SO INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY LA English DT Meeting Abstract CT 24th CINP Congress CY JUN 20-24, 2004 CL Paris, FRANCE SP CINP C1 W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. Bristol Myers Squibb Co, New York, NY 10154 USA. Otsuka Amer Pharmaceut Inc, Rockville, MD USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA SN 1461-1457 J9 INT J NEUROPSYCHOPH JI Int. J. Neuropsychopharmacol. PD JUN PY 2004 VL 7 SU 1 BP S243 EP S243 PG 1 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 864WF UT WOS:000224663001325 ER PT J AU Siever, LJ Goodman, M Buchsbaum, M Frankle, WG Laruelle, M Gelernter, J Goldman, D AF Siever, LJ Goodman, M Buchsbaum, M Frankle, WG Laruelle, M Gelernter, J Goldman, D TI Genes of susceptibility and intermediate phenotypes in the impulsive personality disorders SO INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY LA English DT Meeting Abstract CT 24th CINP Congress CY JUN 20-24, 2004 CL Paris, FRANCE SP CINP C1 Mt Sinai Sch Med, Dept Psychiat 1, New York, NY USA. Bronx Vet Adm Med Ctr, Bronx, NY USA. Columbia Univ, New York State Psychiat Inst, New York, NY 10027 USA. Yale Univ, Sch Med, New Haven, CT 06520 USA. NIAAA, NIH, Bethesda, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA SN 1461-1457 J9 INT J NEUROPSYCHOPH JI Int. J. Neuropsychopharmacol. PD JUN PY 2004 VL 7 SU 1 BP S57 EP S57 PG 1 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 864WF UT WOS:000224663000213 ER PT J AU Schumacher, HR AF Schumacher, HR TI Management strategies for osteoarthritis, ankylosing spondylitis, and gouty arthritis SO JCR-JOURNAL OF CLINICAL RHEUMATOLOGY LA English DT Article; Proceedings Paper CT 67th Annual Scientific Meeting of the American-College-of-Rheumatology/38th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 23-28, 2003 CL ORLANDO, FL SP Amer Coll Rheumatolog DE osteoarthritis; ankylosing spondylitis; gouty arthritis; management; NSAIDs; coxibs ID NECROSIS-FACTOR-ALPHA; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PLACEBO-CONTROLLED TRIAL; CHIMERIC MONOCLONAL-ANTIBODY; SERUM URIC-ACID; DOUBLE-BLIND; RHEUMATOID-ARTHRITIS; MEDICAL-MANAGEMENT; KNEE OSTEOARTHRITIS; CLINICAL-TRIAL AB Rheumatic diseases are among the most frequent causes of pain and disability. Effective management of rheumatic diseases including osteoarthritis (OA), ankylosing spondylitis (AS), and gouty arthritis requires an understanding of the underlying disease mechanisms. Symptoms of OA result from both mechanical factors and elements of inflammation. Current management strategies target both of these factors and generally consist of nonpharmacologic and pharmacologic interventions, including use of nonspecific nonsteroidal antiinflammatory drugs (NSAIDs) and cyclooxygenase-2-specific inhibitors (coxibs), which have analgesic and antiinflammatory properties. Other approaches include intraarticular hyaluronate and the use of alternative therapies under investigation such as acupuncture or glucosamine. Disease mechanisms in AS involve enthesitis, an inflammation at the site of insertion of ligaments, tendons, or joint capsules to bone. Posture and exercise are important nonpharmacologic strategies that may be made easier with the use of NSAIDs or coxibs. Recently developed therapies, including tumor necrosis factor inhibitors, target the underlying disease mechanisms and have demonstrated dramatic symptomatic effects. Disease-modifying effects still need to be established. In gout, hyperuricemia leads to crystal-induced inflammation in some patients. Etoricoxib, one of the newer coxibs, has shown promise in treating acute gout, with efficacy similar to indomethacin, the current standard NSAID often used in these patients. Oral or intraarticular steroids can also be considered. For chronic care uricosurics can be beneficial if renal function is normal and excretion is not excessive, but allopurinol is used most often. Nonpharmacologic modalities, such as rest and cold applications, are useful for acute episodes, and lifestyle modification in the form of diet can also play a role in chronic disease management. C1 Univ Penn, Sch Med, Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Schumacher, HR (reprint author), Univ Penn, Sch Med, Vet Affairs Med Ctr, Univ & Woodland Ave, Philadelphia, PA 19104 USA. EM schumacr@mail.med.upenn.edu NR 85 TC 2 Z9 2 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-1608 J9 JCR-J CLIN RHEUMATOL JI JCR-J. Clin. Rheumatol. PD JUN PY 2004 VL 10 IS 3 SU S BP S18 EP S25 DI 10.1097/01.rhu.0000131745.37852.bb PG 8 WC Rheumatology SC Rheumatology GA 833QE UT WOS:000222352500004 PM 17043496 ER PT J AU Misra, S Ganzini, L AF Misra, S Ganzini, L TI Capacity to consent to research among patients with bipolar disorder SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE research; decision-making capacity; bipolar disorder ID DIFFERENT LEGAL STANDARDS; INFORMED-CONSENT; ALZHEIMERS-DISEASE; PSYCHIATRIC RESEARCH; DEPRESSED-PATIENTS; ELDERLY PATIENTS; MENTAL-ILLNESS; COMPETENCE; SCHIZOPHRENIA; PARTICIPATION AB Experts have debated the influence of mental illness on decision-making capacity. This paper reviews concepts of decision-making capacity and existing research on the influence of mental illness on capacity to consent to research. We propose how bipolar disorder, especially mania, may have an effect on consent capacity. The current conceptualization of capacity utilizes legal standards of 'choice', 'understanding', 'appreciation' and 'rational reasoning', as well as voluntarism, or the assurance that the patient is free to agree or to decline to participate in research. Studies of patients with schizophrenia suggest impaired cognition influences 'understanding' and is more important than severity of psychosis in affecting decision-making abilities. There are no studies of sources and extent of impairment to consent to research among manic patients. Mania may influence a patient's understanding of the research protocol, but also alter the patient's views, values and level of insight, thus impairing decision-making abilities at the 'appreciation' standard even when the patient understands the relevant information. Mania may impact freedom to decide, yet paradoxically, manic patients may be less influenced by others and less vulnerable to coercion, undue influence and undue incentives compared to patients without mental illness. We suggest that in patients with mood disorders, the legal standard of appreciation be thoroughly probed during the consent procedure. Studies of the effect of mania and depression on consent capacity and voluntarism are needed in order to develop processes that increase safeguards in the informed consent process. Published by Elsevier B.V. C1 Oregon Hlth Sci Univ, Dept Psychiat, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Med, Portland, OR 97201 USA. Portland Vet Affairs Med Ctr, Div Mental Hlth, Portland, OR 97239 USA. RP Misra, S (reprint author), Oregon Hlth Sci Univ, Dept Psychiat, Portland, OR 97201 USA. EM misras@ohsu.edu NR 29 TC 5 Z9 5 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD JUN PY 2004 VL 80 IS 2-3 BP 115 EP 123 DI 10.1016/S0165-0327(03)00109-5 PG 9 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 824UB UT WOS:000221711200002 PM 15207924 ER PT J AU Snow, AL Hovanec, L Brandt, J AF Snow, AL Hovanec, L Brandt, J TI A controlled trial of aromatherapy for agitation in nursing home patients with dementia SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE LA English DT Article ID ALZHEIMERS-DISEASE; ALTERNATIVE MEDICINE; ODOR IDENTIFICATION; OLFACTORY DEFICITS; DISTURBANCES; INHALATION; BEHAVIOR; SLEEP; OILS AB Objectives: Two controlled trials of aromatherapy to decrease agitation in persons with dementia have recently produced promising results. However, both studies combined the use of essential oils with massage. Thus, it is unclear if the effect of the aromatherapy intervention was the result of smelling or the cutaneous absorption of the oils. The purpose of this study was to determine whether smelling lavender oil decreases the frequency of agitated behaviors in patients with dementia. Design: The study design was within-subjects ABCBA (A = lavender oil, B = thyme oil, C = unscented grapeseed oil): 4 weeks of baseline measurement, 2 weeks for each of the five treatment conditions (10-week total intervention time), and 2 weeks of postintervention measurement. Oil was placed every 3 hours on an absorbent fabric sachet pinned near the collarbone of each participant's shirt. Setting: A long-term care facility specifically for persons with dementia. Participants: Seven agitated nursing home residents with advanced dementia. Measurements: Agitation was assessed every 2 days using a modified Cohen-Mansfield Agitation Inventory. Olfactory functioning was assessed with structured olfactory identification and discrimination tasks, and with qualitative behavioral observation during those tasks. Results: Split-middle analyses conducted separately for each patient revealed no treatment effects specific to lavender, no treatment effects nonspecific to pleasant smelling substances, and no treatment effects dependent on order of treatment administration. There were no differences between participants with more and less intact olfactory abilities. Conclusion: There is significant evidence in the neurologic and neuropsychologic literature that persons with dementia have impaired olfactory abilities. Concordant with this literature, this study found no support for the use of a purely olfactory form of aromatherapy to decrease agitation in severely demented patients. Cutaneous application of the essential oil may be necessary to achieve the effects reported in previous controlled studies. C1 Michael E Debakey Vet Affairs Med Ctr, Hlth Serv Res & Dev Serv, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA. Copper Ridge Inst, Sykesville, MD USA. Johns Hopkins Univ, Sch Med, Baltimore, MD USA. RP Snow, AL (reprint author), Michael E Debakey Vet Affairs Med Ctr, Hlth Serv Res & Dev Serv, Houston Ctr Qual Care & Utilizat Studies, 2002 Itolcombe Blvd,Mail Code 152, Houston, TX 77030 USA. EM asnow@bcm.tmc.edu OI Brandt, Jason/0000-0001-7381-6244 NR 41 TC 31 Z9 32 U1 2 U2 18 PU MARY ANN LIEBERT INC PUBL PI LARCHMONT PA 2 MADISON AVENUE, LARCHMONT, NY 10538 USA SN 1075-5535 J9 J ALTERN COMPLEM MED JI J. Altern. Complement Med. PD JUN PY 2004 VL 10 IS 3 BP 431 EP 437 PG 7 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA 835ID UT WOS:000222475200005 PM 15253846 ER PT J AU Burkhardt, MS Foster, JK Laws, SM Baker, LD Craft, S Gandy, SE Stuckey, BGA Clarnette, R Nolan, D Hewson-Bower, B Martins, RN AF Burkhardt, MS Foster, JK Laws, SM Baker, LD Craft, S Gandy, SE Stuckey, BGA Clarnette, R Nolan, D Hewson-Bower, B Martins, RN TI Oestrogen replacement therapy may improve memory functioning in the absence of APOE epsilon 4 SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE oestrogen supplementation; post-menopausal women; cognition; apolipoprotein E genotype; Alzheimer's disease ID RANDOMIZED CONTROLLED-TRIAL; HEALTHY POSTMENOPAUSAL WOMEN; FAMILIAL ALZHEIMER-DISEASE; APOLIPOPROTEIN-E; PLUS PROGESTIN; TYPE-4 ALLELE; RISK; GENE; ONSET; POLYMORPHISMS AB There is currently intense controversy regarding the use of hormone replacement therapy (HRT) in postmenopausal women, in relation to its therapeutic efficacy in Alzheimer's disease (AD). It has been suggested that the benefits of HRT may be modified by apolipoprotein E (APOE) genotype (the major genetic risk factor for AD). Here we report the findings of the first study designed to systematically explore the interaction of (a) oestrogen replacement therapy (ERT) and (b) possession of an epsilon4 allele of APOE on specific elements of episodic learning and memory that are commonly used indices of age-related cognitive decline. This data represents a cross-sectional analysis of the interaction of ERT and APOE genotype on learning and memory in a cohort of 181 healthy postmenopausal women [ERT users (n = 101, mean age 65.40 +/- 6.34); ERT non-users (n = 80, mean age 67.03 +/- 6.80)] residing in Perth, Western Australia. The highest level of learning (trials 2-5; P < 0.05) and memory (e.g. total number of items recalled; P < 0.05) performance was observed in women taking ERT who were not carriers of the APOE epsilon4 allele. APOE epsilon4 carriers receiving ERT performed no better on episodic memory testing than APOE epsilon4 carriers who were not receiving ERT. These cognitive differences related to genetic profile, were noted on both recall and recognition (P = 0.005) tests of memory. The findings have significance for evaluating whether and when ERT may be clinically indicated. Specifically, ERT may benefit the cognitive functioning of women not carrying the APOE epsilon4 allele. C1 Univ Western Australia, Sir James McCusker Alzheimers Dis Res Unit, Sch Psychiat & Clin Neurosci, Hollywood Private Hosp, Nedlands, WA 6009, Australia. Murdoch Univ, Sch Psychol, Perth, WA, Australia. Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. Thomas Jefferson Univ, Farber Inst Neurosci, Philadelphia, PA USA. Sir Charles Gairdner Hosp, Dept Endocrinol & Diabet, Keogh Inst Med Res, Nedlands, WA, Australia. Royal Perth Hosp, Ctr Clin Immunol & Biomed Stat, Perth, WA, Australia. Murdoch Univ, Perth, WA, Australia. RP Martins, RN (reprint author), Univ Western Australia, Sir James McCusker Alzheimers Dis Res Unit, Sch Psychiat & Clin Neurosci, Hollywood Private Hosp, 115 Monash Ave, Nedlands, WA 6009, Australia. EM rmartins@cyllene.uwa.edu.au RI Laws, Simon/C-2858-2014 OI Laws, Simon/0000-0002-4355-7082 NR 28 TC 42 Z9 46 U1 1 U2 1 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PD JUN PY 2004 VL 6 IS 3 BP 221 EP 228 PG 8 WC Neurosciences SC Neurosciences & Neurology GA 862NR UT WOS:000224498200002 PM 15201477 ER PT J AU Hashim, S Kwon, DH Abdelal, A Lu, CD AF Hashim, S Kwon, DH Abdelal, A Lu, CD TI The arginine regulatory protein mediates repression by arginine of the operons encoding glutamate synthase and anabolic glutamate dehydrogenase in Pseudomonas aeruginosa SO JOURNAL OF BACTERIOLOGY LA English DT Article ID ESCHERICHIA-COLI K-12; BACILLUS-SUBTILIS; NUCLEOTIDE-SEQUENCE; GLTBDF OPERON; GENE; ARGR; CLONING; EXPRESSION; PURIFICATION; BIOSYNTHESIS AB The arginine regulatory protein of Pseudomonas aeruginosa, ArgR, is essential for induction of operons that encode enzymes of the arginine succinyltransferase (AST) pathway, which is the primary route for arginine utilization by this organism under aerobic conditions. ArgR also induces the operon that encodes a catabolic NAD+-dependent glutamate dehydrogenase (GDH), which converts L-glutamate, the product of the AST pathway, in alpha-ketoglutarate. The studies reported here show that ArgR also participates in the regulation of other enzymes of glutamate metabolism. Exogenous arginine repressed the specific activities of glutamate synthase (GltBD) and anabolic NADP-dependent GDH (GdhA) in cell extracts of strain PAO1, and this repression was abolished in an argR mutant. The promoter regions of the gltBD operon, which encodes GltBD, and the gdhA gene, which encodes GdhA, were identified by primer extension experiments. Measurements of beta-galactosidase expression from gltB::lacZ and gdhA::lacZ translational fusions confirmed the role of ArgR in mediating arginine repression. Gel retardation assays demonstrated the binding of homogeneous ArgR to DNA fragments carrying the regulatory regions for the gltBD and gdhA genes. DNase I footprinting experiments showed that ArgR protects DNA sequences in the control regions for these genes that are homologous to the consensus sequence of the ArgR binding site. In silica analysis of genomic information for P. fluorescens, P. putida, and P. stutzeri suggests that the findings reported here regarding ArgR regulation of operons that encode enzymes of glutamate biosynthesis in P. aeruginosa likely apply to other pseudomonads. C1 Georgia State Univ, Dept Biol, Atlanta, GA 30303 USA. Northeastern Univ, Dept Biol, Boston, MA 02115 USA. Baylor Coll Med, VA Med Ctr, Houston, TX 77030 USA. RP Lu, CD (reprint author), Georgia State Univ, Dept Biol, 24 Peachtree Ctr Ave, Atlanta, GA 30303 USA. EM biocdl@panther.gsu.edu NR 35 TC 15 Z9 15 U1 0 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0021-9193 J9 J BACTERIOL JI J. Bacteriol. PD JUN PY 2004 VL 186 IS 12 BP 3848 EP 3854 DI 10.1128/JB.186.12.3848-3854.2004 PG 7 WC Microbiology SC Microbiology GA 826ZX UT WOS:000221869100021 PM 15175298 ER PT J AU Zile, M Gaasch, W Little, W Francis, G Tavazzi, L Cleland, J Davies, M AF Zile, M Gaasch, W Little, W Francis, G Tavazzi, L Cleland, J Davies, M CA MCC-135 GO1 Investigators TI A phase II, double-blind, randomized, placebo-controlled, dose comparative study of the efficacy, tolerability, and safety of MCC-135 in subjects with chronic heart failure, NYHA class II/III (MCC-135-GO1 study): Rationale and design SO JOURNAL OF CARDIAC FAILURE LA English DT Article DE chronic heart failure; systole; diastole; calcium ID VENTRICULAR EJECTION FRACTION; PRESERVED SYSTOLIC FUNCTION; MYOCARDIAL-INFARCTION; DIASTOLIC DYSFUNCTION; THERAPEUTIC OPTIONS; PART II; OUTCOMES; LEVOSIMENDAN; COMMUNITY; MORTALITY AB Background: Chronic heart failure (CHF) can be caused either by a predominant abnormality in systolic function (systolic heart failure) or a predominant abnormality in diastolic function (diastolic heart failure). Randomized clinical trials have identified a number of pharmaceutical agents that can reduce morbidity and mortality in patients with systolic heart failure. Despite significant therapeutic advances, systolic heart failure continues to result in high rates of morbidity and mortality. In contrast to systolic heart failure, no randomized clinical trials have been performed in patients with diastolic heart failure. Common to the mechanisms causing both systolic and diastolic heart failure are abnormalities in calcium homeostasis. Mitsubishi Pharma Corporation has developed a compound (MCC-135, INN; caldaret) whose mechanism of action is proposed to be modulation of calcium homeostasis at the sarcoplasmic reticulum and cellular membrane. The purpose of this study was to test the safety, tolerability, and efficacy of MCC-135 in patients with mild to moderate heart failure. Methods: This was a phase II, multicenter, randomized, double-blind study of parallel group design comparing 3 oral dose regimens of MCC-135 (5 mg, 25 mg, 50 mg, twice daily) with a placebo control. The treatment period was 24 weeks. A total of 511 patients were recruited from 69 centers in the United States and Europe. One hundred and twenty-five patients were recruited in each of the 4 treatment groups. Patients in each treatment group were divided into 2 cohorts: those with an ejection fraction less than or equal to 40%, and those with an ejection fraction >40% as determined by core laboratory analysis of echocardiographic studies. Conclusion: Patient recruitment was completed in September 2002. Patient follow-up was completed by February 2003; the results will be available for release in 2004. C1 Med Univ S Carolina, Div Cardiol, Dept Med, Gazes Cardiac Res Inst, Charleston, SC 29425 USA. Ralph H Johnson Dept Vet Affairs, Med Ctr, Charleston, SC USA. Lahey Clin Fdn, Dept Cardiovasc Med, Burlington, MA 01805 USA. Wake Forest Univ, Sch Med, Cardiol Sect, Winston Salem, NC 27109 USA. Cleveland Clin Fdn, Cleveland, OH 44195 USA. Osped Gen, Div Cardiol, Pavia, Italy. Univ Hull, Castle Hill Hosp, Kingston Upon Hull, Yorks, England. Mitsubishi Pharma Europe Ltd, London, England. RP Zile, M (reprint author), Med Univ S Carolina, Div Cardiol, Dept Med, Gazes Cardiac Res Inst, 135 Rutledge Ave,Suite 1201,POB 250592, Charleston, SC 29425 USA. OI Cleland, John/0000-0002-1471-7016 NR 40 TC 14 Z9 16 U1 0 U2 1 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD JUN PY 2004 VL 10 IS 3 BP 193 EP 199 DI 10.1016/j.cardfail.2003.10.004 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 831JQ UT WOS:000222191100002 PM 15190528 ER PT J AU Vora, A Karnad, D Goyal, V Naik, A Gupta, A Lokhandwala, Y Kulkarni, H Singh, BN Phil, D AF Vora, A Karnad, D Goyal, V Naik, A Gupta, A Lokhandwala, Y Kulkarni, H Singh, BN Phil, D TI Control of heart rate versus rhythm in rheumatic atrial fibrillation: A randomized study SO JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS LA English DT Article DE amiodarone; direct current cardioversion; ventricular rate; sinus rhythm; rheumatic heart disease ID MAZE-III PROCEDURE; SINUS RHYTHM; EXERCISE CAPACITY; VALVE DISEASE; AMIODARONE; CARDIOVERSION; MAINTENANCE; PREVENTION; WARFARIN; STROKE AB Background: Patients with rheumatic heart disease with atrial fibrillation incur significant morbidity and mortality. Which approach, ventricular rate control or maintenance of sinus rhythm, in this setting might be superior is not known. The role of amiodarone in this patient population for maintaining sinus rhythm has not been evaluated. Methods and Results: We prospectively studied 144 Patients with chronic rheumatic atrial fibrillation in a double-blind protocol in which rhythm control (group I). comprising 48 patients each with amiodarone (group Ia) and placebo (group Ib), were compared with each other and with patients in a ventricular rate control group (group II) in which the effects by diltiazem were determined (n = 48, open-label). Direct current cardioversion was attempted in group I. The mean age of the study population was 38.6 +/- 10.3 years. left atrial size. 4.7 +/- 0.6 cm; atrial fibrillation duration. 6.1 +/- 5.4 years: and 72.9% had valvular interventions performed. At 1 year, 45 patients with sinus rhythm in group I compared with 48 in group II demonstrated an increase in exercise time (2.6 +/- 1.9 vs. 0.6 +/- 2.5 min. P = .001). improvement in New York Heart Association class of 1 or more (P = .002). and improvement in the quality-of-life score of one or greater (P = 0.01) with no difference in hospitalizations. Systemic bleeds. or thromboembolism. Five patients died in group II: none died in group I (P = .02). In group I, 73 of 87 (83.9%) patients converted to sinus rhythm and 45 of 86 (52.3%) patients maintained the rhythm at 1 year. Conversion rates were 38 of 43 (88.4%) with amiodarone versus 34 of 44 (77.3%) with placebo (P = .49): the corresponding rate for maintaining sinus rhythm was 29 of 42 (69.1%) versus 16 of 44 (36.4%) (P = .008). A larger number of electrical cardioversions were required in the placebo group (2.1 vs. 1.4, P = .011). Conclusions: Maintenance Of Sinus rhythm is superior to ventricular rate control in patients with rheumatic atrial fibrillation with respect to effects on exercise capacity, quality of life. morbidity, and possibly mortality. Sinus rhythm could be restored in most patients. and amiodarone was Superior to placebo in the restoration and maintenance of sinus rhythm. C1 VA Greater Los Angeles Healthcare Syst, Div Cardiol, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA. King Edward VII Mem Hosp, Dept Cardiol, Bombay, Maharashtra, India. King Edward VII Mem Hosp, Dept Med, Bombay, Maharashtra, India. RP Singh, BN (reprint author), VA Greater Los Angeles Healthcare Syst, Div Cardiol, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM bsingh@ucla.edu NR 26 TC 15 Z9 18 U1 0 U2 0 PU WESTMINSTER PUBL INC PI GLEN HEAD PA 708 GLEN COVE AVE, GLEN HEAD, NY 11545 USA SN 1074-2484 J9 J CARDIOVASC PHARM T JI J. Cardiovasc. Pharmacol. Ther. PD JUN PY 2004 VL 9 IS 2 BP 65 EP 73 DI 10.1177/107424840400900201 PG 9 WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy GA 885MQ UT WOS:000226161800001 PM 15309242 ER PT J AU Shah, AP Lopez, A Wachsner, RY Meymandi, SK Ei-Bialy, AK Ichiuji, AM AF Shah, AP Lopez, A Wachsner, RY Meymandi, SK Ei-Bialy, AK Ichiuji, AM TI Sinus node dysfunction secondary to hyperparathyroidism SO JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS LA English DT Article DE sinus node dysfunction; hyperparathyroidism; hypercalcemia ID CARDIAC CONDUCTION; HYPERCALCEMIA AB We present two patients who were diagnosed with symptomatic Sinus node dysfunction in the setting of hypercalcemia secondary to hyperparathyroidism. An extensive review Of the literature has not revealed previous reports of this pathologic process. C1 Univ Calif Los Angeles, Sch Med, Dept Cardiol, W Los Angeles VA, Los Angeles, CA 90073 USA. Olive View UCLA Med Ctr, Dept Med, Sylmar, CA 91342 USA. RP Shah, AP (reprint author), Univ Calif Los Angeles, Sch Med, Dept Cardiol, W Los Angeles VA, 11301 Wilshire Blvd 111E, Los Angeles, CA 90073 USA. EM apshah73@ucla.edu NR 12 TC 2 Z9 2 U1 0 U2 5 PU WESTMINSTER PUBL INC PI GLEN HEAD PA 708 GLEN COVE AVE, GLEN HEAD, NY 11545 USA SN 1074-2484 J9 J CARDIOVASC PHARM T JI J. Cardiovasc. Pharmacol. Ther. PD JUN PY 2004 VL 9 IS 2 BP 145 EP 147 DI 10.1177/107424840400900209 PG 3 WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy GA 885MQ UT WOS:000226161800009 PM 15309250 ER PT J AU Cummings, DE Overduin, J Foster-Schubert, KE AF Cummings, DE Overduin, J Foster-Schubert, KE TI Gastric bypass for obesity: Mechanisms of weight loss and diabetes resolution SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article; Proceedings Paper CT 86th Annual Meeting of the Endocrine-Society CY JUN 12-15, 2004 CL New Orleans, LA SP Endocrine Soc ID VERTICAL BANDED GASTROPLASTY; ROUX-EN-Y; PLASMA GHRELIN LEVELS; GLUCAGON-LIKE PEPTIDE-1; MORBID-OBESITY; JEJUNOILEAL BYPASS; FOOD-INTAKE; CIRCULATING GHRELIN; BARIATRIC SURGERY; SHORT-TERM C1 Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. RP Cummings, DE (reprint author), Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, 1660 S Columbian Way,S-111 Endo, Seattle, WA 98108 USA. EM davidec@u.washington.edu FU NIDDK NIH HHS [R01 DK61516] NR 102 TC 283 Z9 319 U1 1 U2 17 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD JUN PY 2004 VL 89 IS 6 BP 2608 EP 2615 DI 10.1210/jc.2004-0433 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 826PB UT WOS:000221839900014 PM 15181031 ER PT J AU Sutton, DA Rinaldi, MG Kielhofner, M AF Sutton, DA Rinaldi, MG Kielhofner, M TI First US report of subcutaneous phaeohyphomycosis caused by Veronaea botryosa in a heart transplant recipient and review of the literature SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Review ID EXOPHIALA-SPINIFERA; BOTHRYOSA; FUNGI AB Veronaea botryosa is a rare agent of human phaeohyphomycosis. We describe the first case of subcutaneous disease occurring in the United States, alert clinicians to the second report of a transplant-associated mycosis in a heart transplant recipient, extend the previously defined area of endemicity, and review the literature. C1 Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. St Lukes Episcopal Hosp, Houston, TX 77030 USA. RP Sutton, DA (reprint author), Univ Texas, Hlth Sci Ctr, Dept Pathol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM suttond@uthscsa.edu NR 16 TC 20 Z9 22 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD JUN PY 2004 VL 42 IS 6 BP 2843 EP 2846 DI 10.1128/JCM.42.6.2843-2846.2004 PG 4 WC Microbiology SC Microbiology GA 829AS UT WOS:000222015800084 PM 15184488 ER PT J AU Mueser, KT Clark, RE Haines, M Drake, RE McHugo, GJ Bond, GR Essock, SM Becker, DR Wolfe, R Swain, K AF Mueser, KT Clark, RE Haines, M Drake, RE McHugo, GJ Bond, GR Essock, SM Becker, DR Wolfe, R Swain, K TI The Hartford study of supported employment for persons with severe mental illness SO JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY LA English DT Article ID TRANSITIONAL EMPLOYMENT; PSYCHIATRIC DISABILITY; HEALTH-SERVICES; WORK; SCHIZOPHRENIA; PEOPLE; REHABILITATION; OUTCOMES; SCALE; PROGRAMS AB The authors compared 3 approaches to vocational rehabilitation for severe mental illness (SMI): the individual placement and support (IPS) model of supported employment, a psychosocial rehabilitation (PSR) program. and standard services. Two hundred four unemployed clients (46% African American, 30% Latino) with SMI were randomly assigned to IPS, PSR, or standard services and followed for 2 years. Clients in IPS had significantly better employment outcomes than clients in PSR and standard Services, including more competitive work (73.9% vs. 18.2% vs. 27.5%, respectively) and any paid work (73.9% vs. 34.8% vs. 53.6%, respectively). There were few differences in nonvocational outcomes between programs. IPS is a more effective model than PSR or standard brokered vocational services for improving employment outcomes in clients with SMI. C1 New Hampshire Dartmouth Psychiat Res Ctr, Dept Psychiat, Concord, NH 03301 USA. Dartmouth Coll Sch Med, Dept Community & Family Med, Hanover, NH USA. Indiana Univ Purdue Univ, Dept Psychol, Indianapolis, IN 46205 USA. Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. Bronx Vet Affairs Med Ctr, Mental Hlth Intervent Res & Clin Ctr, New York, NY USA. RP Mueser, KT (reprint author), New Hampshire Dartmouth Psychiat Res Ctr, Dept Psychiat, Main Bldg,105 Pleasant St, Concord, NH 03301 USA. EM kim.t.mueser@dartmouth.edu FU NIMH NIH HHS [MH00842, MH56147] NR 87 TC 110 Z9 112 U1 11 U2 17 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0022-006X J9 J CONSULT CLIN PSYCH JI J. Consult. Clin. Psychol. PD JUN PY 2004 VL 72 IS 3 BP 479 EP 490 DI 10.1037/0022-006X.72.3.479 PG 12 WC Psychology, Clinical SC Psychology GA 823PH UT WOS:000221624800011 PM 15279531 ER PT J AU Lee, DC Lim, HK McKay, WB Priebe, MM Holmes, SA Sherwood, AM AF Lee, DC Lim, HK McKay, WB Priebe, MM Holmes, SA Sherwood, AM TI Toward an objective interpretation of surface EMG patterns: a voluntary response index (VRI) SO JOURNAL OF ELECTROMYOGRAPHY AND KINESIOLOGY LA English DT Article DE voluntary motor control; surface electromyography; spinal cord injury; index ID SPINAL-CORD INJURY; MOTOR CONTROL; HUMAN LOCOMOTION; GAIT ANALYSIS; SPASTICITY; PROFILES; WALKING; NORMALIZATION; STIMULATION; AMBULATION AB Individuals with incomplete spinal cord injuries (SCI) retain varying degrees of voluntary motor control. The complexity of the motor control system and the nature of the recording biophysics have inhibited efforts to develop objective measures of voluntary motor control. This paper proposes the definition and use of a voluntary response index (VRI) calculated from quantitative analysis of surface electromyographic (sEMG) data recorded during defined voluntary movement as a sensitive measure of voluntary motor control in such individuals. The VRI is comprised of two numeric values, one derived from the total muscle activity recorded for the voluntary motor task (magnitude), and the other from the sEMG distribution across the recorded muscles (similarity index (SI)). Calculated as a vector, the distribution of sEMG from the test subject is compared to the average vector calculated from sEMG recordings of the same motor task from 10 neurologically intact subjects in a protocol called brain motor control assessment (BMCA). To evaluate the stability of the VRI, a group of five healthy subjects were individually compared to the prototype, average healthy-subject vectors for all of the maneuvers. To evaluate the sensitivity of this method, the VRI was obtained from two SCI subjects participating in other research studies. One was undergoing supported treadmill ambulation training, and the other a controlled withdrawal of anti-spasticity medications. The supported treadmill training patient's VRI, calculated from pre- and post-training BMCA recordings, reflected the qualitative changes in sEMG patterns and functional improvement of motor control. The VRI of the patient followed by serial BMCA during medication withdrawal also reflected changes in the motor control as a result of changes in anti-spasticity medication. To validate this index for clinical use, serial studies using larger numbers of subjects with compromised motor control should be performed. (C) 2003 Elsevier Ltd. All rights reserved. C1 Baylor Coll Med, VA Med Ctr, Houston, TX 77030 USA. Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA. Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. RP Sherwood, AM (reprint author), Baylor Coll Med, VA Med Ctr, 2002 Holcombe 153, Houston, TX 77030 USA. EM ams@bem.tme.edu OI Sherwood, Arthur/0000-0002-0110-4317 NR 39 TC 29 Z9 29 U1 0 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1050-6411 J9 J ELECTROMYOGR KINES JI J. Electromyogr. Kinesiol. PD JUN PY 2004 VL 14 IS 3 BP 379 EP 388 DI 10.1016/j.jelekin.2003.10.006 PG 10 WC Neurosciences; Physiology; Rehabilitation; Sport Sciences SC Neurosciences & Neurology; Physiology; Rehabilitation; Sport Sciences GA 818ON UT WOS:000221254500010 PM 15094151 ER PT J AU Burrus, JK Matheson, WD Hong, JS Sorscher, EJ Balkovetz, DF AF Burrus, JK Matheson, WD Hong, JS Sorscher, EJ Balkovetz, DF TI Hepatocyte growth factor stimulates adenoviral-mediated gene transfer across the apical membrane of epithelial cells SO JOURNAL OF GENE MEDICINE LA English DT Article DE cell polarity; tight junction; gene therapy ID ACUTE-RENAL-FAILURE; AIRWAY EPITHELIA; TIGHT JUNCTION; FACTOR ALTERS; POLARITY; RECEPTOR; INFECTION; COXSACKIEVIRUS; EFFICIENCY; VECTORS AB Background The apical surface of polarized epithelial cells is relatively resistant to gene delivery by various agents including adenoviral vectors. Hepatocyte growth factor (HGF) dedifferentiates previously well-polarized Madin-Darby canine kidney (MDCK) cell monolayers by altering cell-surface polarity and inhibiting tight junction function. Methods We used an in vitro model of polarized MDCK cells grown on permeable supports to examine the effects of HGF pretreatment on adenoviral (Ad)-mediated gene delivery through the apical surface of epithelial cell monolayers. Results HGF pretreatment of MDCK cell monolayers for 72 h increased Ad-mediated gene transfer and expression of enhanced green fluorescent protein (EGFP) and luciferase in a dose-dependent fashion. Time-course analysis of HGF-induced stimulation of Ad-mediated gene transfer was seen after 24 h and increased further with pretreatment periods extending to 72 h. HGF pretreatment increased Ad-mediated gene transfer at varying multiplicity of infection (MOI; ranging from 0.2-2000). PCR analysis for adenoviral DNA in control and HGF-pretreated MDCK cells suggested increased entry of viral constructs into HGF-pretreated MDCK cell monolayers. HGF-induced alterations in cell polarity are reversible upon removal of HGF. Conclusions These data demonstrate that HGF pretreatment of MDCK cells increases the sensitivity of the cells to Ad-mediated gene delivery. The mechanism by which this occurs appears to be through increased entry of adenovirus into epithelial cells. These data provide evidence that biological agents that transiently alter epithelial cell polarity and tight junction function can be used to augment Ad-mediated gene delivery into epithelial cells from the apical surface. Copyright (C) 2004 John Wiley Sons, Ltd. C1 Univ Alabama, Dept Med, Birmingham, AL 35294 USA. Univ Alabama, Dept Surg, Birmingham, AL 35294 USA. Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA. Univ Alabama, Dept Physiol, Birmingham, AL 35294 USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA. RP Balkovetz, DF (reprint author), Univ Alabama, Dept Med, 1530 3rd Ave S,LHRB 642, Birmingham, AL 35294 USA. EM balkovet@uab.edu FU NIDDK NIH HHS [P30 DK54781] NR 29 TC 5 Z9 7 U1 0 U2 0 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 1099-498X J9 J GENE MED JI J. Gene. Med. PD JUN PY 2004 VL 6 IS 6 BP 624 EP 630 DI 10.1002/jgm.552 PG 7 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine GA 832OK UT WOS:000222276600004 PM 15170733 ER PT J AU Swarztrauber, K Vickrey, BG AF Swarztrauber, K Vickrey, BG TI Do neurologists and primary care physicians agree on the extent of specialty involvement of patients referred to neurologists? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE referral and consultation; physician's practice patterns ID FINANCIAL INCENTIVES; PARKINSONS-DISEASE; ISCHEMIC-STROKE; MANAGED-CARE; CONSULTATION; PATTERNS; RATES; OUTCOMES; SUBSPECIALISTS; COORDINATION AB OBJECTIVE: Understanding the roles and responsibilities of physicians who manage mutual patients is important for assuring good patient care. Among physicians expressing a preference to involve a neurologist in the care of a patient, we evaluated agreement between neurologists and primary care physicians for the extent of specialty involvement in the evaluation and management of the patient, and the factors influencing those preferences. DESIGN AND SETTING: A self-administered survey containing 3 clinical scenarios was developed with the assistance of a multispecialty advisory board and mailed to a stratified probability sample of physicians. PARTICIPANTS: Six hundred and eight family physicians, 624 general internists, and 492 neurologists in 9 U.S. states. INTERVENTIONS: For each scenario, those respondents who preferred involvement of a specialist were asked about the preferred extent of that involvement: one-time consultation with and without test/medication ordering, consultation and limited follow-up, or taking over ongoing care of the specialty problem as long as it persists. MAIN RESULTS: Survey response rate was 60%. For all 3 scenarios, neurologists preferred a greater extent of specialty involvement compared to primary care physicians (all P < .05). Other physician and practice characteristic factors, including financial incentives, had lesser or no influence on the extent of specialty involvement preferred. CONCLUSIONS: The disagreement between primary care physicians and specialists regarding the preferred extent of specialist involvement in the care of patients with neurological conditions should raise serious concerns among health care providers, policy makers, and educators about whether mutual patient care is coordinated and appropriate. C1 Portland VA Med Ctr, Dept Neurol, Portland, OR 97207 USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Alzheimers Dis Ctr, Los Angeles, CA 90024 USA. Greater Los Angeles VA HealthCare Syst, Parkinsons Dis Res Educ & Clin Ctr, Los Angeles, CA USA. RP Swarztrauber, K (reprint author), Portland VA Med Ctr, Dept Neurol, P-3-PADRECC,POB 1034, Portland, OR 97207 USA. EM swarztra@ohsu.edu NR 47 TC 18 Z9 18 U1 2 U2 2 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2004 VL 19 IS 6 BP 654 EP U34 DI 10.1111/j.1525-1497.2004.30535.x PG 10 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 826TN UT WOS:000221852000006 PM 15209604 ER PT J AU Oslin, DW Thompson, R Kallan, MJ TenHave, T Blow, FC Bastani, R Gould, RL Maxwell, AE Rosansky, J Van Stone, W Jarvik, L AF Oslin, DW Thompson, R Kallan, MJ TenHave, T Blow, FC Bastani, R Gould, RL Maxwell, AE Rosansky, J Van Stone, W Jarvik, L TI Treatment effects from UPBEAT: A randomized trial of care management for behavioral health problems in hospitalized elderly patients SO JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY LA English DT Article DE depression; hospital; alcohol use; collaborative care ID DEPRESSIVE SYMPTOMS; MEDICAL INPATIENTS; ANXIETY DISORDERS; UNITED-STATES; LATE-LIFE; IDENTIFICATION; INTERVENTION; POPULATIONS; PHYSICIANS; COMMUNITY AB The purpose of this study was to examine the impact of the Unified Psychogeriatric Biopsychosocial Evaluation and Treatment (UPBEAT) Program, an interdisciplinary mental health care management program, on the behavioral health symptoms of elderly veterans. Participants, 60 years and older, included 2637 veterans recruited from medical/surgical units who screened positively for significant depressive or anxiety symptoms and/or at-risk alcohol drinking. Participants were randomized to UPBEAT or to usual care. Primary outcomes were measured at baseline and at 6, 12, and 24 months. Participant nonadherence to the protocol was common and is a major limitation. There were no differences between UPBEAT and usual care patients on symptom or functional outcomes at any follow-up point. Exploratory analyses suggested that among participants with more physical health problems, there were greater improvements in depressive symptoms in those assigned to UPBEAT care. Despite a theoretical and practically sound intervention, participation was low and treatment outcomes, while generally good, appeared unaffected by the addition of the program. C1 Univ Penn, Sect Geriatr Psychiat, Dept Psychiat, Philadelphia, PA 19104 USA. Univ Penn, Ctr Study Addict, Dept Psychiat, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA. Univ Penn, Dept Epidemiol & Biostat, Philadelphia, PA 19104 USA. Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. Ann Arbor VA Healthcare Syst, Ann Arbor, MI USA. Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Stat, Los Angeles, CA 90024 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. VA Cent Off, Washington, DC USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Neuropsychiat Inst, Los Angeles, CA 90024 USA. Univ Hosp Calif Los Angeles, Los Angeles, CA USA. RP Oslin, DW (reprint author), Univ Penn, Sect Geriatr Psychiat, Dept Psychiat, 3434 Market St,Room 3002, Philadelphia, PA 19104 USA. EM oslin@mail.med.upenn.edu RI Thompson, Richard/G-5408-2011 OI Thompson, Richard/0000-0003-0127-513X FU NIMH NIH HHS [1K08 MH 01599-01] NR 30 TC 12 Z9 12 U1 2 U2 4 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0891-9887 J9 J GERIATR PSYCH NEUR JI J. Geriatr. Psychiatry Neurol. PD JUN PY 2004 VL 17 IS 2 BP 99 EP 106 DI 10.1177/0891988703262539 PG 8 WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry GA 848NT UT WOS:000223475100008 PM 15157351 ER PT J AU Bourdette, D Winter, R Riscoe, M Marracci, G AF Bourdette, D Winter, R Riscoe, M Marracci, G TI Alpha lipoic acid inhibits matrix metalloproteinase-9 and T cell migration: implications for the treatment of multiple sclerosis SO JOURNAL OF NEUROLOGY LA English DT Meeting Abstract CT 14th Meeting of the European-Neurological-Society CY JUN 26-30, 2004 CL Barcelona, SPAIN SP European Neurol Soc C1 Oregon Hlth & Sci Univ, Portland, OR USA. Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU DR DIETRICH STEINKOPFF VERLAG PI DARMSTADT PA PO BOX 10 04 62, D-64204 DARMSTADT, GERMANY SN 0340-5354 J9 J NEUROL JI J. Neurol. PD JUN PY 2004 VL 251 SU 3 BP 45 EP 45 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 835QK UT WOS:000222500400159 ER PT J AU Vandenbark, A Bartholomew, R Bourdette, D AF Vandenbark, A Bartholomew, R Bourdette, D TI Boosting regulatory T-cells in multiple sclerosis: immunogenicity and safety of a trivalent BV5S2, BV6S5 and BV13S1CDR2 vaccine in incomplete Freund's adjuvant SO JOURNAL OF NEUROLOGY LA English DT Meeting Abstract CT 14th Meeting of the European-Neurological-Society CY JUN 26-30, 2004 CL Barcelona, SPAIN SP European Neurol Soc C1 Portland VA Med Ctr, Portland, OR USA. Oregon Hlth & Sci Univ, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU DR DIETRICH STEINKOPFF VERLAG PI DARMSTADT PA PO BOX 10 04 62, D-64204 DARMSTADT, GERMANY SN 0340-5354 J9 J NEUROL JI J. Neurol. PD JUN PY 2004 VL 251 SU 3 BP 51 EP 52 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 835QK UT WOS:000222500400183 ER PT J AU Kozel, FA Revell, LJ Lorberbaum, JP Shastri, A Elhai, JD Horner, MD Smith, A Nahas, Z Bohning, DE George, MS AF Kozel, FA Revell, LJ Lorberbaum, JP Shastri, A Elhai, JD Horner, MD Smith, A Nahas, Z Bohning, DE George, MS TI A pilot study of functional magnetic resonance imaging brain correlates of deception in healthy young men SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES LA English DT Article; Proceedings Paper CT 12th Annual Meeting of the American-Neuropsychiatric-Association CY FEB 25-27, 2001 CL FT MYERS, FL SP Amer Neuropsychiat Assoc ID SKIN-CONDUCTANCE; PSYCHOPHYSIOLOGICAL DETECTION; INTERFERENCE TASK; MRI; CORTEX; RESPONSES; ATTENTION; DISORDER; SYSTEM; STROOP AB We hypothesized that specific brain regions would activate during deception, and these areas would correlate with changes in electrodermal activity (EDA). Eight men were asked to find money hidden under various objects. While functional MRI images were acquired and EDA was recorded, the subjects gave both truthful and deceptive answers regarding the money's location. The group, analysis revealed significant activation during deception in the orbitofrontal cortex (OFCx) and anterior cingulate (AC), but individual results were not consistent. Individually and as a group, EDA correlated with blood flow changes in the OFCx and AC. Specific brain regions were activated during deception, but the present technique lacks good predictive power for individuals. C1 MUSC, Dept Psychiat, Ctr Adv Imaging Res, Charleston, SC 29425 USA. MUSC, Dept Radiol, Charleston, SC USA. MUSC, Dept Neurol, Charleston, SC USA. Ralph H Johnson VA Med Ctr, Mental Hlth Serv, Charleston, SC USA. Minnesota State Univ, Dept Phys, Moorhead, MN USA. RP Kozel, FA (reprint author), MUSC, Dept Psychiat, Ctr Adv Imaging Res, 67 President St,POB 250861, Charleston, SC 29425 USA. EM kozelfa@musc.edu RI Kozel, Frank/I-5366-2012 NR 37 TC 72 Z9 73 U1 0 U2 4 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0895-0172 J9 J NEUROPSYCH CLIN N JI J. Neuropsychiatr. Clin. Neurosci. PD SUM PY 2004 VL 16 IS 3 BP 295 EP 305 DI 10.1176/appi.neuropsych.16.3.295 PG 11 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 855PN UT WOS:000223986300006 PM 15377736 ER PT J AU Mendez, MF Saghafi, S Clark, DG AF Mendez, MF Saghafi, S Clark, DG TI Semantic dementia in multilingual patients SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES LA English DT Letter ID LANGUAGE C1 Univ Calif Los Angeles, Neurobehav Unit, VA Greater Los Angeles Healthcare, Los Angeles, CA USA. RP Mendez, MF (reprint author), Univ Calif Los Angeles, Neurobehav Unit, VA Greater Los Angeles Healthcare, Los Angeles, CA USA. NR 5 TC 6 Z9 7 U1 0 U2 1 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0895-0172 J9 J NEUROPSYCH CLIN N JI J. Neuropsychiatr. Clin. Neurosci. PD SUM PY 2004 VL 16 IS 3 BP 381 EP 381 DI 10.1176/appi.neuropsych.16.3.381 PG 1 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 855PN UT WOS:000223986300018 PM 15377748 ER PT J AU Chan, PLS Nutt, JG Holford, NHG AF Chan, PLS Nutt, JG Holford, NHG TI Modeling the short- and long-duration responses to exogenous levodopa and to endogenous levodopa production in Parkinson's disease SO JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS LA English DT Article DE pharmacokinetics; pharmacodynamics; levodopa; Parkinson's disease; long-duration response ID ORAL LEVODOPA; DRUG HOLIDAY; L-DOPA; SLEEP BENEFIT; CLINICAL-APPLICATION; MOTOR FLUCTUATIONS; PHARMACOKINETICS; WITHDRAWAL; THERAPY; PHARMACODYNAMICS AB Clinicians recognize levodopa has a short-duration response ( measured in hr) and a long-duration response ( measured in days) in Parkinson's disease. In addition there is a diurnal pattern of motor function with better function in the morning. Previous pharmacokinetic-pharmacodynamic modeling has quantified only the short-duration response. We have developed a pharmacokinetic-pharmacodynamic model for the short- and long-duration responses to exogenous levodopa and the effects of residual endogenous levodopa synthesis in patients with Parkinson's disease. Thirteen previously untreated ( de novo) patients with Parkinson's disease and twelve patients who had received levodopa orally for 9.7 +/- 4.0 years ( chronic) were investigated. A 2 hr IV infusion of levodopa with concomitant oral carbidopa was given on two occasions separated by 3 days with no levodopa in between. A two compartment pharmacokinetic model was used to fit plasma levodopa concentrations. A sigmoid E-max model was used to relate concentrations from endogenous and exogenous sources to tapping rate ( a measure of motor response). A model incorporating three effect compartments ( fast equilibration ( half life, T-eqf), slow equilibration (T-eqs) and dopa synthesis (T-eqd)), yielded the most descriptive model for levodopa pharmacokinetics and pharmacodynamics. Baseline tapping rate reflected endogenous levodopa synthesis and the long-duration response. Partial loss of the long-duration response during the 3 days without levodopa in the chronic group lowered baseline tapping ( 36 +/- 7%, mean +/- SEM) and increased maximum levodopa induced response above baseline ( 112 +/- 31%). The maximum levodopa induced response after the drug holiday is a result of lowered baseline tapping due to the loss of long-duration response and not due to a change in levodopa pharmacokinetics or pharmacodynamics. C1 Univ Auckland, Dept Pharmacol & Clin Pharmacol, Auckland 1, New Zealand. Oregon Hlth & Sci Univ, Portland, OR USA. Portland VA Med Ctr, Dept Neurol & Physiol & Pharmacol, Portland, OR USA. RP Chan, PLS (reprint author), Univ Auckland, Dept Pharmacol & Clin Pharmacol, Auckland 1, New Zealand. EM phylinda.chan@pfizer.com OI Holford, Nick/0000-0002-4031-2514 NR 43 TC 16 Z9 17 U1 1 U2 4 PU KLUWER ACADEMIC/PLENUM PUBL PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1567-567X J9 J PHARMACOKINET PHAR JI J. Pharmacokinet. Pharmacodyn. PD JUN PY 2004 VL 31 IS 3 BP 243 EP 268 DI 10.1023/B:JOPA.0000039566.75368.59 PG 26 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 849QD UT WOS:000223553700003 PM 15518246 ER PT J AU Wee, AG Wee, LA Cheng, AC Cwynar, RB AF Wee, AG Wee, LA Cheng, AC Cwynar, RB TI The use of an intraoral electrolarynx for an edentulous patient: A clinical report SO JOURNAL OF PROSTHETIC DENTISTRY LA English DT Article; Proceedings Paper CT 49th Annual Scientific Meeting of the American-Academy-of-Maxillofacial-Prosthodontics CY OCT, 2001 CL NWE ORLEANS, LA SP Amer Acad Maxillofacial Prosthodnt ID LARYNGEAL-CANCER; VOICE RESTORATION; TOBACCO; ALCOHOL; SPEECH; ASBESTOS; REHABILITATION AB This clinical report describes the clinical requirements, treatment sequence, and use of a relatively new intraoral electrolarynx for a completely edentulous patient. This device consists of a sound source attached to the maxilla and a hand-held controller unit that controls the pitch and volume of the intraoral sound source via transmitted radio waves. C1 Ohio State Univ, Sect Restorat & Prosthet Dent, Columbus, OH 43210 USA. Univ Toronto, Dept Prosthodont, Toronto, ON, Canada. Vet Affairs Pittsburgh Healthcare, Dent Serv, Pittsburgh, PA USA. Univ Pittsburgh, Dept Prosthodont, Pittsburgh, PA 15260 USA. RP Wee, AG (reprint author), Ohio State Univ, Sect Restorat & Prosthet Dent, Columbus, OH 43210 USA. EM Wee.12@osu.edu FU NHLBI NIH HHS [K30 HL 04162] NR 15 TC 1 Z9 1 U1 0 U2 1 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0022-3913 J9 J PROSTHET DENT JI J. Prosthet. Dent. PD JUN PY 2004 VL 91 IS 6 BP 521 EP 524 DI 10.1016/j.prosdent.2004.03.009 PG 4 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 829ZK UT WOS:000222091200004 PM 15211292 ER PT J AU Zhou, XH Tsao, M Qin, GS AF Zhou, XH Tsao, M Qin, GS TI New intervals for the difference between two independent binomial proportions SO JOURNAL OF STATISTICAL PLANNING AND INFERENCE LA English DT Article DE binomial proportion; confidence interval; edgeworth expansion; skewness ID SAMPLE CONFIDENCE-INTERVALS; SUCCESS PROBABILITIES AB In this paper we gave an Edgeworth expansion for the studentized difference of two binomial proportions. We then proposed two new intervals by correcting the skewness in the Edgeworth expansion in a direct and an indirect way. Such the bias-correct confidence intervals are easy to compute, and their coverage probabilities converge to the nominal level at a rate of O(n(-1/2)), where n is the size of the combined samples. Our simulation results suggest that in finite samples the new interval based on the indirect method have the similar performance to the two best existing intervals in terms of coverage accuracy and average interval length and that the another new interval based on the direct method had the best average coverage accuracy but could have poor coverage accuracy when two true binomial proportions are close to the boundary points. (C) 2003 Elsevier B.V. All rights reserved. C1 VA Puget Sound Hlth Care Syst, Biostat Unit, NW HSR&D Ctr Excellence, Seattle, WA 98108 USA. Univ Washington, Dept Biostat, Seattle, WA 98195 USA. Univ Victoria, Dept Math & Stat, Victoria, BC, Canada. Georgia State Univ, Dept Math & Stat, Atlanta, GA 30303 USA. RP Zhou, XH (reprint author), VA Puget Sound Hlth Care Syst, Biostat Unit, NW HSR&D Ctr Excellence, 1660 S Columbian Way, Seattle, WA 98108 USA. EM azhou@u.washington.edu NR 20 TC 25 Z9 25 U1 1 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0378-3758 J9 J STAT PLAN INFER JI J. Stat. Plan. Infer. PD JUN 1 PY 2004 VL 123 IS 1 BP 97 EP 115 DI 10.1016/S0378-3758(03)00146-0 PG 19 WC Statistics & Probability SC Mathematics GA 812IA UT WOS:000220832000007 ER PT J AU Krupitsky, EM Zvartau, EE Masalov, DV Tsoi, MV Burakov, AM Egorova, VY Didenko, TY Romanova, TN Ivanova, EB Bespalov, AY Verbitskaya, EV Neznanov, NG Grinenko, AY O'Brien, CP Woody, GE AF Krupitsky, EM Zvartau, EE Masalov, DV Tsoi, MV Burakov, AM Egorova, VY Didenko, TY Romanova, TN Ivanova, EB Bespalov, AY Verbitskaya, EV Neznanov, NG Grinenko, AY O'Brien, CP Woody, GE TI Naltrexone for heroin dependence treatment in St. Petersburg, Russia SO JOURNAL OF SUBSTANCE ABUSE TREATMENT LA English DT Article DE naltrexone; heroin addiction; treatment ID CLINICAL-EXPERIENCE; OPIOID DEPENDENCE; ADDICTION; THERAPY; EFFICACY AB Naltrexone may be more effective for treating opioid (heroin) dependence in Russia than in the U.S. because patients are mostly young and living with their parents, who can control medication compliance. In this pilot study we randomized 52 consenting patients who completed detoxification in St. Petersburg to a double blind, 6-month course of biweekly drug counseling and naltrexone, or counseling and placebo naltrexone. Significant differences in retention and relapse favoring naltrexone were seen beginning at I month and continuing throughout the study. At the end of 6 months, 12 of the 27 naltrexone patients (44.4%) remained in treatment and had not relapsed as compared to 4 of 25 placebo patients (16%; p < 0.05). Since heroin dependence is the main way HIV is being spread in Russia, naltrexone is likely to improve treatment outcome and help reduce the spread of HIV if it can be made more widely available. (C) 2004 Elsevier Inc. All rights reserved. C1 Univ Penn, Dept Psychiat, Philadelphia, PA 19106 USA. St Petersburg State Pavlov Med Univ, Sci Res Ctr Addict & Psychopharmacol, St Petersburg, Russia. Vet Affairs Med Ctr, Philadelphia, PA USA. RP Woody, GE (reprint author), Univ Penn, Dept Psychiat, 600 Publ Ledger Bldg,150 S Independence Mall W, Philadelphia, PA 19106 USA. EM woody@tresearch.org RI Verbitskaya, Elena/N-3867-2015; Bespalov, Anton/R-6506-2016 OI Verbitskaya, Elena/0000-0003-3770-993X; FU NIDA NIH HHS [P60-DA051861, U10-DA13043] NR 30 TC 70 Z9 71 U1 0 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0740-5472 J9 J SUBST ABUSE TREAT JI J. Subst. Abus. Treat. PD JUN PY 2004 VL 26 IS 4 BP 285 EP 294 DI 10.1016/j.jsat.2004.02.002 PG 10 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 829BQ UT WOS:000222018400006 PM 15182893 ER PT J AU Friedlander, AH Marder, SR Sung, EC Child, JS AF Friedlander, AH Marder, SR Sung, EC Child, JS TI Panic disorder - Psychopathology, medical management and dental implications SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION LA English DT Article ID MITRAL-VALVE-PROLAPSE; SEROTONIN REUPTAKE INHIBITORS; NATIONAL-COMORBIDITY-SURVEY; FOLLOW-UP; BACTERIAL-ENDOCARDITIS; ANXIETY DISORDERS; DRUG-INTERACTIONS; HEART-DISEASE; AGORAPHOBIA; ASSOCIATION AB Background. This article reviews the clinical features, epidemiology, pathophysiology, dental findings, and dental and medical management of the care of patients with panic disorder, or PD. Types of Studies Reviewed. The authors conducted a MEDLINE search for the period 1998 through 2003, using the key term "panic disorder" to define the pathophysiology of the disorder, its epidemiology and dental implications. The articles they selected for further review included those published in peer-reviewed journals. Results. PD is a common and debilitating psychiatric disease in which a person experiences sudden and unpredictable panic attacks, or PAs, with symptoms of overwhelming anxiety, chest pain, palpitations and shortness of breath. Persistent concern about having another attack and worry that it may indicate a heart attack or "going crazy" impairs the person's social, family and working lives. Frequently accompanying the disorder is agoraphobia, depression and mitral valve prolapse, or MVP. Clinical Implications. In patients with PD, the prevalence of dental disease may be extensive because of the xerostomic effects of psychiatric medications used to treat it. Dental treatment consists of preventive dental education and prescribing saliva substitutes and anticaries agents. Precautions must be taken when prescribing or administering analgesics, antibiotics or sedative agents that may have an adverse interaction with the psychiatric medications. Because there is a connection between PAs and MVP, the dentist needs to consult with the patient's physician to determine the presence of MVP and whether there is associated mitral valve regurgitation. Patients with MVP and accompanying mitral valve regurgitation require prophylactic antibiotics when undergoing dental procedures known to cause a bacteremia and heightened risk of endocarditis. C1 Univ Calif Los Angeles, Med Ctr, Hosp Dent Serv, Los Angeles, CA 90024 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA. RP Friedlander, AH (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM arthur.friedlander@med.va.gov NR 61 TC 6 Z9 6 U1 1 U2 3 PU AMER DENTAL ASSN PI CHICAGO PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA SN 0002-8177 J9 J AM DENT ASSOC JI J. Am. Dent. Assoc. PD JUN PY 2004 VL 135 IS 6 BP 771 EP 778 PG 8 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 830WZ UT WOS:000222156200040 PM 15270162 ER PT J AU Steinman, MA Sauaia, A Maselli, JH Houck, PM Gonzales, R AF Steinman, MA Sauaia, A Maselli, JH Houck, PM Gonzales, R TI Office evaluation and treatment of elderly patients with acute bronchitis SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article; Proceedings Paper CT Annual Meeting of the American-Geriatrics-Society CY MAY 15-18, 2003 CL BALTIMORE, MD SP Amer Geriatr Soc DE bronchitis; antibiotics; aged; diagnostic techniques and procedures ID RESPIRATORY-TRACT INFECTIONS; UNCOMPLICATED ACUTE BRONCHITIS; COMMUNITY-ACQUIRED PNEUMONIA; RESISTANT STREPTOCOCCUS-PNEUMONIAE; ANTIBIOTIC USE; NATIONAL-SURVEY; PHYSICIANS; IMPACT; ADULTS; INTERVENTION AB OBJECTIVES: To assess the office evaluation of seniors with uncomplicated acute bronchitis and to determine the association between elements of the clinical evaluation and antibiotic prescribing decisions. DESIGN: Cross-sectional chart review. SETTING: Seventy-seven community-based office practices in the Denver metropolitan area. PARTICIPANTS: Elderly fee-for-service Medicare patients. MEASUREMENTS: Medicare administrative data to identify patients with acute bronchitis; medical record review to confirm the diagnosis and record other clinical data. RESULTS: Of 198 elderly patients with acute bronchitis, the mean age+/-standard deviation was 76+/-8.6; 53% had at least one comorbid condition. Clinically important vital signs were frequently not recorded; temperature was missing from 34% of charts and pulse from 50% of charts. When recorded, significant vital sign abnormalities were uncommon, with 7% having a temperature of 100degreesF and 8% having a pulse of 100 beats per minute or greater. However, antibiotics were prescribed to 83% of patients, with more than half of these prescriptions being for extended-spectrum antibiotics. Treatment with antibiotics was more common in men than women (92% vs 78%, P=.007) but was not associated with clinical factors including vital sign measurement, vital sign results, chest radiography, patient age, duration of illness, or the presence of comorbidities. CONCLUSION: The vast majority of seniors with acute bronchitis are treated with antibiotics, regardless of patient characteristics or the type of evaluation received. Reducing inappropriate antibiotic use in seniors with acute bronchitis may depend on improving the evaluation of these patients and encouraging clinicians to act appropriately on the results. C1 Univ Calif San Francisco, San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA 94143 USA. Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. Univ Colorado, Hlth Sci Ctr, Div Hlth Care Policy & Res, Denver, CO USA. Ctr Medicare & Medicaid Serv, Baltimore, MD USA. RP Gonzales, R (reprint author), Univ Calif San Francisco, Dept Med, Box 1211,3333 Calif St, San Francisco, CA 94118 USA. EM ralphg@medicine.ucsf.edu NR 30 TC 5 Z9 5 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JUN PY 2004 VL 52 IS 6 BP 875 EP 879 DI 10.1111/j.1532-5415.2004.52252.x PG 5 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 822JI UT WOS:000221534900003 PM 15161449 ER PT J AU Bates-Jensen, BM Schnelle, JF Alessi, CA Al-Samarrai, NR Levy-Storms, L AF Bates-Jensen, BM Schnelle, JF Alessi, CA Al-Samarrai, NR Levy-Storms, L TI The effects of staffing on in-bed times of nursing home residents SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE bedfast; quality of care; nursing home residents in-bed time ID MINI-MENTAL-STATE; PRESSURE SORES; SLEEP; QUALITY; CARE AB OBJECTIVES: To examine the effect of staffing level on time observed in bed during the daytime in nursing home (NH) residents. DESIGN: Descriptive, cross-sectional study. SETTING: Thirty-four southern California NHs. PARTICIPANTS: A total of 882 NH residents: 837 had hourly observation data, 777 had mealtime observations, 837 completed interviews, and 817 completed a physical performance test. MEASUREMENTS: Cross-sectional data collected from participants at each NH site included direct observations (hourly and mealtime), resident interviews, medical record review, and physical performance tests. RESULTS: In multivariate analyses, staffing level remained the strongest predictor of time observed in bed after controlling for resident functional measures (odds ratio=4.89; P=.042). Residents observed in bed during the daytime in more than 50% of hourly observations were observed also to experience increased daytime sleeping (P<.001) and less social engagement (P=.026) and consumed less food and fluids during mealtimes than those observed in bed in less than 50% of observations, after adjusting for resident function (P<.001). CONCLUSION: In this sample of NHs, resident functional measures and NH staffing level predicted observed time in bed according to hourly observations, with staffing level the most powerful predictor. Neither of these predictors justifies the excessive in-bed times observed in this study. Staff care practices relevant to encouraging residents to be out of bed and resident preferences for being in bed should be examined and improved. Practice recommendations regarding in-bed time should be considered, and further research should seek to inform the development of such recommendations. C1 Univ Calif Los Angeles, Sch Med, Dept Geriatr, Los Angeles, CA USA. Borun Ctr Gerontol Res, Reseda, CA USA. Jewish Home Aging, Reseda, CA USA. Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. RP Bates-Jensen, BM (reprint author), Univ Calif Los Angeles, Jewish Home Borun Ctr, 7150 Tampa Ave, Reseda, CA 91335 USA. EM batesjen@ucla.edu FU NIA NIH HHS [AG10415] NR 39 TC 41 Z9 41 U1 4 U2 4 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JUN PY 2004 VL 52 IS 6 BP 931 EP 938 DI 10.1111/j.1532-5415.2004.52260.x PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 822JI UT WOS:000221534900011 PM 15161457 ER PT J AU Reuben, DB Levy-Storms, L Yee, MN Lee, M Cole, K Waite, M Nichols, L Frank, JC AF Reuben, DB Levy-Storms, L Yee, MN Lee, M Cole, K Waite, M Nichols, L Frank, JC TI Disciplinary split: A threat to geriatrics interdisciplinary team training SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE geriatric education; team training; interdisciplinary care; teams AB In 1995, the John A. Hartford Foundation launched an initiative to strengthen geriatric interdisciplinary team training (GITT) for advanced practice nursing and masters-level social work students and residents in internal medicine and family practice. As part of the national evaluation of the initiative, case-study and cross-case designs were employed using quantitative and qualitative data to examine the influence of cultures, regulations, and attitudes of individual disciplines on interdisciplinary training efforts at the first eight GITT programs. This evaluation found that attitudinal and cultural traditions of the different health professions faculty and students (disciplinary split) remain as important obstacles to creating an optimal interdisciplinary team-training experience. In general, physician trainees participated least enthusiastically in GITT. In part, this lower level of enthusiasm may have been the result of inconsistent medicine faculty support of the program. At all but one program, physician trainees also had shorter GITT training experiences than other disciplines. In addition, the disparity in level of training by discipline of GITT participants may have contributed to attitudinal barriers to interdisciplinary training. Discipline-specific regulatory and accreditation barriers also impede interdisciplinary training. Nevertheless, GITT experiences at some clinical sites, especially home visits, appeared to promote interdisciplinary training. Some barriers to creating and implementing GITT programs may be best approached at the level of accrediting agencies and certifying organizations. Others will require local and national efforts of leaders in the different disciplines to model and support good team care. C1 Univ Calif Los Angeles, Multicampus Program Geriatr Med & Gerontol, Los Angeles, CA 90095 USA. Univ Hawaii, John A Burns Sch Med, Dept Geriatr Med, Honolulu, HI 96822 USA. VA Long Beach Healthcare Syst, Long Beach, CA USA. VA Greater Los Angeles Healthcare Syst, Ctr Geriatr Res Educ & Clin, Sepulveda Ambulatory Care Ctr & Nursing Home, Sepulveda, CA USA. Univ Tennessee, Ctr Hlth Sci, VA Med Ctr, Dept Prevent & Internal Med, Memphis, TN 38163 USA. RP Reuben, DB (reprint author), Univ Calif Los Angeles, Multicampus Program Geriatr Med & Gerontol, 10945 Le Conte Ave,Suite 2339, Los Angeles, CA 90095 USA. EM dreuben@mednet.ucla.edu NR 11 TC 19 Z9 19 U1 1 U2 7 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JUN PY 2004 VL 52 IS 6 BP 1000 EP 1006 DI 10.1111/j.1532-5415.2004.52272.x PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 822JI UT WOS:000221534900023 PM 15161469 ER PT J AU Gooch, JL Pergola, PE Guler, RL Abboud, HE Barnes, JL AF Gooch, JL Pergola, PE Guler, RL Abboud, HE Barnes, JL TI Differential expression of calcineurin A isoforms in the diabetic kidney SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID GROWTH-FACTOR-BETA; CYCLOSPORINE-A; AQUAPORIN-2; PHOSPHORYLATION; TRANSCRIPTION; HYPERTROPHY; AQP2 AB Calcineurin is an important signaling molecule in mesangial cells in vitro and is involved in some manifestations of diabetic nephropathy in vivo. However, calcineurin acts in a cell-specific and tissue-specific manner in the kidney, and mechanisms of specificity are unknown. Three closely related isoforms of the calcineurin A (CnA) subunit are expressed in a tissue-specific manner. This study was undertaken to determine if specificity of calcineurin action is linked to regulation of CnA isoforms in the diabetic kidney. After induction of diabetes with streptozotocin, expression of all three CnA isoforms rapidly increased, primarily in the thick ascending limb of Henle (TAL). After prolonged diabetes, increase specifically of the a isoform was observed in collecting ducts (CD) and in endothelial cells of glomeruli. Aquaporin 2 (AQP2), a putative substrate of calcineurin phosphatase in the kidney, is also involved in diabetic nephropathy. Co-localization of CnA isoforms with AQP2 revealed that CnA-alpha is the predominant isoform that associates with AQP2 in the diabetic kidney. Furthermore, inhibition of calcineurin with cyclosporin A (CsA) alters AQP2 localization and phosphorylation in principal cells of CD. Alterations in subcellular localization of AQP2 were parallel with CnA-a. Similarly, CsA treatment results in a further increase in urine output compared with diabetes alone, suggesting a functional consequence of inhibiting calcineurin-mediated regulation of AQP2. In conclusion, all three isoforms of CnA are upregulated in the diabetic kidney. Increased expression of CnA-alpha, in particular, is observed in glomeruli and CD and participates in regulation of AQP2 expression, phosphorylation, and function. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Div Nephrol, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Audie Murphy Div, San Antonio, TX USA. RP Gooch, JL (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Nephrol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM Gooch@uthscsa.edu NR 20 TC 26 Z9 26 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD JUN PY 2004 VL 15 IS 6 BP 1421 EP 1429 DI 10.1097/01.ASN.0000128076.91545.BB PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 823YD UT WOS:000221649400006 PM 15153553 ER PT J AU Cummings, BS Gelasco, AK Kinsey, GR Mchowat, J Schnellmann, RG AF Cummings, BS Gelasco, AK Kinsey, GR Mchowat, J Schnellmann, RG TI Inactivation of endoplasmic reticulum bound Ca2+-independent phospholipase A(2) in renal cells during oxidative stress SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID PROTEIN-KINASE-C; P388D(1) MACROPHAGES; BROMOENOL LACTONE; SUPEROXIDE ANION; VENTRICULAR MYOCYTES; SELECTIVE HYDROLYSIS; PANCREATIC-ISLETS; ENDOTHELIAL-CELLS; ANNEXIN-V; INHIBITION AB The purpose of this study was to determine the actions of oxidants on endoplasmic reticulum bound Ca2+ independent phospholipase A(2) (ER-iPLA(2)) and phospholipids in renal cells. Exposure of renal proximal tubule cells (RPTC) to the oxidants tert-butyl hydroperoxide (TBHP), cumene hydroperoxide, and cisplatin resulted in time- and concentration-dependent decreases in the activity of ER-iPLA(2). TBHP-induced ER-iPLA(2) inactivation was reversed by the addition of dithiothreitol to microsomes isolated from treated RPTC. TBHP also directly inactivated ER-iPLA(2) in microsomes isolated from untreated RPTC. Similar to RPTC, dithiothreitol prevented TBHP-induced ER-iPLA(2) inactivation in microsomes as did the reactive oxygen scavengers butylated hydroxytoluene and NN'-diphenyl-p-phenylenediamine and the iron chelator deferoxamine. Electron paramagnetic resonance spin trapping demonstrated that TBHP initiated a carbon-centered radical after 1min of exposure in microsomes, preceding ER-iPLA(2) inactivation, and further studies suggested that the formation of the carbon-centered radical species occurred after or in concert with the formation of oxygen-centered radicals. Phospholipid content was determined after TBHP exposure in the presence and absence of the ER-iPLA(2) inhibitor bromoenol lactone. Treatment of RPTC with TBHP resulted in 35% decreases in (16:0, 20:4)-phosphatidylethanolamine (PtdEtn), (18:0, 18:1)-plasmenylethanolamine (PlsEtn), a 30% decrease in (16:0, 18:3)-phosphatidylcholine (PtdCho), and a 25% decrease in (16:0, 20:4)-phosphatidylcholine (PtdCho). In contrast, treatment of RPTC with bromoenol lactone before TBHP exposure decreased the content of 11 phospholipids, decreasing a majority of PlsEtn phospholipids 60%, and 4 of the 8 PlsCho phospholipids 40%, while PtdCho and PtdEtn were marginally affected compared with TBHP. These data demonstrate that ER-iPLA(2) is inactivated by oxidants, that the mechanism of inactivation involves the oxidation of ER-iPLA(2) sulfhydryl groups, and that ER-iPLA(2) inhibition increases oxidant-induced RPTC phospholipid loss. C1 Med Univ S Carolina, Dept Pharmaceut Sci, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA. Ralph H Johnson VAMC, Charleston, SC USA. St Louis Univ, Dept Pathol, St Louis, MO 63103 USA. RP Cummings, BS (reprint author), Med Univ S Carolina, Dept Pharmaceut Sci, 280 Calhun St,POB 250140, Charleston, SC 29425 USA. EM schnell@musc.edu RI Kinsey, Gilbert/J-8322-2012 FU NCRR NIH HHS [S10 RR 13656]; NIDDK NIH HHS [DK 10079, DK 62028, K25 DK 59950] NR 47 TC 17 Z9 18 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD JUN PY 2004 VL 15 IS 6 BP 1441 EP 1451 DI 10.1097/01.ASN.0000127923.57438.EC PG 11 WC Urology & Nephrology SC Urology & Nephrology GA 823YD UT WOS:000221649400008 PM 15153555 ER PT J AU Ohldin, A Young, B Derleth, A McDonell, M Diehr, P Kiefe, C Fihn, S AF Ohldin, A Young, B Derleth, A McDonell, M Diehr, P Kiefe, C Fihn, S TI Ethnic differences in satisfaction and quality of life in veterans with ischemic heart disease SO JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION LA English DT Article DE quality of life; health status; race; ethnicity; cardiovascular disease; satisfaction; disparities ID ACUTE MYOCARDIAL-INFARCTION; CORONARY-ARTERY-DISEASE; PRIMARY-CARE PERFORMANCE; RACIAL-DIFFERENCES; FUNCTIONAL STATUS; CARDIOVASCULAR PROCEDURES; MEDICAL-CARE; HEALTH; AFFAIRS; RACE AB Objective: To assess differences in self-reported health status and satisfaction between African-American and caucasian veterans with ischemic heart disease (IHD). Data Sources/Study Setting: African-American and caucasian patients enrolled in General Internal Medicine clinics at six Veteran Affairs Medical Centers. Study Design: We conducted a cross-sectional analysis of baseline survey data from the Ambulatory Care Quality Improvement Project (ACQUIP). Patients who responded to an initial health-screening questionnaire were sent follow-up surveys, which included the Medical Outcomes Study 36-item Health Survey (SF-36), the Seattle Outpatient Satisfaction Questionnaire (SOSQ), and the Seattle Angina Questionnaire (SAQ). Principal Findings: Of the 44,965 patients approached, 27,977 (62%) returned the baseline survey, of which 10,385 patients reported IHD and were sent the SAQ. Of those, 7,985 patients (84% caucasian, 16% African-American) responded. Caucasian respondents tended to be older, married, nonsmokers, with annual incomes over $10,000, and had higher educational attainment than African Americans. African-American patients reported significantly fewer cardiac procedures (33% vs. 52%, p<0.001) but were more likely to have diabetes (37% vs. 28%, p<0.001) and hypertension (81% vs. 68%, p<0.001). After adjustment for demographic characteristics, comorbid conditions, clinic site, and site-ethnicity interactions, SF-36 scores for physical function, role physical, bodily pain, and vitality were greater for African Americans than caucasians, while adjusted scores were significantly lower for role emotional. However, because of the site-ethnicity interaction, scores varied significantly by site. For the SAQ, overall adjusted physical function summary scores and disease stability scores were significantly greater for African Americans than caucasians. Adjusted summary satisfaction scores for provider satisfaction were not significantly lower for African Americans overall but were significant at two of six sites. Similarly, on the SAQ, adjusted treatment satisfaction scores were significantly lower for African Americans at half of the sites and minimally but not clinically significant overall. Conclusions: Despite a higher prevalence of cardiac risk factors, African-American patients with CAD who were treated in the VA system appeared to have a greater level of physical functioning, vitality, and angina stability. After adjustment for confounding demographic variables, however, these differences were not consistently significant at all geographic locations. This suggests that many other sociodemographic variables, in addition to ethnicity, influence apparent discrepancies in quality of life, satisfaction, and angina. C1 VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Ctr Excellence, Seattle, WA 98108 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. Univ Washington, Dept Biostat, Seattle, WA 98195 USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. Univ Alabama, Dept Prevent Med, Birmingham, AL USA. RP Young, B (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Ctr Excellence, 1660 S Columbian Way, Seattle, WA 98108 USA. EM youngb@u.washington.edu NR 41 TC 4 Z9 5 U1 1 U2 1 PU NATL MED ASSOC PI WASHINGON PA 1012 10TH ST, N W, WASHINGON, DC 20001 USA SN 0027-9684 J9 J NATL MED ASSOC JI J. Natl. Med. Assoc. PD JUN PY 2004 VL 96 IS 6 BP 799 EP 808 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 840HO UT WOS:000222848900030 PM 15233490 ER PT J AU Levine, GN Ferrando, T AF Levine, GN Ferrando, T TI Degree of anticoagulation after one subcutaneous and one subsequent intravenous booster dose of enoxaparin: Implications for patients with acute coronary syndromes undergoing early percutaneous coronary intervention SO JOURNAL OF THROMBOSIS AND THROMBOLYSIS LA English DT Article DE enoxaparin; anti-Xa level; ENOX time ID MOLECULAR-WEIGHT HEPARIN; UNSTABLE ANGINA; PRETREATMENT; TRIAL AB Background: Many cardiologists continue to be reluctant to utilize low-molecular-weight heparin in the treatment of patients with non-ST-segment-elevation acute coronary syndrome because they are concerned about how to manage such patients if they have received only one dose of subcutaneous enoxaparin and are then taken within hours of such treatment to the cardiac catheterization laboratory for percutaneous coronary intervention (PCI). Although we and others have recommended that such patients who have received only one subcutaneous enoxaparin dose receive an intravenous 0.3 mg/kg enoxaparin "booster" dose immediately prior to PCI, there are little actual data to support this recommendation. Methods: 20 middle-aged subjects were treated with 1 mg/kg subcutaneously-administered enoxaparin and then 6 hours later with a "booster" dose of 0.3 mg/kg intravenously-administered enoxaparin. Anti-Xa levels, as well as ENOX Times, were assessed at baseline, at 2, 4 and 6 hours after the initial SC dose, and at 5 min, 1 and 2 hours after the IV booster dose. Results: At 2 and 6 hours after the initial subcutaneous enoxaparin dose, thirty-five percent of patients had anti-Xa levels below 0.6 IU/mL; twenty percent and ten percent had anti-Xa levels below 0.5 IU/mL at 2 and 6 hours after the initial subcutaneous dose, respectively. After the IV booster dose, all patients had anti-Xa levels in the therapeutic range during the 5 minutes to 2 hours during which blood samples were obtained. There was no significant "overshoot" with this booster dose above what is considered to be the upper therapeutic range. ENOX times showed an overall moderate correlation with anti-Xa levels. Conclusions: A strategy of administering a 0.3 mg/kg IV booster dose to patients who have received only one subcutaneous dose of enoxaparin and then undergo PCI within the first 2-6 hours of such treatment reliably leads to anti-Xa levels in the therapeutic range. C1 Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Houston VA Med Ctr, Cardiol Sect, Houston, TX 77030 USA. RP Levine, GN (reprint author), Houston VAMC 111B, Sect Cardiol 3C 330, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM glevine@bcm.tmc.edu NR 14 TC 19 Z9 19 U1 0 U2 1 PU KLUWER ACADEMIC PUBL PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0929-5305 J9 J THROMB THROMBOLYS JI J. Thromb. Thrombolysis PD JUN PY 2004 VL 17 IS 3 BP 167 EP 171 DI 10.1023/B:THRO.0000040484.99422.77 PG 5 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 852FO UT WOS:000223740900001 PM 15353913 ER PT J AU Freedland, SJ Terris, MK Csathy, GS Kane, CJ Amling, CL Presti, JC Dorey, F Aronson, WJ AF Freedland, SJ Terris, MK Csathy, GS Kane, CJ Amling, CL Presti, JC Dorey, F Aronson, WJ CA Search Database Study Grp TI Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen SO JOURNAL OF UROLOGY LA English DT Article DE prostate; prostatic neoplasms; prostatectomy; prostate-specific antigen; recurrence ID BEAM RADIATION-THERAPY; SEARCH DATABASE; EXTRACAPSULAR EXTENSION; DISEASE RECURRENCE; POSITIVE BIOPSIES; CORES; STAGE; RISK; PSA; INTERMEDIATE AB Purpose: We developed a preoperative model to risk stratify patients for prostate specific antigen (PSA) failure following radical prostatectomy (RP) and identify those at high risk who would be potential candidates for neoadjuvant clinical trials. Materials and Methods: A retrospective survey of 459 patients from the SEARCH Database treated with RP between 1990 and 2002 was done. Multivariate analysis was used to compare the preoperative variables of patient age, race, PSA, biopsy Gleason score, clinical stage and percent of prostate needle biopsy tissue with cancer for the ability to predict time to PSA recurrence following RP. Significant independent predictors were combined to create a novel risk grouping model. Results: On multivariate analysis biopsy Gleason score (p < 0.001), percent of biopsy tissue with cancer (p < 0.001) and serum PSA (p = 0.001) were the only significant independent predictors of PSA failure. Combining these 3 significant predictors of PSA failure using previously published cutoff points for each variable generated a 4 tier preoperative model for predicting biochemical failure following RP (HR 1.91 for each 1 risk category increase, CI 1.62 to 2.26, p < 0.001). The model further stratified patients who were already stratified into low, intermediate and high risk groups based on a previously described model using PSA, biopsy Gleason score and clinical stage. A simplified table was developed to predict the risk of biochemical recurrence within 2 years following surgery, as stratified by percent of tissue with cancer, PSA and biopsy Gleason score. Conclusions: A combination of serum PSA, biopsy Gleason score and percent of prostate biopsy tissue with cancer define a new preoperative model for predicting PSA failure following RP. This model further stratified patients who were already stratified based on PSA, biopsy Gleason score and clinical stage, and it can be used preoperatively to identify patients at high risk who would be candidates for neoadjuvant clinical trials. Using this model an easy to use table was developed to predict preoperatively the 2-year risk of PSA recurrence following RP. C1 Johns Hopkins Univ, Sch Med, Dept Urol, Baltimore, MD 21287 USA. Med Coll Georgia, Urol Sect, Augusta, GA 30912 USA. Vet Adm Greater Los Angeles Healthcare Syst, Dept Pathol, Los Angeles, CA USA. Vet Adm Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Urol, Los Angeles, CA 90024 USA. Vet Adm Med Ctr, Dept Surg, Urol Sect, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Urol, Sch Med, San Francisco, CA 94143 USA. San Diego Naval Hosp, Dept Urol, San Diego, CA USA. Stanford Univ, Sch Med, Dept Urol, Palo Alto, CA 94304 USA. RP Freedland, SJ (reprint author), Johns Hopkins Univ, Sch Med, Dept Urol, 600 N Wolfe St, Baltimore, MD 21287 USA. EM sfreedl1@jhmi.edu OI Terris, Martha/0000-0002-3843-7270 NR 20 TC 39 Z9 41 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD JUN PY 2004 VL 171 IS 6 BP 2215 EP 2220 DI 10.1097/01.ju.0000124463.13319.0a PN 1 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 822BV UT WOS:000221510300021 PM 15126788 ER PT J AU Albertsen, PC Hanley, JA Penson, DF Fine, J AF Albertsen, PC Hanley, JA Penson, DF Fine, J TI Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation SO JOURNAL OF UROLOGY LA English DT Article DE prostatic neoplasms; prostate-specific antigen; outcome assessment ID RADICAL RETROPUBIC PROSTATECTOMY; DOUBLING TIMES; PROGRESSION AB Purpose: Many patients who undergo surgery or radiation therapy to treat localized prostate cancer experience an increase in serum prostate specific antigen (PSA) after treatment. This study documents patterns of PSA recurrence after surgery or radiation to treat localized prostate cancer and quantifies the extent to which an increasing PSA predicts death from prostate cancer. Materials and Methods: Posttreatment PSA levels were measured on a population based cohort of 1,136 men diagnosed with localized prostate cancer in community practice in Connecticut between 1990 and 1992, and treated within 6 months of diagnosis with surgery or radiation with or without androgen withdrawal therapy. The major outcome measure was death from prostate cancer. Results: PSA recurrence followed a log-linear pattern over time. Patients who died of prostate cancer had a median PSA doubling time of 0.8 years (25th and 75th percentiles 0.5 to 1.4 years). Patients who did not die of prostate cancer within 10 years of diagnosis had either no posttreatment increase in serum PSA (40%) or had a PSA doubling time longer than 1 year (44%). Conclusions: Patients whose posttreatment PSA doubling times before the initiation of androgen withdrawal therapy are less than 1 year are at high risk of dying of prostate cancer within 10 years of diagnosis. Men with PSA recurrences that are doubling at rates greater than 1 year are at low risk of death from prostate cancer within 10 years of diagnosis. C1 Univ Connecticut, Ctr Hlth, Div Urol, Farmington, CT 06030 USA. McGill Univ, Montreal, PQ, Canada. Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Albertsen, PC (reprint author), Univ Connecticut, Ctr Hlth, Div Urol, 263 Farmington Ave, Farmington, CT 06030 USA. EM Albertsen@nso.uche.edu FU AHRQ HHS [HS09578] NR 9 TC 49 Z9 51 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD JUN PY 2004 VL 171 IS 6 BP 2221 EP 2225 DI 10.1097/01.ju.0000124381.93689.b4 PN 1 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 822BV UT WOS:000221510300022 PM 15126789 ER PT J AU Okotie, OT Aronson, WJ Wieder, JA Liao, Y Dorey, F deKernion, JB Freedland, SJ AF Okotie, OT Aronson, WJ Wieder, JA Liao, Y Dorey, F deKernion, JB Freedland, SJ TI Predictors of metastatic disease in men with biochemical failure following radical prostatectomy SO JOURNAL OF UROLOGY LA English DT Article DE prostate; prostatic neoplasms; neoplasm metastasis; prostate-specific antigen; diagnostic imaging ID BONE-SCINTIGRAPHY; CANCER; ANTIGEN; PROGRESSION; RECURRENCE; TOMOGRAPHY AB Purpose: We determined clinical and pathological predictors of positive bone scans and computerized tomography (CT) in patients with biochemical recurrence after radical prostatectomy (RP). Materials and Methods: A retrospective analysis of patients treated with RP at West Los Angeles Veterans Affairs Medical Center and University of California-Los Angeles Medical Center was performed to identify men with biochemical recurrence. All postoperative bone scans and pelvic CT following recurrence and prior to the initiation of hormone ablation therapy were reviewed. Preoperative clinical variables, pathological findings, serum prostate specific antigen (PSA) at postoperative imaging and postoperative PSA doubling time were compared between patients with positive and negative imaging study results. Results: A total of 128 patients with biochemical recurrence after RP who had postoperative pelvic CT or bone scans available were identified. A total of 97 bone scans were obtained, of which 11 (11%) were positive, and 71 CT scans were obtained, of which 5 (7%) were positive. Men with PSA doubling time less than 6 months were at increased risk of a positive bone scan (26% vs 3%) or positive CT (24% vs 0%) relative to men with longer PSA doubling time. In men with PSA doubling time less than 6 months the risk of a positive study highly depended on PSA at the time of imaging. In men with PSA less than 10 ng/ml the incidence of a positive study was 0% for pelvic CT and 11% for bone scan. In men with PSA greater than 10 ng/ml the risk of a positive study was 57% for pelvic CT and 46% for bone scan. In men with PSA doubling time greater than 6 months no clear relationship to PSA was seen, although the number of patients with a positive study was extremely low (positive bone scans 3% and positive CT 0%). However, none of the 6 imaging studies performed in men with PSA doubling times greater than 6 months and a markedly elevated PSA of 20 to 90 ng/ml was positive. Conclusions: The risk of detecting metastatic disease by bone scan or pelvic CT in men with biochemical recurrence following RP with PSA doubling time greater than 6 months is low despite marked PSA increases up to 90 ng/ml. In men with PSA doubling time less than 6 months the risk of detecting metastatic disease markedly increases when PSA is greater than 10 ng/ml. These results have important implications for the timing of imaging in patients with biochemical recurrence following RP. C1 Johns Hopkins Sch Med, Dept Urol, Baltimore, MD 21287 USA. Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Dept Biostat, Los Angeles, CA USA. Vet Adm Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA. RP Freedland, SJ (reprint author), Johns Hopkins Sch Med, Dept Urol, 600 N Wolfe St, Baltimore, MD 21287 USA. EM sfreedl1@jhmi.edu NR 20 TC 83 Z9 88 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD JUN PY 2004 VL 171 IS 6 BP 2260 EP 2264 DI 10.1097/01.ju.0000127734.01845.99 PN 1 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 822BV UT WOS:000221510300031 PM 15126798 ER PT J AU Kwiatkowski, B Chen, SYJ Schubach, WH AF Kwiatkowski, B Chen, SYJ Schubach, WH TI CKII site in Epstein-Barr virus nuclear protein 2 controls binding to hSNF5/Ini1 and is important for growth transformation SO JOURNAL OF VIROLOGY LA English DT Article ID CHROMATIN REMODELING COMPLEX; LATENT MEMBRANE-PROTEIN; SWI-SNF COMPLEX; RBP-J-KAPPA; B-CELL; TRANSCRIPTION FACTORS; LYMPHOMA-CELLS; CIS-ELEMENT; C-SRC; ANTIGEN-2 AB Substitution mutagenesis of EBNA2 shows that its interaction with hSNF5/Ini1 involves two sites (286IPP and DQQ313), and a mutation at a CKII phosphorylation site (SS469) is essential for the interaction. An alanine substitution (SS469AA) prevents binding to EBNA2 and diminishes the growth-promotion potential of EBNA2 in the transcomplementation assay. C1 VA Puget Sound Hlth Care Syst, Div Oncol, Dept Med, Seattle, WA 98108 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. RP Schubach, WH (reprint author), VA Puget Sound Hlth Care Syst, Div Oncol, Dept Med, S-111-ONC,1660 S Columbian Way, Seattle, WA 98108 USA. EM wschu@u.washington.edu FU NCI NIH HHS [CA82459] NR 58 TC 15 Z9 15 U1 1 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD JUN PY 2004 VL 78 IS 11 BP 6067 EP 6072 DI 10.1128/JVI.78.11.6067-6072.2004 PG 6 WC Virology SC Virology GA 822CW UT WOS:000221513400057 PM 15141006 ER PT J AU Hoyt, CC Bouchard, RJ Tyler, KL AF Hoyt, CC Bouchard, RJ Tyler, KL TI Novel nuclear herniations induced by nuclear localization of a viral protein SO JOURNAL OF VIROLOGY LA English DT Article ID CELL-CYCLE ARREST; PORE COMPLEX COMPOSITION; VIRUS TYPE-1 VPR; NUCLEOCYTOPLASMIC TRANSPORT; REOVIRUS STRAINS; GENE-EXPRESSION; INFECTED-CELLS; LAMIN-A; KAPPA-B; APOPTOSIS AB A common consequence of viral infection is perturbation of host cell nuclear functions. For cytoplasmically replicating viruses, this process may require regulated transport of specific viral proteins into the nucleus. Here, we describe a novel form of virus-induced perturbation of host cell nuclear structures. Active signal-mediated nuclear import of the reovirus sigma1s protein results in redistribution of nuclear pore complexes and nuclear lamins and formation of nuclear herniations. These herniations represent a previously undescribed mechanism by which cytoplasmic viral infection can perturb nuclear architecture and induce cytopathic effects, which ultimately lead to disease pathogenesis in the infected host. C1 Univ Colorado, Hlth Sci Ctr, Dept Neurol, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Program Neurosci, Denver, CO 80262 USA. Denver Vet Affairs Med Ctr, Denver, CO 80262 USA. RP Tyler, KL (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Neurol, 4200 E 9th Ave, Denver, CO 80262 USA. EM Ken.Tyler@uchsc.edu OI Tyler, Kenneth/0000-0003-3294-5888 FU NIA NIH HHS [1R01 AG 14071] NR 45 TC 14 Z9 15 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD JUN PY 2004 VL 78 IS 12 BP 6360 EP 6369 DI 10.1128/JVI.78.12.6360-6369.2004 PG 10 WC Virology SC Virology GA 825QC UT WOS:000221772000029 PM 15163729 ER PT J AU An, JB Sun, YP Fisher, M Rettig, MB AF An, JB Sun, YP Fisher, M Rettig, MB TI Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-kappa B dependent SO MOLECULAR CANCER THERAPEUTICS LA English DT Article ID TUMOR-SUPPRESSOR GENE; MULTIPLE-MYELOMA; LYMPHOID MALIGNANCIES; THERAPEUTIC TARGET; DRUG-RESISTANCE; NECROSIS-FACTOR; IN-VIVO; CANCER; PS-341; EXPRESSION AB Advanced renal cell carcinoma (RCC) is resistant to cytotoxic chemotherapy, and immunotherapy has modest activity. Proteasome inhibitors represent a novel class of anticancer agents that have activity across a wide spectrum of tumor types. We investigated the efficacy of the proteasome inhibitor bortezomib (VELCADE, formerly known as PS-341) in RCC and found that bortezomib potently induces apoptosis of RCC cell lines. Blockade of the nuclear factor-kappaB (NF-kappaB) pathway is considered a crucial effect in bortezomib-induced apoptosis, but the dependence on NF-kappaB inhibition for bortezornib-mediated death has not been formally demonstrated. Thus, we also studied the contribution of NF-kappaB inhibition as a mechanism of bortezomib-induced apoptosis in RCC cells, which display constitutive NF-kappaB activation. Ectopic expression of the NF-kappaB family members, p65 (Rel A) and p50 (NF-kappaB1), markedly reduced bortezomib-induced apoptosis. However, when we used selective genetic and chemical inhibitors of NF-kappaB, we found that NF-kappaB blockade was not sufficient to induce apoptosis of RCC cells. Thus, we conclude that maximal bortezomib-incluced apoptosis is dependent on its NF-kappaB inhibitory effect, but NF-kappaB-independent effects also play a critical role in the induction of apoptosis by bortezomib. This represents the first report to formally demonstrate that bortezomib-induced NF-kappaB blockade is required to achieve the maximum degree of apoptosis by this drug. C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. RP Rettig, MB (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,Bldg 304,Room E1-113, Los Angeles, CA 90073 USA. EM matthew.rettig@med.va.gov NR 45 TC 55 Z9 60 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 J9 MOL CANCER THER JI Mol. Cancer Ther. PD JUN PY 2004 VL 3 IS 6 BP 727 EP 736 PG 10 WC Oncology SC Oncology GA 831NY UT WOS:000222202400010 PM 15210859 ER PT J AU Gilkeson, GS Yang, J Thurman, J Holers, VM AF Gilkeson, GS Yang, J Thurman, J Holers, VM TI Effect of anti-factor B antibody on lupus like disease in MRL/lpr mice SO MOLECULAR IMMUNOLOGY LA English DT Meeting Abstract CT 20th International Complement Workshop CY JUN 13-18, 2004 CL Honolulu, HI C1 Ralph H Johnson VAMC, Med Res Serv, Charleston, SC USA. Med Univ S Carolina, Charleston, SC 29425 USA. Univ Colorado, Med Ctr, Denver, CO 80202 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0161-5890 J9 MOL IMMUNOL JI Mol. Immunol. PD JUN PY 2004 VL 41 IS 2-3 MA 77 BP 236 EP 236 PG 1 WC Biochemistry & Molecular Biology; Immunology SC Biochemistry & Molecular Biology; Immunology GA 827XK UT WOS:000221936800088 ER PT J AU Thurman, JM Kraus, DM Girardi, G Kang, HJ Hourcade, D Royer, PA Gilkeson, G Salmon, JE Holers, VM AF Thurman, JM Kraus, DM Girardi, G Kang, HJ Hourcade, D Royer, PA Gilkeson, G Salmon, JE Holers, VM TI A novel inhibitor of the alternative pathway of complement protects mice from fetal injury in the antiphospholipid syndrome SO MOLECULAR IMMUNOLOGY LA English DT Meeting Abstract CT 20th International Complement Workshop CY JUN 13-18, 2004 CL Honolulu, HI C1 Univ Colorado, Hlth Sci Ctr, Dept Med, Div Nephrol, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Div Rheumatol, Dept Med, Denver, CO 80262 USA. Hosp Special Surg, Weill Med Coll, Dept Med, New York, NY 10021 USA. Washington Univ, Sch Med, Dept Med, Div Rheumatol, St Louis, MO USA. Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Med Res Serv, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0161-5890 J9 MOL IMMUNOL JI Mol. Immunol. PD JUN PY 2004 VL 41 IS 2-3 MA 254 BP 318 EP 318 PG 1 WC Biochemistry & Molecular Biology; Immunology SC Biochemistry & Molecular Biology; Immunology GA 827XK UT WOS:000221936800261 ER PT J AU Furtado, S Payami, H Lockhart, PJ Hanson, M Nutt, JG Singleton, AA Singleton, A Bower, J Utti, RJ Bird, TD de la Fuente-Femandez, R Tsuboi, Y Klimek, ML Suchowersky, O Hardy, J Calne, DB Wszolek, ZK Farrer, M Gwinn-Hardy, K Stoessl, AJ AF Furtado, S Payami, H Lockhart, PJ Hanson, M Nutt, JG Singleton, AA Singleton, A Bower, J Utti, RJ Bird, TD de la Fuente-Femandez, R Tsuboi, Y Klimek, ML Suchowersky, O Hardy, J Calne, DB Wszolek, ZK Farrer, M Gwinn-Hardy, K Stoessl, AJ TI Profile of families with parkinsonism-predominant spinocerebellar ataxia type 2 (SCA2) SO MOVEMENT DISORDERS LA English DT Review DE parkinsonism; SCA2; Parkinson's disease; genetic mutation; PET; interrupted repeats; phenotype ID ALPHA-SYNUCLEIN GENE; BINDING PROTEIN GENE; REPEAT EXPANSION; RESPONSIVE PARKINSONISM; DISEASE; MUTATION; ONSET; CLONING; PET AB Spinocerebellar ataxia type 2 (SCA2) has been recognized recently as an uncommon cause of parkinsonism, an alternate presentation to the typical cerebellar disorder. This research review summarizes the existing literature on parkinsonism-predominant presentation SCA2 and presents new clinical cases of patients with this condition. Various phenotypes are noted in this subtype of SCA2, including parkinsonism indistinguishable from idiopathic Parkinson's disease (PD), parkinsonism plus ataxia, motor neuron disease, and postural tremor. In several kindreds with multiple affected family members, the SCA2 expansion segregated with disease; in addition, several single cases of parkinsonism with and without a family history are also described. The number of repeats in symptomatic patients ranged from 33 to 43. Interruption of the CAG repeat with CAA, CGG, or CCG was found in some individuals, possibly stabilizing the repeat structure and accounting for the relative stability of the repeat size across generations in some families; allele length is not necessarily indicative of trinucleotide repeat architecture. Positron emission tomography scanning in one family showed reduced fluorodopa uptake and normal to increased raclopride binding with a rostrocaudal gradient similar to that found in idiopathic PD. This review emphasizes the importance of testing for SCA2 in patients with parkinsonism and a family history of neurodegenerative disorders. Testing for SCA2 is also important in studies of inherited parkinsonism. (C) 2004 Movement Disorder Society. C1 Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada. Oregon Hlth Sci Univ, Dept Neurol, Portland, OR 97201 USA. New York State Dept Hlth, Wadsworth Ctr, Albany, NY USA. Mayo Clin Jacksonville, Dept Neurosci, Jacksonville, FL USA. Mayo Clin Jacksonville, Dept Neurol, Jacksonville, FL USA. NIA, Neurogenet Lab, NIH, Bethesda, MD USA. NINDS, Neurogenet Div, Parkinsons Genet Unit, NIH, Bethesda, MD USA. Mayo Clin, Dept Neurol, Rochester, MN USA. Univ Washington, Dept Neurol, Seattle, WA USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. Univ British Columbia, Pacific Parkinsons Res Ctr, Vancouver, BC, Canada. RP Furtado, S (reprint author), Foothills Prov Gen Hosp, Dept Clin Neurosci, 12th Floor,1403-29 St,NW, Calgary, AB T2N 2T9, Canada. EM furtado@ucalgary.ca RI Gwinn, Katrina/C-2508-2009; Singleton, Andrew/C-3010-2009; Hardy, John/C-2451-2009; Lockhart, Paul/E-7753-2011 OI Lockhart, Paul/0000-0003-2531-8413; Gwinn, Katrina/0000-0002-8277-651X FU NINDS NIH HHS [R01 NS36960] NR 28 TC 56 Z9 57 U1 0 U2 3 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD JUN PY 2004 VL 19 IS 6 BP 622 EP 629 DI 10.1002/mds.20074 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 831DL UT WOS:000222173200003 PM 15197699 ER PT J AU Rodriquez, AA Barr, KP Burns, SP AF Rodriquez, AA Barr, KP Burns, SP TI Whiplash: Pathophysiology, diagnosis, treatment, and prognosis SO MUSCLE & NERVE LA English DT Review DE headache; neck pain; neck sprain injury; TMD pain; whiplash; whiplash-associated disorder ID CERVICOCEPHALIC KINESTHETIC SENSIBILITY; CERVICAL MUSCLE DYSFUNCTION; ZYGAPOPHYSEAL-JOINT PAIN; NECK SPRAIN INJURIES; REAR-END COLLISION; BOTULINUM-TOXIN-A; CHRONIC SYMPTOMS; TEMPOROMANDIBULAR DISORDERS; RADIOFREQUENCY NEUROTOMY; MEDICOLEGAL CONTEXT AB We have reviewed the literature relevant to pathophysiology, diagnosis, treatment, and prognosis of whiplash-associated disorder (WAD) since 1995 and provided a brief summary of literature pertaining to forces action on the head and neck during a motor vehicle accident. The scope of the current review is confined to the Quebec guidelines for WAD grades 1-3 but excludes grade 4 (neck complaints and fracture or dislocation). After excluding papers without scientific data and single case reports or case series with fewer than 20 patients, articles were reviewed for methodological quality. The diagnosis remains clinical. No imaging, physiological, or psychological study provides specific diagnostic criteria. In the acute period up to 2 weeks, soft collars or rest and work-leave do not shorten the duration of neck pain. Sick leave is reduced by high-dose methylprednisolone given within 8 h of injury, but confirmatory studies examining the cost-benefit relationship are needed. In the first 6 months, active as opposed to passive treatment results in improved outcomes. Specific exercise strategies have not been studied. For those with symptoms lasting more than 6 months, percutaneous radio-frequency neurotomy can provide pain relief for many months in those responding to blind local anesthetic facet blocks. Intraarticular corticosteroids are ineffective. Uncontrolled trials suggest that multimodal rehabilitation programs result in improved overall function. The overall prognosis for recovery has varied considerably across studies. Such variability is likely due to differences in case identification methods and whether outcome is assessed in terms of symptoms or the receipt of financial compensation for injury. The impact on prognosis of both collision- and patient-related factors is also reviewed. C1 Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Dept Rehabil Med, Seattle, WA 98108 USA. RP Rodriquez, AA (reprint author), C-O Gail Wise,Mail Stop-117,1660 S Columbian Way, Seattle, WA 98108 USA. EM Arthur.Rodriquez@med.va.gov NR 85 TC 41 Z9 43 U1 1 U2 12 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0148-639X J9 MUSCLE NERVE JI Muscle Nerve PD JUN PY 2004 VL 29 IS 6 BP 768 EP 781 DI 10.1002/mus.20060 PG 14 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 826LW UT WOS:000221831600003 PM 15170609 ER PT J AU Gallagher, RM AF Gallagher, RM TI Naturalistic study designs in samples with refractory pain: Advantages and limitations SO PAIN MEDICINE LA English DT Editorial Material C1 Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. RP Gallagher, RM (reprint author), Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. NR 5 TC 10 Z9 10 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 1526-2375 J9 PAIN MED JI Pain Med. PD JUN PY 2004 VL 5 IS 2 BP 143 EP 145 DI 10.1111/j.1526-4637.2004.04036.x PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 827VZ UT WOS:000221933100001 PM 15209966 ER PT J AU Maran, J Prchal, J AF Maran, J Prchal, J TI Polycythemia and oxygen sensing SO PATHOLOGIE BIOLOGIE LA English DT Article DE polycythemia vera (PV); primary familial congenital polycythemia (PFCF); secondary polycythemia; chuvash polycythemia; BFU-E; CFU-E ID ERYTHROPOIETIN RECEPTOR GENE; CONGENITAL POLYCYTHEMIA; ERYTHROID PROGENITORS; CHUVASH POLYCYTHEMIA; VHL GENE; VERA; MUTATIONS; ERYTHROCYTOSIS; CLASSIFICATION; JAK2 AB Polycythemias can be differentiated based on the responsiveness of erythroid progenitors to circulating cytokines. Primary polycythemias are characterized by an augmented response due to acquired somatic or inherited germ-line mutations that are expressed within hematopoietic progenitors causing increased proliferation or decreased apoptosis and resulting in accumulation of red blood cells. In terms of oxygen requirements, primary polycythemias can be viewed as the production of hemoglobin fully dissociated from the tissue oxygen needs and from the oxygen sensing pathway. Polycythemia vera (PV) is the most common primary polycythemia. PV bone marrow progenitors cells can form erythroid colonies in the absence of exogenous erythropoietin in vitro. These endogenous erythroid colonies (EEC) are useful in differentiating PV and secondary polycythemias. They also can differentiate PV where this feature is independent of Epo signalling from primary familial and congenital polycythemia. In this autosomal dominant primary polycythemia, at variance with PV, EEC formation is abolished by anti-Epo and anti-Epo receptor neutralising antibodies. Mutations of the EPOR have been described and resulted in nine cases in truncated EPORs lacking the cytoplasmic carboxy-terminal of the receptor which possesses a negative growth regulatory domain. However, recent data suggest that different mutations may cause PFCP in most cases. Secondary polycythemia can be viewed as either physiological response to satisfy the oxygen needs of the tissues, resulting for instance from high affinity hemoglobins or BPG mutase deficiency, or as the result of germ-line or somatic mutations disturbing the oxygen sensing pathway or its target: Epo. Chuvash polycythemia is a frequently symptomatic disorder with an autosomal recessive inheritance and inappropriately high Epo levels. The erythroid progenitors are hypersensitive to Epo linking this condition to both primary and secondary polycythemia. A germline missense mutation at nucleotide 598 in both alleles of the von Hippel-Lindau gene results in increased hypoxia inducible factor-1 (HIF-1) expression in normoxic conditions. HIF-1 controls the expression of many genes including Epo. Identifying causal defects in other situations like post-renal transplant erythrocytosis and cases of autosomal dominant polycythemia with high Epo levels will help further understanding of the regulation of erythropoiesis. (C) 2004 Elsevier SAS. All rights reserved. C1 Baylor Coll Med, Med Div Hematol Oncol 802E, Houston, TX 77030 USA. Houston VA Med Ctr, Houston, TX 77030 USA. RP Prchal, J (reprint author), Baylor Coll Med, Med Div Hematol Oncol 802E, 1 Baylor Plaza,MS 525D, Houston, TX 77030 USA. EM jprchal@bcm.tmc.edu NR 28 TC 13 Z9 15 U1 1 U2 5 PU EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER PI PARIS PA 23 RUE LINOIS, 75724 PARIS, FRANCE SN 0369-8114 J9 PATHOL BIOL JI Pathol. Biol. PD JUN PY 2004 VL 52 IS 5 BP 280 EP 284 DI 10.1016/j.patbio.2004.02.006 PG 5 WC Pathology SC Pathology GA 838EP UT WOS:000222696600014 PM 15217714 ER PT J AU Amstrong, K Long, JA Shea, JA AF Amstrong, K Long, JA Shea, JA TI Measuring adherence to mammography screening recommendations among low-income women SO PREVENTIVE MEDICINE LA English DT Article DE mammography; low-income women; self-report ID SELF-REPORTED MAMMOGRAPHY; PAP-SMEAR; ALCOHOL-CONSUMPTION; CLAIMS DATA; ACCURACY; VALIDITY; POPULATION; INTERVIEWS; MEDICAID AB Objectives. (1) To describe the accuracy of self-report and administrative claims for measuring mammography adherence among low-income women; (2) to determine whether the accuracy of self-report differed between telephone interview and mailed questionnaire; and (3) to explore whether the method of measuring adherence affected associations between mammography adherence and participant sociodemographic characteristics. Design. Retrospective cohort study of women receiving care from a Philadelphia Medicaid Managed Care Organization (MCO). Participants. Three hundred and ninety-nine low-income women eligible for screening mammography of whom 64% were African American, 14% Caucasian, 13% Hispanic, and 8% Asian American. Measures. Self-reported use of mammography screening, administrative mammography claims data, and dates of mammograms from radiology facility records. The "gold standard" categorized women as having undergone screening if they had either a billing claim or facility record for a mammogram in the past 12 months. Main results. Two hundred and eighty-three of the 399 women reported having had a mammogram in the past 12 months. The sensitivity of self-report was 0.93, specificity was 0.54, positive predictive value was 0.70, and negative predictive value was 0.86. One hundred and seventy-nine of the 399 women had a claim for a mammogram in the past 12 months. The sensitivity of claims data was 0.83 with a negative predictive value of 0.84. The sensitivity of self-report was higher with telephone data collection (0.98) than with mailed data collection (0.82), while the specificity was higher with mail (0.64) than telephone (0.50). African American race was associated with adherence to screening recommendations when mammography use was measured by self-report (RR 1.31, P = 0.002) but not when it was measured by claims or facility validation (RR 1.03, P = 0.56, and RR 1.12, P = 0.15, respectively). Conclusions. Accurate measurement of adherence to mammography screening among low-income women is difficult. Self-report substantially overestimates adherence (particularly when collected through telephone interviews), while also misclassifying some women who underwent screening as not having been screened (particularly when collected through mailed questionnaires). In contrast, administrative claims data substantially underestimates adherence. Inaccurate measurement of mammography adherence can lead to a biased understanding of the factors associated with adherence. (C) 2004 Published by The Institute For Cancer Prevention and Elsevier Inc. C1 Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. Philadelphia VA Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. RP Amstrong, K (reprint author), Univ Penn, Sch Med, Dept Internal Med, 1233 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM karmstro@mail.med.upenn.edu NR 31 TC 0 Z9 0 U1 1 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD JUN PY 2004 VL 38 IS 6 BP 754 EP 760 DI 10.1016/j.ypmed.2003.12.023 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 830IO UT WOS:000222115800009 ER PT J AU Kier, FJ Molinari, V AF Kier, FJ Molinari, V TI Do-it-yourself testing for mental illness: Ethical issues, concerns, and recommendations SO PROFESSIONAL PSYCHOLOGY-RESEARCH AND PRACTICE LA English DT Article ID SMELL IDENTIFICATION TEST; ALZHEIMERS-DISEASE; SCREENING-TEST; HOME; HIV; DEPRESSION; CARE AB Do-it-yourself (DIY) testing for various medical problems has existed for some time and is likely here to stay. However, only relatively recently have such tests been targeted toward mental illness. From the point of view of professional psychology, the development and use of DIY tests for psychological disorders raises numerous ethical issues, including lack of in-person counseling, potential for misuse-abuse, and lack of informed consent. In addition, there is currently little government regulation or professional oversight of DIY tests, possibly increasing the chances for unethical practices. This article reviews some currently available DIY tests for mental illness, examining the ethical issues surrounding such tests and making recommendations for the crafting of ethical guidelines for their development and use. C1 Vet Affairs Pittsburgh Healthcare Syst, Highland Dr Div, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. Univ S Florida, Tampa, FL 33620 USA. RP Kier, FJ (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Highland Dr Div, 116 A-H,7180 Highland Dr, Pittsburgh, PA 15206 USA. EM frederick.kier@med.va.gov NR 28 TC 3 Z9 3 U1 1 U2 3 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0735-7028 J9 PROF PSYCHOL-RES PR JI Prof. Psychol.-Res. Pract. PD JUN PY 2004 VL 35 IS 3 BP 261 EP 267 DI 10.1037/0735-7028.35.3.261 PG 7 WC Psychology, Multidisciplinary SC Psychology GA 824QG UT WOS:000221700500007 ER PT J AU Charnetski, CJ Brennan, FX AF Charnetski, CJ Brennan, FX TI Sexual frequency and salivary immunoglobulin A (IgA) SO PSYCHOLOGICAL REPORTS LA English DT Article ID IMMUNE-SYSTEM; STRESS; STATES; EVENTS AB 112 college students reported the frequency of their sexual encounters and were divided into four categories: none, infrequent (less than once a week), frequent (one to two times per week), and very frequent (three or more times per week). Participants also described their overall sexual satisfaction. Saliva samples were collected and assayed for salivary immunoglobulin A (IgA). Individuals in the frequent group showed significantly higher levels of IgA than the other three groups, which were comparable. Data on length of relationship and sexual satisfaction were not related to the group differences. C1 Wilkes Univ, Dept Psychol, Wilkes Barre, PA 18766 USA. Philadelphia VA Med Ctr, Med Res Serv, Philadelphia, PA USA. RP Charnetski, CJ (reprint author), Wilkes Univ, Dept Psychol, Wilkes Barre, PA 18766 USA. EM charnets@wilkes.edu NR 24 TC 10 Z9 10 U1 1 U2 2 PU PSYCHOLOGICAL REPORTS PI MISSOULA PA P O BOX 9229, MISSOULA, MT 59807 USA SN 0033-2941 J9 PSYCHOL REP JI Psychol. Rep. PD JUN PY 2004 VL 94 IS 3 BP 839 EP 844 PN 1 PG 6 WC Psychology, Multidisciplinary SC Psychology GA 824RI UT WOS:000221703400017 PM 15217036 ER PT J AU McElduff, P Lyratzopoulos, G Edwards, R Heller, RF Shekelle, P Roland, M AF McElduff, P Lyratzopoulos, G Edwards, R Heller, RF Shekelle, P Roland, M TI Will changes in primary care improve health outcomes? Modelling the impact of financial incentives introduced to improve quality of care in the UK SO QUALITY & SAFETY IN HEALTH CARE LA English DT Article ID SERUM-CHOLESTEROL CONCENTRATION; CONGESTIVE-HEART-FAILURE; GENERAL-PRACTICE; INFLUENZA VACCINE; DISEASE; POPULATION; MORTALITY; METAANALYSIS; RISK; PREVALENCE AB Objectives: To estimate the total health gain from improving the quality of care among patients with cardiovascular disease in line with the quality indicator targets in the new contract for general practitioners (GPs) in the UK. Design: Statistical modelling, applying population impact measures to estimate cardiovascular health gains from achieving treatment targets in the GP contract, taking into account current levels of treatment and control. Main outcome measures: Number of events prevented in the population over 5 years applied to a notional general practice population of 10 000. Results: The greatest health gain in those aged 45-84 years would come from reaching cholesterol reduction targets. This could prevent 15 events in people with coronary heart disease, seven events in those with a history of stroke, and seven events in those with diabetes. Achieving blood pressure control targets in hypertensive patients without the above conditions could prevent 15 cardiovascular events, with further benefits from reducing blood pressure in patients with high blood pressure and coronary heart disease, stroke, or diabetes. Achieving other targets would have smaller impacts because high levels of care are already being achieved or because of the low prevalence of conditions or associated event risk. Conclusion: It is possible to quantify the health gain to a practice population of achieving quality targets such as those set in the new GP contract. The amount of health gain is sensitive to current quality of care, prevalence of conditions, and risk factors, and to the size of change anticipated. Nevertheless, it appears that significant health gains could result from achieving the proposed quality targets. C1 Univ Manchester, Evidence Populat Hlth Unit, Sch Med, Sch Epidemiol & Hlth Sci, Manchester M13 9PT, Lancs, England. Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester, Lancs, England. RP McElduff, P (reprint author), Univ Manchester, Evidence Populat Hlth Unit, Sch Med, Sch Epidemiol & Hlth Sci, Oxford Rd, Manchester M13 9PT, Lancs, England. EM patrick.mcelduff@man.ac.uk RI Lyratzopoulos, Georgios/B-6301-2012 OI Lyratzopoulos, Georgios/0000-0002-2873-7421; Heller, Richard/0000-0003-3161-5967 NR 33 TC 34 Z9 34 U1 2 U2 4 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1475-3898 J9 QUAL SAF HEALTH CARE JI Qual. Saf. Health Care PD JUN PY 2004 VL 13 IS 3 BP 191 EP 197 DI 10.1136/qshc.2003.007401 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 825YM UT WOS:000221794900011 PM 15175489 ER PT J AU McGurk, SR Green, MF Wirshing, WC Wirshing, DA Marder, SR Mintz, J Kern, R AF McGurk, SR Green, MF Wirshing, WC Wirshing, DA Marder, SR Mintz, J Kern, R TI Antipsychotic and anticholinergic effects on two types of spatial memory in schizophrenia SO SCHIZOPHRENIA RESEARCH LA English DT Article DE spatial working memory; spatial reference memory; schizophrenia; benztropine; risperidone ID TREATMENT-RESISTANT SCHIZOPHRENIA; RADIAL-ARM MAZE; WORKING-MEMORY; PREFRONTAL CORTEX; TERM-MEMORY; RISPERIDONE; SCOPOLAMINE; HALOPERIDOL; CLOZAPINE; DISSOCIATION AB Spatial memory is of interest in schizophrenia because of widespread impairments in adaptive functioning, including independent living skills. Short-term spatial memory is impaired in this disease, whereas spatial reference memory, a longer-term spatial memory, has not been evaluated. Animal studies have demonstrated that anticholinergics impair short-term spatial memory but not spatial reference memory. The effects of haloperidol and risperidone on these two types of spatial memory were evaluated in a double-blind randomized comparison in inpatients with schizophrenia. It was predicted that risperidone would have a greater beneficial effect on spatial working memory than haloperidol. Computerized measures of spatial working memory and spatial reference memory were developed based on animal assessment of these functions. Subjects with schizophrenia were assessed during a medication-free period and again following 4 weeks of fixed-dose treatment. Risperidone, compared to haloperidol, improved spatial working memory performance, an effect that became nonsignificant when benztropine co-treatment was controlled. There were no treatment effects on spatial reference memory performance. Consistent with animal studies, benztropine impaired spatial working memory but not spatial reference memory. The relative benefits of risperidone on spatial working memory performance were largely explained by differential benztropine treatment for the haloperidol-treated subjects. (C) 2003 Elsevier B.V. All rights reserved. C1 CUNY Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP McGurk, SR (reprint author), CUNY Mt Sinai Sch Med, Dept Psychiat, 1425 Madison Ave,Box 1230, New York, NY 10029 USA. FU NIMH NIH HHS [5-T32-MH 17140] NR 32 TC 40 Z9 41 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD JUN 1 PY 2004 VL 68 IS 2-3 BP 225 EP 233 DI 10.1016/s0920-9964(03)00123-3 PG 9 WC Psychiatry SC Psychiatry GA 817JD UT WOS:000221172900011 PM 15099605 ER PT J AU King, JT Tsevat, J Moossy, JJ Roberts, MS AF King, JT Tsevat, J Moossy, JJ Roberts, MS TI Preference-based quality of life measurement in patients with cervical spondylotic myelopathy SO SPINE LA English DT Article DE cervical vertebrae; health status; outcomes assessment (health care); quality of life; spinal stenosis ID SURGICAL-TREATMENT; STANDARD-GAMBLE; HEALTH SURVEY; ANTERIOR; UTILITIES; SF-36; FUSION; OUTCOMES; INDEX AB Study Design. Prospective cross-sectional observational cohort study. Objectives. To assess the performance of preference-based quality of life (QOL) instruments in patients with cervical spondylotic myelopathy (CSM). Summary of Background Data. Generic health status instruments (e.g., SF-36) or disease-specific health status measures (e.g., myelopathy scales) are typically used to measure QOL in patients with CSM; however, these instruments only examine a limited number of domains that contribute to QOL. An alternative is preference-based QOL methods, which integrate all factors contributing to QOL and provide a comprehensive individualized measure of how patients value their current health state. Methods. We used four preference-based QOL methods to measure QOL in a cohort of 79 patients with CSM: 1) visual analogue scale, 2) standard gamble, 3) time trade-off, and 4) willingness to pay. We measured health status with the SF-36 and with CSM disease-specific scales devised by Nurick, Harsh, Cooper, and the Japanese Orthopedic Association. We used multivariate linear regression techniques to examine the relationships between preference-based QOL, generic health status, CSM disease-specific health status, and patient characteristics. Results. Median preference-based QOL measurements for the CSM cohort were as follows: visual analogue scale, 0.50; standard gamble, 0.79; time trade-off, 0.75, and willingness to pay, $38,256. Preference-based QOL was not well explained by generic health status, CSM disease-specific health status, or patient characteristics, as shown by regression models that were unable to account more than 21% of the variation in preference-based QOL (R-2 less than or equal to 0.21). Conclusions. Preference-based QOL in patients with CSM is poorly correlated with generic health status, CSM disease-specific health status, or patient characteristics. Studies of CSM and other spine diseases should consider incorporating preference-based QOL measures for a fuller evaluation of the impact of spine disease and its treatment on QOL. C1 Vet Affairs Pittsburgh Helathcare Syst, Neurosurg Sect, Pittsburgh, PA USA. Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA. Vet Affairs Piitsburgh Healthcare Syst, Ctr Hlth Equity & Promot, Pittsburgh, PA USA. Univ Pittsburgh, Sect Decis Sci & Clin Syst Modeling, Div Gen Internal Med, Dept Med, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA 15260 USA. Univ Cincinnati, Med Ctr, Dept Internal Med, Sect Outcomes Res,Div Gen Internal Med, Cincinnati, OH 45267 USA. Univ Cincinnati, Med Ctr, Ctr Clin Effect, Inst Hlth Policy & Hlth Serv Res, Cincinnati, OH 45267 USA. Vet Affairs Med Ctr, Cincinnati, OH 45267 USA. RP King, JT (reprint author), W Haven Vet Affairs Med Ctr, VA CT Healthcare Syst, 950 Campbell Ave 112, West Haven, CT 06516 USA. EM Joseph.KingJr@med.va.gov FU NINDS NIH HHS [1K23 NS02169-01] NR 39 TC 25 Z9 26 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0362-2436 J9 SPINE JI SPINE PD JUN 1 PY 2004 VL 29 IS 11 BP 1271 EP 1280 DI 10.1097/00007632-200406010-00018 PG 10 WC Clinical Neurology; Orthopedics SC Neurosciences & Neurology; Orthopedics GA 826ET UT WOS:000221812800017 PM 15167668 ER PT J AU Dergalust, S Cheng, EM Panizzon, KL El-Saden, S Tsuprun, J Rubinova, Z Cohen, SN Wallis, RA AF Dergalust, S Cheng, EM Panizzon, KL El-Saden, S Tsuprun, J Rubinova, Z Cohen, SN Wallis, RA TI The incidence of discontinuation of anti-platelet therapy and warfarin within stroke sub-types SO STROKE LA English DT Meeting Abstract CT 5th World Stroke Congress CY JUN 23-26, 2004 CL Vancouver, CANADA SP Int Stroke Soc, Canadian Stroke Consortium, Natl Stroke Assoc, Canadian Stroke Network C1 VA Greater Los Angeles Healthcare Syst, Dept Neurol, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Dept Pharm, Los Angeles, CA USA. Western Univ Hlth Sci, Sch Pharm, Pomona, CA USA. Cedars Sinai Med Ctr, Dept Neurol, Los Angeles, CA 90048 USA. VA Greater Los Angeles Healthcare Syst, Dept Radiol, Los Angeles, CA 90048 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD JUN PY 2004 VL 35 IS 6 BP E211 EP E211 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 824HF UT WOS:000221676600337 ER PT J AU Vijg, J Calder, RB AF Vijg, J Calder, RB TI Transcripts of aging SO TRENDS IN GENETICS LA English DT Article ID WERNER-SYNDROME; GENE-EXPRESSION; DNA-REPAIR; GENOME; AGE; DEFICIENT; EVOLUTION; PROTEIN; LESSONS; RNA AB Recently, it has been demonstrated that similar alterations in gene expression profiles occur in cells from patients with Werner syndrome and from normally aged individuals. Changes involving the genes that are involved in RNA and DNA metabolism were particularly frequent - highlighting the importance of the smooth progression of replication and transcription for maintaining youthful vigor. In this article, we discuss the implications of this work for our understanding of the molecular basis of aging and the increasingly important role of microarrays for unraveling the functional pathways underlying the aging phenotype. C1 Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78245 USA. Univ Texas, Hlth Sci Ctr, Barshop Ctr Longev & Aging Studies, San Antonio, TX 78245 USA. S Texas Vet Hlth Care Syst, Geriat Res Educ & Clin Ctr, San Antonio, TX 78229 USA. RP Vijg, J (reprint author), Univ Texas, Hlth Sci Ctr, Dept Physiol, 15355 Lambda Dr,Suite 2-200,STCBM Bldg, San Antonio, TX 78245 USA. EM vijg@uthscsa.edu NR 22 TC 13 Z9 15 U1 0 U2 0 PU ELSEVIER SCIENCE LONDON PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 0168-9525 J9 TRENDS GENET JI Trends Genet. PD JUN PY 2004 VL 20 IS 6 BP 221 EP 224 DI 10.1016/j.tig.2004.04.007 PG 4 WC Genetics & Heredity SC Genetics & Heredity GA 852GJ UT WOS:000223743100001 PM 15145572 ER PT J AU O'Connell, JB Maggard, MA Liu, JH Etzioni, DA Livingston, EH Ko, CY AF O'Connell, JB Maggard, MA Liu, JH Etzioni, DA Livingston, EH Ko, CY TI Do young colon cancer patients have worse outcomes? SO WORLD JOURNAL OF SURGERY LA English DT Article ID 40 YEARS OLD; COLORECTAL-CANCER; PATIENTS LESS; LARGE-BOWEL; CARCINOMA; AGE; ADENOCARCINOMA; PROGNOSIS; SURVIVAL; ADULTS AB Previous studies on colon cancer have noted rising incidence rates among young individuals and suggest that they may have more aggressive disease and worse 5-year survivals than their older counterparts. Our study uses a nationwide population-based cancer registry to analyze colon cancer presentations and outcomes in a young versus an older population. The records of patients with colon carcinoma were obtained from the Surveillance, Epidemiology, and End Results (SEER) national cancer database (1991-1999). Two cohorts based on age at diagnosis (20-40 years, n = 1334 vs. 60-80 years, n = 46,457) were compared for patient and tumor characteristics, treatment, and 5-year cancer-specific survival. A multivariate Cox regression was performed to identify predictors of survival. The young group had a higher proportion of black and Hispanic patients than did the older group (p < 0.001). Young patients had less stage I or II disease, more stage III or IV disease (p < 0.001), and worse-grade (poorly differentiated or anaplastic) tumors (p < 0.001). The 5-year stage-specific survival was similar for stage I and III disease (p = NS) but was significantly better for young patients with stage II and IV disease (p < 0.01). Using a nationally representative cancer registry, we found that young colon cancer patients tend to have later-stage and bigher-grade tumors. However, they have equivalent or better 5-year cancer-specific survival compared to older patients. This population-based finding contradicts prior single-institution reports. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. Vet Adm Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA 90073 USA. Univ Texas, SW Med Ctr, Dept Surg, Dallas, TX 75390 USA. RP O'Connell, JB (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, 10833 Le Conte Ave,Room 72-215 CHS, Los Angeles, CA 90095 USA. EM jbocjboc@hotmail.com NR 29 TC 87 Z9 91 U1 1 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0364-2313 J9 WORLD J SURG JI World J.Surg. PD JUN PY 2004 VL 28 IS 6 BP 558 EP 562 DI 10.1007/s00268-004-7306-7 PG 5 WC Surgery SC Surgery GA 831GC UT WOS:000222181900009 PM 15366745 ER PT J AU Kliethermes, CL Metten, P Belknap, JK Buck, KJ Crabbe, JC AF Kliethermes, CL Metten, P Belknap, JK Buck, KJ Crabbe, JC TI Selection for pentobarbital withdrawal severity: correlated differences in withdrawal from other sedative drugs SO BRAIN RESEARCH LA English DT Article DE pentobarbital withdrawal; barbiturate; benzodiazepine; genetics ID NULL MUTANT MICE; ETHANOL WITHDRAWAL; ALCOHOL DEPENDENCE; BARBITURATE WITHDRAWAL; GENETIC-DETERMINANTS; CROSS-TOLERANCE; CANDIDATE GENE; CONVULSIONS; DIAZEPAM; LOCI AB In mice, withdrawal from agents that depress central nervous system function, such as barbiturates and benzodiazepines, results in the production of a withdrawal syndrome, one feature of which is increased severity of handling induced convulsions (HICs). High and Low Pentobarbital Withdrawal mice (HPW and LPW) were selectively bred to display severe and mild pentobarbital withdrawal HICs, respectively. These mice provide a valuable means to assess genetic correlations between withdrawal from pentobarbital and other sedative agents. We tested HPW and LPW mice for severity of HICs elicited during withdrawal from ethanol, diazepam, and zolpidem, and measured consumption of and preference for pentobarbital solutions in HPW and LPW mice. HPW mice displayed greater HICs than LPW mice during ethanol and zolpidem withdrawal, but differed less robustly during diazepam withdrawal. LPW mice consumed more pentobarbital in a solution of a moderate concentration than did HPW mice, but did riot consume more pentobarbital at a higher or lower concentration. These results indicate that some of the same genes that affect the severity of withdrawal from pentobarbital also influence ethanol and zolpidem withdrawal, but that diazepam withdrawal may be less influenced by these genes. (C) 2004 Elsevier B.V. All rights reserved. C1 Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. Portland VA Med Ctr, Vet Affairs Med Ctr, Portland Alcohol Res Ctr, Portland, OR 97239 USA. RP Kliethermes, CL (reprint author), Oregon Hlth & Sci Univ, Dept Behav Neurosci, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM kliether@ohsu.edu FU ADAMHA HHS [AD05228, AD06243]; NIAAA NIH HHS [AA05828, AA10760, P60 AA010760] NR 29 TC 12 Z9 12 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 J9 BRAIN RES JI Brain Res. PD MAY 29 PY 2004 VL 1009 IS 1-2 BP 17 EP 25 DI 10.1016/j.brainres.2004.02.040 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 821TQ UT WOS:000221486000003 PM 15120579 ER PT J AU Samii, A Nutt, JG Ransom, BR AF Samii, A Nutt, JG Ransom, BR TI Parkinson's disease SO LANCET LA English DT Review ID DEEP-BRAIN-STIMULATION; MULTIPLE SYSTEM ATROPHY; PROGRESSIVE SUPRANUCLEAR PALSY; LEVODOPA-INDUCED DYSKINESIAS; ALPHA-SYNUCLEIN; SUBTHALAMIC NUCLEUS; LEWY BODIES; DOPAMINE TRANSPORTER; MOVEMENT-DISORDERS; CLINICAL-FEATURES AB Parkinson's disease is the most common serious movement disorder in the world, affecting about 1% of adults older than 60 years. The disease is attributed to selective loss of neurons in the substantia nigra, and its cause is enigmatic in most individuals. Symptoms of Parkinson's disease respond in varying degrees to drugs, and surgery offers hope for patients no longer adequately controlled in this manner. The high prevalence of the disease, and important advances in its management, mean that generalists need to have a working knowledge of this disorder. This Seminar covers the basics, from terminology to aspects of diagnosis, treatment, and pathogenesis. C1 VA Puget Sound Hlth Care Syst, NW Parkinson Dis Res Educ & Clin Ctr, Seattle, WA 98108 USA. Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. Oregon Hlth Sci Univ, Dept Neurol, Portland, OR 97201 USA. Portland VA Med Ctr, NW Parkinson Dis Res Educ & Clin Ctr, Portland, OR USA. RP Samii, A (reprint author), VA Puget Sound Hlth Care Syst, NW Parkinson Dis Res Educ & Clin Ctr, Mailstop 127,1660 S Columbian Way, Seattle, WA 98108 USA. EM asamii@u.washington.edu NR 156 TC 493 Z9 519 U1 9 U2 93 PU LANCET LTD PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 0140-6736 J9 LANCET JI Lancet PD MAY 29 PY 2004 VL 363 IS 9423 BP 1783 EP 1793 DI 10.1016/S0140-6736(04)16305-8 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 824SD UT WOS:000221705800021 PM 15172778 ER PT J AU Yan, WS Samaha, FF Ramkumar, M Kleyman, TR Rubenstein, RC AF Yan, WS Samaha, FF Ramkumar, M Kleyman, TR Rubenstein, RC TI Cystic fibrosis transmembrane conductance regulator differentially regulates human and mouse epithelial sodium channels in Xenopus oocytes SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID FUNCTIONAL INTERACTIONS; CHLORIDE CHANNELS; DELTA-F508 CFTR; NA+ CHANNEL; CELL LINE; GENISTEIN; ENAC; ACTIVATION; 4-PHENYLBUTYRATE; MECHANISM AB The cystic fibrosis transmembrane conductance regulator ( CFTR), in addition to its well defined Cl- channel properties, regulates other ion channels. CFTR inhibits murine or rat epithelial Na+ channel (mENaC or rENaC) currents in many epithelial and non-epithelial cells, whereas murine or rat ENaC increases CFTR functional expression. These regulatory interactions are reproduced in Xenopus oocytes where both the open probability and surface expression of wild type CFTR Cl- channels are increased when CFTR is co-expressed with alphabetagamma mENaC, and conversely the activity of mENaC is inhibited after wild type CFTR activation. Using the Xenopus oocyte expression system, differences in functional regulatory interactions were observed when CFTR was co-expressed with either alphabetagamma mENaC or alphabetagamma human ENaC (hENaC). Co-expression of CFTR and alphabetagamma mENaC or hENaC resulted in an similar to 3-fold increase in CFTR Cl- current compared with oocytes expressing CFTR alone. Oocytes co-injected with both CFTR and mENaC or hENaC expressed an amiloride-sensitive whole cell current that was decreased compared with that observed with the injection of mENaC or hENaC alone before CFTR activation with forskolin/3-isobutyl-1- methylxanthine. CFTR activation resulted in a further 50% decrease in mENaC-mediated currents, an similar to 20% decrease in alpha-T663-hENaC-mediated currents, and essentially no change in alpha-A663-hENaC-mediated currents. Changes in ENaC functional expression correlated with ENaC surface expression by oocyte surface biotinylation experiments. Assessment of regulatory interactions between CFTR and chimeric mouse/human ENaCs suggest that the 20 C-terminal amino acid residues of alpha ENaC confer species specificity regarding ENaC inhibition by activated CFTR. C1 Univ Pittsburgh, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15261 USA. Childrens Hosp Philadelphia, Div Pulm Med, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Kleyman, TR (reprint author), Univ Pittsburgh, Dept Med, Renal Electrolyte Div, A919 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA. EM kleyman@pitt.edu OI Rubenstein, Ronald/0000-0002-3138-4006 FU NIDDK NIH HHS [DK54354, DK56305, DK58046] NR 34 TC 29 Z9 30 U1 0 U2 0 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD MAY 28 PY 2004 VL 279 IS 22 BP 23183 EP 23192 DI 10.1074/jbc.M402373200 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 822WI UT WOS:000221570900049 PM 15047694 ER PT J AU John, J Wu, MF Boehmer, LN Siegel, JM AF John, J Wu, MF Boehmer, LN Siegel, JM TI Cataplexy-active neurons in the hypothalamus: Implications for the role of histamine in sleep and waking behavior SO NEURON LA English DT Article ID LOCUS-COERULEUS NEURONS; IN-VIVO MICRODIALYSIS; VENTROLATERAL PREOPTIC NUCLEUS; MUSCLE TONE SUPPRESSION; AMINO-ACID RELEASE; RAT HYPOTHALAMUS; HUMAN NARCOLEPSY; HYPOCRETIN NEURONS; OREXIN-2 RECEPTOR; REM-SLEEP AB Noradrenergic, serotonergic, and histaminergic neurons are continuously active during waking, reduce discharge during NREM sleep, and cease discharge during REM sleep. Cataplexy, a symptom associated with narcolepsy, is a waking state in which muscle tone is lost, as it is in REM sleep, while environmental awareness continues, as in alert waking. In prior work, we reported that, during cataplexy, noradrenergic neurons cease discharge, and serotonergic neurons greatly reduce activity. We now report that, in contrast to these other monoaminergic "REM-off" cell groups, histamine neurons are active in cataplexy at a level similar to or greater than that in quiet waking. We hypothesize that the activity of histamine cells is linked to the maintenance of waking, in contrast to activity in noradrenergic and serotonergic neurons, which is more tightly coupled to the maintenance of muscle tone in waking and its loss in REM sleep and cataplexy. C1 Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90095 USA. Vet Adm Greater Los Angeles, Neurobiol Res 151A3, Healthcare Syst, Sepulveda, CA 91343 USA. Univ Calif Los Angeles, Inst Brain Res, Los Angeles, CA 90095 USA. RP Siegel, JM (reprint author), Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90095 USA. EM jsiegel@ucla.edu FU NHLBI NIH HHS [HL41370]; NIMH NIH HHS [MH64109]; NINDS NIH HHS [NS14610] NR 71 TC 113 Z9 119 U1 0 U2 3 PU CELL PRESS PI CAMBRIDGE PA 1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA SN 0896-6273 J9 NEURON JI Neuron PD MAY 27 PY 2004 VL 42 IS 4 BP 619 EP 634 DI 10.1016/S0896-6273(04)00247-8 PG 16 WC Neurosciences SC Neurosciences & Neurology GA 824TA UT WOS:000221708300012 PM 15157423 ER PT J AU Casebeer, AW Baltz, JH Schooley, L McDonald, GO Grover, F Cunningham, F Shroyer, ALW AF Casebeer, AW Baltz, JH Schooley, L McDonald, GO Grover, F Cunningham, F Shroyer, ALW TI The impact of beta-blockers and lipid lowering agent use on risk adjusted six-month mortality in post-CABG veteran patients SO CIRCULATION LA English DT Meeting Abstract CT 2nd Scientific Conference on Compliance in Healthcare and Research CY MAY 17-19, 2004 CL Washington, DC C1 Denver VAMC, Denver, CO USA. Dept Vet Affairs, Washington, DC USA. Chicago VAMC, Chicago, IL USA. RI Shroyer, Annie Laurie/B-8836-2016 OI Shroyer, Annie Laurie/0000-0001-6461-0623 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAY 25 PY 2004 VL 109 IS 20 MA P55 BP E294 EP E295 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 823IN UT WOS:000221604400338 ER PT J AU Chan, AS Steinman, MA Fischer, MA Shlipak, MG Bosworth, HB Oddone, E Martins, SB Coleman, RW Hoffman, BB Goldstein, MK AF Chan, AS Steinman, MA Fischer, MA Shlipak, MG Bosworth, HB Oddone, E Martins, SB Coleman, RW Hoffman, BB Goldstein, MK TI Clinician experience with the athena DSS hypertension management system: Facilitators and barriers to guideline compliance SO CIRCULATION LA English DT Meeting Abstract CT 2nd Scientific Conference on Compliance in Healthcare and Research CY MAY 17-19, 2004 CL Washington, DC C1 Stanford Univ, Sch Med, Stanford, CA 94305 USA. Univ Calif San Francisco, Sch Med, San Francisco VA Med Ctr, San Francisco, CA USA. Univ Massachusetts, Sch Med, Worcester, MA USA. Duke Univ, Sch Med, Durham VA Med Ctr, Durham, NC USA. VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. Harvard Univ, Sch Med, Boston VA Med Ctr, Boston, MA USA. Stanford Univ, Sch Med, Palo Alto VA Med Ctr, Palo Alto, CA 94304 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAY 25 PY 2004 VL 109 IS 20 MA P43 BP E292 EP E292 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 823IN UT WOS:000221604400326 ER PT J AU Chan, AS Martins, SB Coleman, RW Shiplak, MG Bosworth, HB Oddone, E Hoffman, BB Goldstein, MK AF Chan, AS Martins, SB Coleman, RW Shiplak, MG Bosworth, HB Oddone, E Hoffman, BB Goldstein, MK TI Barriers to clinician hypertension guideline adherence identified from clinician comments entered into an automated decision support system SO CIRCULATION LA English DT Meeting Abstract CT 5th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY MAY 15-17, 2003 CL Washington, DC C1 Stanford Med Informat, Stanford, CA USA. VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. San Francisco VA Med Ctr, San Francisco, CA USA. Durham VA Med Ctr, Durham, NC USA. Boston VA Med Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAY 25 PY 2004 VL 109 IS 20 MA P264 BP E283 EP E283 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 823IN UT WOS:000221604400285 ER PT J AU Hemingway, H Junghans, C Timmis, A Cotter, S Black, N Shekelle, P Feder, G AF Hemingway, H Junghans, C Timmis, A Cotter, S Black, N Shekelle, P Feder, G TI Investigation of angina in primary and secondary care: Can experts agree? SO CIRCULATION LA English DT Meeting Abstract CT 5th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY MAY 15-17, 2003 CL Washington, DC C1 UCL Med Sch, London, England. Barts & London NHS Trust, London, England. Queen Mary Univ London, London, England. London Sch Hyg & Trop Med, London WC1, England. Greater Los Angeles Vet Affairs Hlth Care Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAY 25 PY 2004 VL 109 IS 20 MA P197 BP E269 EP E269 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 823IN UT WOS:000221604400219 ER PT J AU Kopjar, B Sun, H Sales, AE Pineros, SL Fihn, SD AF Kopjar, B Sun, H Sales, AE Pineros, SL Fihn, SD TI Comparison of outcomes in patients with acute myocardial infarction in private sector hospitals versus veterans health administration hospitals SO CIRCULATION LA English DT Meeting Abstract CT 5th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY MAY 15-17, 2003 CL Washington, DC C1 Univ Washington, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. RI Sales, Anne/D-9678-2012 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAY 25 PY 2004 VL 109 IS 20 MA 176 BP E265 EP E265 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 823IN UT WOS:000221604400199 ER PT J AU Morgan, A Masoudi, FA Havranek, E Jones, P Peterson, PN Spertus, JA Rumsfeld, JS AF Morgan, A Masoudi, FA Havranek, E Jones, P Peterson, PN Spertus, JA Rumsfeld, JS TI Difficulty with medication adherence is associated with worse health status in heart failure patients SO CIRCULATION LA English DT Meeting Abstract CT 5th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY MAY 15-17, 2003 CL Washington, DC C1 Univ Colorado, Hlth Sci Ctr, Denver, CO USA. Denver Hlth Med Ctr, Denver, CO USA. Mid Amer Heart Inst, UMKC, Kansas City, MO USA. Denver VA Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAY 25 PY 2004 VL 109 IS 20 MA P60 BP E242 EP E242 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 823IN UT WOS:000221604400086 ER PT J AU Sales, AE Plomondon, ME Rumsfeld, S AF Sales, AE Plomondon, ME Rumsfeld, S TI Assessment of a quality improvement intervention to promote VA national lipid electronic clinical reminders SO CIRCULATION LA English DT Meeting Abstract CT 5th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY MAY 15-17, 2003 CL Washington, DC C1 VA Puget Sound Hlth Care Syst, Seattle, WA USA. Eastern Colorado Hlth Care Syst, Denver, CO USA. RI Sales, Anne/D-9678-2012 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAY 25 PY 2004 VL 109 IS 20 MA P52 BP E241 EP E241 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 823IN UT WOS:000221604400079 ER PT J AU Kadish, A Dyer, A Daubert, JP Quigg, R Estes, NAM Anderson, KP Calkins, H Hoch, D Goldberger, J Shalaby, A Sanders, WE Schaechter, A Levine, JH AF Kadish, A Dyer, A Daubert, JP Quigg, R Estes, NAM Anderson, KP Calkins, H Hoch, D Goldberger, J Shalaby, A Sanders, WE Schaechter, A Levine, JH CA DEFINITE Investigators TI Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID CONGESTIVE-HEART-FAILURE; NONSUSTAINED VENTRICULAR-TACHYCARDIA; SEQUENTIAL CLINICAL-TRIALS; CARDIOVERTER-DEFIBRILLATOR; MYOCARDIAL-INFARCTION; SUDDEN-DEATH; EJECTION FRACTION; RANDOMIZED-TRIAL; HIGH-RISK; MORTALITY AB BACKGROUND: Patients with nonischemic dilated cardiomyopathy are at substantial risk for sudden death from cardiac causes. However, the value of prophylactic implantation of an implantable cardioverter-defibrillator (ICD) to prevent sudden death in such patients is unknown. METHODS: We enrolled 458 patients with nonischemic dilated cardiomyopathy, a left ventricular ejection fraction of less than 36 percent, and premature ventricular complexes or nonsustained ventricular tachycardia. A total of 229 patients were randomly assigned to receive standard medical therapy, and 229 to receive standard medical therapy plus a single-chamber ICD. RESULTS: Patients were followed for a mean (+/-SD) of 29.0+/-14.4 months. The mean left ventricular ejection fraction was 21 percent. The vast majority of patients were treated with angiotensin-converting-enzyme (ACE) inhibitors (86 percent) and beta-blockers (85 percent). There were 68 deaths: 28 in the ICD group, as compared with 40 in the standard-therapy group (hazard ratio, 0.65; 95 percent confidence interval, 0.40 to 1.06; P=0.08). The mortality rate at two years was 14.1 percent in the standard-therapy group (annual mortality rate, 7 percent) and 7.9 percent in the ICD group. There were 17 sudden deaths from arrhythmia: 3 in the ICD group, as compared with 14 in the standard-therapy group (hazard ratio, 0.20; 95 percent confidence interval, 0.06 to 0.71; P=0.006). CONCLUSIONS: In patients with severe, nonischemic dilated cardiomyopathy who were treated with ACE inhibitors and beta-blockers, the implantation of a cardioverter-defibrillator significantly reduced the risk of sudden death from arrhythmia and was associated with a nonsignificant reduction in the risk of death from any cause. C1 Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Univ N Carolina, Chapel Hill, NC USA. St Francis Hosp, Roslyn, NY USA. Marshfield Clin Fdn Med Res & Educ, Marshfield, WI 54449 USA. Tufts Univ New England Med Ctr, Boston, MA 02111 USA. Univ Rochester, Med Ctr, Rochester, NY 14642 USA. Northwestern Univ, Sch Med, Dept Med, Div Cardiol,Clin Cardiol Trials Off, Chicago, IL 60611 USA. RP Kadish, A (reprint author), 251 E Huron,Feinberg 8-536, Chicago, IL 60611 USA. EM a-kadish@northwestern.edu NR 30 TC 904 Z9 937 U1 1 U2 17 PU MASSACHUSETTS MEDICAL SOC/NEJM PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAY 20 PY 2004 VL 350 IS 21 BP 2151 EP 2158 DI 10.1056/NEJMoa033088 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 821XM UT WOS:000221496700007 PM 15152060 ER PT J AU Hofer, TP Asch, SM Hayward, RA Rubenstein, LV Hogan, MM Adams, J Kerr, EA AF Hofer, TP Asch, SM Hayward, RA Rubenstein, LV Hogan, MM Adams, J Kerr, EA TI Profiling quality of care: Is there a role for peer review? SO BMC HEALTH SERVICES RESEARCH LA English DT Article ID MEDICAL-CARE; ADVERSE EVENTS; HOSPITAL-CARE; NURSING-CARE; HEALTH-CARE; RELIABILITY; ASSESSMENTS AB Background: We sought to develop a more reliable structured implicit chart review instrument for use in assessing the quality of care for chronic disease and to examine if ratings are more reliable for conditions in which the evidence base for practice is more developed. Methods: We conducted a reliability study in a cohort with patient records including both outpatient and inpatient care as the objects of measurement. We developed a structured implicit review instrument to assess the quality of care over one year of treatment. 12 reviewers conducted a total of 496 reviews of 70 patient records selected from 26 VA clinical sites in two regions of the country. Each patient had between one and four conditions specified as having a highly developed evidence base (diabetes and hypertension) or a less developed evidence base (chronic obstructive pulmonary disease or a collection of acute conditions). Multilevel analysis that accounts for the nested and cross-classified structure of the data was used to estimate the signal and noise components of the measurement of quality and the reliability of implicit review. Results: For COPD and a collection of acute conditions the reliability of a single physician review was quite low (intra-class correlation = 0.16-0.26) but comparable to most previously published estimates for the use of this method in inpatient settings. However, for diabetes and hypertension the reliability is significantly higher at 0.46. The higher reliability is a result of the reviewers collectively being able to distinguish more differences in the quality of care between patients (p < 0.007) and not due to less random noise or individual reviewer bias in the measurement. For these conditions the level of true quality (i.e. the rating of quality of care that would result from the full population of physician reviewers reviewing a record) varied from poor to good across patients. Conclusions: For conditions with a well-developed quality of care evidence base, such as hypertension and diabetes, a single structured implicit review to assess the quality of care over a period of time is moderately reliable. This method could be a reasonable complement or alternative to explicit indicator approaches for assessing and comparing quality of care. Structured implicit review, like explicit quality measures, must be used more cautiously for illnesses for which the evidence base is less well developed, such as COPD and acute, short-course illnesses. C1 Vet Affairs Ann Arbor Healthcare Syst, Vet Affairs Hlth Serv Res & Dev Ctr Excellence, Ann Arbor, MI 48105 USA. Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. Vet Affairs Great Los Angeles Hlth Care Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Div Gen Internal Med, David Geffen Sch Med, Los Angeles, CA USA. RAND Corp, Rand Hlth Program, Santa Monica, CA USA. RP Hofer, TP (reprint author), Vet Affairs Ann Arbor Healthcare Syst, Vet Affairs Hlth Serv Res & Dev Ctr Excellence, Ann Arbor, MI 48105 USA. EM thofer@umich.edu; sasch@rand.org; Rod.Hayward@med.va.gov; Lisar@rand.org; Mary.Hogan@med.va.gov; adams@rand.org; ekerr@umich.edu FU PHS HHS [P60-972573] NR 35 TC 23 Z9 23 U1 0 U2 7 PU BIOMED CENTRAL LTD PI LONDON PA MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND SN 1472-6963 J9 BMC HEALTH SERV RES JI BMC Health Serv. Res. PD MAY 19 PY 2004 VL 4 AR 9 DI 10.1186/1472-6963-4-9 PG 12 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 831WV UT WOS:000222228200001 PM 15151701 ER PT J AU Bean-Mayberry, B Gordon, AJ Fultz, SL AF Bean-Mayberry, B Gordon, AJ Fultz, SL TI The debt repayment paradox for VA clinical investigators SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter C1 Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15260 USA. Yale Univ, VA Connecticut Healthcare Syst, New Haven, CT USA. RP Bean-Mayberry, B (reprint author), Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15260 USA. EM bevanne.bean-mayberry@med.va.gov NR 2 TC 0 Z9 0 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAY 19 PY 2004 VL 291 IS 19 BP 2316 EP 2316 DI 10.1001/jama.291.19.2316-a PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 821JD UT WOS:000221455400017 PM 15150202 ER PT J AU Beique, JC Campbell, B Perring, P Hamblin, MW Walker, P Mladenovic, L Andrade, R AF Beique, JC Campbell, B Perring, P Hamblin, MW Walker, P Mladenovic, L Andrade, R TI Serotonergic regulation of membrane potential in developing rat prefrontal cortex: Coordinated expression of 5-hydroxytryptamine (5-HT)(1A), 5-HT2A, and 5-HT7 receptors SO JOURNAL OF NEUROSCIENCE LA English DT Article DE 5-HT; serotonin; in situ hybridization; postnatal development; prefrontal cortex; in vitro electrophysiology; single-cell RT-PCR ID SINGLE CORTICAL-NEURONS; MESSENGER-RNA; POSTNATAL-DEVELOPMENT; PYRAMIDAL NEURONS; CEREBRAL-CORTEX; K+ CHANNELS; HIPPOCAMPAL-NEURONS; AGONIST RADIOLIGAND; POTASSIUM CHANNELS; MOLECULAR-CLONING AB The developing prefrontal cortex receives a dense serotonergic innervation, yet little is known about the actions of serotonin [5-Hydroxytryptamine (5-HT)] in this region during development. Here, we examined the developmental regulation of 5-HT receptors controlling the excitability of pyramidal neurons of this region. Using whole-cell recordings in in vitro brain slices, we identified a dramatic shift in the effects of 5-HT on membrane potential during the postnatal developmental period. In slices derived from young animals [ postnatal day (P) 6 to P19], administration of 5-HT elicits a robust depolarization of layer V pyramidal neurons, which gradually shifts to a hyperpolarization commencing during the third postnatal week. This progression is the result of coordinated changes in the function of 5-HT7 and 5-HT2A receptors, which mediate different aspects of the depolarization, and of 5-HT1A receptors, which signal the late developing hyperpolarization. The loss of the 5-HT7 receptor-mediated depolarization and the appearance of the 5-HT1A receptor-mediated hyperpolarization appears to reflect changes in receptor expression. In contrast, the decline in the 5-HT2A receptor depolarization with increasing age was associated with changes in the effectiveness with which these receptors could elicit a membrane depolarization, rather than loss of the receptors per se. Together, these results outline coordinated changes in the serotonergic regulation of cortical excitability at a time of extensive synaptic development and thus suggest a key role for these receptor subtypes in the postnatal development of the prefrontal cortex. C1 Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Detroit, MI 48201 USA. Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA. Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Detroit, MI 48201 USA. Univ Washington, Ctr Geriatr Res Educ & Clin, Dept Psychiat, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. Univ Washington, Ctr Geriatr Res Educ & Clin, Dept Behav Sci, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Beique, JC (reprint author), Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, 540 E Canfield,Scott Hall,Room 2115, Detroit, MI 48201 USA. EM jbeique@med.wayne.edu FU NIMH NIH HHS [MH43985] NR 81 TC 109 Z9 114 U1 1 U2 3 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD MAY 19 PY 2004 VL 24 IS 20 BP 4807 EP 4817 DI 10.1523/JNEUROSCI.5113-03.2004 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 823IQ UT WOS:000221604900012 PM 15152041 ER PT J AU Ambrose, JA Barua, RS AF Ambrose, JA Barua, RS TI The pathophysiology of cigarette C-V smoking and cardiovascular disease - An update SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Review ID CORONARY-ARTERY-DISEASE; NITRIC-OXIDE SYNTHASE; ENVIRONMENTAL TOBACCO-SMOKE; CONDENSATE-INDUCED ADHESION; ISCHEMIC-HEART-DISEASE; IN-VITRO DEMONSTRATION; HEALTHY-YOUNG ADULTS; LONG-TERM SMOKING; PASSIVE SMOKING; RISK-FACTORS AB Cigarette smoking (CS) continues to be a major health hazard, and it contributes significantly to cardiovascular morbidity and mortality. Cigarette smoking impacts all phases of atherosclerosis from endothelial dysfunction to acute clinical events, the latter being largely thrombotic. Both active and passive (environmental) cigarette smoke exposure predispose to cardiovascular events. Whether there is a distinct direct dose-dependent correlation between cigarette smoke exposure and risk is debatable, as some recent experimental clinical studies have shown a non-linear relation to cigarette smoke exposure. The exact toxic components of cigarette smoke and the mechanisms involved in CS-related cardiovascular dysfunction are largely unknown, but CS increases inflammation, thrombosis, and oxidation of low-density lipoprotein cholesterol. Recent experimental and clinical data support the hypothesis that cigarette smoke exposure increases oxidative stress as a potential mechanism for initiating cardiovascular dysfunction. (C) 2004 by the American College of Cardiology Foundation. C1 New York Med Coll, St Vincent Catholic Med Ctr New York, Comprehens Cardiovasc Ctr, New York, NY 10029 USA. CUNY Mt Sinai Sch Med, Dept Med, Bronx Vet Affairs Med Ctr, New York, NY 10029 USA. RP Ambrose, JA (reprint author), New York Med Coll, St Vincent Catholic Med Ctr New York, Comprehens Cardiovasc Ctr, New York, NY 10029 USA. EM jamambrose@yahoo.com NR 102 TC 758 Z9 814 U1 9 U2 68 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAY 19 PY 2004 VL 43 IS 10 BP 1731 EP 1737 DI 10.1016/j.jacc.2003.12.047 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 821AQ UT WOS:000221432000002 PM 15145091 ER PT J AU Stern, L Iqbal, N Seshadri, P Chicano, KL Daily, DA McGrory, J Williams, M Gracely, EJ Samaha, FF AF Stern, L Iqbal, N Seshadri, P Chicano, KL Daily, DA McGrory, J Williams, M Gracely, EJ Samaha, FF TI The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: One-year follow-up of a randomized trial SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID LOW-FAT DIET; CARDIOVASCULAR RISK; CHOLESTEROL; NUTRITION; PROGRAM; PLASMA AB Background: A previous paper reported the 6-month comparison of weight loss and metabolic changes in obese adults randomly assigned to either a low-carbohydrate diet or a conventional weight loss diet. Objective: To review the 1-year outcomes between these diets. Design: Randomized trial. Setting: Philadelphia Veterans Affairs Medical Center. Participants: 132 obese adults with a body mass index of 35 kg/m(2) or greater; 83% had diabetes or the metabolic syndrome. Intervention: Participants received counseling to either restrict carbohydrate intake to <30 g per day (low-carbohydrate diet) or to restrict caloric intake by 500 calories per day with <30% of calories from fat (conventional diet). Measurements: Changes in weight, lipid levels, glycemic control, and insulin sensitivity. Results: By 1 year, mean (+/-SD) weight change for persons on the low-carbohydrate diet was -5.1 +/- 8.7 kg compared with -3.1 +/- 8.4 kg for persons on the conventional diet. Differences between groups were not significant (-1.9 kg [95% CI, -4.9 to 1.0 kg]; P = 0.20). For persons on the low-carbohydrate diet, triglyceride levels decreased more (P = 0.044) and high-density lipoprotein cholesterol levels decreased less (P = 0.025). As seen in the small group of persons with diabetes (n = 54) and after adjustment for covariates, hemoglobin A(1c) levels improved more for persons on the low-carbohydrate diet. These more favorable metabolic responses to a low-carbohydrate diet remained significant after adjustment for weight loss differences. Changes in other lipids or insulin sensitivity did not differ between groups. Limitations: These findings are limited by a high dropout rate (34%) and by suboptimal dietary adherence of the enrolled persons. Conclusion: Participants on a low-carbohydrate diet had more favorable overall outcomes at 1 year than did those on a conventional diet. Weight loss was similar between groups, but effects on atherogenic dyslipidemia and glycemic control were still more favorable with a low-carbohydrate diet after adjustment for differences in weight loss. C1 Univ Penn, Med Ctr, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. Drexel Univ, Coll Med, Philadelphia, PA 19104 USA. RP Samaha, FF (reprint author), Univ Penn, Med Ctr, Philadelphia Vet Affairs Med Ctr, 8th Floor,MC 111C,Univ & Woodland Ave, Philadelphia, PA 19104 USA. EM rick.samaha@med.va.gov NR 19 TC 436 Z9 451 U1 3 U2 55 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAY 18 PY 2004 VL 140 IS 10 BP 778 EP 785 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 822EX UT WOS:000221520900002 PM 15148064 ER PT J AU Mandelblatt, J Saha, S AF Mandelblatt, J Saha, S TI Cost-effectiveness of mammography for older women - Response SO ANNALS OF INTERNAL MEDICINE LA English DT Letter ID BREAST-CANCER C1 Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA. Portland Vet Affairs Med Ctr, Portland, OR 97239 USA. RP Mandelblatt, J (reprint author), Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAY 18 PY 2004 VL 140 IS 10 BP 844 EP 844 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 822EX UT WOS:000221520900014 ER PT J AU Chan, FKL Graham, DY AF Chan, FKL Graham, DY TI Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications - review and recommendations based on risk assessment SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Review ID PEPTIC-ULCER DISEASE; HELICOBACTER-PYLORI INFECTION; RANDOMIZED CONTROLLED-TRIAL; RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; DYSPEPTIC SYMPTOMS; DUODENAL-ULCERS; CLINICAL EVENTS; NO-ASPIRIN; NSAID AB The incidence of non-steroidal anti-inflammatory drug-related ulcer complications remains high despite the availability of potent anti-ulcer drugs and selective cyclo-oxygenase-2 inhibitors. Non-steroidal anti-inflammatory drug-related ulcer complications can be minimized by prospective assessment of patients' baseline risk, rational choice and use of non-steroidal anti-inflammatory drugs, and selective use of co-therapy strategies with gastroprotectives. Current recommendations regarding strategies using anti-ulcer drugs and cyclo-oxygenase-2 inhibitors for prevention of clinical non-steroidal anti-inflammatory drug upper gastrointestinal events are largely derived from studies using surrogates such as endoscopic ulcers, erosions, and symptoms in low- to average-risk patients. Conclusions based on surrogate and potentially manipulatable end-points are increasingly suspect with regard to applicability to clinical situations. This article reviews the risks associated with non-steroidal anti-inflammatory drugs including aspirin and includes the effect of the patients' baseline risk, and the confounding effects of Helicobacter pylori infection. In addition, uncertainties regarding the clinical efficacy of anti-ulcer drugs and cyclo-oxygenase-2 inhibitors against non-steroidal anti-inflammatory drug-related ulcer complications are put into perspective. We propose management strategies based on the risk category: low risk (absence of risk factors) (least ulcerogenic non-steroidal anti-inflammatory drug at lowest effective dose), moderate risk (one to two risk factors) (as above, plus an antisecretory agent or misoprostol or a cyclo-oxygenase-2 inhibitor), high risk (multiple risk factors or patients using concomitant low-dose aspirin, steroids, or anticoagulants) (cyclo-oxygenase-2 inhibitor alone with steroids, plus misoprostol with warfarin, or plus a proton pump inhibitors or misoprostol with aspirin), and very high risk (history of ulcer complications) (avoid all non-steroidal anti-inflammatory drugs, if possible or a cyclo-oxygenase-2 plus a proton pump inhibitors and/or misoprostol). The presence of H. pylori infection increases the risk of upper gastrointestinal complications in non-steroidal anti-inflammatory drug users by two- to fourfold suggesting that all patients requiring regular non-steroidal anti-inflammatory drug therapy be tested for H. pylori. C1 Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Peoples R China. Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. RP Graham, DY (reprint author), Vet Adm Med Ctr, Rm 3A-320,111D,2002 Holcombe Blvd, Houston, TX 77030 USA. EM dgraham@bcm.tmc.edu RI Chan, Francis K. L./F-4851-2010 OI Chan, Francis K. L./0000-0001-7388-2436 FU NIDDK NIH HHS [DK 56338] NR 56 TC 71 Z9 74 U1 2 U2 4 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 0269-2813 J9 ALIMENT PHARM THERAP JI Aliment. Pharmacol. Ther. PD MAY 15 PY 2004 VL 19 IS 10 BP 1051 EP 1061 DI 10.1111/j.1365-2036.2004.01935.x PG 11 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 819XV UT WOS:000221350500002 PM 15142194 ER PT J AU Fan, VS Curtis, JR Bryson, CL Fihn, SD Au, DH AF Fan, VS Curtis, JR Bryson, CL Fihn, SD Au, DH TI Inhaled corticosteroids in COPD and mortality: Inaccuracies? SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Letter ID OBSTRUCTIVE PULMONARY-DISEASE; HOSPITALIZATION C1 Univ Washington, Med Ctr, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP Fan, VS (reprint author), Univ Washington, Med Ctr, Seattle, WA 98195 USA. NR 6 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019-4374 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD MAY 15 PY 2004 VL 169 IS 10 BP 1166 EP 1166 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 819KV UT WOS:000221314700021 ER PT J AU Patten, LC Berger, DH Rodriguez-Bigas, M Mansfield, P Delpassand, E Cleary, KR Fagan, SP Curley, SA Hunt, KK Feig, BW AF Patten, LC Berger, DH Rodriguez-Bigas, M Mansfield, P Delpassand, E Cleary, KR Fagan, SP Curley, SA Hunt, KK Feig, BW TI A prospective evaluation of radiocolloid and immunohistochemical staining in colon carcinoma lymphatic mapping SO CANCER LA English DT Article DE colon carcinoma; lymphatic mapping; radiocolloid; sentinel lymph node ID COLORECTAL-CARCINOMA; SENTINEL NODE; TECHNICAL DETAILS; CANCER; MICROMETASTASES; NUMBER; IMPACT; TRIAL AB BACKGROUND. Although the utility of lymphatic mapping (LM) and sentinel lymph node (SLN) biopsy in patients with melanoma and breast carcinoma has been well documented, this same is not true for patients with colon carcinoma. The authors previously reported a high false-negative rate for SLN biopsy in patients with colon carcinoma using isosulfan blue dye alone. The objective of the current study was to determine whether radiocolloid would increase the sensitivity of LM/SLN biopsy in patients with colon carcinoma. METHODS. The authors performed LM on 57 patients with colon carcinoma using both isosulfan blue dye and radiocolloid. The SLN(s) were identified by either their blue color or by increased radioactivity. The SLNs then underwent both routine histologic sectioning and immunohistochemical (IHC) staining for cytokeratins. RESULTS. An SLN was identified in 56 patients (98%). Radiocolloid was able to identify only 1 additional positive SLN (9%). Overall, it was found that the disease had metastasized to the lymph nodes in 22 patients, even though there was no evidence of disease in the SLN(s) in 11 of those 22 patients on routine histologic sectioning (false-negative rate, 50%; sensitivity, 50%). In five patients, IHC of the SLN was the only indicator of metastatic disease. The inclusion of IHC-positive SLNs in these calculations would decrease the false-negative rate to 17% and would increase the sensitivity of SLN biopsy to 83%. CONCLUSIONS. In the current study, the addition of radiocolloid did not increase the sensitivity of detection of positive SLN(s) compared with the use of isosulfan blue dye alone. IHC of the SLN potentially may increase the sensitivity of LM and reduce the false-negative rate. However, the long-term prognostic significance of IHC in patients with colon carcinoma remains controversial. (C) 2004 American Cancer Society. C1 Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA. Baylor Coll Med, Dept Gen Surg, Michael E DeBakey Dept Surg, Houston, TX 77030 USA. Houston Vet Affairs Med Ctr, Dept Gen Surg, Houston, TX USA. Univ Texas, MD Anderson Canc Ctr, Dept Nucl Med, Houston, TX 77030 USA. Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA. RP Feig, BW (reprint author), Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, 1515 Holcombe Blvd,Box 444, Houston, TX 77030 USA. EM bwfeig@mail.mdanderson.org NR 23 TC 29 Z9 30 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0008-543X J9 CANCER JI Cancer PD MAY 15 PY 2004 VL 100 IS 10 BP 2104 EP 2109 DI 10.1002/cncr.20233 PG 6 WC Oncology SC Oncology GA 817DA UT WOS:000221157000007 PM 15139051 ER PT J AU Khan, M Sekhon, B Jatana, M Giri, S Gilg, AG Sekhon, C Singh, I Singh, AK AF Khan, M Sekhon, B Jatana, M Giri, S Gilg, AG Sekhon, C Singh, I Singh, AK TI Administration of N-acetylcysteine after focal cerebral ischemia protects brain and reduces inflammation in a rat model of experimental stroke SO JOURNAL OF NEUROSCIENCE RESEARCH LA English DT Article DE stroke; inflammation; apoptosis; antioxidant; N-acetylcysteine ID NITRIC-OXIDE SYNTHASE; ALPHA-LIPOIC ACID; TUMOR-NECROSIS-FACTOR; REPERFUSION INJURY; LIPID-PEROXIDATION; ARTERY OCCLUSION; CELL-DEATH; NEUROLOGICAL DEFICIT; HYDROGEN-PEROXIDE; OXIDATIVE STRESS AB Free radicals and inflammatory mediators are involved in transient focal cerebral ischemia (FCI). Preadministration of N-acetylcysteine (NAC) has been found to attenuate the cerebral ischemia-reperfusion injury in a rat model of experimental stroke. This study was undertaken to investigate the neuroprotective potential of NAC administered after ischemic events in experimental stroke. FCI was induced for 30 min by occluding the middle cerebral artery (MCA). NAC (150 mg/kg) was administered intraperitoneally at the time of reperfusion followed by another dose 6 hr later. Animals were sacrificed after 24 hr of reperfusion. The cerebral infarct consistently involved the cortex and striatum. Infarction was assessed by staining the brain sections with 2,3,5-triphenyltetrazolium chloride. Animals treated with NAC showed a significant reduction in infarct area and infarct volume and an improvement in neurologic scores and glutathione level. Reduction in infarction was significant even when a single dose of NAC was administered at 6 hr of reperfusion. Immunohistochemical and quantitative real-time PCR studies demonstrated a reduction in the expression of proinflammatory cytokines such as tumor necrosis factor alpha (TNFalpha) and interleukin 1beta (IL-1beta) and inducible nitric oxide synthase (NOS) in NAC compared to that in vehicle-treated animals. The expression of activated macrophage/microglia (ED1) and apoptotic cell death in ischemic brain was also reduced by NAC treatment. These results indicate that in a rat model of experimental stroke, administration of NAC even after ischemia onset protected the brain from free radical injury, apoptosis, and inflammation, with a wide treatment window. (C) 2004 Wiley-Liss, Inc. C1 Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Khan, M (reprint author), Med Univ S Carolina, Dept Pediat, 316 CSB,96 Jonathan Lucas St, Charleston, SC 29425 USA. EM khanm@musc.edu FU NINDS NIH HHS [NS-22576, NS-34741, NS-37766, NS-40144, NS-40810] NR 62 TC 127 Z9 134 U1 1 U2 7 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA SN 0360-4012 J9 J NEUROSCI RES JI J. Neurosci. Res. PD MAY 15 PY 2004 VL 76 IS 4 BP 519 EP 527 DI 10.1002/jnr.20087 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 818IR UT WOS:000221239300010 PM 15114624 ER PT J AU Dracheva, S Elhakem, SL McGurk, SR Davis, KL Haroutunian, V AF Dracheva, S Elhakem, SL McGurk, SR Davis, KL Haroutunian, V TI GAD67 and GAD65 mRNA and protein expression in cerebrocortical regions of elderly patients with schizophrenia SO JOURNAL OF NEUROSCIENCE RESEARCH LA English DT Article DE schizophrenia; Alzheimer's disease; dorsolateral prefrontal cortex; gene expression; real-time RT-PCR; molecular beacons; glutamic acid decarboxylase; GAD; GAD65; GAD67; RNA ID GLUTAMIC-ACID DECARBOXYLASE; DORSOLATERAL PREFRONTAL CORTEX; GABA UPTAKE SITES; GENE-EXPRESSION; MOLECULAR BEACONS; ALZHEIMER-DISEASE; RAT-BRAIN; COMPARATIVE LOCALIZATION; MULTIPLEX DETECTION; CEREBRAL-CORTEX AB gamma-Aminobutyric acid (GABA), the principal inhibitory neurotransmitter of CNS, has been consistently implicated in the pathophysiology of schizophrenia. GABA is synthesized from glutamate by the enzyme glutamic acid decarboxylase (GAD). Two isoforms of GAD have been identified and have been named GAD65 and GAD67 based on their apparent molecular weights. In this study, GAD65 and GAD67 rnRNA and protein levels were measured by using real-time RT-PCR and immunoblotting, respectively, in post-mortem brain tissue from the dorsolateral prefrontal cortex (DLPFC) and the occipital cortex of the elderly persons with schizophrenia and matched normal controls. In addition, the mRNA expression of GAT-1, one of the principal transporters of GABA, was also studied in the same subjects. Expression of GAD65 and GAD67 mRNA in the DLPFC and in the occipital cortex was significantly elevated in patients with schizophrenia, whereas the expression of the corresponding proteins and GAT-1 mRNA was unchanged. Although the levels of GAD65 and GAD67 messages were increased in schizophrenia subjects, the proportion of the two GAD isoforms remained constant in controls and schizophrenics. In the human DLPFC, GAD65 mRNA was found to be expressed significantly less than the message for GAD67, approximately 16% of that observed for GAD67. On the contrary, the abundance of GAD65 protein in the DLPFC was about 350% of that observed for GAD67. The results suggest a substantial dysregulation of GAD mRNA expression in schizophrenia and, taken together with the results of protein expression studies, raise the possibility that both cortical and subcortical GABA function may be compromised in the disease. (C) 2004 Wiley-Liss, Inc. C1 Bronx Vet Adm Med Ctr, Bronx, NY 10468 USA. Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. RP Haroutunian, V (reprint author), Bronx Vet Adm Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM vh@doc.msm.edu FU NIMH NIH HHS [MH45212, MH064673] NR 66 TC 63 Z9 68 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA SN 0360-4012 J9 J NEUROSCI RES JI J. Neurosci. Res. PD MAY 15 PY 2004 VL 76 IS 4 BP 581 EP 592 DI 10.1002/jnr.20122 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 818IR UT WOS:000221239300016 PM 15114630 ER PT J AU Vollmer, T Key, L Durkalski, V Tyor, W Corboy, J Markovic-Plese, S Preiningerova, J Rizzo, M Singh, L AF Vollmer, T Key, L Durkalski, V Tyor, W Corboy, J Markovic-Plese, S Preiningerova, J Rizzo, M Singh, L TI Oral simvastatin treatment in relapsing-remitting multiple sclerosis SO LANCET LA English DT Article ID LOVASTATIN; DISEASE; MS AB Many drugs have been approved for relapsing forms of multiple sclerosis but are only partly effective, are injected, and are expensive. We aimed to investigate use of of oral simvastatin (80 mg) in 30 individuals with relapsing-remitting multiple sclerosis. The mean number of gadolinium-enhancing lesions at months 4, 5, and 6 of treatment was compared with the mean number of lesions noted on pretreatment brain MRI scans. Number and volume of Gd-enhancing lesions declined by 44%, (p<0.0001) and 41% (p=0.0018), respectively. Treatment was well tolerated. Oral simvastatin might inhibit inflammatory components of multiple sclerosis that lead to neurological disability. C1 Med Univ S Carolina, Charleston, SC 29425 USA. St Josephs Hosp, Barrow Neurol Inst, Phoenix, AZ USA. Clin Innovat Grp, Charleston, SC USA. Univ N Carolina, Dept Neurol, Chapel Hill, NC USA. Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA. Univ Colorado, Hlth Sci Ctr, Denver, CO USA. Ralph H Johnson Vet Affairs Med Ctr, Neurol Serv, Charleston, SC USA. Denver Vet Affairs Med Ctr, Denver, CO USA. W Haven Vet Affairs Med Ctr, West Haven, CT USA. RP Singh, L (reprint author), Med Univ S Carolina, 316 Clin Sci Bldg,171 Ashley Ave, Charleston, SC 29425 USA. EM singhi@musc.edu RI Lizrova Preiningerova, Jana/F-8959-2017 OI Lizrova Preiningerova, Jana/0000-0003-0337-3462 NR 5 TC 331 Z9 354 U1 3 U2 11 PU LANCET LTD PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 0140-6736 J9 LANCET JI Lancet PD MAY 15 PY 2004 VL 363 IS 9421 BP 1607 EP 1608 DI 10.1016/S0140-6736(04)16205-3 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 820SE UT WOS:000221408800012 PM 15145635 ER PT J AU Hu, W Xu, RJ Bielawski, J Bielawska, A Osta, W Obeid, L Mao, CG AF Hu, W Xu, RJ Bielawski, J Bielawska, A Osta, W Obeid, L Mao, CG TI Human alkaline ceramidase-a is essential for anchorage-dependent cell growth and survival SO FASEB JOURNAL LA English DT Meeting Abstract CT Annual Meeting of the American-Society-for-Biochemistry-and-Molecular-Biology/8th Congress of the International-Union-for-Biochemistry-and-Molecular-Biology CY JUN 12-16, 2004 CL Boston, MA SP Amer Soc BioChem & Mol Biol, Int Union Biochem & Mol Biol C1 Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA. Ralph H Johnson Vet Adm Hosp, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAY 14 PY 2004 VL 18 IS 8 SU S BP C57 EP C57 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 823UP UT WOS:000221639100262 ER PT J AU Khan, M Haq, E Giri, S Singh, AK Singh, I AF Khan, M Haq, E Giri, S Singh, AK Singh, I TI Peroxisome participation in psychosine-mediated lipotoxicity: Implication for Krabbe disease SO FASEB JOURNAL LA English DT Meeting Abstract CT Annual Meeting of the American-Society-for-Biochemistry-and-Molecular-Biology/8th Congress of the International-Union-for-Biochemistry-and-Molecular-Biology CY JUN 12-16, 2004 CL Boston, MA SP Amer Soc BioChem & Mol Biol, Int Union Biochem & Mol Biol C1 Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. Ralph Johnson Vet Affairs Med Ctr, Dept Pathol & Lab Med, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAY 14 PY 2004 VL 18 IS 8 SU S BP C270 EP C270 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 823UP UT WOS:000221639101247 ER PT J AU Liu, Y Teeter, MM Durand, CJ Neve, KA AF Liu, Y Teeter, MM Durand, CJ Neve, KA TI Identification of an allosteric Zn 2+binding site on the dopamine D2L receptor SO FASEB JOURNAL LA English DT Meeting Abstract CT Annual Meeting of the American-Society-for-Biochemistry-and-Molecular-Biology/8th Congress of the International-Union-for-Biochemistry-and-Molecular-Biology CY JUN 12-16, 2004 CL Boston, MA SP Amer Soc BioChem & Mol Biol, Int Union Biochem & Mol Biol C1 Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. Portland Vet Affairs Med Ctr, Portland, OR 97239 USA. Univ Calif Davis, Dept Psychiat, Davis, CA 95616 USA. Univ Calif Davis, Dept Chem, Davis, CA 95616 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAY 14 PY 2004 VL 18 IS 8 SU S BP C78 EP C78 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 823UP UT WOS:000221639100357 ER PT J AU Florez-McClure, ML Linseman, DA Chu, CT Barker, PA Bouchard, RJ Le, SS Laessig, TA Heidenreich, KA AF Florez-McClure, ML Linseman, DA Chu, CT Barker, PA Bouchard, RJ Le, SS Laessig, TA Heidenreich, KA TI The p75 neurotrophin receptor can induce autophagy and death of cerebellar Purkinje neurons SO JOURNAL OF NEUROSCIENCE LA English DT Article DE autophagy; Purkinje neuron; p75ntr; cell death; neurotrophin; vacuoles ID NERVE GROWTH-FACTOR; AFFINITY NGF RECEPTOR; ENDOSOMAL-LYSOSOMAL SYSTEM; METHYL-D-ASPARTATE; CELL-DEATH; GRANULE NEURONS; FACTOR-I; ALZHEIMERS-DISEASE; HIPPOCAMPAL-NEURONS; GLUTAMATE-RECEPTOR AB The cellular mechanisms underlying Purkinje neuron death in various neurodegenerative disorders of the cerebellum are poorly understood. Here we investigate an in vitro model of cerebellar neuronal death. We report that cerebellar Purkinje neurons, deprived of trophic factors, die by a form of programmed cell death distinct from the apoptotic death of neighboring granule neurons. Purkinje neuron death was characterized by excessive autophagic-lysosomal vacuolation. Autophagy and death of Purkinje neurons were inhibited by nerve growth factor (NGF) and were activated by NGF-neutralizing antibodies. Although treatment with antisense oligonucleotides to the p75 neurotrophin receptor (p75ntr) decreased basal survival of cultured cerebellar neurons, p75ntr-antisense decreased autophagy and completely inhibited death of Purkinje neurons induced by trophic factor withdrawal. Moreover, adenoviral expression of a p75ntr mutant lacking the ligand-binding domain induced vacuolation and death of Purkinje neurons. These results suggest that p75ntr is required for Purkinje neuron survival in the presence of trophic support; however, during trophic factor withdrawal, p75ntr contributes to Purkinje neuron autophagy and death. The autophagic morphology resembles that found in neurodegenerative disorders, suggesting a potential role for this pathway in neurological disease. C1 Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA. Denver Vet Affairs Med Ctr, Denver, CO 80262 USA. Univ Pittsburgh, Sch Med, Dept Pathol, Div Neuropathol, Pittsburgh, PA 15213 USA. Univ Pittsburgh, Sch Med, Pittsburgh Inst Neurodegenerat Dis, Pittsburgh, PA 15213 USA. McGill Univ, Montreal Neurol Inst, Ctr Neuronal Survival, Montreal, PQ H3A 2B4, Canada. RP Heidenreich, KA (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, C236,4200 E 9th Ave, Denver, CO 80262 USA. EM kim.heidenreich@uchsc.edu RI Chu, Charleen/B-1601-2008 OI Chu, Charleen/0000-0002-5052-8271 FU NINDS NIH HHS [NS38619-01A1, NS40817, R01 NS038619, R01 NS040817] NR 90 TC 69 Z9 70 U1 4 U2 8 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD MAY 12 PY 2004 VL 24 IS 19 BP 4498 EP 4509 DI 10.1523/JNEUROSCI.5744-03.2004 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 821QM UT WOS:000221477200002 PM 15140920 ER PT J AU Edwards, ER Lindquist, K Yaffe, K AF Edwards, ER Lindquist, K Yaffe, K TI Clinical profile and course of cognitively normal patients evaluated in memory disorders clinics SO NEUROLOGY LA English DT Article ID ALZHEIMERS-DISEASE; ELDERLY PERSONS; COMPLAINTS; IMPAIRMENT; DEMENTIA; DIAGNOSIS AB The authors investigated 499 patients that were found to be cognitively normal at the Alzheimer's Disease Research Centers of California between 1988 and 1999. Patients reported high rates of depression (39%) and family history of dementia (51%). Thirty-six percent returned for follow-up, and of those, 65% received a diagnosis of dementia or mild cognitive impairment. Patients evaluated at memory clinics who are considered cognitively normal may merit periodic re-evaluation. C1 Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. RP Yaffe, K (reprint author), 4150 Clement St,181G, San Francisco, CA 94121 USA. EM kyaffe@itsa.ucsf.edu FU NIA NIH HHS [AG00888] NR 10 TC 20 Z9 23 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD MAY 11 PY 2004 VL 62 IS 9 BP 1639 EP 1642 PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA 819XU UT WOS:000221350400040 PM 15136703 ER PT J AU Vig, EK Pearlman, RA AF Vig, EK Pearlman, RA TI Good and bad dying from the perspective of terminally ill men SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT Annual Meeting of the American-Geriatrics-Society CY MAY, 2001 CL CHICAGO, IL SP Amer Geriatr Soc ID GOOD DEATH; OF-LIFE; FAMILY MEMBERS; CARE; PERCEPTIONS; PREFERENCES; CANCER; VIEWS; END; OUTPATIENTS AB Background: Understanding the range of patients' views about good and bad deaths may be useful to clinicians caring for terminally ill patients. Our current understanding of good and bad deaths, however, comes primarily from input from families and clinicians. This study aimed to learn how terminally ill men conceptualize good and bad deaths. Methods: We conducted semistructured interviews with 26 men identified as having terminal heart disease or cancer. Participants described good and bad deaths in a section of open-ended questions. Participants also answered closed-ended questions about specific end-of-life scenarios. The open-ended questions were tape recorded, transcribed, and analyzed using grounded theory methods. The closed-ended questions were analyzed using descriptive statistics. Results: We found heterogeneity in responses to questions about good deaths, bad deaths, and preferred dying experiences. Participants voiced multiple reasons for why dying in one's sleep led to a good death and why prolonged dying or suffering led to a bad death. Participants did not hold uniform views about the presence of others at the very end of life or preferred location of dying. Conclusions: In discussing the end of life with terminally ill patients, clinicians may want to identify not only their patients' views of good and bad deaths but also how the identified attributes contribute to a good or bad death. The discussion can then focus on what might interfere with patients' attainment of their preferred dying experience and what may be available to help them achieve a death that is most consistent with their wishes. C1 Univ Washington, Dept Med, Seattle, WA 98195 USA. Univ Washington, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Ctr Clin, Seattle, WA USA. RP Vig, EK (reprint author), S182 GEC,1660 S Columbian Way, Seattle, WA 98108 USA. EM vigster@u.washington.edu NR 29 TC 37 Z9 37 U1 1 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD MAY 10 PY 2004 VL 164 IS 9 BP 977 EP 981 DI 10.1001/archinte.164.9.977 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 818XF UT WOS:000221277100008 PM 15136306 ER PT J AU Hu, KK Boyko, EJ Scholes, D Normand, E Chen, CL Grafton, J Fihn, SD AF Hu, KK Boyko, EJ Scholes, D Normand, E Chen, CL Grafton, J Fihn, SD TI Risk factors for urinary tract infections in postmenopausal women SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID THERAPY; PROPHYLAXIS AB Background: Urinary tract infections (UTI) occur frequently in postmenopausal women and account for substantial morbidity and economic costs. Although extensively studied in younger women and older, debilitated women, the risk factors for UTI among healthy community-dwelling postmenopausal women have not been well described. Methods: We conducted a population-based, case-control study of women aged between 55 and 75 years enrolled in a large, staff-model health maintenance organization. Cases were identified using computerized laboratory and outpatient records. Controls were randomly selected from the plan's enrollment files. We interviewed subjects regarding their habits, general health, and potential risk factors for UTI. Results: We interviewed 899 study subjects and 911 controls. Sociodemographic characteristics were similar in subjects and controls. Most women were insured and white. Like younger women, postmenopausal women with current UTI were more likely to be sexually active (odds ratio [OR], 1.42; 95% confidence interval [CI], 1.07-1.87) and have a history of UTI (OR, 4.20; 95% CI, 3.25-5.42). Like older debilitated women, study subjects were more likely to have diabetes mellitus (OR, 2.78; 95% CI, 1.78-4.35) and to be incontinent (OR, 1.36; 95% CI, 1.03-1.78). Oral estrogen replacement did not reduce UTI risk. Conclusions: In this population, the risk factors of healthy community-dwelling postmenopausal women reflect the health status of women as they transition toward old age. Sexual activity, history of UTI, treated diabetes, and incontinence were all associated with a higher risk of UTI. The therapeutic role of oral estrogen remains uncertain. Prospective studies in different patient populations are needed to better understand the risk factors of UTI. C1 VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. NW Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA. Epidemiol Res & Informat Ctr, Seattle, WA USA. Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA. RP Hu, KK (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,HSR&D 152, Seattle, WA 98108 USA. EM kenthu@u.washington.edu OI Boyko, Edward/0000-0002-3695-192X FU NIDDK NIH HHS [R01 DK431341] NR 19 TC 62 Z9 65 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD MAY 10 PY 2004 VL 164 IS 9 BP 989 EP 993 DI 10.1001/archinte.164.9.989 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 818XF UT WOS:000221277100010 PM 15136308 ER PT J AU Wang, ZH Yang, CL Ellison, DH AF Wang, ZH Yang, CL Ellison, DH TI Comparison of WNK4 and WNK1 kinase and inhibiting activities SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE serine/threonine kinases; sodium chloride transporter; WNK kinases; distal tubule; kidney; distal convoluted tubules; chloride transport ID HYPERTENSION; DOMAIN; SODIUM; KIDNEY; GENE AB WNK kinases are novel serine/threonine protein kinases. Mutations in two members of the WNK family, WNK1 and WNK4, cause familial hyperkalemic hypertension. These kinases regulate ion transport across diverse epithelia; WNK4 reduces activity of the Na-Cl cotransporter activity and the potassium channel, ROMK, by reducing their appearance at the plasma membrane. We examined the kinase activity of WNK I and WNK4 in vitro. A glutathione S-transferase (GST) fusion protein of the WNK1 kinse domain phosphorylated itself and a substrate protein, as reported previously. A longer construct, containing the autoinhibitory domain, did not. A GST WNK4 kinase domain construct demonstrated no kinase activity, in vitro or in HEK 293 cells. WNK4 constructs that included a region homologous to the autoinhibitory domain of WNK1 inhibited WNK1 kinase activity. Inhibition by a short WNNK4 segment. WNK4 (444-518), was greater than inhibition by WNK4 (444-563). Together, these results suggest that WNK4 must be activated by currently unknown factors to exhibit kinase activity and that WNK4 contains an inhibitory domain that can inhibit the kinase activity of WNK1. (C) 2004 Elsevier Inc. All rights reserved. C1 Oregon Hlth & Sci Univ, Dept Med, Div Nephrol & Hypertens, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97239 USA. Portland Vet Affairs Med Ctr, Portland, OR USA. RP Ellison, DH (reprint author), Oregon Hlth & Sci Univ, Dept Med, Div Nephrol & Hypertens, Portland, OR 97239 USA. EM ellisond@ohsu.edu OI Ellison, David/0000-0003-2915-265X FU NIDDK NIH HHS [R01 DK51496] NR 15 TC 26 Z9 27 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD MAY 7 PY 2004 VL 317 IS 3 BP 939 EP 944 DI 10.1016/j.bbrc.2004.03.132 PG 6 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 814QZ UT WOS:000220990500038 PM 15081430 ER PT J AU Chandrasekar, B Vemula, K Surabhi, RM Li-Weber, M Owen-Schaub, LB Jensen, LE Mummidi, S AF Chandrasekar, B Vemula, K Surabhi, RM Li-Weber, M Owen-Schaub, LB Jensen, LE Mummidi, S TI Activation of intrinsic and extrinsic proapoptotic signaling pathways in interleukin-18-mediated human cardiac endothelial cell death SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; FAS-MEDIATED APOPTOSIS; NITRIC-OXIDE; REPERFUSION INJURY; SMOOTH-MUSCLE; CYTOCHROME-C; FACTOR-ALPHA; RECEPTOR; IL-18 AB Endothelial cells are the primary targets of circulating immune and inflammatory mediators. We hypothesize that interleukin-18, a proinflammatory cytokine, induces endothelial cell apoptosis. Human cardiac microvascular endothelial cells (HCMEC) were treated with interleukin (IL) 18. mRNA expression was analyzed by ribonuclease protection assay, protein levels by immunoblotting, and cell death by enzyme-linked immunosorbent assay and fluorescence-activated cell sorter analysis. We also investigated the signal transduction pathways involved in IL18-mediated cell death. Treatment of HCMEC with IL-18 increases 1) NF-kappaB DNA binding activity; 2) induces kappaB-driven luciferase activity; 3) induces IL-1beta and TNF-alpha expression via NF-kappaB activation; 4) inhibits anti-apoptotic Bcl-2 and Bcl-X-L; 5) up-regulates proapoptotic Fas, Fas-L, and Bcl-X-S expression; 6) induces fas and Fas-L promoter activities via NF-kappaB activation; 7) activates caspases-8, -3, -9, and BID; 8) induces cytochrome c release into the cytoplasm; 9) inhibits FLIP; and 10) induces HCME cell death by apoptosis as seen by increased annexin V staining and increased levels of mono- and oligonucleosomal fragmented DNA. Whereas overexpression of Bcl-2 significantly attenuated IL-18-induced endothelial cell apoptosis, Bcl-2/Bcl-X-L chimeric phosphorothioated 2'-MOE-modified antisense oligonucleotides potentiated the proapoptotic effects of IL-18. Furthermore, caspase-8, IKK-alpha, and NF-kappaB p65 knockdown or dominant negative IkappaB-alpha and dominant negative IkappaB-beta or kinase dead IKK-beta significantly attenuated IL-18-induced HCME cell death. Effects of IL-18 on cell death are direct and are not mediated by intermediaries such as IL-1beta, tumor necrosis factor-alpha, or interferon-gamma. Taken together, our results indicate that IL-18 activates both intrinsic and extrinsic proapoptotic signaling pathways, induces endothelial cell death, and thereby may play a role in myocardial inflammation and injury. C1 Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA. Univ Pittsburgh, Inst Canc, Dept Pathol, Pittsburgh, PA 15213 USA. German Canc Res Ctr, Tumor Immunol Program, D-69120 Heidelberg, Germany. Univ Calif Riverside, Dept Biomed Sci, Riverside, CA 92521 USA. Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA. Univ Penn, Ctr Pharmacogenet, Philadelphia, PA 19104 USA. S Texas Vet Hlth Care Syst, Vet Affairs Ctr HIV & AIDS, San Antonio, TX 78229 USA. RP Chandrasekar, B (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM chandraseka@uthscsa.edu RI Mummidi, Srinivas/C-1004-2008 OI Mummidi, Srinivas/0000-0002-4068-6380 FU NHLBI NIH HHS [HL 68020] NR 68 TC 67 Z9 72 U1 0 U2 2 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD MAY 7 PY 2004 VL 279 IS 19 BP 20221 EP 20233 DI 10.1074/jbc.M313980200 PG 13 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 817FX UT WOS:000221164500099 PM 14960579 ER PT J AU Taha, TA Osta, W Kozhaya, L Bielawski, J Johnson, KR Gillanders, WE Dbaibo, GS Hannun, YA Obeid, LM AF Taha, TA Osta, W Kozhaya, L Bielawski, J Johnson, KR Gillanders, WE Dbaibo, GS Hannun, YA Obeid, LM TI Down-regulation of sphingosine kinase-1 by DNA damage - Dependence on proteases and p53 SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID TUMOR-NECROSIS-FACTOR; TIME RT-PCR; CELL-DEATH; CERAMIDE; APOPTOSIS; SPHINGOSINE-1-PHOSPHATE; PATHWAY; STRESS; ACTINOMYCIN; ACTIVATION AB Sphingosine kinase 1 (SK1), a key enzyme in sphingosine 1-S1P) synthesis, regulates various aspects of cell behavior, including cell survival and proliferation. DNA damaging anti-neoplastic agents have been shown to induce p53, ceramide levels, and apoptosis; however, the effects of anti-neoplastic agents on SK have not been assessed. In this study, we investigated the effects of a DNA damaging agent, actinomycin D ( Act D), on the function of sphingosine kinase ( SK1). Act D caused a reduction in the protein levels of SK1, as indicated by Western blot analysis, with a concomitant decrease in SK activity. The down-regulation was posttranscriptional, because the mRNA levels of SK1 remained unchanged. Similar decreases in SK1 protein were observed with other DNA damaging agents such as doxorubicin, etoposide, and gamma-irradiation. ZVAD, the pancaspase inhibitor, and Bcl-2 annulled the effect of Act D on SK1, demonstrating a role for cysteine proteases downstream of Bcl-2 in the down-regulation of SK1. Inhibition of caspases 3, 6, 7, and 9 only partially reversed Act D-induced SK1 loss. Inhibition of cathepsin B, a lysosomal protease, produced a significant reversal of SK1 decline by Act D, suggesting that a multitude of ZVAD-sensitive cysteine proteases downstream of Bcl-2 mediated the SK1 decrease. When p53 up-regulation after Act D treatment was inhibited, SK1 down-regulation was rescued, demonstrating p53 dependence of SK1 modulation. Treatment of cells with S1P, the product of SK1, partially inhibited Act D-induced cell death, raising the possibility that a decrease in SK1 may be in part necessary for cell death to occur. Furthermore, the knockdown of SK1 by small interfering RNA in MCF-7 cells resulted in a significant reduction in cell viability. These studies demonstrate that SK1 is down-regulated by genotoxic stress, and that basal SK1 function may be necessary for the maintenance of tumor cell growth. C1 Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Div Gen Internal Med, Charleston, SC 29401 USA. Amer Univ Beirut, Dept Biochem, Beirut, Lebanon. Amer Univ Beirut, Dept Pediat, Beirut, Lebanon. RP Obeid, LM (reprint author), Med Univ S Carolina, Dept Med, 114 Doughty St,POB 250779, Charleston, SC 29425 USA. EM obeidl@musc.edu OI obeid, lina/0000-0002-0734-0847 FU NCI NIH HHS [P01 CA 097132] NR 34 TC 77 Z9 81 U1 1 U2 3 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD MAY 7 PY 2004 VL 279 IS 19 BP 20546 EP 20554 DI 10.1074/jbc.M401259200 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 817FX UT WOS:000221164500134 PM 14988393 ER PT J AU Zile, MR Baicu, CF Gaasch, WH AF Zile, MR Baicu, CF Gaasch, WH TI Diastolic heart failure - Abnormalities in active relaxation and passive stiffness of the left ventricle SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID TWO-DIMENSIONAL ECHOCARDIOGRAPHY; PRESERVED EJECTION FRACTION; SYSTOLIC FUNCTION; 2-DIMENSIONAL ECHOCARDIOGRAPHY; MYOCARDIAL RELAXATION; THERAPEUTIC OPTIONS; DIAGNOSTIC-CRITERIA; MAGNETIC-RESONANCE; PART I; VOLUME AB BACKGROUND Patients with signs and symptoms of heart failure and a normal left ventricular ejection fraction are said to have diastolic heart failure. It has traditionally been thought that the pathophysiological cause of heart failure in these patients is an abnormality in the diastolic properties of the left ventricle; however, this hypothesis remains largely unproven. METHODS We prospectively identified 47 patients who met the diagnostic criteria for definite diastolic heart failure; all the patients had signs and symptoms of heart failure, a normal ejection fraction, and an increased left ventricular end-diastolic pressure. Ten patients who had no evidence of cardiovascular disease served as controls. Left ventricular diastolic function was assessed by means of cardiac catheterization and echocardiography. RESULTS The patients with diastolic heart failure had abnormal left ventricular relaxation and increased left ventricular chamber stiffness. The mean ( +/- SD) time constant for the isovolumic-pressure decline (tau) was longer in the group with diastolic heart failure than in the control group ( 59 +/- 14 msec vs. 35 +/- 10 msec, P = 0.01). The diastolic pressure - volume relation was shifted up and to the left in the patients with diastolic heart failure as compared with the controls. The corrected left ventricular passive-stiffness constant was significantly higher in the group with diastolic heart failure than in the control group (0.03 +/- 0.01 vs. 0.01 +/- 0.01, P< 0.001). CONCLUSIONS Patients with heart failure and a normal ejection fraction have significant abnormalities in active relaxation and passive stiffness. In these patients, the pathophysiological cause of elevated diastolic pressures and heart failure is abnormal diastolic function. C1 Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Div Cardiol, Charleston, SC 29425 USA. Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. Lahey Clin Fdn, Dept Cardiovasc Med, Burlington, MA USA. Univ Massachusetts, Sch Med, Div Cardiovasc Med, Worcester, MA USA. RP Zile, MR (reprint author), Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Div Cardiol, 135 Rutledge Ave,Suite 1201,POB 250592, Charleston, SC 29425 USA. EM zilem@musc.edu NR 43 TC 678 Z9 715 U1 4 U2 23 PU MASSACHUSETTS MEDICAL SOC/NEJM PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAY 6 PY 2004 VL 350 IS 19 BP 1953 EP 1959 DI 10.1056/NEJMoa032566 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 818AU UT WOS:000221218800007 PM 15128895 ER PT J AU Byram, SC Carson, MJ DeBoy, CA Serpe, CJ Sanders, VM Jones, KJ AF Byram, SC Carson, MJ DeBoy, CA Serpe, CJ Sanders, VM Jones, KJ TI CD4-positive T cell-mediated neuroprotection requires dual compartment antigen presentation SO JOURNAL OF NEUROSCIENCE LA English DT Article DE microglia; chimera mice; antigen-presenting cell; motoneuron survival; CD4(+) T lymphocytes; neuro-immune interactions; facial motoneuron ID FACIAL MOTOR NUCLEUS; CENTRAL-NERVOUS-SYSTEM; NATURAL-KILLER-CELLS; PERIPHERAL-NERVE; SPINAL-CORD; MOTONEURON SURVIVAL; IMMUNE SURVEILLANCE; CNS; NEURONS; DEGENERATION AB Our laboratory discovered that CD4-positive (CD4(+)) T cells of the immune system convey transitory neuroprotection to injured mouse facial motoneurons (FMNs) (Serpe et al., 1999, 2000, 2003). A fundamental question in the mechanisms responsible for neuroprotection concerns the identity of the cell(s) that serves as the antigen-presenting cell (APC) to activate the CD4(+) T cells. Here, we first establish that CD4(+) T cells reactive to non-CNS antigen fail to support FMN survival and, second, demonstrate a two-compartment model of CD4(+) T cell activation. Mouse bone marrow (BM) chimeras were developed that discriminate between resident antigen-presenting host cell and BM-derived antigen-presenting donor cell expression of major histocompatibility complex II within central and peripheral compartments, respectively. After facial nerve transection, neither compartment alone is sufficient to result in activated CD4(+) T cell-mediated FMN survival. Rather, CD4(+) T cell-mediated neuroprotection appears to depend on both resident microglial cells in the central compartment and a BM-derived APC in the peripheral compartment. This is the first in vivo report demonstrating a neuroprotective mechanism requiring APC functions by resident (i.e., parenchymal) microglial cells. C1 Loyola Univ, Dept Cell Biol Neurobiol & Anat, Maywood, IL 60153 USA. US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res & Dev Serv, Hines, IL 60141 USA. Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA. Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA. RP Jones, KJ (reprint author), Loyola Univ, Dept Cell Biol Neurobiol & Anat, 2160 S 1st Ave, Maywood, IL 60153 USA. EM kjones1@lumc.edu FU NINDS NIH HHS [R01 NS039508-05, NS045735, NS39508, NS40433, R01 NS039508, R01 NS039508-01A1, R01 NS039508-01A1S1, R01 NS039508-02, R01 NS039508-03, R01 NS039508-04, R01 NS039508-06, R01 NS040433, R01 NS045735, R01 NS045735-01] NR 42 TC 90 Z9 93 U1 0 U2 0 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD MAY 5 PY 2004 VL 24 IS 18 BP 4333 EP 4339 DI 10.1523/JNEUROSCI.5276-03.2004 PG 7 WC Neurosciences SC Neurosciences & Neurology GA 819NS UT WOS:000221322400006 PM 15128847 ER PT J AU Ho, PM Masoudi, FA Peterson, ED Grunwald, GK Hammermeister, KE Rumsfeld, JS AF Ho, PM Masoudi, FA Peterson, ED Grunwald, GK Hammermeister, KE Rumsfeld, JS TI Cardiology management improves secondary prevention measures among patients with coronary artery disease SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article ID ACUTE MYOCARDIAL-INFARCTION; CONGESTIVE-HEART-FAILURE; HIGH-RISK PATIENTS; BLOOD-PRESSURE; SERUM-CHOLESTEROL; UNITED-STATES; PRIMARY-CARE; MORTALITY; OUTCOMES; PHYSICIANS AB OBJECTIVES The goal of this study was to determine if cardiology subspecialty involvement improves the attainment of recommended low-density lipoprotein (LDL) cholesterol and blood pressure (BP) targets in coronary artery disease (CAD) patients. BACKGROUND The impact of physician specialty on secondary prevention measures for CAD in ambulatory care is unknown. METHODS This was a retrospective cohort study of 13,995 patients with CAD seen at eight ambulatory care Veteran Affairs facilities from 1998 to 2000. Patients with cardiology involvement were defined as those seen in cardiology clinic in addition to primary care. The main outcomes of interest were LDL cholesterol less than or equal to100 mg/dl and BP less than or equal to130/85 mm Hg. Multivariable hierarchical regression analyses were used to determine the independent association of cardiology involvement with improved LDL cholesterol and BP control. RESULTS Overall, 3,771 (27.0%) patients had cardiology involvement. A higher proportion of patients with cardiology involvement achieved LDL cholesterol (55.6% vs. 45.6%; p < 0.01) and BP (45.3% vs. 35.9%; p < 0.01) goals. In multivariable hierarchical regression analysis, cardiology involvement was independently associated with better LDL cholesterol (odds ratio [OR], 1.59; 95% confidence interval [CI], 1.40 to 1.82) and BP (OR, 1.52; 95% CI, 1.32 to 1.77) control. The benefit of cardiology involvement was consistent across a range of LDL and BP targets, in analysis of LDL and BP as continuous outcomes, and among subgroups of high-risk patients, including diabetic patients, the elderly, and those with prior revascularization. CONCLUSIONS Cardiology involvement is associated with better LDL cholesterol and BP control among CAD patients. However, significant room for improvement in secondary prevention measures remains, irrespective of physician specialty. (C) 2004 by the American College of Cardiology Foundation. C1 Univ Colorado, Hlth Sci Ctr, Denver Vet Affairs Med Ctr, Hlth Serv Res, Boulder, CO 80309 USA. Univ Colorado, Hlth Sci Ctr, Denver Vet Affairs Med Ctr, Cardiol & Hlth Serv Res, Boulder, CO 80309 USA. Univ Colorado, Hlth Sci Ctr, Div Cardiol, Denver Hlth Med Ctr, Boulder, CO 80309 USA. Univ Colorado, Hlth Sci Ctr, Div Geriatr Med, Denver Hlth Med Ctr, Boulder, CO 80309 USA. Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA. Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, Denver, CO 80202 USA. VA Puget Sound Hlth Care Syst, IHD QUERI, Hlth Serv Res & Dev, Seattle, WA USA. RP Ho, PM (reprint author), 1055 Clermont St,111B, Denver, CO 80220 USA. EM Michael.ho@uchsc.edu RI Sales, Anne/D-9678-2012 OI Sales, Anne/0000-0001-9360-3334 FU NIA NIH HHS [K08-AG01011] NR 35 TC 20 Z9 20 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAY 5 PY 2004 VL 43 IS 9 BP 1517 EP 1523 DI 10.1016/j.jacc.2003.12.037 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 817CI UT WOS:000221155200004 PM 15120805 ER PT J AU Higashi, T Shekelle, PG Solomon, DH Knight, EL Roth, C Chang, JT Kamberg, CJ MaClean, CH Young, RT Adams, J Reuben, DB Avorn, J Wenger, NS AF Higashi, T Shekelle, PG Solomon, DH Knight, EL Roth, C Chang, JT Kamberg, CJ MaClean, CH Young, RT Adams, J Reuben, DB Avorn, J Wenger, NS TI The quality of pharmacologic care for vulnerable older patients SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID INAPPROPRIATE MEDICATION USE; ACUTE MYOCARDIAL-INFARCTION; ADVERSE DRUG-REACTIONS; EXPLICIT CRITERIA; ELDERLY-PATIENTS; CLINICAL-TRIALS; BEERS CRITERIA; HEART-FAILURE; HEALTH-CARE; COMMUNITY AB Background: Although pharmacotherapy is critical to the medical care of older patients, medications can have considerable toxicity in this age group. To date, research has focused on inappropriate prescribing and policy efforts have aimed at access, but no comprehensive measurement of the quality of pharmacologic management using explicit criteria has been performed. Objective: To evaluate the broad range of pharmacologic care processes for vulnerable older patients. Design: Observational cohort study. Setting: 2 managed care organizations enrolling older persons. Patients: community-dwelling high-risk patients 65 years of age or older continuously enrolled in the managed care organizations from 1 July 1998 to 31 July 1999. Measurements: Patients' receipt of care as specified in 43 quality indicators covering 4 domains of pharmacologic care: 1) prescribing indicated medications; 2) avoiding inappropriate medications; 3) education, continuity, and documentation; and 4) medication monitoring. Results: Of 475 vulnerable older patients, 372 (78%) consented to participate and had medical records that could be abstracted.The percentage of appropriate pharmacologic management ranged from 10% for documentation of risks of nonsteroidal anti-inflammatory drugs to 100% for avoiding short-acting calcium-channel blockers in patients with heart failure and avoiding beta-blockers in patients with asthma. Pass rates for quality indicators in the "avoiding inappropriate medications" domain (97% [95% Cl, 96% to 98%]) were significantly higher than pass rates for "prescribing indicated medications" (50% [Cl, 45% to 55%]); "education, continuity, and documentation" (81% [Cl, 79% to 84%]); and "medication monitoring" (64% [Cl, 60% to 68%]). Limitations: Fewer than 10 patients were eligible for many of the quality indicators measured, and the generalizabiIity of these findings in 2 managed care organizations to the general geriatric population is uncertain. Conclusions: Failures to prescribe indicated medications, monitor medications appropriately, document necessary information, educate patients, and maintain continuity are more common prescribing problems than use of inappropriate drugs in older patients. C1 Univ Calif Los Angeles, Div Gen Internal Med, Los Angeles, CA 90095 USA. Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA 90095 USA. RAND Hlth, Washington, DC USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Higashi, T (reprint author), Univ Calif Los Angeles, Div Gen Internal Med, 911 Broxton Plaza, Los Angeles, CA 90095 USA. FU BHP HRSA HHS [PE-19001] NR 45 TC 134 Z9 138 U1 2 U2 5 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAY 4 PY 2004 VL 140 IS 9 BP 714 EP 720 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 816XR UT WOS:000221143100005 PM 15126255 ER PT J AU Humphrey, LL Teutsch, S Johnson, M AF Humphrey, LL Teutsch, S Johnson, M TI Lung cancer screening with sputum cytologic examination, chest radiography, and computed tomography: An update for the US Preventive Services Task Force SO ANNALS OF INTERNAL MEDICINE LA English DT Review ID SUSTAINED-RELEASE BUPROPION; NEOPLASM RESEARCH-PROJECT; DOSE SPIRAL CT; BRONCHOGENIC-CARCINOMA; SMOKING-CESSATION; FOLLOW-UP; NEW-YORK; CONTROLLED-TRIAL; SURGICAL RESECTION; DETECTION PROGRAM AB Background: Lung cancer is the leading cause of cancer-related death in the United States and worldwide. No major professional organizations, including the U.S. Preventive Services Task Force (USPSTF), currently recommend screening for lung cancer. Purpose: To examine the evidence evaluating screening for lung cancer with chest radiography, sputum cytologic examination, and low-dose computed tomography (CT) to aid the USPSTF in updating its recommendation on lung cancer screening. Data Sources: MEDLINE, the Cochrane Library, reviews, editorials, and experts. Study Selection: Studies that evaluated mass screening programs for lung cancer involving the tests of interest were selected. All studies were reviewed, but only studies with control groups were rated in quality since these would most directly influence the USPSTF screening recommendation. Data Extraction: Data were abstracted to data collection forms. Studies were graded according to criteria developed by the USPSTF. Data Synthesis: None of the 6 randomized trials of screening for lung cancer with chest radiography alone or in combination with sputum cytologic examination showed benefit among those screened. All studies were limited because some level of screening occurred in the control population. Five case-control studies from Japan suggested benefit to both high- and low-risk men and women. All studies were limited by potential healthy screenee bias. Six cohort studies showed that when CT was used to screen for lung cancer, lung cancer was diagnosed at an earlier stage than in usual clinical care. However, these studies did not have control groups, making mortality evaluation difficult. In addition, the studies demonstrated a high rate of false-positive findings. Conclusions: current data do not support screening for lung cancer with any method. These data, however, are also insufficient to conclude that screening does not work, particularly in women. Two randomized trials of screening with chest radiography or low-dose CT are currently under way and will better inform lung cancer screening decisions. C1 Oregon Hlth Sci Univ, Evidence Based Practice Ctr, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Portland Vet Affairs Med Ctr, Portland, OR 97201 USA. Merck & Co Inc, W Point, PA USA. Univ Med & Dent New Jersey, Sch Med, Newark, NJ 07103 USA. RP Humphrey, LL (reprint author), Oregon Hlth Sci Univ, Evidence Based Practice Ctr, Portland, OR 97201 USA. FU PHS HHS [290-97-0018] NR 124 TC 122 Z9 128 U1 1 U2 15 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAY 4 PY 2004 VL 140 IS 9 BP 740 EP 753 PG 14 WC Medicine, General & Internal SC General & Internal Medicine GA 816XR UT WOS:000221143100009 PM 15126259 ER PT J AU Spiegel, BMR Gralnek, IM AF Spiegel, BMR Gralnek, IM TI Cost-effectiveness of cyclooxygenase-2 inhibitors in chronic arthritis - Response SO ANNALS OF INTERNAL MEDICINE LA English DT Letter C1 Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Spiegel, BMR (reprint author), Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAY 4 PY 2004 VL 140 IS 9 BP 761 EP 762 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 816XR UT WOS:000221143100013 ER PT J AU Walter, CA Intano, GW McMahan, CA Kelner, K McCarrey, JR Walter, RB AF Walter, CA Intano, GW McMahan, CA Kelner, K McCarrey, JR Walter, RB TI Mutation spectral changes in spermatogenic cells obtained from old mice SO DNA REPAIR LA English DT Article DE paternal age; germline mutagenesis; lacI; spermatogenic cells; mutational spectrum ID LACI TRANSGENIC MICE; GERM-CELLS; MORPHOLOGICAL CHARACTERIZATION; MUTAGENIC PROPERTIES; ESCHERICHIA-COLI; SECTORED PLAQUES; GENETIC-DISEASE; EXCISION-REPAIR; MUTANT PLAQUES; LOCUS TEST AB Male reproductive health is compromised with increased paternal age, due at least in part, to an increased frequency of de novo germline mutations. Because of technical and sample limitations, there is a dearth of empirical information on the mechanism(s) that mediate this age-related increase in mutant frequency. To study this phenomenon, investigators have used as a model system a transgenic mouse strain that carries a lacI mutagenesis reporter transgene. This transgene displays a paternal age effect and overcomes many of the technical difficulties that have inhibited experimental analyses of age-related changes in the male germline. In this study, approximately 300 mutant lacI transgenes were recovered from defined spermatogenic cell types obtained from various aged lacI transgenic mice and sequenced. The spectrum representing mutations from spermatogenic cells of old mice revealed an increased prevalence of transversions compared to spectra for young and middle-aged mice. Five mutation hotspots were identified in spectra for spermatogenic cells from young and middle-aged mice, but no hotspots were identified in the spectrum for spermatogenic cells from old mice. These results suggest that the challenges to germline DNA change as the animal ages and that the increased mutant frequency observed with increased paternal age is not simply a greater accumulation of mutagenic events characteristic of spermatogenic cells from the young animal. (C) 2004 Elsevier B.V. All rights reserved. C1 Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. Audie Murphy Mem VA Hosp, S Texas Vet Hlth Care Syst, Div Res, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78229 USA. SW Texas State Univ, Dept Biochem & Mol Biol, San Marcos, TX 78666 USA. Univ Texas, Dept Biol, San Antonio, TX 78249 USA. RP Walter, CA (reprint author), Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM walter@uthscsa.edu FU NCI NIH HHS [CA75137]; NIA NIH HHS [AG21163]; NIEHS NIH HHS [ES09136] NR 63 TC 15 Z9 15 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1568-7864 J9 DNA REPAIR JI DNA Repair PD MAY 4 PY 2004 VL 3 IS 5 BP 495 EP 504 DI 10.1016/j.dnarep.2004.01.005 PG 10 WC Genetics & Heredity; Toxicology SC Genetics & Heredity; Toxicology GA 817CU UT WOS:000221156400006 PM 15084311 ER PT J AU Lorenz, KA Steckart, MJ Rosenfeld, KE AF Lorenz, KA Steckart, MJ Rosenfeld, KE TI End-of-life education using the dramatic arts: The wit educational initiative SO ACADEMIC MEDICINE LA English DT Article; Proceedings Paper CT 24th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 02-05, 2001 CL SAN DIEGO, CA SP Soc Gen Internal Med ID MEDICAL-EDUCATION; CARE; INTERNSHIP; REFLECTION; DOCTORS; EMPATHY; DEATH; MOOD AB Caring for dying persons requires skill in interpersonal aspects of care, which may be difficult to teach using conventional educational methods. The Pulitzer Prize-winning play Wit relates the personal story of a patient dying from metastatic ovarian cancer and describes the protagonist's experience with medical care from diagnosis to death. Members of the Department of Medicine at the VA Greater Los Angeles Health care System and the David Geffen School of Medicine, UCLA developed a program that utilized Wit to educate medical students, residents, and staff providers in the humanistic elements of end-of-life care. Between February 2000 and January 2002 the Wit Educational Initiative organized on-site readings of Wit by local professional theatre companies at medical centers throughout the United States and Canada, inviting medical students, housestaff, and other providers to attend the play followed by structured discussions of the play's themes. The Initiative provided extensive support for potential program sites including publicity, providing a handbook with a step-by-step guide to organizing local programs, and feedback of postperformance survey results. The Initiative was successful in organizing performances at 32 out of 54 (59%) medical centers where a local production of Wit was identified. Survey respondents confirmed the appeal, emotional impact, and perceived relevance of drama in end-of-life education. An educational program using theatre to educate trainees in the humanistic aspects of end-of-life care was enthusiastically received by medical schools and rated highly by attendees. C1 Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Vet Integrated Palliat Program, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Vet Integrated Palliat Program, Los Angeles, CA 90073 USA. RP Lorenz, KA (reprint author), VA GLAHS, Div Gen Internal Med, 11301 Wilshire Blvd,111-G, Los Angeles, CA 90073 USA. EM Karl.Lorenz@med.va.gov NR 28 TC 28 Z9 28 U1 2 U2 8 PU ASSOC AMER MEDICAL COLLEGES PI WASHINGTON PA 2450 N ST N W, WASHINGTON, DC 20037-1126 USA SN 1040-2446 J9 ACAD MED JI Acad. Med. PD MAY PY 2004 VL 79 IS 5 BP 481 EP 486 DI 10.1097/00001888-200405000-00020 PG 6 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 840BK UT WOS:000222831800017 PM 15107289 ER PT J AU Stromberg, MF Rukstalis, MR Lerman, C AF Stromberg, MF Rukstalis, MR Lerman, C TI The effect of bupropion on alcohol and sucrose consumption in the rat SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 27th Annual Meeting of the Research-Society-on-Alcoholism CY JUN 26-30, 2004 CL Vancouver, CANADA SP Res Soc Alcoholism C1 Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD MAY PY 2004 VL 28 IS 5 SU S BP 18A EP 18A PG 1 WC Substance Abuse SC Substance Abuse GA 822OK UT WOS:000221549300071 ER PT J AU Beresford, TP Alfers, J Clapp, L Martin, BK AF Beresford, TP Alfers, J Clapp, L Martin, BK TI Family history and alcohol withdrawal symptoms: Genetic implication SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 27th Annual Meeting of the Research-Society-on-Alcoholism CY JUN 26-30, 2004 CL Vancouver, CANADA SP Res Soc Alcoholism C1 Univ Colorado, Hlth Sci Ctr, Denver VA Med Ctr 151, Denver, CO 80220 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD MAY PY 2004 VL 28 IS 5 SU S BP 49A EP 49A PG 1 WC Substance Abuse SC Substance Abuse GA 822OK UT WOS:000221549300255 ER PT J AU Wu, PH Taylor, AM Proctor, WR AF Wu, PH Taylor, AM Proctor, WR TI Effects of ethanol on the GABAA- and NMDA-synaptic responses in hippocampal and neocortical pyramidal neurons of inbred long sleep (ILS) and short sleep (ISS) mice. SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 27th Annual Meeting of the Research-Society-on-Alcoholism CY JUN 26-30, 2004 CL Vancouver, CANADA SP Res Soc Alcoholism C1 Univ Colorado, Hlth Sci Ctr, Denver VA Med Ctr, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Denver, CO 80262 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD MAY PY 2004 VL 28 IS 5 SU S BP 58A EP 58A PG 1 WC Substance Abuse SC Substance Abuse GA 822OK UT WOS:000221549300309 ER PT J AU Beresford, TP Dimartini, A Martin, BK Alfers, J Clapp, L AF Beresford, TP Dimartini, A Martin, BK Alfers, J Clapp, L TI Drinking and HCV transmission risk in liver transplant candidates cross center data SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 27th Annual Meeting of the Research-Society-on-Alcoholism CY JUN 26-30, 2004 CL Vancouver, CANADA SP Res Soc Alcoholism C1 Univ Colorado, Hlth Sci Ctr, Denver VA Med Ctr 151, Denver, CO 80220 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD MAY PY 2004 VL 28 IS 5 SU S BP 71A EP 71A PG 1 WC Substance Abuse SC Substance Abuse GA 822OK UT WOS:000221549300389 ER PT J AU Kozel, LB Rademacher, B Belknap, JK Hofstetter, J Mayeda, A Buck, KJ AF Kozel, LB Rademacher, B Belknap, JK Hofstetter, J Mayeda, A Buck, KJ TI Fine mapping of a quantitative trait locus involved in ethanol physiological dependence and associated withdrawal episodes. SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 27th Annual Meeting of the Research-Society-on-Alcoholism CY JUN 26-30, 2004 CL Vancouver, CANADA SP Res Soc Alcoholism C1 Oregon Hlth Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Portland Alcohol Res Ctr, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR 97239 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD MAY PY 2004 VL 28 IS 5 SU S BP 88A EP 88A PG 1 WC Substance Abuse SC Substance Abuse GA 822OK UT WOS:000221549300486 ER PT J AU Beresford, TP Dimartini, A Martin, BK Alfers, J Clapp, L AF Beresford, TP Dimartini, A Martin, BK Alfers, J Clapp, L TI Alcohol and tobacco use in liver transplant candidates: A multi-center study SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 27th Annual Meeting of the Research-Society-on-Alcoholism CY JUN 26-30, 2004 CL Vancouver, CANADA SP Res Soc Alcoholism C1 Univ Colorado, Hlth Sci Ctr, Denver VA Med Ctr, Denver, CO 80220 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD MAY PY 2004 VL 28 IS 5 SU S BP 119A EP 119A PG 1 WC Substance Abuse SC Substance Abuse GA 822OK UT WOS:000221549300673 ER PT J AU Cao, Q Mak, KM Lieber, CS AF Cao, Q Mak, KM Lieber, CS TI Cytochrome P4502E1 primes macrophages to increase TNF-for all production in response to lipopolysaccharide stimuli SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 27th Annual Meeting of the Research-Society-on-Alcoholism CY JUN 26-30, 2004 CL Vancouver, CANADA SP Res Soc Alcoholism C1 Bronx Vet Affairs Med Ctr, Alcohol Res Ctr, Bronx, NY USA. Mt Sinai Sch Med, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD MAY PY 2004 VL 28 IS 5 SU S BP 123A EP 123A PG 1 WC Substance Abuse SC Substance Abuse GA 822OK UT WOS:000221549300697 ER PT J AU Veatch, LM Crigler, BC Ralston, LA AF Veatch, LM Crigler, BC Ralston, LA TI Seizure propensity differs by sex in a mouse model of repeated alcohol withdrawal SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 27th Annual Meeting of the Research-Society-on-Alcoholism CY JUN 26-30, 2004 CL Vancouver, CANADA SP Res Soc Alcoholism C1 Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. Med Univ S Carolina, Womens Res Ctr, Charleston, SC 29425 USA. Med Univ S Carolina, Charleston Alcohol Res Ctr, Charleston, SC 29425 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD MAY PY 2004 VL 28 IS 5 SU S BP 138A EP 138A PG 1 WC Substance Abuse SC Substance Abuse GA 822OK UT WOS:000221549300791 ER PT J AU Conigliaro, J McGinnis, KA Maisto, S Gordon, AJ Kraemer, KL Day, N Samet, J Fultz, SL Rimtand, D AF Conigliaro, J McGinnis, KA Maisto, S Gordon, AJ Kraemer, KL Day, N Samet, J Fultz, SL Rimtand, D CA AC Justice VACS Project Team TI Alcohol use/abuse and depression among HIV positive and negative veterans SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 27th Annual Meeting of the Research-Society-on-Alcoholism CY JUN 26-30, 2004 CL Vancouver, CANADA SP Res Soc Alcoholism C1 VA Pittsburgh Healthcare Syst, VACS Project Team, Pittsburgh, PA 15240 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD MAY PY 2004 VL 28 IS 5 SU S BP 161A EP 161A PG 1 WC Substance Abuse SC Substance Abuse GA 822OK UT WOS:000221549300925 ER PT J AU Oslin, DW AF Oslin, DW TI Pharmacogenetics of mu opioid receptor gene polymorphism in addiction SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 27th Annual Meeting of the Research-Society-on-Alcoholism CY JUN 26-30, 2004 CL Vancouver, CANADA SP Res Soc Alcoholism C1 Univ Penn, Ctr Study Addict, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA. Univ Penn, Sect Geriatr Psychiat, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD MAY PY 2004 VL 28 IS 5 SU S BP 177A EP 177A PG 1 WC Substance Abuse SC Substance Abuse GA 822OK UT WOS:000221549301019 ER PT J AU Buck, KJ Hood, HM Metten, P Crabbe, JC Belknap, K AF Buck, KJ Hood, HM Metten, P Crabbe, JC Belknap, K TI GABA(A) receptors and risk for alcohol physiological dependence and withdrawal SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 27th Annual Meeting of the Research-Society-on-Alcoholism CY JUN 26-30, 2004 CL Vancouver, CANADA SP Res Soc Alcoholism C1 Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Portland Alcohol Res Ctr, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR 97239 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD MAY PY 2004 VL 28 IS 5 SU S BP 185A EP 185A PG 1 WC Substance Abuse SC Substance Abuse GA 822OK UT WOS:000221549301068 ER PT J AU Myrick, H Voronin, K Drobes, D Wang, W Henderson, S Anton, R AF Myrick, H Voronin, K Drobes, D Wang, W Henderson, S Anton, R TI Safety of gabapentin in treating alcoholism SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 27th Annual Meeting of the Research-Society-on-Alcoholism CY JUN 26-30, 2004 CL Vancouver, CANADA SP Res Soc Alcoholism C1 Med Univ S Carolina, Dept Psychiat, Alcohol Res Ctr, Charleston, SC 29425 USA. Ralph H Johnson VAMC, Charleston, SC USA. Univ S Florida, Moffitt Canc Ctr, Tampa, FL USA. NR 0 TC 1 Z9 1 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD MAY PY 2004 VL 28 IS 5 SU S BP 193A EP 193A PG 1 WC Substance Abuse SC Substance Abuse GA 822OK UT WOS:000221549301113 ER PT J AU Saxon, A AF Saxon, A TI Planning subject flow. Workload and consistency during long-term studies SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 27th Annual Meeting of the Research-Society-on-Alcoholism CY JUN 26-30, 2004 CL Vancouver, CANADA SP Res Soc Alcoholism C1 Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD MAY PY 2004 VL 28 IS 5 SU S BP 199A EP 199A PG 1 WC Substance Abuse SC Substance Abuse GA 822OK UT WOS:000221549301152 ER PT J AU Gupta, S Yu, F Klaustermeyer, WB AF Gupta, S Yu, F Klaustermeyer, WB TI New-variant hereditary angioedema in three brothers with normal C1 esterase inhibitor level and function SO ALLERGY LA English DT Editorial Material DE angioedema; C1 esterase inhibitor; complement deficiency; hereditary angioedema ID ANGIONEUROTIC EDEMA C1 VA Greater LA Healthcare Syst, Los Angeles, CA 90073 USA. RP Gupta, S (reprint author), VA Greater LA Healthcare Syst, 11301 Wilshire Blvd,111R, Los Angeles, CA 90073 USA. EM william.klaustermeyer@med.va.gov NR 6 TC 12 Z9 12 U1 0 U2 0 PU BLACKWELL MUNKSGAARD PI COPENHAGEN PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK SN 0105-4538 J9 ALLERGY JI Allergy PD MAY PY 2004 VL 59 IS 5 BP 557 EP 558 DI 10.1111/j.1398-9995.2004.00428.x PG 2 WC Allergy; Immunology SC Allergy; Immunology GA 810KM UT WOS:000220703200018 PM 15080842 ER PT J AU Crawford, WW Gowda, VC Klaustermeyer, WB AF Crawford, WW Gowda, VC Klaustermeyer, WB TI Age effects on objective measures of atopy in adult asthma and rhinitis SO ALLERGY AND ASTHMA PROCEEDINGS LA English DT Article ID SKIN-TEST REACTIVITY; IMMUNOGLOBULIN-E LEVELS; COMMUNITY POPULATION-SAMPLE; SERUM IGE LEVELS; GENERAL-POPULATION; SMOKING; ASSOCIATION; RESPONSIVENESS; EPIDEMIOLOGY; PREVALENCE AB A cross-sectional survey of 132 adult men referred to the outpatient allergy clinic at the West Los Angeles Veterans Affairs Medical Center was performed to assess age effects on allergic disease in the elderly. Total serum immunoglobulin E (IgE), immediate hypersensitivity skin testing, and serum eosinophil count were measured in all subjects. Subjects were stratified by age into one of five groups for comparison. In asthma, prevalence of allergy skin test reactivity and mean total serum IgE levels did not decline with advancing age, suggesting that IgE-dependent mechanisms continue to be significant in elderly patients with asthma. In subjects with rhinitis, prevalence of allergy skin test reactivity and mean total serum IgE did decline among elderly subjects relative to younger subjects. However, the prevalence of allergic rhinitis did not decline in the elderly. This suggests that although allergic rhinitis is common in elderly patients, nonallergic causes of rhinitis may become more prevalent with advancing age. C1 Univ Calif Los Angeles, David Geffen Sch Med, Vet Affairs Greater Los Angeles Hlth Care Syst, Dept Med,Div Allergy & Immunol 111R, Los Angeles, CA 90073 USA. RP Klaustermeyer, WB (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Vet Affairs Greater Los Angeles Hlth Care Syst, Dept Med,Div Allergy & Immunol 111R, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 31 TC 12 Z9 13 U1 0 U2 4 PU OCEAN SIDE PUBLICATIONS INC PI PROVIDENCE PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA SN 1088-5412 J9 ALLERGY ASTHMA PROC JI Allergy Asthma Proc. PD MAY-JUN PY 2004 VL 25 IS 3 BP 175 EP 179 PG 5 WC Allergy SC Allergy GA 835OO UT WOS:000222493300007 PM 15317322 ER PT J AU Sontag, SJ O'Connell, S Miller, TQ Bernsen, M Seidel, J AF Sontag, SJ O'Connell, S Miller, TQ Bernsen, M Seidel, J TI Asthmatics have more nocturnal gasping and reflux symptoms than nonasthmatics, and they are related to bedtime eating SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID GASTROESOPHAGEAL REFLUX; PREVALENCE; THERAPY AB OBJECTIVES: Certain pulmonary diseases are now recognized as possible complications of gastroesophageal reflux (GER) disease. To further clarify the relationship between GER and asthma, we determined the prevalence, nature, and patterns of reflux symptoms in consecutive asthmatics and a well-defined patient population control group. METHODS: Two hundred and sixty-one asthmatic outpatients with well-documented asthma were interviewed in person using an extensive questionnaire. To avoid selection bias, we (a) used no selection criteria other than asthma, (b) interviewed every identified asthmatic from either the outpatient general medical clinic or pulmonary clinic (and excluded the gastroenterology clinic), and (c) excluded asthmatics referred because of gastrointestinal symptoms. A control group comprised 218 consecutive outpatients chosen from the same general medical clinics in which the asthmatics were enrolled. Interviews were conducted by one of two investigators. RESULTS: The control and asthmatic groups were similar with regard to age, gender, ethnicity, and consumption of tobacco and alcohol. There were major significant differences between the asthmatics and controls with regard to the age of onset of pulmonary and reflux symptoms, prevalence of eating before bedtime, prevalence of reflux symptoms, the quality of reflux symptoms, and the factors that promote and relieve reflux symptoms. Heartburn, regurgitation, and dysphagia were present in 71%, 45%, and 22% of asthmatics compared with 51%, 30%, and 5% of controls (p < 0.001). Three times as many asthmatics as controls had heartburn occurring throughout the day and night (OR; 95% Cl: 19.5; 4.5-85.7), and three times as many asthmatics as controls had sudden nocturnal awakening with reflux symptoms and reflux-associated pulmonary symptoms that occurred simultaneously with the reflux symptoms (p < 0.001). Within the asthma group, reflux symptoms were similar in those who required and those who did not require continuous bronchodilator therapy. In these asthmatics, however, those requiring continuous bronchodilator therapy (more severe asthma) developed pulmonary and GER symptoms at a significantly older age. Eating before bedtime was recognized by significantly more asthmatics than controls as a promoter of serious nocturnal GER symptoms (4.5; 2.7-7.7). In terms of patient awareness, one-third of the asthmatics with heartburn had previously considered a relationship between their reflux symptoms and their asthma. CONCLUSION: Compared to nonasthmatics, asthmatics have significantly more frequent and more severe day and night GER symptoms and significantly more of the pulmonary symptoms (nocturnal suffocation, cough, or wheezing) so often attributed to GER. The habit of eating before bedtime appears in asthmatics to have serious and life-threatening consequences. C1 Vet Affairs Hosp, Dept Med, Hines, IL 60141 USA. Loyola Univ, Stritch Sch Med, Maywood, IL 60153 USA. RP Sontag, SJ (reprint author), US Dept Vet Affairs, Med Ctr, Bldg 1,Room B321, Hines, IL 60141 USA. NR 10 TC 25 Z9 26 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD MAY PY 2004 VL 99 IS 5 BP 789 EP 796 DI 10.1111/j.1572-0241.2004.2004.04141.x PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 821XX UT WOS:000221497800005 PM 15128338 ER PT J AU El-Serag, HB Gilger, M Carter, J Genta, RM Rabeneck, L AF El-Serag, HB Gilger, M Carter, J Genta, RM Rabeneck, L TI Childhood GERD is a risk factor for GERD in adolescents and young adults SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID GASTROESOPHAGEAL REFLUX DISEASE; BARRETTS-ESOPHAGUS; FOLLOW-UP; HIATAL-HERNIA; CHILDREN; PREVALENCE; SYMPTOMS AB OBJECTIVE: The clinical course of gastroesophageal reflux disease (GERD) in children without comorbid illness (neurological deficits, congenital esophageal anomalies, chronic obstructive airway conditions) is unclear. Whether GERD in childhood progresses or predisposes to GERD in adulthood remains unknown. METHODS: We identified a cohort of individuals encloscopically diagnosed with GERD in childhood between 1990 and 1996. We excluded patients with comorbid illnesses. Eligible persons were contacted by telephone in person or through a household member and requested to complete a validated (in adults) symptom questionnaire between February 2001 and February 2003. Respondents were invited to undergo an upper endoscopy or to share results of any endoscopic examination performed within the past 12 months. We calculated the proportion of persons with GERD symptoms (monthly, weekly), and with current use of antisecretory medications (histamine-2-receptror antagonists [H2RA], proton pump inhibitors [PPI]). RESULTS: A total of 207 persons satisfied the inclusion and exclusion criteria and were contacted. Of those, 80 (39%) completed the questionnaire and 14/80 (18%) had an upper endoscopy. The mean age of participants was 20 years (SD = 4, range 10-40); most were Caucasian (73%), and 60% were female. GERD was documented at a mean age of 5 years (approximately a 15-yr duration of follow-up). Most participants (64/80, 80%) had at least monthly heartburn and/or acid regurgitation reported within the past 12 months; 18/80 (23%) reported at least weekly symptoms, and an additional three patients were asymptomatic but taking antisecretory therapy (H2RA or PPI). If all nonresponders were considered free of symptoms, then at least 31% had monthly symptoms, and 9% had weekly symptoms. Overall, 24 (30%) were currently taking either H2RA or PPI, and 19 patients had undergone fundoplication. There were no statistically significant differences between those who reported monthly GERD symptoms, weekly GERD symptoms, or no GERD symptoms as far as demographic features, age of GERD onset, receipt of fundoplication, or current GERD treatment. At endoscopy, three patients had mild to moderate erosive esophagitis. CONCLUSIONS: GERD in otherwise normal children can persist through adolescence and adulthood in a significant proportion of patients who continue to have GERD symptoms and signs, and use antisecretory medications. Childhood GERD is a risk factor for GERD in adolescence and adulthood. C1 Houston Vet Affairs Med Ctr, Sect Hlth Serv Res, Houston, TX 77030 USA. Houston Vet Affairs Med Ctr, Gastroenterol Sect, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. Inst Clin Evaluat Sci, Toronto, ON, Canada. Univ Toronto, Div Gastroenterol, Toronto, ON, Canada. Univ Toronto, Dept Med, Toronto, ON, Canada. RP El-Serag, HB (reprint author), Houston Vet Affairs Med Ctr, Sect Hlth Serv Res, 2002 Holcombe Blvd, Houston, TX 77030 USA. FU NIDDK NIH HHS [K24 DK59318] NR 17 TC 38 Z9 40 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD MAY PY 2004 VL 99 IS 5 BP 806 EP 812 DI 10.1111/j.1572-0241.2004.30098.x PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 821XX UT WOS:000221497800008 PM 15128341 ER PT J AU Bower, AN Tang, HM Guglielmo, BJ AF Bower, AN Tang, HM Guglielmo, BJ TI Compliance in two medical centers with criteria for use of caspofungin and lipid-based amphotericin B SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY LA English DT Article; Proceedings Paper CT Annual Meeting of the Infectious-Disease-Society-America CY OCT, 2002 CL Chicago, CA SP Infect Dis Soc Amer DE amphotericin B; antifungals; caspofungin; compliance; drug use; hospitals; kidney failure; liposomes; prototols; toxicity ID NEPHROTOXICITY; ASPERGILLOSIS; ECHINOCANDIN; THERAPY AB Purpose. Patterns of use and compliance with guidelines for use of lipid-based amphotericin B (LBA) and caspofungin at two medical institutions were studied. Methods. Charts of all adult patients receiving LBA or caspofungin or both in combination at the University of California at San Francisco Medical Center (UCSF) and the University of California at San Diego Medical Center (UCSD) between January 1 and October 22, 2001, were reviewed. Results. A total of 140 episodes of use of LBA, caspofungin, or the combination were identified at the two institutions. The primary indication for therapy with LBA was candidiasis (34% of episodes), whereas caspofungin and the drug combination were most commonly used for aspergillosis (43% and 71% of episodes, respectively). UCSF used the antifungal agents in accordance with its guidelines in 25% of the episodes of use and UCSD in 56%. Despite a higher qualifying serum creatinine (SCr) concentration for use of LBA at UCSF than at UCSD, the mean SCr concentration upon use was lower at Among UCSF patients who did not meet the strict SCr criteria for use of either agent, most had concomitant renal failure as defined by a creatinine clearance of <25 mL/, min, known risk factors for amphotericin B-associated nephrotoxicity, or breakthrough fungal infections while receiving alternative antifungal therapy. The UCSF pharmacy and therapeutics committee recommended that these factors be included in the indications for use of these agents. Conclusion. Compliance with criteria ,for use of LBA and caspofungin at two medical centers was inconsistent, probably because the initial criteria were insufficient in defining the conditions that justified the drugs use. C1 Univ Calif San Francisco, Sch Pharm, San Francisco, CA 94143 USA. Mayo Med Syst, Hosp Pharm Serv, Rochester, MN USA. Univ Calif San Francisco, Sch Pharm, San Francisco, CA 94143 USA. Portland Vet Affairs Med Ctr, Portland, OR USA. Univ Calif San Francisco, Sch Pharm, San Francisco, CA 94143 USA. RP Guglielmo, BJ (reprint author), Univ Calif San Francisco, Sch Pharm, C-152,Box 0622,521 Parnassus Ave, San Francisco, CA 94143 USA. NR 12 TC 1 Z9 2 U1 0 U2 0 PU AMER SOC HEALTH-SYSTEM PHARMACISTS PI BETHESDA PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 USA SN 1079-2082 J9 AM J HEALTH-SYST PH JI Am. J. Health-Syst. Pharm. PD MAY 1 PY 2004 VL 61 IS 9 BP 915 EP 920 PG 6 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 817KW UT WOS:000221177400011 PM 15156967 ER PT J AU Barzilay, JI Pressel, S Davis, BR Margolis, KL Cutler, J Ong, STG Basile, J Sadler, LS Summerson, J Whelton, PK AF Barzilay, JI Pressel, S Davis, BR Margolis, KL Cutler, J Ong, STG Basile, J Sadler, LS Summerson, J Whelton, PK CA ALLHAT Collaborat Res Grp TI Risk and impact of incident glucose disorders in hypertensive older adults treated with an ace inhibitor, a diuretic, or a calcium channel blocker: A report from the ALLHAT trial SO AMERICAN JOURNAL OF HYPERTENSION LA English DT Meeting Abstract CT 19th Annual Scientific Meeting of the American-Society-of-Hypertension CY MAY 18-22, 2004 CL New York, NY SP Amer Soc Hyperters DE diabetes; fasting glucose; CVD risk C1 Kaiser Permanente Georgia, Tucker, GA USA. Univ Texas, Hlth Sci Ctr, Sch Publ Hlth, Coordinating Ctr Clin Trials, Houston, TX USA. Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA. NHLBI, NIH, Bethesda, MD 20892 USA. Ong Med Ctr, Oxon Hill, MD USA. Ralph H Johnson VA Med Ctr, Charleston, SC USA. St Vincent Char Hosp & Hlth Ctr, Lipid Res Ctr, Cleveland, OH USA. Wake Forest Sch Med, Dept Publ Hlth Sci, Winston Salem, NC USA. Tulane Univ, Hlth Sci Ctr, New Orleans, LA 70118 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0895-7061 J9 AM J HYPERTENS JI Am. J. Hypertens. PD MAY PY 2004 VL 17 IS 5 MA OR2 BP 1A EP 1A PN 2 PG 1 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 818YW UT WOS:000221281400003 ER PT J AU Egan, BM Basile, JN Lackland, DT Hutchinson, FN AF Egan, BM Basile, JN Lackland, DT Hutchinson, FN TI Treatment and conrol of hypertension & associated risk factors at VA & non-VA in the Southeast SO AMERICAN JOURNAL OF HYPERTENSION LA English DT Meeting Abstract CT 19th Annual Scientific Meeting of the American-Society-of-Hypertension CY MAY 18-22, 2004 CL New York, NY SP Amer Soc Hyperters DE hypertension; treatment; risk factors C1 Med Univ S Carolina, Med Hypertens Sect, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC USA. Med Univ S Carolina, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0895-7061 J9 AM J HYPERTENS JI Am. J. Hypertens. PD MAY PY 2004 VL 17 IS 5 MA P15 BP 38A EP 38A PN 2 PG 1 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 818YW UT WOS:000221281400090 ER PT J AU Furmaga, EM Cunningham, FE Cushman, WC Glassman, PA Basile, J Dong, D Katz, LA Rutan, GH AF Furmaga, EM Cunningham, FE Cushman, WC Glassman, PA Basile, J Dong, D Katz, LA Rutan, GH TI Treatment and control of hypertension in the Veterans Health Administration SO AMERICAN JOURNAL OF HYPERTENSION LA English DT Meeting Abstract CT 19th Annual Scientific Meeting of the American-Society-of-Hypertension CY MAY 18-22, 2004 CL New York, NY SP Amer Soc Hyperters DE antihypertensive medications; combination therapy; blood pressure control C1 Dept Vet Affairs, Pharm Benefits Management Strateg Healthcare Grp, Hines, IL USA. Dept Vet Affairs, PBM Pharmacoepidemiol Outcomes Res, Hines, IL USA. Memphis VAMC, Memphis, TN USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Charleston VAMC, Charleston, SC USA. VA NY Harbor Healthcare Syst, Special Emphasis Program & Qual Management, New York, NY USA. Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN USA. NR 0 TC 1 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0895-7061 J9 AM J HYPERTENS JI Am. J. Hypertens. PD MAY PY 2004 VL 17 IS 5 MA P201 BP 107A EP 107A PN 2 PG 1 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 818YW UT WOS:000221281400279 ER PT J AU Eslami, P Corry, DB Nyby, MD Tuck, ML AF Eslami, P Corry, DB Nyby, MD Tuck, ML TI Inhibition of oxidative stress and improvement of nitric oxide production by ACE inhibitors and AT(1) receptor blockers in uric acid stimulated vascular smooth muscle cells SO AMERICAN JOURNAL OF HYPERTENSION LA English DT Meeting Abstract CT 19th Annual Scientific Meeting of the American-Society-of-Hypertension CY MAY 18-22, 2004 CL New York, NY SP Amer Soc Hyperters DE angiotensin II; nitric oxide; uric C1 Univ Calif Los Angeles, SFVP, Sepulveda, CA USA. Univ Calif Los Angeles, SFVP, Sylmar, CA USA. VA Greater Los Angeles Healthcare Syst, Sepulveda, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0895-7061 J9 AM J HYPERTENS JI Am. J. Hypertens. PD MAY PY 2004 VL 17 IS 5 MA P329 BP 154A EP 155A PN 2 PG 2 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 818YW UT WOS:000221281400407 ER PT J AU Rehman, SU Egan, BM Hutchison, FN AF Rehman, SU Egan, BM Hutchison, FN TI Racial differences in blood pressure control rates in the VA Medical center SO AMERICAN JOURNAL OF HYPERTENSION LA English DT Meeting Abstract CT 19th Annual Scientific Meeting of the American-Society-of-Hypertension CY MAY 18-22, 2004 CL New York, NY SP Amer Soc Hyperters DE hypertension; racial differences; Department of Veterans Affair C1 Ralph H Johnson VA Med Ctr, Charleston, SC USA. Med Univ S Carolina, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0895-7061 J9 AM J HYPERTENS JI Am. J. Hypertens. PD MAY PY 2004 VL 17 IS 5 MA P467 BP 203A EP 204A PN 2 PG 2 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 818YW UT WOS:000221281400543 ER PT J AU Nyby, MD Abedi, K Eslami, P Hernandez, G Smutko, V Berger, ME Tuck, ML AF Nyby, MD Abedi, K Eslami, P Hernandez, G Smutko, V Berger, ME Tuck, ML TI Dietary fish oil prevents hypertension, oxidative stress and suppression of endothelial nitric oxide synthase expression in fructose-fed rats SO AMERICAN JOURNAL OF HYPERTENSION LA English DT Meeting Abstract CT 19th Annual Scientific Meeting of the American-Society-of-Hypertension CY MAY 18-22, 2004 CL New York, NY SP Amer Soc Hyperters DE nitric oxide synthase; fructose fed rats; fish oil C1 Univ Calif Los Angeles, SFVP, Dept Med, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Dept Med, Sepulveda, CA USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0895-7061 J9 AM J HYPERTENS JI Am. J. Hypertens. PD MAY PY 2004 VL 17 IS 5 MA P501 BP 216A EP 216A PN 2 PG 1 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 818YW UT WOS:000221281400577 ER PT J AU Hu, KK Lipsky, BA Veenstra, DL Saint, S AF Hu, KK Lipsky, BA Veenstra, DL Saint, S TI Using maximal sterile barriers to prevent central venous catheter-related infection: A systematic evidence-based review SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article ID BLOOD-STREAM INFECTION; PRECAUTIONS; INSERTION; RISK; METAANALYSIS AB Background: Catheter-related infections cause increased morbidity, mortality, and health care costs. Infection control experts advocate using maximal sterile barriers to reduce the incidence of these infections. Low compliance rates suggest that clinicians are not convinced or are not aware that available data support adopting this more cumbersome, time-consuming, and relatively more expensive technique. Accordingly, we conducted a systematic, evidence-based review of the medical literature to determine the value of maximal sterile barriers. Data sources: We used multiple computerized databases, reference lists of identified articles, and queries of prominent investigators. Study selection: We selected studies comparing infectious outcomes using maximal sterile barriers versus using less stringent sterile barrier techniques during central venous catheter insertion. Data synthesis: We found only 3 primary research studies. Although each study suggests maximal sterile barriers may reduce infectious complications, the evidence supporting this conclusion is incomplete. The only randomized controlled trial limited enrollment to ambulatory oncology patients. These 3 studies differed notably in their patient populations, research designs, and health care settings. Conclusion: The medical literature suggests maximal sterile barriers are advantageous in at least one setting and may be useful in others. While we believe the available evidence does support the use of maximal sterile barriers during routine insertion of central venous catheters, prospective studies and economic analyses would better clarify its value. C1 Univ Washington, NW Hlth Serv Res & Dev Program, Seattle, WA 98195 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. Pharmaceut Outcomes Res & Policy Program, Ann Arbor, MI USA. Hlth Serv Res & Dev Serv, Ann Arbor, MI USA. Ann Arbor VA Med Ctr, Ann Arbor, MI USA. Univ Michigan, Ann Arbor, MI 48109 USA. RP Hu, KK (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,HSR&D 152, Seattle, WA 98108 USA. OI Lipsky, Benjamin A./0000-0001-9886-5114 FU AHRQ HHS [P20 HS 11540] NR 22 TC 35 Z9 37 U1 0 U2 2 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0196-6553 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD MAY PY 2004 VL 32 IS 3 BP 142 EP 146 DI 10.1016/j.ajic.2003.10.006 PG 5 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 819TV UT WOS:000221339500005 PM 15153925 ER PT J AU Trautner, BW Darouiche, RO AF Trautner, BW Darouiche, RO TI Role of biofilm in catheter-associated urinary tract infection SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Review ID SPINAL-CORD INJURY; UROPATHOGENIC ESCHERICHIA-COLI; NURSING-HOME PATIENTS; INDWELLING URETHRAL CATHETERS; ASYMPTOMATIC BACTERIURIA; INTERMITTENT CATHETERIZATION; STAPHYLOCOCCUS-EPIDERMIDIS; BLADDER INSTILLATIONS; REDUCING BACTERIURIA; ELDERLY PATIENTS AB The predominant form of life for the majority of microorganisms in any hydrated biologic system is a cooperative community termed a "biofilm." A biofilm on an indwelling urinary catheter consists of adherent microorganisms, their extracellular products, and host components deposited on the catheter. The biofilm mode of life conveys a survival advantage to the microorganisms associated with it and, thus, biofilm on urinary catheters results in persistent infections that are resistant to antimicrobial therapy. Because chronic catheterization leads almost inevitably to bacteriuria, routine treatment of asymptomatic bacteriuria in persons who are catheterized is not recommended. When symptoms of a urinary tract infection develop in a person who is catheterized, changing the catheter before collecting urine improves the accuracy of urine culture results. Changing the catheter may also improve the response to antibiotic therapy by removing the biofilm that probably contains the infecting organisms and that can serve as a nidus for reinfection. Currently, no proven effective strategies exist for prevention of catheter-associated urinary tract infection in persons who are chronically catheterized. C1 Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Infect Dis Sect, Houston, TX 77030 USA. Michael E DeBakey Vet Affairs Med Ctr, Dept Phys Med & Rehabil, Ctr Prostheses Infect, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. RP Trautner, BW (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Infect Dis Sect, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM trautner@bcm.tmc.edu FU NICHD NIH HHS [1K23 HD 42014-01, K23 HD042014, K23 HD042014-02] NR 90 TC 90 Z9 98 U1 1 U2 16 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0196-6553 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD MAY PY 2004 VL 32 IS 3 BP 177 EP 183 DI 10.1016/j.ajilc.2003.08.005 PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 819TV UT WOS:000221339500010 PM 15153930 ER PT J AU Wong, MD Asch, SM Andersen, RM Hays, RD Shapiro, MF AF Wong, MD Asch, SM Andersen, RM Hays, RD Shapiro, MF TI Racial and ethnic differences in patients' preferences for initial care by specialists SO AMERICAN JOURNAL OF MEDICINE LA English DT Article ID RENAL-TRANSPLANTATION; LUNG-CANCER; ACCESS; RELIABILITY; DISEASE; SURGERY; RACE AB PURPOSE: To examine racial and ethnic differences in patients' preferences for initial care by specialists, and to determine whether trust in the physician and health beliefs account for these differences. METHODS: We conducted a cross-sectional study of 646 patients in the waiting room of three acedemic-based internal medicine outpatient practices. We asked subjects about their preference to see their primary care provider or a specialist first regarding the actual health problem that had brought them to see their physician as well as regarding three hypothetical scenarios (2 weeks of new-onset exertional chest pain, 2 months of knee pain, and rash for 4 weeks). We examined the relation among patients' preference for initial care by a specialist and their demographic characteristics, global ratings of their primary care physician and health plan, trust in their primary care physician, and other health beliefs and attitudes. RESULTS: Averaged for the three scenarios and actual health problem, 13% of patients preferred to see a specialist first. Adjusting for all other covariates, blacks (risk ratio [RR] = 0.55; 95% confidence interval [Cl]: 0.20 to 0.92) and Asians (RR = 0.46; 95% Cl: 0.19 to 0.75) were Much less likely to prefer a specialist than were whites. Patients with less confidence in their primary care physician and greater certainty about needed tests and treatments were more likely to prefer a specialist. These variables, however, did not explain the difference in preference for specialist care among blacks, Asians, and whites. CONCLUSION: Blacks and Asians are less likely than whites to prefer initial care by a specialist. Future studies should examine whether differences in preference for care lead minorities to underutilize appropriate specialty care or lead whites to overuse specialty care. (C)2004 by Excerpta Medica Inc. C1 Univ Calif Los Angeles, Div Gen Internal Med & Hlth Serv Res, Sch Publ Hlth, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Dept Hlth Serv, Sch Publ Hlth, Los Angeles, CA 90095 USA. Vet Adm Greater Los Angeles Healthcare Syst, Div Gen Internal Med, Los Angeles, CA USA. RP Wong, MD (reprint author), Univ Calif Los Angeles, Div Gen Internal Med & Hlth Serv Res, Sch Publ Hlth, 911 Broxton Plaza, Los Angeles, CA 90095 USA. EM mitchellwong@mednet.ucla.edu RI Hays, Ronald/D-5629-2013 OI Wong, Mitchell/0000-0002-4800-8410 FU BHP HRSA HHS [6 T32 PE-190001-13 R]; NIA NIH HHS [AG-02-004]; NIMHD NIH HHS [P20-MD00148-01] NR 22 TC 10 Z9 11 U1 1 U2 1 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD MAY 1 PY 2004 VL 116 IS 9 BP 613 EP 620 DI 10.1016/j.amjmed.2003.09.051 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 816XV UT WOS:000221143500006 PM 15093758 ER PT J AU Andrikopoulos, S Hull, RL Verchere, B Wang, F Wilbur, SM Wight, TN Marzban, L Kahn, SE AF Andrikopoulos, S Hull, RL Verchere, B Wang, F Wilbur, SM Wight, TN Marzban, L Kahn, SE TI Extended life span is associated with insulin resistance in a transgenic mouse model of insulinoma secreting human islet amyloid polypeptide (vol 286, pg E418, 2004) SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM LA English DT Correction C1 Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA USA. Univ Washington, Seattle, WA 98195 USA. NR 1 TC 1 Z9 1 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1849 J9 AM J PHYSIOL-ENDOC M JI Am. J. Physiol.-Endocrinol. Metab. PD MAY PY 2004 VL 286 IS 5 BP E862 EP E862 DI 10.1152/ajpendo.00081.2004 PG 1 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA 813SR UT WOS:000220927300023 ER PT J AU Lopez, I Aguilera-Tejero, E Estepa, JC Rodriguez, M Felsenfeld, AJ AF Lopez, I Aguilera-Tejero, E Estepa, JC Rodriguez, M Felsenfeld, AJ TI Role of acidosis-induced increases in calcium on PTH secretion in acute metabolic and respiratory acidosis in the dog SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM LA English DT Article DE hypercalcemia; metabolic acidosis; parathyroid hormone; respiratory acidosis ID PARATHYROID-HORMONE SECRETION; BASE HOMEOSTASIS; IONIZED CALCIUM; VITAMIN-D; HYPOCALCEMIA; HYPERCALCEMIA; BONE; BICARBONATE; HYSTERESIS; ALKALOSIS AB Recently, we showed that both acute metabolic acidosis and respiratory acidosis stimulate parathyroid hormone (PTH) secretion in the dog. To evaluate the specific effect of acidosis, ionized calcium (iCa) was clamped at a normal value. Because iCa values normally increase during acute acidosis, we now have studied the PTH response to acute metabolic and respiratory acidosis in dogs in which the iCa concentration was allowed to increase (nonclamped) compared with dogs with a normal iCa concentration (clamped). Five groups of dogs were studied: control, metabolic (clamped and nonclamped), and respiratory (clamped and nonclamped) acidosis. Metabolic (HCl infusion) and respiratory (hypoventilation) acidosis was progressively induced during 60 min. In the two clamped groups, iCa was maintained at a normal value with an EDTA infusion. Both metabolic and respiratory acidosis increased (P < 0.05) iCa values in nonclamped groups. In metabolic acidosis, the increase in iCa was progressive and greater (P < 0.05) than in respiratory acidosis, in which iCa increased by 0.04 mM and then remained constant despite further pH reductions. The increase in PTH values was greater (P < 0.05) in clamped than in nonclamped groups (metabolic and respiratory acidosis). In the nonclamped metabolic acidosis group, PTH values first increased and then decreased from peak values when iCa increased by >0.1 mM. In the nonclamped respiratory acidosis group, PTH values exceeded (P < 0.05) baseline values only after iCa values stopped increasing at a pH of 7.30. For the same increase in iCa in the nonclamped groups, PTH values increased more in metabolic acidosis. In conclusion, 1) both metabolic acidosis and respiratory acidosis stimulate PTH secretion; 2) the physiological increase in the iCa concentration during the induction of metabolic and respiratory acidosis reduces the magnitude of the PTH increase; 3) in metabolic acidosis, the increase in the iCa concentration can be of sufficient magnitude to reverse the increase in PTH values; and 4) for the same degree of acidosis-induced hypercalcemia, the increase in PTH values is greater in metabolic than in respiratory acidosis. C1 Univ Cordoba, Dept Med & Cirurgia Anim, Cordoba 14014, Spain. Hosp Univ Reina Sofia, Dept Nefrol, Cordoba 14004, Spain. Hosp Univ Reina Sofia, Unidad Invest, Cordoba 14004, Spain. Univ Calif Los Angeles, Los Angeles, CA 90024 USA. W Los Angeles Vet Affairs Med Ctr, Dept Med, Los Angeles, CA 90024 USA. RP Aguilera-Tejero, E (reprint author), Univ Cordoba, Dept Med & Cirurgia Anim, Campus Univ Rabanales,Ctra Madrid Cadiz Km 396, Cordoba 14014, Spain. EM pv1agtee@uco.es RI Rodriguez, teresa/H-5452-2011 NR 28 TC 14 Z9 14 U1 0 U2 9 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1849 J9 AM J PHYSIOL-ENDOC M JI Am. J. Physiol.-Endocrinol. Metab. PD MAY PY 2004 VL 286 IS 5 BP E780 EP E785 DI 10.1152/ajpendo.00473.2003 PG 6 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA 813SR UT WOS:000220927300014 PM 14722029 ER PT J AU Johnson, FK Durante, W Peyton, KJ Johnson, RA AF Johnson, FK Durante, W Peyton, KJ Johnson, RA TI Heme oxygenase-mediated endothelial dysfunction in DOCA-salt, but not in spontaneously hypertensive, rat arterioles SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE hypertension; vascular tone; carbon monoxide ID NITRIC-OXIDE SYNTHASE; GRACILIS MUSCLE ARTERIOLES; CARBON-MONOXIDE; ANGIOTENSIN-II; SMOOTH-MUSCLE; VENTRICULAR HYPERTROPHY; GUANYLYL CYCLASE; INDUCED DILATION; DIETARY SALT; RENAL INJURY AB Vascular heme oxygenase (HO) metabolizes heme to form carbon monoxide. Carbon monoxide inhibits nitric oxide synthase and promotes endothelium-dependent vasoconstriction. We reported HO-1-mediated endothelial dysfunction in Dahl salt-sensitive hypertension. Previous studies suggested that salt-sensitive hypertensive rats, but not spontaneously hypertensive rats (SHR), display endothelial dysfunction. This study examines the hypothesis that HO-1-mediated arteriolar endothelial dysfunction develops in deoxycorticosterone acetate (DOCA)-salt hypertensive (DOCA) rats, but not in SHR. Uninephrectomized (isoflurane anesthesia) male Sprague-Dawley rats received DOCA injections and saline drinking solution for 4 wk. Rats subjected to sham surgery received vehicle injections and tap water. Blood pressure was elevated in DOCA rats and SHR compared with sham and Wistar-Kyoto (WKY) groups. Aortic HO-1 expression and blood carboxyhemoglobin levels were elevated in the DOCA group, but not in SHR. In isolated gracilis muscle arterioles, ACh caused concentration-related vasodilation in all groups, with attenuated maximum responses in DOCA, but not in SHR, arterioles. Acute pretreatment with an inhibitor of HO, chromium mesoporphyrin, restored ACh-induced responses in DOCA arterioles to sham levels. ACh responses remained the same in SHR and WKY arterioles after chromium mesoporphyrin treatment. These data show that HO-1 levels and activity are increased and arteriolar responses to ACh are decreased in DOCA rats, but not in SHR. Furthermore, in DOCA arterioles, an inhibitor of HO restores ACh-induced vasodilation to sham levels. These results suggest that elevated HO-1 levels and activity, not resulting from hypertension per se, contribute to endothelial dysfunction in DOCA rats. C1 Tulane Univ, Hlth Sci Ctr, Dept Physiol, New Orleans, LA 70112 USA. Tulane Univ, Hlth Sci Ctr, Tulane Hypertens & Renal Ctr Excellence, New Orleans, LA 70112 USA. Baylor Coll Med, Houston Vet Affairs Med Ctr, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA. RP Johnson, FK (reprint author), Tulane Univ, Hlth Sci Ctr, Dept Physiol, 1430 Tulane Ave,SL39, New Orleans, LA 70112 USA. EM Fruzsi123@aol.com FU NCRR NIH HHS [P20 RR-017659]; NHLBI NIH HHS [R01 HL-59976, R01 HL-64577] NR 49 TC 19 Z9 19 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD MAY PY 2004 VL 286 IS 5 BP H1681 EP H1687 DI 10.1152/ajpheart.00409.2003 PG 7 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA 810XH UT WOS:000220736500012 PM 14693679 ER PT J AU Diamant, AL Hays, RD Morales, LS Ford, W Calmes, D Asch, S Duan, NH Fielder, E Kim, S Fielding, J Sumner, G Shapiro, MF Hayes-Bautista, D Gelberg, L AF Diamant, AL Hays, RD Morales, LS Ford, W Calmes, D Asch, S Duan, NH Fielder, E Kim, S Fielding, J Sumner, G Shapiro, MF Hayes-Bautista, D Gelberg, L TI Delays and unmet need for health care among adult primary care patients in a restructured urban public health system SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID WORKING-AGE ADULTS; MEDICAL-CARE; INSURANCE STATUS; BEHAVIORAL-MODEL; HOMELESS ADULTS; LOS-ANGELES; ACCESS; WOMEN; SERVICES; MASSACHUSETTS AB Objectives. We estimated the prevalence and determinants of delayed and unmet needs for medical care among patients in a restructured public health system. Methods. We conducted a stratified cross-sectional probability sample of primary care patients in the Los Angeles County Department of Health Services. Face-to-face interviews were conducted with 1819 adult patients in 6 languages. The response rate was 80%. The study sample was racially/ethnically diverse. Results. Thirty-three percent reported delaying needed medical care during the preceding 12 months; 25% reported an unmet need for care because of competing priorities; and 46% had either delayed or gone without care. Conclusions. Barriers to needed health care continue to exist among patients receiving care through a large safety net system. Competing priorities for basic necessities and lack of insurance contribute importantly to unmet health care needs. C1 Univ Calif Los Angeles, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Natl Ctr Excellence Womens Hlth, Los Angeles, CA 90095 USA. RAND Hlth, Santa Monica, CA USA. W Los Angeles Vet Adm, Los Angeles, CA USA. Los Angeles Cty Dept Hlth Serv, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Social Sci Res Inst, Los Angeles, CA 90024 USA. Pochon CHA Univ, Dept Prevent Med, Pochon, South Korea. Univ Calif Los Angeles, Dept Family Med, Los Angeles, CA 90024 USA. RP Diamant, AL (reprint author), Univ Calif Los Angeles, Div Gen Internal Med & Hlth Serv Res, 911 Broxton Ave, Los Angeles, CA 90095 USA. EM adiamant@mednet.ucla.edu RI Hays, Ronald/D-5629-2013 FU NIA NIH HHS [P30 AG021684]; NIMHD NIH HHS [P20 MD000148] NR 35 TC 51 Z9 52 U1 1 U2 7 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 1015 FIFTEENTH ST NW, WASHINGTON, DC 20005 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD MAY PY 2004 VL 94 IS 5 BP 783 EP 789 DI 10.2105/AJPH.94.5.783 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 816LM UT WOS:000221111400022 PM 15117701 ER PT J AU Patel, SS Butt, AA AF Patel, SS Butt, AA TI Inadvertent rupture of an echinococcal cyst: Case report and review of literature SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES LA English DT Review DE echinococcosis; traumatic rupture ID ANAPHYLACTIC SHOCK; TRAUMATIC RUPTURE; ABDOMINAL-TRAUMA; HYDATID CYSTS; LIVER; DISEASE; PATIENT AB Echinococcal disease is infrequently seen in developed countries. In the United States, most cases are imported from endemic areas. Although frequently asymptomatic, enlarging cysts can cause local symptoms. Cysts can rupture spontaneously or as a result of trauma. Optimal management of accidental rupture of echinococcal cysts with little or no symptoms is not well known. The authors describe a case of inadvertent rupture of an echinococcal cyst and review the English literature to determine an acceptable management strategy. C1 Univ Pittsburgh, Div Infect Dis, Pittsburgh, PA USA. Ctr Hlth Equ Res & Promot, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Butt, AA (reprint author), 3601 5th Ave,Suite 3A,Falk Med Bldg, Pittsburgh, PA 15213 USA. EM butta@msx.dept-med.pitt.edu NR 20 TC 7 Z9 7 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0002-9629 J9 AM J MED SCI JI Am. J. Med. Sci. PD MAY PY 2004 VL 327 IS 5 BP 268 EP 271 DI 10.1097/00000441-200405000-00026 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 821YT UT WOS:000221500000010 PM 15166748 ER PT J AU Austin, GL Sasaki, AW Zaman, A Rabkin, JM Olyaei, A Ruimy, R Orloff, SL Ham, J Rosen, HR AF Austin, GL Sasaki, AW Zaman, A Rabkin, JM Olyaei, A Ruimy, R Orloff, SL Ham, J Rosen, HR TI Comparative analysis of outcome following liver transplantation in US veterans SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Article DE hepatitis C; liver transplantation; MELD (model for endstage liver disease); outcomes ID HEPATITIS-C; UNITED-STATES; DONOR AGE; SURVIVAL; DISEASE; PREVALENCE; MODEL; MELD; RECIPIENTS; PREDICTORS AB The purpose of this study was to evaluate whether there was a difference in mortality following orthotopic liver transplantation (OLT) in a US veteran (VA) population (n = 149) compared to a non-VA (university) population (n = 285) and what factors could explain this difference. Survival following OLT for 149 VA patients was compared with that of 285 university patients. By Kaplan-Meier survival analysis, VA patients had higher mortality than university patients with respective 1-year, 3-year, and 5-year survival of 82%,75%, and 68% vs. 87%,82%, and 78% (p = 0.006). Gender, etiology of end-stage liver disease (ESLD) and donor age (i.e. older than 34 years) also significantly influenced survival. However, when donor and recipient age, gender, model for end-stage liver disease (MELD) score, and etiology of liver disease were included with hospital status in a multivariate Cox proportional hazards model, the VA population did not have higher mortality. A final model to predict mortality following transplantation was derived for all 434 patients where individuals were assigned risk scores based on the equation R = 0.219 (gender) + 0.018 (donor age) + 0.032 (recipient age) + 0.021 (MELD), where recipient age, donor age, and MELD score are the respective continuous variables and gender = 1 (men) and 0 for women (c-statistic = 0.71). C1 Portland Vet Affairs, Ctr Med, Dept Med, Div Gastroenterol & Hepatol, Portland, OR 97207 USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. Portland Vet Affairs Med Ctr, Liver Transplantat Program, Dept Surg, Portland, OR USA. RP Rosen, HR (reprint author), Portland Vet Affairs, Ctr Med, Dept Med, Div Gastroenterol & Hepatol, Portland, OR 97207 USA. EM rosenhu@ohsu.edu RI Ruimy , Raymond/P-6068-2016 NR 26 TC 17 Z9 18 U1 0 U2 2 PU BLACKWELL MUNKSGAARD PI COPENHAGEN PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD MAY PY 2004 VL 4 IS 5 BP 788 EP 795 DI 10.1111/j.1600-6143.2004.00388.x PG 8 WC Surgery; Transplantation SC Surgery; Transplantation GA 818CT UT WOS:000221223900020 PM 15084176 ER PT J AU Magid, DJ Houry, D Ellis, J Lyons, E Rumsfeld, JS AF Magid, DJ Houry, D Ellis, J Lyons, E Rumsfeld, JS TI Health-related quality of life predicts emergency department utilization for patients with asthma SO ANNALS OF EMERGENCY MEDICINE LA English DT Article; Proceedings Paper CT American-College-of-Emergency-Physicians Research Forum CY OCT 23-24, 2000 CL PHILADELPHIA, PA SP Amer Coll Emergency Physicians ID MORTALITY; HOSPITALIZATION; QUESTIONNAIRE AB Study objective: The objective of this study is to evaluate health-related quality of life as a risk factor for subsequent emergency department (ED) utilization in a cohort of patients with asthma. Methods: We conducted a 1-year prospective cohort study of 1,406 adult asthma patients. Baseline physical and mental health status were measured using the Physical Component Summary and Mental Component Summary scores from Short Form-12 health status survey. Asthma-specific health-related quality of life wasmeasured with the mini-Asthma Quality of Life Questionnaire. Multivariable regression was used to assess the independent association between baseline Physical Component Summary, Mental Component Summary, and Asthma Quality of Life Questionnaire scores and asthma-related ED visits during the subsequent year. Results: During the 1-year follow-up period, 116 patients made at least 1 asthma-related ED visit. After adjustment for multiple sociodemographic and clinical factors, both the Physical Component Summary score (odds ratio [OR] 1.72; 95% confidence interval [CI] 1.46 to 2.02) and the Asthma Quality of Life Questionnaire score (OR 1.34; 95% CI 1.18 to 1.52) were associated with subsequent asthma-related ED utilization. In contrast, overall mental health status was not associated with subsequent asthma-related ED utilization (OR 1.17; 95% CI 0.96 to 1.44). Conclusion: Overall physical health status and asthma-specific quality of life predict subsequent ED utilization. Health-related quality of life may be useful in identifying patients at increased risk for asthma exacerbation requiring emergency care. C1 Emory Univ, Rollins Sch Publ Hlth, Ctr Injury Control, Atlanta, GA 30322 USA. Denver VA Med Ctr, Denver, CO USA. Emory Univ, Sch Med, Dept Emergency Med, Atlanta, GA 30322 USA. Univ Colorado, Hlth Sci Ctr, Div Cardiol, Denver, CO 80202 USA. Univ Colorado, Hlth Sci Ctr, Div Emergency Med, Denver, CO 80202 USA. Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, Denver, CO 80202 USA. Colorado Permanente Med Grp, Clin Res Unit, Denver, CO USA. RP Houry, D (reprint author), Emory Univ, Rollins Sch Publ Hlth, Ctr Injury Control, 1518 Clifton Rd,Suite 230, Atlanta, GA 30322 USA. EM dhoury@emory.edu NR 19 TC 27 Z9 27 U1 1 U2 2 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0196-0644 J9 ANN EMERG MED JI Ann. Emerg. Med. PD MAY PY 2004 VL 43 IS 5 BP 551 EP 557 DI 10.1016/j.annemergmed.2003.11.021 PG 7 WC Emergency Medicine SC Emergency Medicine GA 816TG UT WOS:000221131600001 PM 15111913 ER PT J AU Shi, CW Asch, SM Fielder, E Gelberg, L Nichol, MB AF Shi, CW Asch, SM Fielder, E Gelberg, L Nichol, MB TI Consumer knowledge of over-the-counter phenazopyridine SO ANNALS OF FAMILY MEDICINE LA English DT Article DE pharmacy; survey; over-the-counter drugs; phenazopyridine ID PRESCRIPTION AB BACKGROUND Effective use of over-the-counter (OTC) medications depends on purchasers' knowledge of their indications. This study examines consumer knowledge regarding the urinary tract analgesic phenazopyridine, which recently became available without prescription. METHOD We conducted a cross-sectional survey of a stratified cluster random sample of purchasers of OTC phenazopyridine (N = 434) in 31 Los Angeles retail pharmacies. RESULTS The response rate was 58%. Only 42% correctly characterized the likely cause of their symptoms, and only 57% correctly characterized the action of the drug. Worse consumer knowledge was associated with nonwhite race, first-time use, and less contact with health providers. CONCLUSION Many consumers possess poor knowledge about phenazopyridine, potentially leading to undertreatment, especially in groups with worse access to care. C1 Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA. RAND, Santa Monica, CA USA. Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Social Sci Res Inst, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Family Med, Los Angeles, CA 90024 USA. Univ So Calif, Dept Pharmaceut Econ & Policy, Los Angeles, CA USA. RP Shi, CW (reprint author), Univ Calif San Diego, Dept Family & Prevent Med, 9500 Gilman Dr,Mailcode-0807, La Jolla, CA 92093 USA. EM cwshi@ucsd.edu FU AHRQ HHS [F32 HS11507-01] NR 12 TC 10 Z9 10 U1 0 U2 2 PU ANNALS FAMILY MEDICINE PI LEAWOOD PA 11400 TOMAHAWK CREEK PARKWAY, LEAWOOD, KS 66211-2672, UNITED STATES SN 1544-1709 J9 ANN FAM MED JI Ann. Fam. Med. PD MAY-JUN PY 2004 VL 2 IS 3 BP 240 EP 244 DI 10.1370/afm.61 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 879JT UT WOS:000225714800011 PM 15209201 ER PT J AU Bennett, CL Shirk, AJ Huynh, HM Street, VA Nelis, E Van Maldergem, L De Jonghe, P Jordanova, A Guergueltcheva, V Tournev, I Van den Bergh, P Seeman, P Mazanec, R Prochazka, T Kremensky, I Haberlova, J Weiss, MD Timmerman, V Bird, TD Chance, PF AF Bennett, CL Shirk, AJ Huynh, HM Street, VA Nelis, E Van Maldergem, L De Jonghe, P Jordanova, A Guergueltcheva, V Tournev, I Van den Bergh, P Seeman, P Mazanec, R Prochazka, T Kremensky, I Haberlova, J Weiss, MD Timmerman, V Bird, TD Chance, PF TI SIMPLE mutation in demyelinating neuropathy and distribution in sciatic nerve SO ANNALS OF NEUROLOGY LA English DT Article ID MARIE-TOOTH-DISEASE; ADULT-ONSET LEUKODYSTROPHY; PERONEAL MUSCULAR ATROPHY; SENSORY NEURON DISEASES; ELECTROPHYSIOLOGIC FINDINGS; AUTOSOMAL-DOMINANT; LOWER MOTOR; PROTEIN; GENE; TSG101 AB Charcot-Marie-Tooth neuropathy type 1C (CMT1C) is an autosomal dominant demyelinating peripheral neuropathy caused by missense mutations in the small integral membrane protein of lysosome/late endosome (SIMPLE) gene. To investigate the prevalence of SIMPLE mutations, we screened a cohort of 152 probands with various types of demyelinating or axonal and pure motor or sensory inherited neuropathies. SIMPLE mutations were found only in CMT1 patients, including one G112S and one W116G missense mutations. A novel 1741 polymorphism was identified, yet no splicing defect of SIMPLE is likely. Haplotype analysis of STR markers and intragenic SNPs linked to the gene dem-onstrated that families with the same mutation are unlikely to be related. The clustering of the G112S, T115N, and W116G mutations within five amino acids suggests this domain may be critical to peripheral nerve myelination. Elec-trophysiological studies showed that CMT1C patients from six pedigrees (n = 38) had reduced nerve conduction velocities ranging from 7.5 to 27.0m/sec (peroneal). Two patients had temporal dispersion of nerve conduction and irregularity of conduction Slowing, which is unusual for CMT1 patients. We report the expression of SIMPLE in various cell types of the sciatic nerve, including Schwann cells, the affected cell type in CMT1C. C1 Univ Washington, Dept Pediat, Div Genet & Dev Med, Seattle, WA 98195 USA. Univ Washington, Dept Otolaryngol, Seattle, WA 98195 USA. Univ Antwerp VIB, Dept Mol Genet, B-2020 Antwerp, Belgium. Ctr Human Genet, Inst Pathol Genet, Loverval, Belgium. Med Univ Sofia, Lab Mol Pathol, Sofia, Bulgaria. Med Univ Sofia, Dept Neurol, Sofia, Bulgaria. Univ Catholique Louvain, Clin Univ St Luc, Serv Neurol, B-1200 Brussels, Belgium. Charles Univ, Sch Med 2, Dept Child Neurol, Prague, Czech Republic. Charles Univ, Sch Med 2, Dept Neurol, Prague, Czech Republic. Univ Washington, Dept Neurol, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Bennett, CL (reprint author), Univ Washington, Dept Pediat, Div Genet & Dev Med, Box 356320, Seattle, WA 98195 USA. EM cbenet@u.washington.edu RI Jordanova, Albena/H-8323-2015; Van Maldergem, Lionel/G-9849-2017 OI Jordanova, Albena/0000-0002-3833-3754; Van Maldergem, Lionel/0000-0001-8880-5214 NR 31 TC 45 Z9 48 U1 1 U2 8 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA SN 0364-5134 J9 ANN NEUROL JI Ann. Neurol. PD MAY PY 2004 VL 55 IS 5 BP 713 EP 720 DI 10.1002/ana.20094 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 816NE UT WOS:000221115800015 PM 15122712 ER PT J AU Rumsfeld, JS Ho, PM Magid, DJ McCarthy, M Shroyer, ALW MaWhinney, S Grover, FL Hammermeister, KE AF Rumsfeld, JS Ho, PM Magid, DJ McCarthy, M Shroyer, ALW MaWhinney, S Grover, FL Hammermeister, KE TI Predictors of health-related quality of life after coronary artery bypass surgery SO ANNALS OF THORACIC SURGERY LA English DT Article ID GRAFT-SURGERY; MYOCARDIAL-INFARCTION; HEART-SURGERY; DEPRESSION; MORTALITY; OUTCOMES; SMOKING; DISEASE; SURVIVAL; RECOVERY AB Background. Little is known about the determinants of health-related quality of life after coronary artery bypass surgery. We determined the predictors of overall physical and mental health status 6 months after the operation. Methods. We evaluated 1,973 patients enrolled in a multicenter Veterans Affairs prospective cohort study who completed preoperative and 6-month postoperative Short Form-36 (SF-36) health status surveys. Multiple linear regression was used to identify the significant independent predictors of 6-month physical and mental component summary scores from the SF-36. Results. In multivariable analyses adjusting for baseline health status, significant predictors of postoperative physical health status were a history of neurologic disease, peripheral vascular disease, chronic obstructive pulmonary disease, hypertension, current smoking,forced expiratory volume, left ventricular ejection fraction, and serum creatinine. Significant predictors of postoperative mental health status were a history of psychiatric disease, chronic obstructive pulmonary disease, current smoking, age, and New York Heart Association functional class. Conclusions. These predictors of health-related quality of life after coronary artery bypass surgery may be useful for preoperative risk assessment and counseling of patients with regard to anticipated health status outcomes. Factors such as current smoking and psychiatric disease may be targets for interventions to improve health-related quality of life outcomes. (C) 2004 by The Society of Thoracic Surgeons. C1 Univ Colorado, Ctr Hlth Sci, Denver VA Med Ctr, Cardiol & Hlth Serv Res, Boulder, CO 80309 USA. Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, Denver, CO 80262 USA. Northwestern Univ, Sch Med, Dept Prevent Med, Chicago, IL USA. Univ Colorado, Hlth Sci Ctr, Dept Surg, Denver, CO 80262 USA. RP Rumsfeld, JS (reprint author), Denver VA Med Ctr, 1055 Clermont St,Cardiol 111B, Denver, CO 80220 USA. EM john.rumsfeld@med.va.gov RI Shroyer, Annie Laurie/B-8836-2016 OI Shroyer, Annie Laurie/0000-0001-6461-0623 NR 29 TC 47 Z9 48 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD MAY PY 2004 VL 77 IS 5 BP 1508 EP 1513 DI 10.1016/j.athoracsur.2003.10.056 PG 6 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 816VX UT WOS:000221138500001 PM 15111134 ER PT J AU Doyle, PJ AF Doyle, PJ TI Preface SO APHASIOLOGY LA English DT Editorial Material C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15260 USA. RP Doyle, PJ (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15260 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PSYCHOLOGY PRESS PI HOVE PA 27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND SN 0268-7038 J9 APHASIOLOGY JI Aphasiology PD MAY-JUL PY 2004 VL 18 IS 5-7 BP 405 EP 405 DI 10.1080/02687030444000282 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 817NC UT WOS:000221183200001 ER PT J AU Fossett, TRD McNeil, MR Doyle, PJ Rubinsky, H Nixon, S Hula, W Brady, J AF Fossett, TRD McNeil, MR Doyle, PJ Rubinsky, H Nixon, S Hula, W Brady, J TI Assessing the validity of multiple-choice questions for RAPP story comprehension SO APHASIOLOGY LA English DT Article; Proceedings Paper CT 33rd Annual Clinical Aphasiology Conference CY MAY, 2003 CL Orcas Isl, WA ID SENTENCE READING-COMPREHENSION; APHASIA; ADULTS; DISCOURSE AB Background: Passage dependency (PD) is a measure of how much information is required to answer test questions based only on information provided in the relevant text (Tuiman, 1974). Prior learning, information included in other test questions or responses, and the ability to eliminate less plausible or irrelevant foils are all factors that may affect PD. The PD of the multiple-choice questions for the auditory story comprehension task in the RAPP software environment has yet to be established. Aims: The purpose of this experiment was to investigate the validity of newly developed multiple-choice comprehension questions for the story comprehension tasks used in the RAPP software environment. Methods & Procedures: Participants were 40 young adults without speech or language impairment, 20 of whom heard each of 12 stimulus stories and answered 10 multiple-choice questions with 5 response choices, and 20 who answered the multiple-choice questions but were not exposed to the stimulus stories. Questions concerned information about stated and implied main ideas and details presented in the stories. Based on four pre-determined story forms (three stories each), analyses examined the questions' validity in terms of their PD compared to chance performance and to a pre-established Passage Dependency Index (PDI) criterion (.60). Significant differences in the PDI and in the percentage of correctly answered questions among predetermined forms were also evaluated. Analyses also examined the PD of questions based on the type of information queried both within and among forms. Outcomes & Results: Results provide support for the validity of the multiple-choice questions without consideration of the nature of the information queried by them. The percentage of correctly answered questions exceeded chance for all story forms, PDIs met or exceeded the pre-established criterion, there were no significant differences in the PDIs among the four forms and there were no significant differences in the percentage of correctly answered questions among the four forms. There were no significant differences in the PDIs among the four question types by story form or among question types within a form and all PDIs met or exceeded pre-established criteria (except detail implied questions in one form). Conclusions: These results provide support for the PD of the multiple-choice questions constructed for the four story forms that make up this version of a story-length auditory comprehension task. Results suggest that the questions are not biased relative to the content of the stories and results add to the overall validity of the task. C1 Univ Pittsburgh, Pittsburgh, PA 15232 USA. VA Pittsburgh Health Syst, Pittsburgh, PA USA. RP Fossett, TRD (reprint author), Univ Pittsburgh, 4033 Forbes Tower, Pittsburgh, PA 15232 USA. EM fossett@shrs.pitt.edu NR 14 TC 3 Z9 3 U1 0 U2 3 PU PSYCHOLOGY PRESS PI HOVE PA 27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND SN 0268-7038 J9 APHASIOLOGY JI Aphasiology PD MAY-JUL PY 2004 VL 18 IS 5-7 BP 493 EP 519 DI 10.1080/02687030444000066 PG 27 WC Clinical Neurology SC Neurosciences & Neurology GA 817NC UT WOS:000221183200007 ER PT J AU McNeil, MR Doyle, PJ Hula, WD Rubinsky, HJ Fossett, TRD Matthews, CT AF McNeil, MR Doyle, PJ Hula, WD Rubinsky, HJ Fossett, TRD Matthews, CT TI Using resource allocation theory and dual-task methods to increase the sensitivity of assessment in aphasia SO APHASIOLOGY LA English DT Article; Proceedings Paper CT 33rd Annual Clinical Aphasiology Conference CY MAY, 2003 CL Orcas Isl, WA ID STORY RETELL PROCEDURE; DIVIDED-ATTENTION; QUANTITATIVE-ANALYSIS; MULTIPLE RESOURCES; MANUAL TRACKING; PERFORMANCE; INDIVIDUALS; LANGUAGE; SPEECH; COMPREHENSION AB Background: Quantifying the severity of language impairment and measuring change in language performance over time are two important objectives in the assessment of aphasia. The notion of cognitive effort as understood from a resource allocation perspective provides a potentially useful complement to traditional constructs employed in aphasia assessment. Aims: The series of experiments described in this paper used resource allocation theory and dual-task methodology (1) to assess whether a language comprehension task (Story Retell Procedure) and a visual-manual tracking task trade performance under dual-task conditions, and (2) to investigate the potential utility of these methods in clinical assessment of aphasia. In Experiment 1, the validity of a difficulty manipulation of the SRP was investigated. In Experiments 2 and 3, the reliability and validity of the visual-manual tracking task were evaluated. Experiment 4 investigated whether the two tasks trade performance under dual-task conditions. Methods & Procedures: In Experiment 1, 20 normal participants listened to and retold stories presented by a normal speaker and speakers with mild, moderate, and severe aphasia. Participants' comprehension performance was measured by calculating the amount of information retold per unit time. In Experiment 2, root mean square (RMS) tracking error data were collected under fixed joystick displacement conditions. In Experiment 3, 20 normal participants performed single-task tracking across 12 trials at each of three difficulty levels, and performance was evaluated in terms of RMS error. In Experiment 4, three groups of 20 normal individuals performed the tracking task while listening to stories told by the normal speaker and speakers with aphasia. Story retell performance was evaluated between subjects across three tracking difficulty levels and tracking performance was evaluated within subjects across story difficulty (normal, mild, moderate, and severe aphasia). Outcomes & Results: The results of Experiments 1-3 supported the reliability and validity of the difficulty manipulations for the story retell and tracking tasks. In Experiment 4, tracking performance was found to vary significantly across story difficulty, with subjects demonstrating better tracking performance while listening to stories told by a mildly aphasic speaker than during stories told by a speaker with moderate aphasia. There was no effect of tracking difficulty on story comprehension as measured by subsequent story retell performance. Conclusions: The results provide qualified support for both a resource allocation view of language performance in normal individuals and the potential utility of these methods in the assessment of aphasia. These conclusions, however, are mitigated by the finding of only a unidirectional (as opposed to bidirectional) performance trade, and by the fact that the effect of story difficulty on tracking performance was observed across only two levels of aphasia severity. C1 Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA 15260 USA. VA Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. RP McNeil, MR (reprint author), Univ Pittsburgh, Dept Commun Sci & Disorders, 4033 Forbes Tower, Pittsburgh, PA 15260 USA. EM mcneil@csd.pitt.edu NR 62 TC 11 Z9 11 U1 2 U2 6 PU PSYCHOLOGY PRESS PI HOVE PA 27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND SN 0268-7038 J9 APHASIOLOGY JI Aphasiology PD MAY-JUL PY 2004 VL 18 IS 5-7 BP 521 EP 542 DI 10.1080/02687030444000138 PG 22 WC Clinical Neurology SC Neurosciences & Neurology GA 817NC UT WOS:000221183200008 ER PT J AU Khachaturian, AS Corcoran, CD Mayer, LS Zandi, PP Breitner, JCS AF Khachaturian, AS Corcoran, CD Mayer, LS Zandi, PP Breitner, JCS CA Cache County Study Invest TI Apolipoprotein E epsilon 4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility - The cache county study SO ARCHIVES OF GENERAL PSYCHIATRY LA English DT Article ID COMMUNITY POPULATION; DEMENTIA; RELIABILITY; PREVALENCE; PREDICTS; DECLINE; SCREEN; AD AB Background: The incidence of Alzheimer disease (AD) increases strongly with age, but little is known about the cumulative incidence of AD over a lifetime of 100 years, or its relationship to the polymorphic APOE locus that encodes apolipoprotein E. APOE is a strong genetic risk factor for AD. Objectives: To estimate the occurrence of AD as a function of age and number of APOE epsilon4 alleles; and to explore evidence for heterogeneity of AD risk related to APOE genotype and to other sources. Design: Nonparametric and parametric survival analyses of AD incidence in prospective longitudinal study. Setting and Participants: A total of 3308 elderly residents of Cache County, Utah. Main Outcome Measures: Cumulative incidence of AD; in mixture models assuming susceptible and nonsusceptible individuals, the proportion of individuals not susceptible to AD at any age. Results: Models that assumed a proportion of invulnerable individuals provided strongly improved fit to the data. These models estimated the 100-year lifetime incidence of AD at 72%, implying that 28% of individuals would not develop AD over any reasonable life expectancy. We confirmed the acceleration of AD onset in individuals with 1 or, especially, 2 APOE epsilon4 alleles, but observed no meaningful difference in 100-year lifetime incidence related to number Of epsilon4 alleles. Conclusions: The APOE epsilon4 allele acts as a potent risk factor for AD by accelerating onset. However, the risk of AD appears heterogeneous in ways independent of APOE. Some individuals seem destined to escape AD, even over an extended lifespan. Their relative invulnerability may reflect other genes or environmental factors that can be investigated. C1 Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Vet Affairs Puget Sound Healthcare Syst, GRECC S182, Seattle, WA 98108 USA. Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA. Banner Good Samaritan Med Ctr, Alzheimers Res Ctr, Phoenix, AZ USA. Utah State Univ, Dept Math, Logan, UT 84322 USA. Utah State Univ, Ctr Epidemiol Studies, Logan, UT 84322 USA. Khachaturian & Associates Inc, Potomac, MD USA. RP Breitner, JCS (reprint author), Vet Affairs Puget Sound Healthcare Syst, GRECC S182, 1660 S Columbian Way, Seattle, WA 98108 USA. EM jcsb@u.washington.edu FU NIA NIH HHS [AG-11380]; NIMH NIH HHS [MH-14592] NR 26 TC 110 Z9 114 U1 1 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0003-990X J9 ARCH GEN PSYCHIAT JI Arch. Gen. Psychiatry PD MAY PY 2004 VL 61 IS 5 BP 518 EP 524 DI 10.1001/archpsyc.61.5.518 PG 7 WC Psychiatry SC Psychiatry GA 817LK UT WOS:000221178800011 PM 15123497 ER PT J AU Diab, ME Johnston, MV AF Diab, ME Johnston, MV TI Relationships between level of disability and receipt of preventive health services SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article; Proceedings Paper CT Annual Meeting of the American-College-of-Preventive-Medicine CY FEB 23, 2001 CL Miami, FL SP Amer Coll Prevent Med DE disability evaluation; mass screening; preventive medicine; primary prevention; rehabilitation; vaccination ID FACTOR SURVEILLANCE SYSTEM; PHYSICAL-DISABILITIES; BREAST; RISK; WOMEN; CARE AB Objectives: To examine relationships between level of disability and receipt of certain preventive health services, including demographic and systems variables that may explain or confound these relationships. Design: Analysis of recent (1998 and 2000) data from the Behavioral Risk Factor Surveillance System, a nationwide telephone survey. Setting: States reporting data on disability (13 in 1998, 18 in 2000). Participants: Noninstitutionalized persons living in the community. Interventions: Not applicable. Main Outcome Measures: Frequency of receipt of recommended preventive health services, including colorectal, cervical, and breast cancer screening, and influenza and pneumococcal vaccination. An ordinal index of disability severity was constructed from questions on activity limitations. Results: In 2000, people with mild and moderate disability received influenza and pneumonia vaccinations somewhat more frequently than people without disabilities, but people with the most severe disabilities least frequently received vaccinations that year. Disabled women received fewer Papanicolaou tests and clinical breast examinations, but significant differences did not occur for mammograms in 2000. Fewer differences as a function of disability level were apparent in 2000 than 1998. Demographic variables affected receipt of most preventive services. Access to routine checkups affected all preventive services independent of disability level in both years. Conclusions: Severity of disability is related to receipt of certain preventive services but not necessarily in a simple or unidirectional way. Regardless of disability, receipt of a checkup was an important determinant of receipt of preventive health services. For almost all services and groups studied, preventive care remained below targeted goals for Healthy People 2010. C1 Kessler Med Rehabil Res & Educ Corp, W Orange, NJ 07052 USA. Bronx Vet Affairs Med Ctr, Bronx, NY USA. Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA. RP Johnston, MV (reprint author), Kessler Med Rehabil Res & Educ Corp, 1199 Pleasant Valley Way, W Orange, NJ 07052 USA. EM mjohnston@kmrrec.org NR 39 TC 84 Z9 85 U1 1 U2 6 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD MAY PY 2004 VL 85 IS 5 BP 749 EP 757 DI 10.1016/j.apmr.2003.06.028 PG 9 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 818XC UT WOS:000221276800009 PM 15129399 ER PT J AU Fass, MV Cooper, RA Fitzgerald, SG Schmeler, M Boninger, ML Algood, SD Ammer, WA Rentschler, AJ Duncan, J AF Fass, MV Cooper, RA Fitzgerald, SG Schmeler, M Boninger, ML Algood, SD Ammer, WA Rentschler, AJ Duncan, J TI Durability, value, and reliability of selected electric powered wheelchairs SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE fatigue; life cycle; reference standards; rehabilitation; wheelchairs ID MANUAL WHEELCHAIRS; LIFE AB Objective: To compare the durability, value, and reliability of selected electric powered wheelchairs (EPWs), purchased in 1998. Design: Engineering standards tests of quality and performance. Setting: A rehabilitation engineering center. Specimens: Fifteen EPWs: 3 each of the Jazzy, Quickie, Lancer, Arrow, and Chairman models. Interventions: Not applicable. Main Outcome Measures: Wheelchairs were evaluated for durability (lifespan), value (durability, cost), and reliability (rate of repairs) using 2-drum and curb-drop machines in accordance with the standards of the American National Standards Institute and Rehabilitation Engineering and Assistive Technology Society of North America. Results: The 5 brands differed significantly (Pless than or equal to.05) in durability, value, and reliability, except in terms of reliability of supplier repairs. The Arrow had the highest durability, value, and reliability in terms of the number of consumer failures, supplier failures, repairs, failures, consumer repairs and failures, and supplier repairs and failures. The Lancer had the poorest durability and reliability, and the Chairman had the lowest value. K0014 wheelchairs (Arrow, Permobil) were significantly more durable than K0011 wheelchairs (Jazzy, Quickie, Lancer). No significant differences in durability with respect to rear-wheel-drive (Arrow, Lancer, Quickie), mid-wheel-drive (Jazzy), or front-wheel-drive (Chairman) wheelchairs were found. Conclusions: The Arrow consistently outperformed the other wheelchairs in nearly every area studied, and K0014 wheelchairs were more durable than K0011 wheelchairs. These results can be used as an objective comparison guide for clinicians and consumers, as long as they are used in conjunction with other important selection criteria. Manufacturers can use these results as a guide for continued efforts to produce higher quality wheelchairs. Care should be taken when making comparisons, however, because the 5 brands had different features. Purchased in 1998, these models may be used for several more years. In addition, problem areas in these models may still be present in newer models. C1 VA Pittsburgh Healthcare Syst, Human Engn Res Labs, VA Rehabil Res & Dev Ctr, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15260 USA. RP Cooper, RA (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, VA Rehabil Res & Dev Ctr, 151-RI,7180 Highland Dr, Pittsburgh, PA 15206 USA. EM rcooper+@pitt.edu OI Boninger, Michael/0000-0001-6966-919X FU PHS HHS [H133E990001, H129E990004] NR 18 TC 17 Z9 17 U1 1 U2 4 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD MAY PY 2004 VL 85 IS 5 BP 805 EP 814 DI 10.1016/j.apmr.2003.08.096 PG 10 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 818XC UT WOS:000221276800016 PM 15129406 ER PT J AU Reusch, JE Jobin, C Watson, PA Nesterova, A Grippa, J AF Reusch, JE Jobin, C Watson, PA Nesterova, A Grippa, J TI C-reactive protein regulates the cAMP response element binding protein in vascular smooth muscle cells SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY LA English DT Meeting Abstract CT 5th Annual Conference on Arteriosclerosis, Thrombosis, and Vascular Biology CY MAY 06-08, 2004 CL San Francisco, CA C1 Denver VAMC, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1079-5642 J9 ARTERIOSCL THROM VAS JI Arterioscler. Thromb. Vasc. Biol. PD MAY PY 2004 VL 24 IS 5 MA P52 BP E10 EP E10 PG 1 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 818VN UT WOS:000221272700083 ER PT J AU Cunnane, G Chan, OTM Cassafer, G Brindis, S Kaufman, E Yen, TSB Daikh, DI AF Cunnane, G Chan, OTM Cassafer, G Brindis, S Kaufman, E Yen, TSB Daikh, DI TI Prevention of renal damage in murine lupus nephritis by CTLA-41g and cyclophosphamide SO ARTHRITIS AND RHEUMATISM LA English DT Article ID B-CELLS; NZW MICE; AUTOIMMUNITY; CTLA4IG; DISEASE; ERYTHEMATOSUS; EXPRESSION; ACTIVATION; ANTIBODY; BIOPSY AB Objective. To compare the effects of combined administration of clyclophosphamide (CYC) and CTLA-4Ig with the effects of these agents alone on the immunopathology and progression of renal damage in (NZB x NZW)F-1 (B/W) lupus-prone mice, and to explore the clinical implications of this combination by evaluating the ability of CTLA-4Ig to sustain the benefit of CYC in patients with lupus nephritis. Methods. We carried out a detailed, prospective pathologic and immunohistochemical analysis of the effects of CYC and CTLA-4Ig, alone and in combination, in kidney tissue from B/W mice. The acute effects of these agents on immune cells in the kidney were evaluated by fluorescence-activated cell sorting. We also compared the effect of brief CYC plus sustained CTLA-4Ig administration with the effect of sustained administration of both agents on the progression of renal disease in B/W mice. Results. As a single agent, CTLA-4Ig was generally as effective, and in some cases more effective, than CYC in slowing progression of renal disease. Combined therapy with these two agents very effectively arrested the progression of renal damage and, in some respects, reversed renal pathology. Induction therapy with both CTLA-4Ig and CYC precluded the need for continuous administration of CYC. Conclusion. Our results indicate that the combination of CTLA-4Ig and CYC very effectively arrests the progression of murine lupus nephritis. These findings have direct implications for the treatment of lupus nephritis. C1 Univ Calif San Francisco, San Francisco, CA 94121 USA. San Francisco VA Med Ctr, San Francisco, CA USA. RP Daikh, DI (reprint author), Univ Calif San Francisco, 4150 Clement St, San Francisco, CA 94121 USA. EM daikh@itsa.ucsf.edu FU NIAID NIH HHS [K08 AI 01520] NR 28 TC 27 Z9 30 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD MAY PY 2004 VL 50 IS 5 BP 1539 EP 1548 DI 10.1002/art.20147 PG 10 WC Rheumatology SC Rheumatology GA 819UI UT WOS:000221340900022 PM 15146424 ER PT J AU Li, XB Nahas, Z Kozel, FA Anderson, B Bohning, DE George, MS AF Li, XB Nahas, Z Kozel, FA Anderson, B Bohning, DE George, MS TI Acute left prefrontal transcranial magnetic stimulation in depressed patients is associated with immediately increased activity in prefrontal cortical as well as subcortical regions SO BIOLOGICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Annual Convention of the Society-of-Biological-Psychiatry CY MAY 17, 2003 CL San Francisco, CA SP Soc Biolog Psychiatry DE brain networks; depression; fMRI; limbic system; prefrontal cortex; transcranial magnetic stimulation ID CEREBRAL-BLOOD-FLOW; DANISH PET/DEPRESSION PROJECT; RECURRENT MAJOR DEPRESSION; LATE-LIFE-DEPRESSION; MOOD DISORDERS; ELECTROCONVULSIVE-THERAPY; ELECTRICAL-STIMULATION; GLUCOSE-METABOLISM; BRAIN METABOLISM; CORTEX AB Background Focal prefrontal cortex repetitive transcranial magnetic stimulation (rTMS) was originally investigated as a potential antidepressant under the assumption that in depressed patients, Prefrontal cortex stimulation would produce changes in connected limbic regions involved in mood regulation. Methods. Fourteen adult patients with depression were scanned in a 1.5-T scanner using interleaved rTMS (I Hz) applied on the left prefrontal cortex over 7.35 min. Images were analyzed with Statistical Parametric Mapping A and principal component analysis. Results. Over the left prefrontal cortex, 1-Hz TMS was associated with increased activity at the site of stimulation as well as in connected limbic regions: bilateral middle prefrontal cortex, right orbital frontal cortex, left hippocampus, mediodorsal nucleus of the thalamus, bilateral putamen, pulvinar, and insula (t = 3.85, p < .001). Significant deactivation was found in the right ventromedial frontal cortex. Conclusions. In depressed patients, 1-Hz TMS at 100% motor threshold over the left prefrontal cortex induces activation underneath the coil, activates frontal-subcortical neuronal circuits, and decreases activity in the right ventromedial cortex. Further work is needed to understand whether these immediate changes vary as a function of TMS use parameters (intensity, frequency, location) and whether they relate to neurobiologic effects and antidepressant mechanisms of TMS. C1 Med Univ S Carolina, IOP, Brain Stimulat Lab, Dept Psychiat, Charleston, SC 29425 USA. Med Univ S Carolina, Ctr Adv Imaging Res, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Radiol, Charleston, SC 29425 USA. Ralph H Johnson Dept Vet Affairs Med Ctr, Mental Hlth Serv, Charleston, SC USA. RP Li, XB (reprint author), Med Univ S Carolina, IOP, Brain Stimulat Lab, Dept Psychiat, Room 502 N,67 President St, Charleston, SC 29425 USA. RI Kozel, Frank/I-5366-2012 FU NCRR NIH HHS [R01 RR 14080-02, R01 RR14080-01]; NIAAA NIH HHS [2 P50 AA10761-03]; NINDS NIH HHS [R01 NS40956-1] NR 72 TC 67 Z9 68 U1 3 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 1 PY 2004 VL 55 IS 9 BP 882 EP 890 DI 10.1016/j.biopsych.2004.01.017 PG 9 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 813QR UT WOS:000220922100002 PM 15110731 ER PT J AU Klein, RF AF Klein, RF TI Osteoblasts make for good neighbors SO BLOOD LA English DT Editorial Material ID HEMATOPOIETIC STEM-CELL; NICHE C1 Oregon Hlth Sci Univ, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. RP Klein, RF (reprint author), Oregon Hlth Sci Univ, Portland, OR 97201 USA. NR 3 TC 2 Z9 3 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD MAY 1 PY 2004 VL 103 IS 9 BP 3247 EP 3247 DI 10.1182/blood-2004-02-0687 PG 1 WC Hematology SC Hematology GA 822UJ UT WOS:000221565600001 ER PT J AU Piqueras, L Tache, Y Martinez, V AF Piqueras, L Tache, Y Martinez, V TI Peripheral PACAP inhibits gastric acid secretion through somatostatin release in mice SO BRITISH JOURNAL OF PHARMACOLOGY LA English DT Article DE PACAP; somatostatin; SSTR2; gastric acid secretion; PRL-2903 ID CYCLASE-ACTIVATING POLYPEPTIDE; VASOACTIVE-INTESTINAL-PEPTIDE; ENTEROCHROMAFFIN-LIKE CELLS; BOMBESIN-INDUCED INHIBITION; ISOLATED MOUSE STOMACH; ADENYLATE-CYCLASE; RAT STOMACH; GASTROINTESTINAL-TRACT; HISTAMINE-RELEASE; MONOCLONAL-ANTIBODY AB 1 Studies in rats suggest that PACAP modulates gastric acid secretion through the release of both histamine and somatostatin. 2 We characterized the effects of exogenous PACAP on gastric acid secretion in urethane-anesthetized mice implanted with a gastric cannula and in conscious 2-h pylorus ligated mice, and determined the involvement of somatostatin and somatostatin receptor type 2 (SSTR2) by using somatostatin immunoneutralization, the SSTR2 antagonist, PRL-2903, and SSTR2 knockout mice. 3 Urethane-anesthetized wild-type mice had low basal acid secretion (0.10+/-0.01 mumol (10 min)(-1)) compared with SSTR2 knockout mice (0.93+/-0.07 mumol (10 min)(-1)). Somatostatin antibody and PRL-2903 increased basal secretion in wild-type mice but not in SSTR2 knockout animals. 4 In wild-type urethane-anesthetized mice, PACAP-38 (3-270 mug kg(-1) h(-1)) did not affect the low basal acid secretion, but inhibited the acid response to pentagastrin, histamine, and bethanechol. 5 In wild-type urethane-anesthetized mice pretreated with somatostatin antibody or PRL-2903 and in SSTR2 knockout mice, peripheral infusion of PACAP-38 or somatostatin-14 did not inhibit the increased basal gastric acid secretion. 6 In conscious wild-type mice, but not in SSTR2 knockout mice, PACAP-38 inhibited gastric acid secretion induced by 2-h pylorus ligation. The antisecretory effect of PACAP-38 was prevented by immunoneutralization of somatostatin. 7 These results indicate that, in mice, peripheral PACAP inhibits gastric acid secretion through the release of somatostatin and the activation of SSTR2 receptors. There is no evidence for stimulatory effects of PACAP on acid secretion in mice. C1 Cardenal Herrera CEU Univ, Dept Physiol Pharmacol & Toxicol, Valencia, Spain. Univ Calif Los Angeles, Dept Med,Div Digest Dis, VA Greater Los Angeles Hlth Care Syst, CURE,Digest Dis Res Ctr,Ctr Neurovisceral Sci, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA. RP Martinez, V (reprint author), AstraZeneca R&D, Integrat Pharmacol Gastrointestinal Biol, SE-43183 Molndal, Sweden. EM vicente.martinez@astrazeneca.com RI Martinez, Vicente/N-1189-2014 FU NIDDK NIH HHS [DK-30110, DK-41301, P30 DK041301] NR 57 TC 16 Z9 19 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0007-1188 J9 BRIT J PHARMACOL JI Br. J. Pharmacol. PD MAY PY 2004 VL 142 IS 1 BP 67 EP 78 DI 10.1038/sj.bjp.0705739 PG 12 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 823DL UT WOS:000221589800012 PM 15023860 ER PT J AU Dulai, GS Farmer, MM Ganz, PA Bernaards, CA Qi, K Dietrich, AJ Bastani, R Belman, MJ Kahn, KL AF Dulai, GS Farmer, MM Ganz, PA Bernaards, CA Qi, K Dietrich, AJ Bastani, R Belman, MJ Kahn, KL TI Primary care provider perceptions of barriers to and facilitators of colorectal cancer screening in a managed care setting SO CANCER LA English DT Article; Proceedings Paper CT 24th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 02-05, 2001 CL SAN DIEGO, CA SP Soc Gen Internal Med DE screening; managed care; health services research; survey; colorectal cancer ID CONTROLLED TRIAL; PREVENTIVE CARE; FLEXIBLE SIGMOIDOSCOPY; DISEASE PREVENTION; CLINICAL-PRACTICE; HEALTH PROMOTION; COLON-CANCER; NEW-YORK; PHYSICIANS; RECOMMENDATIONS AB BACKGROUND. Colorectal cancer (CRC) screening tests (e.g., fecal occult blood testing [FOBT], flexible sigmoidoscopy [FS], etc.) are underused. Primary care providers (PCPs) play a critical role in screening, but barriers to and facilitators of screening as perceived by PCPs in managed care settings are poorly understood. The objectives of the current study were to describe current CRC screening practices and to explore determinants of test use by PCPs in a managed care setting. METHODS. In 2000, a self-administered survey was mailed to a stratified, random sample of 1340 PCPs in a large, network model health maintenance organization in California. RESULTS. The survey response rate was 67%. PCPs indicated that 79% of their standard-risk patients were screened for CRC. PCP-reported median rates of recommendation for the use of specific screening tests were 90% for FOBT and 70% for FS. In logistic regression models, perceived barriers to the use of FOBT and FS included patient characteristics (e.g., education) and PCP-related barriers (e.g., failure to recall that patients were due for testing). Perceived facilitators of the use of FOBT and FS included interventions targeting certain aspects of the health care system (e.g., reimbursement) and interventions targeting certain aspects of the tests themselves (e.g., provision of evidence of a test's effectiveness). Assignment of high priority to screening, integrated medical group (as opposed to independent practice association) affiliation, and the proportion of patients receiving routine health maintenance examinations were positively associated with reported test use. CONCLUSIONS. CRC screening tests appear to be underused in the managed care setting examined in the current study. The perceived barriers and facilitators that were identified can be used to guide interventions aimed at increasing recommendations for, as well as actual performance of, CRC screening. C1 Greater Los Angeles Vet Adm Healthcare Syst, Ctr Ulcer Res & Educ, Digest Dis Res Ctr, Div Gastroenterol, Los Angeles, CA USA. Univ Calif Los Angeles, Ctr Neurovisceral Sci & Womens Hlth, Ctr Study Digest Healthcare Qual & Outcomes, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Publ Hlth, Jonsson Comprehens Canc Ctr, Div Canc Prevent & Control Res, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Stat, Los Angeles, CA USA. Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Community & Family Med, Hanover, NH 03756 USA. Blue Cross Calif, Woodland Hills, CA USA. RAND Corp, Santa Monica, CA USA. Univ Calif Los Angeles, Div Gen Internal Med, Los Angeles, CA USA. RP Dulai, GS (reprint author), Greater Los Angeles Vet Adm Healthcare Syst, Ctr Study Digest Healthcare Qual & Outcomes, CURE, Bldg 115,Room 215C,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM gdulai@mednet.ucla.edu FU NCI NIH HHS [R01 CA75544]; NCRR NIH HHS [K23 RR1618801] NR 51 TC 46 Z9 47 U1 3 U2 4 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0008-543X J9 CANCER JI Cancer PD MAY 1 PY 2004 VL 100 IS 9 BP 1843 EP 1852 DI 10.1002/cncr.20209 PG 10 WC Oncology SC Oncology GA 813TI UT WOS:000220929000010 PM 15112264 ER PT J AU Saika, T Satoh, T Kusaka, N Ebara, S Mouraviev, VB Timme, TL Thompson, TC AF Saika, T Satoh, T Kusaka, N Ebara, S Mouraviev, VB Timme, TL Thompson, TC TI Route of administration influences the antitumor effects of bone marrow-derived dendritic cells engineered to produce interleukin-12 in a metastatic mouse prostate cancer model SO CANCER GENE THERAPY LA English DT Article DE dendritic cell; interleukin-12; prostate cancer; immunotherapy ID SITU GENE-THERAPY; COLONY-STIMULATING FACTOR; RESPONSES IN-VITRO; INTRATUMORAL INJECTION; ADENOVIRUS; IMMUNITY; IMMUNOTHERAPY; INDUCTION; IL-12; VIVO AB Gene-modified dendritic cells ( DC) provide unique therapeutic strategies for prostate cancer; however, the comparative evaluation of specific delivery options using appropriate preclinical models has not been described. In this study, bone marrow-derived DC were genetically engineered to express high levels of interleukin-12 (IL-12) with or without the costimulatory molecule B7-1, by ex vivo infection with recombinant adenoviral vectors. We used an orthotopic metastatic mouse prostate cancer preclinical model (178-2 BMA) to compare two therapeutic protocols for DC delivery, in situ and subcutaneous. DC were generated from bone marrow of syngeneic 129/Sv mice by culturing in the presence of GM-CSF and IL-4. In vitro DC/IL-12 or DC/IL-12/B7 produced high levels of biologically active IL-12. In situ delivery of DC/IL-12 or DC/IL-12/B7 induced a significant suppression of primary tumor growth compared to DC/betagal controls (P = 0328 and P = 0019, respectively), as well as reduced numbers of spontaneous lung metastatic nodules (P = 1404 and P = 0335, respectively). In survival experiments, in situ DC/IL-12 injection demonstrated a small but statistically significant advantage (P = 0041). Subcutaneous, tumor lysate pulsed DC/IL-12 significantly decreased tumor size (P = 0152) and increased survival (P = 0.0433) compared to HBSS controls but the decrease in the number of spontaneous lung metastases did not achieve statistical significance. Both in situ and subcutaneous treatments enhanced cytolytic activities of natural killer (NK) cells and cytotoxic T lymphocytes (CTL). In this preclinical model, gene-modified DC-based intratumoral immunotherapy was shown to be an effective therapeutic strategy for locally advanced prostate cancer based on tumor growth suppression, inhibition of metastasis and survival improvement. C1 Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA. Houston Vet Affairs Med Ctr, Houston, TX USA. Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA. Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA. RP Thompson, TC (reprint author), 6560 Fannin,Suite 2100, Houston, TX 77030 USA. EM timothyt@www.urol.bcm.tmc.edu FU NCI NIH HHS [P50-CA58204] NR 35 TC 23 Z9 25 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0929-1903 J9 CANCER GENE THER JI Cancer Gene Ther. PD MAY PY 2004 VL 11 IS 5 BP 317 EP 324 DI 10.1038/sj.cgt.7700709 PG 8 WC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity; Research & Experimental Medicine GA 815FA UT WOS:000221027000002 PM 15044961 ER PT J AU Young, MRI AF Young, MRI TI Trials and tribulations of immunotherapy as a treatment option for patients with squamous cell carcinoma of the head and neck SO CANCER IMMUNOLOGY IMMUNOTHERAPY LA English DT Review DE head and neck cancer; HNSCC; immune; immunotherapy; immunosuppression ID COLONY-STIMULATING FACTOR; TUMOR-BEARING MICE; SUPPRESSIVE CD34(+) CELLS; GROWTH-FACTOR RECEPTOR; MACROPHAGE PROGENITOR CELLS; T-CELLS; DENDRITIC CELLS; CANCER-PATIENTS; IMMUNE SUPPRESSION; PERIPHERAL-BLOOD AB Head and neck squamous cell carcinoma (HNSCC) is an aggressive epithelial malignancy that is the sixth most common neoplasm in the world. Despite numerous advances in treatments involving surgery, radiation, and chemotherapy, the 5-year survival has remained at less than 50% for the last 30 years primarily due to local recurrences [66]. Consequently, the possibility of developing immunotherapeutic approaches as a treatment for HNSCC has gained interest. The present review has 3 objectives pertaining to immunotherapeutic means to treat HNSCC patients: (1) to summarize the feasibility of such approaches, (2) to provide an overview of the obstacles to attaining protective immune reactivity, and (3) to consider how these obstacles can be overcome to stimulate immune reactivity to HNSCC. These objectives will also be considered in the context of what lessons have been learned from immunotherapeutic trials for other solid malignancies and the applicability of this information to HNSCC. C1 Ralph H Johnson VA Med Ctr, Res Serv 151, Charleston, SC 29401 USA. Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Otolaryngol, Charleston, SC 29425 USA. RP Young, MRI (reprint author), Ralph H Johnson VA Med Ctr, Res Serv 151, 109 Bee St, Charleston, SC 29401 USA. EM rita.young@med.va.gov NR 91 TC 16 Z9 16 U1 0 U2 0 PU SPRINGER-VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 USA SN 0340-7004 J9 CANCER IMMUNOL IMMUN JI Cancer Immunol. Immunother. PD MAY PY 2004 VL 53 IS 5 BP 375 EP 382 DI 10.1007/s00262-003-0456-x PG 8 WC Oncology; Immunology SC Oncology; Immunology GA 814RP UT WOS:000220992100001 PM 14634795 ER PT J AU Lathers, DMR Clark, JI Achille, NJ Young, MRI AF Lathers, DMR Clark, JI Achille, NJ Young, MRI TI Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D-3 SO CANCER IMMUNOLOGY IMMUNOTHERAPY LA English DT Article DE CD34(+) cells; cytokines; HNSCC patients; immunotherapy; vitamin D-3 ID SUPPRESSIVE CD34(+) CELLS; GROWTH-FACTOR-BETA; VITAMIN-D ANALOGS; PERIPHERAL-BLOOD; PROGENITOR CELLS; DENDRITIC CELLS; 1-ALPHA,25-DIHYDROXYVITAMIN D3; MYELOID DIFFERENTIATION; IN-VITRO; TUMOR AB Patients with head and neck squamous cell carcinoma (HNSCC) have profound immune defects. These defects are associated with a poor prognosis and are mediated, in part, by immune inhibitory CD34(+) progenitor cells, whose numbers are increased in the peripheral blood of HNSCC patients. Immune inhibitory CD34(+) cells are also present within HNSCC tumors. A phase IB clinical trial was conducted with HNSCC patients to determine if treatment with the differentiation-inducer 25-hydroxyvitamin D-3 could diminish CD34(+) cell levels and improve a panel of immune parameters. Here we present the results of treatment with orally administered escalating doses (20, 40, 60 mug) of 25-hydroxyvitamin D-3, with an emphasis on the six patients who received the maximum dosage of 60 mug per day. Peripheral blood was collected at 0, 1, 2, 4, and 6 weeks, and assessed for markers of immune activity. Although no clinical responses were observed, results of this pilot study demonstrated that treatment of HNSCC patients with 25-hydroxyvitamin D-3 reduces the number of immune suppressive CD34(+) cells, increases HLA-DR expression, increases plasma IL-12 and IFN-gamma levels, and improves T-cell blastogenesis. In contrast, 25-hydroxyvitamin D-3 treatment did not modulate plasma IL-1beta, IL-2, IL-4, IL-6, IL-10, GM-CSF, or TGF-beta levels. C1 Ralph H Johnson Vet Affairs Med Ctr, Res Serv 151, Charleston, SC 29401 USA. Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Otolaryngol, Charleston, SC 29425 USA. Loyola Univ, Stritch Sch Med, Dept Pathol, Maywood, IL 60153 USA. Loyola Univ, Stritch Sch Med, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA. RP Young, MRI (reprint author), Ralph H Johnson Vet Affairs Med Ctr, Res Serv 151, 109 Bee St, Charleston, SC 29401 USA. EM rita.young@med.va.gov FU NCI NIH HHS [R01-CA45080, R01-CA85266, R21-CA77108] NR 36 TC 61 Z9 68 U1 0 U2 1 PU SPRINGER-VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 USA SN 0340-7004 J9 CANCER IMMUNOL IMMUN JI Cancer Immunol. Immunother. PD MAY PY 2004 VL 53 IS 5 BP 422 EP 430 DI 10.1007/s00262-003-0459-7 PG 9 WC Oncology; Immunology SC Oncology; Immunology GA 814RP UT WOS:000220992100006 PM 14648070 ER PT J AU Miller, YE Keith, RL AF Miller, YE Keith, RL TI Lung cancer over 17 years of aspen lung conferences SO CHEST LA English DT Editorial Material C1 Denver Vet Affairs Med Ctr, Div Pulm Sci & Crit Care Med, Denver, CO 80220 USA. Univ Colorado Comprehens Canc Ctr, Univ Colorado Hlth Sci Ctr, Boulder, CO USA. RP Miller, YE (reprint author), Denver Vet Affairs Med Ctr, Div Pulm Sci & Crit Care Med, Pulm 111A,1055 Clermont St, Denver, CO 80220 USA. EM york.miller@nchsc.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD MAY PY 2004 VL 125 IS 5 SU S BP 79S EP 79S DI 10.1378/chest.125.5_suppl.79S PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 823GT UT WOS:000221598800001 ER PT J AU Holden, WE Lewinsohn, DM Osborne, ML Griffin, C Spencer, A Duncan, C Deffebach, ME AF Holden, WE Lewinsohn, DM Osborne, ML Griffin, C Spencer, A Duncan, C Deffebach, ME TI Use of a clinical pathway to manage unsuspected radiographic findings SO CHEST LA English DT Article DE chest radiograph; clinical pathway; lung cancer; lung nodule; radiology; radiographic findings; radiology information systems ID SOLITARY PULMONARY NODULE; LUNG-CANCER; COMMUNICATION; CARCINOMA; PROJECT; CT AB Study objectives: To describe our 5-year experience with a clinical pathway used to ensure the timely communication and evaluation of unsuspected radiologic findings (URFs) noted on clinically requested chest imaging. Design: Prospective data collection on clinical practice. Setting: Academically affiliated Veterans Affairs medical center. Participants: Pulmonary physicians, nurses, and radiologists. Results: Over a period of 5 years, 1,629 URFs were referred to the pathway (from chest radiographs, 1,359 [83.4%]; from CT scans, 270 [16.6%]). Most URFs (78%) were nodules, with a specific diagnosis made in one third of URFs, and with a specific diagnosis thought to be clinically significant in another one third of URFs. The most common diagnosis was neoplasm, with over two thirds of these diagnoses being lung cancer. One third of lung cancers detected were either stage 1 or 2, with 1 in 17 of all URFs being stage IA lung cancer. The cost of the pathway was estimated at $28,600 per year. Conclusions: URFs noted on chest imaging are frequently clinically significant, and a systematic approach to managing URFs, such as a clinical pathway, can significantly improve care in a large teaching hospital. C1 Portland VA Med Ctr, Med Serv, Portland, OR 97201 USA. Portland VA Med Ctr, Pulm & Crit Care Sect, Portland, OR 97201 USA. Portland VA Med Ctr, Diagnost Radiol Serv, Portland, OR 97201 USA. RP Holden, WE (reprint author), Portland VA Med Ctr, Med Serv, P3-PULM,3710SW US Vet Hosp Rd, Portland, OR 97201 USA. EM william.holden@med.va.gov RI Lewinsohn, David/I-4936-2013 OI Lewinsohn, David/0000-0001-9906-9494 NR 12 TC 6 Z9 6 U1 0 U2 1 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD MAY PY 2004 VL 125 IS 5 BP 1753 EP 1760 DI 10.1378/chest.125.5.1753 PG 8 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 820ZM UT WOS:000221428700027 PM 15136387 ER PT J AU Taylor, SL Hefle, SL Bindslev-Jensen, C Atkins, FM Andre, C Bruijnzeel-Koomen, C Burks, AW Bush, RK Ebisawa, M Eigenmann, PA Host, A Hourihane, JO Isolauri, E Hill, DJ Knulst, A Lack, G Sampson, HA Moneret-Vautrin, DA Rance, F Vadas, PA Yunginger, JW Zeiger, RS Salminen, JW Madsen, C Abbott, P AF Taylor, SL Hefle, SL Bindslev-Jensen, C Atkins, FM Andre, C Bruijnzeel-Koomen, C Burks, AW Bush, RK Ebisawa, M Eigenmann, PA Host, A Hourihane, JO Isolauri, E Hill, DJ Knulst, A Lack, G Sampson, HA Moneret-Vautrin, DA Rance, F Vadas, PA Yunginger, JW Zeiger, RS Salminen, JW Madsen, C Abbott, P TI A consensus protocol for the determination of the threshold doses for allergenic foods: how much is too much? SO CLINICAL AND EXPERIMENTAL ALLERGY LA English DT Article DE allergy; clinical trial; DBPCFC; exposure; food; threshold; risk assessment ID CASEIN HYDROLYSATE FORMULA; DOUBLE-BLIND; IGE CONCENTRATIONS; ATOPIC-DERMATITIS; PEANUT ALLERGY; EGG ALLERGY; COW MILK; CHALLENGES; HYPERSENSITIVITY; IDENTIFICATION AB Background While the ingestion of small amounts of an offending food can elicit adverse reactions in individuals with IgE-mediated food allergies, little information is known regarding these threshold doses for specific allergenic foods. While low-dose challenge trials have been conducted on an appreciable number of allergic individuals, a variety of different clinical protocols were used making the estimation of the threshold dose very difficult. Objective A roundtable conference was convened to develop a consensus clinical protocol for low-dose challenge trials for the estimation of threshold doses for specific allergenic foods. Methods In May 2002, 20 clinical allergists and other interested parties were invited to participate in a roundtable conference to develop consensus of the key elements of a clinical protocol for low-dose challenge trials. Results A consensus protocol was developed. Patients with convincing histories of food allergies and supporting diagnostic evidence including past challenge trials or high CAP-RAST scores can be enrolled in low-dose challenge trials. Care must be taken with younger patients to assure that they have not outgrown their food allergy. An approach was developed for the medication status of patients entering such trials. Challenge materials must be standardized, for example, partially defatted peanut flour composed of equal amounts of the three major varieties of peanuts (Florunner, Virginia, Spanish). Challenge materials must be appropriately blinded with sensory evaluation used to confirm the adequacy of blinding. A double-blind, placebo-controlled design should be used for low-dose challenge trials. Low-dose challenge trials would begin at doses of 10 mug of the allergenic food and would continue with doses of 100 mug and 1 mg followed by specific higher doses up to 100 mg depending upon the expert judgement of the physician; even higher doses might be applied to assure that the patient is indeed reactive to the particular food. A 30-min time interval would be used between doses, and reactive doses would be expressed as both discrete and cumulative doses. The goal of each challenge would be to develop objective symptoms; trials should not be discontinued on the basis of subjective symptoms only. Statistically, a minimum of 29 patients would be enrolled in low-dose challenge trials for each allergenic food because 0 reactors out of 29 patients at a particular dose allow the conclusion that there is 95% certainty that 90% of allergic individuals will not react to that dose. Conclusion A consensus protocol was developed. Using this protocol, it will be possible to estimate threshold doses for allergenic foods, the lowest amount that elicits mild, objective symptoms in highly sensitive individuals. C1 Univ Nebraska, Food Allergy Res & Resource Program, Lincoln, NE 68583 USA. Odense Univ Hosp, Dept Dermatol, DK-5000 Odense, Denmark. Natl Jewish Med & Res Ctr, Denver, CO USA. Stallergenes, Antony, France. Univ Med Ctr, Dept Dermatol Allergol, Utrecht, Netherlands. Arkansas Childrens Hosp, Little Rock, AR 72202 USA. Univ Wisconsin Hosp & Clin, William S Middleton Mem Vet Adm Hosp, Madison, WI 53792 USA. Natl Sagamihara Hosp, Kanagawa, Japan. Hop Enfants, Geneva, Switzerland. Odense Univ Hosp, Dept Pediat, DK-5000 Odense, Denmark. Univ Southampton, Southampton, Hants, England. Univ Turku, Dept Pediat, Turku, Finland. Royal Childrens Hosp, Parkville, Vic 3052, Australia. St Marys Hosp, London, England. CUNY Mt Sinai Sch Med, New York, NY 10029 USA. Univ Hosp, Dept Internal Med Clin Immunol & Allergol, Nancy, France. Hop Enfants, Dept Allergol, Toulouse, France. Wellesley Cent Hosp, Toronto, ON, Canada. Mayo Clin, Rochester, MN USA. Kaiser Permanente Med Ctr, San Diego, CA USA. Hlth Prod & Foods Branch, Chem Hlth Hazard Assessment Div, Ottawa, ON, Canada. Danish Vet & Food Adm, Soborg, Denmark. Food Stand Australia New Zealand, Canberra, ACT, Australia. RP Taylor, SL (reprint author), Univ Nebraska, Food Allergy Res & Resource Program, 143 Food Ind Bldg, Lincoln, NE 68583 USA. EM staylor2@unl.edu RI Bindslev-Jensen, Carsten/H-1877-2011; Osborne, Nicholas/N-4915-2015; Eigenmann, Philippe/A-6569-2017 OI Bindslev-Jensen, Carsten/0000-0002-8940-038X; Osborne, Nicholas/0000-0002-6700-2284; Eigenmann, Philippe/0000-0003-1738-1826 NR 33 TC 116 Z9 119 U1 2 U2 5 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 0954-7894 J9 CLIN EXP ALLERGY JI Clin. Exp. Allergy PD MAY PY 2004 VL 34 IS 5 BP 689 EP 695 DI 10.1111/j.1365-2222.2004.1886.x PG 7 WC Allergy; Immunology SC Allergy; Immunology GA 820PN UT WOS:000221401900005 PM 15144458 ER PT J AU Forrest, TJ Allen, DN Goldstein, G AF Forrest, TJ Allen, DN Goldstein, G TI Malingering indexes for the Halstead Category Test SO CLINICAL NEUROPSYCHOLOGIST LA English DT Article ID PERFORMANCE; ATTORNEYS; DISSIMULATION; IMPAIRMENT; BATTERY; INJURY; FAKING AB Two studies were conducted to evaluate potential malingering indexes on the Halstead Category Test. The aim of the first study was that of documenting that groups of individuals with established cognitive impairment did not score positively on the proposed indexes. Of the indexes considered, it was found that these groups made very few errors on subtests I and II of the test and improved their performance on subtest VI relative to V. Subtests I and II are very simple and both subtest V and VI involve the same principle. It was proposed that malingerers would make excessive numbers of errors on subtests I and II, and would not show improvement on subtest VI over subtest V. The second study compared the performance of patients with brain damage to students who were either trained to malinger or encouraged to perform as well as they could on the Category Test. Comparisons were made on the malingering indexes among these groups showing that mean scores of the patients with brain damage on several of the indexes did not differ from those of the students encouraged to do well, but both of these groups did significantly better than the student malingerers. A discriminant analysis of the set of malingering indexes classified 20% of the student malingerers as brain damaged, and 3.4% of the patients with brain damage as malingerers. A stepwise analysis indicated that number of errors on subtests I and II and Total Errors were particularly sensitive to malingering. C1 Univ Nevada, Dept Psychol, Las Vegas, NV 89154 USA. VA Pittsburgh Healthcare Syst, Highland Dr Div, Pittsburgh, PA USA. RP Allen, DN (reprint author), Univ Nevada, Dept Psychol, 4505 Maryland Pkwy,Box 455030, Las Vegas, NV 89154 USA. EM dallen@ccmail.nevada.edu NR 29 TC 13 Z9 13 U1 2 U2 2 PU SWETS ZEITLINGER PUBLISHERS PI LISSE PA P O BOX 825, 2160 SZ LISSE, NETHERLANDS SN 0920-1637 J9 CLIN NEUROPSYCHOL JI Clin. Neuropsychol. PD MAY PY 2004 VL 18 IS 2 BP 334 EP 347 DI 10.1080/13854040490501673 PG 14 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA 850HU UT WOS:000223602600012 PM 15587679 ER PT J AU Gilliam, M Knight, S McCarthy, M AF Gilliam, M Knight, S McCarthy, M TI Success with oral contraceptives: a pilot study SO CONTRACEPTION LA English DT Article DE oral contraceptives; self-efficacy; African-American; subsequent pregnancy; intervention ID REPEAT ADOLESCENT PREGNANCIES; TEENAGE MOTHERS; POSTPARTUM; PROGRAM; FAMILY; TRIAL AB The objective of this pilot study was to examine the effectiveness of a postpartum educational intervention aimed at increasing compliance with oral contraception (OCs) and decreasing repeat pregnancies in young, African American women in the year following an unplanned pregnancy. In this longitudinal study, 43 young, pregnant women attending Prentice Ambulatory Care, Northwestern Hospital, were enrolled and 33 were randomized to receive an antepartum, multicomponent intervention consisting of counseling, a videotape about OCs and written material or resident-physician counseling (usual care). Questionnaire data were collected at enrollment, immediately following the intervention, at 6 weeks, 6 months and 12 months. At 1 year, 25 women remained in the study. More women in the intervention group were not pregnant and still using contraception, and were able to successfully switch contraceptive methods compared to women in the control group. There was no decrease in repeat pregnancy in the intervention group at 1 year compared to the control group. Our intervention resulted in a sustained increase in knowledge of OCs throughout the study period. However, more is needed to promote postpartum contraceptive compliance and decrease repeat pregnancies in young, low-income African Americans with unintended pregnancies. (C) 2004 Elsevier Inc. All rights reserved. C1 Northwestern Univ, Sch Med, Mcgaw Med Ctr, Dept Obstet & Gynecol, Chicago, IL 60612 USA. Univ Calif San Francisco, Dept Psychiat, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Urol, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. RP Gilliam, M (reprint author), Northwestern Univ, Sch Med, Mcgaw Med Ctr, Dept Obstet & Gynecol, 820 S Wood St,MC 808, Chicago, IL 60612 USA. EM mgilli2@uic.edu NR 24 TC 28 Z9 29 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 J9 CONTRACEPTION JI Contraception PD MAY PY 2004 VL 69 IS 5 BP 413 EP 418 DI 10.1016/j.contraception.2003.12.006 PG 6 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 817KI UT WOS:000221176000012 PM 15105065 ER PT J AU Dobs, AS Matsumoto, AM Wang, C Kipnes, MS AF Dobs, AS Matsumoto, AM Wang, C Kipnes, MS TI Short-term pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient men SO CURRENT MEDICAL RESEARCH AND OPINION LA English DT Article DE AndroGel((R)); buccal mucoadhesive; hormone replacement therapy; hypogonadism; pharmacokinetics; striant((R)); testosterone ID HYPOGONADAL MEN; SERUM TESTOSTERONE; ELDERLY-MEN; THERAPY; DENSITY AB Objective: The primary objective of the study was to compare the percentage of men with mean serum total T (Cave(0-24)) within normal range during the 24-h pharmacokinetic (PK) sampling period on Days 14 and 15. Methods: Treatment with a new testosterone (T) buccal system, (Striant*), 30 mg twice daily was compared to a transdermal gel delivery system, (T-gel) [AndroGeldagger 5 g containing 1% (50 mg) T] daily for 14 days in T-deficient men. Safety parameters included laboratory assessments and collection of adverse events. Patients were otherwise healthy T-deficient men with total T less than or equal to 8.7 nmol/L (less than or equal to 2.5 ng/mL). Results: Twenty-six of the 28 patients enrolled completed the 24-h PK assessment. Of the evaluable patients, 92.3% of T buccal system and 83.3% of T-gel patients had Cave(0-24) within the normal range of 10.4-36.4 nmol/L (3.0-10.5 ng/mL). Mean total T values were not different in the T buccal system group ( C(ave(0-24))16.7 +/- 4.7 nmol/L; 4.8 +/- 1.4 ng/mL) compared to the T-gel group (C(ave(0-24))15.9 +/- 4.8 nmol/L; 4.6 +/- 1.4 ng/mL). All T values returned to baseline levels after the study drug was stopped. Serum LH and FSH levels decreased, and E, increased as expected following T administration. Differences in DHT concentrations between treatment groups were significant (p = 0.012) with mean DHT levels on Day 14 of 1.9 +/- 1.4 nmol/L (0.55 +/- 0.42 ng/mL) for the T buccal system and 3.2 +/- 1.3 nmol/L (0.93 +/- 0.38 ng/mL) for T-gel, which was greater than the upper level of normal (2.9 nmol/L; 0.85 ng/mL). Statistically significant differences were seen in the mean T/DHT ratio on Days 14 and 15 with the T buccal system (9.3) and T-gel (5.0) (normal 9-12) (Day 14, p < 0.00001; Day 15, p < 0.0001). All adverse events were mild to moderate in severity. Three of 12 adverse events were considered related to the study drug and included headache (11 for each of the T buccal system and T-gel), and breast pain (T-gel). Summary and conclusions: In this short-term study, the T buccal system produced steady-state T levels comparable to those with T-Gel without significant adverse effects in T-deficient men. The T buccal system provides an additional safe, effective and convenient option for testosterone replacement therapy in hypogonadal men. C1 Johns Hopkins Univ, Sch Med, Baltimore, MD 21287 USA. VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. Harbor UCLA Med Ctr, Dept Med, Div Endocrinol, Torrance, CA 90509 USA. Res & Educ Inst, Torrance, CA USA. Diabet & Glandular Dis Res Associates, San Antonio, TX USA. RP Dobs, AS (reprint author), Johns Hopkins Univ, Sch Med, 1830 Monument St, Baltimore, MD 21287 USA. EM adobs@jhu.edu FU NCRR NIH HHS [M01-RR0425] NR 18 TC 21 Z9 22 U1 0 U2 1 PU LIBRAPHARM PI NEWBURY PA C/O DR. PETER L CLARKE, 26-32 VENTURE WEST, NEW GREENHAM PARK, NEWBURY RG19 6HX, BERKSHIRE, ENGLAND SN 0300-7995 J9 CURR MED RES OPIN JI Curr. Med. Res. Opin. PD MAY PY 2004 VL 20 IS 5 BP 729 EP 738 DI 10.1185/030079904125003494 PG 10 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 822VR UT WOS:000221569100021 PM 15140340 ER PT J AU Brady, KT AF Brady, KT TI What treatment for which patient? SO CURRENT OPINION IN PSYCHIATRY LA English DT Editorial Material C1 Ralph H Johnson Vet Adm Med Ctr, CTN, MUSC, Dept Psychiat, Charleston, SC 29401 USA. RP Brady, KT (reprint author), Ralph H Johnson Vet Adm Med Ctr, CTN, MUSC, Dept Psychiat, 109 Bee St, Charleston, SC 29401 USA. EM bradyk@musc.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0951-7367 J9 CURR OPIN PSYCHIATR JI Curr. Opin. Psychiatr. PD MAY PY 2004 VL 17 IS 3 BP 159 EP 159 DI 10.1097/01.yco.0000126544.23545.c9 PG 1 WC Psychiatry SC Psychiatry GA 818GC UT WOS:000221232600001 ER PT J AU McNeely, MJ Boyko, EJ AF McNeely, MJ Boyko, EJ TI Type 2 diabetes prevalence in Asian subjects SO DIABETES CARE LA English DT Letter C1 Univ Washington, Div Gen Internal Med, Dept Med, Seattle, WA 98105 USA. Vet Affairs Puget Sound Hlth Care Syst, Vet Affairs Epidemiol Res & Informat Ctr, Seattle, WA USA. RP McNeely, MJ (reprint author), Univ Washington, Div Gen Internal Med, Dept Med, UW Box 354981, Seattle, WA 98105 USA. EM mcneely@u.washington.edu NR 2 TC 0 Z9 0 U1 0 U2 0 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD MAY PY 2004 VL 27 IS 5 BP 1252 EP 1252 DI 10.2337/diacare.27.5.1252 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 817DB UT WOS:000221157100064 ER PT J AU Maciejewski, ML Maynard, C AF Maciejewski, ML Maynard, C TI Diabetesm related utilization and costs for inpatient and outpatient services in the veterans administration SO DIABETES CARE LA English DT Article ID AFFAIRS; SYSTEM AB OBJECTIVE - The purpose of this study was to calculate the total number of inpatient hospitalizations, outpatient clinic visits, and total direct health care costs associated with veterans with diabetes receiving care in Veterans Administration (VA) facilities. RESEARCH DESIGN AND METHODS - The number of inpatient hospitalizations is tracked for years 1994-1998, and outpatient clime visits are tracked for years 1997 and 1998. Trends in utilization across different age and racial groups, as well as total direct inpatient and outpatient costs for 1998, are presented. RESULTS - Between 1.994 and 1998, hospitalization rates decreased from 1.68 to 1.61. The average number of outpatient visits was 4.5 in 1997 and 4.6 in 1998. VA incurred $214.8 million in outpatient expenditures and $1.45 billion in inpatient expenditures for veterans with diabetes receiving VA care. CONCLUSIONS - Health care delivery systems and payers track the cost and utilization of services by specific patient groups to Support disease management, quality improvement, external reporting, and cost containment. Tracking the utilization and cost of diabetes care is necessary to understand the financial impact of diabetes on health care systems and the overall burden of diabetes on individuals. C1 VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, Seattle, WA 98108 USA. Univ Washington, Dept Hlth Sci, Seattle, WA 98195 USA. RP Maciejewski, ML (reprint author), VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, 152,1660 S Columbian Way, Seattle, WA 98108 USA. EM mlmaciej@u.washington.edu RI Maynard, Charles/N-3906-2015 OI Maynard, Charles/0000-0002-1644-7814 NR 11 TC 37 Z9 39 U1 0 U2 0 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD MAY PY 2004 VL 27 SU 2 BP B69 EP B73 DI 10.2337/diacare.27.suppl_2.B69 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 819MU UT WOS:000221319800012 PM 15113786 ER PT J AU Mayfield, JA Reiber, GE Maynard, C Czerniecki, J Sangeorzan, B AF Mayfield, JA Reiber, GE Maynard, C Czerniecki, J Sangeorzan, B TI The epidemiology of lower extremity disease in veterans with diabetes SO DIABETES CARE LA English DT Article AB OBJECTIVE - To describe the epidemiology of lower-extremity complications of diabetes in veterans who are users of the Department of Veterans Affairs (VA). RESEARCH DESIGN AND METHODS - Hospital discharge records for care provided in all VA hospitals in 1998 were obtained. All hospitalizations for lower-extremity ulceration, peripheral vascular procedures, and amputation were analyzed using frequency tables. A diabetes denominator was defined as a veteran with at least three ambulatory care visits with at least one diabetes diagnosis code. Age-specific and total age-adiusted rates of discharge with ulceration, vascular procedures, and amputation were calculated. RESULTS - Veterans with diabetes comprised over half of all hospitalizations for lower-extremity ulceration, one-third of all hospitalizations for peripheral vascular procedures, and two-thirds of all hospitalizations for amputation. The age-specific discharge rate per 1,000 diabetic persons for age 0-64 years, 65-74 years, and 75 years and older for ulceration were 28.4, 31.0, and 37.9; for vascular procedures, the rates were 3.5, 4.4, and 4.41 and for amputation, the rates were 7.3, 9.0, and 1.0.0, respectively. CONCLUSIONS - Veterans With diabetes comprise a significant proportion of hospitalizations for lower-extremity ulceration, peripheral vascular bypass, and amputation. Age-specific rates of diabetic amputation in Veterans are lower than U.S. rates. C1 Vet Affairs Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA 98108 USA. Ctr Excellence Amputat Prosthet & Limb Loss Preve, Seattle, WA USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. Univ Washington, Dept Orthoped Surg, Seattle, WA 98195 USA. RP Reiber, GE (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, 152,1660 S Columbin Way, Seattle, WA 98108 USA. EM greiber@u.washington.edu RI Maynard, Charles/N-3906-2015 OI Maynard, Charles/0000-0002-1644-7814 NR 9 TC 18 Z9 18 U1 0 U2 4 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD MAY PY 2004 VL 27 SU 2 BP B39 EP B44 DI 10.2337/diacare.27.suppl_2.B39 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 819MU UT WOS:000221319800007 PM 15113781 ER PT J AU Maynard, C Chapko, MK AF Maynard, C Chapko, MK TI Data resources in the Department of Veterans Affairs SO DIABETES CARE LA English DT Article ID MEDICAL-CARE SYSTEM; HOSPITALS; FILES AB OBJECTIVE - To provide an overview of databases that are maintained by the Department of Veterans Affairs (VA) and are of relevance to investigators involved in epidemiologic, clinical, and health services research. RESEARCH DESIGN AND METHODS - We reviewed both national and local VA databases and identified their strengths and limitations. We also referenced specific studies that have assessed the validity and reliability of VA databases. RESULTS - There are numerous national databases housed at the Austin Automation Center in Austin, Texas. These include the Patient Treatment File (hospital abstracts), the Outpatient Care File, the Beneficiary Identification Record Locator System death file for assessing vital status, and the Decision Support System, which provides integrated clinical and financial information for managerial decision making. The major limitation of these databases is that clinical detail below the level of ICD-9-CM diagnosis and procedure codes is not uniformly available nationally. These databases offer an excellent opportunity to monitor the health of veterans over time because they track all inpatient and outpatient utilization in the VA. However, at the local or medical center level, the Veterans Health information and Systems and Technology Architecture contains extensive clinical information, but has fewer patients, varies in format across medical centers, and poses difficulties with data extraction for statistical analysis. CONCLUSIONS - Both local and national VA databases are valuable resources for investigators who have interests in a wide array of research topics, including diabetes. The potential for investigating important scientific questions with VA databases becomes greater as communications and database management technologies improve. C1 VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, Seattle, WA 98108 USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. RP Maynard, C (reprint author), VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, 152,1660 S Columbian Way, Seattle, WA 98108 USA. EM cmaynard@u.washington.edu RI Maynard, Charles/N-3906-2015 OI Maynard, Charles/0000-0002-1644-7814 NR 11 TC 68 Z9 69 U1 2 U2 4 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD MAY PY 2004 VL 27 SU 2 BP B22 EP B26 DI 10.2337/diacare.27.suppl_2.B22 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 819MU UT WOS:000221319800004 PM 15113778 ER PT J AU Orcutt, J Avakian, A Koepsell, TD Maynard, C AF Orcutt, J Avakian, A Koepsell, TD Maynard, C TI Eye disease in veterans with diabetes SO DIABETES CARE LA English DT Article ID RETINOPATHY; MELLITUS; CARE AB OBJECTIVE - To describe the screening, prevalence, and management of eye disease in veterans cared for by the Veterans Affairs (VA) System. RESEARCH DESIGN AND METHODS - Eye examinations, treatments, and diseases were identified in veterans with diabetes who received care in inpatient and outpatient VA settings during FY1998. Analysis was conducted to characterize the patient population and screened population and to compare them to the total VA patient population with diabetes. Logistic regression was performed to predict eye screening. RESULTS - Overall 48% of veterans with diabetes had an eye examination in FY1998. One-third of all veterans had an eye condition and 8.6% of veterans had ophthalmic manifestations of diabetes. In addition 11% reported glaucoma and 17.8% reported cataract surgery. Approximately 11,500 (2.7%) veterans were blind. CONCLUSIONS - Visual impairment is a common complication of diabetes. Half of this population of veterans had a visual examination recorded in VA. The VA is testing a more targeted screening and treatment approach for diabetic eye disease in order to prevent the serious eye complications. C1 VA Paget Sound Hlth Care Syst, Dept Opthalmol, Seattle, WA 98108 USA. Univ Washington, Dept Opthamol, Seattle, WA 98195 USA. Seattle ERIC, VA Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. RP Orcutt, J (reprint author), VA Paget Sound Hlth Care Syst, Dept Opthalmol, 1660 S Columbian Way, Seattle, WA 98108 USA. EM jorcutt@u.washington.edu RI Maynard, Charles/N-3906-2015 OI Maynard, Charles/0000-0002-1644-7814 NR 12 TC 7 Z9 7 U1 0 U2 1 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD MAY PY 2004 VL 27 SU 2 BP B50 EP B53 DI 10.2337/diacare.27.suppl_2.B50 PG 4 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 819MU UT WOS:000221319800009 PM 15113783 ER PT J AU Reiber, GE Boyko, EJ AF Reiber, GE Boyko, EJ TI Diabetes research in the department of veterans affairs SO DIABETES CARE LA English DT Article ID TRIAL AB OBJECTIVE - To provide an overview of the Department of Veterans Affairs (VA) research activities, highlighting diabetes-related research. RESEARCH DESIGN AND METHODS - Diabetes is an important component of the VA research portfolio. All four VA research services support aspects of diabetes research. VA diabetes research projects and funding were examined from 1998 to 2003. RESULTS - VA scientists are conducting research on diabetes genetics, etiology, diagnosis, therapy, epidemiology, health services, and rehabilitation. VA research funding is available to answer important veteran-relevant questions through peer review, Center of Excellence activities, and multisite trial mechanisms. Many VA scientists also receive research support from nonfederal sources, including private corporations and nonprofit foundations. The VA Office of Research and Development actively supports training the next generation of researchers through their career development awards and the VA health profession training programs. CONCLUSIONS - The VA's diabetes research portfolio is extensive and includes many investigators, trainees, and fellows. There is substantial leveraging of VA diabetes research with support from other federal and nonfederal funding agencies, foundations, and private corporations. VA diabetes research findings benefit the global diabetes care community. C1 VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA 98108 USA. HSR&D Ctr Excellence, Seattle, WA USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. RP Reiber, GE (reprint author), VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, 152,1660 S Columbian Way, Seattle, WA 98108 USA. EM greiber@u.washington.edu NR 4 TC 6 Z9 6 U1 0 U2 0 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD MAY PY 2004 VL 27 SU 2 BP B95 EP B98 DI 10.2337/diacare.27.suppl_2.B95 PG 4 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 819MU UT WOS:000221319800016 PM 15113790 ER PT J AU Reiber, GE Au, D McDonell, M Fihn, SD AF Reiber, GE Au, D McDonell, M Fihn, SD TI Diabetes quality improvement in department of veterans affairs - Ambulatory care clinics - A group-randomized clinical trial SO DIABETES CARE LA English DT Article ID MANAGEMENT; GUIDELINES; SYSTEM AB OBJECTIVE - To conduct a group-randomized clinical trial to determine whether regular feedback to primary care providers of synthesized information on patients' health, function, and satisfaction would demonstrate improved outcomes for their patients with diabetes. RESEARCH DESIGN AND METHODS - Patients in General Internal Medicine Clinics Department of Veterans Affairs (VA) Medical Centers were randomized into seven intervention or control firms. Patient self-reported information was collected by mail on general health, diabetes, and up to five other chronic conditions. Patients with diabetes received the Seattle Diabetes Questionnaire, the 36-item Medical Outcomes Study short form (SF-36), and a validated patient Satisfaction questionnaire at regular intervals. Data from self-report, clinical, Pharmacy, and laboratory sources were synthesized into patient-specific feedback reports that intervention providers received before patients visits. RESULTS - The timely delivery to primary care providers of state-of-the-art patient-feedback reports that identified patient issues and areas for improvement did not result in significant improvements in patient outcomes between the intervention and control firms. CONCLUSIONS - Outcomes in diabetic patients whose providers received synthesized patient data before visits were no better than in those receiving care from control firms. Future studies may benefit from substantial involvement in patients discussing, problem solving, and goal setting in addition to use of timely synthesized patient data. C1 VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Dept Vet Affairs, Seattle, WA 98108 USA. Puget Sound Hlth Care Syst, Dept Vet Affairs, Hlth Serv Res & Dev, Seattle, WA USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. RP Reiber, GE (reprint author), VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Dept Vet Affairs, Seattle, WA 98108 USA. EM greiber@u.washington.edu NR 18 TC 9 Z9 9 U1 0 U2 0 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD MAY PY 2004 VL 27 SU 2 BP B61 EP B68 DI 10.2337/diacare.27.suppl_2.B61 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 819MU UT WOS:000221319800011 PM 15113785 ER PT J AU Reiber, GE Koepsell, TD Maynard, C Haas, LB Boyko, EJ AF Reiber, GE Koepsell, TD Maynard, C Haas, LB Boyko, EJ TI Diabetes in nonveterans, veterans, and veterans receiving Department of Veterans Affairs health care SO DIABETES CARE LA English DT Article ID DISEASE AB \OBJECTIVE - To compare behavioral risk factors and health and disease characteristics among three groups of adults with diabetes: nonveterans, veterans not receiving Department of Veterans Affairs (VA) health care, and veterans using VA services. RESEARCH DESIGN AND METHODS - Two data sources were used to describe the veteran population. First, the 2000 Behavioral Risk Factor Surveillance System (BRFSS) characterized the U.S. adult population by preventive health practices and risk behaviors linked to chronic and preventable diseases. New to the 2000 survey were questions on veteran status, which were administered in all states. Second, VA administrative and veterans benefits data were analyzed to describe comorbidity, education services, and veterans benefits. RESULTS - The estimated prevalence of diabetes in male veterans receiving VA care was 16%. Male veterans with diabetes using VA care were more likely to be nonwhite, not employed, have lower income, lower health status, and more activity limitations than male veterans not using these services. Computerized records indicate VA users with diabetes also had high concurrent comorbidity. Frequency of VA diabetes and preventive care services, as measured by selected quality indicators, was equivalent to or higher than the levels reported by veterans not receiving VA care and nonveterans. in addition to health care, nearly one-fourth of veterans with diabetes also received monthly awards for compensation and pension. CONCLUSIONS - Males receiving VA care with self-reported diabetes indicated receiving preventive care services at equivalent or higher levels than their counterparts receiving care outside the VA and nonveterans. C1 VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA 98108 USA. Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. Veterans Affairs Sound Hlth Care Syst, Primary & Specialty Med Care Serv, Seattle, WA USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. RP Reiber, GE (reprint author), VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, 152,1660 S Columbian Way, Seattle, WA 98108 USA. EM greiber@u.washington.edu RI Maynard, Charles/N-3906-2015 OI Maynard, Charles/0000-0002-1644-7814 NR 21 TC 39 Z9 39 U1 0 U2 0 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD MAY PY 2004 VL 27 SU 2 BP B3 EP B9 DI 10.2337/diacare.27.suppl_2.B3 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 819MU UT WOS:000221319800002 PM 15113776 ER PT J AU Reiber, GE Boyko, EJ Maynard, C Koepsell, TD Pogach, LM AF Reiber, GE Boyko, EJ Maynard, C Koepsell, TD Pogach, LM TI Diabetes in the Department of Veterans Affairs SO DIABETES CARE LA English DT Article ID HEALTH-CARE-SYSTEM C1 VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA 98108 USA. Veterans Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. Vet Affairs Puget Sound Hlth Care Syst, Primary & Specialty Med Care Serv, Seattle, WA USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. VA New Jersey Hlth Care Syst, E Orange, NJ USA. Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA. RP Reiber, GE (reprint author), VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, 152,1660 S Columbian Way, Seattle, WA 98108 USA. EM greiber@u.washington.edu RI Maynard, Charles/N-3906-2015 OI Maynard, Charles/0000-0002-1644-7814 NR 6 TC 5 Z9 5 U1 0 U2 0 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD MAY PY 2004 VL 27 SU 2 BP B1 EP B2 DI 10.2337/diacare.27.suppl_2.B1 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 819MU UT WOS:000221319800001 PM 15113775 ER PT J AU Smith, NL Maynard, C AF Smith, NL Maynard, C TI The burden of diabetes-associated cardiovascular hospitalizations in veterans administration (VA) and non-VA medical facilities SO DIABETES CARE LA English DT Article ID CORONARY-HEART-DISEASE; IMPAIRED FASTING GLUCOSE; MICROVASCULAR COMPLICATIONS; MYOCARDIAL-INFARCTION; CHOLESTEROL LEVELS; INSULIN; EVENTS; RISK; PRAVASTATIN AB OBJECTIVE - This study examines the relative burden of cardiovascular disease in diabetic and nondiabetic admissions to Veterans Administration (VA) and non-VA hospitals. RESEARCH DESIGN AND METHODS - Calendar year 1997 hospitalization data were collected from the VA Patient Treatment File and the National Hospital Discharge Survey, National Center for Health Statistics. Discharge diagnoses based on ICD-9 codes were used to classify cardiovascular events and procedures and diabetes. Proportionate hospitalization ratios (PHRs) were calculated based on the number of cardiovascular hospitalizations from among all hospitalizations. RESULTS - We identified 119,653 VA hospitalizations (19.1%) and 3,765,696 non-VA hospitalizations (16.8%) that coded diabetes among the discharge diagnoses. Cardiovascular hospitalizations, primarily coronary in origin, accounted for nearly 50% of all hospitalizations of persons with diabetes within VA and non-VA medical care systems. Coronary events and procedures (PHR = 1.85 and 1.68) and, to a lesser extent, cerebrovascular events and procedures (PHR = 1.55 and 1.33) were more common in VA hospitalizations where diabetes was listed as a comorbidity than in VA hospitalizations where diabetes was not listed. The burden of coronary hospitalizations was larger in VA than non-VA facilities for men (PHR = 1.82 vs. 1.66) and smaller in VA than non-VA facilities for women (PHR = 3.11 vs. 3.44) in age and race-standardized analyses. The burden of coronary hospitalization was higher for whites and blacks in VA facilities (PHR = 1.83 and 2.01) when compared with non-VA facilities (PHR = 1.68 and 1.84). CONCLUSIONS - The burden of cardiovascular hospitalizations is not equally borne across hospitalizations with and without diabetes and across VA and non-VA facilities. C1 VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle Div, Seattle, WA 98108 USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. Univ Washington, Dept Hlth Serv, Seattle, WA USA. RP Smith, NL (reprint author), VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle Div, 1660 S Columbian Way,Mailstop 152E, Seattle, WA 98108 USA. EM nlsmith@u.washington.edu RI Maynard, Charles/N-3906-2015 OI Maynard, Charles/0000-0002-1644-7814 NR 16 TC 10 Z9 10 U1 1 U2 1 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD MAY PY 2004 VL 27 SU 2 BP B27 EP B32 DI 10.2337/diacare.27.suppl_2.B27 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 819MU UT WOS:000221319800005 PM 15113779 ER PT J AU Smith, NL Chen, L Au, DH McDonell, M Fihn, SD AF Smith, NL Chen, L Au, DH McDonell, M Fihn, SD TI Cardiovascular risk factor control among veterans with diabetes - The ambulatory care quality improvement project SO DIABETES CARE LA English DT Article ID BLOOD-PRESSURE; PROGRAM; DISEASE AB OBJECTIVE - To describe the extent to which hyperglycemia, hypertension, and dyslipidemia are currently detected, treated, and controlled in U.S. veterans with diabetes with and Without ischemic heart disease (IHD). RESEARCH DESIGN AND METHODS - A cohort of 3,769 veterans who self-reported diabetes and who received all health care from the Veterans Administration (VA) medical centers were selected from subjects enrolled in the Ambulatory Care Quality Improvement Project, a randomized health services intervention at seven VA primary care clinics. IHD was defined by a self-reported history of myocardial ischemia, infarction, or revascularization. Mean values of HbA(1c), blood pressure, and cholesterol subfractions were collected from computerized laboratory databases. Medication data were collected from computerized pharmacy databases. RESULTS - Mean HbA(1c) and optimal control (HbA(1c) <7%) did not differ for those without and with IHD: 8.1 vs. 8.0%, and 26 vs. 24%, respectively. Veterans with IHD were more likely to have hypertension (73 vs. 64%), to be treated (88 vs. 78%), and to have optimal blood pressure control (19 vs. 10%) compared with veterans without IHD (all P values <0.01). Veterans with IHD were more likely to have dyslipidemia (81 vs. 53%), were equally likely to be treated (54 vs. 50%), and were more likely to have optimal LDL levels (30 vs. 16%) compared with veterans without IHD, all P values <0.01. CONCLUSIONS - Optimal cardiovascular risk factor control was the exception in this cohort of diabetic veterans attending primary care clinics. More aggressive management of cardiovascular risk factors in veterans with diabetes may be warranted, especially among those without prevalent (IHD). C1 VA Puget Sound Hlth Care System, Seattle Epidemiol Res & Informat Ctr, Seattle Div, Seattle, WA 98108 USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. Univ Rochester, Ctr Med, Cardiol Unit, Rochester, NY USA. VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. RP Smith, NL (reprint author), VA Puget Sound Hlth Care System, Seattle Epidemiol Res & Informat Ctr, Seattle Div, 1660 S Columbian Way,Mailstop 152E, Seattle, WA 98108 USA. EM nlsmith@u.washington.edu NR 14 TC 7 Z9 7 U1 0 U2 0 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD MAY PY 2004 VL 27 SU 2 BP B33 EP B38 DI 10.2337/diacare.27.suppl_2.B33 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 819MU UT WOS:000221319800006 PM 15113780 ER PT J AU Young, BA Pugh, JA Maynard, C Reiber, G AF Young, BA Pugh, JA Maynard, C Reiber, G TI Diabetes and renal disease in veterans SO DIABETES CARE LA English DT Article ID PIMA-INDIANS; GROSS PROTEINURIA; MELLITUS; MICROALBUMINURIA; NEPHROPATHY; MORTALITY; DETERMINANTS; PREVALENCE; SURVIVAL; NIDDM AB OBJECTIVE - To describe the frequency and sequelae of diabetic renal disease in veterans who receive health care from the Veterans Administration (VA). RESEARCH DESIGN AND METHODS - Veterans With a diagnosis of diabetes, diabetic nephropathy, other kidney diseases, and end-stage renal disease (ESRD) were identified by diagnosis codes from national VA databases for FY1998. Data were obtained and analyzed for prevalence of renal disease, comorbid conditions, and 1-year mortality. RESULTS - A total of 44,671 (10.7%) of the 415,910 veterans with diabetes had a concomitant diagnosis of any renal disease. The average age was 67 years; 98% were male and 60% were white. The prevalence of diabetic nephropathy was 6.0% (n = 25,263). ESPD secondary to diabetes was present in 4.2% (17,636) of subjects. The age-standardized prevalence of diabetes and any renal disease was 72.6/1,000 persons and differed by race (white 76.1/1,000, black 103.4/1,000 persons). Diabetes-associated ESRD prevalence was higher among black versus white veterans and male versus female veterans. One-year age-standardized mortality was 10.7%. CONCLUSIONS - Nephropathy is prevalent in veterans with diabetes. Greater mortality is observed among those with renal disease compared with those without renal disease. Additional surveillance is needed to identify persons likely to progress to diabetic nephropathy and to plan for appropriate and timely health care for these individuals. C1 VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Dept Vet Affairs, Seattle, WA 98108 USA. Puget Sound Hlth Care Syst, Dept Vet Affairs, Hlth Serv Rs & Dev, Seattle, WA USA. Puget Sound Hlth Care Syst, Dept Vet Affairs, Dept Med, Div Gen Med, Seattle, WA USA. NW Kidney Ctr, Seattle, WA USA. Dept Vet Affairs, VERDICT Hlth Serv Res & Dev Ctr Excellence, S Texas Vet Hlth Ctr, San Antonio, TX USA. Univ Texas, Ctr Hlth Sci, Dept Med, Div Gen Internal Med, San Antonio, TX 78285 USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. RP Young, BA (reprint author), VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Dept Vet Affairs, 152E,1660 S Columbian Way, Seattle, WA 98108 USA. EM youngb@u.washmgton.edu RI Maynard, Charles/N-3906-2015 OI Maynard, Charles/0000-0002-1644-7814 NR 32 TC 19 Z9 19 U1 0 U2 1 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD MAY PY 2004 VL 27 SU 2 BP B45 EP B49 DI 10.2337/diacare.27.suppl_2.B45 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 819MU UT WOS:000221319800008 PM 15113782 ER PT J AU Lipsky, BA AF Lipsky, BA TI A report from the international consensus on diagnosing and treating the infected diabetic foot SO DIABETES-METABOLISM RESEARCH AND REVIEWS LA English DT Article; Proceedings Paper CT 4th International Symposium on the Diabetic Foot CY MAY 22-24, 2003 CL Noordwijkerhout, NETHERLANDS DE diabetic foot infections; osteomyelitis; antibiotic therapy; wound cultures; guidelines; foot complications ID COLONY-STIMULATING FACTOR; RESISTANT STAPHYLOCOCCUS-AUREUS; CONTROLLED TRIAL; ANTIBIOTIC-THERAPY; LIMB; OSTEOMYELITIS; MELLITUS; PENETRATION; MANAGEMENT; AMPICILLIN/SULBACTAM AB in persons with diabetes, foot infection, that is, invasion and multiplication of microorganisms in tissues accompanied by tissue destruction or a host usually begins with skin trauma or ulceration inflammatory response, [1]. While most foot infections remain superficial, they can spread to subcutaneous tissues, including muscle, joints, and bone. Many diabetic foot ulcers eventuate in an amputation; infection plays a role in approximately 60% of cases [2-4]. Neuropathy is the main factor leading to skin breaks, while arterial perfusion largely affects infection outcome. Among the factors predisposing diabetic patients to foot infections are ill-defined immunological perturbations [5,6]; foot anatomy may foster proximal spread of infection and ischemic necrosis [7,8]. Published in 2004 by John Wiley Sons, Ltd. RP Lipsky, BA (reprint author), VA Puget Sound HCS, S-111 GIMC,1660 S Columbian Way, Seattle, WA 98108 USA. EM Benjamin.Lipsky@med.va.gov OI Lipsky, Benjamin A./0000-0001-9886-5114 NR 64 TC 121 Z9 124 U1 1 U2 5 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 1520-7552 J9 DIABETES-METAB RES JI Diabetes-Metab. Res. Rev. PD MAY-JUN PY 2004 VL 20 SU 1 BP S68 EP S77 DI 10.1002/dmrr.453 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 826GD UT WOS:000221816400016 PM 15150818 ER PT J AU Deng, XY Wood, PG Eagon, PK Whitcomb, DC AF Deng, XY Wood, PG Eagon, PK Whitcomb, DC TI Chronic alcohol-induced alterations in the pancreatic secretory control mechanisms SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE pancreatic secretion; chronic alcoholics; CCK; 2-DG; meal; rat ID CERULEIN-INDUCED PANCREATITIS; CHRONIC ETHANOL-CONSUMPTION; ACINAR CELL-FUNCTION; EXOCRINE SECRETION; PROTEIN-SYNTHESIS; ENZYME-SECRETION; HEAVY DRINKERS; AREA POSTREMA; ANIMAL-MODELS; RAT PANCREAS AB Chronic alcohol ingestion appears to increase susceptibility of the pancreas to pancreatitis through multiple mechanisms. The aim of the current study was to determine the effect of chronic low- and high-dose alcohol consumption on the neurohormonal control of the exocrine pancreas in rats. Male Wistar rats were fed Lieber DeCarli liquid control-, low-, and high-dose alcohol diets for 3 months. Pancreatic exocrine secretion was measured under basal and 2-deoxy-D-glucose (2-DG)-, CCK-, bethanechol-, or meal-stimulated conditions while on chronic alcohol diets and after 2-DG or CCK stimulation during alcohol withdrawal in awake rats. Chronic alcohol ingestion was associated with a dose-related inhibition of basal pancreatic protein secretion, which was reversed upon alcohol withdrawal. Low-dose alcohol feeding had no effect on bethanechol- stimulated pancreatic secretion but altered 2-DG-stimulated pancreatic secretion. In chronic high-dose alcohol rats, meal- and bethanechol- stimulated protein secretion was significantly potentiated during early and late phases. The response to CCK appeared to be disinhibited, whereas the response to 2-DG was uniformly blunted. Upon withdrawal of low- dose alcohol, the response to 2-DG was potentiated, whereas with the withdrawal of high-dose alcohol, the response to CCK was potentiated. Adaptation to chronic alcohol consumption differs depending on the alcohol dose. The most significant effects were seen after high-dose alcohol withdrawal, with apparent loss of central inhibitory regulation combined with exaggerated response at the acinar cell level. This combination of factors could increase susceptibility to acute alcoholic pancreatitis through a hyperstimulation mechanism. C1 Univ Pittsburgh, Dept Med, Div Gastroenterol Hepatol & Nutrit, Pittsburgh, PA 15261 USA. Univ Pittsburgh, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA. Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA. VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. RP Whitcomb, DC (reprint author), Univ Pittsburgh, Dept Med, Div Gastroenterol Hepatol & Nutrit, Room 571,Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA. EM whitcomb@pitt.edu FU NIAAA NIH HHS [R01-AA10855]; NIDDK NIH HHS [R01 DK 50236, R29 DK45781] NR 57 TC 22 Z9 23 U1 0 U2 1 PU KLUWER ACADEMIC/PLENUM PUBL PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD MAY PY 2004 VL 49 IS 5 BP 805 EP 819 DI 10.1023/B:DDAS.0000030093.25897.61 PG 15 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 826RU UT WOS:000221847000017 PM 15259503 ER PT J AU Zaccagni, H Fried, J Cornell, J Padilla, P Brey, RL AF Zaccagni, H Fried, J Cornell, J Padilla, P Brey, RL TI Soluble adhesion molecule levels, neuropsychiatric lupus and lupus-related damage SO FRONTIERS IN BIOSCIENCE LA English DT Article DE systemic lupus erythematosus; adhesion molecules; neuropsychiatric disease ID CENTRAL-NERVOUS-SYSTEM; ENDOTHELIAL-CELL ADHESION; DISEASE-ACTIVITY; E-SELECTIN; ANTIPHOSPHOLIPID ANTIBODIES; CEREBROSPINAL-FLUID; MULTIPLE-SCLEROSIS; UP-REGULATION; IN-VITRO; ERYTHEMATOSUS AB Nervous system dysfunction may occur in as many as 80% of patients with Systemic Lupus Erythematous (SLE) at some point in their disease course. Upregulation of adhesion molecules has been linked to acute SLE-related disease activity and chronic damage. We evaluated the relationship between soluble adhesion molecule levels and neuropsychiatric lupus (NPSLE) manifestations using the American College of Rheumatology (ACR) case definitions to investigate for evidence of a link between upregulation of adhesion molecules and NPSLE manifestations. Sera from the initial study visit of 133 SLE patients enrolled in the San Antonio Lupus Study of Neuropsychiatric Disease (SALUD) and 40 controls were evaluated for soluble adhesion molecule levels (VCAM-1, ICAM-1 and E-selectin) and antiphospholipid antibodies. A subset of 57 SLE patients were evaluated for soluble adhesion molecule levels and antiphospholipid antibodies on two subsequent study visits, as well. NPSLE manifestations at the time of sera ascertainment were recorded using ACR case definitions and SLE-related acute activity and damage were measured. Elevated levels of all three soluble adhesion molecules were seen in SLE patients compared to normal control values. Soluble VCAM-1 levels correlated with measures of current disease activity, NPSLE manifestations and deep venous thrombosis. Persistently positive levels of ICAM-1 and VCAM-1, but not E-selectin were association with increased SLE-related damage. Elevated levels of all soluble adhesion molecule levels correlated with abnormal levels of antiphospholipid antibodies, which are associated with some NPSLE manifestations and have been shown to upregulate adhesion molecule expression. C1 S Texas Vet Hlth Care Syst, Audie L Murphy Div, Div Neurol,Dept Med, VERDICT Ctr Excellence, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, Dept Med, Div Geriatr & Gerontol, San Antonio, TX 78284 USA. RP Brey, RL (reprint author), Dept Med, Div Neurol 7883, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM brey@uthscsa.edu FU NCRR NIH HHS [M01RR 01346-19]; NINDS NIH HHS [R01 NS35477] NR 41 TC 21 Z9 25 U1 0 U2 1 PU FRONTIERS IN BIOSCIENCE INC PI MANHASSET PA C/O NORTH SHORE UNIV HOSPITAL, BIOMEDICAL RESEARCH CENTER, 350 COMMUNITY DR, MANHASSET, NY 11030 USA SN 1093-9946 J9 FRONT BIOSCI JI Front. Biosci. PD MAY PY 2004 VL 9 BP 1654 EP 1659 DI 10.2741/1273 PG 6 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 779ZA UT WOS:000189333700052 PM 14977576 ER PT J AU Freeman, JW DeArmond, D Lake, M Huang, WQ Venkatasubbarao, K Zhao, SJ AF Freeman, JW DeArmond, D Lake, M Huang, WQ Venkatasubbarao, K Zhao, SJ TI Alterations of cell signaling pathways in pancreatic cancer SO FRONTIERS IN BIOSCIENCE LA English DT Article DE pancreatic cancer; cell signaling; growth factors; growth factor receptors; TGF beta; review ID GROWTH-FACTOR-BETA; LINE MIA PACA-2; II RECEPTOR EXPRESSION; TUMOR-SUPPRESSOR GENE; MYC DOWN-REGULATION; TGF-BETA; BREAST-CANCER; C-MYC; CYCLIN D1; FACTOR INDEPENDENCE AB Pancreatic ductal adenocarcinomas continue to have the worst prognosis of any adult malignancy with a five-year survival rate of less than 4%. One approach to improve patient survival from pancreatic cancer is to identify new biological targets that contribute to the aggressive pathogenecity of this disease and to develop reagents that will interfere with the function of these targets. Apart from the identification of the genetic profile of pancreatic cancer, a number of studies have focused on aberrant cell signaling pathways and their role in pancreatic cancer biology and response to therapy. This review, although not comprehensive, will discuss the salient features of several of these pathways. These include the roles of TGFbeta signaling in both tumor suppression and tumor promotion and the effects of deregulation of phosphotyrosine kinase receptor signaling pathways in pancreatic cancer. C1 Univ Texas, Hlth Sci Ctr, Div Med Oncol, Dept Med, San Antonio, TX 78229 USA. Audie L Murphy Mem Vet Adm Med Ctr, Res & Dev, San Antonio, TX 78229 USA. RP Freeman, JW (reprint author), Univ Texas, Hlth Sci Ctr, Div Med Oncol, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM freemanjw@uthscsa.edu RI Huang, Weiqi/E-4341-2010 FU NCI NIH HHS [CA96122] NR 87 TC 12 Z9 14 U1 3 U2 3 PU FRONTIERS IN BIOSCIENCE INC PI MANHASSET PA C/O NORTH SHORE UNIV HOSPITAL, BIOMEDICAL RESEARCH CENTER, 350 COMMUNITY DR, MANHASSET, NY 11030 USA SN 1093-9946 J9 FRONT BIOSCI JI Front. Biosci. PD MAY PY 2004 VL 9 BP 1889 EP 1898 DI 10.2741/1388 PG 10 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 779ZA UT WOS:000189333700071 PM 14977595 ER PT J AU Ioannou, GN Dominitz, JA Weiss, NS Heagerty, PJ Kowdley, KV AF Ioannou, GN Dominitz, JA Weiss, NS Heagerty, PJ Kowdley, KV TI The effect of alcohol consumption on the prevalence of iron overload, iron deficiency, and iron deficiency anemia SO GASTROENTEROLOGY LA English DT Article ID SERUM FERRITIN; UNITED-STATES; HEREDITARY HEMOCHROMATOSIS; LIVER DISEASE; ABSORPTION; CIRRHOSIS; MEN; STORES; POPULATION; DIAGNOSIS AB Background & Aims: Our aim was to investigate the relationship between alcohol consumption and iron overload, iron deficiency, or iron deficiency anemia in the U.S. population. Methods: Adult participants of the Third National Health and Nutrition Examination Survey who did not consume alcohol (n = 8839) were compared with participants who consumed less than or equal to1 (n = 4976), >1 to less than or equal to2 (n = 1153), or >2 (n = 915) alcoholic drinks/day during the preceding 12 months. We examined the following markers of iron overload: elevated serum transferrin-iron saturation (TS) level (>45%, >50%, and >60%), elevated serum ferritin level (>300, >400, >500, and >600 ng/mL), and combinations of both elevated serum TS and ferritin levels. Iron deficiency was defined as the presence of at least 2 of the following: serum ferritin level <12 ng/mL, serum TS level <15%, and erythrocyte protoporphyrin level >1.24 mumol/L. Iron deficiency anemia was defined as the presence of both iron deficiency and anemia. Results: Compared with nondrinkers, the prevalence of all markers of iron overload was significantly elevated among those who consumed >2 alcoholic drinks/day after adjusting for potential confounders. Consumption of any amount of alcohol was associated with a 40% reduction in the risk of iron deficiency anemia. Conclusions: Consumption of up to 2 alcoholic drinks/day seems to be associated with reduced risk of iron deficiency and iron deficiency anemia without a concomitant increase in the risk of iron overload. Consumption of >2 alcoholic drinks/day is associated with a significant elevation in the risk of iron overload. C1 Univ Washington, Med Ctr, Dept Med, Seattle, WA 98195 USA. Univ Washington, Med Ctr, Div Gastroenterol, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. Univ Washington, Dept Biostat, Seattle, WA 98195 USA. RP Ioannou, GN (reprint author), Vet Adm Med Ctr, S-111 Gastro,1660 S Columbian Way, Seattle, WA 98108 USA. EM georgei@medicine.washington.edu OI Dominitz, Jason/0000-0002-8070-7086 FU NIDDK NIH HHS [K24 DK 02957] NR 52 TC 73 Z9 79 U1 0 U2 5 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD MAY PY 2004 VL 126 IS 5 BP 1293 EP 1301 DI 10.1053/j.gastro.2004.01.020 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 818AD UT WOS:000221217100011 PM 15131790 ER PT J AU Nath, SK Namjou, B Garriott, CP Frank, S Joslin, PA Kilpatrick, J Kelly, JA Harley, JB AF Nath, SK Namjou, B Garriott, CP Frank, S Joslin, PA Kilpatrick, J Kelly, JA Harley, JB TI Linkage analysis of SLE susceptibility: confirmation of SLER1 at 5p15.3 SO GENES AND IMMUNITY LA English DT Article DE systemic lupus erythematosus; rheumatoid arthritis; linkage; genome scan ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; SIB-PAIR FAMILIES; RHEUMATOID-ARTHRITIS; AUTOIMMUNE-DISEASES; TELOMERASE ACTIVITY; REVISED CRITERIA; GENOME SCAN; COMPLEX; GENES; GENETICS AB We detected a novel susceptibility gene, SLER1, for systemic lupus erythematosus (SLE) at 5p15.3.(1) This finding was based on a selected subgroup of SLE families, where two or more family members have had alleged rheumatoid arthritis (SLE-RA). The main objective of this study was to replicate the linkage at 5p15.3 based on an independent data set of 88 SLE-RA families. Heterogeneity in the genetic model led us to use a nonparametric allele-sharing method. Since our a priori hypothesis of linkage at 5p15.3 was fixed, we genotyped six markers at the linked region. Our new results replicate the initial linkage at 5p15.3 (Zlr = 2.58, P<0.005, LOD = 1.45). Moreover, evidence of linkage was sustained when analysis was restricted to the subset of SLE families who had 3 or more individuals with alleged RA ( Zlr = 3.32, P = 0.008, LOD = 2.40) The results of our previous findings, together with these new results, confirm the SLER1 linkage at 5p15.3. Our results also demonstrate the utility of clinically defined subgroup analysis for detecting susceptibility loci for complex genetic diseases, such as SLE. C1 Oklahoma Med Res Fdn, Genet Epidemiol Unit, Oklahoma City, OK 73104 USA. Arthrit & Immunol Res Program, Oklahoma City, OK USA. Cardiol Clin Muskogee, Muskogee, OK USA. Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA. US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. RP Nath, SK (reprint author), Oklahoma Med Res Fdn, Genet Epidemiol Unit, 825 NE 13th St, Oklahoma City, OK 73104 USA. EM swapan-nath@omrf.ouhsc.edu OI Frank, Summer/0000-0003-0779-4926 FU NIAID NIH HHS [AI24717, AI31584]; NIAMS NIH HHS [AR048928, AR048940, AR049084, AR12253, AR15577, AR42460] NR 32 TC 10 Z9 10 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1466-4879 J9 GENES IMMUN JI Genes Immun. PD MAY PY 2004 VL 5 IS 3 BP 209 EP 214 DI 10.1038/sj.gene.6364060 PG 6 WC Genetics & Heredity; Immunology SC Genetics & Heredity; Immunology GA 814CC UT WOS:000220951800009 PM 15014430 ER PT J AU Schwartz, SR McDowell, J Yueh, B AF Schwartz, SR McDowell, J Yueh, B TI Numeracy and the shortcomings of utility assessment in head and neck cancer patients SO HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK LA English DT Article; Proceedings Paper CT Meeting of the Western-Section of the Triological-Society CY FEB 01, 2003 CL Indian Wells, CA SP Triolog Soc, W Sect DE utility; numeracy; head and neck cancer; quality of life; function ID QUALITY-OF-LIFE; HEALTH LITERACY; PERFORMANCE; VALIDITY; SCALE AB Background. Because survival differences between surgical and nonsurgical treatment for head and neck cancer (HNC) are hard to detect, increasing focus has been placed on quality of life (QOL) differences after treatment. Utility assessment provides insight into COL. Evidence suggests that a patient's comfort with numerical concepts ("numeracy") may influence utility measures. We hypothesize that patients who are nonnumerate provide inconsistent utility data in COIL studies. Methods. New HNC (n = 18) patients were recruited to participate. Patients completed a numeracy questionnaire, a utility assessment, and a global COIL questionnaire. Higher scores reflect better function. Interviewers rated the functional level of each patient. For both numerate and nonnumerate patients, utility scores were compared with global QOL (good vs poor) and observer-rated function. Results. Half of the patients were numerate. Numerate patients who rated their COIL as good had significantly higher utility scores than did patients with poor global COIL (0.95 vs 0.43, p =.03). In contrast, nonnumerate patients with good COIL had lower utility scores than did patients with poor COIL (0.45 vs 0.77 NS). Utility scores for numerate patients correlated well with observer-rated function (r= 0.41 to r= 0.57), whereas those of nonnumerate patients did not (r = -0.16 to r = 0.06). Conclusions. QOL evaluation through utility assessment may provide inaccurate and contradictory data about patient functioning for nonnumerate patients. This may confound COIL assessment when interpreting utility data. (C) 2004 Wiley Periodicals, Inc.* C1 Univ Washington, Med Ctr, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Serv, Seattle, WA USA. Univ Washington, Dept Hlth Serv, Sch Publ Hlth & Community Med, Seattle, WA 98195 USA. RP Schwartz, SR (reprint author), Univ Washington, Med Ctr, Dept Otolaryngol Head & Neck Surg, 1959 NE Pacific St,Box 356515, Seattle, WA 98195 USA. EM schwarsr@u.washington.edu OI Yueh, Bevan/0000-0003-1380-1053 NR 17 TC 24 Z9 24 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1043-3074 J9 HEAD NECK-J SCI SPEC JI Head Neck-J. Sci. Spec. Head Neck PD MAY PY 2004 VL 26 IS 5 BP 401 EP 407 DI 10.1002/hed.10383 PG 7 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 818HQ UT WOS:000221236600003 PM 15122656 ER PT J AU Polgreen, P Flutz, SL Justice, AC Wagner, JH Diekema, DJ Rabeneck, L Weissman, S Stapleton, JT AF Polgreen, P Flutz, SL Justice, AC Wagner, JH Diekema, DJ Rabeneck, L Weissman, S Stapleton, JT TI Association of hypocholesterolaemia with hepatitis C virus infection in HIV-infected people SO HIV MEDICINE LA English DT Article; Proceedings Paper CT 14th International AIDS Conference CY JUL 07-12, 2002 CL BARCELONA, SPAIN DE cholesterol; HCV; hepatitis C; HIV; lipids ID HUMAN-IMMUNODEFICIENCY-VIRUS; DENSITY-LIPOPROTEIN RECEPTOR; CLINICAL-TRIALS GROUP; ANTIRETROVIRAL THERAPY; SERUM-CHOLESTEROL; VERY-LOW; PARTICLES; LIPIDS; PREVALENCE; CIRRHOSIS AB Objective To study the impact of hepatitis C virus (HCV) status on serum cholesterol levels in HIV-infected patients. Methods We retrospectively analysed data front the 881 participants of the Veterans Ageing Cohort 3 Site Study. Four different models were constructed using total cholesterol, low-density lipid (LDL) cholesterol, high-density lipid (HDL) cholesterol and triglycerides as dependent variables. The relevant covariates included HCV antibody status, HIV medication class, CD4 count, HIV viral load, glucose level, lipid-lowering drug use, gender, race, age, liver function test results, ethanol use, drug use, and HIV exposure category. Variables excluded from the final model included niacin use, gender, race, age, current ethanol use, and HIV exposure category. Results Of the 881 HIV-positive patients enrolled in the study, 700 (79%) were screened for HCV antibody, with 300 (42.8%) HCV antibody positive and 400 (57.2%) HCV antibody negative. A positive HCV antibody status was independently associated with lower total cholesterol levels (P = 0.001) and LDL cholesterol levels (P< 0.00 1) but not with lower HDL cholesterol or triglyceride levels. HCV-positive patients had predicted LDL levels 19 mg/dL lower than those of HCV-negative subjects. HCV infection was also associated with a decreased use of lipid-lowering medication, and protease inhibitor use was associated with increased LDL and total cholesterol levels. Conclusions HCV infection has been associated with lower cholesterol levels in HIV-negative individuals, and the same appears to be true with HIV-infected patients. This is an interesting finding given that HCV particles bind to LDL receptors in vitro and also because HCV-lipid interactions appear to be important in the HCV replication cycle. C1 Iowa City Vet Adm, Med Ctr, Iowa City, IA USA. Univ Iowa, Iowa City, IA 52242 USA. Univ Pittsburgh, Ctr Hlth Equ Res & Promot, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA 15260 USA. Houston VAMC, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. Hosp St Raphael, New Haven, CT USA. RP Stapleton, JT (reprint author), UIHC, Dept Internal Med, SW34-P,GH,200 Hawkins Dr, Iowa City, IA 52242 USA. EM jack-stapleton@uiowa.edu OI Diekema, Daniel/0000-0003-1273-0724 FU NIA NIH HHS [K23 AG 00826]; NIAAA NIH HHS [AA 12671, AA 13566] NR 31 TC 35 Z9 36 U1 0 U2 0 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 1464-2662 J9 HIV MED JI HIV Med. PD MAY PY 2004 VL 5 IS 3 BP 144 EP 150 DI 10.1111/j.1468-1293.2004.00202.x PG 7 WC Infectious Diseases SC Infectious Diseases GA 822KZ UT WOS:000221539600004 PM 15139979 ER PT J AU Siffledeen, JS Fedorak, RN Siminoski, K Jen, H Vaudan, E Abraham, N Seinhart, H Greenberg, G AF Siffledeen, JS Fedorak, RN Siminoski, K Jen, H Vaudan, E Abraham, N Seinhart, H Greenberg, G TI Bones and Crohn's - Risk factors associated with low bone mineral density in patients with Crohn's disease SO INFLAMMATORY BOWEL DISEASES LA English DT Article DE bone mineral density; Crohn's disease; inflammatory bowel disease; osteopenia; osteoporosis ID INFLAMMATORY-BOWEL-DISEASE; POPULATION-BASED COHORT; ULCERATIVE-COLITIS; FRACTURE RISK; HIP FRACTURE; I COLLAGEN; OSTEOPOROSIS; METABOLISM; DIAGNOSIS; WOMEN AB Previous studies have confirmed that the prevalence of decreased bone mineral density is elevated in patients with inflammatory bowel disease. The objective of the current study was to determine the prevalence of osteopenia and osteoporosis in a cross-sectional outpatient population of 242 adult patients with Crohn's disease and to determine which clinical characteristics and serum and urine biochemical factors might be predictive of bone loss. Thirty-seven percent had normal bone density, 50.0% were osteopenic, and 12.9% were osteoporotic. Among the sites used to diagnose low bone mineral density, the femoral neck demonstrated the highest prevalence of osteopenia and the ultra-distal radius the highest prevalence of osteoporosis. However, low bone mineral density at one site was always predictive of low bone mineral density at the other. Corticosteroid use during the year before assessment was found to be consistently predictive of low bone mineral density in males but not in females. In contrast, low body mass index and high platelet counts were consistently predictive of low bone mineral density in females but not in males. Disease location, smoking, and age were not predictive of changes in bone mineral density. C1 Univ Alberta, Div Gastroenterol, Edmonton, AB T6G 2C1, Canada. Univ Alberta, Div Endocrinol, Edmonton, AB T6G 2C1, Canada. Univ Toronto, Div Gastroenterol, Toronto, ON, Canada. Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. RP Fedorak, RN (reprint author), Univ Alberta, Div Gastroenterol, Edmonton, AB T6G 2C1, Canada. EM Richard.fedorak@ualberta.ca RI Greenberg, Gordon/C-4620-2015 OI Fedorak, Richard/0000-0002-7382-0080 NR 49 TC 58 Z9 59 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1078-0998 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD MAY PY 2004 VL 10 IS 3 BP 220 EP 228 DI 10.1097/00054725-200405000-00007 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 817NM UT WOS:000221184200007 PM 15290915 ER PT J AU Lewinsohn, DA Gennaro, ML Scholvinck, L Lewinsohn, DM AF Lewinsohn, DA Gennaro, ML Scholvinck, L Lewinsohn, DM TI Tuberculosis immunology in children: diagnostic and therapeutic challenges and opportunities SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Review DE tuberculosis; child; infant; immunity; cellular; dendritic cells ID T-CELL RESPONSES; GROWTH-FACTOR-BETA; ACTIVE PULMONARY TUBERCULOSIS; NECROSIS-FACTOR-ALPHA; HUMAN DENDRITIC CELLS; RESPIRATORY SYNCYTIAL VIRUS; CALMETTE-GUERIN VACCINATION; ACELLULAR PERTUSSIS-VACCINE; INTERFERON-GAMMA PRODUCTION; HEALTHY HOUSEHOLD CONTACTS AB Tuberculosis (TB) is one of the most important causes of infectious morbidity and mortality worldwide. Young children are more likely to develop severe disease from the causative agent Mycobacterium tuberculosis. These clinical observations likely reflect fundamental differences in the immune systems of young children and adults. Essential to effective TB immunity are functioning macrophages, dendritic cells, strong Th1-type T-cell immunity and a relative absence of Th2-type T-cell immunity. Critical differences between adults and children relevant to TB immunity include deficiencies in macrophage and dendritic cell function, deficiencies in the development of Th1-type T-cells in response to pathogens, and the propensity for infants and young children to develop Th2-type CD4(+) T-cells in response to immunogens. In this article, knowledge about the requisite components of protective immunity, differences between the immune systems of children and adults relevant to pediatric tuberculosis, M. tuberculosis-specific T-cell immunity in children, and potential application to immunodiagnostics and vaccine development will be reviewed. C1 Oregon Hlth Sci Univ, Dept Pediat, CDRCP, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA. Publ Hlth Res Inst, Dept Pediat, Newark, NJ USA. Univ London Imperial Coll Sci Technol & Med, St Marys, London SW7 2AZ, England. Portland VA Med Ctr, Portland, OR USA. RP Lewinsohn, DA (reprint author), Oregon Hlth Sci Univ, Dept Pediat, CDRCP, 707 SW Gaines Rd, Portland, OR 97239 USA. EM lewinsde@ohsu.edu RI Lewinsohn, David/I-4936-2013 OI Lewinsohn, David/0000-0001-9906-9494 NR 229 TC 72 Z9 73 U1 0 U2 2 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD MAY PY 2004 VL 8 IS 5 BP 658 EP 674 PG 17 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA 818PF UT WOS:000221256300028 PM 15137550 ER PT J AU Kuritzkes, DR Bassett, RL Hazelwood, JD Barrett, H Rhodes, RA Young, RK Johnson, VA AF Kuritzkes, DR Bassett, RL Hazelwood, JD Barrett, H Rhodes, RA Young, RK Johnson, VA CA Adult ACTG Protocol 306 and 370 Te TI Rate of thymidine analogue resistance mutation accumulation with zidovudine- or stavudine-based regimens SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article; Proceedings Paper CT 11th International Workshop on HIV Drug Resistance and Treatment Strategies CY JUL 02-05, 2002 CL SEVILLE, SPAIN DE zidovudine; stavudine; drug resistance; thymidine analogues ID IMMUNODEFICIENCY-VIRUS TYPE-1; DRUG-RESISTANCE; REVERSE-TRANSCRIPTASE; LAMIVUDINE; THERAPY; TRIAL; COMBINATION; DIDANOSINE; INFECTION; PATTERNS AB Zidovudine (ZDV) and stavudine (d4T) select for the same set of thymidine analogue resistance mutations (TAMs). To compare the rate at which TAMs emerge, genotypic analysis of HIV-1 was performed on serial plasma samples from treatment-naive subjects randomly assigned to receive ZDV or d4T in combination with lamivudine. After 72 weeks of follow-up, TAMs were detected in samples from 50% of ZDV-treated subjects and 45% of d4T-treated subjects (P = 0.79). The frequency of K70R and T215Y or F mutations was similar in both groups, although M41L was observed more frequently in samples from ZDV-treated subjects. This randomized study shows that TAMs accumulate at similar rates during treatment with ZDV or d4T, but the specific pattern of mutations may differ somewhat in patients treated with these thymidine analogues. C1 Univ Colorado, Ctr Hlth Sci, Denver, CO 80202 USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. Univ Alabama, Med Sch Birmingham, Birmingham, AL USA. RP Kuritzkes, DR (reprint author), Brigham & Womens Hosp, Sect Retroviral Therapeut, 65 Landsdowne St,Room 449, Cambridge, MA 02139 USA. EM dkuritzkes@partners.org FU NCRR NIH HHS [RR00051, RR16482]; NIAID NIH HHS [AI42567, AI40876, AI 32775, AI38858, AI38855, AI32770] NR 19 TC 26 Z9 26 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD MAY 1 PY 2004 VL 36 IS 1 BP 600 EP 603 DI 10.1097/00126334-200405010-00008 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 817KX UT WOS:000221177500008 PM 15097303 ER PT J AU Brogan, TV Robertson, HT Lamm, WJE Souders, JE Swenson, ER AF Brogan, TV Robertson, HT Lamm, WJE Souders, JE Swenson, ER TI Carbon dioxide added late in inspiration reduces ventilation-perfusion heterogeneity without causing respiratory acidosis SO JOURNAL OF APPLIED PHYSIOLOGY LA English DT Article DE hypercapnia; respiratory acidosis; oxygen; dog; multiple inert-gas elimination technique ID BLOOD-FLOW DISTRIBUTION; TRACHEAL SMOOTH-MUSCLE; INTRACELLULAR PH; PULMONARY VASOCONSTRICTION; LUNG; CO2; HYPERCAPNIA; AIRWAY; GAS; HYPOCAPNIA AB We have shown previously that inspired CO2 (3-5%) improves ventilation-perfusion ((V)over dotA/(Q)over dot)matching but with the consequence of mild arterial hypercapnia and respiratory acidosis. We hypothesized that adding CO2 only late in inspiration to limit its effects to the conducting airways would enhance (V)over dotA/(Q)over dot matching and improve oxygenation without arterial hypercapnia. CO2 was added in the latter half of inspiration in a volume aimed to reach a concentration of 5% in the conducting airways throughout the respiratory cycle. Ten mixed-breed dogs were anesthetized and, in a randomized order, ventilated with room air, 5% CO2 throughout inspiration, and CO2 added only to the latter half of inspiration. The multiple inert-gas elimination technique was used to assess (V)over dotA/(Q)over dot heterogeneity. Late-inspired CO2 produced only very small changes in arterial pH (7.38 vs. 7.40) and arterial CO2 (40.6 vs. 39.4 Torr). Compared with baseline, late-inspired CO2 significantly improved arterial oxygenation (97.5 vs. 94.2 Torr), decreased the alveolar-arterial PO2 difference (10.4 vs. 15.7 Torr) and decreased the multiple inert-gas elimination technique-derived arterial-alveolar inert gas area difference, a global measurement of (V)over dotA/(Q)over dot heterogeneity(0.36 vs. 0.22). These changes were equal to those with 5% CO2 throughout inspiration (arterial PO2, 102.5 Torr; alveolar-arterial PO2 difference, 10.1 Torr; and arterial-alveolar inert gas area difference, 0.21). In conclusion, we have established that the majority of the improvement in gas exchange efficiency with inspired CO2 can be achieved by limiting its application to the conducting airways and does not require systemic acidosis. C1 Childrens Hosp & Reg Med Ctr, Dept Pediat, Seattle, WA 98105 USA. Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Med Serv, Seattle, WA 98105 USA. Univ Washington, Dept Anesthesiol, Seattle, WA 98105 USA. Univ Washington, Dept Physiol & Biophys, Seattle, WA 98105 USA. Univ Washington, Dept Med, Seattle, WA 98105 USA. RP Brogan, TV (reprint author), Childrens Hosp & Reg Med Ctr, Dept Pediat, 4800 Sand Point Way NE,CH-05, Seattle, WA 98105 USA. EM botcho@u.washington.edu FU NHLBI NIH HHS [HL-03796, HL-45591] NR 32 TC 23 Z9 23 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 8750-7587 J9 J APPL PHYSIOL JI J. Appl. Physiol. PD MAY 1 PY 2004 VL 96 IS 5 BP 1894 EP 1898 DI 10.1152/japplphysiol.00160.2003 PG 5 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA 810XM UT WOS:000220737000042 PM 14660515 ER PT J AU Haake, DA Suchard, MA Kelley, MM Dundoo, M Alt, DP Zuerner, RL AF Haake, DA Suchard, MA Kelley, MM Dundoo, M Alt, DP Zuerner, RL TI Molecular evolution and mosaicism of leptospiral outer membrane proteins involves horizontal DNA transfer SO JOURNAL OF BACTERIOLOGY LA English DT Article ID SURFACE-EXPOSED LIPOPROTEIN; LATERAL GENE EXCHANGE; PATHOGENIC LEPTOSPIRA; BAYESIAN-INFERENCE; SEQUENCE-ANALYSIS; NEISSERIA-MENINGITIDIS; NUCLEOTIDE-SEQUENCES; MAMMALIAN INFECTION; INTERROGANS; SELECTION AB Leptospires belong to a genus of parasitic bacterial spirochetes that have adapted to a broad range of mammalian hosts. Mechanisms of leptospiral molecular evolution were explored by sequence analysis of four genes shared by 38 strains belonging to the core group of pathogenic Leptospira species: L. interrogans, L. kirschneri, L. noguchii, L. borgpetersenii, L. santarosai, and L. weilii. The 16S rRNA and lipL32 genes were highly conserved, and the lipL41 and ompL1 genes were significantly more variable. Synonymous substitutions are distributed throughout the ompL1 gene, whereas nonsynonymous substitutions are clustered in four variable regions encoding surface loops. While phylogenetic trees for the 16S, lipL32, and lipL41 genes were relatively stable, 8 of 38 (20%) ompL1 sequences had mosaic compositions consistent with horizontal transfer of DNA between related bacterial species. A novel Bayesian multiple change point model was used to identify the most likely sites of recombination and to determine the phylogenetic relatedness of the segments of the mosaic ompL1 genes. Segments of the mosaic oinpL1 genes encoding two of the surface-exposed loops were likely acquired by horizontal transfer from a peregrine allele of unknown ancestry. Identification of the most likely sites of recombination with the Bayesian multiple change point model, an approach which has not previously been applied to prokaryotic gene sequence analysis, serves as a model for future studies of recombination in molecular evolution of genes. C1 VA Greater LA Healthcare Syst, Div Infect Dis, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Biomath, Los Angeles, CA USA. USDA ARS, Natl Anim Dis Ctr, Ames, IA 50010 USA. RP Haake, DA (reprint author), VA Greater LA Healthcare Syst, Div Infect Dis, 111F,10021 Wilshire Blvd, Los Angeles, CA 90073 USA. EM dhaake@ucia.edu FU NCI NIH HHS [CA 16042, P30 CA016042]; NIAID NIH HHS [R01 AI034431, AI 34431, R01 AI034431-07, R21 AI034431, R29 AI034431]; NIGMS NIH HHS [GM 068955, R01 GM068955] NR 52 TC 80 Z9 93 U1 0 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0021-9193 J9 J BACTERIOL JI J. Bacteriol. PD MAY PY 2004 VL 186 IS 9 BP 2818 EP 2828 DI 10.1128/JB.186.9.2818-2828.2004 PG 11 WC Microbiology SC Microbiology GA 816DR UT WOS:000221091100036 PM 15090524 ER PT J AU Kha, HT Basseri, B Shouhed, D Richardson, J Tetradis, S Hahn, TJ Parhami, F AF Kha, HT Basseri, B Shouhed, D Richardson, J Tetradis, S Hahn, TJ Parhami, F TI Oxysterols regulate differentiation of mesenchymal stem cells: Pro-bone and anti-fat SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Article DE oxysterols; stein cells; osteogenesis; adipogenesis; bone morphogenetic protein ID MARROW STROMAL CELLS; CHOLESTEROL BIOSYNTHETIC-PATHWAY; ACTIVATED PROTEIN-KINASE; ARACHIDONIC-ACID RELEASE; OSTEOBLASTIC DIFFERENTIATION; NONHEMATOPOIETIC TISSUES; OSTEOGENESIS IMPERFECTA; MORPHOGENETIC PROTEIN-2; NRK-49F CELLS; GLA PROTEIN AB Pluripotent mesenchymal stem cells can undergo lineage-specific differentiation in adult organisms. However, understanding of the factors and mechanisms that drive this differentiation is limited. We show the novel ability of specific oxysterols to regulate lineage-specific differentiation of mesenchymal stem cells into osteogenic cells while inhibiting their adipogenic differentiation. Such effects may have important implications for intervention with osteoporosis. C1 Univ Calif Los Angeles, Sch Dent, Hlth Sci Ctr, Dept Cardiol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Parhami, F (reprint author), Univ Calif Los Angeles, Sch Dent, Hlth Sci Ctr, Dept Cardiol, Room 47-123 10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM fparhami@mednet.ucla.edu NR 64 TC 112 Z9 125 U1 3 U2 9 PU AMER SOC BONE & MINERAL RES PI WASHINGTON PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD MAY PY 2004 VL 19 IS 5 BP 830 EP 840 DI 10.1359/JBMR.040115 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 814GB UT WOS:000220962100018 PM 15068507 ER PT J AU Raitt, MH Kusumoto, W Giraud, G McAnulty, JH AF Raitt, MH Kusumoto, W Giraud, G McAnulty, JH TI Reversal of electrical remodeling after cardioversion of persistent atrial fibrillation SO JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY LA English DT Article DE atrial fibrillation; cardioversion; refractory period; conduction velocity; signal averaging ID SINUS NODE FUNCTION; AVERAGED P-WAVE; DURATION; REFRACTORINESS; RECURRENCE; VULNERABILITY; PREDICTION; MECHANISMS; RECOVERY; HUMANS AB Reverse Atrial Electrical Remodeling. Introduction: In animals, atrial fibrillation results in reversible atrial electrical remodeling manifested as shortening of the atrial effective refractory period, slowing of intra-atrial conduction, and prolongation of sinus node recovery time. There is limited information on changes in these parameters after cardioversion in patients with persistent atrial fibrillation. Methods and Results: Thirty-eight patients who had been in atrial fibrillation for 1 to 12 months underwent electrophysiologic testing 10 minutes and 1 hour after cardioversion. At 1 week, 19 patients still in sinus rhythm returned for repeat testing. Reverse remodeling of the effective refractory period was not uniform across the three atrial sites tested. At the lateral right atrium, there was a highly significant increase in the effective refractory period between 10 minutes and 1 hour after cardioversion (drive cycle length 400 ms: 204+/-17 ms vs 211+/-20 ms, drive cycle length 550 ms: 213+/-18 ms vs 219+/-23 ms, P<0.001). The effective refractory period at the coronary sinus and distal coronary sinus did not change in the first hour but had increased by 1 week. The corrected sinus node recovery time did not change in the first hour but was shorter at 1 week (606+/-311 ms vs 408+/-160 ms, P=0.009). P wave duration also was shorter at 1 week (135+/-18 ms vs 129+/-13 ms, P=0.04) consistent with increasing atrial conduction velocity. Conclusion: The atrial effective refractory period increases, sinus node function improves, and atrial conduction velocity goes up in the first week after cardioversion of long-standing atrial fibrillation in humans. Reverse electrical remodeling of the effective refractory period occurs at different rates in different regions of the atrium. C1 Portland VA Med Ctr, Div Cardiol, Portland, OR USA. Oregon Hlth Sci Univ, Div Cardiol, Portland, OR 97201 USA. Colorado Permanente & St Josephs Hosp, Denver, CO USA. RP Raitt, MH (reprint author), P-3-CARD,3710 SW US Vet Rd, Portland, OR 97239 USA. EM merritt.raitt@med.va.gov NR 27 TC 43 Z9 44 U1 0 U2 3 PU BLACKWELL FUTURA PUBLISHING, INC PI MALDEN PA 350 MAIN STREET, MALDEN, MA 01248-5018 USA SN 1045-3873 J9 J CARDIOVASC ELECTR JI J. Cardiovasc. Electrophysiol. PD MAY PY 2004 VL 15 IS 5 BP 507 EP 512 DI 10.1046/j.1540-8167.2004.03217.x PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 821IC UT WOS:000221452600001 PM 15149416 ER PT J AU Binder, LM Campbell, KA AF Binder, LM Campbell, KA TI Medically unexplained symptoms and neuropsychological assessment SO JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY LA English DT Review ID CHRONIC-FATIGUE-SYNDROME; POSTTRAUMATIC-STRESS-DISORDER; MULTIPLE CHEMICAL-SENSITIVITY; GULF-WAR VETERANS; CEREBRAL BLOOD-FLOW; IDIOPATHIC ENVIRONMENTAL INTOLERANCES; BORDERLINE PERSONALITY-DISORDER; FUNCTIONAL SOMATIC SYNDROMES; CONNECTIVE-TISSUE DISEASES; SILICONE BREAST IMPLANTS AB Several illnesses expressed somatically that do not have clearly demonstrated pathophysiological origin and that are associated with neuropsychological complaints are reviewed. Among them are nonepileptic seizures, fibromyalgia, chronic fatigue syndrome, Persian Gulf War unexplained illnesses, toxic mold and sick building syndrome, and silicone breast implant disease. Some of these illnesses may be associated with objective cognitive abnormalities, but it is not likely that these abnormalities are caused by traditionally defined neurological disease. Instead, the cognitive abnormalities may be caused by a complex interaction between biological and psychological factors. Nonepileptic seizures serve as an excellent model of medically unexplained symptoms. Although nonepileptic seizures clearly are associated with objective cognitive abnormalities, they are not of neurological origin. There is evidence that severe stressors and PTSD are associated with immune system problems, neurochemical changes, and various diseases; these data blur the distinctions between psychological and organic etiologies. Diagnostic problems are intensified by the fact that many patients are poor historians. Patients are prone to omit history of severe stressors and psychiatric problems, and the inability to talk about stressors increases the likelihood of suffering from physiological forms of stress. C1 Oregon Hlth & Sci Univ, Portland, OR USA. Portland VA Med Ctr, Portland, OR USA. RP Binder, LM (reprint author), 4900 SW Griffith Dr Suite 244, Beaverton, OR 97005 USA. EM pdxlarry@aol.com NR 177 TC 31 Z9 32 U1 3 U2 6 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1380-3395 J9 J CLIN EXP NEUROPSYC JI J. Clin. Exp. Neuropsychol. PD MAY PY 2004 VL 26 IS 3 BP 369 EP 392 DI 10.1080/13803390490510095 PG 24 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA 859GP UT WOS:000224251700006 PM 15512927 ER PT J AU Wang, C Cunningham, G Dobs, A Iranmanesh, A Matsumoto, AM Snyder, PJ Weber, T Berman, N Hull, L Swerdloff, RS AF Wang, C Cunningham, G Dobs, A Iranmanesh, A Matsumoto, AM Snyder, PJ Weber, T Berman, N Hull, L Swerdloff, RS TI Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article; Proceedings Paper CT 84th Annual Meeting of the Endocrine-Society CY JUN 19-22, 2002 CL SAN FRANCISCO, CA SP Endocrine Soc ID CLINICAL-RESEARCH-CENTER; TRANSDERMAL TESTOSTERONE; BODY-COMPOSITION; AROMATASE DEFICIENCY; MUSCLE STRENGTH; OLDER MEN; REPLACEMENT; GENE; AGE; PHARMACOKINETICS AB Transdermal testosterone ( T) delivery represents an effective alternative to injectable androgens. We studied 163 hypogonadal men who applied 5, 7.5, or 10 g AndroGel (T gel) 1% CIII per day for up to 42 months. Efficacy data were presented in 123 subjects considered evaluable. Continuous AndroGel treatment normalized mean serum T and free T levels. Mean serum 5alpha-dihydrotestosterone concentrations and 5alpha-dihydrotestosterone/T ratio slightly increased, mean serum estradiol/T ratio doubled, and mean serum FSH and LH levels were suppressed by T replacement. Sexual function and mood parameters improved rapidly and were maintained throughout T treatment. Lean body mass increased (P = 0.0001) and fat mass decreased (P = 0.0001), and these changes were maintained with treatment but were not accompanied by significant increases in muscle strength. Increases in serum bone markers suggestive of increased bone formation were followed by gradual and progressive increases in bone mineral density more in the spine (P = 0.0001) than the hip (P = 0.0004). Mild local skin irritation occurred in 12 subjects, resulting in discontinuation in only one subject. Except for the anticipated increase in hematocrit and hemoglobin, there were no clinically significant changes in blood counts or biochemistry. In three subjects with elevated serum prostate-specific antigen, prostate biopsies showed cancer. We conclude that continued application of AndroGel resulted in beneficial effects similar to those with injectables and other transdermal preparations. This study was neither placebo controlled nor powered to determine the effects of T treatment on prostate cancer risk. Thus, monitoring for prostatic disease and assessment for erythrocytosis are strongly advised to reduce the risk of adverse events with T treatment of hypogonadal men. C1 Harbor UCLA Med Ctr, Gen Clin Res Ctr, Dept Med Pediat, Div Endocrinol, Torrance, CA 90509 USA. Harbor UCLA Res & Educ Inst, Dept Med Pediat, Div Endocrinol, Torrance, CA 90509 USA. Baylor Coll Med, Vet Affairs Med Ctr, Houston, TX 77030 USA. Johns Hopkins Univ, Baltimore, MD 21287 USA. Vet Affairs Med Ctr, Salem, VA 24153 USA. Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA 98108 USA. Univ Penn, Med Ctr, Philadelphia, PA 19104 USA. Duke Univ, Med Ctr, Durham, NC 27705 USA. RP Wang, C (reprint author), Harbor UCLA Med Ctr, Gen Clin Res Ctr, Dept Med Pediat, Div Endocrinol, 1000 W Carson St, Torrance, CA 90509 USA. EM wang@gcrc.rei.edu FU NCRR NIH HHS [M01-RR-0030, M01-RR-00425] NR 38 TC 345 Z9 354 U1 1 U2 15 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD MAY PY 2004 VL 89 IS 5 BP 2085 EP 2098 DI 10.1210/jc.2003-032006 PG 14 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 818BH UT WOS:000221220100016 PM 15126525 ER PT J AU Bausell, RB Lee, WL Soeken, KL Li, YF Berman, BM AF Bausell, RB Lee, WL Soeken, KL Li, YF Berman, BM TI Larger effect sizes were associated with higher quality ratings in complementary and alternative medicine randomized controlled trials SO JOURNAL OF CLINICAL EPIDEMIOLOGY LA English DT Article DE randomized controlled trials; complementary and alternative medicine; trial quality; effect sizes ID ACUTE MYOCARDIAL-INFARCTION; DESIGN AFFECTS OUTCOMES; CLINICAL-TRIALS; METHODOLOGICAL QUALITY; METAANALYSIS; PLACEBO; BIAS; HOMEOPATHY; EFFICACY; DISCREPANCIES AB Objective: To determine if the quality of, complementary and alternative medicine (CAM) placebo controlled randomized controlled trials (RCTs) is related to the effect sizes they produce when the type of interventions and outcome variables are controlled. Study Design and Setting: A sample of 25 CAM meta-analyses was identified from MEDLINE and hand searches containing published effect sizes for at least three efficacy trials employing placebo control groups. From these 25 reviews, 26 pairs of trials were selected: the one reporting the largest effect size and the matching trial reporting the smallest effect size. Quality and publication characteristics were then abstracted from each trial. Results: Unlike the preponderance of past evidence examining the relationship between quality and effect size, the present study found that trials possessing the largest effect sizes within a meta-analysis were also associated with higher quality ratings than their counterparts possessing the lowest effect sizes (P = .019). Conclusions: Possible theoretical reasons for this unexpected positive relationship include (a) sampling error, (b) reduced within group variation, (c) fraudulent reporting, and (d) the restriction of the analyses to placebo controlled trial. (C) 2004 Elsevier Inc. All rights reserved. C1 Univ Maryland, Sch Nursing, Baltimore, MD 21201 USA. Univ Maryland, Kernan Hosp Mans, Sch Med, Complementary Med Program, Baltimore, MD 21207 USA. VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Bausell, RB (reprint author), Univ Maryland, Sch Nursing, 655 W Lombard St, Baltimore, MD 21201 USA. EM bbausell@compmed.umm.edu NR 52 TC 6 Z9 7 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0895-4356 J9 J CLIN EPIDEMIOL JI J. Clin. Epidemiol. PD MAY PY 2004 VL 57 IS 5 BP 438 EP 446 DI 10.1016/j.jclinepi.2003.11.001 PG 9 WC Health Care Sciences & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 832OM UT WOS:000222276800002 PM 15196613 ER PT J AU Nguyen, VH Lawrence, HJ AF Nguyen, VH Lawrence, HJ TI Use of gabapentin in the prevention of taxane-induced arthralgias and myalgias SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Letter ID COLONY-STIMULATING FACTOR; HIGH-DOSE PACLITAXEL; BREAST-CANCER; PHASE-II; CHEMOTHERAPY; TRIAL; PAIN C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. RP Nguyen, VH (reprint author), Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 18 TC 25 Z9 27 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 1 PY 2004 VL 22 IS 9 BP 1767 EP 1769 DI 10.1200/JCO.2004.99.298 PG 3 WC Oncology SC Oncology GA 817VS UT WOS:000221205600040 PM 15118009 ER PT J AU Mani, A Napel, S Paik, DS Jeffrey, RB Yee, J Olcott, EW Prokesch, R Davila, M Schraedley-Desmond, P Beaulieu, CF AF Mani, A Napel, S Paik, DS Jeffrey, RB Yee, J Olcott, EW Prokesch, R Davila, M Schraedley-Desmond, P Beaulieu, CF TI Computed tomography colonography - Feasibility of computer-aided polyp detection in a "First reader" paradigm SO JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY LA English DT Article; Proceedings Paper CT 88th Scientific Assembly and Annual Meeting of the Radiologic-Society-of-North-America CY DEC 01-06, 2002 CL Chicago, IL SP Radiol Soc N Amer DE colon; polyps; computed tomography colonography; virtual colonoscopy; computer-aided diagnosis; interpretation accuracy; interpretation efficiency ID SPIRAL CT COLONOGRAPHY; VIRTUAL COLONOSCOPY; COLORECTAL POLYPS; COLONIC POLYPS; CONVENTIONAL COLONOSCOPY; DIAGNOSTIC PERFORMANCE; DATA-ACQUISITION; COLOGRAPHY; SUPINE; PRONE AB Objective: To determine the feasibility of a computer-aided detection (CAD) algorithm as the "first reader" in computed tomography colonography (CTC). Methods: In phase 1 of a 2-part blind trial, we measured the performance of 3 radiologists reading 41 CTC studies without CAD. In phase 2, readers interpreted the same cases using a CAD list of 30 potential polyps. Results: Unassisted readers detected, on average, 63% of polyps greater than or equal to10 mm in diameter. Using CAD, the sensitivity was 74% (not statistically different). Per-patient analysis showed a trend toward increased sensitivity for polyps greater than or equal to10mm in diameter, from 73% to 90% with CAD (not significant) without decreasing specificity. Computer-aided detection significantly decreased interobserver variability (P = 0.017). Average time to detection of the first polyp decreased significantly with CAD, whereas total reading case reading time was unchanged. Conclusion: Computer-aided detection as a first reader in CTC was associated with similar per-polyp and per-patient detection sensitivity to unassisted reading. Computer-aided detection decreased interobserver variability and reduced the time required to detect the first polyp. C1 Stanford Univ, Med Ctr, Dept Radiol, Stanford, CA 94305 USA. Stanford Med Sch, Stanford, CA USA. Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA. San Francisco Vet Adm Med Ctr, San Francisco, CA USA. Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA. Univ Vienna, Dept Radiol, Vienna, Austria. Stanford Univ, Ctr Med, Dept Med, Stanford, CA USA. RP Beaulieu, CF (reprint author), Stanford Univ, Med Ctr, Dept Radiol, MC 5105,300 Pasteur Dr, Stanford, CA 94305 USA. EM beaulieu@stanford.edu FU NCI NIH HHS [1R01 CA72023]; NCRR NIH HHS [1P41 RR09784-01] NR 60 TC 53 Z9 53 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0363-8715 J9 J COMPUT ASSIST TOMO JI J. Comput. Assist. Tomogr. PD MAY-JUN PY 2004 VL 28 IS 3 BP 318 EP 326 DI 10.1097/00004728-200405000-00003 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 818GV UT WOS:000221234500003 PM 15100534 ER PT J AU Chiu, HK Palmer, JP AF Chiu, HK Palmer, JP TI Autoimmune diabetes: More than just one flavor? SO JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION LA English DT Editorial Material DE Type 1 diabetes; latent autoimmune diabetes in adults; Type 1.5 diabetes ID GLUTAMIC-ACID DECARBOXYLASE; ISLET-CELL ANTIBODIES; CLINICAL-DIAGNOSIS; INSULIN THERAPY; ADULT-ONSET; MELLITUS; TYPE-1; AUTOANTIBODIES; IDDM; GAD C1 Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Chiu, HK (reprint author), 1660 S Columbian Way,Endo 111, Seattle, WA 98108 USA. EM chiuh@u.washington.edu FU NIDDK NIH HHS [P30DK17047] NR 60 TC 5 Z9 6 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0391-4097 EI 1720-8386 J9 J ENDOCRINOL INVEST JI J. Endocrinol. Invest. PD MAY PY 2004 VL 27 IS 5 BP 480 EP 484 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 832DB UT WOS:000222246300016 PM 15279084 ER PT J AU Gill, TM McDermott, MM Ibrahim, SA Petersen, LA Doebbeling, BN AF Gill, TM McDermott, MM Ibrahim, SA Petersen, LA Doebbeling, BN TI Getting funded - Career development awards for aspiring clinical investigators SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT 26th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 30-MAY 03, 2003 CL VANCOUVER, CANADA SP Soc Gen Internal Med DE career development; academic medicine; research training ID GENERAL INTERNAL-MEDICINE; PERSPECTIVE AB For aspiring clinical investigators, career development awards provide a primary mechanism for "getting funded." The objective of this article is to provide information that will facilitate a successful application for a research career development award. Specifically, we discuss important issues that cut across the diverse array of awards, and we highlight the most common sources of funding, including the unique opportunities that are available for underrepresented minorities. The target audience includes junior faculty and fellows who are pursuing or considering a research career in academic medicine, as well as their mentors and program directors. C1 Yale Univ, Sch Med, Dorothy Adler Geriatr Assessment Ctr, Dept Internal Med, New Haven, CT 06504 USA. Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA. Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA. VA Pittsburgh Healthcare Syst, VA Ctr Excellence Hlth Equ Res & Prom, Pittsburgh, PA USA. Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. Houston VA Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. Baylor Coll Med, Sect Hlth Serv Res, Houston, TX 77030 USA. Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN 46202 USA. Indiana Univ, Sch Med, Dept Med, Indianapolis, IN USA. Regenstrief Inst Hlth Care Res, Indianapolis, IN USA. RP Gill, TM (reprint author), Yale Univ, Sch Med, Dorothy Adler Geriatr Assessment Ctr, Dept Internal Med, 20 York St, New Haven, CT 06504 USA. EM gill@ynhh.org FU NIA NIH HHS [K24 AG021507]; NIOSH CDC HHS [K01 OH00131] NR 6 TC 8 Z9 8 U1 1 U2 2 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2004 VL 19 IS 5 BP 472 EP 478 DI 10.1111/j.1525-1497.2004.30293.x PN 1 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 816VR UT WOS:000221137900012 PM 15109347 ER PT J AU Houston, TK Connors, RL Cutler, N Nidiry, MA AF Houston, TK Connors, RL Cutler, N Nidiry, MA TI A primary care musculoskeletal clinic for residents - Success and sustainability SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE musculoskeletal; housestaff; primary care ID EDUCATION; MEDICINE; FACULTY; IMPACT AB Musculoskeletal complaints are common, but are often under-emphasized in residency training. We evaluated the experience of residents (12) in 4 sessions of an innovative concentrated ambulatory, community-based musculoskeletal (MS) clinic precepted by general internists with additional training in teaching MS medicine. Compared with the yearlong longitudinal house staff (HS) clinic experience, the mean number of musculoskeletal diagnoses per resident seen in MS clinic was higher (13.9 [standard deviation 4.0] vs 5.4 [standard deviation 4.0]; P < .01). Common diagnoses in MS clinic included shoulder, hip, and knee tendonitis/bursitis, and the majority of diagnoses in HS clinic were nonspecific arthralgia (66%). Fifty-two injections were performed in MS clinic over the year, compared with one in HS clinic. C1 Johns Hopkins Bayview Med Ctr, Baltimore, MD USA. RP Houston, TK (reprint author), Univ Alabama, Div Gen Internal Med, Birmingham Vet Affairs Med Ctr,Dept Med, Deep S Effectiveness Targeted Res Enhancement Pro, 1813 6th Ave S,MEB 621, Birmingham, AL 35294 USA. EM tkhouston@uabmc.edu RI Houston, Thomas/F-2469-2013 NR 16 TC 9 Z9 9 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2004 VL 19 IS 5 BP 524 EP 529 DI 10.1111/j.1525-1497.2004.30173.x PN 2 PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 821IB UT WOS:000221452500009 PM 15109317 ER PT J AU Tyler, KL Barton, ES Ibach, ML Robinson, C Campbell, JA O'Donnell, SM Valyi-Nagy, T Clarke, P Wetzel, JD Dermody, TS AF Tyler, KL Barton, ES Ibach, ML Robinson, C Campbell, JA O'Donnell, SM Valyi-Nagy, T Clarke, P Wetzel, JD Dermody, TS TI Isolation and molecular characterization of a novel type 3 reovirus from a child with meningitis SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID CENTRAL-NERVOUS-SYSTEM; ATTACHMENT PROTEIN SIGMA-1; JUNCTION ADHESION MOLECULE; INDUCED APOPTOSIS; SIALIC-ACID; MONOCLONAL-ANTIBODIES; MAMMALIAN REOVIRUSES; SEQUENCE DIVERSITY; INFECTION; PATHOGENESIS AB Mammalian reoviruses are nonenveloped viruses that contain a segmented, double-stranded RNA genome. Reoviruses infect most mammalian species, although infection with these viruses in humans is usually asymptomatic. We report the isolation of a novel reovirus strain from a 6.5-week-old child with meningitis. Hemagglutination and neutralization assays indicated that the isolate is a serotype 3 strain, leading to the designation T3/Human/Colorado/1996 (T3C/96). Sequence analysis of the T3C/96 S1 gene segment, which encodes the viral attachment protein, sigmal, confirmed the serotype assignment for this strain and indicated that T3C/96 is a novel reovirus isolate. T3C/96 is capable of systemic spread in newborn mice after peroral inoculation and produces lethal encephalitis. These results suggest that serotype 3 reoviruses can cause meningitis in humans. C1 Vanderbilt Univ, Sch Med, Elizabeth B Lamb Ctr Pediat Res, Nashville, TN 37232 USA. Univ Colorado, Hlth Sci Ctr, Dept Neurol, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Microbiol & Immunol, Denver, CO 80262 USA. Denver Vet Affairs Med Ctr, Denver, CO USA. Childrens Hosp, Dept Pathol, Denver, CO 80218 USA. Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA. Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA. Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37232 USA. RP Dermody, TS (reprint author), Vanderbilt Univ, Sch Med, Elizabeth B Lamb Ctr Pediat Res, D7235 MCN, Nashville, TN 37232 USA. EM ken.tyler@uchsc.edu; terry.dermody@vanderbilt.edu OI Tyler, Kenneth/0000-0003-3294-5888 FU NCI NIH HHS [T32 CA09385]; NIAID NIH HHS [R01 AI38296, T32 AI07474] NR 70 TC 37 Z9 44 U1 2 U2 5 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD MAY 1 PY 2004 VL 189 IS 9 BP 1664 EP 1675 DI 10.1086/383129 PG 12 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 814BX UT WOS:000220951300015 PM 15116303 ER PT J AU Reusch, JEB AF Reusch, JEB TI Time management in academic medicine SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Article C1 Univ Colorado, Hlth Sci Ctr, Denver VA Med Ctr, Denver, CO 80220 USA. RP Reusch, JEB (reprint author), Univ Colorado, Hlth Sci Ctr, Denver VA Med Ctr, Endocrinol 111-H,1055 Clermont St, Denver, CO 80220 USA. EM Jane.Reusch@uchsc.edu NR 0 TC 1 Z9 1 U1 0 U2 1 PU B C DECKER INC PI HAMILTON PA 20 HUGHSON ST SOUTH, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD MAY PY 2004 VL 52 IS 4 BP 259 EP 261 DI 10.2310/6650.2004.00015 PG 3 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 860ST UT WOS:000224364200022 PM 15521549 ER PT J AU Vielma, SA Mironova, M Ku, JR Lopes-Virella, MF AF Vielma, SA Mironova, M Ku, JR Lopes-Virella, MF TI Oxidized LDL further enhances expression of adhesion molecules in Chlamydophila pneumoniae-infected endothelial cells SO JOURNAL OF LIPID RESEARCH LA English DT Article DE intracellular adhesion molecule-1; E-selectin; vascular cell adhesion molecule-1; oxidized low density lipoprotein; cell adhesion molecules ID LOW-DENSITY-LIPOPROTEIN; CIRCULATING IMMUNE-COMPLEXES; ACUTE MYOCARDIAL-INFARCTION; CORONARY-ARTERY-DISEASE; FACTOR-KAPPA-B; CHLAMYDIA-PNEUMONIAE; HEART-DISEASE; E-SELECTIN; ATHEROSCLEROSIS; INFLAMMATION AB Chlamydophila pneumoniae is a common respiratory pathogen that has been shown to be associated with coronary, artery disease. Recent studies have shown that one of the possible mechanisms of the atherogenicity of C. pneumioniae is overexpression of cell adhesion molecules (CAMs) in infected endothelial cells. We investigated whether exposure of C. pneumoniae-infected endothelial cells to oxidized LDL (oxLDL) leads to further upregulation of CAMs. Flow cytometry and immunoblot analysis of human aortic endothelial cells (HAECs) was performed for intracellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin. ICAM-1 was expressed in 78.7% of C. pneumoniae-infected HAECs. The addition of oxLDL (100 mug/ml) to infected HAECs increased the proportion of ICAM-1-positive cells to 92%. VCAM-I was only observed in 9.3% of infected HAECs, and the addition of oxLDL had no further effect on the surface expression of VCAM-1. C. pneumoniae also upregulated the surface expression of E-selectin on 52.2% of the cells, and incubation with oxLDL further increased the proportion of positive cells to 63.64%.jlr; In conclusion, C. pneumoniae upregulated the expression of the adhesion molecules ICAM-1, VCAM-1. and E-selectin on HAECs. The addition of oxLDL to the infected cells further enhanced the surface expression of ICAM-1 and E-selectin.-Vielma, S. A. M. Mironova,a, J-R. Ku. and M. F. Lopes-Virella. Oxidized LDL further enhances expression of adhesion molecules in Chlamydophila pneumoniae-infected endothelial cells. J. Lipid Res. 2004. 45: 873-880. C1 Med Univ S Carolina, Div Metab Endocrinol & Nutr, Dept Med, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Lopes-Virella, MF (reprint author), Med Univ S Carolina, Div Metab Endocrinol & Nutr, Dept Med, Charleston, SC 29425 USA. EM virellam@musc.edu FU NHLBI NIH HHS [R01 HL-46815, P01 HL-55782] NR 43 TC 10 Z9 10 U1 0 U2 0 PU LIPID RESEARCH INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0022-2275 J9 J LIPID RES JI J. Lipid Res. PD MAY PY 2004 VL 45 IS 5 BP 873 EP 880 DI 10.1194/jlr.M300456-JLR200 PG 8 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 814TS UT WOS:000220997600010 PM 14967815 ER PT J AU Prommer, E AF Prommer, E TI Re: Chronic lymphocytic leukemia resembling metastatic bone disease SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Letter ID IN-SITU HYBRIDIZATION; BREAST-CANCER; PATIENT; HYPERCALCEMIA; TRISOMY-12 C1 VA Greater Los Angeles Healthcare Syst, Vet Integrated Palliat Care Program, Los Angeles, CA USA. RP Prommer, E (reprint author), VA Greater Los Angeles Healthcare Syst, Vet Integrated Palliat Care Program, Los Angeles, CA USA. NR 21 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD MAY PY 2004 VL 27 IS 5 BP 393 EP 395 DI 10.1016/j.jpainsymman.2004.02.007 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 822BH UT WOS:000221508900010 PM 15120767 ER PT J AU Gong, H McGinty, D Guzman-Marin, R Chew, KT Stewart, D Szymusiak, R AF Gong, H McGinty, D Guzman-Marin, R Chew, KT Stewart, D Szymusiak, R TI Activation of c-fos in GABAergic neurones in the preoptic area during sleep and in response to sleep deprivation SO JOURNAL OF PHYSIOLOGY-LONDON LA English DT Article ID WAKING DISCHARGE PATTERNS; POSTERIOR LATERAL HYPOTHALAMUS; MONOAMINERGIC CELL GROUPS; DORSAL RAPHE NEURONS; EYE-MOVEMENT SLEEP; BASAL FOREBRAIN; GALANINERGIC NEURONS; RATS; NUCLEUS; PROJECTIONS AB Neurones in the median preoptic nucleus (MnPN) and the ventrolateral preoptic area (vlPOA) express immunoreactivity for c-Fos protein following sustained sleep, and display elevated discharge rates during both non-REM and REM sleep compared to waking. We evaluated the hypothesis that MnPN and vlPOA sleep-active neurones are GABAergic by combining staining for c-Fos protein with staining for glutamic acid decarboxylase (GAD). In a group of six rats exhibiting spontaneous total sleep times averaging 82.2 +/- 5.1% of the 2 h immediately prior to death, >75% of MnPN neurones that were Fos-immunoreactive (IR) were also GAD-IR. Similar results were obtained in the vlPOA. In a group of 11 rats exhibiting spontaneous sleep times ranging from 20 to 92%, the number of Fos + GAD-IR neurones in MnPN and vlPOA was positively correlated with total sleep time. Compared to control animals, Fos + GAD-IR cell counts in the MnPN were significantly elevated in rats that were sleep deprived for 24 h and permitted 2 h of recovery sleep. These findings demonstrate that a majority of MnPN and vlPOA neurones that express Fos-IR during sustained spontaneous sleep are GABAergic. They also demonstrate that sleep deprivation is associated with increased activation of GABAergic neurones in the MnPN and vlPOA. C1 VA Greater Los Angeles Healthcare Syst, Res Serv 151A3, North Hills, CA 91343 USA. Univ Calif Los Angeles, Sch Med, Dept Psychol, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. RP Szymusiak, R (reprint author), VA Greater Los Angeles Healthcare Syst, Res Serv 151A3, 16111 Plummer St, North Hills, CA 91343 USA. EM rszym@ucla.edu FU NHLBI NIH HHS [P50 HL060296, HL60296]; NIMH NIH HHS [MH63323, R01 MH063323, R01 MH047480, MH47480] NR 41 TC 93 Z9 97 U1 1 U2 4 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 0022-3751 J9 J PHYSIOL-LONDON JI J. Physiol.-London PD MAY 1 PY 2004 VL 556 IS 3 BP 935 EP 946 DI 10.1113/jphysiol.2003.056622 PG 12 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA 818TE UT WOS:000221266600020 PM 14966298 ER PT J AU New, AS Trestman, RF Mitropoulou, V Goodman, M Koenigsberg, HH Silverman, J Siever, LJ AF New, AS Trestman, RF Mitropoulou, V Goodman, M Koenigsberg, HH Silverman, J Siever, LJ TI Low prolactin response to fenfluramine in impulsive aggression SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE serotonin; fenfluramine; personality disorder; impulsive aggression ID POSITRON-EMISSION-TOMOGRAPHY; FLUID AMINE METABOLITES; CEREBROSPINAL-FLUID; PERSONALITY-DISORDER; SEROTONERGIC FUNCTION; VIOLENT OFFENDERS; SUICIDAL-BEHAVIOR; FIRE SETTERS; INDEXES; 5-HIAA AB To examine the prolactin (prl) response to d,l-fenfluramine in a large sample of personality disorder patients with impulsive aggression. Patients were screened from clinics at the Bronx VAMC and the Mount Sinai Medical Center and from press releases. One hundred and forty-six personality disorder patients (90M;56F) and 23 normal controls (15M;8F) underwent oral d,l-fenfluramine challenge. The peak change in prolactin(deltapkprl) was calculated by subtracting baseline prolactin from peak response following fenfluramine administration (3 h). Analysis of variance and regression analysis were used to detect group differences in deltapkprl. Deltapkprl in impulsive aggressive men, but not women, with personality disorders was blunted compared with controls. Men with suicide histories also had a blunted deltapkprl compared with those without, which was not accounted for by depression. This study represents a replication of previous studies, in a much larger sample, showing a blunted PRL response to fenfluramine of male patients with personality disorder in relation to impulsive aggression and to suicide attempts. (C) 2003 Elsevier Ltd. All rights reserved. C1 Bronx Vet Adm Med Ctr, Psychiat Serv 116A, Bronx, NY 10468 USA. Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. Mt Sinai Sch Med, Gen Clin Res Ctr, New York, NY USA. Univ Connecticut, Dept Psychiat, Storrs, CT 06269 USA. RP New, AS (reprint author), Bronx Vet Adm Med Ctr, Psychiat Serv 116A, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM antonia.new@med.va.gov OI Trestman, Robert/0000-0002-3306-4380 FU NCRR NIH HHS [5-M01-RR00071]; NIMH NIH HHS [5-R01-MH566606] NR 36 TC 31 Z9 32 U1 0 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 J9 J PSYCHIAT RES JI J. Psychiatr. Res. PD MAY-JUN PY 2004 VL 38 IS 3 BP 223 EP 230 DI 10.1016/j.jpsychires.2003.09.001 PG 8 WC Psychiatry SC Psychiatry GA 804YU UT WOS:000220334800001 PM 15003426 ER PT J AU Krahl, SE Senanayake, SS Pekary, AE Sattin, A AF Krahl, SE Senanayake, SS Pekary, AE Sattin, A TI Vagus nerve stimulation (VNS) is effective in a rat model of antidepressant action SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE vagus nerve stimulation (VNS); forced-swim test (FST); depression; antidepressant; desipramine; electroconvulsant shock (ECS) ID FORCED SWIMMING TEST; SEIZURES AB Depression is a common but debilitating illness that afflicts a large population and costs the US economy a staggering $40 billion dollars per year. Clinical studies have demonstrated that vagus nerve stimulation (VNS) is an effective treatment for medication-resistant depression. Understanding VNS's antidepressant mechanisms is key to improving the therapy and selecting the best surgical candidates, and demonstration that VNS is effective in a validated test of antidepressant activity allows us to elucidate these mechanisms in a cost-effective manner. In the present study, Wistar Kyoto rats were implanted with a cuff electrode on the left cervical vagus nerve. The next day, they were placed into a water-filled Plexiglas cylinder for 15 min. After this forced-swim session, one of three treatment conditions were administered over 4 consecutive days: 30 min per day of continuous VNS, 10 mg/kg of desipramine twice per day, or three daily electroconvulsive shocks (ECS). Yoked controls underwent sham procedures, but received no treatment. On the fourth day, the rats were given a 5-min, videotaped swim test. A blinded observer used the videotape to calculate the percentage of time that the rats were immobile (an index of depression) during the swim test. VNS significantly reduced immobility time as compared to unstimulated controls, indicating good antidepressant efficacy. This reduction did not differ statistically from that obtained from rats treated with either desipramine or ECS, two standard antidepressant treatments. These results indicate that VNS is an effective antidepressant in the forced-swim test, allowing us to now investigate possible therapeutic mechanisms. Published by Elsevier Ltd. C1 VA Greater Los Angeles Healthcare Syst, Neurol Serv, Los Angeles, CA 90073 USA. VA Greater Los Angeles Healthcare Syst, Res & Dev Serv, Los Angeles, CA 90073 USA. VA Greater Los Angeles Healthcare Syst, Psychiat Serv, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Div Neurosurg, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA USA. RP Krahl, SE (reprint author), VA Greater Los Angeles Healthcare Syst, Neurol Serv, Bldg 114,Suite 217,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM scott.krahl@med.va.gov NR 18 TC 59 Z9 59 U1 3 U2 7 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 J9 J PSYCHIAT RES JI J. Psychiatr. Res. PD MAY-JUN PY 2004 VL 38 IS 3 BP 237 EP 240 DI 10.1016/j.jpsychires.2003.11.005 PG 4 WC Psychiatry SC Psychiatry GA 804YU UT WOS:000220334800003 PM 15003428 ER PT J AU Lum, PS Taub, E Schwandt, D Postman, M Hardin, P Uswatte, G AF Lum, PS Taub, E Schwandt, D Postman, M Hardin, P Uswatte, G TI Automated Constraint-Induced Therapy Extension (AutoCITE) for movement deficits after stroke SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE automated rehabilitation; cerebrovascular accident; CI therapy; Constraint-Induced Movement therapy; movement; upper limb ID REHABILITATION AB We report progress in the development of AutoCITE, a workstation that delivers the task practice component of upper-limb Constraint-Induced Movement therapy and that can potentially be used in the clinic or the home without the need for one-on-one supervision from a therapist. AutoCITE incorporates a computer and eight task devices arranged on a modified cabinet. Task performance is automatically recorded, and several types of feedback are provided. In preliminary testing, nine chronic stroke subjects with mild to moderate motor deficits practiced with AutoCITE for 3 h each weekday for 2 weeks. Subjects wore a padded mitt on the less-affected hand for a target of 90% of their waking hours. In terms of effect sizes, gains were large and significant on the Motor Activity Log, and moderate to large on the Wolf Motor Function Test. These gains were comparable to the gains of a matched group of 12 subjects who received standard Constraint-Induced Movement therapy. C1 Virginia Commonwealth Univ, Richmond, VA 23298 USA. Hunter Holmes McGuire Dept Vet Affairs, Ctr Med, Richmond, VA USA. VA Palo Alto Healthcare Syst, Rehabil Res & Dev Ctr, Palo Alto, CA USA. Birmingham VA Med Ctr, Birmingham, AL USA. Univ Alabama, Dept Psychol, Birmingham, AL 35294 USA. RP Lum, PS (reprint author), Virginia Commonwealth Univ, MCV Campus,1112 E Clay St,Room 220,POB 980694, Richmond, VA 23298 USA. EM plum@vcu.edu RI Uswatte, Gitendra/C-4913-2009 NR 15 TC 42 Z9 44 U1 0 U2 1 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PD MAY-JUN PY 2004 VL 41 IS 3A BP 249 EP 257 DI 10.1682/JRRD.2003.06.0092 PG 9 WC Rehabilitation SC Rehabilitation GA 859ES UT WOS:000224246800014 PM 15543442 ER PT J AU Robinson-Whelen, S Bodenheimer, C AF Robinson-Whelen, S Bodenheimer, C TI Health practices of veterans with unilateral lower-limb loss: Identifying correlates SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE amputees; foot-care practices; health behavior; health beliefs; psychological adjustment ID DEPRESSIVE SYMPTOMS; LIFE SCALE; AMPUTEES; SATISFACTION; AMPUTATIONS; VALIDATION; BEHAVIORS; SMOKING AB Persons with a nontraumatic lower-limb amputation are at high risk of losing their contralateral limb in the years postamputation. In this study, veterans with a unilateral lower-limb amputation participated in a survey about health beliefs and health practices known to affect risk of amputation (foot care and smoking). Most participants reported good footcare practices (93% checked the top of their foot, 73% checked the bottom of their foot, 75% checked between their toes, and 72% washed their foot-daily); however, a small percentage engaged in important foot-care practices less than once a week (2% checked the top of their foot, 7% checked the bottom of their foot, and 7% checked between their toes less than once a week). In addition, nearly a third still smoked. The belief in one's ability to engage in good foot care and the belief that good foot care reduces the risk of future foot problems were significantly correlated with foot-care practices. In addition, psychological well-being (life satisfaction) was significantly related to foot care and smoking status. Longitudinal research is needed to identify determinants of health behaviors to better direct intervention efforts. C1 Baylor Coll Med, Ctr Res Women Disabil, Houston, TX 77046 USA. Baylor Coll Med, VA Med Ctr, Dept Vet Affairs, Res & Dev Serv, Houston, TX 77046 USA. RP Robinson-Whelen, S (reprint author), Baylor Coll Med, Ctr Res Women Disabil, 3440 Richmond Ave,Suite B, Houston, TX 77046 USA. EM susanrw@bcm.tmc.edu NR 26 TC 9 Z9 9 U1 1 U2 1 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PD MAY-JUN PY 2004 VL 41 IS 3B BP 453 EP 460 DI 10.1682/JRRD.2004.03.0453 PG 8 WC Rehabilitation SC Rehabilitation GA 859ET UT WOS:000224246900010 PM 15543463 ER PT J AU Holroyd-Leduc, JM Mehta, KM Covinsky, KE AF Holroyd-Leduc, JM Mehta, KM Covinsky, KE TI Urinary incontinence and its association with death, nursing home admission, and functional decline SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article; Proceedings Paper CT 26th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 30-MAY 03, 2003 CL VANCOUVER, CANADA SP Soc Gen Internal Med DE urinary incontinence; mortality; nursing homes; activities of daily living ID ELDERLY-PEOPLE; HEALTH DYNAMICS; OLDER-PEOPLE; RISK-FACTORS; PREVALENCE; COMMUNITY; WOMEN; FRAILTY; IMPACT; LIFE AB OBJECTIVES: To determine whether urinary incontinence (UI) is an independent predictor of death, nursing home admission, decline in activities of daily living (ADLs), or decline in instrumental activities of daily living (IADLs). DESIGN: A population-based prospective cohort study from 1993 to 1995. SETTING: Community-dwelling within the United States. PARTICIPANTS: Six thousand five hundred six of the 7,447 subjects aged 70 and older in the Asset and Health Dynamics Among the Oldest Old study who had complete information on continence status and did not require a proxy interview at baseline. MEASUREMENTS: The predictor was UI, and the outcomes were death, nursing home admission, ADL decline, and IADL decline. Potential confounders considered were comorbid conditions, baseline function, sensory impairment, cognition, depressive symptoms, body mass index, smoking and alcohol, demographics, and socioeconomic status. RESULTS: The prevalence of UI was 14.8% (18.5% in women; 8.5% in men). At 2-year follow-up, subjects incontinent at baseline were more likely to have died (10.9% vs 8.7%; unadjusted odds ratio (OR)=1.29, 95% confidence interval (CI)=1.02-1.64), be admitted to a nursing home (4.4% vs 2.6%, OR=1.77; 95% CI=1.18-2.63), and to have declined in ADL function (13.6% vs 8.1%; OR=1.78, 95% CI=1.36-2.33) and IADL function (21.2% vs 13.8%; OR 1.69, 95% CI 1.39-2.05). However, after adjusting for confounders, UI was not an independent predictor of death (adjusted OR (AOR)= 0.90, 95% CI=0.67-1.21), nursing home admission (AOR=1.33, 95% CI=0.86-2.04), or ADL decline (AOR=1.24, 95% CI=0.92-1.68). Incontinence remained a predictor of IADL decline (AOR=1.31; 95% CI=1.05-1.63), although adjustment markedly reduced the strength of this association. CONCLUSION: Higher levels of baseline illness severity and functional impairment appear to mediate the relationship between UI and adverse outcomes. The results suggest that, although UI appears to be a marker of frailty in community-dwelling elderly, it is not a strong independent risk factor for death, nursing home admission, or functional decline. C1 San Francisco VA Med Ctr, San Francisco, CA 94121 USA. Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. RP Holroyd-Leduc, JM (reprint author), San Francisco VA Med Ctr, 181G,4150 Clement St,Bldg 1, San Francisco, CA 94121 USA. EM Jayna.Holroyd-Leduc@med.va.gov FU AHRQ HHS [K02 HS00006-01]; NIA NIH HHS [T32-AG00212-08, R01AG19827] NR 35 TC 74 Z9 74 U1 1 U2 10 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2004 VL 52 IS 5 BP 712 EP 718 DI 10.1111/j.1532-5415.2004.52207.x PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 812QZ UT WOS:000220855300008 PM 15086650 ER PT J AU Lorenz, KA Asch, SM Rosenfeld, KE Liu, H Ettner, SL AF Lorenz, KA Asch, SM Rosenfeld, KE Liu, H Ettner, SL TI Hospice admission practices: Where does hospice fit in the continuum of care? SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article; Proceedings Paper CT 26th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 30-MAY 03, 2003 CL VANCOUVER, CANADA SP Soc Gen Internal Med DE hospice; terminal care; geriatrics ID TREATMENT PREFERENCES; MEDICAL-CARE; ILL PATIENTS; DEATH; LIFE; PLACE; RULES; END AB OBJECTIVES: To evaluate selected hospice admission practices that could represent barriers to hospice use and the association between these admission practices and organizational characteristics. DESIGN: From December 1999 to March 2000, hospices were surveyed about selected admission practices, and their responses were linked to the 1999 California Office of Statewide Health Planning and Development's Home and Hospice Care Survey that describes organizational characteristics of California hospices. SETTING: California statewide. PARTICIPANTS: One hundred of 149 (67%) operational licensed hospices. MEASUREMENTS: Whether hospices admit patients who lack a caregiver; would not forgo hospital admissions; or are receiving total parenteral nutrition (TPN), tube feedings, radiotherapy, chemotherapy, or transfusions. RESULTS: Sixty-three percent of hospices restricted admission on at least one criterion. A significant minority of hospices would not admit patients lacking a caregiver (26%). Patients unwilling to forgo hospitalization could not be admitted to 29% of hospices. Receipt of complex medical care, including TPN (38%), tube feedings (3%), transfusions (25%), radiotherapy (36%), and chemotherapy (48%), precluded admission. Larger program size was significantly associated with a lower likelihood of all admission practices except restricting the admission of patients receiving TPN or tube feedings. Hospice programs that were part of a hospice chain were less likely to restrict the admission of patients using TPN, radiotherapy, or chemotherapy than were freestanding programs. CONCLUSION: Patients who are receiving complex palliative treatments could face barriers to hospice enrollment. Policy makers should consider the clinical capacity of hospice providers in efforts to improve access to palliative care and more closely incorporate palliation with other healthcare services. C1 VA Greater Los Angeles Healthcare Syst, Div Gen Internal Med, Vet Integrated Palliat Program, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Los Angeles, CA USA. RAND Corp, Los Angeles, CA USA. RP Lorenz, KA (reprint author), VA Greater Los Angeles Healthcare Syst, Div Gen Internal Med, Vet Integrated Palliat Program, 11303 Wilshire Blvd,Code 111-G, Los Angeles, CA 90073 USA. EM karl.lorenz@med.va.gov NR 27 TC 40 Z9 40 U1 1 U2 6 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2004 VL 52 IS 5 BP 725 EP 730 DI 10.1111/j.1532-5415.2004.52209.x PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 812QZ UT WOS:000220855300010 PM 15086652 ER PT J AU Chodosh, J Solomon, DH Roth, CP Chang, JT MacLean, CH Ferrell, BA Shekelle, PG Wenger, NS AF Chodosh, J Solomon, DH Roth, CP Chang, JT MacLean, CH Ferrell, BA Shekelle, PG Wenger, NS TI The quality of medical care provided to vulnerable older patients with chronic pain SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article; Proceedings Paper CT Annual Meeting of the American-Geriatrics-Society CY MAY, 2001 CL CHICAGO, IL SP Amer Geriatr Soc DE quality of care; chronic pain; managed care; quality indicators ID NURSING-HOME; MANAGEMENT; INDICATORS; PREVALENCE; ELDERS/; POPULATION; COMMUNITY; SYMPTOMS; PEOPLE; HEALTH AB OBJECTIVES: To assess the quality of chronic pain care provided to vulnerable older persons. DESIGN: Observational study evaluating 11 process-of-care quality indicators using medical records and interviews with patients or proxies covering care received from July 1998 through July 1999. SETTING: Two senior managed care plans. PARTICIPANTS: A total of 372 older patients at increased risk of functional decline or death identified by interview of a random sample of community dwellers aged 65 and older enrolled in these managed-care plans. MEASUREMENTS: Percentage of quality indicators satisfied for patients with chronic pain. RESULTS: Fewer than 40% of vulnerable patients reported having been screened for pain over a 2-year period. One hundred twenty-three patients (33%) had medical record documentation of a new episode of chronic pain during a 13-month period, including 18 presentations for headache, 66 for back pain, and 68 for joint pain. Two or more history elements relevant to the presenting pain complaint were documented for 39% of patients, and at least one relevant physical examination element was documented for 68% of patients. Treatment was offered to 86% of patients, but follow-up occurred in only 66%. Eleven of 18 patients prescribed opioids reported being offered a bowel regimen, and 10% of patients prescribed noncyclooxygenase-selective nonsteroidal antiinflammatory medications received appropriate attention to potential gastrointestinal toxicity. CONCLUSION: Chronic pain management in older vulnerable patients is inadequate. Improvement is needed in screening, clinical evaluation, follow-up, and attention to potential toxicities of therapy. C1 Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Div Rheumatol, Los Angeles, CA USA. RAND Corp, Hlth, Santa Monica, CA USA. RP Chodosh, J (reprint author), UCLA Geriatr, 10945 Le Conte Ave,Suite 2339, Los Angeles, CA 90095 USA. EM jchodosh@mednet.ucla.edu OI Chodosh, Joshua/0000-0001-7784-4306 NR 29 TC 51 Z9 52 U1 1 U2 4 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2004 VL 52 IS 5 BP 756 EP 761 DI 10.1111/j.1532-5415.2004.52214.x PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 812QZ UT WOS:000220855300015 PM 15086657 ER PT J AU Weintraub, D Moberg, PJ Duda, JE Katz, IR Stern, MB AF Weintraub, D Moberg, PJ Duda, JE Katz, IR Stern, MB TI Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE Parkinson's disease; disability; psychiatric; depression; cognition ID DAYTIME SLEEPINESS; RISK-FACTORS; DEPRESSION; SCALE; COMORBIDITY; DEMENTIA; VALIDITY AB OBJECTIVES: To examine the effect of depression and other nonmotor symptoms on functional ability in Parkinson's disease (PD). DESIGN: A cross-sectional study of a convenience sample of PD patients receiving specialty care. SETTING: The Parkinson's Disease Research, Education and Clinical Center at the Philadelphia Veterans Affairs Medical Center. PARTICIPANTS: One hundred fourteen community-dwelling patients with idiopathic PD. MEASUREMENTS: The Unified Parkinson's Disease Rating Scale (UPDRS); Hoehn and Yahr Stage; Mini-Mental State Examination; Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, depression module; probes for psychotic symptoms; Hamilton Depression Rating Scale; Geriatric Depression Scale-Short Form; Apathy Scale; and Epworth Sleepiness Scale. Disability was rated using the UPDRS activity of daily living (ADL) score and the Schwab and England ADL score. Multivariate analysis determined effect of depression and other nonmotor symptoms on disability. RESULTS: The presence of psychosis, depressive disorder, increasing depression severity, age, duration of PD, cognitive impairment, apathy, sleepiness, motor impairment, and percentage of time with dyskinesias were related to greater disability in bivariate analyses. Entering these factors into two multiple regression analyses, only the increasing severity of depression and worsening cognition were associated with greater disability using the UPDRS ADL score, accounting for 37% of the variance in disability (P<.001). These two factors plus increasing severity of PD accounted for 54% of the variance in disability using the Schwab and England ADL score (P<.001). CONCLUSION: Results support and extend previous findings that psychiatric and other nonmotor symptoms contribute significantly to disability in PD. Screening for nonmotor symptoms in PD is necessary to more fully explain functional limitations. Further study is required to determine whether identifying and treating these symptoms will improve function and quality of life. C1 Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA USA. Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. RP Weintraub, D (reprint author), 3535 Market St,Room 3003, Philadelphia, PA 19104 USA. EM weintrau@mail.med.upenn.edu NR 28 TC 194 Z9 201 U1 1 U2 19 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2004 VL 52 IS 5 BP 784 EP 788 DI 10.1111/j.1532-5415.2004.52219.x PG 5 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 812QZ UT WOS:000220855300020 PM 15086662 ER PT J AU Boockvar, K Vladeck, BC AF Boockvar, K Vladeck, BC TI Improving the quality of transitional care for persons with complex care needs SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Letter C1 Bronx Vet Affairs Med Ctr, Bronx, NY 10468 USA. Mt Sinai Sch Med, New York, NY 10029 USA. RP Boockvar, K (reprint author), Bronx Vet Affairs Med Ctr, Bronx, NY 10468 USA. OI Boockvar, Kenneth/0000-0003-1165-5558 NR 10 TC 4 Z9 6 U1 1 U2 6 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2004 VL 52 IS 5 BP 855 EP 856 DI 10.1111/j.1532-5415.2004.52230_15.x PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 812QZ UT WOS:000220855300045 PM 15086688 ER PT J AU Richardson-Burns, SM Tyler, KL AF Richardson-Burns, SM Tyler, KL TI Regional differences in viral growth and central nervous system injury correlate with apoptosis SO JOURNAL OF VIROLOGY LA English DT Article ID REOVIRUS-INDUCED APOPTOSIS; ATTACHMENT PROTEIN SIGMA-1; NF-KAPPA-B; SIALIC-ACID; TYPE-3; INFECTION; PATHOGENESIS; ACTIVATION; REQUIRES; MUTATIONS AB Infection of neonatal mice with reovirus T3 Dearing (T3D)), the prototypic neurotropic reovirus, causes fatal encephalitis associated with neuronal injury and virus-induced apoptosis throughout the brain. T3D variant K (VarK) is an antigenic variant that has a nearly 1 million-fold reduction in neurovirulence following intracerebral (i.c.) inoculation compared to T3D) and a restricted pattern of central nervous system injury with damage limited to the hippocampus, sparing other brain regions. We wished to determine whether the restricted pattern of VarK-induced injury was due to a reduced capacity to replicate in or injure cortical, as opposed to hippocampal, tissue. We found that following i.c. inoculation, VarK grew to similar titers as T3D in the hippocampus but had significantly lower titers in the cortex. Both viruses grew to identical titers and infected the same percentage of cells in mouse primary hippocampal cultures (MHC. In mouse primary cortical cultures (MCC) both the number of infected cells and the viral yield per infected cell were significantly lower for VarK than T3D. VarK-induced apoptosis was limited to the hippocampus in vivo, and in vitro both viruses induced apoptosis equally in MHC but VarK induced significantly less apoptosis than T3D in MCC. Growth of T3D in MCC was reduced to levels comparable to those of VarK following treatment of MCC with caspase inhibitors. Conversely, induction of apoptosis in VarK-infected MCC with fatty acid synthase-activating antibody significantly enhanced viral yield. These results suggest that the decreased neurovirulence of VarK may be due to its failure to efficiently induce apoptosis in cortical neurons. C1 Univ Colorado, Hlth Sci Ctr, Dept Neurol, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Neurosci Program, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA. Denver Vet Affairs Med Ctr, Denver, CO 80262 USA. RP Tyler, KL (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Neurol, B-182,4200 E 9th Ave, Denver, CO 80262 USA. EM ken.tyler@uchsc.edu OI Tyler, Kenneth/0000-0003-3294-5888 NR 27 TC 30 Z9 30 U1 0 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD MAY PY 2004 VL 78 IS 10 BP 5466 EP 5475 DI 10.1128/JVI.78.10.5466-5475.2004 PG 10 WC Virology SC Virology GA 817YF UT WOS:000221212100052 PM 15113925 ER PT J AU Asthana, S Bhasin, S Butler, RN Fillit, H Finkelstein, J Harman, SM Holstein, L Korenman, SG Matsumoto, AM Morley, JE Tsitouras, P Urban, R AF Asthana, S Bhasin, S Butler, RN Fillit, H Finkelstein, J Harman, SM Holstein, L Korenman, SG Matsumoto, AM Morley, JE Tsitouras, P Urban, R TI Masculine vitality: Pros and cons of testosterone in treating the andropause SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article ID BONE-MINERAL DENSITY; OLDER MEN; SERUM TESTOSTERONE; BODY-COMPOSITION; MUSCLE STRENGTH; YOUNG MEN; HEALTHY; CANCER; AGE; SUPPLEMENTATION C1 USA, Int Longev Ctr, New York, NY 10028 USA. Univ Wisconsin, Sch Med, Madison, WI 53706 USA. Charles R Drew Univ Med & Sci, Los Angeles, CA 90059 USA. Harvard Univ, Sch Med, Cambridge, MA 02138 USA. Kronos Longev Res Inst, Phoenix, AZ USA. Miraval Life Balance Resort, Tucson, AZ USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. St Louis Univ, Sch Med, St Louis, MO 63103 USA. Univ Texas, Med Branch, Galveston, TX 77550 USA. RP Butler, RN (reprint author), USA, Int Longev Ctr, 60 E 86th St, New York, NY 10028 USA. EM robertb@ilcusa.org; robertb@ilcusa.org RI morley, john/F-9177-2011 OI morley, john/0000-0001-6444-2965 NR 47 TC 22 Z9 23 U1 3 U2 3 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD MAY PY 2004 VL 59 IS 5 BP 461 EP 465 PG 5 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 820TB UT WOS:000221411100010 PM 15123756 ER PT J AU Rubenstein, LZ AF Rubenstein, LZ TI Joseph T. Freeman award lecture - Comprehensive geriatric assessment: From miracle to reality SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Biographical-Item C1 GRECC, VA Med Ctr, Sepulveda, CA 91343 USA. Greater Los Angeles VA Med Ctr, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA. RP Rubenstein, LZ (reprint author), GRECC, VA Med Ctr, 11E,16111 Plummer St, Sepulveda, CA 91343 USA. EM lzrubens@ucla.edu NR 0 TC 36 Z9 37 U1 0 U2 0 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD MAY PY 2004 VL 59 IS 5 BP 473 EP 477 PG 5 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 820TB UT WOS:000221411100012 PM 15123758 ER PT J AU Butt, AA Aldridge, KE Sanders, CV AF Butt, AA Aldridge, KE Sanders, CV TI Infections related to the ingestion of seafood. Part II: parasitic infections and food safety SO LANCET INFECTIOUS DISEASES LA English DT Review ID ANISAKIS-SIMPLEX; CRYPTOSPORIDIUM-PARVUM; NANOPHYETUS-SALMINCOLA; ALLERGIC REACTIONS; ACUTE URTICARIA; FISH; SHELLFISH; DISEASES; ANAPHYLAXIS; OUTBREAK AB Parasites are responsible for a substantial number of seafood-associated infections. The factor most commonly associated with infection is consumption of raw or undercooked seafood. People with underlying disorders, particularly liver disease, are more susceptible to infection. In the first part of this review, published last month, we discussed the viral and bacterial agents associated with consumption of seafood. In part II, we discuss the parasites commonly associated with seafood consumption. Parasites readily identifiable from both consumable seafood and infected human beings include nematodes, trematodes, cestodes, and protozoa. The salient features associated with seafood-related parasite infestations are discussed. To provide a safe product for consumers, the seafood industry and the government in the USA have undertaken specific measures, which include good manufacturing practices and hazards analysis and critical control points implemented by the government and regulatory agencies. Consumers should take common precautions including obtaining seafood from reputable sources especially if the seafood is to be consumed uncooked. Adequate cooking of seafood is the safest way of preventing related infections. C1 Univ Pittsburgh, Div Infect Dis, Pittsburgh, PA 15213 USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. Louisiana State Univ, Ctr Hlth Sci, Dept Med, Infect Dis Sect, New Orleans, LA USA. RP Butt, AA (reprint author), Univ Pittsburgh, Div Infect Dis, 3601 5th Ave,Suite 3A,Falk Bldg, Pittsburgh, PA 15213 USA. EM butta@msx.dept-med.pitt.edu NR 61 TC 37 Z9 38 U1 1 U2 18 PU LANCET LTD PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 1473-3099 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD MAY PY 2004 VL 4 IS 5 BP 294 EP 300 DI 10.1016/S1473-3099(04)01005-9 PG 7 WC Infectious Diseases SC Infectious Diseases GA 817ER UT WOS:000221161300020 PM 15120346 ER PT J AU Hirshkowitz, M AF Hirshkowitz, M TI Normal human sleep: an overview SO MEDICAL CLINICS OF NORTH AMERICA LA English DT Article ID CYCLE; BRAIN; AGE AB This article discusses normal human sleep. Landmarks leading up to the understanding of human sleep, electroencephalographic definitions, and general characteristics of normal human sleep are presented. Actuarial laboratory data, for both night 1 and night 2, are provided with an explanation of how they are compiled. Finally, the mechanisms governing sleep and wakefulness are reviewed. This information is critical to understanding abnormal sleep associated with sleep disorders. C1 Baylor Coll Med, Dept Psychiat, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Houston Vet Affairs Med Ctr, Sleep Ctr, Houston, TX 77030 USA. Methodist Hosp, Sleep Diagnost Lab, Houston, TX USA. RP Hirshkowitz, M (reprint author), Baylor Coll Med, Dept Psychiat, 1 Baylor Plaza, Houston, TX 77030 USA. EM maxh@bcm.tmc.edu NR 24 TC 39 Z9 42 U1 4 U2 16 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0025-7125 J9 MED CLIN N AM JI Med. Clin. N. Am. PD MAY PY 2004 VL 88 IS 3 BP 551 EP + DI 10.1016/j.mcn.2004.01.001 PG 16 WC Medicine, General & Internal SC General & Internal Medicine GA 815NS UT WOS:000221049600002 PM 15087204 ER PT J AU Chattopadhyay, M Wolfe, DP Goins, WC Huang, SH Glorioso, JC Mata, M Fink, DJ AF Chattopadhyay, M Wolfe, DP Goins, WC Huang, SH Glorioso, JC Mata, M Fink, DJ TI Prolonged bioactive transgene expression driven by the HSV latency active promoter 2 (LAP2) in the peripheral nervous system SO MOLECULAR THERAPY LA English DT Meeting Abstract CT 7th Annual Meeting of the American-Society-of-Gene-Therapy CY JUN 02-06, 2004 CL Minneapolis, MN SP Amer Soc Gene Therapy C1 Univ Pittsburgh, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, GRECC, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1525-0016 J9 MOL THER JI Mol. Ther. PD MAY PY 2004 VL 9 SU 1 MA 219 BP S85 EP S85 PG 1 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine GA 833DM UT WOS:000222316600220 ER PT J AU Goss, JR Fetterolf, C Goins, W Wolfe, D Huang, SH Krisky, D Glorioso, JC Mata, M Fink, DJ AF Goss, JR Fetterolf, C Goins, W Wolfe, D Huang, SH Krisky, D Glorioso, JC Mata, M Fink, DJ TI Additive effects of HSV vectors expressing proenkephalin, interleukin-4, and tumor necrosis factor alpha soluble receptor to treat bone cancer SO MOLECULAR THERAPY LA English DT Meeting Abstract CT 7th Annual Meeting of the American-Society-of-Gene-Therapy CY JUN 02-06, 2004 CL Minneapolis, MN SP Amer Soc Gene Therapy C1 Univ Pittsburgh, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, GRECC, Pittsburgh, PA USA. NR 0 TC 1 Z9 1 U1 1 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1525-0016 J9 MOL THER JI Mol. Ther. PD MAY PY 2004 VL 9 SU 1 MA 214 BP S82 EP S82 PG 1 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine GA 833DM UT WOS:000222316600215 ER PT J AU Puskovic, V Wolfe, D Goss, JR Hang, SH Glorioso, JC Mata, M Finnk, DJ AF Puskovic, V Wolfe, D Goss, JR Hang, SH Glorioso, JC Mata, M Finnk, DJ TI Prolonged biologically active transgene expression driven by HSV latency active promoter 2 (LAP2) in brain in vivo SO MOLECULAR THERAPY LA English DT Meeting Abstract CT 7th Annual Meeting of the American-Society-of-Gene-Therapy CY JUN 02-06, 2004 CL Minneapolis, MN SP Amer Soc Gene Therapy C1 Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, GRECC, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1525-0016 J9 MOL THER JI Mol. Ther. PD MAY PY 2004 VL 9 SU 1 MA 220 BP S85 EP S85 PG 1 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine GA 833DM UT WOS:000222316600221 ER PT J AU D'Andrea, MR Cole, GM Ard, MD AF D'Andrea, MR Cole, GM Ard, MD TI The microglial phagocytic role with specific plaque types in the Alzheimer disease brain SO NEUROBIOLOGY OF AGING LA English DT Article; Proceedings Paper CT Conference on Challenging Views of Alzheimers Disease CY 2003 CL Cincinnati, OH DE Alzheimer's disease; amyloid plaques; beta-amyloid; microglia; astrocytes; transgenic mice; neuropathology; inflammation; plaque formation; phagocytosis; dense-core plaques; diffuse plaques; cerebellum; entorhinal cortex ID AMYLOID-BETA-PEPTIDE; TRANSGENIC MICE; SENILE PLAQUES; A-BETA; MOUSE MODEL; SCAVENGER RECEPTOR; PROTEIN; DIFFUSE; CELLS; ACTIVATION AB Alzheimer disease (AD) involves glial inflammation associated with amyloid plaques. The role of the microglial cells in the AD brain is controversial, as it remains unclear if the microglia form the amyloid fibrils of plaques or react to them in a macrophage-phagocytic role. Also, it is not known why microglia are preferentially associated with some amyloid plaque types. This review will provide substantial evidence to support the phagocytic role of microglia in the brain as well as explain why microglia are generally associated with specific plaque types that may be explained through their unique mechanisms of formation. In summary, the data presented suggests that plaque associated microglial activation is typically subsequent to specific amyloid plaque formations in the AD brain. (C) 2004 Elsevier Inc. All rights reserved. C1 Johnson & Johnson Pharmaceut Res & Dev, Drug Discovery, Spring House, PA 19477 USA. Univ Calif Los Angeles, Greater Los Angeles VA Med Ctr, GRECC Res, Dept Med,Alzheimers Dis Res Ctr, Los Angeles, CA USA. Univ Calif Los Angeles, Greater Los Angeles VA Med Ctr, GRECC Res, Dept Neurol,Alzheimers Dis Res Ctr, Los Angeles, CA USA. Univ Mississippi, Med Ctr, Dept Anat, Jackson, MS 39216 USA. RP D'Andrea, MR (reprint author), Johnson & Johnson Pharmaceut Res & Dev, Drug Discovery, D404, Spring House, PA 19477 USA. EM mdandrea@prdus.jnj.com NR 73 TC 112 Z9 113 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD MAY-JUN PY 2004 VL 25 IS 5 BP 675 EP 683 DI 10.1016/j.neurobiolaging.2003.12.026 PG 9 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 832FZ UT WOS:000222254000018 PM 15172747 ER PT J AU Einwohner, R Bernardini, J Fried, L Piraino, B AF Einwohner, R Bernardini, J Fried, L Piraino, B TI The effect of depressive symptoms on survival in peritoneal dialysis patients SO PERITONEAL DIALYSIS INTERNATIONAL LA English DT Article DE depression; comorbidity; mortality ID STAGE RENAL-DISEASE; QUALITY-OF-LIFE; HEMODIALYSIS-PATIENTS; MAJOR DEPRESSION; PSYCHOSOCIAL PREDICTORS; UNITED-STATES; MORTALITY; HOSPITALIZATION; ASSOCIATION; OUTPATIENTS AB Objective:There is little information on the relationship between depressive symptoms and survival in peritoneal dialysis (PD) patients. We examined whether a single measurement of depressive symptoms using a simple self-administered tool predicts survival. Design: Screening test of depressive symptoms as a predictor of outcome. Setting: Three dialysis centers in Southwestern Pennsylvania. Participants: 66 adult PD subjects were screened in 1997-1998 for depression using the Zung scale. Main Outcome Measures: Baseline data collection included assessments of comorbidity, residual renal function, total Kt/V, nPNA, previous renal transplant, and serum albumin. Outcomes were collected prospectively after completion of the depression survey to 12/01. Cox regression analysis of patient survival was performed using all cofactors with p < 0.05 on univariate analysis. Results: One third of patients had depressive symptoms. Compared to nondepressed patients, depressive symptom patients were older (62.5 vs 52.5 years, p = 0.012), had borderline lower serum albumin levels (3.47 vs 3.70 g/dL, p = 0.058), and were more disabled (Karnofsky score 70 vs 90, p < 0.001), but had similar Kt/V, residual renal function, and previous time on PD at the point of the testing. Using multivariate analysis and controlling for comorbidity (using a measurement that includes diabetes mellitus and age) and serum albumin, the survival of patients with depressive symptoms was significantly reduced compared to nondepressed patients. Conclusion: A single measurement of depressive symptoms using a simple self-administered test was an independent predictor of death in a cohort of PD patients, which extends observations in hemodialysis patients. Screening for depressive symptoms should be routine for dialysis patients, and those depressed should have thorough assessment and treatment. Whether treating depression will have an impact on survival is unclear and needs to be studied. C1 Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Piraino, B (reprint author), Univ Pittsburgh, Sch Med, Dept Med, Suite 200,3504 5th Ave, Pittsburgh, PA 15213 USA. EM piraino@pitt.edu OI Piraino, Beth/0000-0001-5061-0841 NR 30 TC 48 Z9 49 U1 2 U2 2 PU MULTIMED INC PI TORONTO PA 66 MARTIN ST, TORONTO, ON L9T 2R2, CANADA SN 0896-8608 J9 PERITON DIALYSIS INT JI Perit. Dial. Int. PD MAY-JUN PY 2004 VL 24 IS 3 BP 256 EP 263 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 825KS UT WOS:000221756700007 PM 15185774 ER PT J AU Kinder, LS Carnethon, MR Palaniappan, LP King, AC Fortmann, SP AF Kinder, LS Carnethon, MR Palaniappan, LP King, AC Fortmann, SP TI Depression and the metabolic syndrome in young adults: Findings from the third national health and nutrition examination survey SO PSYCHOSOMATIC MEDICINE LA English DT Article DE depression; the metabolic syndrome; the third national health and nutrition examination survey ID HEART-RATE-VARIABILITY; CORONARY-ARTERY-DISEASE; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; PSYCHOLOGICAL-FACTORS; MORTALITY; PREVALENCE; ASSOCIATION; RISK; SYMPTOMATOLOGY AB Objective: Previous reports have suggested that depression may lead to the development of cardiovascular disease through its association with the metabolic syndrome; however, little is known about the relationship between depression and the metabolic syndrome. The aim of this study was to establish an association between depression and the metabolic syndrome in a nationally representative sample. Methods: The Third National Health and Nutrition Examination Survey is a population-based health survey of noninstitutionalized US citizens completed between 1988 and 1994. Three thousand one hundred eighty-six men and 3003 women, age 17 to 39, free of coronary heart disease and diabetes, completed the depression module from the Diagnostic Interview Schedule and a medical examination that provided clinical data needed to establish the presence of the metabolic syndrome, as defined by the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Cholesterol in Adults. Results: Women with a history of a major depressive episode were twice as likely to have the metabolic syndrome compared with those with no history of depression. The relationship between depression and metabolic syndrome remained after controlling for age, race, education, smoking, physical inactivity, carbohydrate consumption, and alcohol use. Men with a history of depression were not significantly more likely to have the metabolic syndrome. Conclusions: The prevalence of the metabolic syndrome is elevated among women with a history of depression. It is important to better understand the role depression may play in the effort to reduce the prevalence of the metabolic syndrome and its health consequences. C1 Stanford Univ, Sch Med, Stanford Ctr Res Dis Prevent, Stanford, CA USA. RP Kinder, LS (reprint author), VA Puget Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA. EM lskinder@stanfordalumni.org FU NHLBI NIH HHS [5 T32 HL 07034, F32 HL 10338] NR 41 TC 199 Z9 215 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0033-3174 J9 PSYCHOSOM MED JI Psychosom. Med. PD MAY-JUN PY 2004 VL 66 IS 3 BP 316 EP 322 DI 10.1097/01.psy.0000124755.91880.f4 PG 7 WC Psychiatry; Psychology; Psychology, Multidisciplinary SC Psychiatry; Psychology GA 822OA UT WOS:000221548300005 PM 15184689 ER PT J AU Naliboff, BD Mayer, M Fass, R Fitzgerald, LZ Chang, L Bolus, R Mayer, EA AF Naliboff, BD Mayer, M Fass, R Fitzgerald, LZ Chang, L Bolus, R Mayer, EA TI The effect of life stress on symptoms of heartburn SO PSYCHOSOMATIC MEDICINE LA English DT Article DE vital exhaustion; visceral sensitivity; gastroesophageal reflux disease ID IRRITABLE-BOWEL-SYNDROME; GASTROESOPHAGEAL-REFLUX DISEASE; VITAL EXHAUSTION; GASTROINTESTINAL-TRACT; MYOCARDIAL-INFARCTION; EVENTS; DYSFUNCTION; PERCEPTION; POPULATION; DISORDER AB Objective: Psycbosocial stressors have been associated with exacerbations of symptoms in functional and inflammatory disorders of the gastrointestinal tract. The present longitudinal study tests the general hypothesis that life stressors can exacerbate symptoms in patients with chronic heartburn. Methods: Sixty subjects with current heartburn symptoms were recruited by community advertisement and assessed for presence of stressful life events retrospectively over the preceding 6 months and prospectively for 4 months. Symptom severity by daily diary, quality of life, and psychological symptoms of anxiety, depression, and vital exhaustion were also measured. Results: The presence of a severe, sustained life stress during the previous 6 months significantly predicted increased heartburn symptoms during the following 4 months. In addition, symptoms showed a strong, independent correlation with vital exhaustion. Affective and subjective stress ratings were not strongly related to heartburn severity; however, anxiety showed the strongest relationship to impaired quality of life and depression to heartburn medication use. Conclusions: As with other chronic conditions such as irritable bowel syndrome (IBS), heartburn severity appears to be most responsive to major life events and not an accumulation of more minor stressors or fluctuations in mood. In addition, vital exhaustion, which may in part result from sustained stress, may represent the psychophysiological symptom complex most closely associated with heartburn exacerbation. Potential mechanisms for these results include increased level and frequency of esophageal acid exposure, inhibition of gastric emptying of acid, or stress-induced hypersensitivity. C1 Univ Calif Los Angeles, Dept Med, Ctr Neurovisceral Sci & Womens Hlth, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Physiol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. VA Med Ctr, Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Arizona, VA Med Ctr, GI Div, Tucson, AZ USA. RP Naliboff, BD (reprint author), VA Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr, Neuroenter Dis Program, Bldg 115,Room 223,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM naliboff@ucla.edu FU NIDDK NIH HHS [P50 DK64539]; NINR NIH HHS [NR007768] NR 43 TC 66 Z9 72 U1 3 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0033-3174 J9 PSYCHOSOM MED JI Psychosom. Med. PD MAY-JUN PY 2004 VL 66 IS 3 BP 426 EP 434 DI 10.1097/01.psy.0000124756.37520.84 PG 9 WC Psychiatry; Psychology; Psychology, Multidisciplinary SC Psychiatry; Psychology GA 822OA UT WOS:000221548300023 PM 15184707 ER PT J AU Beresford, TP Martin, B Alfers, J AF Beresford, TP Martin, B Alfers, J TI Developing a brief monitoring procedure for alcohol dependent liver graft recipients SO PSYCHOSOMATICS LA English DT Article ID BRIEF INTERVENTIONS; TRANSPLANT RECIPIENTS; DRINKERS; TRIAL AB To address the occurrence of deaths in later Postoperative years among alcohol-dependent liver graft recipients, the authors developed the Brief Active Focused Follow-Up protocol as an instrument for monitoring alcohol use following liver transplant. In this preliminary study, patient receptiveness to its use was tested and its ability, to identify patient drinking was noted. Alcohol dependent liver transplant recipients (N = 24) and alcohol-dependent nontransplant patients (N = 25) were asked to rate their receptiveness to the Brief Active Focused Follow-Up in three areas. Subjects used a five-point scale for which 5 indicated the highest positive response. Liver transplant recipients responded positively to the Brief Active Focused Follow-Up, with mean responses of 4.92, 4.08, and 4.63 with regard to clarity, usefulness, and ease of completion, respectively. Nontransplant subjects responded similarly, with mean responses of 4.88, 4.12, and 4.52. The two groups were not significantly different in their receptiveness to the Brief Active Focused Follow-Up interview The Brief Active Focused Follow-Up identified alcohol use within the last 30 days: 8% (N = 2 of 24) in the transplant group, and 56% (N = 14 of 25) in the nontransplant group. These results suggest that 1) this manualized, brief monitoring technique is well received by alcohol-dependent liver transplant patients, and 2) the Brief Active Focused Follow-Up's, I user friendliness" makes it a potentially appropriate instrument for long-term monitoring of alcohol use among alcohol-dependent liver graft recipients. C1 Denver VA Med Ctr 151, Denver, CO 80220 USA. Dept Vet Affairs Med Ctr, Denver, CO USA. Univ Colorado, Hlth Sci Ctr, Denver, CO 80202 USA. RP Beresford, TP (reprint author), Denver VA Med Ctr 151, 1055 Clermont St, Denver, CO 80220 USA. EM thomas.beresford@uchsc.edu FU NIAAA NIH HHS [AA-12095] NR 15 TC 5 Z9 5 U1 1 U2 1 PU AMER PSYCHIATRIC PRESS, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0033-3182 J9 PSYCHOSOMATICS JI Psychosomatics PD MAY-JUN PY 2004 VL 45 IS 3 BP 220 EP 223 DI 10.1176/appi.psy.45.3.220 PG 4 WC Psychiatry; Psychology SC Psychiatry; Psychology GA 816JZ UT WOS:000221107500006 PM 15123847 ER PT J AU Johansen, KL AF Johansen, KL TI Testosterone metabolism and replacement therapy in patients with end-stage renal disease SO SEMINARS IN DIALYSIS LA English DT Review ID CLINICAL-RESEARCH-CENTER; CORONARY-ARTERY-DISEASE; RANDOMIZED CONTROLLED-TRIAL; PITUITARY-TESTICULAR AXIS; BONE-MINERAL DENSITY; HYPOGONADAL MEN; TRANSDERMAL TESTOSTERONE; OLDER MEN; AGING MALE; ERECTILE DYSFUNCTION AB Hypogonadism is common among men with end-stage renal disease (ESRD), beginning before the need for dialysis and not improved with the initiation of dialysis. Many of the manifestations of hypogonadism, such as bone disease and muscle wasting, are also frequently seen among dialysis patients. There have been few studies of testosterone replacement therapy in this patient population, but available data suggest that testosterone can be administered without adjustment of the doses used in hypogonadal men with normal renal function. Extrapolation from results of treatment of hypogonadal older men with normal renal function suggests that testosterone replacement could improve libido and could have salutary effects on muscle mass and bone mineral density in patients with kidney disease. However, caution is warranted because of the potential side effects of testosterone therapy, and further research is needed to more precisely define the balance of risk and benefit in patients with chronic kidney disease. Specifically it will be important to determine the prevalence and clinical significance of hypogonadism in ESRD patients in the modern era and to measure the effects of replacement therapy on various symptoms of hypogonadism as well as on overall quality of life, physical functioning, and survival. C1 San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA 94121 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Johansen, KL (reprint author), San Francisco VA Med Ctr, Nephrol Sect, 111J,4150 Clement St, San Francisco, CA 94121 USA. EM johanse@itsa.ucsf.edu NR 73 TC 29 Z9 32 U1 1 U2 8 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0894-0959 J9 SEMIN DIALYSIS JI Semin. Dial. PD MAY-JUN PY 2004 VL 17 IS 3 BP 202 EP 208 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 821HS UT WOS:000221451600010 PM 15144546 ER PT J AU Wang, PL Watnick, SG AF Wang, PL Watnick, SG TI Depression: A common but underrecognized condition associated with end-stage renal disease SO SEMINARS IN DIALYSIS LA English DT Article ID QUALITY-OF-LIFE; DIALYSIS PATIENTS; HEMODIALYSIS-PATIENTS; MAJOR DEPRESSION; SYMPTOMS; VALIDATION; MORTALITY; INVENTORY; ANXIETY; SCALE AB We describe a patient with end-stage renal disease (ESRD) who developed depression over the period of dialysis initiation. Depression is an extremely common but underrecognized disorder in the dialysis population, which is one of the rationales for this case report. Here we present the epidemiology, mechanisms for diagnosis, associations with medical morbidity, and treatment modalities specifically for patients on dialysis. C1 Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR USA. RP Watnick, SG (reprint author), Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, PP262,3314 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM watnicks@ohsu.edu NR 33 TC 14 Z9 15 U1 2 U2 3 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0894-0959 J9 SEMIN DIALYSIS JI Semin. Dial. PD MAY-JUN PY 2004 VL 17 IS 3 BP 237 EP 240 PG 4 WC Urology & Nephrology SC Urology & Nephrology GA 821HS UT WOS:000221451600016 PM 15144552 ER PT J AU Littner, MR Kushida, C Anderson, WM Bailey, D Berry, RB Hirshkowitz, M Kapen, S Kramer, M Lee-Chiong, T Li, KK Loube, DL Morgenthaler, T Wise, M AF Littner, MR Kushida, C Anderson, WM Bailey, D Berry, RB Hirshkowitz, M Kapen, S Kramer, M Lee-Chiong, T Li, KK Loube, DL Morgenthaler, T Wise, M TI Practice parameters for the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder SO SLEEP LA English DT Article DE dopaminergic agents; dopamine agonists; restless legs syndrome; periodic limb movement disorder AB Dopaminergic agents, particularly dopamine agonists, have been used with increasing frequency in the treatment of restless legs syndrome and periodic limb movement disorder. These evidence-based practice parameters are complementary to the Practice Parameters for the Treatment of Restless Legs Syndrome and Periodic Limb Movement Disorder, published in 1999.1 These practice parameters were developed by the Standards of Practice Committee and reviewed and approved by the Board of Directors of the American Academy of Sleep Medicine. Recommendations are based on the accompanying comprehensive review of the medical literature regarding the dopaminergic treatment of restless legs syndrome (RLS) and periodic limb movement disorder (PLMD), which was developed by a task force commissioned by the American Academy of Sleep Medicine. The following recommendations serve as a guide to the appropriate use of dopaminergic agents in the treatment of RLS and PLMD. Levodopa with decarboxylase inhibitor, and the dopaminergic agonists pergolide, pramipexole, and ropinirole are effective in the treatment of RLS and PLMD. Other dopamine agonists (talipexole, cabergoline, piribidel, and alpha-dihydroergocryptine) and the dopaminergic agents amantadine and selegiline may be effective in the treatment of RLS and PLMD, but the level of effectiveness of these medications is not currently established. Lastly, no specific recommendations can be made regarding dopaminergic treatment of children or pregnant women with RLS or PLMD. C1 VA Greater Los Angeles Healthcare Syst, Sepulveda, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Sepulveda, CA USA. Stanford Univ, Ctr Excellence Sleep Disorders, Stanford, CA 94305 USA. Univ S Florida, Coll Med, Tampa, FL USA. Univ Florida, Malcom Randall VAMC, Gainesville, FL USA. Baylor Coll Med, Houston, TX 77030 USA. VA Med Ctr, Houston, TX USA. Wayne State Univ, Detroit, MI USA. SUNY Hlth Sci Ctr, Dept Psychiat, Maimonides Med Ctr, Brooklyn, NY 11203 USA. NYU, Sch Med, New York, NY USA. Nalt Jewish Med & Res Ctr, Sleep Clin, Denver, CO USA. Stanford Sleep Disorders Clin & Res Ctr, Stanford, CA USA. Swedish Med Ctr, Sleep Med Inst, Seattle, WA USA. Mayo Clin & Mayo Fdn, Mayo Sleep Disorders Ctr, Rochester, MN 55905 USA. Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA. Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. RP Littner, MR (reprint author), VA Greater Los Angeles Healthcare Syst, Sepulveda, CA USA. OI Morgenthaler, Timothy/0000-0002-2614-3793 NR 4 TC 93 Z9 93 U1 0 U2 1 PU AMER ACADEMY SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CENTER STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PD MAY 1 PY 2004 VL 27 IS 3 BP 557 EP 559 PG 3 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 844OU UT WOS:000223169000031 PM 15164914 ER PT J AU Zhao, JB Bauman, WA Huang, RJ Caplan, AJ Cardozo, C AF Zhao, JB Bauman, WA Huang, RJ Caplan, AJ Cardozo, C TI Oxandrolone blocks glucocorticoid signaling in an androgen receptor-dependent manner SO STEROIDS LA English DT Article DE glucocorticoids; anabolic steroids; androgen receptor antagonists; polychlorobiphenyl xenobiotics; steroid hormone receptors; crosstalk ID ANABOLIC-STEROIDS; TRANSCRIPTIONAL ACTIVITY; SEVERE BURN; WEIGHT-LOSS; CROSS-TALK; RAT MUSCLE; INHIBITION; TERMINUS; PATHWAY; BINDING AB The anabolic steroid oxandrolone is increasingly used to preserve or restore muscle mass in those with HIV infection or serious bums. These effects are mediated, in part, by the androgen receptor (AR). Anti-glucocorticoid effects have also been reported for some anabolic steroids, and the goal of our studies was to determine whether oxandrolone had a similar mechanism of action. Studies with in vitro translated glucocorticoid receptor (GR), however, showed no inhibition of cortisol binding by oxandrolone. Conversely, experiments in cell culture systems demonstrated significant antagonism of corti sol-induced transcriptional activation by oxandrolone in cells expressing both the AR and GR. Inhibition was not overcome by increased cortisol concentration, and no inhibition by oxandrolone was observed in cells expressing GR alone, confirming that non-competitive mechanisms were involved. AR-dependent repression of transcriptional activation by oxandrolone was also observed with the synthetic glucocorticoids dexamethasone and methylprednisolone. Furthermore, the AR antagonists 2-hydroxyflutamide and DDE also repressed GR transactivation in an AR-dependent manner. A mutant AR lacking a functional nuclear localization signal (AR(4RKM)) was active in oxandrolone-mediated repression of GR even though oxandrolone-bound AR(4RKM) failed to enter the nucleus and did not affect nuclear import of GR. These data indicate a novel action of oxandrolone to suppress glucocorticoid action via crosstalk between AR and GR. (C) 2004 Elsevier Inc. All rights reserved. C1 Bronx Vet Adm Med Ctr, Spinal Cord Damage Res Ctr, Rehabil & Res Dev Ctr Excellence Med Consequences, Bronx, NY 10468 USA. Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA. Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, New York, NY 10029 USA. Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA. RP Cardozo, C (reprint author), Bronx Vet Adm Med Ctr, Spinal Cord Damage Res Ctr, Rehabil & Res Dev Ctr Excellence Med Consequences, Room 1E-02,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM chris.cardozo@mssm.edu FU NCI NIH HHS [R24 CA095823-01]; NIDDK NIH HHS [DK60598]; PHS HHS [P4207384] NR 34 TC 24 Z9 25 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0039-128X J9 STEROIDS JI Steroids PD MAY PY 2004 VL 69 IS 5 BP 357 EP 366 DI 10.1016/j.steroids.2004.01.006 PG 10 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 838FO UT WOS:000222699100007 PM 15219414 ER PT J AU Habra, MA Hijazi, R Verstovsek, G Marcelli, M AF Habra, MA Hijazi, R Verstovsek, G Marcelli, M TI Medullary thyroid carcinoma associated with hyperthyroidism: A case report and review of the literature SO THYROID LA English DT Review ID ELEVATED SERUM CALCITONIN; GRAVES-DISEASE; ROUTINE MEASUREMENT; IMMUNOREACTIVE CALCITONIN; HASHIMOTOS THYROIDITIS; PROGNOSTIC FACTORS; ACUTE-PANCREATITIS; CELL-CARCINOMA; CANCER; SOMATOSTATIN AB Thyroid cancer is occasionally associated with hyperthyroidism. Papillary thyroid carcinoma is the most frequently reported histologic type followed by follicular thyroid carcinoma. Medullary thyroid carcinoma (MTC) has been rarely described in association with Graves' disease or other forms of hyperthyroidism. To our knowledge, only 14 cases have been described in which MTC was associated with hyperthyroidism. We report a 70-year-old male who had a clinically significant MTC discovered in the course of diagnostic work-up for hyperthyroidism. We also summarize the clinical features of the other 14 reported cases. C1 Joint Baylor Coll Med & MD Anderson Canc Ctr Fell, Houston, TX USA. Baylor Coll Med, Dept Pathol & Lab Med, VA Med Ctr, Houston, TX USA. Baylor Coll Med, Div Endocrinol, VA Med Ctr, Houston, TX USA. RP Marcelli, M (reprint author), Baylor Coll Med, Div Endocrinol Diabet & Metab, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM marcelli@bcm.tmc.edu NR 45 TC 6 Z9 6 U1 0 U2 0 PU MARY ANN LIEBERT INC PUBL PI LARCHMONT PA 2 MADISON AVENUE, LARCHMONT, NY 10538 USA SN 1050-7256 J9 THYROID JI Thyroid PD MAY PY 2004 VL 14 IS 5 BP 391 EP 396 DI 10.1089/105072504774193249 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 825RE UT WOS:000221775100011 PM 15186618 ER PT J AU Tiffany, NM Wersinger, EM Garzotto, M Beer, TM AF Tiffany, NM Wersinger, EM Garzotto, M Beer, TM TI Imatinib mesylate and zoledronic acid in an drogen-in dependent prostate cancer SO UROLOGY LA English DT Article ID CHRONIC MYELOID-LEUKEMIA; ABL TYROSINE KINASE; BONE METASTASES; SIGNAL-TRANSDUCTION; RANDOMIZED-TRIAL; CLINICAL-TRIALS; PHASE-II; GROWTH; INHIBITOR; CARCINOMA AB Objectives. To determine the safety and efficacy of zoledronic acid (Zometa) combined with imatinib mesylate (Gleevec) in patients with bone pain due to androgen-independent prostate cancer. Methods. Fifteen patients were treated with zoledronic acid 4 mg intravenously every 28 days and imatinib mesylate 400 mg/day. The pain response, defined as a 2-point reduction in the Present Pain Intensity Scale or normalization if the initial score was 1, was the primary endpoint. Secondary endpoints included palliative response, prostate-specific antigen response, measurable disease response, time to progression, impact on quality of life, decrease in markers of bone turnover, and tolerability of the drug combination. Results. The study was stopped early because of a lack of activity. No palliative or clinical activity was detected for the combination, and no prostate-specific antigen responses were observed. The median time to progression was 4 weeks (95% confidence interval 3 to 5), and the median duration of treatment was 8 weeks (range 1.6 to 16.7). The median overall survival was 54 weeks (95% confidence interval 18 to 90). Therapy was associated with a reduction in urine N-telopeptides and a trend toward a reduction in serum osteocalcin, but no change occurred in bone-specific alkaline phosphatase. Conclusions. In this patient population, imatinib mesylate and zoledronic acid produced no prostate-specific antigen responses and had no palliative or clinical activity. (C) 2004 Elsevier Inc. C1 Oregon Hlth Sci Univ, Dept Med, Div Hematol & Med Oncol, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Div Urol, Portland, OR 97239 USA. Portland Vet Affairs Med Ctr, Portland, OR USA. RP Beer, TM (reprint author), Oregon Hlth Sci Univ, Dept Med, Div Hematol & Med Oncol, Mail Code CR-145,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. FU NCRR NIH HHS [3M01RR00334-33S2] NR 31 TC 30 Z9 32 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 J9 UROLOGY JI Urology PD MAY PY 2004 VL 63 IS 5 BP 934 EP 939 DI 10.1016/j.urology.2003.12.022 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 824ET UT WOS:000221669400034 PM 15134984 ER PT J AU Sadetsky, N Kneier, A Latini, DM Knight, S Loi, J Carroll, PR AF Sadetsky, N Kneier, A Latini, DM Knight, S Loi, J Carroll, PR TI Short-term psychosocial counseling for patients with newly-diagnosed prostate cancer SO VALUE IN HEALTH LA English DT Meeting Abstract C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 1098-3015 J9 VALUE HEALTH JI Value Health PD MAY-JUN PY 2004 VL 7 IS 3 BP 252 EP 252 DI 10.1016/S1098-3015(10)62163-8 PG 1 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 819ZW UT WOS:000221356600102 ER PT J AU Wen, L Parchman, M Linn, W Lee, S AF Wen, L Parchman, M Linn, W Lee, S TI Self-monitoring of blood glucose among veterans with diabetes managed on oral therapy SO VALUE IN HEALTH LA English DT Meeting Abstract C1 S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 1098-3015 J9 VALUE HEALTH JI Value Health PD MAY-JUN PY 2004 VL 7 IS 3 BP 338 EP 338 DI 10.1016/S1098-3015(10)62431-X PG 1 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 819ZW UT WOS:000221356600370 ER PT J AU Wen, L Parchman, M Linn, W AF Wen, L Parchman, M Linn, W TI Hospitalizations within the VA among veterans with diabetes SO VALUE IN HEALTH LA English DT Meeting Abstract C1 S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 1098-3015 J9 VALUE HEALTH JI Value Health PD MAY-JUN PY 2004 VL 7 IS 3 BP 345 EP 345 DI 10.1016/S1098-3015(10)62453-9 PG 1 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 819ZW UT WOS:000221356600392 ER PT J AU Turney, MK Nicholson, WE Kovacs, WJ AF Turney, MK Nicholson, WE Kovacs, WJ TI Gene expression phenotyping of an ACTH-producing small cell lung cancer line SO MOLECULAR AND CELLULAR ENDOCRINOLOGY LA English DT Article DE proopiomelanocortin; small cell lung cancer; ectopic ACTH; microarray (human) ID TRANSCRIPTION FACTOR-I; ULNAR-MAMMARY SYNDROME; PROOPIOMELANOCORTIN GENE; GLUCOCORTICOID-RECEPTOR; NEUROENDOCRINE TUMORS; METASTATIC PULMONARY; NONPITUITARY TISSUES; PRECURSOR PEPTIDES; HUMAN-PLASMA; PITUITARY AB DNA microarray techniques were used to compare gene expression in an adrenocorticotropin (ACTH)-producing human small cell lung carcinoma line (DMS-79) with six other small cell lung cancer (SCLC) lines that do not produce ACTH. Twelve genes were expressed at more than five-fold higher levels in DMS-79 cells. Two transcription factors were the genes that exhibited the most remarkable over-expression: T-box 3 mRNA was detected at levels 19.31 +/- 3.78 times those observed in the SCLCs. Thyroid transcription factor (TTF-1, T/ebp, Nkx2.1) was expressed at 14.24 +/- 3.41-fold higher in DMS-79 cells. Seven genes were identified whose expression levels were at least five-fold lower in the ACTH-producing cell line. Variation in culture medium formulation did not significantly affect the gene expression profile of DMS-79 cells and expression data observed in microarray experiments were corroborated by northern blot analysis of RNA from the same cell lines. These experiments reveal new candidate genes that could be involved in the dysregulation of POMC gene expression manifested by ACTH-producing nonpituitary tumors. (C) 2004 Elsevier Ireland Ltd. All rights reserved. C1 Vanderbilt Univ, Sch Med, Div Endocrinol Diabet & Metab, Nashville, TN 37232 USA. US Dept Vet Affairs, Tennessee Valley Hlth Care Syst, Nashville, TN USA. RP Kovacs, WJ (reprint author), Vanderbilt Univ, Sch Med, Div Endocrinol Diabet & Metab, Nashville, TN 37232 USA. EM wiilliam.kovacs@vanderbilt.edu OI Kovacs, William/0000-0002-3940-2109 FU NIDDK NIH HHS [P60 DK020593] NR 51 TC 3 Z9 3 U1 0 U2 0 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0303-7207 J9 MOL CELL ENDOCRINOL JI Mol. Cell. Endocrinol. PD APR 30 PY 2004 VL 219 IS 1-2 BP 105 EP 113 DI 10.1016/j.mce.2004.01.005 PG 9 WC Cell Biology; Endocrinology & Metabolism SC Cell Biology; Endocrinology & Metabolism GA 826NJ UT WOS:000221835500012 PM 15149732 ER PT J AU Brody, AL Mandelkern, MA Lee, G Smith, E Sadeghi, M Saxena, S Jarvik, ME London, ED AF Brody, AL Mandelkern, MA Lee, G Smith, E Sadeghi, M Saxena, S Jarvik, ME London, ED TI Attenuation of cue-induced cigarette craving and anterior cingulate cortex activation in bupropion-treated smokers: a preliminary study SO PSYCHIATRY RESEARCH-NEUROIMAGING LA English DT Article; Proceedings Paper CT 9th Annual Meeting of the Society-for-Research-on-Nicotine-and-Tobacco CY FEB 19-22, 2003 CL NEW ORLEANS, LA SP Soc Res Nicotine & Tobacco DE positron emission tomography; nicotine dependence; brain metabolism; anterior cingulate cortex; orbitofrontal cortex; bupropion hydrochloride ID SUSTAINED-RELEASE BUPROPION; SMOKING-CESSATION; DOPAMINE TRANSPORTER; ORBITOFRONTAL CORTEX; HUMAN BRAIN; NOREPINEPHRINE OUTPUT; COGNITIVE-PROCESSES; RAT; STRESS; WITHDRAWAL AB In untreated smokers, exposure to cigarette-related cues increases both the intensity of cigarette craving and relative glucose metabolism of the perigenual/ventral anterior cingulate cortex (ACC). Given that treatment with bupropion HCl reduces overall cigarette craving levels in nicotine dependent subjects, we performed a preliminary study of smokers to determine if bupropion HCl treatment attenuates cue-induced cigarette craving and associated brain metabolic activation. Thirty-seven, otherwise healthy smokers (20 untreated and 17 who had received open-label treatment with bupropion HCl) underwent two F-18-fluorodeoxyglucose positron emission tomography scanning sessions in randomized order-one when presented with neutral cues and the other when presented with cigarette-related cues. Bupropion-treated smokers had smaller cigarette cue-induced increases in craving scores on the Urge to Smoke (UTS) Scale and less activation of perigenual/ventral ACC metabolism from the neutral to the cigarette cue scan than untreated smokers. Thus, in addition to its known effects on spontaneous cigarette craving and withdrawal symptoms, bupropion HCl diminishes cue-induced cigarette craving and appears to attenuate cigarette cue-induced ACC activation. These results are consistent with the known effects of bupropion HCl, including its enhancement of catecholaminergic neurotransmission. (C) 2004 Elsevier Ireland Ltd. All rights reserved. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. Greater Los Angeles Vet Affairs Healthcare Syst, Positron Emiss Tomog Ctr, Los Angeles, CA USA. Univ Calif Irvine, Dept Phys, Irvine, CA 92717 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90024 USA. RP Brody, AL (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, 300 Med Plaza,Suite 2200, Los Angeles, CA 90095 USA. EM abrody@ucla.edu FU NIDA NIH HHS [R01 DA15059, R01 DA014093, R01 DA015059, R01 DA015059-04, R01 DA14093]; NIMH NIH HHS [K23 MH001694] NR 75 TC 106 Z9 108 U1 3 U2 5 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0925-4927 J9 PSYCHIAT RES-NEUROIM JI Psychiatry Res. Neuroimaging PD APR 30 PY 2004 VL 130 IS 3 BP 269 EP 281 DI 10.1016/j.psychresns.2003.12.006 PG 13 WC Clinical Neurology; Neuroimaging; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 824GB UT WOS:000221673200005 PM 15135160 ER PT J AU Turner, JH Gelasco, AK Raymond, JR AF Turner, JH Gelasco, AK Raymond, JR TI Calmodulin interacts with the third intracellular loop of the serotonin 5-hydroxytryptamine(1A) receptor at two distinct sites - Putative role in receptor phosphorylation by protein kinase C SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID HUMAN 5-HT1A RECEPTOR; GROWTH-FACTOR RECEPTOR; MEDIATED ERK ACTIVATION; MEMBRANE CA2+ PUMP; RAT HIPPOCAMPUS; NA+/H+ EXCHANGE; COUPLING DOMAIN; BINDING DOMAINS; CHO-K1 CELLS; NEURONS AB The serotonin 5-HT1A receptor couples to heterotrimeric G proteins and intracellular second messengers, yet no studies have investigated the possible role of additional receptor-interacting proteins in 5-HT1A receptor signaling. We have found that the ubiquitous Ca2+-sensor calmodulin (CaM) co-immunoprecipitates with the 5-HT1A receptor in Chinese hamster ovary fibroblasts. The human 5-HT1A receptor contains two putative CaM binding motifs, located in the N- and C-terminal juxtamembrane regions of the third intracellular loop of the receptor. Peptides encompassing both the N- terminal (i3N) and C-terminal (i3C) CaM-binding domains were tested for CaM binding. Using in vitro binding assays in combination with gel shift analysis, we demonstrated Ca2+-dependent formation of complexes between CaM and both peptides. We determined kinetic data using a combination of BIAcore surface plasmon resonance (SPR) and dansyl-CaM fluorescence. SPR analysis gave an apparent K-D of similar to110 nM for the i3N peptide and similar to700 nM for the i3C peptide. Both peptides also caused characteristic shifts in the fluorescence emission spectrum of dansyl-CaM, with apparent affinities of 87 +/- 23 nM and 1.70 +/- 0.16 muM. We used bioluminescence resonance energy transfer to show that CaM interacts with the 5-HT1A receptor in living cells, representing the first in vivo evidence of a G protein-coupled receptor interacting with CaM. Finally, we showed that CaM binding and phosphorylation of the 5-HT1A receptor i3 loop peptides by protein kinase C are antagonistic in vitro, suggesting a possible role for CaM in the regulation of 5-HT1A receptor phosphorylation and desensitization. These data suggest that the 5-HT1A receptor contains high and moderate affinity CaM binding regions that may play important roles in receptor signaling and function. C1 Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Med Serv, Charleston, SC USA. Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC USA. RP Raymond, JR (reprint author), Med Univ S Carolina, Dept Med, Div Nephrol, 96 Jonathan Lucas St,Rm 829 CSB,POB 250623, Charleston, SC 29425 USA. EM raymondj@musc.edu FU NIDDK NIH HHS [DK52448, DK59950]; NIGMS NIH HHS [GM63909]; NIMH NIH HHS [MH64795] NR 57 TC 49 Z9 52 U1 0 U2 3 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD APR 23 PY 2004 VL 279 IS 17 BP 17027 EP 17037 DI 10.1074/jbc.M313919200 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 812WU UT WOS:000220870400019 PM 14752100 ER PT J AU Shelkovnikov, S Merlic, CA Gonick, HC AF Shelkovnikov, S Merlic, CA Gonick, HC TI Influence of nitric oxide donors and peroxynitrite on the contractile effect and concentration of norepinephrine SO LIFE SCIENCES LA English DT Article DE norepinephrine; nitric oxide; peroxynitrite; rat; aorta; contraction ID VASCULAR SMOOTH-MUSCLE; PULMONARY-ARTERY; NITROGEN-OXIDES; RAT AORTA; CHANNELS; VASODILATION; NITRATION; NO; CATECHOLAMINES; HYPERTENSION AB Nitric oxide (NO) and peroxynitrite (ONOO) are said to destroy norepinephrine (NE). We studied the role of NE decomposition by NO donors and ONOO as they affect the contractile activity of NE in rat denuded thoracic aorta. First, we determined the relaxing effect of NO donors (SNAP, PROLI/NO, Sodium nitrite, SIN-1) and ONOO after precontraction by NE (1 muM). SNAP and SIN-1 (EC50 50-110 nM) were more active than PROLI/ NO, Sodium nitrite or ONOO (EC50 19-30 muM). The relaxing effect of NO donors and ONOO were decreased by ODQ (10 muM), a guanylate cyclase inhibitor. Second, we compared the contractile activity of NE before and after preincubation with NO donors or ONOO in presence of ODQ. NE (1 muM) was incubated with NO donors or ONOO at the concentrations of 0.1 mM in both Krebs solution or phosphate buffer (PH 7.4; 0.1 M) for 10 minutes at 37degreesC. NE evoked the aorta contraction in the same concentrations before and after preincubation with NO donors. In contrast, ONOO decreased effect of NE, EC50 was measured at 4.3 +/- 0.3 nM and 13.4 +/- 1.6 nM, before and after preincubation of NE with ONOO respectively. Third, we measured the NE concentration using the HPLC method. We revealed that the concentration of NE after preincubation with NO donors was unaltered. However HPLC measurement revealed that NE concentration after preincubation with ONOO was reduced 2-3-fold. Therefore, under these experimental conditions ONOO, but not NO donors, was capable of destroying NE. (C) 2004 Elsevier Inc. All rights reserved. C1 W Los Angeles Vet Affairs Med Ctr, Med & Res Serv, Nephrol Sect, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Los Angeles, CA 90095 USA. RP Shelkovnikov, S (reprint author), W Los Angeles Vet Affairs Med Ctr, Med & Res Serv, Nephrol Sect, Room 304,Bld 114,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM shelkovnikov@pcmagic.net NR 33 TC 8 Z9 8 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0024-3205 J9 LIFE SCI JI Life Sci. PD APR 23 PY 2004 VL 74 IS 23 BP 2919 EP 2928 DI 10.1016/j.lfs.2003.11.006 PG 10 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA 809HX UT WOS:000220628900011 PM 15050429 ER PT J AU Lorberbaum, JP Williams, WR AF Lorberbaum, JP Williams, WR TI Are there really no evolutionarily stable strategies in the iterated prisoner's dilemma? (vol 214, pg 155) SO JOURNAL OF THEORETICAL BIOLOGY LA English DT Correction C1 Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. Ralph H Johnson Vet Adm Med Ctr, Charleston, SC 29425 USA. RP Lorberbaum, JP (reprint author), Med Univ S Carolina, Dept Psychiat, POB 250861,67 President St, Charleston, SC 29425 USA. EM lorberjp@musc.edu NR 1 TC 0 Z9 0 U1 0 U2 1 PU ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0022-5193 J9 J THEOR BIOL JI J. Theor. Biol. PD APR 21 PY 2004 VL 227 IS 4 BP 593 EP 593 DI 10.1016/j.jtbi.2004.01.005 PG 1 WC Biology; Mathematical & Computational Biology SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational Biology GA 809ZH UT WOS:000220674100012 ER PT J AU Rita, M Young, I AF Rita, M Young, I TI Tumor skewing of CD34(+) progenitor cell differentiation into endothelial cells SO INTERNATIONAL JOURNAL OF CANCER LA English DT Article DE angiogenesis; angiopoietin-1; CD34(+); endothelial cells; progenitor cells; vasculogenesis; VEGF ID COLONY-STIMULATING FACTOR; LEWIS LUNG-CARCINOMA; HEMATOPOIETIC STEM-CELLS; IMMUNE SUPPRESSOR CELLS; GROWTH-FACTOR-BETA; BONE-MARROW; NECK-CANCER; PERIPHERAL-BLOOD; MICE BEARING; ANGIOGENIC FACTORS AB Tumor production of granulocyte-macrophage colony-stimulating factor (GM-CSF) results in the mobilization of CD34(+) progenitor cells into the peripheral blood and tumor tissue. Using the Lewis lung carcinoma (LLC) model, in vitro studies showed that LLC cells could chemoattract CD34(+) cells predominantly through tumor production of VEGF. Addition of LLC-conditioned medium to CD34(+) cells that were cultured under conditions that support myeloid lineage cells skewed the differentiation of these precursor cells toward endothelial cells expressing CD31 and CD144. This differentiation of CD34(+) cells toward endothelial cells was attributed predominantly to angiopoietin-1 in the tumor-conditioned medium. The CD34(+) cells expressed the angiopoietin receptor Tie-2 and their differentiation into endothelial cells was blocked with neutralizing angiopoietin-1 antibodies. In vivo studies showed that infusion of lacZ(+) CD34(+) cells from the bone marrow of transgenic mice into wild-type mice bearing LLC tumors resulted in the accumulation of lacZ(+) cells within the tumor mass, particularly at the tumor's periphery. That these infused CD34(+) progenitor cells could develop into endothelial cells of the tumor vasculature was supported by their acquisition of the endothelial cell markers CD31 or CD144 within the tumor tissue. These studies demonstrate the capacity of tumor to attract CD34(+) cells to the tumor site and to direct the differentiation of these CD34(+) cells into endothelial cells that can become a component of the tumor vasculature. (C) 2004 Wiley-Liss, Inc. C1 Loyola Univ, Stritch Sch Med, Dept Pathol, Maywood, IL 60153 USA. Loyola Univ, Stritch Sch Med, Dept Otolaryngol, Maywood, IL 60153 USA. US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv, Hines, IL 60141 USA. RP Young, I (reprint author), Ralph H Johnson Vet Affairs Hosp, Res Serv 151, 109 Bee St, Charleston, SC 29401 USA. EM rita.young@med.va.gov NR 58 TC 16 Z9 19 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA SN 0020-7136 J9 INT J CANCER JI Int. J. Cancer PD APR 20 PY 2004 VL 109 IS 4 BP 516 EP 524 DI 10.1002/ijc.2003 PG 9 WC Oncology SC Oncology GA 803UY UT WOS:000220257200005 ER PT J AU Martin, LF Hall, MH Leonard, S Olincy, A Freedman, R AF Martin, LF Hall, MH Leonard, S Olincy, A Freedman, R TI Diminished P50 suppression is associated with alpha-7 nicotinic receptor gene promoter region single nucleotide polymorphisms in schizoaffective disorder, bipolar type SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 59th Annual Meeting of the Society-of-Biological-Psychiatry CY APR 29-MAY 01, 2004 CL NEW YORK, NY SP Soc Biol Psychiat C1 Univ Colorado, Hlth Sci Ctr, Denver, CO USA. Denver Vet Affairs Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2004 VL 55 SU 8 MA 78 BP 23S EP 23S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 811EN UT WOS:000220755300080 ER PT J AU Reddy, R Keshavan, MS Yao, JK AF Reddy, R Keshavan, MS Yao, JK TI Blunted serotonergic responsivity in platelets from neuroleptic-naive patients at first episode of schizophrenia SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 59th Annual Meeting of the Society-of-Biological-Psychiatry CY APR 29-MAY 01, 2004 CL NEW YORK, NY SP Soc Biol Psychiat C1 Univ Pittsburgh, Pittsburgh, PA 15260 USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15260 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2004 VL 55 SU 8 MA 81 BP 24S EP 24S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 811EN UT WOS:000220755300083 ER PT J AU Brambilla, P Stanley, JA Nicoletti, MA Sassi, RB Mallinger, AG Kupfer, DJ Frank, E Keshavan, MS Soares, JC AF Brambilla, P Stanley, JA Nicoletti, MA Sassi, RB Mallinger, AG Kupfer, DJ Frank, E Keshavan, MS Soares, JC TI H-1 magneticresonance spectroscopy investigation of dorso-lateral prefrontal cortex in adult bipolar disorder patients SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 59th Annual Meeting of the Society-of-Biological-Psychiatry CY APR 29-MAY 01, 2004 CL NEW YORK, NY SP Soc Biol Psychiat C1 Univ Verona, Dept Med & Publ Hlth, Sect Psychiat, I-37100 Verona, Italy. Univ Udine, Dept Pathol & Expt & Clin Med, Sect Psychiat, I-33100 Udine, Italy. Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15260 USA. Univ Texas, Dept Psychiat, San Antonio, TX 78285 USA. Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. RI brambilla, paolo/B-4184-2010 OI brambilla, paolo/0000-0002-4021-8456 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2004 VL 55 SU 8 MA 103 BP 30S EP 30S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 811EN UT WOS:000220755300105 ER PT J AU Chen, HH Monkul, ES Nicoletti, MA Hatch, JP Sassi, RB Axelson, D Brambilla, P Keshavan, MS Ryan, ND Birmaher, B Soares, JC AF Chen, HH Monkul, ES Nicoletti, MA Hatch, JP Sassi, RB Axelson, D Brambilla, P Keshavan, MS Ryan, ND Birmaher, B Soares, JC TI Abnormal left superior temporal gyrus volumes in children and adolescents with bipolar disorder SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 59th Annual Meeting of the Society-of-Biological-Psychiatry CY APR 29-MAY 01, 2004 CL NEW YORK, NY SP Soc Biol Psychiat C1 Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, Dept Psychiat, San Antonio, TX 78284 USA. Dokuz Eylul Univ, Sch Med, Dept Psychiat, Izmir, Turkey. Univ Sao Paulo, Sch Med, Dept Psychiat, BR-05508 Sao Paulo, Brazil. Univ Pittsburgh, Sch Med, Dept Psychiat, Western Psychiat Inst & Clin, Pittsburgh, PA USA. Univ Verona, Sch Med, Dept Med & Publ Hlth, Sect Psychiat, I-37100 Verona, Italy. RI brambilla, paolo/B-4184-2010 OI brambilla, paolo/0000-0002-4021-8456 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2004 VL 55 SU 8 MA 104 BP 30S EP 30S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 811EN UT WOS:000220755300106 ER PT J AU Glahn, DC Kaur, S Bearden, CE Monkul, ES Sanches, M Najt, P Villarreal, V Bowden, CL Soares, JC AF Glahn, DC Kaur, S Bearden, CE Monkul, ES Sanches, M Najt, P Villarreal, V Bowden, CL Soares, JC TI Declarative memory dysfunction in patients with bipolar disorder SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 59th Annual Meeting of the Society-of-Biological-Psychiatry CY APR 29-MAY 01, 2004 CL NEW YORK, NY SP Soc Biol Psychiat C1 Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Dept Psychiat, San Antonio, TX USA. Univ Calif Los Angeles, Inst Neuropsychiat, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2004 VL 55 SU 8 MA 108 BP 32S EP 32S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 811EN UT WOS:000220755300110 ER PT J AU Yao, JK Magan, S Sonel, AF Gurklis, JA Sanders, R Reddy, RD AF Yao, JK Magan, S Sonel, AF Gurklis, JA Sanders, R Reddy, RD TI Effects of omega-3 fatty acids on platelet serotonin responsivity in patients with schizophrenia SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 59th Annual Meeting of the Society-of-Biological-Psychiatry CY APR 29-MAY 01, 2004 CL NEW YORK, NY SP Soc Biol Psychiat C1 VA Pittsburgh Healthcare Syst, Med Res Serv, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, Nursing Serv, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, Med Serv, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, Psychiat Serv, Pittsburgh, PA USA. Dayton VA Med Ctr, Psychiat Serv, Dayton, OH USA. Univ Pittsburgh, Med Ctr Hlth Syst, Dept Psychiat, Pittsburgh, PA 15260 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2004 VL 55 SU 8 MA 147 BP 42S EP 43S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 811EN UT WOS:000220755300149 ER PT J AU Olincy, A Ross, RG Rieger, KP Zerbe, GO Johnson, LL Freedman, R AF Olincy, A Ross, RG Rieger, KP Zerbe, GO Johnson, LL Freedman, R TI Admixture analysis of an antisaccade eye movement task in probands with schizophrenia and their relatives SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 59th Annual Meeting of the Society-of-Biological-Psychiatry CY APR 29-MAY 01, 2004 CL NEW YORK, NY SP Soc Biol Psychiat C1 Univ Colorado, Hlth Sci Ctr, Dept Biostat & Prevent Med, Denver, CO USA. Denver Vet Affairs Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2004 VL 55 SU 8 MA 215 BP 62S EP 62S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 811EN UT WOS:000220755300217 ER PT J AU Kennedy, A Rosengren, K Kilzieh, N Wood, AE Tapp, A AF Kennedy, A Rosengren, K Kilzieh, N Wood, AE Tapp, A TI Does depression predict quality of life in outpatients with schizophrenia spectrum disorders? SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 59th Annual Meeting of the Society-of-Biological-Psychiatry CY APR 29-MAY 01, 2004 CL NEW YORK, NY SP Soc Biol Psychiat C1 Univ Washington, Dept Psychiat & Behav Sci, Tacoma, WA USA. Vet Affairs Puget Sound Hlth Care Syst, Mental Hlth Serv, Tacoma, WA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2004 VL 55 SU 8 MA 259 BP 73S EP 74S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 811EN UT WOS:000220755300259 ER PT J AU Rassovsky, Y Green, MF Nuechterlein, KH Breitmeyer, BG Mintz, J AF Rassovsky, Y Green, MF Nuechterlein, KH Breitmeyer, BG Mintz, J TI Visual masking and attentional processing in schizophrenia SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 59th Annual Meeting of the Society-of-Biological-Psychiatry CY APR 29-MAY 01, 2004 CL NEW YORK, NY SP Soc Biol Psychiat C1 Univ Calif Los Angeles, Los Angeles, CA 90024 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. Univ Houston, Houston, TX 77004 USA. RI Mintz, Jim/N-7385-2014 OI Mintz, Jim/0000-0002-8299-5851 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2004 VL 55 SU 8 MA 272 BP 77S EP 77S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 811EN UT WOS:000220755300272 ER PT J AU Kaur, S de Macedo-Soares, CMS Brambilla, P Nicoletti, MA Sassi, RB Axelson, D Hatch, JP Keshavan, MS Ryan, ND Birmaher, B Soares, JC AF Kaur, S de Macedo-Soares, CMS Brambilla, P Nicoletti, MA Sassi, RB Axelson, D Hatch, JP Keshavan, MS Ryan, ND Birmaher, B Soares, JC TI Corpus callosum signal intensity in young bipolar disorder patients SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 59th Annual Meeting of the Society-of-Biological-Psychiatry CY APR 29-MAY 01, 2004 CL NEW YORK, NY SP Soc Biol Psychiat C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. ABC Med Sch, Sao Paulo, Brazil. Univ Verona, Dept Med & Publ Hlth, Sect Psychiat, I-37100 Verona, Italy. Univ Sao Paulo, Sch Med, Inst Psychiat, BR-05508 Sao Paulo, Brazil. Univ Pittsburgh, Med Ctr, Western Psychiat Inst & Clin, Pittsburgh, PA 15260 USA. RI brambilla, paolo/B-4184-2010 OI brambilla, paolo/0000-0002-4021-8456 NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2004 VL 55 SU 8 MA 290 BP 82S EP 82S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 811EN UT WOS:000220755300289 ER PT J AU Soares, JC Kochunov, P Monkul, ES Nicoletti, MA Brambilla, P Sassi, RB Mallinger, AG Frank, E Kupfer, DJ Lancaster, J Fox, PT AF Soares, JC Kochunov, P Monkul, ES Nicoletti, MA Brambilla, P Sassi, RB Mallinger, AG Frank, E Kupfer, DJ Lancaster, J Fox, PT TI Gender specific structural abnormalities in bipolar disorder by deformation field morphometry SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 59th Annual Meeting of the Society-of-Biological-Psychiatry CY APR 29-MAY 01, 2004 CL NEW YORK, NY SP Soc Biol Psychiat C1 Univ Texas, Hlth Sci Ctr, Dept Psychiat, Mood & Anxiety Disorders Div, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, Res Imaging Ctr, San Antonio, TX USA. Dokuz Eylul Univ, Sch Med, Dept Psychiat, Izmir, Turkey. Univ Verona, Sch Med, Dept Med & Publ Hlth, I-37100 Verona, Italy. Univ Sao Paulo, Sch Med, Dept Psychiat, BR-05508 Sao Paulo, Brazil. Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Dept Psychiat, Pittsburgh, PA USA. Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA. Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA 15260 USA. RI brambilla, paolo/B-4184-2010 OI brambilla, paolo/0000-0002-4021-8456 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2004 VL 55 SU 8 MA 291 BP 82S EP 82S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 811EN UT WOS:000220755300290 ER PT J AU Monkul, ES Fawthrop, SC Brambilla, P Nicoletti, MA Sassi, RB Lacerda, ALT Mallinger, AG Kupfer, DJ Keshavan, MS Frank, E Soares, JC AF Monkul, ES Fawthrop, SC Brambilla, P Nicoletti, MA Sassi, RB Lacerda, ALT Mallinger, AG Kupfer, DJ Keshavan, MS Frank, E Soares, JC TI Fronto-limbic brain structures in suicidal and nonsuicidal patients with unipolar depression SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 59th Annual Meeting of the Society-of-Biological-Psychiatry CY APR 29-MAY 01, 2004 CL NEW YORK, NY SP Soc Biol Psychiat C1 Univ Texas, Hlth Sci Ctr, Dept Psychiat, Mood & Anxiety Disorders Div, San Antonio, TX 78284 USA. Dokuz Eylul Univ, Sch Med, Dept Psychiat, Izmir, Turkey. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. Univ Verona, Dept Med & Publ Hlth, Sect Psychiat, I-37100 Verona, Italy. Univ Sao Paulo, Sch Med, Inst Psychiat, BR-05508 Sao Paulo, Brazil. State Univ Campinas, Sch Med Sci, Dept Med Psychol & Psychiat, Campinas, SP, Brazil. Univ Pittsburgh, Med Ctr, Western Psychiat Inst & Clin, Dept Psychiat, Pittsburgh, PA 15260 USA. Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX 78284 USA. RI Lacerda, Acioly/A-7052-2010; brambilla, paolo/B-4184-2010 OI Lacerda, Acioly/0000-0002-9370-0449; brambilla, paolo/0000-0002-4021-8456 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2004 VL 55 SU 8 MA 305 BP 86S EP 86S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 811EN UT WOS:000220755300303 ER PT J AU Koenigsberg, HW Siever, LJ Gu, XD New, AS Goodman, M Prohovnik, I AF Koenigsberg, HW Siever, LJ Gu, XD New, AS Goodman, M Prohovnik, I TI An fMRI study of emotion processing in borderline personality disorder patients SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 59th Annual Meeting of the Society-of-Biological-Psychiatry CY APR 29-MAY 01, 2004 CL NEW YORK, NY SP Soc Biol Psychiat C1 Mt Sinai Sch Med, Bronx, NY USA. Bronx Vet Affairs Med Ctr, Mirecc, Bronx, NY USA. NR 0 TC 1 Z9 1 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2004 VL 55 SU 8 MA 317 BP 89S EP 90S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 811EN UT WOS:000220755300315 ER PT J AU Caetano, SC Nicoletti, MA Hatch, JP Brambilla, P Sassi, RB Mallinger, AG Frank, E Kupfer, DJ Keshavan, MS Soares, JC AF Caetano, SC Nicoletti, MA Hatch, JP Brambilla, P Sassi, RB Mallinger, AG Frank, E Kupfer, DJ Keshavan, MS Soares, JC TI Associations of age and length of illness with hippocampus and amygdala volumes in mood disorder patients SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 59th Annual Meeting of the Society-of-Biological-Psychiatry CY APR 29-MAY 01, 2004 CL NEW YORK, NY SP Soc Biol Psychiat C1 Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78284 USA. Univ Sao Paulo, Sch Med, Dept Psychiat, BR-05508 Sao Paulo, Brazil. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. Univ Verona, Dept Med & Publ Hlth, Sect Psychiat, I-37100 Verona, Italy. Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Dept Psychiat, Pittsburgh, PA USA. Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA. Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA. Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX 78284 USA. RI brambilla, paolo/B-4184-2010; Caetano, Sheila/H-5010-2012 OI brambilla, paolo/0000-0002-4021-8456; Caetano, Sheila/0000-0001-8403-7078 NR 0 TC 2 Z9 2 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2004 VL 55 SU 8 MA 394 BP 109S EP 110S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 811EN UT WOS:000220755300384 ER PT J AU Caetano, SC Olvera, R Hunter, K Nicoletti, MA Dalwani, M Ortiz, O Hatch, JP Bazan, C Bowden, CL Pliszka, SR Soares, JC AF Caetano, SC Olvera, R Hunter, K Nicoletti, MA Dalwani, M Ortiz, O Hatch, JP Bazan, C Bowden, CL Pliszka, SR Soares, JC TI Abnormal amygdala volumes in pediatric bipolar disorder SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 59th Annual Meeting of the Society-of-Biological-Psychiatry CY APR 29-MAY 01, 2004 CL NEW YORK, NY SP Soc Biol Psychiat C1 Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, Dept Psychiat, San Antonio, TX 78284 USA. Univ Sao Paulo, Sch Med, Dept Psychiat, BR-05508 Sao Paulo, Brazil. Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX 78284 USA. RI Caetano, Sheila/H-5010-2012 OI Caetano, Sheila/0000-0001-8403-7078 NR 0 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2004 VL 55 SU 8 MA 398 BP 111S EP 111S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 811EN UT WOS:000220755300388 ER PT J AU Dracheva, S Elhakem, SL Marcus, SM Siever, LJ McGurk, SR Haroutunian, V AF Dracheva, S Elhakem, SL Marcus, SM Siever, LJ McGurk, SR Haroutunian, V TI RNA editing and alternative splicing of human serotonin 2C receptor in schizophrenia SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 59th Annual Meeting of the Society-of-Biological-Psychiatry CY APR 29-MAY 01, 2004 CL NEW YORK, NY SP Soc Biol Psychiat C1 Bronx Vet Adm Med Ctr, Dept Psychiat, Bronx, NY USA. Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2004 VL 55 SU 8 MA 419 BP 117S EP 117S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 811EN UT WOS:000220755300409 ER PT J AU Caetano, SC Olvera, R Hunter, K Najt, P Hatch, JP Bowden, CL Pliszka, SR Soares, JC AF Caetano, SC Olvera, R Hunter, K Najt, P Hatch, JP Bowden, CL Pliszka, SR Soares, JC TI Association of psychotic symptoms and suicidal plans in pediatric bipolar patients SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 59th Annual Meeting of the Society-of-Biological-Psychiatry CY APR 29-MAY 01, 2004 CL NEW YORK, NY SP Soc Biol Psychiat C1 Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Dept Psychiat, Audie L Murphy Div, San Antonio, TX USA. Univ Sao Paulo, Sch Med, Inst Psychiat, Dept Psychiat, BR-05508 Sao Paulo, Brazil. Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX 78284 USA. RI Caetano, Sheila/H-5010-2012 OI Caetano, Sheila/0000-0001-8403-7078 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2004 VL 55 SU 8 MA 494 BP 138S EP 138S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 811EN UT WOS:000220755300482 ER PT J AU Brambilla, P Stanley, JA Sassi, RB Mallinger, AG Kupfer, DJ Frank, E Keshavan, MS Soares, JC AF Brambilla, P Stanley, JA Sassi, RB Mallinger, AG Kupfer, DJ Frank, E Keshavan, MS Soares, JC TI Investigation of dorso-lateral prefrontal cortex in unipolar disorder patients with H-1 magnetic resonance spectroscopy SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 59th Annual Meeting of the Society-of-Biological-Psychiatry CY APR 29-MAY 01, 2004 CL NEW YORK, NY SP Soc Biol Psychiat C1 Univ Verona, Dept Med & Publ Hlth, Sect Psychiat, I-37100 Verona, Italy. Univ Udine, Dept Pathol & Expt & Clin Med, Sect Psychiat, I-33100 Udine, Italy. Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15260 USA. Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. Univ Texas, Dept Psychiat, San Antonio, TX 78285 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78285 USA. RI brambilla, paolo/B-4184-2010 OI brambilla, paolo/0000-0002-4021-8456 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2004 VL 55 SU 8 MA 500 BP 139S EP 140S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 811EN UT WOS:000220755300488 ER PT J AU Kose, S Lorberbaum, JP Dubno, JR Horwitz, AR Newman, JD Kose, R Hamner, MB Arana, GW George, MS AF Kose, S Lorberbaum, JP Dubno, JR Horwitz, AR Newman, JD Kose, R Hamner, MB Arana, GW George, MS TI An fMRI study of healthy fathers hearing infant cries SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 59th Annual Meeting of the Society-of-Biological-Psychiatry CY APR 29-MAY 01, 2004 CL NEW YORK, NY SP Soc Biol Psychiat C1 Med Univ S Carolina, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Mental Hlth Clin, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA. NICHHD, NIH, Poolesville, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2004 VL 55 SU 8 MA 582 BP 163S EP 163S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 811EN UT WOS:000220755300569 ER PT J AU Lorberbaum, JP Kose, S Dubno, JR Horwitz, AR Newman, JD Kose, R Hamner, MB Bohning, DE Arana, GW George, MS AF Lorberbaum, JP Kose, S Dubno, JR Horwitz, AR Newman, JD Kose, R Hamner, MB Bohning, DE Arana, GW George, MS TI A third fMRI study of healthy mothers hearing infant cries SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 59th Annual Meeting of the Society-of-Biological-Psychiatry CY APR 29-MAY 01, 2004 CL NEW YORK, NY SP Soc Biol Psychiat C1 Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Mental Hlth Serv, Charleston, SC USA. NICHHD, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2004 VL 55 SU 8 MA 728 BP 204S EP 204S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 811EN UT WOS:000220755300713 ER PT J AU Jakary, A Davis, KA Deicken, RF AF Jakary, A Davis, KA Deicken, RF TI Bilateral N-acetylaspartate deficits in the mediodorsal and anterior thalamus in schizophrenia verified by tissue segmentation and thalamic volume mask techniques SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 59th Annual Meeting of the Society-of-Biological-Psychiatry CY APR 29-MAY 01, 2004 CL NEW YORK, NY SP Soc Biol Psychiat C1 San Francisco VA Med Ctr, Mental Hlth Serv, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2004 VL 55 SU 8 MA 778 BP 218S EP 218S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 811EN UT WOS:000220755300761 ER PT J AU Steinhauer, SR Siegle, GJ Condray, R Carter, KN Yanuzo, AD AF Steinhauer, SR Siegle, GJ Condray, R Carter, KN Yanuzo, AD TI Disruption of the temporal course of central inhibition in schizophrenia as reflected by the pupillomotor system SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 59th Annual Meeting of the Society-of-Biological-Psychiatry CY APR 29-MAY 01, 2004 CL NEW YORK, NY SP Soc Biol Psychiat C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2004 VL 55 SU 8 MA 801 BP 225S EP 225S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 811EN UT WOS:000220755300784 ER PT J AU Truesdell, KC Glahn, DC Kaur, S Monkul, ES Sanches, M Najt, P Villarreal, V Bowden, CL Soares, JC AF Truesdell, KC Glahn, DC Kaur, S Monkul, ES Sanches, M Najt, P Villarreal, V Bowden, CL Soares, JC TI Attention deficits in bipolar disorder: A comparison of performance on the continuous performance task SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 59th Annual Meeting of the Society-of-Biological-Psychiatry CY APR 29-MAY 01, 2004 CL NEW YORK, NY SP Soc Biol Psychiat C1 S Texas Vet Hlth Care Syst, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, Dept Psychiat, Div Mood & Anxiety Disorders, San Antonio, TX 78284 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2004 VL 55 SU 8 MA 823 BP 231S EP 231S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 811EN UT WOS:000220755300806 ER PT J AU Kaur, S Brambilla, P Sassi, RB Nicoletti, MA Caetano, SC Hatch, JP Keshavan, MS Mallinger, AG Kupfer, DJ Frank, E Soares, JC AF Kaur, S Brambilla, P Sassi, RB Nicoletti, MA Caetano, SC Hatch, JP Keshavan, MS Mallinger, AG Kupfer, DJ Frank, E Soares, JC TI Smaller Cingulate gray matter volumes in unipolar depression SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 59th Annual Meeting of the Society-of-Biological-Psychiatry CY APR 29-MAY 01, 2004 CL NEW YORK, NY SP Soc Biol Psychiat C1 Univ Texas, Hlth Sci Ctr, Dept Psychiat, Div Mood & Anxiety Disorders, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, Dept Psychiat, San Antonio, TX USA. Univ Verona, Dept Med & Publ Hlth, Sect Psychiat, I-37100 Verona, Italy. Univ Sao Paulo, Sch Med, Inst Psychiat, Dept Psychiat, BR-05508 Sao Paulo, Brazil. Univ Pittsburgh, Med Ctr, Western Psychiat Inst & Clin, Dept Psychiat, Pittsburgh, PA 15260 USA. Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX 78284 USA. RI brambilla, paolo/B-4184-2010; Caetano, Sheila/H-5010-2012 OI brambilla, paolo/0000-0002-4021-8456; Caetano, Sheila/0000-0001-8403-7078 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2004 VL 55 SU 8 MA 832 BP 233S EP 234S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 811EN UT WOS:000220755300815 ER PT J AU Mu, QW Bohning, DE Nahas, Z Walker, J Anderson, B Johnson, KA Denslow, S Lomarev, M Moghadam, P Chae, JH George, MS AF Mu, QW Bohning, DE Nahas, Z Walker, J Anderson, B Johnson, KA Denslow, S Lomarev, M Moghadam, P Chae, JH George, MS TI Acute vagus nerve stimulation using different pulse widths produces varying brain effects SO BIOLOGICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT Annual Convention of the Society-of-Biological-Psychiatry CY MAY 17, 2003 CL San Francisco, CA SP Soc Biolog Psychiatry DE vagus nerve stimulation; pulse width; depression; functional magnetic resonance imaging ID BLOOD-FLOW; ELECTRICAL-STIMULATION; REFRACTORY EPILEPSY; VAGAL-STIMULATION; RESISTANT DEPRESSION; PARTIAL SEIZURES; CELL-BODIES; FMRI; THERAPY; VNS AB Background: Vagus nerve stimulation (VNS) is an approved treatment for epilepsy and has been investigated in clinical trials of depression. Little is known about the relationship of VNS parameters to brain function. Using the interleaved VATS functional magnetic. resonance imaging (fMPI) technique, we tested whether variations of VNS pulse width (PW) would produce different immediate brain activation in a manner consistent with single neuron PWstudies. Methods: Twelve adult patients with major depression, treated with VNS. underwent three consecutive VNS/fMRI scans, each randomly using one of three PWs (130 mus, 250 mus, or 500 mus). The data were analyzed with SPM2. Results: Global activations induced by PWs 250 and 500 were both significantly greater than that induced by PW 130 but not significantly different from each other. For global deactivation, PWs 130 and 250 were both signifcantly greater than PW 500 but not significantly different from each other. Regional similarities and differences were also seen with the various PWs. Conclusions: The data confirm our hypothesis that VNS at PW500 globally produces no more activation than does PW 250. and PW 130 is insufficient for activation of some regions. These data suggest that PW is an important variable in producing VNS brain effects. C1 Med Univ S Carolina, Inst Psychiat, Brain Stimulat Lab, Ctr Adv Imaging, Charleston, SC 29425 USA. Med Univ S Carolina, Inst Psychiat, Dept Radiol, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Mu, QW (reprint author), Med Univ S Carolina, Inst Psychiat, Brain Stimulat Lab, Ctr Adv Imaging, 502 N,67 President St, Charleston, SC 29425 USA. FU NIA NIH HHS [R01 AG 40956] NR 51 TC 42 Z9 43 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2004 VL 55 IS 8 BP 816 EP 825 DI 10.1016/j.biopsych.2003.12.004 PG 10 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 811EL UT WOS:000220755100007 PM 15050863 ER PT J AU Freedland, SJ Aronson, WJ Presti, JC Amling, CL Terris, MK Trock, B Kane, CJ AF Freedland, SJ Aronson, WJ Presti, JC Amling, CL Terris, MK Trock, B Kane, CJ TI Predictors of prostate-specific antigen progression among men with seminal vesicle invasion at the time of radical prostatectomy SO CANCER LA English DT Article DE prostate carcinoma; radical prostatectomy; prostate-specific antigen recurrence; seminal vesicle invasion; Gleason score ID SEXTANT BIOPSIES; PROGNOSTIC-SIGNIFICANCE; CANCER; RECURRENCE; INVOLVEMENT; ADENOCARCINOMA; RADIOTHERAPY; FAILURE; RACE; RISK AB BACKGROUND. Seminal vesicle (SV) invasion at the time of radical prostatectomy (RP) generally is considered to be indicative of poor outcome. The authors examined whether there was a subset of men with SV invasion who had long-term prostate-specific antigen (PSA) progression-free survival. METHODS. Data were examined from 1687 men who underwent RP between 1988 and 2002 at 5 equal-access medical centers. Patients were grouped based on the presence or absence of SV invasion at the time of RP. Clinical and pathologic variables as well as biochemical outcome data were compared across the groups using rank-sum, chi-square, and log-rank tests. Multivariate Cox proportional hazards analysis was used to determine the significant predictors of time to PSA failure among men with SV invasion. RESULTS. Men with SV invasion had significantly higher PSA values, higher clinical stage, higher grade tumors, and were more likely to have concomitant extracapsular extension or a positive surgical margin. The 5-year PSA progression-free rates for men who had SV invasion was 36%, compared with 70% among men who had no SV invasion. Among men who had SV invasion, using multivariate analysis, only age (P = 0.023), pathologic Gleason score (P = 0.041), and surgical margin status (P = 0.019) were found to be independent predictors of PSA failure. By combining significant prognostic variables, the authors identified a subset of men with SV invasion, low-grade tumors (Gleason score 2-6), and negative surgical margins who had a 5-year PSA progression-free rate of 69%. Men with SV invasion, Gleason scores 2-6 tumors, negative surgical margins, and age greater than or equal to 60 years (n = 11; 8%) had a 5-year PSA progression-free rate of 100%. CONCLUSIONS. Although the majority of men with SV invasion have high-grade disease and a short time to biochemical failure, the authors identified a subset of men with low-grade disease, negative surgical margins, and older age who, despite SV invasion, had an extremely favorable clinical course. Thus, SV invasion does not uniformly suggest an unfavorable prognosis. (C) 2004 American Cancer Society. C1 Johns Hopkins Sch Med, Dept Urol, Baltimore, MD 21287 USA. Vet Adm Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA 90024 USA. Stanford Univ, Sch Med, Dept Urol, Stanford, CA 94305 USA. San Diego Naval Hosp, Dept Urol, San Diego, CA USA. Med Coll Georgia, Div Urol, Augusta, GA 30912 USA. San Francisco Vet Adm Med Ctr, Dept Surg, Urol Sect, San Francisco, CA USA. Univ Calif San Francisco, Sch Med, Dept Urol, San Francisco, CA 94143 USA. RP Freedland, SJ (reprint author), Johns Hopkins Sch Med, Dept Urol, 600 N Wolfe St, Baltimore, MD 21287 USA. EM sfreedl1@jhmi.edu OI Terris, Martha/0000-0002-3843-7270 NR 21 TC 23 Z9 23 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0008-543X J9 CANCER JI Cancer PD APR 15 PY 2004 VL 100 IS 8 BP 1633 EP 1638 DI 10.1002/cncr.20122 PG 6 WC Oncology SC Oncology GA 810TA UT WOS:000220725400011 PM 15073850 ER PT J AU Yang, SC Hillinger, S Riedl, K Zhang, L Zhu, L Huang, M Atianzar, K Kuo, BY Gardner, B Batra, RK Strieter, RM Dubinett, SM Sharma, S AF Yang, SC Hillinger, S Riedl, K Zhang, L Zhu, L Huang, M Atianzar, K Kuo, BY Gardner, B Batra, RK Strieter, RM Dubinett, SM Sharma, S TI Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity SO CLINICAL CANCER RESEARCH LA English DT Article ID LYMPHOID-TISSUE CHEMOKINE; COLONY-STIMULATING FACTOR; GROWTH-FACTOR-BETA; ANGIOGENESIS IN-VIVO; X-C-CHEMOKINE; MHC CLASS-I; LUNG-CANCER; MURINE TUMORS; GENE-THERAPY; T-CELLS AB To achieve in situ tumor antigen uptake and presentation, intratumoral administration of ex vivo-generated, gene-modified murine bone marrow-derived dendritic cells (DC) was used in a murine lung cancer model. To attract mature host DC and activated T cells at the tumor site, the DC were transduced with an adenoviral vector expressing secondary lymphoid tissue chemokine (CCL21/SLC). Sixty percent of the mice treated with 106 DC-AdCCL21 intratumorally (7-10 ng/ml/10(6) cells/24 h of CCL21) at weekly intervals for 3 weeks showed complete tumor eradication, whereas only 25% of mice had complete resolution of tumors when mice were treated with fibroblasts expressing CCL21. In contrast only 12% of the mice treated with unmodified or control vector modified DC (DC-AdCV) showed complete tumor eradication. DC-AdCCL21 administration led to increases in the CD4(+), CD8(+), and CD3(+)CXCR3(+) T cells, as well as DC expressing CD11c(+) DEC205(+). CD4(+)CD25(+) T-regulatory cells infiltrating the tumors were markedly reduced after DC-AdCCL21 therapy. The tumor site cellular infiltrates were accompanied by the enhanced elaboration of granulocyte macrophage colony-stimulating factor, IFN-gamma, MIG/CXCL9, IP-10/CXCL10, and interleukin 12, but decreases in the immunosuppressive mediators transforming growth factor beta and prostaglandin E-2. DC-AdCCL21-treated tumor-bearing mice showed enhanced frequency of tumor-specific T lymphocytes secreting IFN-gamma, and tumor protective immunity was induced after DC-AdCCL21 therapy. In vivo depletion of IP-10/CXCL10, MIG/CXCL9, or IFN-gamma significantly reduced the antitumor efficacy of DC-AdCCL21. These findings provide a strong rationale for the evaluation of DC-AdCCL21 in cancer immunotherapy. C1 Univ Calif Los Angeles, David Geffen Sch Med, Div Pulm & Crit Care Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Dept Med, Lung Canc Res Program, Los Angeles, CA 90024 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Mol Gene Med Lab, Los Angeles, CA USA. RP Sharma, S (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Pulm & Crit Care Med, Jonsson Comprehens Canc Ctr, 37-131 Ctr Hlth Sci,10833 LeConte Ave, Los Angeles, CA 90095 USA. EM sharmasp@ucla.edu FU NCI NIH HHS [CA71818, 1P50 CA90388, CA78654, R01 CA078654-03, R01 CA78654] NR 82 TC 75 Z9 85 U1 0 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 J9 CLIN CANCER RES JI Clin. Cancer Res. PD APR 15 PY 2004 VL 10 IS 8 BP 2891 EP 2901 DI 10.1158/1078-0432.CCR-03-0380 PG 11 WC Oncology SC Oncology GA 813VE UT WOS:000220933800042 PM 15102698 ER PT J AU Volberding, PA AF Volberding, PA TI Meeting challenges - Overcoming limitations: Advances of the protease inhibitor class - Proceedings of an expert roundtable SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Editorial Material C1 San Francisco Vet Affairs Med Ctr, Med Serv, San Francisco, CA 94121 USA. RP Volberding, PA (reprint author), San Francisco Vet Affairs Med Ctr, Med Serv, 4150 Clement St,VAMC 111V, San Francisco, CA 94121 USA. EM Paul.Volberding@med.va.gov NR 4 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD APR 15 PY 2004 VL 35 SU 1 BP S1 EP S2 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 811TK UT WOS:000220794000001 ER PT J AU Ghosh, PM Bedolla, R Thomas, CA Kreisberg, JI AF Ghosh, PM Bedolla, R Thomas, CA Kreisberg, JI TI Role of protein kinase C in arginine vasopressin-stimulated ERK and p70S6 kinase phosphorylation SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Article DE proliferation; EGF-R; PI3K ID GLOMERULAR MESANGIAL CELLS; GROWTH-FACTOR RECEPTOR; FREE CALCIUM-CONCENTRATION; SMOOTH-MUSCLE CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; HIGH GLUCOSE; S6 KINASE; PHOSPHOINOSITIDE 3-KINASE; ANGIOTENSIN-II; PI 3-KINASE AB We previously showed in rat renal glomerular mesangial cells, that arginine vasopressin (AVP)-stimulated cell proliferation was mediated by epidermal growth factor receptor (EGF-R) transactivation, and activation (phosphorylation) of ERK1/2 and p70S6 kinase (Ghosh et al. [2001]: Am J Physiol Renal Physiol 280:F972-F979]. In this paper, we extend these observations and show that different protein kinase C (PKC) isoforms play different roles in mediating AVP-stimulated ERK1/2 and p70S6 kinase phosphorylation and cell proliferation. AVP treatment for 0-60 min stimulated the serine/threonine phosphorylation of PKC isoforms alpha, delta, epsilon, and zeta. The activation of PKC was dependent on EGF-R and phosphatidylinositol 3-kinase (PI3K) activation. In addition, inhibition of conventional and novel PKC isoforms by chronic (24 h) exposure to phorbol 12-myristate 13-acetate (PMA) inhibited AVP-induced activation of ERK and p70S6 kinase as well as EGF-R phosphorylation. Rottlerin, a specific inhibitor of PKCdelta, inhibited both ERK and p70S6 kinase phosphorylation and cell proliferation. In contrast, a PKCepsilon translocation inhibitor decreased ERK1/2 activation without affecting p70S6 kinase or cell proliferation, while a dominant negative PKCzeta (K281W) cDNA delayed p70S6 kinase activation without affecting ERK1/2. On the other hand, Go6976, an inhibitor of conventional PKC isoforms, did not affect p70S6 kinase, but stimulated ERK1/2 phosphorylation without affecting cell proliferation. Our results indicate that PKCdelta plays an important role in AVP-stimulated ERK and p70S6 kinase activation and cell proliferation. (C) 2004 Wiley-Liss, Inc. C1 Univ Texas, Hlth Sci Ctr, Dept Surg, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Med Hematol, San Antonio, TX 78229 USA. Audie L Murphy Mem Vet Adm Med Ctr, S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Kreisberg, JI (reprint author), Univ Texas, Hlth Sci Ctr, Dept Surg, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM Kreisberg@uthscsa.edu NR 67 TC 17 Z9 18 U1 0 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD APR 15 PY 2004 VL 91 IS 6 BP 1109 EP 1129 DI 10.1002/jcb.10789 PG 21 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 810JQ UT WOS:000220701000003 PM 15048868 ER PT J AU Netscher, DT Spira, M AF Netscher, David T. Spira, Melvin TI Basal Cell Carcinoma: An Overview of Tumor Biology and Treatment SO PLASTIC AND RECONSTRUCTIVE SURGERY LA English DT Article AB Learning Objectives: After studying this article, the participant should be able to: 1. Describe the epidemiology and etiology of basal cell carcinomas. 2. Understand the biology, histogenesis, predisposing conditions, and syndromes associated with basal cell carcinomas. 3. Have a clear understanding of tumor types and their clinical behavior. 4. Discuss the importance of diagnostic tumor biopsy and treatment options as they pertain to anatomic site, tumor type, and patient age. 5. Understand the basis for surgical management of basal cell carcinomas, the margins of excision, indications for frozen section, and Mohs micrographic surgery. 6. Discuss the value of patient follow-up after treatment of a primary basal cell carcinoma. 7. Review the most recently published literature on this topic and understand new concepts in tumor biology as they relate to diagnosis and treatment options. C1 Baylor Coll Med, Div Plast Surg, Houston, TX 77030 USA. Dept Vet Affairs Med Ctr, Plast Surg Serv, Houston, TX USA. RP Netscher, DT (reprint author), 6560 Fannin,Suite 800, Houston, TX 77030 USA. EM netscher@bcm.tmc.edu NR 99 TC 29 Z9 31 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0032-1052 J9 PLAST RECONSTR SURG JI Plast. Reconstr. Surg. PD APR 15 PY 2004 VL 113 IS 5 BP 74E EP 94E DI 10.1097/01.PRS.0000113025.69154.D1 PG 21 WC Surgery SC Surgery GA V13NG UT WOS:000207672900001 ER PT J AU Orosz, GM Magaziner, J Hannan, EL Morrison, RS Koval, K Gilbert, M McLaughlin, M Halm, EA Wang, JJ Litke, A Silberzweig, SB Siu, AL AF Orosz, GM Magaziner, J Hannan, EL Morrison, RS Koval, K Gilbert, M McLaughlin, M Halm, EA Wang, JJ Litke, A Silberzweig, SB Siu, AL TI Association of timing of surgery for hip fracture and patient outcomes SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID FEMORAL FRACTURE; ELDERLY PATIENTS; OPERATIVE DELAY; MORTALITY; TIME; COMPLICATIONS; MORBIDITY; ADMISSION; RECOVERY; IMPACT AB Context. Previous studies of surgical timing in patients with hip fracture have yielded conflicting findings on mortality and have not focused on functional outcomes. Objective To examine the association of timing of surgical repair of hip fracture with function and other outcomes, Design Prospective cohort study including analyses matching cases of early (:524 hours) and late (>24 hours) surgery with propensity scores and excluding patients who might not. be candidates for early surgery. Setting Four hospitals in the New York City metropolitan area. Participants A total of 1206 patients aged 50 years or older admitted with hip fracture over 29 months, ending December 1999. Main Outcome Measures Function (using the Functional Independence Measure), survival, pain, and length of stay (LOS). Results Of the patients treated with surgery (n=1178), 33.8% had surgery within 24 hours. Earlier surgery was not associated with improved mortality (hazard ratio, 0.75; 95% confidence interval [CI], 0.52-1.08) or improved locomotion (difference of -0.04 points; 95% Cl, -0.49 to 0.39). Earlier surgery was associated with fewer days of severe and very severe pain (difference of -0.22 days; 95% Cl, -0.41 to -0.03) and shorter LOS by 1.94 days (P<.001), but postoperative pain and LOS after surgery did not differ: Analyses with propensity scores yielded similar results. When the cohort included only patients who were medically stable at admission and therefore eligible for early surgery, the results were unchanged except that early surgery was associated with fewer major complications (odds ratio, 0.26; 95% Cl, 0.07-0.95). Conclusions Early surgery was not associated with improved function or mortality, but it was associated with reduced pain and LOS and probably major complications among patients medically stable at admission. Additional research is needed on whether functional outcomes may be improved. In the meantime, patients with hip fracture who are medically stable should receive early surgery when possible. C1 Mt Sinai Sch Med, Dept Geriatr, New York, NY USA. Mt Sinai Sch Med, Dept Orthoped, New York, NY USA. Mt Sinai Sch Med, Dept Med, New York, NY USA. Mt Sinai Sch Med, Dept Hlth Policy, New York, NY USA. Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA. SUNY Albany, Sch Publ Hlth, Dept Hlth Policy & Management, Albany, NY 12222 USA. Hosp Joint Dis & Med Ctr, Dept Orthoped, New York, NY USA. Bronx Vet Adm Med Ctr, GRECC, Bronx, NY USA. RP Siu, AL (reprint author), Mt Sinai Med Ctr, Box 1070,1 Gustave L Levy Pl, New York, NY 10029 USA. EM albert.siu@mssm.edu FU AHRQ HHS [U18 HS009459, R01 HS009973, U18HS09459-0, R01HS09973]; NIA NIH HHS [K08AG00833-01, K24 AG000918, R01 AG021992] NR 28 TC 215 Z9 230 U1 1 U2 8 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 14 PY 2004 VL 291 IS 14 BP 1738 EP 1743 DI 10.1001/jama.291.14.1738 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 811RJ UT WOS:000220788700031 PM 15082701 ER PT J AU Tschanz, JT Corcoran, C Skoog, I Khachaturian, AS Herrick, J Hayden, KM Welsh-Bohmer, KA Calvert, T Norton, MC Zandi, P Breitner, JCS AF Tschanz, JT Corcoran, C Skoog, I Khachaturian, AS Herrick, J Hayden, KM Welsh-Bohmer, KA Calvert, T Norton, MC Zandi, P Breitner, JCS CA Cache Cty Study Grp TI Dementia: The leading predictor of death in a defined elderly population - The Cache County Study SO NEUROLOGY LA English DT Article ID 5-YEAR FOLLOW-UP; ALZHEIMERS-DISEASE; VASCULAR-DEMENTIA; SURVIVAL; MORTALITY; AGE; QUESTIONNAIRE; DIAGNOSIS; DECLINE; SAMPLE AB Objective: To examine the relative risk and population attributable risk ( PAR) of death with dementia of varying type and severity and other risk factors in a population of exceptional longevity. Methods: Deaths were monitored over 5 years using vital statistics records and newspaper obituaries in 355 individuals with prevalent dementia and 4,328 without in Cache County, UT. Mean age was 83.3 (SD 7.0) years with dementia and 73.7 (SD 6.8) years without. History of coronary artery disease, hypertension, diabetes, and other life-shortening illness was ascertained from interviews. Results: Death certificates implicated dementia as an important cause of death, but other data suggested a stronger association. Adjusted Cox relative hazard and PAR of death were higher with dementia than with any other illness studied. Relative hazard of death with dementia was highest at ages 65 to 74, but the high prevalence of dementia after age 85 resulted in 27% PAR among the oldest old. Mortality increased substantially with severity of dementia. Alzheimer disease shortened survival time most dramatically in younger participants, but vascular dementia posed a greater mortality risk among the oldest old. Conclusion: In this population, dementia was the strongest predictor of mortality, with a risk two to three times those of other life-shortening illnesses. C1 Utah State Univ, Ctr Epidemiol Studies, Logan, UT 84322 USA. Utah State Univ, Dept Psychol, Logan, UT 84322 USA. Utah State Univ, Dept Math & Stat, Logan, UT 84322 USA. Utah State Univ, Dept Family Consumer & Human Dev, Logan, UT 84322 USA. Khachaturian Radebaugh & Associates Inc, Potomac, MD USA. Johns Hopkins Univ, Dept Mental Hyg, Baltimore, MD USA. Duke Univ, Med Ctr, Ctr Study Aging & Human Dev, Durham, NC 27710 USA. Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA. Duke Univ, Med Ctr, Joseph & Kathleen Bryan Alzheimers Dis Res Ctr, Durham, NC USA. Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Gothenburg, Inst Clin Neurosci, Neuropsychiat Epidemiol Unit, Gothenburg, Sweden. RP Tschanz, JT (reprint author), Utah State Univ, Ctr Epidemiol Studies, 4440 Old Main Hill, Logan, UT 84322 USA. EM joannt@cc.usu.edu RI Corcoran, Chris/F-2155-2010; Tschanz, JoAnn/E-5986-2010; Norton, Maria/E-6994-2013; Hayden, Kathleen/B-6442-2012 OI Hayden, Kathleen/0000-0002-7745-3513 FU NIA NIH HHS [AG11380, AG21136] NR 37 TC 96 Z9 103 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD APR 13 PY 2004 VL 62 IS 7 BP 1156 EP 1162 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 811JX UT WOS:000220769300021 PM 15079016 ER PT J AU Halpern, SD Karlawish, JHT Casarett, D Berlin, JA Asch, DA AF Halpern, SD Karlawish, JHT Casarett, D Berlin, JA Asch, DA TI Empirical assessment of whether moderate payments are undue or unjust inducements for participation in clinical trials SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT 24th Annual Meeting of the Society-for-Medical-Decision-Making CY OCT 19-23, 2002 CL BALTIMORE, MD SP Soc Med Decis Making ID SUBJECT AB Background: Paying patients to participate in clinical trials is ethically controversial. However, there has been no empirical documentation regarding whether payment represents an undue or unjust inducement. Methods: To evaluate these questions, we described hypothetical placebo-controlled trials of a new antihypertensive drug to 126 patients with mild-to-moderate hypertension recruited from hypertension and general medicine clinics at a university hospital. Using a 3x3, within-subjects design, we altered a risk to participation (either adverse effect rate or rate of randomization to placebo) and the payment participants would receive ($100, $1000, and $2000) and asked patients to indicate their willingness to participate (WTP) in each trial using a 6-point scale. Results: Clustered ordinal logistic regression models revealed that patients' WTP decreased with higher risk of adverse effects (P<.001), higher risk of being assigned to placebo (P=.02), and lower payment level (P<.001). There were no significant interactions between payment level and either risk variable, suggesting that increasing payments do not alter peoples' perceptions of risk. There was a trend toward a positive interaction between income and the influence of payment on WTP (P=.09), suggesting that payment more strongly influences WTP among wealthier people. Wealthier patients were more likely to state that payment was important in their participation decision (37% vs 20%, P=.05). Conclusion: Although higher payment motivates research participation, we found no evidence that commonly used payment levels represent undue or unjust inducements. C1 Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Ctr Bioeth, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Ctr Educ & Res Therapeut, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. RP Halpern, SD (reprint author), Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, 115 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM shalpern@cceb.med.upenn.edu NR 10 TC 82 Z9 84 U1 0 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD APR 12 PY 2004 VL 164 IS 7 BP 801 EP 803 DI 10.1001/archinte.164.7.801 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 812GR UT WOS:000220828500013 PM 15078651 ER PT J AU Zou, JH Barahmand-pour, F Blackburn, ML Matsui, Y Chansky, HA Yang, L AF Zou, JH Barahmand-pour, F Blackburn, ML Matsui, Y Chansky, HA Yang, L TI Survival motor neuron (SMN) protein interacts with transcription corepressor mSin3A SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID SPINAL MUSCULAR-ATROPHY; DISEASE GENE-PRODUCT; HISTONE DEACETYLASES; SINGLE NUCLEOTIDE; BINDING-PROTEIN; COMPLEX; REPRESSION; SIN3; METHYLTRANSFERASE; IDENTIFICATION AB Spinal muscular atrophy (SMA) is the leading genetic cause of infant mortality. SMA results from loss of survival motor neuron (SMN) expression and subsequent death of motor neuron cells. To study SMN-associated proteins that may be involved in transcriptional regulation, we carried out immunoprecipitation experiments and found that the transcription corepressor mSin3A associates with SMN protein. Deletional analysis localized the mSin3A-interacting domain to the exon 6 region of SMN. When targeted to a promoter, wild-type SMN was able to repress transcription of a downstream luciferase reporter gene. This repression was relieved by treatment with the histone deacetylase inhibitor trichostatin A in a dose-dependent manner, and deletion of exon 6 abolished the ability of SMN to repress the reporter gene. Analysis of SMN missense mutations within the exon 6 region implicated the SMA-associated mutation Y272C with impairment of the mSin3A-interaction. Gel filtration experiments revealed that wild-type SMN, via the exon 6 region, forms protein supra-complexes exceeding 40,000 kDa in size, whereas the Y272C mutation may affect higher order protein assembly, as the mutant SMN was more abundant in smaller complexes. Together, these findings provide a potential mechanism by which lack of fully functional SMN protein is detrimental to motor neuron survival. C1 Univ Washington, Dept Orthoped & Sports Med, Seattle, WA 98108 USA. Univ Washington, Dept Med Hematol, Seattle, WA 98108 USA. Vet Affairs Puget Sound Hlth Care Syst, Med Res Serv, Seattle, WA 98108 USA. RP Yang, L (reprint author), Univ Washington, Dept Orthoped & Sports Med, 1660 S Columbian Way,GMR-151, Seattle, WA 98108 USA. EM lyang@u.washington.edu FU NCI NIH HHS [1R01CA90941] NR 35 TC 14 Z9 14 U1 0 U2 4 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD APR 9 PY 2004 VL 279 IS 15 BP 14922 EP 14928 DI 10.1074/jbc.M309218200 PG 7 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 808UT UT WOS:000220594700054 PM 14749338 ER PT J AU Mahimainathan, L Choudhury, GG AF Mahimainathan, L Choudhury, GG TI Inactivation of platelet-derived growth factor receptor by the tumor suppressor PTEN provides a novel mechanism of action of the phosphatase SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID FORKHEAD TRANSCRIPTION FACTORS; MESANGIAL CELL-PROLIFERATION; INDUCED DNA-SYNTHESIS; PDGF-BETA-RECEPTOR; NEGATIVE REGULATION; PROTEIN-KINASE; C-FOS; MICE; AKT; ACTIVATION AB PTEN, mutated in a variety of human cancers, is a dual specificity protein phosphatase and also possesses D3-phosphoinositide phosphatase activity on phosphatidylinositol 3,4,5-tris-phosphate (PIP3), a product of phosphatidylinositol 3-kinase. This PIP3 phosphatase activity of PTEN contributes to its tumor suppressor function by inhibition of Akt kinase, a direct target of PIP3. We have recently shown that Akt regulates PDGF-induced DNA synthesis in mesangial cells. In this study, we demonstrate that expression of PTEN in mesangial cells inhibits PDGF-induced Akt activation leading to reduction in PDGF-induced DNA synthesis. As a potential mechanism, we show that PTEN inhibits PDGF-induced protein tyrosine phosphorylation with concomitant dephosphorylation and inactivation of tyrosine phosphorylated and activated PDGF receptor. Recombinant as well as immunopurified PTEN dephosphorylates autophosphorylated PDGF receptor in vitro. Expression of phosphatase deficient mutant of PTEN does not dephosphorylate PDGF-induced tyrosine phosphorylated PDGF receptor. Rather its expression increases tyrosine phosphorylation of PDGF receptor. Furthermore, expression of PTEN attenuated PDGF-induced signal transduction including phosphatidylinositol 3-kinase and Erk1/2 MAPK activities. Our data provide the first evidence that PTEN is physically associated with platelet-derived growth factor (PDGF) receptor and that PDGF causes its dissociation from the receptor. Finally, we show that both the C2 and tail domains of PTEN contribute to binding to the PDGF receptor. These data demonstrate a novel aspect of PTEN function where it acts as an effector for the PDGF receptor function and negatively regulates PDGF receptor activation. C1 Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA. RP Choudhury, GG (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Mail Code 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM choudhuryg@uthscsa.edu OI /0000-0001-5077-3552 FU NIDDK NIH HHS [P50 DK 61597, R01 DK 55815] NR 64 TC 80 Z9 83 U1 0 U2 3 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD APR 9 PY 2004 VL 279 IS 15 BP 15258 EP 15268 DI 10.1074/jbc.M314328200 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 808UT UT WOS:000220594700093 PM 14718524 ER PT J AU Olshansky, B Rosenfeld, LE Warner, AL Solomon, AJ O'Neill, G Sharma, A Platia, E Feld, GK Akiyama, T Brodsky, MA Greene, HL AF Olshansky, B Rosenfeld, LE Warner, AL Solomon, AJ O'Neill, G Sharma, A Platia, E Feld, GK Akiyama, T Brodsky, MA Greene, HL CA AFFIRM Investigators TI The atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study - Approaches to control rate in atrial fibrillation SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article ID VENTRICULAR RATE CONTROL; HEART-RATE CONTROL; LOW-DOSE DILTIAZEM; EXERCISE CAPACITY; INTRAVENOUS DILTIAZEM; CALCIUM-ANTAGONISTS; ORAL VERAPAMIL; SINUS RHYTHM; DIGOXIN; EFFICACY AB OBJECTIVES We sought to evaluate approaches used to control rate, the effectiveness of rate control, and switches from one drug class to another in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. BACKGROUND The AFFIRM study showed that atrial fibrillation (AF) can be treated effectively with rate control and anticoagulation, but drug efficacy to control rate remains uncertain. METHODS Patients (n = 2,027) randomized to rate control in the AFFIRM study were given rate-controlling drugs by their treating physicians. Standardized rate-control efficacy criteria developed a priori included resting heart rate and 6-min walk tests and/or ambulatory electrocardiographic results. RESULTS Average follow-up was 3.5 +/- 1.3 years. Initial treatment included a beta-adrenergic blocker (beta-blocker) alone in 24%, a calcium channel blocker alone in 17%, digoxin alone in 16%, a beta-blocker and digoxin in 14%, or a calcium channel blocker and digoxin in 14% of patients. Overall rate control was achieved in 70% of patients given beta-blockers as the first drug (with or without digoxin), 54% with calcium channel blockers (with or without digoxin), and 58% with digoxin alone. Adequate overall rate control was achieved in 58% of patients with the first drug or combination. Multivariate analysis revealed an association between first drug class and several clinical variables. There were more changes to beta-blockers than to the other two-drug classes (p < 0.0001). CONCLUSIONS Rate control in AF is possible in the majority of patients with AF. Beta-blockers were the most effective drugs. To achieve the goal of adequate rate control in all patients, frequent medication changes and drug combinations were needed. (C) 2004 by the American College of Cardiology Foundation. C1 Univ Iowa, Iowa City, IA 52242 USA. Yale Univ, Sch Med, New Haven, CT 06520 USA. W Los Angeles Vet Adm Med Ctr, Los Angeles, CA USA. Georgetown Univ, Med Ctr, Washington, DC 20057 USA. Sutter Inst Med Res, Sacramento, CA USA. Washington Hosp Ctr, Washington, DC 20010 USA. Univ Calif San Diego, San Diego, CA 92103 USA. Univ Rochester, Rochester, NY 14627 USA. Univ Calif Irvine, Irvine, CA 92717 USA. Univ Washington, Seattle, WA 98195 USA. Axio Res Corp, Seattle, WA USA. RP Olshansky, B (reprint author), Univ Iowa Hosp & Clin, 200 Hawkins Dr, Iowa City, IA 52242 USA. EM brian-olshansky@uiowa.edu FU NHLBI NIH HHS [N01-HC-55139] NR 40 TC 157 Z9 167 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD APR 7 PY 2004 VL 43 IS 7 BP 1201 EP 1208 DI 10.1016/j.jacc.2003.11.032 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 809MI UT WOS:000220640400012 PM 15063430 ER PT J AU Le, A Dasgupta, S Planque, S Paul, S Thiagarajan, P AF Le, A Dasgupta, S Planque, S Paul, S Thiagarajan, P TI Lupus-derived antiprothrombin autoantibodies from a V gene phage display library are specific for the kringle 2 domain of prothrombin SO BIOCHEMISTRY LA English DT Article ID MIDDLE-AGED MEN; ANTIPHOSPHOLIPID ANTIBODIES; PROTEIN-C; MYOCARDIAL-INFARCTION; ALPHA-THROMBIN; ACTIVATION; MEIZOTHROMBIN; BINDING; ANTICOAGULANTS; COAGULATION AB Autoantibodies to prothrombin are common in patients with systemic lupus erythematosus. Although their presence is a risk factor for thrombosis, neither their origin nor their precise role in inducing the procoagulant state is known. We have developed a phage-display antibody library from patients with systemic lupus erythematosus with antiprothrombin antibodies, and we have selected two single-chain Fv antibody fragments (ScFvs) by panning on a prothrombin-coated surface. In prothrombin activation assays using purified components, these antibodies promoted prothrombin activation. These ScFvs, termed AN78 and AN129, bound to immobilized prothrombin in a concentration-dependent specific manner but not to other anionic phospholipid binding proteins such as beta2-glycoprotein I or annexin V. Phosphatidylserine-bound prothrombin, but not soluble prothrombin, inhibited the binding suggesting that the epitope is available only on immobilized prothrombin. To localize the epitope, prothrombin was treated with thrombin or factor Xa and various prothrombin activation fragments were subsequently isolated and tested in ELISA with the ScFvs. Both AN78 and AN129 bound to prethrombin I (the fragment lacking the Gla domain and the first kringle domain), to fragment 1.2 (containing Gla and the two kringle domains only) and to fragment 2 but not to thrombin, thus localizing the cognate epitope to the kringle 2 domain in prothrombin. Analysis of the cDNA sequences of these antibodies show clustered mutational patterns in the complementarity determining region, suggesting that variable domains are the products of antigen-driven B cell clonal maturation. C1 Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Univ Texas, Hlth Sci Ctr, Dept Pathol, Houston, TX USA. RP Thiagarajan, P (reprint author), VA Med Ctr, Mail 113,2002 Holcombe Blvd, Houston, TX 77030 USA. EM perumalt@bcm.tmc.edu FU NHLBI NIH HHS [HL 65096] NR 40 TC 4 Z9 4 U1 0 U2 1 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0006-2960 J9 BIOCHEMISTRY-US JI Biochemistry PD APR 6 PY 2004 VL 43 IS 13 BP 4047 EP 4054 DI 10.1021/bi030167f PG 8 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 808PC UT WOS:000220580000031 PM 15049712 ER PT J AU Hasty, P Vijg, J AF Hasty, P Vijg, J TI Accelerating aging by mouse reverse genetics: a rational approach to understanding longevity SO AGING CELL LA English DT Editorial Material DE accelerated aging; genome maintenance; mouse models; progeroid syndromes ID TRANSCRIPTION FACTOR FOXO3A; WERNER-SYNDROME HELICASE; OXIDATIVE STRESS; DNA-REPAIR; LIFE-SPAN; SOMATIC MUTATIONS; NATURAL-SELECTION; MUTANT MICE; CHROMOSOME-ABERRATIONS; TELOMERE DYSFUNCTION AB Investigating the molecular basis of aging has been difficult, primarily owing to the pleiotropic and segmental nature of the aging phenotype. There are many often interacting symptoms of aging, some of which are obvious and appear to be common to every aged individual, whereas others affect only a subset of the elderly population. Although at first sight this would suggest multiple molecular mechanisms of aging, there now appears to be almost universal consensus that aging is ultimately the result of the accumulation of somatic damage in cellular macromolecules, with reactive oxygen species likely to be the main damage-inducing agent. What remains significant is unravelling how such damage can give rise to the large variety of aging symptoms and how these can be controlled. Although humans, with over a century of clinical observations, remain the obvious target of study, the mouse, with a relatively short lifespan, easy genetic accessibility and close relatedness to humans, is the tool par excellence to model aging-related phenotypes and test strategies of intervention. Here we present the argument that mouse models with engineered defects in genome maintenance systems are especially important because they often exhibit a premature appearance of aging symptoms. Confirming studies on human segmental progeroid syndromes, most of which are based on heritable mutations in genes involved in genome maintenance, the results thus far obtained with mouse models strongly suggest that lifespan and onset of aging are directly related to the quality of DNA metabolism. This may be in keeping with the recent discovery of a possible 'universal survival' pathway that improves antioxidant defence and genome maintenance and simultaneously extends lifespan in the mouse and several invertebrate species. C1 Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX 78245 USA. Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78245 USA. Univ Texas, Hlth Sci Ctr, Barshop Ctr Longev & Aging Studies, San Antonio, TX 78245 USA. S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA. RP Hasty, P (reprint author), Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX 78245 USA. EM hastye@uthscsa.edu; vijg@uthscsa.edu FU NCI NIH HHS [R01 CA76317-05A1]; NIA NIH HHS [AG20438, AG 17242]; NIEHS NIH HHS [ES11044] NR 79 TC 46 Z9 52 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1474-9718 J9 AGING CELL JI Aging Cell PD APR PY 2004 VL 3 IS 2 BP 55 EP 65 DI 10.1111/j.1474-9728.2004.00082.x PG 11 WC Cell Biology; Geriatrics & Gerontology SC Cell Biology; Geriatrics & Gerontology GA 812GN UT WOS:000220828100004 PM 15038819 ER PT J AU Hasty, P Vijg, J AF Hasty, P Vijg, J TI Rebuttal to Miller: "Accelerated aging": a primrose path to insight?' SO AGING CELL LA English DT Editorial Material ID MOUSE; GENES C1 Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX 78245 USA. Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78245 USA. Univ Texas, Hlth Sci Ctr, Barshop Ctr Longev & Aging Studies, San Antonio, TX 78245 USA. S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA. RP Hasty, P (reprint author), Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX 78245 USA. EM vijg@uthscsa.edu NR 9 TC 8 Z9 8 U1 0 U2 0 PU BLACKWELL PUBL LTD PI OXFORD PA 108 COWLEY RD, OXFORD OX4 1JF, OXON, ENGLAND SN 1474-9718 J9 AGING CELL JI Aging Cell PD APR PY 2004 VL 3 IS 2 BP 67 EP 69 DI 10.1111/j.1474-9728.2004.00087.x PG 3 WC Cell Biology; Geriatrics & Gerontology SC Cell Biology; Geriatrics & Gerontology GA 812GN UT WOS:000220828100005 PM 15038820 ER PT J AU Masoudi, FA Plomondon, ME Magid, DJ Sales, A Rumsfeld, JS AF Masoudi, FA Plomondon, ME Magid, DJ Sales, A Rumsfeld, JS TI Renal insufficiency and mortality from acute coronary syndromes SO AMERICAN HEART JOURNAL LA English DT Article ID ACUTE MYOCARDIAL-INFARCTION; NATIONAL REGISTRY; FAILURE; DISEASE; DYSFUNCTION; OUTCOMES; SURVIVAL; SURGERY; MILD AB Background Although there is accumulating evidence that renal insufficiency is an independent risk factor for mortality after acute myocardial infarction (AMI), it is not known whether renal dysfunction is associated with an increased mortality rate after a broad range of acute coronary syndromes, including unstable angina. Methods We examined consecutive patients from 24 Veterans Affairs hospitals with confirmed AMI or unstable angina between March 1998 and February 1999, who were categorized into groups according to estimated glomerular filtration rate (GFR). Multivariable regression was used to assess the independent association between GFR and the 7-month mortality rate, adjusting for differences in patient characteristics and treatment. Results Of the 2706 patients, 436 (16%) had normal renal function (GFR >90 mL/min/1.73 m(2)), 1169 (43%) had mild renal insufficiency (GFR 60-89 mL/min/1.73 m(2)), 864 (32%) had moderate renal insufficiency (GFR 30-59 mL/ min/1.73 m(2)), and 237 (9%) had severe renal insufficiency (GFR <30 mL/min/1.73 m(2)). Patients with renal insufficiency were less likely to undergo coronary angiography or to receive aspirin or beta-blockers of discharge. In multivariable models, renal insufficiency was associated with a higher odds of death (mild renal insufficiency: odds ratio [OR] = 1.76; 95% Cl, 0.93-3.33; moderate renal insufficiency: OR = 272; 95% Cl, 1.43-5.15; and severe renal insufficiency: OR = 6.18; 95% Cl, 3.09-12.36; all compared with normal renal function). The associations between renal insufficiency and mortality rate were similar in both the AMI and unstable angina subgroups (P value for interaction =.45). Conclusions Renal insufficiency is common and is associated with higher risks for death in patients with a broad range of ACS at presentation. Future efforts should be dedicated to determining whether more aggressive treatment will optimize outcomes in this patient population. C1 Denver Hlth Med Ctr, Div Cardiol, Dept Med, Denver, CO 80204 USA. Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO USA. Denver VA Med Ctr, Dept Med, Denver, CO USA. Colorado Permanente Med Grp, Clin Res Unit, Denver, CO USA. VA Puget Sound Hlth Care Syst, Hlth Serv Res, Seattle, WA USA. RP Masoudi, FA (reprint author), Denver Hlth Med Ctr, Div Cardiol, Dept Med, MC0960,777 Bannock St, Denver, CO 80204 USA. EM fred.mosoudi@uchsc.edu OI Sales, Anne/0000-0001-9360-3334 FU NIA NIH HHS [K08-AG01011] NR 29 TC 71 Z9 81 U1 0 U2 0 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD APR PY 2004 VL 147 IS 4 BP 623 EP 629 DI 10.1016/j.ahj.2003.12.010 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 895XG UT WOS:000226896900010 PM 15077076 ER PT J AU Mozaffarian, D Pischon, T Hankinson, SE Rifai, N Joshipura, K Willett, WC Rimm, EB AF Mozaffarian, D Pischon, T Hankinson, SE Rifai, N Joshipura, K Willett, WC Rimm, EB TI Dietary intake of trans fatty acids and systemic inflammation in women SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article DE trans Fatty acids; diet; inflammation; tumor necrosis factor receptors; women ID TUMOR-NECROSIS-FACTOR; CORONARY-HEART-DISEASE; INTERLEUKIN-6 GENE POLYMORPHISM; FOOD FREQUENCY QUESTIONNAIRE; MALE HEALTH-PROFESSIONALS; INSULIN-RESISTANCE; FACTOR-ALPHA; ENDOTHELIAL-CELLS; SOLUBLE RECEPTORS; UNITED-STATES AB Background: trans Fatty acid (TFA) intake predicts risks of coronary artery disease and diabetes. Systemic inflammation may be involved in the pathogenesis of such conditions; however, relations between TFA intake and systemic inflammation are not well established. Objective: We investigated the relations between TFA intake and inflammatory markers. Design: In 823 generally healthy women in the Nurses' Health Study I and II, concentrations of soluble tumor necrosis factor a receptors 1 and 2 (sTNF-R1, sTNF-R2), interleukin 6 (IL-6), and C-reactive protein (CRP) were measured. Usual dietary intakes assessed from 2 semiquantitative food-frequency questionnaires were averaged for each subject. Results: In age-adjusted analyses, TFA intake was positively associated with sTNF-R1 and sTNF-R2 (P for trend < 0.001 for each): sTNF-R1 and sTNF-R2 concentrations were 10% (+ 108 pg/mL; 95% CI: 50,167 pg/mL) and 12% (+258 pg/mL; 138,377 pg/mL) higher, respectively, in the highest intake quintile than m the lowest. These associations were not appreciably altered by adjustment for body mass index, smoking, physical activity, aspirin and nonsteroidal antiinflammatory drug use, alcohol consumption, and intakes of saturated fat, protein, n-6 and n-3 fatty acids, fiber, and total energy. Adjustment for serum lipid concentrations partly attenuated these associations, which suggests that they may be partly mediated by effects of TFAs on serum lipids. TFA intake was not associated with IL-6 or CRP concentrations overall but was positively associated with IL-6 and CRP in women with higher body mass index (P for interaction = 0.03 for each). Conclusions: TFA intake is positively associated with markers of systemic inflammation in women. Further investigation of the influences of TFAs on inflammation and of implications for coronary disease, diabetes, and other conditions is warranted. C1 Brigham & Womens Hosp, Channing Lab, Dept Med, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. Humboldt Univ, Franz Volhard Clin, Charite, D-1086 Berlin, Germany. Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA. Harvard Univ, Sch Dent Med, Dept Oral Hlth Policy & Epidemiol, Boston, MA 02115 USA. RP Mozaffarian, D (reprint author), 665 Huntington Ave,Bldg 2,Room 315, Boston, MA 02115 USA. EM darymd@hotmail.com RI Mozaffarian, Dariush/B-2276-2008 FU NCI NIH HHS [CA40356, CA50385, R01 CA040356, R01 CA050385]; NHLBI NIH HHS [HL24074, HL34594, K08 HL075628, R01 HL034594]; NIDCR NIH HHS [DE12102, R01 DE012102]; NIDDK NIH HHS [T32DK07703, DK07703, DK46200, P30 DK046200, T32 DK007703] NR 53 TC 211 Z9 233 U1 2 U2 15 PU AMER SOC CLINICAL NUTRITION PI BETHESDA PA 9650 ROCKVILLE PIKE, SUBSCRIPTIONS, RM L-3300, BETHESDA, MD 20814-3998 USA SN 0002-9165 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD APR PY 2004 VL 79 IS 4 BP 606 EP 612 PG 7 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 807IZ UT WOS:000220496500013 PM 15051604 ER PT J AU Shi, CW Gralnek, IM Dulai, GS Towfigh, A Asch, S AF Shi, CW Gralnek, IM Dulai, GS Towfigh, A Asch, S TI Consumer usage patterns of nonprescription histamine2-receptor antagonists SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID SELF-MEDICATION; THERAPY; WOMEN; DRUGS AB OBJECTIVE: Prescription to over-the-counter (OTC) drug switches are increasingly common. Yet little is known about how the public uses these reclassified products. Histamine2-receptor antagonists (H2RAs) are popular examples, although they may be supplanted by OTC proton pump inhibitors (PPIs). We examined the extent to which consumers substitute OTC H2RAs for physician care and/or engage in off-label use of these medications. METHODS: Self-administered anonymous survey of 1,116 adult OTC H2RA consumers in a random sample of 20 Los Angeles pharmacies from a major retail chain. Off-label use was defined by FDA warning label (e.g., bloody stools, dysphagia). Substitution was defined by intent to use H2RA instead of going to a physician. RESULTS: Forty-six percent engaged in off-label use of OTC H2RAs. Off-label use was independently associated with lower income, substitution for physician care, prior gastrointestinal disease, and past prescription H2RA use. Thirty-four percent substituted OTC H2RA use for physician care, and 54% of these met the criteria for off-label use. Substitution was associated with lack of health insurance, lack of time to see a physician, the belief that OTC H2RA was cheaper than clinic visits, and nonwhite race. CONCLUSION: Almost one-half of adult consumers reported using OTC H2RAs in a manner inconsistent with FDA labeling, and this off-label use was associated with substitution for physician care. Traditionally vulnerable populations were more prone to off-label use and to substituting H2RAs for physician care. Further studies are needed to assess patient outcomes, identify remedies, and explore implications for the reclassification of PPIs. C1 Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA. Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst,Ctr Study, Div Gastroenterol & Hepatol,CURE Digest Dis Res C, David Geffen Sch Med,Ctr Hlth Sci,Div Digest Dis, Los Angeles, CA 90024 USA. Va Greater Los Angeles Healthcare Syst, Dept Internal Med, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. RP Shi, CW (reprint author), Univ Calif San Diego, Dept Family & Prevent Med, 9500 Gilman Dr,Mailcode 0807, La Jolla, CA 92093 USA. NR 23 TC 12 Z9 12 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD APR PY 2004 VL 99 IS 4 BP 606 EP 610 DI 10.1111/j.1572-0241.2004.04130.x PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 816KF UT WOS:000221108100007 PM 15089889 ER PT J AU Chen, YM Polci, R Litchfield, P Gaczynska, M Riley, DJ AF Chen, YM Polci, R Litchfield, P Gaczynska, M Riley, DJ TI Nek1 regulates renal epithelial cell apoptosis through phosphorylation of the mitochondrial transition pore channel VDAC SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Meeting Abstract CT Annual Clinical Meeting of the National-Kidney-Foundation CY APR 28-MAY 02, 2004 CL Chicago, IL SP Natl Kidney Fdn C1 Univ Texas, Hlth Sci Ctr, Inst Biotechnol, San Antonio, TX USA. Univ Roma La Sapienza, Policlin Umberto I, Div Nephrol, Rome, Italy. S Texas Vet Hlth Care Syst, Div Res, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD APR PY 2004 VL 43 IS 4 MA 17 BP A19 EP A19 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 811RR UT WOS:000220789500043 ER PT J AU Dean, B Dylan, M Gano, A Knight, K Chan, W Ofman, JJ Levine, B AF Dean, B Dylan, M Gano, A Knight, K Chan, W Ofman, JJ Levine, B TI Erythropoiesis-stimulating protein therapy and decline of renal function SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Meeting Abstract CT Annual Clinical Meeting of the National-Kidney-Foundation CY APR 28-MAY 02, 2004 CL Chicago, IL SP Natl Kidney Fdn C1 Zynx Hlth, Beverly Hills, CA USA. Amgen Inc, Thousand Oaks, CA 91320 USA. Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD APR PY 2004 VL 43 IS 4 MA 26 BP A21 EP A21 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 811RR UT WOS:000220789500052 ER PT J AU Wagner, B Gorin, Y Ghosh-Choudhury, G Ricono, JM Abboud, HE AF Wagner, B Gorin, Y Ghosh-Choudhury, G Ricono, JM Abboud, HE TI NAD(P)H oxidase signaling in platelet-derived growth factor-BB stimulated metanephric mesenchymal cells SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Meeting Abstract CT Annual Clinical Meeting of the National-Kidney-Foundation CY APR 28-MAY 02, 2004 CL Chicago, IL SP Natl Kidney Fdn C1 Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA. UTHSCSA, Div Nephrol, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD APR PY 2004 VL 43 IS 4 MA 122 BP A45 EP A45 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 811RR UT WOS:000220789500148 ER PT J AU Goldzweig, CL Parkerton, PH Washington, DL Lanto, AB Yano, EM AF Goldzweig, CL Parkerton, PH Washington, DL Lanto, AB Yano, EM TI Primary care practice and facility quality orientation: Influence on breast and cervical cancer screening rates SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID HEALTH-CARE; PHYSICIAN GENDER; AMBULATORY CARE; SERVICES; WOMEN; INTERVENTIONS; IMPROVEMENT; PREDICTORS; BIAS AB Background: Despite the importance of early cancer detection, variation in screening rates among physicians is high. Insights into factors influencing variation can guide efforts to decrease variation and increase screening rates. Objectives: To explore the association of primary care practice features and a facility's quality orientation with breast and cervical cancer screening rates. Study Design: Cross-sectional study of screening rates among 144 Department of Veterans Affairs (VA) medical centers and for a national sample of women. Methods: We linked practice structure and quality improvement characteristics of individual VA medical centers from 2 national surveys (I to primary care directors and I to a stratified random sample of employees) to breast and cervical cancer screening rates determined from a review of random medical records. We conducted bivariate analyses and multivariate logistic regression of primary care practice and facility features on cancer screening rates, above and below the median. Results: While the national screening rates were high for breast (87%) and cervical cancer (90%), higher screening rates were more likely when primary care providers were consistently notified of specialty visits and when staff perceived a greater organizational commitment to quality and anticipated rewards and recognition for better performance. Conclusions: Organization and quality orientation of the primary care practice and its facility can enhance breast and cervical cancer screening rates. Internal recognition of quality performance and an overall commitment to quality improvement may foster improved prevention performance, with impact varying by clinical service. C1 VA Greater Los Angeles Healthcare Syst, Div Gen Internal Med, Los Angeles, CA 90073 USA. VA Greater Los Angeles Healthcare Syst, Hlth Serv Res & Dev Ctr, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, DAvid Geffen Sch Med, Dept Med, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA USA. RP Goldzweig, CL (reprint author), VA Greater Los Angeles Healthcare Syst, Div Gen Internal Med, 11301 Wilshire Blvd 111-G, Los Angeles, CA 90073 USA. EM caroline.goldzweig@med.va.gov NR 30 TC 23 Z9 24 U1 2 U2 6 PU AMER MED PUBLISHING, M W C COMPANY PI JAMESBURG PA 241 FORSGATE DR, STE 102, JAMESBURG, NJ 08831 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD APR PY 2004 VL 10 IS 4 BP 265 EP 272 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 811SO UT WOS:000220791800004 PM 15124503 ER PT J AU Schwetz, I Bradesi, S McRoberts, JA Sablad, M Miller, JC Zhou, HP Ohning, G Mayer, EA AF Schwetz, I Bradesi, S McRoberts, JA Sablad, M Miller, JC Zhou, HP Ohning, G Mayer, EA TI Delayed stress-induced colonic hypersensitivity in male Wistar rats: role of neurokinin-1 and corticotropin-releasing factor-1 receptors SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY LA English DT Article DE visceral pain; stress ID IRRITABLE-BOWEL-SYNDROME; INDUCED VISCERAL HYPERSENSITIVITY; MESSENGER-RIBONUCLEIC-ACID; PARAVENTRICULAR NUCLEUS; GASTROINTESTINAL-TRACT; RECTAL DISTENSION; MAST-CELLS; HYPERALGESIA; CRF; HYPOTHALAMUS AB The mechanism(s) underlying stress-induced colonic hypersensitivity (SICH) are incompletely understood. Our aims were to assess the acute and delayed (24 h) effect of water avoidance (WA) stress on visceral nociception in awake male Wistar rats and to evaluate the role of two stress-related modulation systems: the substance P/neurokinin-1 receptor (SP/NK(1)R)and the corticotropin-releasing factor (CRF)/CRF(1) receptor (CRF/CRF(1)R) systems, as well as the possible involvement of the sympathetic nervous system. Visceral pain responses were measured as the visceromotor response to colorectal distension (CRD) at baseline, immediately after WA and again 24 h later. The NK(1)R antagonists RP-67580 and SR-140333 and the CRF(1)R antagonist CP-154526 were injected 15 min before WA or 1 h before the CRD on day 2. Chemical sympathectomy was performed by repeated injection of 6-hydroxydopamine. WA stress resulted in a significant increase in the visceromotor response on day 2, but no change immediately after WA. Injection of CP-154526 abolished delayed SICH when applied either before WA stress or before the CRD on day 2. Both NK(1)R antagonists only decreased SICH when injected before the CRD on day 2. Chemical sympathectomy did not affect delayed SICH. Our results indicate that in male Wistar rats, both NK(1)R and CRF(1)R activation, but not sympathetic nervous system activation, play a role in the development of SICH. C1 Vet Affairs Greater Los Angeles Healthcare Syst, Ctr Neurovisceral Sci & Womens Hlth, W Los Angeles Healthcare Ctr, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurovisceral Sci & Womens Hlth, Dept Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurovisceral Sci & Womens Hlth, Dept Physiol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurovisceral Sci & Womens Hlth, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. RP Mayer, EA (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Ctr Neurovisceral Sci & Womens Hlth, W Los Angeles Healthcare Ctr, Bldg 115 Ctr Ulcer Res & Educ,Rm 223,11301 Wilshi, Los Angeles, CA 90073 USA. EM emayer@ucla.edu FU NIDDK NIH HHS [1P50-DK64539-01, P30-DK-41301] NR 44 TC 54 Z9 55 U1 0 U2 4 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1857 J9 AM J PHYSIOL-GASTR L JI Am. J. Physiol.-Gastroint. Liver Physiol. PD APR PY 2004 VL 286 IS 4 BP G683 EP G691 DI 10.1152/ajpgi.00358.2003 PG 9 WC Gastroenterology & Hepatology; Physiology SC Gastroenterology & Hepatology; Physiology GA 801HE UT WOS:000220086200020 PM 14615283 ER PT J AU Zirwas, MJ Kress, DW Deng, JS AF Zirwas, MJ Kress, DW Deng, JS TI The utility of antihistone antibody screening in the diagnosis of drug-induced lupus erythematosus SO ARCHIVES OF DERMATOLOGY LA English DT Letter C1 VA Pittsburgh Healthcare Syst, Dermatol Serv, Pittsburgh, PA 15240 USA. EM jau-shyong.deng@med.va.gov NR 5 TC 2 Z9 2 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0003-987X J9 ARCH DERMATOL JI Arch. Dermatol. PD APR PY 2004 VL 140 IS 4 BP 494 EP 495 DI 10.1001/archderm.140.4.494 PG 2 WC Dermatology SC Dermatology GA 922BU UT WOS:000228811600024 PM 15096389 ER PT J AU Wells, K Sherbourne, C Schoenbaum, M Ettner, S Duan, N Miranda, J Unutzer, J Rubenstein, L AF Wells, K Sherbourne, C Schoenbaum, M Ettner, S Duan, N Miranda, J Unutzer, J Rubenstein, L TI Five-year impact of quality improvement for depression - Results of a group-level randomized controlled trial SO ARCHIVES OF GENERAL PSYCHIATRY LA English DT Article ID PRIMARY-CARE PATIENTS; MANAGED PRIMARY-CARE; COST-EFFECTIVENESS; COLLABORATIVE MANAGEMENT; HEALTH-CARE; AFRICAN-AMERICAN; CHRONIC ILLNESS; IMPROVING CARE; UNITED-STATES; RACE AB Background: Quality improvement (QI) programs for depressed primary care patients can improve health outcomes for 6 to 28 months; effects for longer than 28 months are unknown. Objective: To assess how QI for depression affects health outcomes, quality of care, and health outcome disparities at 57-month follow-up. Design: A group-level randomized controlled trial. Setting: Forty-six primary care practices in 6 managed care organizations. Patients: Of 1356 primary care patients who screened positive for depression and enrolled in the trial, 991 (73%, including 451 Latinos and African Americans) completed 57-month telephone follow-up. Interventions: Clinics were randomly assigned to usual care or to I of 2 QI programs supporting QI teams, provider training, nurse assessment, and patient education, plus resources to support medication management (QI-meds) or psychotherapy (QI-therapy) for 6 to 12 months. Main Outcome Measures: Probable depressive disorder in the previous 6 months, mental health-related quality of life in the previous 30 days, primary care or mental health specialty visits, counseling or antidepressant medications in the previous 6 months, and unmet need, defined as depressed but not receiving appropriate care. Results: Combined QI-meds and QI-therapy, relative to usual care, reduced the percentage of participants with probable disorder at 5 years by 6.6 percentage points (P=.04). QI-therapy improved health outcomes and reduced unmet need for appropriate care among Latinos and African Americans combined but provided few long-term benefits among whites, reducing outcome disparities related to usual care (P=.04 for QI-ethnicity interaction for probable depressive disorder). Conclusions: Programs for QI for depressed primary care patients implemented by managed care practices can improve health outcomes 5 years after implementation and reduce health outcome disparities by markedly improving health outcomes and unmet need for appropriate care among Latinos and African Americans relative to whites; thus, equity was improved in the long run. C1 RAND Corp, Hlth Program, Santa Monica, CA 90407 USA. Univ Calif Los Angeles, Inst Neuropsychiat, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Biobehav Serv, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Hlth Serv Res Ctr, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Ctr Community Hlth, Los Angeles, CA 90024 USA. VA Greater Los Angeles Healthcare Syst, Dept Med, Div Gen Internal Med & Hlth Serv Res, Sepulveda, CA USA. RP Wells, K (reprint author), RAND Corp, Hlth Program, 1700 Main St, Santa Monica, CA 90407 USA. EM kwells@ucla.edu FU AHRQ HHS [R01-HS08349]; NIMH NIH HHS [R01MH57992, P50MH54623] NR 64 TC 139 Z9 139 U1 1 U2 11 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0003-990X J9 ARCH GEN PSYCHIAT JI Arch. Gen. Psychiatry PD APR PY 2004 VL 61 IS 4 BP 378 EP 386 DI 10.1001/archpsyc.61.4.378 PG 9 WC Psychiatry SC Psychiatry GA 811CD UT WOS:000220749100007 PM 15066896 ER PT J AU Anzai, Y Weymuller, EA Yueh, B Maronian, N Jarvik, JG AF Anzai, Y Weymuller, EA Yueh, B Maronian, N Jarvik, JG TI The impact of sinus computed tomography on treatment decisions for chronic sinusitis SO ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY LA English DT Article ID CHRONIC RHINOSINUSITIS; RECURRENT SINUSITIS; SURGERY; HEALTH; CARE; ANTROSTOMY; DIAGNOSIS; OUTCOMES AB Objectives: To determine the impact of sinus computed tomography (CT) on treatment decisions by otolaryngologists and to explore the factors leading to choice of surgical treatment for patients suspected of having chronic sinusitis. Design: Prospective cohort study. Setting: A tertiary academic medical center Patients: Questionnaires were administered to 3 otolaryngologists in a tertiary academic institution regarding diagnosis and treatment decisions in 27 patients suspected of having chronic sinusitis, before and after they reviewed sinus CT scans. Main Outcome Measures: The dichotomous decisions regarding surgical or nonsurgical treatment and the agreement of treatment decisions among surgeons were evaluated. The factors strongly influencing surgeons' treatment decisions regarding patients selected for surgery were also determined. Results: The dichotomous treatment decisions were changed in one third of patients (9 of 27) after the sinus CT scans were reviewed. The agreement of treatment decisions among the 3 surgeons was markedly improved after they reviewed sinus CT scans. The factors favorably influencing surgical treatment were obstruction of the ostiomeatal complex on CT and concordance of CT abnormality with a patient's symptoms. Lund-Mackay stage, symptoms, and corticosteroid or antibiotic use were not significant predictors. Conclusions: Despite the common belief that treatment decisions for chronic sinusitis should be solely based on clinical grounds, with sinus CT providing only anatomic detail before surgery, our study indicates that the decision to perform surgery was altered by CT in a substantial portion of the patients. In our preliminary study, CT increased the tendency to elect surgical treatment by all 3 surgeons. C1 Univ Washington, Dept Radiol, Seattle, WA 98195 USA. Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP Anzai, Y (reprint author), Univ Washington, Dept Radiol, Box 357115,RR-215,1959 NE Pacific St, Seattle, WA 98195 USA. EM anzai@u.washington.edu OI Yueh, Bevan/0000-0003-1380-1053 NR 29 TC 17 Z9 18 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0886-4470 J9 ARCH OTOLARYNGOL JI Arch. Otolaryngol. Head Neck Surg. PD APR PY 2004 VL 130 IS 4 BP 423 EP 428 DI 10.1001/archotol.130.4.423 PG 6 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 812GS UT WOS:000220828600005 PM 15096424 ER PT J AU Weaver, EM Kapur, V Yueh, B AF Weaver, EM Kapur, V Yueh, B TI Polysomnography vs self-reported measures in patients with sleep apnea SO ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY LA English DT Article; Proceedings Paper CT Meeting of teh Association-of-Professional-Sleep-Societies CY JUN 19, 2000 CL LAS VEGAS, NV SP Assoc Profess Sleep Societies ID QUALITY-OF-LIFE; DAYTIME SLEEPINESS; HEALTH-STATUS; RATED HEALTH; SCALE; HYPERTENSION; ASSOCIATION; INDEX; MORTALITY; COMMUNITY AB Background: While obstructive sleep apnea syndrome is defined by both polysomnographic (PSG) abnormalities and symptoms, severity is quantified primarily by the apnea-hypopnea index (AHI) alone. Objective: To determine the correlation between standard PSG indices (AHI and others) and self-reported sleepiness, mental health status, and general health in patients with sleep apnea. Design: Cross-sectional study. Setting: University-affiliated outpatient sleep laboratory Patients: Ninety-six consecutive patients with PSG-confirmed sleep apnea (AHI; : 5). Measurements: Patients completed a questionnaire that included the Epworth Sleepiness Scale, Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) mental health domain, and self-rated health on the evening of diagnostic PSG. Spearman correlation coefficients were computed. This sample had 85% power to detect a correlation of 0.3 or greater. The associations between PSG indices and self-reported measures were further assessed with multivariable regression techniques, adjusting for age, sex, body mass index, comorbidity, and PSG type. Results: The PSG parameters correlated poorly with self-reported measures (15 correlations; range of magnitude, 0.004-0.24; mean, 0.09). AHI was not associated with self-reported sleepiness or general health, and it was associated with the SF-36 Health Status mental health domain only on multiple linear regression (P=.04) but not on multiple logistic regression (adjusted odds ratio, 1.02; 95% confidence interval, 1.00-1.04; P=.09). Conclusions: In general, PSG measures, and AHI in particular, correlated poorly with self-reported measures in a clinical sleep laboratory sample. After adjustment for potentially confounding variables, weak associations were found between some PSG indices and selected self-reported measures. These findings suggest that sleep apnea disease burden should be quantified with both physiologic and subjective measures. C1 Univ Washington, Dept Otolaryngol Head & Neck Surg, Sleep Disorders Ctr, Seattle, WA 98195 USA. Univ Washington, Ctr Cost & Outcomes, Seattle, WA 98195 USA. Univ Washington, Div Pulm & Crit Care Med, Dept Med, Seattle, WA 98195 USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Surg & Perioperat Care Serv, Seattle, WA USA. Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Serv, Seattle, WA USA. RP Weaver, EM (reprint author), 1660 S Columbian Way 112 OTO, Seattle, WA 98108 USA. EM eweaver@u.washington.edu RI Kapur, Vishesh/K-1054-2014 OI Kapur, Vishesh/0000-0002-5417-1097; Yueh, Bevan/0000-0003-1380-1053 FU NHLBI NIH HHS [K23 HL068849, K23 HL068849-01A2]; ODCDC CDC HHS [CD-98318] NR 34 TC 48 Z9 52 U1 1 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0886-4470 J9 ARCH OTOLARYNGOL JI Arch. Otolaryngol. Head Neck Surg. PD APR PY 2004 VL 130 IS 4 BP 453 EP 458 DI 10.1001/archotol.130.4.453 PG 6 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 812GS UT WOS:000220828600011 PM 15096430 ER PT J AU Rentschler, AJ Cooper, RA Fitzgerald, SG Boninger, ML Guo, SF Ammer, WA Vitek, M Algood, D AF Rentschler, AJ Cooper, RA Fitzgerald, SG Boninger, ML Guo, SF Ammer, WA Vitek, M Algood, D TI Evaluation of selected electric-powered wheelchairs using the ANSI/RESNA standards SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE reference standards; rehabilitation; safety; wheelchairs ID OCCUPIED WHEELCHAIRS; MANUAL WHEELCHAIRS; STABILITY; LOADS; LIFE; REAR AB Objectives: To compare the performance characteristics of different electric-powered wheelchairs (EPWs) and to evaluate the effectiveness of the American National Standards Institute/Rehabilitation Engineering and Assistive Technology Society of North America (ANSI/RESNA) wheelchair standards. Design: Five types of EPWs were selected. Three wheelchairs of each type were tested according to the ANSI/RESNA wheelchair standards. Setting: Rehabilitation engineering center. Specimens: Fifteen wheelchairs. Interventions: Not applicable. Main Outcome Measures: Static tipping angle; dynamic tipping score; braking distance; energy consumption; static, impact, and fatigue strength; and climatic conditioning. Results: There were significant differences (P<.05) among the 5 types of EPWs for static stability when facing both uphill and downhill in the most-stable and least-stable configurations. There were significant differences (P<.05) among the EPWs on most of the dynamic stability tests. There were also significant differences (P<.05) among EPWs for all the effectiveness of brakes conditions, as well as between 2 wheelchairs for the energy consumption testing. There were several failures among the wheelchairs during the static, impact, and fatigue strength testing and during the climatic testing. Conclusions: The results show that EPWs can vary greatly with respect to static and dynamic stability, braking distance, range, strength testing, and climatic conditioning. All these factors have a substantial effect on safety and performance. C1 VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Healthcare Syst, Pittsburgh, PA USA. Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. RP Cooper, RA (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, 151-RI,7180 Highland Dr, Pittsburgh, PA 15206 USA. EM rcooper@pitt.edu OI Boninger, Michael/0000-0001-6966-919X NR 16 TC 16 Z9 17 U1 1 U2 4 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD APR PY 2004 VL 85 IS 4 BP 611 EP 619 DI 10.1016/j.apmr.2003.06.023 PG 9 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 810MM UT WOS:000220708400013 PM 15083438 ER PT J AU Homik, JE Suarez-Almazor, M AF Homik, JE Suarez-Almazor, M TI An economic approach to health care SO BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY LA English DT Article DE cost-effectiveness; economic analysis; rheumatoid arthritis; anti-tumor necrosis factor agents; COX-2 inhibitors ID COST-EFFECTIVENESS ANALYSIS; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RHEUMATOID-ARTHRITIS; TREATMENT OPTIONS; 2ND-LINE DRUGS; ACCES MODEL; OSTEOARTHRITIS; METHOTREXATE; MISOPROSTOL; CELECOXIB AB Economic analyses have the potential to put all of the positive and negative outcomes of an intervention into perspective to aid decision making. The quality of the data upon which the analysis is based has an impact on the resulting quality of the analysis itself. Analysis of cost-effectiveness requires the input of many types of data, and where data are not available, assumptions must be made. There are many instances where the analysis may go wrong, and it is important to remain cognizant of these. The critical parts of the analysis, which have also been identified in quality assessment tools, include the following: design of the study question, sources of probability estimates and cost data, sensitivity analysis, and the interpretation of results. If the readers are able to identify the assumptions of the analysis they are better equipped to judge the validity. We have reviewed economic analyses relating to two hot economic topics in rheumatology. These are the cost-effectiveness of cyclooxygenase-2 (COX-2) inhibitors for 'arthritis' and cost-effectiveness of anti-tumor necrosis factor alpha (anti-TNF) agents for rheumatoid arthritis (KA). The results of the COX-2 analyses vary by review. Some show cost savings, while others calculate a significant cost in order to achieve any change in quality of life. Given the unanswered questions that still exist, it seems reasonable to conclude that COX-2 inhibitors may be cost effective when used in patients at a high risk of GI complications. Unanswered questions remain regarding the concomitant use of low-dose ASA and proton pump inhibitors and how they may affect the results of these economic analyses. The cost-effectiveness of anti-TNF agents has not been explored in as much detail as that of the COX-2 agents. Two studies have presented cost-effectiveness models that include a hypothetical biologic agent. Two economic analyses report on the cost-effectiveness of etanercept compared with traditional disease-modifying anti-rheumatic drugs (DMARDs) in methotrexate-resistant and methotrexate-naive patients with RA. Both the analyses show that etanercept has a cost-effectiveness ratio of around US$40 000 for every patient who achieves an American College of Rheumatology 20% improvement score (ACR 20) within a 6-month period. A cost-utility analysis was published regarding the use of infliximab in methotrexate resistant RA. It showed a cost-utility ratio of 3400:34 000 Euro per quality adjusted life year (QALY) gained, depending on the country evaluated (Sweden and the UK, respectively). An important finding in all three studies was that indirect costs dominate costs in RA; therefore, they should be included in all future analyses of this disease. C1 Univ Alberta, Heritage Med Res Ctr 562, Edmonton, AB T6G 2S2, Canada. Houston Vet Affairs Med Ctr 152, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA. RP Homik, JE (reprint author), Univ Alberta, Heritage Med Res Ctr 562, Edmonton, AB T6G 2S2, Canada. EM joanne.homik@ualberta.ca NR 41 TC 5 Z9 5 U1 1 U2 1 PU BAILLIERE TINDALL PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 1521-6942 J9 BEST PRACT RES CL RH JI Best Pract. Res. Clin. Rheumatol. PD APR PY 2004 VL 18 IS 2 BP 203 EP 218 DI 10.1016/j.berh.2004.02.001 PG 16 WC Rheumatology SC Rheumatology GA 825NM UT WOS:000221765200008 PM 15121040 ER PT J AU Riley, DE Krieger, JN AF Riley, DE Krieger, JN TI Short tandem repeats are associated with diverse mRNAs encoding membrane-targeted proteins SO BIOESSAYS LA English DT Article ID ANDROGEN RECEPTOR GENE; PROSTATE-CANCER; UNTRANSLATED REGION; FUNCTIONAL-ANALYSIS; MYOTONIC-DYSTROPHY; MOLECULAR-CLONING; BINDING PROTEIN; CDNA CLONING; EXPRESSION; MOUSE AB Within the genomes of multicellular organisms, short tandem repeating sequences (STRs) are ubiquitous, yet usage patterns remain obscure. The repeats (AC)n and (GU)n appear frequently in the untranslated regions (UTRs) of messenger RNAs (mRNAs). To investigate STR usage patterns, we used three approaches: (1) comparisons of individual mRNA database sequences including annotations and linked references, (2) statistical analysis of complete, UTR databases and (3) study of a large gene family, the aquaporins. Among 500 (AC)n- or (GU)n-containing mRNAs, 58 (12%) had known functions. Of these, 50 (86%) encoded proteins whose activities involved membranes or lipids, including integral membrane proteins, peripheral membrane proteins, ion channels, lipid enzymes, receptors and secreted proteins. A control sequence (AU)n also occurred in mRNAs, but only 5% encoded membrane-related functions. Investigation of all reported 3' UTR sequences, demonstrated that the STR (AC)n was 9 times more common in mRNAs encoding membrane functions than in the total UTR database (P < 0.001). Similarly, (GU)n was 8 times more common in membrane-function mRNAs than in the total database (P < 0.001). These observations suggest that (AC)n and (GU)n may be UTR signals for some mRNAs encoding membrane-targeted proteins. This article contains supplementary material which may be viewed at the BioEssays website at http://www.interscience.wiley.com/jpages/0265-9247/suppmat/index.html. (C) 2004 Wiley Periodicals, Inc. C1 VA Puget Sound Hlth Care Syst, Dept Res, Seattle, WA USA. Univ Washington, Dept Urol, Seattle, WA 98195 USA. RP Riley, DE (reprint author), Vet Adm Med Ctr, Room 517,Bldg 1,1660 S Columbian Way, Seattle, WA 98108 USA. EM dri@u.washington.edu FU NIDDK NIH HHS [R01 DK38955] NR 74 TC 7 Z9 7 U1 0 U2 2 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 0265-9247 J9 BIOESSAYS JI Bioessays PD APR PY 2004 VL 26 IS 4 BP 434 EP 444 DI 10.1002/bies.20001 PG 11 WC Biochemistry & Molecular Biology; Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics GA 808PH UT WOS:000220580500011 PM 15057941 ER PT J AU Chattopadhyay, M Goss, J Wolfe, D Goins, WC Huang, S Glorioso, JC Mata, M Fink, DJ AF Chattopadhyay, M Goss, J Wolfe, D Goins, WC Huang, S Glorioso, JC Mata, M Fink, DJ TI Protective effect of herpes simplex virus-mediated neurotrophin gene transfer in cisplatin neuropathy SO BRAIN LA English DT Article DE nerve growth factors; gene therapy; herpes; neuropathy ID NERVE GROWTH-FACTOR; ROOT GANGLION NEURONS; PERIPHERAL NEUROPATHY; DIABETIC NEUROPATHY; SYMPATHETIC NEURONS; INDUCED APOPTOSIS; SENSORY NEURONS; SPINAL-CORD; IN-VIVO; RECEPTORS AB Attempts to develop clinical treatments for neuropathy using neurotrophins have not been successful. We tested whether neurotrophin gene delivery to dorsal root ganglia (DRGs) using non-replicating herpes simplex virus (HSV)-based vectors could prevent the development of neuropathy caused by administration of cisplatin. Following subcutaneous inoculation of HSV vectors expressing nerve growth factor (NGF) or neurotrophin-3 (NT-3), neurons in the DRG were transduced to produce NGF or NT-3 in vivo. Inoculation of either the NGF- or the NT-3-expressing vectors 3 days before the start of a 6-week course of cisplatin treatment protected against cisplatin-induced neuropathy assessed by electrophysiological, histological and behavioural measures 2 months later. Iatrogenic neuropathy caused by administration of chemotherapeutic drugs represents an excellent target for a human trial to assess the potential of gene therapy to prevent neuropathy. C1 Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA. Univ Pittsburgh, Dept Mol Genet, Pittsburgh, PA 15213 USA. Univ Pittsburgh, Dept Biochem, Pittsburgh, PA 15213 USA. VA Pittsburgh Healthcare Syst, GRECC, Pittsburgh, PA 15213 USA. RP Fink, DJ (reprint author), 1914 Taubman Ctr,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA. EM djfink@umich.edu NR 49 TC 40 Z9 44 U1 0 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0006-8950 J9 BRAIN JI Brain PD APR PY 2004 VL 127 BP 929 EP 939 DI 10.1093/brain/awh103 PN 4 PG 11 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 807ET UT WOS:000220485500025 PM 14749293 ER PT J AU Nascimento, ALTO Verjovski-Almeida, S Van Sluys, MA Monteiro-Vitorello, CB Camargo, LEA Digiampietri, LA Harstkeerl, RA Ho, PL Marques, MV Oliveira, MC Setubal, JC Haake, DA Martins, EAL AF Nascimento, ALTO Verjovski-Almeida, S Van Sluys, MA Monteiro-Vitorello, CB Camargo, LEA Digiampietri, LA Harstkeerl, RA Ho, PL Marques, MV Oliveira, MC Setubal, JC Haake, DA Martins, EAL TI Genome features of Leptospira interrogans serovar Copenhageni SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH LA English DT Article DE Leptospira interrogans; outer membrane proteins; lipopolysaccharides; transport; regulatory systems ID OUTER-MEMBRANE PROTEIN; PATHOGEN XYLELLA-FASTIDIOSA; BORRELIA-BURGDORFERI; SIGNAL-TRANSDUCTION; TREPONEMA-PALLIDUM; MAMMALIAN INFECTION; SEQUENCE-ANALYSIS; ESCHERICHIA-COLI; DNA-REPLICATION; DOMAINS AB We report novel features of the genome sequence of Leptospira interrogans serovar Copenhageni, a highly invasive spirochete. Leptospira species colonize a significant proportion of rodent populations worldwide and produce life-threatening infections in mammals. Genomic sequence analysis reveals the presence of a competent transport system with 13 families of genes encoding for major transporters including a three-member component efflux system compatible with the long-term survival of this organism. The leptospiral genome contains a broad array of genes encoding regulatory system, signal transduction and methyl-accepting chemotaxis proteins, reflecting the organism's ability to respond to diverse environmental stimuli. The identification of a complete set of genes encoding the enzymes for the cobalamin biosynthetic pathway and the novel coding genes related to lipopolysaccharide biosynthesis should bring new light to the study of Leptospira physiology. Genes related to toxins, lipoproteins and several surface-exposed proteins may facilitate a better understanding of the Leptospira pathogenesis and may serve as potential candidates for vaccine. C1 Inst Butantan, Ctr Biotecnol, BR-05503900 Sao Paulo, Brazil. Univ Sao Paulo, Inst Quim, BR-05508 Sao Paulo, Brazil. Univ Sao Paulo, Inst Biociencias, BR-05508 Sao Paulo, Brazil. Univ Sao Paulo, Inst Ciencias Biomed, BR-05508 Sao Paulo, Brazil. Univ Sao Paulo, Escola Super Agr Luiz Queiroz, Piracicaba, SP, Brazil. Univ Estadual Campinas, Inst Computacao, Lab Bioinformat, Campinas, SP, Brazil. Royal Trop Inst, KIT Biomed Res, NL-1105 AZ Amsterdam, Netherlands. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA USA. Virginia Polytech Inst & State Univ, Virginia Bioinformat Inst, Blacksburg, VA 24061 USA. Virginia Polytech Inst & State Univ, Dept Comp Sci, Blacksburg, VA 24061 USA. RP Nascimento, ALTO (reprint author), Inst Butantan, Ctr Biotecnol, Av Vital Brazil,1500, BR-05503900 Sao Paulo, Brazil. EM tabet@butantan.gov.br RI Martins, Elizabeth/B-7135-2015; IB/USP, Botanica/Q-7627-2016; Setubal, Joao/C-7305-2012; Verjovski-Almeida, Sergio/E-4082-2012; Oliveira, Mariana /G-2512-2012; Van Sluys, Marie-Anne/A-8483-2012; Nascimento, Ana Lucia/E-8488-2012; Camargo, Luis Eduardo/C-2735-2012; Ho, Paulo/P-8267-2015; Monteiro-Vitorello, Claudia/F-2436-2012; Digiampietri, Luciano/B-8597-2012; Marques, Marilis/C-3085-2013 OI Martins, Elizabeth/0000-0002-2333-9379; Setubal, Joao/0000-0001-9174-2816; Verjovski-Almeida, Sergio/0000-0002-6356-2401; Oliveira, Mariana /0000-0001-8495-2962; Van Sluys, Marie-Anne/0000-0002-6506-2734; Nascimento, Ana Lucia/0000-0003-4851-0870; Camargo, Luis Eduardo/0000-0002-5650-5695; Ho, Paulo/0000-0003-3652-241X; Monteiro-Vitorello, Claudia/0000-0002-1238-9354; Digiampietri, Luciano/0000-0003-4890-1548; FU NIAID NIH HHS [R01 AI034431, R01 AI034431-07] NR 60 TC 121 Z9 125 U1 1 U2 9 PU ASSOC BRAS DIVULG CIENTIFICA PI SAO PAULO PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, BRAZIL SN 0100-879X J9 BRAZ J MED BIOL RES JI Brazilian J. Med. Biol. Res. PD APR PY 2004 VL 37 IS 4 BP 459 EP 478 DI 10.1590/S0100-879X2004000400003 PG 24 WC Biology; Medicine, Research & Experimental SC Life Sciences & Biomedicine - Other Topics; Research & Experimental Medicine GA 815MI UT WOS:000221046000003 PM 15064809 ER PT J AU Tache, Y Martinez, V Wang, L Million, M AF Tache, Y Martinez, V Wang, L Million, M TI CRF1 receptor signaling pathways are involved in stress-related alterations of colonic function and viscerosensitivity: implications for irritable bowel syndrome SO BRITISH JOURNAL OF PHARMACOLOGY LA English DT Review DE corticotropin releasing factor; CRF; urocortin; CRF antagonists; CRF receptors; colonic motility; enteric nervous system; stress; irritable bowel syndrome ID CORTICOTROPIN-RELEASING-FACTOR; PITUITARY-ADRENAL AXIS; WATER-AVOIDANCE STRESS; PARAVENTRICULAR NUCLEUS; RAT-BRAIN; NERVOUS-SYSTEM; MOTOR FUNCTION; COMPETITIVE ANTAGONISTS; FOS EXPRESSION; MESSENGER-RNA AB 1 The characterization of corticotropin releasing factor (CRF) and, more recently, the discovery of additional CRF-related ligands, urocortin 1, urocortin 2 and urocortin 3, the cloning of two distinct CRF receptor subtypes, 1 (CRF1) and 2 (CRF2), and the development of selective CRF receptor antagonists provided new insight to unravel the mechanisms of stress. Activation of brain CRF1 receptor signaling pathways is implicated in stress-related endocrine response and the development of anxiety-like behaviors. 2 Compelling evidence in rodents showed also that both central and peripheral injection of CRF and urocortin 1 mimic acute stress-induced colonic response ( stimulation of motility, transit, defecation, mucus and watery secretion, increased ionic permeability and occurrence of diarrhea) in rodents. Central CRF enhances colorectal distention-induced visceral pain in rats. Peripheral CRF reduced pain threshold to colonic distention and increased colonic motility in humans. 3 Nonselective CRF1/CRF2 antagonists and selective CRF1 antagonists inhibit exogenous (central or peripheral) CRF- and acute stress-induced activation of colonic myenteric neurons, stimulation of colonic motor function and visceral hyperalgesia while selective CRF2 antagonists have no effect. None of the CRF antagonists influence basal or postprandial colonic function in nonstressed animals. 4 These findings implicate CRF1 receptors in stress-related stimulation of colonic function and hypersensitivity to colorectal distention. Targeting CRF1-dependent pathways may have potential benefit against stress or anxiety-/depression-related functional bowel disorders. C1 Univ Calif Los Angeles, CURE, Digest Dis Res Ctr, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Med,Div Digest Dis, W Los Angeles Vet Affairs Med Ctr, Ctr Neurovisceral Sci & Womans Hlth, Los Angeles, CA 90024 USA. AStraZeneca R&D Molndal, Integrat Pharmacol Gastrointestinal Biol, SE-43183 Molndal, Sweden. RP Tache, Y (reprint author), VA Greater Los Angeles Hlth Care Syst, CURE, Bldg 115,Room 117,1130 Wilshire Blvd, Los Angeles, CA 90073 USA. EM ytache@ucla.edu RI Martinez, Vicente/N-1189-2014 FU NIAMS NIH HHS [P50 AR 049550]; NIDDK NIH HHS [DK 41301, R01 DK 33061, DK 57238-01A1S1, R01 DK 57238, R01 DK033061, R01 DK057238, P30 DK041301] NR 119 TC 131 Z9 144 U1 1 U2 6 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0007-1188 J9 BRIT J PHARMACOL JI Br. J. Pharmacol. PD APR PY 2004 VL 141 IS 8 BP 1321 EP 1330 DI 10.1038/sj.bjp.0705760 PG 10 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 817MT UT WOS:000221182300009 PM 15100165 ER PT J AU Skloot, G Goldman, M Fischler, D Goldman, C Schechter, C Levin, S Teirstein, A AF Skloot, G Goldman, M Fischler, D Goldman, C Schechter, C Levin, S Teirstein, A TI Respiratory symptoms and physiologic assessment of ironworkers at the World Trade Center disaster site SO CHEST LA English DT Article DE exposure; forced oscillation; ironworkers; September 11, 2001; spirometry; World Trade Center disaster ID FORCED OSCILLATION TECHNIQUE; LUNG-FUNCTION; IMPULSE OSCILLOMETRY; IRRITANT INHALATION; BRONCHIAL CHALLENGE; ASTHMATIC-CHILDREN; NORMAL VALUES; COLD-AIR; RESPONSIVENESS; METHACHOLINE AB Study objectives: To characterize respiratory abnormalities in a convenience sample of ironworkers exposed at the World Trade Center (WTC) disaster site for varying lengths of time between September 11, 2001, and February 8, 2002. Design: Cross-sectional study. Setting: The Mount Sinai Medical Center, a large tertiary hospital. Participants: Ninety-six ironworkers engaged in rescue and recovery with exposure onset between September 11, 2001, and September 15, 2001, who responded to an invitation to undergo respiratory evaluation. Measurements: Medical and exposure history, physical examination, spirometry, forced oscillation (FO), and chest radiographs. The relationships of prevalence of respiratory symptoms and presence of obstructive physiology to smoking, exposure on September 11, duration of exposure, and type of respiratory protection were examined using univariate and linear and logistic regression analyses. Results; Seventy-four of 96 workers (77%) had one or more respiratory symptoms (similar in smokers [49 of 63 subjects, 78%] and nonsmokers [25 of 33 subjects, 76%]). Cough was the most common symptom (62 of 96 subjects, 65%), and was associated with exposure on September 11. Chest examination and radiograph findings were abnormal in 10 subjects (10%) and 19 subjects (20%), respectively. FO revealed dysfunction in 34 of 64 subjects tested (53%), while spirometry suggested obstruction in only 11 subjects (17%). Lack of a respirator with canister was a risk factor for large airway dysfunction, and cigarette smoking was a risk factor for small airway dysfunction. No other relationships reached statistical significance. Conclusions: Respiratory symptoms occurred in the majority of ironworkers at the WTC disaster site and were not attributable to smoking. Exposure on September 11 was associated with a greater prevalence of cough. Objective evidence of lung disease was less common. Spirometry underestimated the prevalence of lung function abnormalities in comparison to FO. Continuing evaluation of symptoms, chest radiographs, and airway dysfunction should determine whether long-term clinical sequelae will exist. C1 CUNY, Mt Sinai Med Ctr, Div Pulm & Crit Care Med, New York, NY 10029 USA. Univ Calif Los Angeles, Dept Med, Sch Med, Los Angeles, CA 90024 USA. W Los Angeles Vet Affairs Med Ctr, Dept Obstet Gynecol & Gen Internal Med, Los Angeles, CA 90073 USA. Albert Einstein Coll Med, New York, NY USA. Mt Sinai Sch Med, Div Environm & Occupat Med, New York, NY USA. RP Skloot, G (reprint author), CUNY, Mt Sinai Med Ctr, Div Pulm & Crit Care Med, 1 Gustave L Levy Pl,Box 1232, New York, NY 10029 USA. EM Gwen.Skloot@msnyuhealth.org NR 43 TC 88 Z9 88 U1 3 U2 4 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD APR PY 2004 VL 125 IS 4 BP 1248 EP 1255 DI 10.1378/chest.125.4.1248 PG 8 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 825YB UT WOS:000221793700015 PM 15078731 ER PT J AU El-Serag, HB Garewel, H Kuebeler, M Sampliner, RE AF El-Serag, Hashem B. Garewel, Harinder Kuebeler, Mark Sampliner, Richard E. TI Is the Length of Newly Diagnosed Barrett's Esophagus Decreasing? The Experience of a VA Health Care System SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article AB Background & Aims: Secular trends in the length of newly diagnosed Barrett's esophagus (BE) are unknown. We have anecdotally noticed less frequent new diagnoses of long segments of BE. Methods: This is a retrospective analysis of prospectively collected information on a well-characterized large cohort of patients with documented BE that was diagnosed between 1981 and 2000 at Southern Arizona Department of Veterans Affairs Health Care System. We examined temporal changes in the length of BE at the time of diagnosis (frequency and proportions). We conducted correlation analyses, as well as multivariate linear regression analyses, to examine the association between year of diagnosis and BE length while adjusting for temporal differences in age, sex, ethnicity, previous use of antisecretory therapy, and the presence of intestinal metaplasia (IM) of the gastric cardia. Results: There were 340 patients with BE first diagnosed between 1981 and 2000. All cases were defined by the presence of areas of salmoncolored mucosa in the lower end of the tubular esophagus and IM in biopsy specimens obtained from these areas on at least 2 endoscopic examinations. There were no significant changes over time in mean age of patients with BE (61 yr) or proportion of white patients (84%). The mean length of BE at the time of first diagnosis declined progressively over time. In the earliest period (1981-1985), mean BE length was 6 +/- 3.8 cm, whereas mean BE length in 1996-2000 was 3.6 +/- 2.9 cm. This observation was explained not only by more frequent diagnoses of short BE, but also by less frequent diagnoses of long BE (>= 3 cm). There was a strong inverse correlation between BE length at the time of diagnosis and year of diagnosis (Pearson's correlation coefficient, -0.29; P <0.0001). In the multivariate linear regression model, a more recent year of BE diagnosis was an independent predictor of shorter BE length (P <0.0001). Similar results were obtained in analyses restricted to veteran patients or those with BE >= 3 cm. Conclusions: There has been a progressive decline in the length of newly diagnosed BE as a result of an increase in short-segment BE, but, curiously, also because of a decline in long-segment BE (>= 3 cm). These changes cannot be explained fully by changes in demographic features of patients, previous therapy, or the increasing emphasis on IM of the gastric cardia. The role of referral bias and/or temporal changes in the definitions cannot be excluded. C1 [El-Serag, Hashem B.] Gastroenterol Sect, Houston, TX USA. [El-Serag, Hashem B.; Kuebeler, Mark] Sect Hlth Serv Res, Houston, TX 77030 USA. [El-Serag, Hashem B.; Kuebeler, Mark] Houston Vet Affairs Med Ctr, Houston, TX USA. [Garewel, Harinder; Sampliner, Richard E.] Univ Arizona, Hlth Sci Ctr, Gastroenterol Sect, Tucson, AZ USA. [Garewel, Harinder; Sampliner, Richard E.] So Arizona Vet Affairs Hlth Care Syst, Gastroenterol Sect, Tucson, AZ USA. [El-Serag, Hashem B.; Kuebeler, Mark] Baylor Coll Med, Houston, TX 77030 USA. RP El-Serag, HB (reprint author), 2002 Holcombe Blvd 152, Houston, TX 77030 USA. EM hasheme@bcm.tmc.edu FU Veterans Affairs [RCD00-013-2] FX H.B.E.-S. is a Veterans Affairs Health Services Research and Development Awardee (RCD00-013-2). NR 17 TC 11 Z9 12 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD APR PY 2004 VL 2 IS 4 BP 296 EP 300 DI 10.1053/S1542-3565(04)00058-8 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA V19KP UT WOS:000208071600005 PM 15067623 ER PT J AU Craig, WA AF Craig, WA TI Proof of concept: performance testing in models SO CLINICAL MICROBIOLOGY AND INFECTION LA English DT Article; Proceedings Paper CT 13th European Congress of Clinical Microbiology and Infectious Diseases CY MAY, 2003 CL GLASGOW, SCOTLAND DE amoxicillin/clavulanate; pharmacokinetics; pharmacodynamics; animal model; drug development ID PHARMACOKINETICALLY ENHANCED FORMULATION; RESPIRATORY-TRACT INFECTION; STREPTOCOCCUS-PNEUMONIAE; AMOXICILLIN-CLAVULANATE; ANTIMICROBIAL AGENTS; DOSAGE REGIMENS; PHARMACODYNAMICS; EFFICACY; STRAINS; AMOXICILLIN/CLAVULANATE AB Pharmacokinetic (PK) and pharmacodynamic (PD) principles that predict antimicrobial efficacy can be used to set targets for antimicrobial design and optimisation. Although current formulations of amoxicillin and amoxicillin/clavulanate have retained their efficacy against many, but not all, penicillin-nonsusceptible Streptococcus pneumoniae, additional coverage is required to address the growing problem of drug-resistant strains. Accordingly, two new oral formulations of amoxicillin/clavulanate, a paediatric formulation at 90/6.4 mg/kg/day and a pharmacokinetically enhanced formulation at 2000/125 mg twice daily for adults, were designed using PK/PD principles. These principles indicate that for amoxicillin and amoxicillin/clavulanate, a time above MIC of 35-40% of the dosing interval is predictive of high bacterial efficacy. In line with PK/PD predictions, simulation of human pharmacokinetics in in-vitro kinetic models and in a rat model of pneumonia, amoxicillin/clavulanate 2000/125 mg twice daily was highly effective against S. pneumoniae strains with amoxicillin MICs of 4 or 8 mg/L. Against strains with amoxicillin MICs of 4 mg/L, amoxicillin/clavulanate 2000/125 mg twice daily was significantly more effective than the conventional 875/125 mg twice daily formulation, azithromycin and levofloxacin, even though all levofloxacin MICs were less than or equal to 1 mg/L. Following infection with S. pneumoniae strains with amoxicillin MICs of 8 mg/L, the amoxicillin/clavulanate 2000/125 mg twice daily formulation was more effective than the conventional amoxicillin/clavulanate formulations of 875/125 mg twice daily and three times daily and 1000/125 mg three times daily, and had similar or better efficacy than azithromycin and levofloxacin, depending on the strain. These data indicate the potential benefit of therapy with amoxicillin/clavulanate 2000/125 mg twice daily compared with conventional formulations and other marketed antimicrobials in the treatment of respiratory tract infection. C1 William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. Univ Wisconsin, Madison, WI USA. RP Craig, WA (reprint author), William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace, Madison, WI 53705 USA. EM wac@medicine.wisc.edu NR 24 TC 13 Z9 13 U1 0 U2 3 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 1198-743X J9 CLIN MICROBIOL INFEC JI Clin. Microbiol. Infect. PD APR PY 2004 VL 10 SU 2 BP 12 EP 17 DI 10.1111/j.1470-9465.2004.00865.x PG 6 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA 814BT UT WOS:000220950900003 PM 14759229 ER PT J AU Tsai, EC Fujimoto, WY Matsumoto, AM Boyko, EJ AF Tsai, EC Fujimoto, WY Matsumoto, AM Boyko, EJ TI Association of bioavailable, free, and total testosterone with insulin resistance - Influence of sex hormone-binding globulin and body fat SO DIABETES CARE LA English DT Article ID DEPENDENT DIABETES-MELLITUS; COMPUTED-TOMOGRAPHY; STEROID-HORMONES; PLASMA-INSULIN; ADIPOSE-TISSUE; VISCERAL FAT; RISK-FACTORS; MEN; GLUCOSE; OBESITY AB OBJECTIVE - Previous reports of in association between low testosterone levels and diabetes risk were often confounded by covariation of sex hormone-binding globulin (SHBG) and testosterone measurements. Measurements of bioavailable and free testosterone, more reliable indexes of biologically active testosterone, were examined for their associations with markets of insulin resistance and body fat measures in 221 middle-aged nondiabetic men. RESEARCH DESIGN AND METHODS - Bioavailable and free testosterone were calculated from the concentrations of total testosterone, SHBG, and albumin, and they were not significantly correlated with SHBG (r = 0.07-0.1). In contrast, total testosterone Correlated significantly with SHBG (r = 0.63). We evaluated the relationship between these measures of circulating testosterone and markers for insulin resistance (i.e., fasting insulin, C-peptide, and homeostasis model assessment for insulin resistance [HOMA-IR]) as well as total body fat (assessed by dual-energy X-ray absorptiometry [DEXA]) and abdominal fat distribution (assessed by single-slice computed tomography [CT]). RESULTS - Bioavailable, free, and total testosterone and SHBG all correlated significantly with fasting insulin (age-adjusted r = -0.15[P=0.03],-0.14[P=0.03],-0.32[P<0.0001], and -0.38[P<0.0001], respectively), fasting C-peptide (r = -0.18[P=0.009] to -0.41 [P<0.0001]) HOMA-IR (r = -0.15 [P = 0.03] to -0.39 [P<0.0001]), and body fat measures (r = -0.17 [P = 0.008] to -0.44 [P < 0.0001]). Only SHBG and total testosterone were significantly associated with fasting glucose (r = -0.20 [P = 0.003] to -0.21 [P = 0.002]). In multivariate analysis bioavailable or free testosterone was significantly and inversely associated with Insulin, C-peptide, and HOMA-IR, but this was not independent of total body or abdominal fat. SHBG was a significant determinant of insulin, C-peptide, and HOMA-IR, independent of body fat. The associations between total testosterone and insulin resistance were confounded by SHBG. CONCLUSIONS - The inverse association between testosterone and insulin resistance, independent of SHBG, was mediated through body fat. C1 VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. Univ Washington, Seattle, WA 98195 USA. RP Tsai, EC (reprint author), VA Puget Sound Hlth Care Syst, 152E,1660 S Columbian Way, Seattle, WA 98108 USA. EM tsaichin@u.washington.edu RI Perez , Claudio Alejandro/F-8310-2010 OI Perez , Claudio Alejandro/0000-0001-9688-184X; Boyko, Edward/0000-0002-3695-192X NR 37 TC 145 Z9 154 U1 0 U2 3 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD APR PY 2004 VL 27 IS 4 BP 861 EP 868 DI 10.2337/diacare.27.4.861 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 809AG UT WOS:000220609000001 PM 15047639 ER PT J AU Shinkai, RSA Cornell, JE Hatch, JP Yeh, CK AF Shinkai, RSA Cornell, JE Hatch, JP Yeh, CK TI Intraoral tactile sensitivity in adults with diabetes SO DIABETES CARE LA English DT Article ID MELLITUS; NEUROPATHY AB OBJECTIVE - The intraoral tactile sensitivity (ITS) of diabetic and nondiabetic subjects was compared. The effects of age, ethnicity, sex, and intraoral site were considered. RESEARCH DESIGN AND METHODS - The sample comprised 589 participants of the Oral Health: San Antonio Longitudinal Study of Aging. A total Of 107 subjects (61.8 +/- 10.0 years; 48 women, 59 men) met American Diabetes Association diagnostic criteria For diabetes and 482 subjects (58.8 +/- 11.1 years; 274 women, 208 men) did not. ITS was assessed with an oral microaesthesiometer with a cross-modality matching procedure. The dependent variable was the slope Of the psychophysical function relating physical Stimulus intensity (air pressure) and subjects' judgments of stimulus intensity. Data were analyzed using ANOVA for repeated measures with between-subject factors of age, sex, ethnicity, and diabetes and the within-subject factor of intraoral site. RESULTS - Diabetic and nondiabetic subjects. showed no significant differences in ITS at any of the three test sites. European Americans demonstrated greater soft-palate Sensitivity (mean +/- SD 0.26 +/- 0.15) compared with Mexican Americans (0.24 +/- 0.16; P = 0.046). The three intraoral test sites differed in tactile sensitivity (P < 0.001); posterior tongue (0.33 +/- 0.22) was most sensitive, followed by the soft palate (0.25 +/- 0.15) and the anterior tongue (0.23 +/- 0.13). Potentially confounding factors were not associated with ITS. CONCLUSIONS - Our results Suggest that diabetes per se may not influence ITS. C1 Pontif Cathol Univ Rio Grande do Sul, Dept Prosthodont, Porto Alegre, RS, Brazil. Univ Texas, Hlth Sci Ctr, Dept Orthodont, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Med, S Texas Vet Hlth Care Syst,Audie L Murphy Div, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Dent Diagnost Sci, S Texas Vet Hlth Care Syst,Audie L Murphy Div, San Antonio, TX 78284 USA. RP Shinkai, RSA (reprint author), Ave Cristovao Colombo 3084,CJ 708-709, BR-90560002 Porto Alegre, RS, Brazil. EM rshinkai@pucrs.br RI Shinkai, Rosemary/I-3510-2013 OI Shinkai, Rosemary/0000-0002-4107-5661 FU NIDCR NIH HHS [P50-DE-10756] NR 18 TC 4 Z9 4 U1 0 U2 0 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD APR PY 2004 VL 27 IS 4 BP 869 EP 873 DI 10.2337/diacare.27.4.869 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 809AG UT WOS:000220609000002 PM 15047640 ER PT J AU Lopes-Virella, MF Mironova, M Stephan, E Durazo-Arvizu, R Virella, G AF Lopes-Virella, MF Mironova, M Stephan, E Durazo-Arvizu, R Virella, G TI Role of simvastatin as an immunomodulator in type 2 diabetes SO DIABETES CARE LA English DT Article ID CONTAINING IMMUNE-COMPLEXES; LOW-DENSITY-LIPOPROTEIN; CORONARY-ARTERY-DISEASE; MODIFIED LDL ANTIBODIES; OXIDIZED LDL; ATHEROSCLEROTIC LESIONS; MACROVASCULAR DISEASE; HEART-DISEASE; ATHEROGENESIS; CHOLESTEROL AB OBJECTIVE - To test the hypothesis that simvastatin reduces the levels of circulating immune complexes (ICs) containing modified lipoproteins (mLDLs; mLDL-ICs), which may represent an additional mechanism for the reduced incidence of cardiovascular events in patients treated With simvastatin. RESEARCH DESIGN AND METHODS - A total of 26 patients With type 2 diabetes and triglyceride levels <400 mg/dl who were not receiving lipid-lowering medications or CYP 3A4 inhibitors were enrolled in the study. After 2 weeks on a lipid-lowering diet and exercise, the patients were started on simvastatin 20 mg/day. The dose of simvastatin was adjusted until the levels of LDL cholesterol were less than or equal to100 mg/dl. Blood was collected at baseline, 3 and 6 months after LDL cholesterol levels reached target, and 3 months after stopping simvastatin to measure advanced glycation end product LDL and oxidized LDL antibodies, mLDL-IC, intracellular adhesion molecule-1 (ICAM-1), vascular adhesion molecule-1 (VCAM-1), E-selectin, metalloprotemase-1 (MMP-1), lipid profile, liver function tests, creatinine kinase, glucose, and HbA(1c). RESULTS - Twenty-one patients completed the Study. Their HbA(1c) remained within 1% of baseline levels. There was a highly significant decrease in mLDL-IC levels after 3 and 6 months of treatment With simvastatin, with a return to near baseline levels after discontinuation. CONCLUSIONS - Simvastatin significantly reduced the concentration of mLDL-IC, probably as a consequence of both a decrease in the formation of mLDL and to a reduction in the titers of mLDL antibodies. This effect is likely to have a beneficial impact in the inflammatory reaction associated with atherosclerosis. C1 Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Dept Med, Charleston, SC 29425 USA. Vet Affairs Med Ctr, Ralph H Johnson Dept, Charleston, SC 29403 USA. Med Univ S Carolina, Dept Biometry & Epidemiol, Charleston, SC USA. Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. RP Lopes-Virella, MF (reprint author), Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Dept Med, Storm Thurmond Res Bldg,114 Doughty St,Room 529, Charleston, SC 29425 USA. EM virellam@musc.edu NR 25 TC 9 Z9 10 U1 0 U2 1 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD APR PY 2004 VL 27 IS 4 BP 908 EP 913 DI 10.2337/diacare.27.4.908 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 809AG UT WOS:000220609000009 PM 15047647 ER PT J AU Liao, YL Kwon, SH Shaughnessy, S Wallace, P Hutto, A Jenkins, AJ Klein, RL Garvey, WT AF Liao, YL Kwon, SH Shaughnessy, S Wallace, P Hutto, A Jenkins, AJ Klein, RL Garvey, WT TI Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia SO DIABETES CARE LA English DT Article ID NUTRITION EXAMINATION SURVEY; NUCLEAR-MAGNETIC-RESONANCE; 3RD NATIONAL-HEALTH; PARTICLE-SIZE; CARDIOVASCULAR-DISEASE; METABOLIC SYNDROME; US ADULTS; ATHEROSCLEROSIS; PREVALENCE; SECRETION AB OBJECTIVE - The goal of this study was to evaluate the efficacy of the Third Report of the National Cholesterol Education Program Expert Panel on Detection and Treatment Evaluation,, of High Blood Cholesterol in Adults (ATP III) in identifying insulin resistance. RESEARCH DESIGN AND METHODS - This study included 74 nondiabetic Caucasians who were evaluated for insulin resistance and risk factors associated with the metabolic syndrome. Glucose disposal rate (GDR) was measured by hyperinsulinemic-euglycemic clamp and was used to quantify insulin resistance. Sensitivity and specificity of ATP III criteria in detecting insulin resistance were calculated for various cutoffs of GDR. RESULTS - insulin resistance was associated with increased waist circumference, fasting glucose, blood pressure, triglycerides, and decreased levels of HDL cholesterol. Only 1.2.2% of study subjects met ATP III criteria for metabolic syndrome, and ATP III criteria exhibited low sensitivity for detecting insulin resistance. Although high in specificities (>90%), the sensitivities of ATP III criteria ranged only between 20 and 50% when insulin resistance was defined as various GDR cutoff values below 10 to 12 mg(.)kg(-1.)min(-1). The larger number of subjects who were insulin resistant but did not meet ATP III criteria were found to have an adverse cardiovascular disease risk profile, including higher BMI, waist circumference, fasting glucose, triglycerides, and an unfavorable lipoprotein subclass profile determined by nuclear magnetic resonance compared with insulin-sensitive individuals (i.e., increased large VLDL, increased small LDL, and decreased large HDL particle concentrations). CONCLUSIONS - ATP III criteria have low sensitivity for identifying insulin resistance with dyslipidemia in nondiabetic individuals who are at increased risk for cardiovascular disease and diabetes. More sensitive criteria should be developed for clinical assessment of metabolic and cardiovascular disease risk relevant to the metabolic syndrome. C1 Univ Alabama, Dept Nutr Sci, Birmingham, AL 35294 USA. Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Biometry & Epidemiol, Charleston, SC 29425 USA. Univ Melbourne, Dept Med, Melbourne, Vic, Australia. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Garvey, WT (reprint author), Univ Alabama, Dept Nutr Sci, Webb 232,1675 Univ Blvd, Birmingham, AL 35294 USA. EM garveyt@uab.edu RI Jenkins, Alicia/N-2482-2015 FU NCRR NIH HHS [M01-RR-1070]; NHLBI NIH HHS [P01 HL-55782]; NIDDK NIH HHS [DK-38764] NR 25 TC 128 Z9 137 U1 0 U2 1 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD APR PY 2004 VL 27 IS 4 BP 978 EP 983 DI 10.2337/diacare.27.4.978 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 809AG UT WOS:000220609000021 PM 15047659 ER PT J AU Weinberg, BM Oh, DS Ohning, GV Pisegna, JR AF Weinberg, BM Oh, DS Ohning, GV Pisegna, JR TI Reflux laryngitis in a patient with Zollinger Ellison syndrome and the role of epidermal growth factor SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE reflux laryngitis; Zollinger Ellison syndrome; epidermal growth factor ID SALIVARY; MANAGEMENT; OMEPRAZOLE; ACID; DIAGNOSIS; DISEASE C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Olive View UCLA Med Ctr, UCLA San Fernando Valley Program, Dept Med, Sylmar, CA 91342 USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90073 USA. RP Pisegna, JR (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jpisegna@ucla.edu NR 19 TC 1 Z9 1 U1 0 U2 1 PU KLUWER ACADEMIC/PLENUM PUBL PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD APR PY 2004 VL 49 IS 4 BP 693 EP 696 DI 10.1023/B:DDAS.0000026320.17006.14 PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 817KY UT WOS:000221177600027 PM 15185880 ER PT J AU Schnelle, JF Bates-Jensen, BM Levy-Storms, L Grbic, V Yoshii, J Cadogan, M Simmons, SF AF Schnelle, JF Bates-Jensen, BM Levy-Storms, L Grbic, V Yoshii, J Cadogan, M Simmons, SF TI The minimum data set prevalence of restraint quality indicator: Does it reflect differences in care? SO GERONTOLOGIST LA English DT Article DE MDS; quality indicator; physical restraint ID NURSING-HOME RESIDENTS; VULNERABLE ELDERS; INJURIES AB Purpose: This study investigated whether the use of restraining devices and related measures of care quality are different in nursing homes that score in the upper and lower quartiles on the Minimum Data Set (MDS) "prevalence of restraint" quality indicator, which assesses daily use of restraining devices when residents are out of bed. Design and Methods: The study was a cross-sectional study, with 413 residents in 14 nursing facilities. Eight homes scored in the lower quartile (25th percentile; low prevalence, 0-5%) on the MDS restraint prevalence quality indicator, and six homes scored in the upper quartile (75th percentile; high prevalence, 28-48%). Eight care processes related to the management of restraints and gait and balance problems were defined and operationalized into clinical indicators. Research staff conducted direct observations during three 12-hr days (7 a.m. -7 p.m.) to determine the prevalence of restraining devices and identify resident and staff behaviors that may be affected by restraint use. Results: Residents in high-restraint homes were in bed during the day on more observations than residents in low-restraint homes (44% vs. 33%; p < .001), were more frequently observed with bed rails in use (74% of residents vs. 64% of residents; p < .03), and received less feeding assistance during meals (2.7 min vs. 4.1 min; p < .001). There were no differences between homes in the use of out-of-bed restraints, nor were there any differences on any care process measure related to the management of restraints, gait and balance problems, or measures of physical or social activity. Implications: A home's score on the MDS-generated prevalence of restraint quality indicator was not associated with differences in the use of restraints, physical activity, or any care process measure when residents were out of bed. However, there were differences in the use of in-bed restraining devices, and residents in high-restraint homes were in bed more often during the day. These differences were associated with poor feeding assistance and reflect important differences in quality of care between homes, even though these differences are not what the restraint prevalence quality indicator purports to measure. Methods to monitor and improve the quality of care related to exercise, in-bed times, and resident freedom of movement are discussed. C1 Univ Calif Los Angeles, JHA, Borun Ctr Gerontol Res, Reseda, CA 91335 USA. Univ Calif Los Angeles, Dept Med, Reseda, CA 91335 USA. VA Greater Los Angeles Healthcare Syst, Ctr Geriatr Res Educ & Clin, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Nursing, Reseda, CA 91335 USA. RP Schnelle, JF (reprint author), Univ Calif Los Angeles, JHA, Borun Ctr Gerontol Res, 7150 Tampa Ave, Reseda, CA 91335 USA. EM jschnell@ucla.edu NR 25 TC 33 Z9 33 U1 1 U2 3 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD APR PY 2004 VL 44 IS 2 BP 245 EP 255 PG 11 WC Gerontology SC Geriatrics & Gerontology GA 813FA UT WOS:000220891800011 PM 15075421 ER PT J AU Schnelle, JF Simmons, SF Harrington, C Cadogan, M Garcia, E Bates-Jensen, BM AF Schnelle, JF Simmons, SF Harrington, C Cadogan, M Garcia, E Bates-Jensen, BM TI Relationship of nursing home staffing to quality of care SO HEALTH SERVICES RESEARCH LA English DT Article DE staffing; quality of care ID REFLECT DIFFERENCES; VULNERABLE ELDERS; INDICATORS; RESIDENTS; OUTCOMES AB Objective. To compare nursing homes (NHs) that report different staffing statistics on quality of care. Data Sources. Staffing information generated by California NHs on state cost reports and during onsite interviews. Data independently collected by research staff describing quality of care related to 27 care processes. Study Design. Two groups of NHs (n = 21) that reported significantly different and stable staffing data from all data sources were compared on quality of care measures. Data Collection. Direct observation, resident and staff interview, and chart abstraction methods. Principal Findings. Staff in the highest staffed homes (n = 6), according to state cost reports, reported significantly lower resident care loads during onsite interviews across day and evening shifts (7.6 residents per nurse aide [NA]) compared to the remaining homes that reported between 9 to 10 residents per NA (n = 15). The highest-staffed homes performed significantly better on 13 of 16 care processes implemented by NAs compared to lower-staffed homes. Conclusion. The highest-staffed NHs reported significantly lower resident care loads on all staffing reports and provided better care than all other homes. C1 UCLA Borun Ctr, Reseda, CA 91335 USA. Univ Calif Los Angeles, Dept Med, Div Geriatr, Los Angeles, CA USA. Jewish Home Aging Borun Ctr Gerontol Res, Reseda, CA USA. Sepulveda Geriatr Res Educ & Clin Ctr, Sepulveda, CA USA. Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA. RP Schnelle, JF (reprint author), UCLA Borun Ctr, 7150 Tampa Ave, Reseda, CA 91335 USA. FU NIA NIH HHS [AG10415, P60 AG010415] NR 32 TC 128 Z9 128 U1 3 U2 11 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0017-9124 J9 HEALTH SERV RES JI Health Serv. Res. PD APR PY 2004 VL 39 IS 2 BP 225 EP 250 DI 10.1111/j.1475-6773.2004.00225.x PG 26 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 801MU UT WOS:000220100800002 PM 15032952 ER PT J AU Brau, N Rodriguez-Torres, M Prokupek, D Bonacini, M Giffen, CA Smith, JJ Frost, KR Kostman, JR AF Brau, N Rodriguez-Torres, M Prokupek, D Bonacini, M Giffen, CA Smith, JJ Frost, KR Kostman, JR CA amfAR DCRI 010 Study Grp TI Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon alpha-2b+ full-course vs 16-week delayed ribavirin SO HEPATOLOGY LA English DT Article; Proceedings Paper CT 52nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases/International-Liver -Transplantation-Society CY NOV 09-13, 2001 CL DALLAS, TX SP Amer Assoc Study Liver Dis, Int Liver Transplant Soc ID HUMAN-IMMUNODEFICIENCY-VIRUS; PLACEBO-CONTROLLED TRIAL; HIV-INFECTED PATIENTS; PLUS RIBAVIRIN; COMBINATION THERAPY; INITIAL TREATMENT; DOUBLE-BLIND; RANDOMIZED-TRIAL; LIVER-DISEASE; IN-VITRO AB Human immunodeficiency virus (HIV)-infected patients increasingly experience the consequences of chronic hepatitis C virus (HCV) coinfection. This trial randomized 107 patients coinfected with HIV and HCV to receive 48 weeks of interferon alfa-2b (IFN) 3 million units three times weekly plus either a full course of ribavirin (RBV) at 800 mg/day (group A, n = 53) or 16 weeks of placebo, followed by RBV (group B; n = 54). The primary endpoint of sustained viral response (SVR) rate (undetectable HCV RNA at posttreatment week 24) was not different between groups A (11.3%) and B (5.6%; P = .32). Within group A, the SVR rate was lower in genotype 1 (2.5%) than in genotypes 2 through 4 (41.7%; P = .002). Fifty-five patients discontinued therapy prematurely, mostly because of adverse events or patient decisions. At treatment week 12, the percentage of CD4+ cells rose in group A (+4.1%; P < .001), but not in group B (-0.3%). A significant proportion (22%) of patients who were HIV viremic at baseline had undetectable HIV RNA at week 12. By week 16, the hemoglobin level decreased more in group A (-2,52 g/dL) than in group B (-1.02 g/dL; P < .001). In group A, the hemoglobin decline was steeper in patients receiving zidovudine (azidothymidine [AZT], -3.64 g/dL vs. no AZT, -2.08 g/dL), and patients receiving zidovudine had more anemia-related RBV dose reductions (AZT, 60% vs. no AZT, 16%). In conclusion, HCV therapy with IFN plus RBV is relatively safe in patients coinfected with HIV and HCV, but frequent treatment discontinuations and anemia-related RBV dose reductions contribute to a poor SVR rate. Control of HIV infection improves rather than worsens during therapy. C1 Amer Fdn AIDS Res, New York, NY 10005 USA. Bronx Vet Affairs Med Ctr, Bronx, NY USA. CUNY Mt Sinai Sch Med, New York, NY 10029 USA. Fdn Invest Diego, San Juan, PR USA. AIDS Healthcare Fdn, Los Angeles, CA USA. Calif Pacific Med Ctr, San Francisco, CA USA. Informat Management Serv Inc, Silver Spring, MD USA. Philadelphia FIGHT, Philadelphia, PA USA. RP Smith, JJ (reprint author), Amer Fdn AIDS Res, 120 Wall St,13th Floor, New York, NY 10005 USA. EM jeff.smith@amfar.org NR 30 TC 54 Z9 55 U1 1 U2 1 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD APR PY 2004 VL 39 IS 4 BP 989 EP 998 DI 10.1002/hep.20107 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 807ZL UT WOS:000220539300016 PM 15057903 ER PT J AU Zickmund, S Hillis, SL Barnett, MJ Ippolito, L LaBrecque, DR AF Zickmund, S Hillis, SL Barnett, MJ Ippolito, L LaBrecque, DR TI Hepatitis C virus-infected patients report communication problems with physicians SO HEPATOLOGY LA English DT Article ID QUALITY-OF-LIFE; PEGINTERFERON ALPHA-2A; PSYCHIATRIC-SYMPTOMS; DIFFICULT PATIENT; FAMILY PHYSICIANS; CARE; SATISFACTION; RIBAVIRIN; INTERFERON-ALPHA-2B; STIGMATIZATION AB We examined the prevalence and nature of perceived problems in the interaction between physicians and patients diagnosed with hepatitis C virus (HCV) infection. This cross-sectional study included 322 outpatients diagnosed with chronic HCV infection and treated at a tertiary referral hospital's hepatology clinic. Patients were asked to provide demographic information and to complete a semistructured interview, the Sickness Impact Profile (SIP) and Hospital Anxiety Depression (HAD) scale. A team of two blinded coders analyzed the interviews. A total of 131 (41%) study patients reported communication difficulties with physicians involved in their care. The main difficulties were the poor communication skills of physicians (91 [28%]), physician incompetence regarding the diagnosis and treatment of HCV infection (74 [23%]), feelings of being misdiagnosed, misled, or abandoned (51 [16%]), or being stigmatized by their physician (29 [9%]). Patients were twice as likely to report difficulties with subspecialists as compared with generalists. Nonresponse with anti-viral therapy correlated with perceived physician conflict even after adjusting for treatment in relation to the time of interview, whereas previous or ongoing substance abuse and mode of acquisition did not. In a multivariate model, patients' psychosocial problems were the best predictors of communication difficulties. In conclusion, a substantial number of patients with HCV infection report difficulties when interacting with physicians, which may be due to coexisting emotional or social problems. However, perceived stigmatization by physicians and a sense of abandonment reflect the need for further educational efforts. These should target both specialists and primary care providers to inform them about the psychosocial challenges facing these patients. C1 Univ Pittsburgh, Coll Med, Dept Med,Div Gen Internal Med, VA Pittsburgh Healthcare Syst,Ctr Hlth Equity Res, Pittsburgh, PA 15240 USA. Vet Affairs Med Ctr, Program Interdisciplinary Res Hlth Care Org, Iowa City, IA 52242 USA. Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA. RP Zickmund, S (reprint author), Univ Pittsburgh, Coll Med, Dept Med,Div Gen Internal Med, VA Pittsburgh Healthcare Syst,Ctr Hlth Equity Res, Univ Dr C,Bldg 28 1A118, Pittsburgh, PA 15240 USA. EM susan.zickmund@med.va.gov OI Hillis, Stephen/0000-0002-4886-8584 FU NHLBI NIH HHS [HL07121] NR 44 TC 89 Z9 89 U1 1 U2 3 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD APR PY 2004 VL 39 IS 4 BP 999 EP 1007 DI 10.1002/hep.20132 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 807ZL UT WOS:000220539300017 PM 15057904 ER PT J AU Kim, N Marcus, EA Wen, Y Weeks, DL Scott, DR Jung, HC Song, IS Sachs, G AF Kim, N Marcus, EA Wen, Y Weeks, DL Scott, DR Jung, HC Song, IS Sachs, G TI Genes of Helicobacter pylori regulated by attachment to AGS cells SO INFECTION AND IMMUNITY LA English DT Article ID GASTRIC EPITHELIAL-CELLS; MICROARRAY ANALYSIS; PROTEIN TRANSLOCATION; ESCHERICHIA-COLI; TYROSINE PHOSPHORYLATION; OLIGONUCLEOTIDE ARRAYS; CHLAMYDIA-TRACHOMATIS; DIFFERENTIAL DISPLAY; LOW-TEMPERATURE; CANCER CELLS AB Reciprocal interactions between Helicobacter pylori and cells of the gastric epithelium to which it adheres may affect colonization. Changes in gene expression of H. pylori induced by adhesion to AGS gastric cancer cells by coculture were compared to changes in gene expression of H. pylori cultured without AGS cells by using cDNA filter macroarrays. Adhesion was quantitatively verified by confocal microscopy of green fluorescent protein-expressing bacteria. Four experiments showed that 22 and 21 H. pylori genes were consistently up- and down-regulated, respectively. The up-regulated genes included pathogenicity island, motility, outer membrane protein, and translational genes. The sigma(28) factor antagonist flgM, flgG, the stress response gene,flaA, omp11, and the superoxide dismutase gene (sodB) were down-regulated. The up-regulation of cag3,flgB, tonB, rho, and deaD was confirmed by quantitative PCR, and the up-regulation of lpxD, omp6, secG, fabH, HP1285, HP0222, and HP0836 was confirmed by reverse transcription (RT)-PCR. The down-regulation of flaA, sodB, and HP0874 was confirmed by quantitative PCR, and the down-regulation of omp11 was confirmed by RT-PCR. The alteration of gene expression in H. pylori after adhesion to gastric cells in vitro suggests that changes in motility, outer membrane composition, and stress responses, among other changes, may be involved in gastric colonization. C1 VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Geffen Sch Med, Dept Physiol & Med, Los Angeles, CA 90073 USA. Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Seoungnam 464707, Gyeonggi Do, South Korea. Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110799, South Korea. Liver Res Inst, Seoul 110799, South Korea. RP Scott, DR (reprint author), VA Greater Los Angeles Hlth Care Syst, Bldg 113,Room 32A,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM dscott@ucla.edu RI Kim, Nayoung/J-5387-2012; Jung, Hyun Chae/J-5654-2012 FU NIDDK NIH HHS [DK17294, DK46917, DK53462, P30 DK041301, R01 DK046917] NR 56 TC 49 Z9 52 U1 0 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 J9 INFECT IMMUN JI Infect. Immun. PD APR PY 2004 VL 72 IS 4 BP 2358 EP 2368 DI 10.1128/IAI.72.4.2358-2368.2004d PG 11 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 807DG UT WOS:000220481600059 PM 15039361 ER PT J AU Anzueto, A Frutos-Vivar, F Esteban, A Alia, I Brochard, L Stewart, T Benito, S Tobin, MJ Elizalde, J Palizas, F David, CM Pimentel, J Gonzalez, M Soto, L D'Empaire, G Pelosi, P AF Anzueto, A Frutos-Vivar, F Esteban, A Alia, I Brochard, L Stewart, T Benito, S Tobin, MJ Elizalde, J Palizas, F David, CM Pimentel, J Gonzalez, M Soto, L D'Empaire, G Pelosi, P TI Incidence, risk factors and outcome of barotrauma in mechanically ventilated patients SO INTENSIVE CARE MEDICINE LA English DT Article DE barotrauma; pneumothorax; mechanical ventilation; tidal volume; PEEP; ARDS ID RESPIRATORY-DISTRESS-SYNDROME; ACUTE LUNG INJURY; PULMONARY BAROTRAUMA; MORTALITY; STRATEGY AB Objective. To determine the incidence, risk factors, and outcome of barotrauma in a cohort of mechanically ventilated patients where limited tidal volumes and airway pressures were used. Design and setting. Prospective cohort of 361 intensive care units from 20 countries. Patients and participants. A total of 5183 patients mechanically ventilated for more than 12 h. Measurements and results. Baseline demographic data, primary indication for mechanical ventilation, daily ventilator settings, multiple-organ failure over the course of mechanical ventilation and outcome were collected. Barotrauma was present in 154 patients (2.9%). The incidence varied according to the reason for mechanical ventilation: 2.9% of patients with chronic obstructive pulmonary disease; 6.3% of patients with asthma; 10.0% of patients with chronic interstitial lung disease (ILD); 6.5% of patients with acute respiratory distress syndrome (ARDS); and 4.2% of patients with pneumonia. Patients with and without barotrauma did not differ in any ventilator parameter. Logistic regression analysis identified as factors independently associated with barotrauma: asthma [RR 2.58 (1.05-6.50)], ILD [RR 4.23 (95%CI 1.78-10.03)]; ARDS as primary reason for mechanical ventilation [RR 2.70 (95%CI 1.55-4.70)]; and ARDS as a complication during the course of mechanical ventilation [RR 2.53 (95%CI 1.40-4.57)]. Case-control analysis showed increased mortality in patients with barotrauma (51.4 vs 39.2%; p=0.04) and prolonged ICU stay. Conclusions. In a cohort of patients in whom airway pressures and tidal volume are limited, barotrauma is more likely in patients ventilated due to underlying lung disease (acute or chronic). Barotrauma was also associated with a significant increased in the ICU length of stay and mortality. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Div Pulm Med Crit Care Med, San Antonio, TX 78284 USA. Audie L Murphy Mem Vet Adm Med Ctr, S Texas Vet Hlth Care Syst, San Antonio, TX 78284 USA. Hosp Univ Getafe, Madrid, Spain. Hop Henri Mondor, F-94010 Creteil, France. Univ Toronto, Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada. Hosp Santa Cruz & San Pablo, E-08025 Barcelona, Spain. US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. Loyola Univ, Chicago, IL 60611 USA. Hosp ABC, Mexico City, DF, Mexico. Clin Bazterrica, Buenos Aires, DF, Argentina. Hosp Univ Clementito Fraga Filho, Rio De Janeiro, Brazil. Univ Hosp, Coimbra, Portugal. Hosp Gen Medellin, Medellin, Colombia. Inst Nacl Torax, Santiago, Chile. Hosp Clin, Caracas, Venezuela. Univ Insubria, Hosp Circolo, Varese, Italy. RP Anzueto, A (reprint author), 7400 Merton Minter Blvd,11E, San Antonio, TX 78229 USA. EM anzueto@uthscsa.edu OI benito, salvador/0000-0002-6333-5823; Frutos-Vivar, Fernando/0000-0002-4648-9636 NR 24 TC 52 Z9 56 U1 1 U2 6 PU SPRINGER-VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 USA SN 0342-4642 J9 INTENS CARE MED JI Intensive Care Med. PD APR PY 2004 VL 30 IS 4 BP 612 EP 619 DI 10.1007/s00134-004-2187-7 PG 8 WC Critical Care Medicine SC General & Internal Medicine GA 808IM UT WOS:000220562800011 PM 14991090 ER PT J AU Thom, DH Kravitz, RL Kelly-Reif, S Sprinkle, RV Hopkins, JR Rubenstein, LV AF Thom, DH Kravitz, RL Kelly-Reif, S Sprinkle, RV Hopkins, JR Rubenstein, LV TI A new instrument to measure appropriateness of services in primary care SO INTERNATIONAL JOURNAL FOR QUALITY IN HEALTH CARE LA English DT Article DE diagnostic tests; prescription; process assessment; referral; utilization review ID HEALTH-CARE; QUALITY; RELIABILITY; CRITERIA AB Objective. To develop a new instrument for judging the appropriateness of three key services (new prescription, diagnostic test, and referral) as delivered in primary care outpatient visits. Design. Candidate items were generated by a seven-member expert panel, using a five-step nominal technique, for each of three service categories in primary care: new prescriptions, diagnostic tests, and referrals. Expert panelists and a convenience sample of 95 community-based primary care physicians ranked items for (i) importance and (ii) feasibility of ascertaining from a typical office chart record. Resulting items were used to construct a measure of appropriateness using principals of structured implicit review. Two physician reviewers used this measure to judge the appropriateness of 421 services from 160 outpatient visits. Setting. Primary care practices in a staff model health maintenance organization and a large preferred provider network. Measures. Inter-rater agreement was measured using intraclass correlation coefficient (ICC) and kappa statistic. Results. For overall appropriateness, the ICC and kappa were 0.52 and 0.44 for new medication, 0.35 and 0.32 for diagnostic test, and 0.40 and 0.41 for referral, respectively. Only 3% of services were judged to be inappropriate by either reviewer. The proportion of services judged to be less than definitely appropriate by one or both reviewers was 56% for new medication, 31% for diagnostic test, and 22% for referral. Conclusions. This new measure of appropriateness of primary care services has fair inter-rater agreement for new medications and referrals, similar to appropriateness measures of other general services, but poor agreement for diagnostic tests. It may be useful as a tool to assess the appropriateness of common primary care services in studies of health care quality, but is not suitable for evaluating performance of individual physicians. C1 Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA USA. Univ Calif Davis, Sch Med, Dept Med, Ctr Hlth Serv Res Primary Care, Davis, CA USA. Univ Calif Davis, Sch Med, Div Gen Internal Med, Davis, CA USA. Permanente Med Grp Inc, Dept Med, Sacramento, CA USA. UC Davis Med Grp, Davis, CA USA. Stanford Univ, Sch Med, Dept Med, Palo Alto, CA 94304 USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA. VA Greater Los Angeles, Dept Med, Los Angeles, CA USA. RP Thom, DH (reprint author), Univ Calif San Francisco, San Francisco Gen Hosp, Dept Family & Community Med, 1001 Potrero Ave,Bldg 80-83, San Francisco, CA 94110 USA. EM dthom@itsa.ucsf.edu OI Kravitz, Richard/0000-0001-5575-529X NR 30 TC 4 Z9 5 U1 0 U2 4 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1353-4505 J9 INT J QUAL HEALTH C JI Int. J. Qual. Health Care PD APR PY 2004 VL 16 IS 2 BP 133 EP 140 DI 10.1093/intqhc/mzh029 PG 8 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 809CJ UT WOS:000220614500003 PM 15051707 ER PT J AU Delaney, CM Perlman, JI Sothern, R Murray, D Thira, J Ryan, M Shirazi, P Nemchausky, BA Kanabrocki, EL AF Delaney, CM Perlman, JI Sothern, R Murray, D Thira, J Ryan, M Shirazi, P Nemchausky, BA Kanabrocki, EL TI Circadian, and overall relationships between intraocular pressure, blood pressure, heart rate and nitric oxide in men SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology CY APR 24-29, 2004 CL Ft Lauderdale, FL SP Assoc Res Vis & Ophthalmol C1 Loyola Univ, Maywood, IL 60153 USA. US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. Univ Minnesota, Minneapolis, MN USA. Oxis Int, Res, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD APR PY 2004 VL 45 SU 2 MA 5031 BP U564 EP U564 PG 1 WC Ophthalmology SC Ophthalmology GA 846TC UT WOS:000223338202206 ER PT J AU Jirawuthiworavong, GV Morales, SA Shimazaki, K Heckenlively, JR Seigel, GM Gordon, LK AF Jirawuthiworavong, GV Morales, SA Shimazaki, K Heckenlively, JR Seigel, GM Gordon, LK TI A flow cytometric assay for the detection of pro-apoptotic antiretinal antibodies in human serum SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology CY APR 24-29, 2004 CL Ft Lauderdale, FL SP Assoc Res Vis & Ophthalmol C1 Univ Calif Los Angeles, Jules Stein Eye Inst, David Geffen Sch Med, Los Angeles, CA 90024 USA. SUNY Coll Buffalo, Buffalo, NY USA. Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD APR PY 2004 VL 45 SU 1 MA 2684 BP U986 EP U986 PG 1 WC Ophthalmology SC Ophthalmology GA 846TA UT WOS:000223338002619 ER PT J AU Lee, RH Ng, PS Faull, KF AF Lee, RH Ng, PS Faull, KF TI In vivo phosphorylation at the serine-8 residue affects the conformation and the phosphorylation characterstics of phosducin. SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology CY APR 24-29, 2004 CL Ft Lauderdale, FL SP Assoc Res Vis & Ophthalmol C1 VA Greater LA Healthcare Syst, Mol Neurobiol Lab, Sepulveda, CA USA. Univ Calif Los Angeles, Dept Chem & Biochem, Jules Stein Eye Inst, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD APR PY 2004 VL 45 SU 1 MA 1279 BP U529 EP U529 PG 1 WC Ophthalmology SC Ophthalmology GA 846TA UT WOS:000223338001239 ER PT J AU Mareninov, S Gordon, LK AF Mareninov, S Gordon, LK TI Age-dependent survival of retinal ganglion cells in vitro SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology CY APR 24-29, 2004 CL Ft Lauderdale, FL SP Assoc Res Vis & Ophthalmol C1 Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90024 USA. Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD APR PY 2004 VL 45 SU 2 MA 5377 BP U642 EP U642 PG 1 WC Ophthalmology SC Ophthalmology GA 846TC UT WOS:000223338202550 ER PT J AU Sproule, M Forooghian, F O'Connor, P Gordon, L Jirawuthiworavong, G Wastall, C AF Sproule, M Forooghian, F O'Connor, P Gordon, L Jirawuthiworavong, G Wastall, C TI Autoimmune retinopathy in multiple sclerosis: A pilot study SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology CY APR 24-29, 2004 CL Ft Lauderdale, FL SP Assoc Res Vis & Ophthalmol C1 Univ Toronto, Toronto, ON, Canada. Hosp Sick Children, Toronto, ON M5G 1X8, Canada. St Michaels Hosp, Toronto, ON M5B 1W8, Canada. Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Los Angeles, CA USA. Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD APR PY 2004 VL 45 SU 1 MA 1592 BP U585 EP U585 PG 1 WC Ophthalmology SC Ophthalmology GA 846TA UT WOS:000223338001555 ER PT J AU Wen, Y Feng, J Sachs, G AF Wen, Y Feng, J Sachs, G TI Expression of LEP503 gene in early development of mouse lens SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology CY APR 24-29, 2004 CL Ft Lauderdale, FL SP Assoc Res Vis & Ophthalmol C1 Univ Calif Los Angeles, Membrane Biol Lab, VA Greater Los Angeles Hlth Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD APR PY 2004 VL 45 SU 1 MA 2642 BP U977 EP U977 PG 1 WC Ophthalmology SC Ophthalmology GA 846TA UT WOS:000223338002573 ER PT J AU Nascimento, ALTO Ko, AI Martins, EAL Monteiro-Vitorello, CB Ho, PL Haake, DA Verjovski-Almeida, S Hartskeerl, RA Marques, MV Oliveira, MC Menck, CFM Leite, LCC Carrer, H Coutinho, LL Degrave, WM Dellagostin, OA El-Dorry, H Ferro, ES Ferro, MIT Furlan, LR Gamberini, M Giglioti, EA Goes-Neto, A Goldman, GH Goldman, MHS Harakava, R Jeronimo, SMB Junqueira-de-Azevedo, ILM Kimura, ET Kuramae, EE Lemos, EGM Lemos, MVF Marino, CL Nunes, LR de Oliveira, RC Pereira, GG Reis, MS Schriefer, A Siqueira, WJ Sommer, P Tsai, SM Simpson, AJG Ferro, JA Camargo, LEA Kitajima, JP Setubal, JC Van Sluys, MA AF Nascimento, ALTO Ko, AI Martins, EAL Monteiro-Vitorello, CB Ho, PL Haake, DA Verjovski-Almeida, S Hartskeerl, RA Marques, MV Oliveira, MC Menck, CFM Leite, LCC Carrer, H Coutinho, LL Degrave, WM Dellagostin, OA El-Dorry, H Ferro, ES Ferro, MIT Furlan, LR Gamberini, M Giglioti, EA Goes-Neto, A Goldman, GH Goldman, MHS Harakava, R Jeronimo, SMB Junqueira-de-Azevedo, ILM Kimura, ET Kuramae, EE Lemos, EGM Lemos, MVF Marino, CL Nunes, LR de Oliveira, RC Pereira, GG Reis, MS Schriefer, A Siqueira, WJ Sommer, P Tsai, SM Simpson, AJG Ferro, JA Camargo, LEA Kitajima, JP Setubal, JC Van Sluys, MA TI Comparative genomics of two Leptospira interrogans serovars reveals novel insights into physiology and pathogenesis SO JOURNAL OF BACTERIOLOGY LA English DT Article ID PSEUDOMONAS-AERUGINOSA; TREPONEMA-PALLIDUM; ESCHERICHIA-COLI; MOLECULAR CHARACTERIZATION; SUPEROXIDE REDUCTASE; NUCLEOTIDE-SEQUENCE; SYPHILIS SPIROCHETE; XYLELLA-FASTIDIOSA; PROTEIN; IDENTIFICATION AB Leptospira species colonize a significant proportion of rodent populations worldwide and produce life-threatening infections in accidental hosts, including humans. Complete genome sequencing of Leptospira interrogans serovar Copenhageni and comparative analysis with the available Leptospira interrogans serovar Lai genome reveal that despite overall genetic similarity there are significant structural differences, including a large chromosomal inversion and extensive variation in the number and distribution of insertion sequence elements. Genome sequence analysis elucidates many of the novel aspects of leptospiral physiology relating to energy metabolism, oxygen tolerance, two-component signal transduction systems, and mechanisms of pathogenesis. A broad array of transcriptional regulation proteins and two new families of afimbrial adhesins which contribute to host tissue colonization in the early steps of infection were identified. Differences in genes involved in the biosynthesis of lipopolysaccharide 0 side chains between the Copenhageni and Lai serovars were identified, offering an important starting point for the elucidation of the organism's complex polysaccharide surface antigens. Differences in adhesins and in lipopolysaccharide might be associated with the adaptation of serovars Copenhageni and Lai to different animal hosts. Hundreds of genes encoding surface-exposed lipoproteins and transmembrane outer membrane proteins were identified as candidates for development of vaccines for the prevention of leptospirosis. C1 Univ Sao Paulo, Ctr Biotechnol, Inst Butantan, BR-05503900 Sao Paulo, SP, Brazil. Univ Sao Paulo, Inst Quim, Sao Paulo, Brazil. Univ Sao Paulo, Inst Ciencias Biomed, BR-05508 Sao Paulo, Brazil. Univ Sao Paulo, Inst Biociencias, Sao Paulo, Brazil. Univ Sao Paulo, Inst Biol, Sao Paulo, Brazil. Univ Sao Paulo, Piracicaba, Brazil. Univ Estadual Paulista, Fac Ciencias Agrarias & Vet, Jaboticabal, Brazil. Univ Fed Sao Carlos, Ctr Ciencias Agrarias, Araras, Brazil. Fac Ciencias Farmaceut, Ribeirao Preto, Brazil. Fac Filosofia Ciencias & Letras, Ribeirao Preto, Brazil. Univ Sao Paulo, BR-14049 Ribeirao Preto, Brazil. Univ Mogi Cruzes, Fac Ciencias Agron, Mogi Cruzes, Brazil. Univ Mogi Cruzes, Inst Biociencias, Mogi Cruzes, Brazil. Univ Estadual Paulista, Botucatu, SP, Brazil. Univ Mogi Cruzes, Nucleo Integrado Biotecnol, Mogi Das Cruzes, Brazil. Univ Estadual Paulista, Dept Genet & Evolucao, Campinas, SP, Brazil. Univ Estadual Paulista, Inst Computacao, Campinas, SP, Brazil. Univ Estadual Paulista, Inst Agron Campinas, Campinas, SP, Brazil. Univ Estadual Paulista, Ctr Biol Mol & Engn Genet, Campinas, SP, Brazil. Univ Fed Bahia, Serv Immunol, BR-41170290 Salvador, BA, Brazil. UEFS, LAPEM, Dept Ciencias Biol, Feira De Santana, BA, Brazil. Inst Oswaldo Cruz, Dept Bioquim & Biol Mol, BR-20001 Rio De Janeiro, Brazil. Univ Fed Pelotas, Ctr Biotechnol, Pelotas, Brazil. Univ Fed Rio Grande Norte, Ctr Biociencias, BR-59072970 Natal, RN, Brazil. Cornell Univ, Weill Med Coll, Div Int Med & Infect Dis, New York, NY USA. Ludwig Inst Canc Res, New York, NY USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. Vet Affairs Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA USA. Koninklin Inst Tropen, Royal Trop Inst, KIT Biomed Res, Amsterdam, Netherlands. RP Nascimento, ALTO (reprint author), Univ Sao Paulo, Ctr Biotechnol, Inst Butantan, Avenida Vital Brazil 1500, BR-05503900 Sao Paulo, SP, Brazil. EM tabet@usp.br RI Verjovski-Almeida, Sergio/E-4082-2012; LEMOS, ELIANA/A-3604-2008; Degrave, Wim/B-4162-2009; Dellagostin, Odir/C-2331-2009; Menck, Carlos/G-6321-2011; Junqueira-de-Azevedo, Inacio/H-5239-2011; Setubal, Joao/C-7305-2012; Coutinho, Luiz/C-8455-2012; Leite, Luciana/D-1353-2012; FERRO, MARIA INES/D-3634-2012; Costa de Oliveira, Regina/A-4571-2017; IB/USP, Botanica/Q-7627-2016; Martins, Elizabeth/B-7135-2015; Marino, Celso/L-2448-2013; Nunes, Luiz/M-4804-2013; Jeronimo, Selma/M-8672-2014; Ferro, Emer/D-3908-2012; Tsai, Siu /C-2793-2012; Ko, Albert/P-2343-2015; Ho, Paulo/P-8267-2015; Goldman, Maria Helena /D-1424-2012; Kuramae, Eiko/F-4738-2012; Monteiro-Vitorello, Claudia/F-2436-2012; Marques, Marilis/C-3085-2013; Oliveira, Mariana /G-2512-2012; Van Sluys, Marie-Anne/A-8483-2012; Carrer, Helaine/C-3159-2012; Nascimento, Ana Lucia/E-8488-2012; Camargo, Luis Eduardo/C-2735-2012; Ferro, Jesus/C-8251-2013; Goes-Neto, Aristoteles/A-6955-2013; Kimura, Edna/D-7334-2012; Harakava, Ricardo/C-4471-2012; Reis, Marcelo/K-4075-2012; Goldman, Gustavo/F-1848-2013 OI Verjovski-Almeida, Sergio/0000-0002-6356-2401; Dellagostin, Odir/0000-0003-2803-4088; Setubal, Joao/0000-0001-9174-2816; Menck, Carlos FM/0000-0003-1941-0694; Costa de Oliveira, Regina/0000-0002-2446-5510; Martins, Elizabeth/0000-0002-2333-9379; Nunes, Luiz/0000-0001-9619-269X; Ferro, Emer/0000-0003-1651-9192; Tsai, Siu /0000-0002-3733-6312; Ko, Albert/0000-0001-9023-2339; Ho, Paulo/0000-0003-3652-241X; Goldman, Maria Helena /0000-0002-6786-9320; Kuramae, Eiko/0000-0001-6701-8668; Monteiro-Vitorello, Claudia/0000-0002-1238-9354; Oliveira, Mariana /0000-0001-8495-2962; Van Sluys, Marie-Anne/0000-0002-6506-2734; Carrer, Helaine/0000-0002-9329-1841; Nascimento, Ana Lucia/0000-0003-4851-0870; Camargo, Luis Eduardo/0000-0002-5650-5695; Ferro, Jesus/0000-0002-3966-1303; Goes-Neto, Aristoteles/0000-0002-7692-6243; Kimura, Edna/0000-0001-8403-4459; Harakava, Ricardo/0000-0003-1431-2665; Reis, Marcelo/0000-0002-3754-9115; FU NIAID NIH HHS [R01 AI034431, R01 AI034431-07] NR 52 TC 248 Z9 636 U1 2 U2 30 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0021-9193 J9 J BACTERIOL JI J. Bacteriol. PD APR PY 2004 VL 186 IS 7 BP 2164 EP 2172 DI 10.1128/JB.186.7.2164-2172.2004 PG 9 WC Microbiology SC Microbiology GA 805JS UT WOS:000220363200029 PM 15028702 ER PT J AU Massie, BM Krol, WF Ammon, SE Armstrong, PW Cleland, JG Collins, JF Ezekowitz, M Jafri, SM O'Connor, CM Packer, M Schulman, KA Warren, S AF Massie, BM Krol, WF Ammon, SE Armstrong, PW Cleland, JG Collins, JF Ezekowitz, M Jafri, SM O'Connor, CM Packer, M Schulman, KA Warren, S TI The warfarin and Antiplatelet Therapy in Heart Failure Trial (WATCH): Rationale, design, and baseline patient characteristics SO JOURNAL OF CARDIAC FAILURE LA English DT Article DE heart failure; clinical trial; anticoagulation; antiplatelet therapy; warfarin; aspirin; clopidogrel ID LEFT-VENTRICULAR DYSFUNCTION; ACUTE MYOCARDIAL-INFARCTION; CONVERTING-ENZYME-INHIBITORS; DILATED CARDIOMYOPATHY; THROMBOEMBOLIC EVENTS; SYSTOLIC DYSFUNCTION; COHORT ANALYSIS; ACE-INHIBITORS; DOUBLE-BLIND; ASPIRIN AB Background: The role of anticoagulation in patients with chronic heart failure has long been an area of interest and controversy. Traditionally the goal of anticoagulation has been to prevent embolic events, but recent trials also demonstrated that oral anticoagulation also prevents vascular events in patients with prior myocardial infarction, who constitute the majority of heart failure patients. Although antiplatelet agents also reduce postinfarction vascular events, few data are available in heart failure patients, and some evidence suggests that aspirin may also have the potential to worsen heart failure morbidity and mortality, possibly by interfering with the effects of angiotensin-converting enzyme inhibitors. Methods and Results: The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial was undertaken to determine the optimal antithrombotic agent for heart failure patients. WATCH was a prospective-randomized trial in which symptomatic heart failure patients in sinus rhythm with ejection fractions less than or equal to35% taking angiotensin-converting enzyme inhibitors (unless not tolerated) and diuretics were randomized to open-label warfarin (target International Normalized Ratio 2.5-3.0) or double-blind antiplatelet therapy with aspirin 162 mg or clopidogrel 75 mg. Two primary comparisons were specified: anticoagulation with warfarin versus antiplatelet therapy with aspirin and antiplatelet therapy with clopidogrel versus antiplatelet therapy with aspirin. The primary outcome is the composite of death from all causes, nonfatal myocardial infarction, and nonfatal stroke analyzed as time to first event using the intent-to-treat approach. The secondary endpoint was the broader composite of death from all causes, nonfatal myocardial infarction, non-fatal stroke, and hospitalizations for worsening heart failure, unstable angina pectoris, and systemic or pulmonary artery embolic events. Additional prespecified analyses include heart failure events, coronary events, and resource utilization. Conclusions: Although the trial was designed to enter 4500 patients, it was terminated 18 months prematurely in June 2003 by the VA Cooperative Study Program because of poor enrollment with a resulting reduction of its power to achieve its original objective. This manuscript describes the study rationale, protocol design, and the baseline characteristics of the 1587 patients who were entered into the study. The WATCH trial will help define the optimal approach to antithrombotic therapy in the contemporary management of patients with chronic heart failure resulting from left ventricular systolic dysfunction. C1 San Francisco VAMC, Div Cardiol, San Francisco, CA 94121 USA. RP Massie, BM (reprint author), San Francisco VAMC, Div Cardiol, 111C,4150 Clement St, San Francisco, CA 94121 USA. OI Cleland, John/0000-0002-1471-7016 NR 51 TC 54 Z9 57 U1 1 U2 4 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD APR PY 2004 VL 10 IS 2 BP 101 EP 112 DI 10.1016/j.cardfail.2004.02.006 PG 12 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 816ZK UT WOS:000221147600002 PM 15101020 ER PT J AU Van Do, N Mino, L Merriam, GR LeMar, H Case, HS Palinkas, LA Reedy, K Reed, HL AF Van Do, N Mino, L Merriam, GR LeMar, H Case, HS Palinkas, LA Reedy, K Reed, HL TI Elevation in serum thyroglobulin during prolonged antarctic residence: Effect of thyroxine supplement in the polar 3,5,3 '-triiodothyronine syndrome SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article; Proceedings Paper CT 83rd Annual Meeting of the Endocrine-Society CY JUN 20-23, 2001 CL DENVER, CO SP Endocrine Soc ID RECOMBINANT HUMAN THYROTROPIN; THYROID-CARCINOMA; CLINICAL-PRACTICE; PITUITARY; KINETICS AB Extended Antarctic residence (AR) is associated with an increase in serum TSH, a decrease in free T(4), and an increase in T(3) production and clearance. It is not clear whether these adaptations reflect changes in clearance alone or whether intrinsic thyroidal synthetic activity also changes. Thyroglobulin (Tg) secretion is an independent marker of intrinsic thyroid activity whose kinetics are independent of those of T(3) and T(4). In this study we examined changes in Tg levels in healthy subjects before and during AR and their responses to thyroid supplementation to help determine whether alterations in thyroid activity, and not just kinetics of clearance, underlie the changes seen with the polar T(3) syndrome. In cohort 1, we compared measurements of TSH and Tg in 12 subjects before deployment and monthly for 11 months during AR. In cohort 2, we compared the same measurements in 12 subjects monthly for 11 months of AR. Subjects were randomized to receive either placebo or levothyroxine in cohort 1 for 7 months and in cohort 2 for 11 months. Tg increased over baseline during the first 4 months of AR by 17.0+/-4.6% and after 7 more months by 31.7+/-4.3% over baseline in the placebo group of both cohorts ( P<0.0002). When L-T(4) was taken, Tg returned to a value not different from baseline (4.5 +/- 3.9%). The percent changes from baseline in serum TSH and Tg during AR were highly correlated (P<0.00003) in the placebo group for both cohorts. The rise in Tg with TSH and the reduction in Tg with L-T(4) provide evidence of target tissue response to TSH and further confirm the TSH rise as physiologically significant. The results also suggest that the adaptive changes in thyroid hormone economy with AR reflect TSH-dependent changes in thyroid synthetic activity, which may help explain a portion of the increases in T(3) production found with AR. C1 Madigan Army Med Ctr, Internal Med Serv, Tacoma, WA 98431 USA. New Mexico Resonance, Albuquerque, NM USA. Vet Affairs Puget Sound Hlth Care Syst, Tacoma, WA 98493 USA. Univ Washington, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. William Beaumont Army Med Ctr, Endocrine Serv, El Paso, TX 79920 USA. McDaniel Coll, Dept Exercise Sci & Phys Educ, Westminster, MD 21157 USA. Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA. US FDA, Rockville, MD 20857 USA. Multicare Med Grp, Tacoma, WA 98415 USA. RP Van Do, N (reprint author), Stanford Med Informat, Sch Med, Off Bldg,X-215,251 Campus Dr, Stanford, CA 94305 USA. EM nhan.do@us.army.mil NR 23 TC 2 Z9 3 U1 0 U2 0 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD APR PY 2004 VL 89 IS 4 BP 1529 EP 1533 DI 10.1210/jc.2003-031747 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 810OV UT WOS:000220714500004 PM 15070908 ER PT J AU McLaughlin, T Abbasi, F Lamendola, C Frayo, RS Cummings, DE AF McLaughlin, T Abbasi, F Lamendola, C Frayo, RS Cummings, DE TI Plasma ghrelin concentrations are decreased in insulin-resistant obese adults relative to equally obese insulin-sensitive controls SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID MEDIATED GLUCOSE DISPOSAL; POLYCYSTIC-OVARY-SYNDROME; PRADER-WILLI-SYNDROME; BODY-WEIGHT GAIN; CIRCULATING GHRELIN; FOOD-INTAKE; ACYLATED PEPTIDE; LOWER RATES; HUMANS; SECRETION AB Ghrelin, an orexigenic hormone that may play a role in body weight regulation, is reduced in states of obesity. Because obesity is associated with insulin resistance and compensatory hyperinsulinemia, we determined whether these metabolic characteristics were independently associated with suppressed ghrelin concentrations. To investigate this hypothesis, using steady-state plasma glucose concentrations, we identified 20 insulin-resistant (IR) and 20 insulin-sensitive (IS) individuals who were equally obese. The mean body mass indexes were 32.5+/-0.4 and 32.0+/-0.4 kg/m(2) for the IR and IS groups, respectively. Fasting insulin concentrations were 19.5 and 7.4 muU/ml (P<0.001), respectively. Ghrelin concentrations were suppressed in the IR group (252 +/- 19 pg/ml) relative to the IS group (412 +/- 35 pg/ml; P<0.001). Ghrelin correlated inversely with both insulin resistance (r=-0.64; P<0.001) and fasting insulin concentration (r=-0.58; P<0.001). Multivariate analysis confirmed that both insulin resistance and hyperinsulinemia independently predicted low ghrelin concentrations. Our results demonstrate that in obese individuals, insulin resistance and hyperinsulinemia are inversely associated with ghrelin concentrations. Thus, insulin resistance or related metabolic abnormalities may constitute part of a feedback mechanism by which body weight is regulated in humans. C1 Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Div Endocrinol, Seattle, WA 98108 USA. Stanford Univ, Sch Med, Stanford, CA 94305 USA. RP Cummings, DE (reprint author), Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Div Endocrinol, 1660 S Columbian Way,S-111 Endo, Seattle, WA 98108 USA. EM davidec@u.washington.edu FU NCRR NIH HHS [RR-000070-40, RR-16071-01]; NIDDK NIH HHS [R01-DK-61516] NR 46 TC 176 Z9 192 U1 0 U2 3 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD APR PY 2004 VL 89 IS 4 BP 1630 EP 1635 DI 10.1210/jc.2003-031572 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 810OV UT WOS:000220714500018 PM 15070922 ER PT J AU Wahlstrom, JT Fowler, MJ Nicholson, WE Kovacs, WJ AF Wahlstrom, JT Fowler, MJ Nicholson, WE Kovacs, WJ TI A novel mutation in the preprovasopressin gene identified in a kindred with autosomal dominant neurohypophyseal diabetes insipidus SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID MUTANT VASOPRESSIN PRECURSORS; REGULATED SECRETORY PATHWAY; SINGLE-BASE SUBSTITUTION; NEUROPHYSIN-II; ENDOPLASMIC-RETICULUM; SIGNAL PEPTIDE; CODING REGION; PROHORMONE; TRAFFICKING AB Autosomal dominant neurohypophyseal diabetes insipidus (ADNDI) is a defect in free water conservation caused by mutations in the single gene that encodes both vasopressin (VP) and its binding protein, neurophysin II (NP II). Most of the human mutations in this gene have been in the portion encoding the NP molecule; the resultant abnormal gene products are believed to cause cellular toxicity as improperly folded precursor molecules accumulate in the endoplasmic reticulum. We identified a new American kindred with ADNDI and found a novel mutation in the VP molecule. A 78-yr-old man was noted to have hypotonic polyuria and plasma hyperosmolarity; the urinary concentration defect was reversed by administration of VP. His symptomatology dated to childhood, and his family history was consistent with autosomal transmission of the polyuric syndrome, with affected members in three generations, including several females. Affected individuals were found to be heterozygous for a 3-bp deletion in exon 1 of arginine VP (AVP)-NP II, predicting a deletion of phenylalanine 3 (known to be critical for receptor binding) in the VP nonapeptide. Neuro 2A cells stably transfected with the mutant AVP-NP construct showed increased rates of apoptosis as assessed by flow cytometric methods. These observations support the concept that cellular toxicity of abnormal AVP-NP gene products underlies the development of ADNDI, and the data further demonstrate that mutations affecting the AVP moiety can result in initiation of these pathological processes. C1 Vanderbilt Univ, Sch Med, Div Endocrinol Diabet & Metab, Nashville, TN 37232 USA. Tennessee Valley Healthcare Syst, US Dept Vet Affairs, Nashville, TN 37212 USA. RP Kovacs, WJ (reprint author), Vanderbilt Univ, Sch Med, Div Endocrinol Diabet & Metab, Room 715 Preston Res Bldg, Nashville, TN 37232 USA. EM william.kovacs@vanderbilt.edu OI Kovacs, William/0000-0002-3940-2109 FU NIDDK NIH HHS [P60 DK020593] NR 19 TC 16 Z9 16 U1 1 U2 1 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD APR PY 2004 VL 89 IS 4 BP 1963 EP 1968 DI 10.1210/jc.2003-031542 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 810OV UT WOS:000220714500066 PM 15070970 ER PT J AU Niquet, J Wasterlain, CG AF Niquet, J Wasterlain, CG TI Bim, Bad, and Bax: a deadly combination in epileptic seizures SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Editorial Material ID APOPTOSIS-INDUCING FACTOR; INDUCED NEURONAL DEATH; CELL-DEATH; ACTIVATION; HIPPOCAMPUS; PROTEINS; CLEAVAGE; PATHWAYS; BRAIN AB Several Bcl-2 family members, including Bim, may contribute to programmed cell death by inducing mitochondrial cytochrome c release, which activates caspase-9 and then caspase-3, the "executioner" of the cell. In this issue of the JCI, Shinoda and collaborators show the key role of Bim in epileptic seizure-induced neuronal injury and identify the contribution of transcription factors responsible for seizure-induced Bim upregulation (see the related article beginning on page 1059). C1 Vet Affairs Greater Los Angeles Healthcare Syst, Epilepsy Res Lab, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90024 USA. RP Niquet, J (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Epilepsy Res Lab, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jniquet@ucla.edu NR 17 TC 24 Z9 36 U1 0 U2 2 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD APR PY 2004 VL 113 IS 7 BP 960 EP 962 DI 10.1172/JCI200421478 PG 3 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 809QR UT WOS:000220651700007 PM 15057301 ER PT J AU Miller, AL Hall, CS Buchanan, RW Buckley, PF Chiles, JA Conley, RR Crismon, ML Ereshefsky, L Essock, SM Finnerty, M Marder, SR Miller, DD McEvoy, JP Rush, AJ Saeed, SA Schooler, NR Shon, SP Stroup, S Tarin-Godoy, B AF Miller, AL Hall, CS Buchanan, RW Buckley, PF Chiles, JA Conley, RR Crismon, ML Ereshefsky, L Essock, SM Finnerty, M Marder, SR Miller, DD McEvoy, JP Rush, AJ Saeed, SA Schooler, NR Shon, SP Stroup, S Tarin-Godoy, B TI The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID TREATMENT-RESISTANT SCHIZOPHRENIA; MAJOR DEPRESSIVE DISORDER; SCHIZOAFFECTIVE DISORDER; DOUBLE-BLIND; ATYPICAL ANTIPSYCHOTICS; CLOZAPINE AUGMENTATION; CONTROLLED-TRIALS; PHASE-3 TMAP-3; ARIPIPRAZOLE; PLACEBO AB Background: The Texas Medication Algorithm Project (TMAP) has been a public-academic collaboration in which guidelines for medication treatment of schizophrenia, bipolar disorder, and major depressive disorder were used in selected public outpatient clinics in Texas. Subsequently, these algorithms were implemented throughout Texas and are being used in other states. Guidelines require updating when significant new evidence emerges; the antipsychotic algorithm for schizophrenia was last updated in 1999. This article reports the recommendations developed in 2002 and 2003 by a group of experts, clinicians, and administrators. Method: A conference in January 2002 began the update process. Before the conference, experts in the pharmacologic treatment of schizophrenia, clinicians, and administrators reviewed literature topics and prepared presentations. Topics included ziprasidone's inclusion in the algorithm, the number of antipsychotics tried before clozapine, and the role of first generation antipsychotics. Data were rated according to Agency for Healthcare Research and Quality criteria. After discussing the presentations, conference attendees arrived at consensus recommendations. Consideration of aripiprazole's inclusion was subsequently handled by electronic communications. Results: The antipsychotic algorithm for schizophrenia was updated to include ziprasidone and aripiprazole among the first-line agents. Relative to the prior algorithm, the number of stages before clozapine was reduced. First generation antipsychotics were included but not as first-line choices. For patients refusing or not responding to clozapine and clozapine augmentation, preference was given to trying monotherapy with another antipsychotic before resorting to antipsychotic combinations. Conclusion: Consensus on algorithm revisions was achieved, but only further well-controlled research will answer many key questions about sequence and type of medication treatments of schizophrenia. C1 Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78229 USA. El Paso Community Mental Hlth & Mental Retardat C, El Paso, TX USA. Univ N Carolina, Dept Psychiat, Chapel Hill, NC USA. Hillside Hosp, Long Isl Jewish Med Ctr, Long Isl City, NY USA. Univ Illinois, Coll Med, Dept Psychiat & Behav Sci, Peoria, IL 61656 USA. Univ Texas, SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75235 USA. Duke Univ, Dept Psychiat & Behav Sci, Durham, NC USA. Univ Iowa, Coll Med, Dept Psychiat, Iowa City, IA 52242 USA. W Los Angeles VA Hlth Care Ctr, Los Angeles, CA USA. New York Off State Mental Hlth, Albany, NY USA. Vet Adm, Mental Illness Res Educ & Clin Ctr, Bronx, NY USA. Mt Sinai Sch Med, New York, NY USA. Texas Dept Mental Hlth & Mental Retardat Unit, Austin, TX USA. Univ Texas, Coll Pharm, Austin, TX 78712 USA. Univ Washington, Sch Med, Dept Psychiat, Seattle, WA USA. Med Coll Georgia, Dept Psychiat, Augusta, GA 30912 USA. Maryland Psychiat Res Ctr, Baltimore, MD 21228 USA. San Antonio State Hosp, San Antonio, TX USA. RP Miller, AL (reprint author), Univ Texas, Hlth Sci Ctr, Dept Psychiat, 7703 Floyd Curl Dr,MC 7792, San Antonio, TX 78229 USA. EM millera@uthscsa.edu RI Stroup, Thomas/F-9188-2014 OI Stroup, Thomas/0000-0002-3123-0672; Rush, Augustus/0000-0003-2004-2382 NR 74 TC 122 Z9 128 U1 2 U2 8 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD APR PY 2004 VL 65 IS 4 BP 500 EP 508 PG 9 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 831JL UT WOS:000222190600008 PM 15119912 ER PT J AU Spollen, JJ Wooten, RG Cargile, C Bartztokis, G AF Spollen, JJ Wooten, RG Cargile, C Bartztokis, G TI Prolactin levels and erectile function in patients treated with risperidone SO JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY LA English DT Article ID CORPUS CAVERNOSUM PENIS; SEXUAL DYSFUNCTION; SCHIZOPHRENIC-PATIENTS; INTERNATIONAL INDEX; HYPERPROLACTINEMIA; OLANZAPINE; SCALE; MEN AB Treatment with risperidone is associated with prolactin (PRL) elevation, and PRL elevations are associated with erectile dysfunction (ED). We evaluated whether the PRL elevations caused by risperidone treatment of subjects with schizophrenia are associated with objective measures of erectile function. Subjects were hospitalized for 2 nights, and serum measurements of PRL, total testosterone, and free and weakly bound testosterone were performed in the morning and afternoon of each day. Risperidone levels, parent compound, and 9-hydroxy metabolite levels were drawn on the first day. Erectile function assessments, using the RigiScan, an instrument that measures nocturnal penile tumescence and rigidity, were performed on both nights. Consistent with previous reports, the correlation between total risperidone level and PRL was very high (r = 0.92, df = 12, P < 0.0001), but risperidone did not appear to affect either testosterone (r = 0.29, df = 5, P = 0.51) or free and weakly bound testosterone (r = -0.11, df = 10, P = 0.72). Contrary to expectations, PRL levels from the second night were positively correlated with erectile function (r = 0.68, df = 9, P = 0.022). Using objective measures, we were unable to confirm a detrimental association between PRL levels and male erectile function. These results are tentative given the small sample. C1 Cent Arkansas Vet Hlth Syst, N Little Rock, AR 72114 USA. Univ Arkansas Med Sci, Dept Psychiat, Little Rock, AR 72205 USA. Greater Los Angeles Vet Hlth Syst, N Little Rock, VA USA. Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. RP Spollen, JJ (reprint author), Cent Arkansas Vet Hlth Syst, 2200 Ft Roots Dr,116-F2, N Little Rock, AR 72114 USA. EM John.Spollen@med.va.gov NR 31 TC 14 Z9 14 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0271-0749 J9 J CLIN PSYCHOPHARM JI J. Clin. Psychopharmacol. PD APR PY 2004 VL 24 IS 2 BP 161 EP 166 DI 10.1097/01.jcp.0000115664.45074.44 PG 6 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA 804PK UT WOS:000220310400008 PM 15206663 ER PT J AU Woo, HE Fung, CH AF Woo, HE Fung, CH TI Nontuberculous Mycobacterium as a cause of bursitis. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 27th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 12-15, 2004 CL Chicago, IL SP Soc Gen Internal Med C1 Univ Calif Los Angeles, Los Angeles, CA 90024 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2004 VL 19 SU 1 BP 64 EP 64 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 816RA UT WOS:000221125800170 ER PT J AU Shrank, WH Kravitz, R Ettner, S Glassman, PA Young, HN Asch, SM AF Shrank, WH Kravitz, R Ettner, S Glassman, PA Young, HN Asch, SM TI Are the incentives in incentive-based pharmaceutical benefit plans operating as intended? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 27th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 12-15, 2004 CL Chicago, IL SP Soc Gen Internal Med C1 Univ Calif Los Angeles, Greater Los Angeles VA Healthcare Syst, Los Angeles, CA 90024 USA. Univ Calif Davis, Sacramento, CA 95817 USA. RAND Corp, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2004 VL 19 SU 1 BP 120 EP 120 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 816RA UT WOS:000221125800409 ER PT J AU Williams, E Kivlahan, D Saitz, R Merrill, J Bradley, K AF Williams, E Kivlahan, D Saitz, R Merrill, J Bradley, K TI Are primary care patients with at-risk drinking ready to change? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 27th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 12-15, 2004 CL Chicago, IL SP Soc Gen Internal Med C1 Univ Washington, Seattle, WA 98195 USA. Boston Univ, Boston, MA 02215 USA. VA Puget Sound, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2004 VL 19 SU 1 BP 120 EP 120 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 816RA UT WOS:000221125800407 ER PT J AU Gurmankin, A Volpp, K AF Gurmankin, A Volpp, K TI Beliefs about smoking risks, intentions to quit and enrollment in a smoking cessation program. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 27th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 12-15, 2004 CL Chicago, IL SP Soc Gen Internal Med C1 Rutgers State Univ, New Brunswick, NJ 08903 USA. Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2004 VL 19 SU 1 BP 126 EP 126 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 816RA UT WOS:000221125800431 ER PT J AU Corson, K Gerrity, M Dobscha, S AF Corson, K Gerrity, M Dobscha, S TI Brief screens for depression and suicidality in primary care: Two items are better than one. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 27th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 12-15, 2004 CL Chicago, IL SP Soc Gen Internal Med C1 Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2004 VL 19 SU 1 BP 127 EP 127 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 816RA UT WOS:000221125800436 ER PT J AU Sussman, JB Jain, S Jha, AK Luck, J Peabody, JW AF Sussman, JB Jain, S Jha, AK Luck, J Peabody, JW TI Clinical vignettes to examine the effect of fatigue on quality of care. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 27th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 12-15, 2004 CL Chicago, IL SP Soc Gen Internal Med C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2004 VL 19 SU 1 BP 130 EP 131 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 816RA UT WOS:000221125800451 ER PT J AU Bean-Mayberry, BA Chang, CH McNeil, MA Hayes, PM Scholle, SH AF Bean-Mayberry, BA Chang, CH McNeil, MA Hayes, PM Scholle, SH TI Comprehensive care for women veterans: Indicators of dual use of VA and non-VA providers. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 27th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 12-15, 2004 CL Chicago, IL SP Soc Gen Internal Med C1 Univ Pittsburgh, Pittsburgh, PA 15260 USA. Natl Comm Qual Assurance, Washington, DC USA. VA Pittsburgh Healthcare Syst, VA Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2004 VL 19 SU 1 BP 131 EP 131 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 816RA UT WOS:000221125800455 ER PT J AU Lorenz, K Ryan, G Chan, K Morton, SC Shekelle, PG AF Lorenz, K Ryan, G Chan, K Morton, SC Shekelle, PG TI Comparing primary care clinician and physician managers uses and views' of evidence. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 27th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 12-15, 2004 CL Chicago, IL SP Soc Gen Internal Med C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RAND Corp, Los Angeles, CA USA. RAND Corp, Santa Monica, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2004 VL 19 SU 1 BP 131 EP 131 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 816RA UT WOS:000221125800453 ER PT J AU Vargas, RB Mangione, CM Keesey, J Asch, S Schonlau, M Keeler, E AF Vargas, RB Mangione, CM Keesey, J Asch, S Schonlau, M Keeler, E TI Do collaborative quality improvement programs reduce cardiovascular risk for persons with diabetes? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 27th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 12-15, 2004 CL Chicago, IL SP Soc Gen Internal Med C1 Univ Calif Los Angeles, Los Angeles, CA 90024 USA. RAND Corp, Santa Monica, CA USA. W Los Angeles Vet Adm, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2004 VL 19 SU 1 BP 142 EP 142 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 816RA UT WOS:000221125800500 ER PT J AU Gopal, R Glasheen, JJ Miyoshi, TJ Prochazka, A AF Gopal, R Glasheen, JJ Miyoshi, TJ Prochazka, A TI Does personality hardiness protect against resident burnout? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 27th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 12-15, 2004 CL Chicago, IL SP Soc Gen Internal Med C1 Denver VAMC, Denver, CO USA. Univ Colorado, Hlth Sci Ctr, Denver, CO USA. Denver VA, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2004 VL 19 SU 1 BP 145 EP 145 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 816RA UT WOS:000221125800511 ER PT J AU Hofer, TP Asch, S Hayward, RA Hogan, MM Rubenstein, LV Adams, JL Kerr, EM AF Hofer, TP Asch, S Hayward, RA Hogan, MM Rubenstein, LV Adams, JL Kerr, EM TI How many reviews do you need? Measuring the quality of care at clinic sites with implicit physician review. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 27th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 12-15, 2004 CL Chicago, IL SP Soc Gen Internal Med C1 Univ Michigan, Ann Arbor, MI 48109 USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. Ann Arbor VAMC Ctr Practice Management & Outcomes, Ann Arbor, MI USA. RAND Corp, Sepulveda, CA USA. RAND Corp, Santa Monica, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2004 VL 19 SU 1 BP 160 EP 160 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 816RA UT WOS:000221125800575 ER PT J AU Friedman, J Vazirani, S Tillisch, J Wenger, NS AF Friedman, J Vazirani, S Tillisch, J Wenger, NS TI Improving medical resident fatigue may require more than work hour limits. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 27th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 12-15, 2004 CL Chicago, IL SP Soc Gen Internal Med C1 Univ Calif Los Angeles, Los Angeles, CA 90024 USA. Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2004 VL 19 SU 1 BP 166 EP 166 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 816RA UT WOS:000221125800601 ER PT J AU Gerrity, MS Williams, JW Dobscha, SK Deveau, J Holsinger, T Gaynes, BN Moser, BK Dietrich, AJ AF Gerrity, MS Williams, JW Dobscha, SK Deveau, J Holsinger, T Gaynes, BN Moser, BK Dietrich, AJ TI Improving depression care: Systematic review of multifaceted interventions in primary care settings. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 27th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 12-15, 2004 CL Chicago, IL SP Soc Gen Internal Med C1 Portland VA Med Ctr, Portland, OR USA. Duke Univ, Med Ctr, Durham, NC 27706 USA. Univ N Carolina, Chapel Hill, NC 27515 USA. Dartmouth Coll Sch Med, Hanover, NH USA. RI Williams, Jr., John/A-3696-2008 OI Williams, Jr., John/0000-0002-5267-5558 NR 0 TC 3 Z9 3 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2004 VL 19 SU 1 BP 166 EP 166 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 816RA UT WOS:000221125800600 ER PT J AU Sherman, SE Takahashi, N Kalra, P Kuschner, W Canfield, J Gifford, E Kelly, J Finney, J AF Sherman, SE Takahashi, N Kalra, P Kuschner, W Canfield, J Gifford, E Kelly, J Finney, J TI Increasing referrals to telephone counseling for smoking cessation. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 27th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 12-15, 2004 CL Chicago, IL SP Soc Gen Internal Med C1 VA Greater Los Angeles Healthcare Syst, Sepulveda, CA USA. VA Palo Alto Healthcare Syst, Palo Alto, CA USA. Stanford Univ, Stanford, CA 94305 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2004 VL 19 SU 1 BP 167 EP 168 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 816RA UT WOS:000221125800607 ER PT J AU Long, JA Metlay, JP AF Long, JA Metlay, JP TI Meeting the mandate to care for low-income veterans. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 27th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 12-15, 2004 CL Chicago, IL SP Soc Gen Internal Med C1 Univ Penn, Philadelphia, PA 19104 USA. Philadelphia VA Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2004 VL 19 SU 1 BP 179 EP 180 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 816RA UT WOS:000221125800659 ER PT J AU Haidet, P Kroll, T Sharf, B AF Haidet, P Kroll, T Sharf, B TI Patients' illness narratives: The meaning of active participation in health decisions. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 27th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 12-15, 2004 CL Chicago, IL SP Soc Gen Internal Med C1 Baylor Coll Med, Houston VA Med Ctr, Houston, TX 77030 USA. Texas A&M Univ, College Stn, TX 77843 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2004 VL 19 SU 1 BP 188 EP 188 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 816RA UT WOS:000221125800696 ER PT J AU Takahashi, TA Binswanger, I Baernstein, A Merrill, JO Bradley, KA AF Takahashi, TA Binswanger, I Baernstein, A Merrill, JO Bradley, KA TI Predictors of hospitalization for injection drug users with soft tissue infections. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 27th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 12-15, 2004 CL Chicago, IL SP Soc Gen Internal Med C1 Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2004 VL 19 SU 1 BP 195 EP 195 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 816RA UT WOS:000221125800724 ER PT J AU Singhal, R Chan, AY Eidem, E AF Singhal, R Chan, AY Eidem, E TI Providing preventive health care to low income uninsured women using a community partnered mobile van program. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 27th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 12-15, 2004 CL Chicago, IL SP Soc Gen Internal Med C1 VA Greater Los Angeles HSR&D Ctr Excellence, Sepulveda, CA USA. Los Angeles Cty Dept Hlth Serv, Data Collect & Anal Unit, Los Angeles, CA USA. Los Angeles Cty Dept Hlth Serv, Off Womens Hlth, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2004 VL 19 SU 1 BP 200 EP 200 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 816RA UT WOS:000221125800744 ER PT J AU Rehman, SU Egan, BM Hutchison, FN AF Rehman, SU Egan, BM Hutchison, FN TI Racial differences in blood pressure control rates in the VA Medical Center. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 27th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 12-15, 2004 CL Chicago, IL SP Soc Gen Internal Med C1 Med Univ S, Ralph H Johnson VA Med Ctr, Mt Pleasant, MI USA. Med Univ S Carolina, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2004 VL 19 SU 1 BP 202 EP 202 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 816RA UT WOS:000221125800753 ER PT J AU Haidet, P O'Malley, K Cooper, LA Street, RL AF Haidet, P O'Malley, K Cooper, LA Street, RL TI Redefining concordance: Patients' perceptions of relational similarity. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 27th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 12-15, 2004 CL Chicago, IL SP Soc Gen Internal Med C1 Baylor Coll Med, Houston VA Med Ctr, Houston, TX 77030 USA. Pearson Educ Measurement, Austin, TX USA. Johns Hopkins Univ, Baltimore, MD 21218 USA. Texas A&M Univ, College Stn, TX 77843 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2004 VL 19 SU 1 BP 204 EP 204 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 816RA UT WOS:000221125800763 ER PT J AU Kast, D Prochazka, A Miyoshi, TJ Bublitz, C Oboler, SK Fryer, GE Anderson, RJ AF Kast, D Prochazka, A Miyoshi, TJ Bublitz, C Oboler, SK Fryer, GE Anderson, RJ TI The annual physical examination: Estimates from the National Ambulatory Medical Care Survey. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 27th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 12-15, 2004 CL Chicago, IL SP Soc Gen Internal Med C1 Univ Colorado, Hlth Sci Ctr, Denver, CO USA. Denver VA, Denver, CO USA. Denver VAMC, Denver, CO USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2004 VL 19 SU 1 BP 214 EP 214 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 816RA UT WOS:000221125800806 ER PT J AU Mortensen, E Restrepo, M Anzueto, A Pugh, J AF Mortensen, E Restrepo, M Anzueto, A Pugh, J TI The association between statin and ACE inhibitor use and mortality for patients hospitalized with community-acquired pneumonia. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 27th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 12-15, 2004 CL Chicago, IL SP Soc Gen Internal Med C1 Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2004 VL 19 SU 1 BP 215 EP 215 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 816RA UT WOS:000221125800809 ER PT J AU Seshamani, M Volpp, KG AF Seshamani, M Volpp, KG TI The effect of cuts in Medicare reimbursement on quality of hospital care. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 27th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 12-15, 2004 CL Chicago, IL SP Soc Gen Internal Med C1 Univ Penn, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2004 VL 19 SU 1 BP 216 EP 217 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 816RA UT WOS:000221125800816 ER PT J AU Volpp, KG Gurmankin, A Asch, DA Murphy, JJ Gomez, A Sox, HC Lerman, C AF Volpp, KG Gurmankin, A Asch, DA Murphy, JJ Gomez, A Sox, HC Lerman, C TI The effect of financial incentives on smoking cessation program attendance and completion. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 27th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 12-15, 2004 CL Chicago, IL SP Soc Gen Internal Med C1 Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. Annals Internal Med, Philadelphia, PA USA. Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2004 VL 19 SU 1 BP 217 EP 217 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 816RA UT WOS:000221125800819 ER PT J AU Mangrulkar, RS Lencoski, K Gerrity, M Hayward, RS Straus, S AF Mangrulkar, RS Lencoski, K Gerrity, M Hayward, RS Straus, S CA T SGIM EBM Task Force TI The impact of a series of workshops to improve evidence based clinical practice. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 27th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 12-15, 2004 CL Chicago, IL SP Soc Gen Internal Med C1 Univ Michigan, Ann Arbor, MI 48109 USA. SGIM, Washington, DC USA. Portland VA Med Ctr, Portland, OR USA. Univ Alberta, Edmonton, AB T6G 2M7, Canada. Univ Toronto, Toronto, ON, Canada. NR 0 TC 2 Z9 2 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2004 VL 19 SU 1 BP 219 EP 219 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 816RA UT WOS:000221125800829 ER PT J AU Garibaldi, KL Gibson, RW Reiss, J Villarreal, GB Haidet, P AF Garibaldi, KL Gibson, RW Reiss, J Villarreal, GB Haidet, P TI Transition from pediatric to adult healthcare: The experiences of young adults with spina bifida. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 27th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 12-15, 2004 CL Chicago, IL SP Soc Gen Internal Med C1 Baylor Coll Med, Houston, TX 77030 USA. Univ Florida, Gainesville, FL 32611 USA. Houston VA Med Ctr, Houston, TX USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2004 VL 19 SU 1 BP 229 EP 229 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 816RA UT WOS:000221125800869 ER PT J AU Diamant, AL Hays, RD Asch, S Dyer, I Gelberg, L AF Diamant, AL Hays, RD Asch, S Dyer, I Gelberg, L TI Unmet need for dental care in a publicly funded system of health care. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 27th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 12-15, 2004 CL Chicago, IL SP Soc Gen Internal Med C1 Univ Calif Los Angeles, Los Angeles, CA 90024 USA. W Los Angeles Vet Adm, Los Angeles, CA USA. Los Angeles Cty Dept Hlth Serv, Los Angeles, CA USA. RI Hays, Ronald/D-5629-2013 NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2004 VL 19 SU 1 BP 231 EP 231 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 816RA UT WOS:000221125800878 ER PT J AU Fung, CH Woods, JN Asch, S Glassman, PA Doebbeling, BN AF Fung, CH Woods, JN Asch, S Glassman, PA Doebbeling, BN TI Variation in the use of computerized clinical reminders in an integrated national delivery system. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 27th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 12-15, 2004 CL Chicago, IL SP Soc Gen Internal Med C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Iowa, Iowa City, IA 52242 USA. Indiana Univ Purdue Univ, Indianapolis, IN 46202 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2004 VL 19 SU 1 BP 235 EP 235 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 816RA UT WOS:000221125800895 ER PT J AU Shekelle, PG Morton, SC Jungvig, LK Udani, J Spar, M Tu, WL Suttorp, MJ Coulter, I Newberry, SJ Hardy, M AF Shekelle, PG Morton, SC Jungvig, LK Udani, J Spar, M Tu, WL Suttorp, MJ Coulter, I Newberry, SJ Hardy, M TI Effect of supplemental vitamin E for the prevention and treatment of cardiovascular disease SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Review DE vitamin E; antioxidants; meta-analysis; systematic review; cardiovascular disease ID BETA-CAROTENE SUPPLEMENTS; PLACEBO-CONTROLLED TRIAL; CORONARY-HEART-DISEASE; ACUTE MYOCARDIAL-INFARCTION; RANDOMIZED CONTROLLED TRIAL; ANTIOXIDANT VITAMINS; ALPHA-TOCOPHEROL; CLINICAL-TRIALS; ANGINA-PECTORIS; RISK AB OBJECTIVE: To evaluate and synthesize the evidence on the effect of supplements of vitamin E on the prevention and treatment of cardiovascular disease. DESIGN: Systematic review of placebo-controlled randomized controlled trials; meta-analysis where justified. MEASUREMENTS AND MAIN RESULTS: Eighty-four eligible trials were identified. For the outcomes of all-cause mortality, cardiovascular mortality, fatal or nonfatal myocardial infarction, and blood lipids, neither supplements of vitamin E alone nor vitamin E given with other agents yielded a statistically significant beneficial or adverse pooled relative risk (for example, pooled relative risk of vitamin E alone = 0.96 [95% confidence interval (CI), 0.84 to 1.10]; 0.97 [95% CI, 0.80 to 1.90]; and 0.72 [95% CI, 0.51 to 1.02] for all-cause mortality, cardiovascular mortality, and nonfatal myocardial infarction, respectively. CONCLUSIONS: There is good evidence that vitamin E supplementation does not beneficially or adversely affect cardiovascular outcomes. C1 RAND Corp, So Calif Evidence Based Practice Ctr, Santa Monica, CA 90407 USA. Northridge Hosp Integrat Med Program, Los Angeles, CA USA. Univ Calif Los Angeles, Geffen Sch Med, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. RP Shekelle, PG (reprint author), RAND Corp, So Calif Evidence Based Practice Ctr, 1700 Main St,POB 2138, Santa Monica, CA 90407 USA. EM shekelle@rand.org NR 51 TC 85 Z9 86 U1 1 U2 4 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2004 VL 19 IS 4 BP 380 EP U49 PG 49 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 808CC UT WOS:000220546200012 PM 15061748 ER PT J AU Rodriguez-Torres, M Torriani, FJ Lissen, E Brau, N Sulkowski, M Sola, R Clotet, B Clumeck, N Cooper, D Dieterich, D AF Rodriguez-Torres, M Torriani, FJ Lissen, E Brau, N Sulkowski, M Sola, R Clotet, B Clumeck, N Cooper, D Dieterich, D TI Early prediction of sustained virological response (SVR) during treatment with peginterferon alfa-2a (40KD) (PEGASYS (R)) plus ribavirin (RBV) (COPEGUS (R)) in patients with HCV/HIV co-infection: Results from the AIDS PEGASYS ribavirin international co-infectio SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 39th Annual Meeting of the European-Association-for-the-Study-of-the-Liver CY APR 14-18, 2004 CL Berlin, GERMANY SP European Assoc Study Liver C1 Fdn Invest De Diego, Santurce, PR USA. Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA. Virgen Del Rocio Univ Hosp, Seville, Spain. Bronx Vet Adm Med Ctr, Bronx, NY USA. Johns Hopkins Univ, Sch Med, Baltimore, MD USA. Rovira & Virgili Univ, Reus, Spain. Hosp Germans Trias & Pujol, Barcelona, Spain. CHU St Pierre, Brussels, Belgium. Univ New S Wales, Sydney, NSW, Australia. Mt Sinai Sch Med, New York, NY USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 J9 J HEPATOL JI J. Hepatol. PD APR PY 2004 VL 40 SU 1 MA 507 BP 149 EP 149 DI 10.1016/S0168-8278(04)90507-7 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 814BS UT WOS:000220950800508 ER PT J AU Ha, TS Duraisamy, S Faulkner, JL Kasinath, BS AF Ha, TS Duraisamy, S Faulkner, JL Kasinath, BS TI Regulation of glomerular endothelial cell proteoglycans by glucose SO JOURNAL OF KOREAN MEDICAL SCIENCE LA English DT Article DE diabetes mellitus; diabetic nephropathies; endothelium; heparan sulfate proteoglycan; kidney glomerulus; proteinuria ID HEPARAN-SULFATE PROTEOGLYCAN; BASEMENT-MEMBRANE; EPITHELIAL-CELLS; INCREASED PERMEABILITY; DIABETIC NEPHROPATHY; FILTRATION CHANGES; GENE-EXPRESSION; PROTEIN; GLYCOSAMINOGLYCANS; LOCALIZATION AB The presence of heparan sulfate proteoglycan (HSPG) in anionic sites in the lamina rara interna of glomerular basement membrane suggests that the proteoglycan may be deposited by the glomerular endothelial cells (G Endo). We have previously demonstrated that bovine GEndo in vitro synthesize perlecan, a species of glomerular basement membrane HSPG. In this study we examined whether high glucose medium regulates the GEndo metabolism of glycopeptides including perlecan. Metabolic labeling of glycoconjugates with S-35-SO4, sequential ion exchange and Sepharose CL-4B chromatography of labeled glycoconjugates, and northern analysis were performed. Incubation of GEndo for 8 to 14 weeks (but not for 1-2 weeks) in medium containing 30 mM glucose resulted in nearly 50% reduction in the synthesis of cell layer and medium (SO4)-S-35-labeled low anionic glycoproteins and proteoglycans, including that of basement membrane HSPG (K-av 0.42) compared to GEndo grown in 5 mM glucose medium; no changes in anionic charge density or hydrodynamic size of proteoglycans were noted. Northern analysis demonstrated that the mRNA abundance of perlecan was reduced by 47% in cells incubated with 30 mM glucose. Our data suggest that high glucose medium reduces the GEndo synthesis of perlecan by regulating its gene expression. Reduced synthesis of perlecan by GEndo may contribute to proteinuria seen in diabetic nephropathy. C1 Chungbuk Natl Univ, Coll Med, Dept Pediat, Chonju 361240, South Korea. Univ Texas, Hlth Sci Ctr, S Texas Vet Hlth Care Syst, Dept Med, San Antonio, TX 78284 USA. RP Ha, TS (reprint author), Chungbuk Natl Univ, Coll Med, Dept Pediat, 48 Gaesin Dong, Chonju 361240, South Korea. EM tsha@med.chungbuk.ac.kr FU NIDDK NIH HHS [R37 DK033665, DK 33665, R01 DK033665, R01 DK077295] NR 34 TC 9 Z9 9 U1 0 U2 0 PU KOREAN ACAD MEDICAL SCIENCES PI SEOUL PA 302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA SN 1011-8934 J9 J KOREAN MED SCI JI J. Korean Med. Sci. PD APR PY 2004 VL 19 IS 2 BP 245 EP 252 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 814UB UT WOS:000220998500014 PM 15082898 ER PT J AU Griffin, WC Middaugh, LD Cook, JE Tyor, WR AF Griffin, WC Middaugh, LD Cook, JE Tyor, WR TI The severe combined immunodeficient (SCID) mouse model of human immunodeficiency virus encephalitis: Deficits in cognitive function SO JOURNAL OF NEUROVIROLOGY LA English DT Article DE AIDS; animal model; dementia; HIV-associated dementia; HIV encephalitis; SCID ID AIDS DEMENTIA COMPLEX; TYPE-1 ENCEPHALITIS; HIV ENCEPHALITIS; MURINE MODEL; WATER-MAZE; MICE; MORRIS; MEMORY; NAVIGATION; RATS AB The severe combined immunodeficient (SCID) mouse model of human immunodeficiency virus (HIV) encephalitis exhibits many of the histopathological and pathophysiological features of human HIV-associated dementia (HAD). Although deficits that may resemble HAD in humans have been reported for HIV-infected SCID mice, the cognitive deficit aspect of the model has very limited empirical support. Here, the authors report that HIV-infected SCID mice display cognitive deficits on a task requiring the animal to learn and remember the spatial relationship of cues in its environment in order to locate a submerged platform in a Morris water maze. The cognitive deficits manifest as longer latencies to locate the platform on the last day of the maze acquisition period and during a retention test 8 days later. Control experiments indicated that the poor performance by HIV-infected mice in comparison to controls was not due to impaired motor function or swimming ability, impaired visual acuity, or increased susceptibility to fatigue. Thus, the increased times required for HIV-infected mice to locate the submerged platform during the acquisition and memory tests likely reflect a cognitive deficit, rather than sensorimotor or emotional abnormalities. These behavioral deficits are associated with significant increases in astrogliosis and microgliosis in the HIV-infected mice. The results of this study strengthen the SCID mouse model of HIV encephalitis by definitively establishing cognitive deficits for the model in addition to its previously reported neuropathological features. C1 Med Univ S Carolina, Ctr Drug & Alochol Programs, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Physiol & Neurosci, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Neurol, Charleston, SC 29425 USA. RP Tyor, WR (reprint author), Ralph H Johnson VAMC, Serv Neurol, 109 Bee St, Charleston, SC 29401 USA. EM william.tyor@med.va.gov FU NIDA NIH HHS [DA11870-04, T32 DA07288-11]; NIMH NIH HHS [MH62697-03] NR 20 TC 15 Z9 16 U1 1 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1355-0284 J9 J NEUROVIROL JI J. Neurovirol. PD APR PY 2004 VL 10 IS 2 BP 109 EP 115 DI 10.1080/13550280490428333 PG 7 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 801WR UT WOS:000220126500004 PM 15204929 ER PT J AU Martinez, V Wang, LX Rivier, J Grigoriadis, D Tache, Y AF Martinez, V Wang, LX Rivier, J Grigoriadis, D Tache, Y TI Central CRF, urocortins and stress increase colonic transit via CRF1 receptors while activation of CRF2 receptors delays gastric transit in mice SO JOURNAL OF PHYSIOLOGY-LONDON LA English DT Article ID CORTICOTROPIN-RELEASING-FACTOR; ANXIETY-LIKE BEHAVIOR; MOTOR FUNCTION; COMPETITIVE ANTAGONISTS; BINDING-PROTEIN; ACID SECRETION; HIGH-AFFINITY; RATS; FAMILY; ANTISAUVAGINE-30 AB Recently characterized selective agonists and developed antagonists for the corticotropin releasing factor (CRF) receptors are new tools to investigate stress-related functional changes. The influence of mammalian CRF and related peptides injected intracerebroventricularly (I.C.V.) on gastric and colonic motility, and the CRF receptor subtypes involved and their role in colonic response to stress were studied in conscious mice. The CRF1/CRF2 agonists rat urocortin 1 (rUcn 1) and rat/human CRF (r/h CRF), the preferential CRF1 agonist ovine CRF (oCRF), and the CRF2 agonist mouse (m) Ucn 2, injected I.C.V. inhibited gastric emptying and stimulated distal colonic motor function (bead transit and defecation) while oCRF(9-33) OH (devoid of CRF receptor affinity) showed neither effects. mUcn 2 injected peripherally had no colonic effect. The selective CRF2 antagonist astressin(2)-B (I.C.V.), at a 20:1 antagonist: agonist ratio, blocked I.C.V. r/hCRF and rUcn 1 induced inhibition of gastric transit and reduced that of mUcn 2, while the CRF1 antagonist NBI-35965 had no effect. By contrast, the colonic motor stimulation induced by I.C.V. r/hCRF and rUcn 1 and 1 h restraint stress were antagonized only by NBI-35965 while stimulation induced by mUcn 2 was equally blocked by both antagonists. None of the CRF antagonists injected I.C.V.. alone influenced gut transit. These data establish in mice that brain CRF1 receptors mediate the stimulation of colonic transit induced by central CRF, urocortins (1 and 2) and restraint stress, while CRF2 receptors mediate the inhibitory actions of these peptides on gastric transit. C1 Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr, Dept Med,Digest Dis Div, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Ctr Neurovisceral Sci, Dept Med,Digest Dis Div, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Brain Res Inst, Los Angeles, CA 90073 USA. Salk Inst Biol Studies, Clayton Fdn, Labs Peptide Biol, La Jolla, CA 92037 USA. Neurocrine Biosci Inc, San Diego, CA 92121 USA. RP Tache, Y (reprint author), Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr, Dept Med,Digest Dis Div, Bldg 115,Rm 117,11301 Whilshire Blvd, Los Angeles, CA 90073 USA. EM ytache@ucla.edu RI Martinez, Vicente/N-1189-2014 FU NIDDK NIH HHS [DK-26741, DK-41301, DK-57238, DK33061, P01 DK026741, R01 DK033061, R37 DK033061, R01 DK057238, P30 DK041301] NR 44 TC 118 Z9 122 U1 0 U2 2 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 0022-3751 J9 J PHYSIOL-LONDON JI J. Physiol.-London PD APR 1 PY 2004 VL 556 IS 1 BP 221 EP 234 DI 10.1113/jphysiol.2003.059659 PG 14 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA 813DJ UT WOS:000220887500017 PM 14755002 ER PT J AU Guzman, JS Sohn, L Harada, ND AF Guzman, JS Sohn, L Harada, ND TI Living alone and outpatient care use by older veterans SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article; Proceedings Paper CT Annual Meeting of the American-Geriatrics-Society CY MAY 08-12, 2002 CL WASHINGTON, DC SP Amer Geriatr Soc DE veterans; elderly; outpatient; living alone ID HEALTH-SERVICES; EMERGENCY ROOM; SOCIAL SUPPORT; MARITAL-STATUS; HOSPITALIZATION; PHYSICIAN; ADULTS; PATTERNS AB In nonveteran older adults, living alone influences outpatient care use, but its importance in the veteran population has not been well studied. The aims of this study are to describe the use of outpatient care by older veterans who live alone versus those who live with others and determine whether living alone influences outpatient use by older veterans. The data come from the 2001 Veteran Identity Program Survey designed to measure Department of Veterans Affairs (VA) and non-VA outpatient care use. Univariate and bivariate analyses were conducted to examine distributional properties, associations, and subgroup differences in outpatient care use. Poisson regression was used to assess the role of living alone on outpatient care use, controlling for predisposing, other enabling, and need factors. Results found that older veterans who use the VA, whether they live alone or not, have similar numbers of VA outpatient visits. Older veterans who use VA and non-VA facilities and who live alone have greater total outpatient visits than those who live with others. Regression results indicate that living alone is a predictor of VA routine medical visits, VA prescription refill visits, and total VA and non-VA outpatient visits but does not influence VA emergency room visits. These findings suggest that living alone is associated with differences in outpatient care use by older veterans. It is important for the VA to understand this relationship with the aim of developing interventions to improve access, effectiveness, and efficiency of health services for older veterans. C1 VA Greater Los Angeles Healthcare Syst, WLA, Ctr Geriatr Res Educ & Clin, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. RP Guzman, JS (reprint author), VA Greater Los Angeles Healthcare Syst, WLA, Ctr Geriatr Res Educ & Clin, 11301 Wilshire Blvd 11G, Los Angeles, CA 90073 USA. EM jenice.guzman@med.va.gov NR 27 TC 7 Z9 7 U1 1 U2 2 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2004 VL 52 IS 4 BP 617 EP 622 DI 10.1111/j.1532-5415.2004.52172.x PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 805GO UT WOS:000220355000021 PM 15066081 ER PT J AU Salerno, JA Cooley, SG AF Salerno, JA Cooley, SG TI Tribute to Marsha Goodwin-Beck, RN-C, MA, MSN SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Biographical-Item C1 NIA, NIH, Bethesda, MD 20892 USA. US Dept Vet Affairs, Geriatr Res & Evaluat Geriatr & Extended Care Str, Washington, DC USA. RP Salerno, JA (reprint author), NIA, NIH, Bldg 31,Rm 5C35,MSC 2292, Bethesda, MD 20892 USA. EM salernoj@nia.nih.gov NR 1 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2004 VL 52 IS 4 BP 623 EP 624 DI 10.1111/j.1532-5415.2004.52189.x PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 805GO UT WOS:000220355000022 ER PT J AU Brown, CJ Allman, RM AF Brown, CJ Allman, RM TI Predictors of regaining ambulatory ability at hospital discharge. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 17-21, 2004 CL Las Vegas, NV SP Amer Geriatr Soc C1 Birmingham VAMC, GRECC, Birmingham, AL USA. Univ Alabama, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2004 VL 52 IS 4 SU S MA P360 BP S140 EP S140 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 813HV UT WOS:000220899100405 ER PT J AU Chiang, L MacLean, CH Reuben, DB Wenger, NS AF Chiang, L MacLean, CH Reuben, DB Wenger, NS TI Predictors of quality of care in vulnerable elders. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 17-21, 2004 CL Las Vegas, NV SP Amer Geriatr Soc C1 Univ Calif Los Angeles, Los Angeles, CA USA. Rand Hlth, Santa Monica, CA USA. Greater Los Angeles VA Med Ctr, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2004 VL 52 IS 4 SU S MA P247 BP S101 EP S101 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 813HV UT WOS:000220899100292 ER PT J AU Chun, AK Fernandez, H Evelyn, G AF Chun, AK Fernandez, H Evelyn, G TI Training geriatric fellows as teachers. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 17-21, 2004 CL Las Vegas, NV SP Amer Geriatr Soc C1 CUNY Mt Sinai Sch Med, New York, NY 10029 USA. Bronx Vet Affairs Med Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2004 VL 52 IS 4 SU S MA P352 BP S137 EP S137 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 813HV UT WOS:000220899100397 ER PT J AU Kinosian, B Martingdale, M Ripley, B Stallard, E AF Kinosian, B Martingdale, M Ripley, B Stallard, E TI Geographic barriers to nursing home access among priority group IA veterans. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 17-21, 2004 CL Las Vegas, NV SP Amer Geriatr Soc C1 Univ Penn, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. Dept Vet Affairs, Washington, DC USA. Dept Vet Affairs, Gainesville, FL USA. Duke Univ, Durham, NC USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2004 VL 52 IS 4 SU S MA P378 BP S146 EP S146 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 813HV UT WOS:000220899100423 ER PT J AU LoConte, M Mahoney, J Shea, T Przybelski, R Hansen, K AF LoConte, M Mahoney, J Shea, T Przybelski, R Hansen, K TI Fall frequency and baseline characteristics: How many falls does it take to be different? SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 17-21, 2004 CL Las Vegas, NV SP Amer Geriatr Soc C1 Univ Wisconsin, Dept Geriatr, Madison, WI USA. Univ Wisconsin Hosp & Clin, William S Middleton Mem Vet Adm Hosp, GRECC, Madison, WI 53792 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2004 VL 52 IS 4 SU S MA P70 BP S41 EP S41 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 813HV UT WOS:000220899100116 ER PT J AU Mader, SL Benton, N Ansari, Y Baird, C Harper, R Chapman, K Donius, M Jenkins, K Jackson, J Setka, D Medcraft, M AF Mader, SL Benton, N Ansari, Y Baird, C Harper, R Chapman, K Donius, M Jenkins, K Jackson, J Setka, D Medcraft, M TI Program @ Home: A VA program to deliver hospital care in the home. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 17-21, 2004 CL Las Vegas, NV SP Amer Geriatr Soc C1 Portland VA Med Ctr, Portland, OR USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2004 VL 52 IS 4 SU S MA P533 BP S200 EP S200 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 813HV UT WOS:000220899100578 ER PT J AU Mader, SL Fuglee, K Allen, D Werner, L Wanlass, W Pagel, K Beliel, K McEuen, J Stephens, E Allison, N McWhorter, K Holtorf, S Vandling, J AF Mader, SL Fuglee, K Allen, D Werner, L Wanlass, W Pagel, K Beliel, K McEuen, J Stephens, E Allison, N McWhorter, K Holtorf, S Vandling, J TI Development of a protocol for capillary blood glucose (CBG) testing in nursing home and rehabilitation settings. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 17-21, 2004 CL Las Vegas, NV SP Amer Geriatr Soc C1 Portland VA Med Ctr, Portland, OR USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2004 VL 52 IS 4 SU S MA P95 BP S49 EP S50 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 813HV UT WOS:000220899100141 ER PT J AU Markland, AD Wang, C Lee, S Gerety, MB Hazuda, HP AF Markland, AD Wang, C Lee, S Gerety, MB Hazuda, HP TI Ethnic differences and urinary incontinence in a cross-sectional analysis of older, community-based Mexican and European Americans. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 17-21, 2004 CL Las Vegas, NV SP Amer Geriatr Soc C1 Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2004 VL 52 IS 4 SU S MA P332 BP S130 EP S131 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 813HV UT WOS:000220899100377 ER PT J AU McDonald, M Hertz, RP Stafkey, D Yu, H Peterson, N Sonali, SN AF McDonald, M Hertz, RP Stafkey, D Yu, H Peterson, N Sonali, SN TI Comparison of the Department of Veterans Affairs healthcare utilization among veterans with Alzheimers disease, other mental disorders, and the overall system user. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 17-21, 2004 CL Las Vegas, NV SP Amer Geriatr Soc C1 Pfizer Inc, US Outcomes Res, New York, NY USA. Pfizer Inc, Outcomes Res, Ann Arbor, MI USA. Houston Ctr Qual Care & Utilizat Studies, Hlth Serv Res & Dev Serv, Dept Vet Affairs Med Ctr, Houston, TX USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2004 VL 52 IS 4 SU S MA P508 BP S191 EP S191 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 813HV UT WOS:000220899100553 ER PT J AU Perkins, CH Bergstrom, N Garcia, AD AF Perkins, CH Bergstrom, N Garcia, AD TI Pressure ulcer knowledge in primary care residencies. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 17-21, 2004 CL Las Vegas, NV SP Amer Geriatr Soc C1 Baylor Coll Med, Houston VAMC, Houston, TX 77030 USA. Univ Texas, Hlth Sci Ctr, UT Houston Sch Nursing, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2004 VL 52 IS 4 SU S MA P479 BP S181 EP S181 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 813HV UT WOS:000220899100524 ER PT J AU Richter, HE Duxbury, AS Granieri, E Halli, A Redden, DT Goode, PS AF Richter, HE Duxbury, AS Granieri, E Halli, A Redden, DT Goode, PS TI Pelvic floor surgery in the older woman: Effect of enhanced preoperative evaluation on functional and general health outcomes. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 17-21, 2004 CL Las Vegas, NV SP Amer Geriatr Soc C1 Univ Alabama, Birmingham, AL USA. Bronx Vet Affairs Med Ctr, New York, NY USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2004 VL 52 IS 4 SU S MA P585 BP S217 EP S218 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 813HV UT WOS:000220899100630 ER PT J AU Salazar, JA Raji, MA Schindler, JB AF Salazar, JA Raji, MA Schindler, JB TI Defining accessibility barriers to health care among a geriatric population in an urban minority community. A qualitative study. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 17-21, 2004 CL Las Vegas, NV SP Amer Geriatr Soc C1 Houston VA Med Ctr, Houston, TX USA. Univ Texas, Dept Med, Galveston, TX 77555 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2004 VL 52 IS 4 SU S MA P244 BP S100 EP S100 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 813HV UT WOS:000220899100289 ER PT J AU Unwin, BK AF Unwin, BK TI Post traumatic stress disorder and the geriatrician. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 17-21, 2004 CL Las Vegas, NV SP Amer Geriatr Soc C1 Madigan Army Med Ctr, Vet Affairs Puget Sound Hlth Care Syst, Tacoma, WA 98431 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2004 VL 52 IS 4 SU S MA P306 BP S121 EP S122 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 813HV UT WOS:000220899100351 ER PT J AU Vance, DE Sims, RV Chatman, T Ball, KK AF Vance, DE Sims, RV Chatman, T Ball, KK TI Physiological and psychosocial predictors of speed of processing in older community-dwelling adults. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 17-21, 2004 CL Las Vegas, NV SP Amer Geriatr Soc C1 Birmingham VAMC, Birmingham, AL USA. Univ Alabama Birmingham, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2004 VL 52 IS 4 SU S MA P75 BP S43 EP S43 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 813HV UT WOS:000220899100121 ER PT J AU Vance, DE Sims, RV Chatman, T Ball, KK AF Vance, DE Sims, RV Chatman, T Ball, KK TI Medical and psychosocial predictors of falling and balance in community-dwelling older adults. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 17-21, 2004 CL Las Vegas, NV SP Amer Geriatr Soc C1 Birmingham VAMC, Birmingham, AL USA. Univ Alabama Birmingham, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2004 VL 52 IS 4 SU S MA P76 BP S43 EP S43 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 813HV UT WOS:000220899100122 ER PT J AU Webber, AP Harker, JO Martin, JL Josephson, KR Alessi, CA AF Webber, AP Harker, JO Martin, JL Josephson, KR Alessi, CA TI Predictors of outcome of post-acute rehabilitation in nursing homes. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 17-21, 2004 CL Las Vegas, NV SP Amer Geriatr Soc C1 VA Greater Los Angeles Healthcare Syst, Sepulveda GRECC, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2004 VL 52 IS 4 SU S MA P431 BP S164 EP S164 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 813HV UT WOS:000220899100476 ER PT J AU Wiesenfeld, LA AF Wiesenfeld, LA TI Grannyland: Using a board game to teach geriatric psychiatry. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 17-21, 2004 CL Las Vegas, NV SP Amer Geriatr Soc C1 Bronx Vet Adm Med Ctr, Bronx, NY USA. Mt Sinai Sch Med, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2004 VL 52 IS 4 SU S MA P200 BP S85 EP S85 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 813HV UT WOS:000220899100245 ER PT J AU Young, AJ Rodriguez, KL AF Young, AJ Rodriguez, KL TI External health locus of control and advance directives: A matched-pair analysis of VA patients and providers. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 17-21, 2004 CL Las Vegas, NV SP Amer Geriatr Soc C1 VA Pittsburgh Healthcare Syst, GRECC, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, CHERP, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2004 VL 52 IS 4 SU S MA P426 BP S162 EP S163 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 813HV UT WOS:000220899100471 ER PT J AU Han, ES Wu, YM McCarter, R Nelson, JF Richardson, A Hilsenbeck, SG AF Han, ES Wu, YM McCarter, R Nelson, JF Richardson, A Hilsenbeck, SG TI Reproducibility, sources of variability, pooling, and sample size: Important considerations for the design of high-density oligonucleotide array experiments SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article ID PROBE LEVEL DATA; GENE-EXPRESSION; SACCHAROMYCES-CEREVISIAE; QUANTITATIVE HYBRIDIZATION; MICROARRAY EXPERIMENTS; MESSENGER-RNA; BREAST-CANCER; PROFILES; NORMALIZATION; PREDICTION AB We have undertaken a series of experiments to examine several issues that directly affect design of gene expression studies using Affymetrix GeneChip arrays: probe-level analysis, need for technical replication, relative contribution of various sources of variability, and utility of pooling RNA from different samples. Probe-level data were analyzed by Affymetrix MAS 5.0, and three model-based methods, PM-MM and PM-only models by dChip, and the RMA model by Bioconductor, with the latter two providing the best performance. We found that replicate chips of the same RNA have limited value in reducing total variability, and for relatively highly expressed genes in this biologically homogeneous animal model of aging, about 11% of total variation is due to day effects and the remainder is approximately equally split between sample and residual sources. We also found that pooling samples is neither advantageous nor detrimental. Finally we suggest a strategy for sample size calculations using formulas appropriate when coefficients of variation are known, target effects are expressed as fold changes, and data can be assumed to be approximately lognormally distributed. C1 Univ Tulsa, Dept Biol Sci, Tulsa, OK 74104 USA. Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. Baylor Coll Med, Breast Ctr, Houston, TX 77030 USA. RP Han, ES (reprint author), Univ Tulsa, Dept Biol Sci, 600 S Coll Ave, Tulsa, OK 74104 USA. EM eun-han@utulsa.edu FU NCI NIH HHS [P01CA30195]; NIA NIH HHS [AG-14674-04S1, AG-00746] NR 37 TC 49 Z9 52 U1 0 U2 1 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD APR PY 2004 VL 59 IS 4 BP 306 EP 315 PG 10 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 812JM UT WOS:000220835800002 PM 15071073 ER PT J AU Yang, H Shi, MJ Story, J Richardson, A Guo, ZM AF Yang, H Shi, MJ Story, J Richardson, A Guo, ZM TI Food restriction attenuates age-related increase in the sensitivity of endothelial cells to oxidized lipids SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article ID GENETICALLY OBESE RATS; LOW CALORIE DIET; NITRIC-OXIDE; ADHESION MOLECULE-1; LEUKOCYTE ADHESION; OXIDATIVE STRESS; ATHEROSCLEROSIS; EXPRESSION; HYPERTENSION; DYSFUNCTION AB Age-related endothelial dysfunction has been suggested to play a role in atherogenesis. Food restriction (FR) has been shown to retard the development of atherosclerosis. The goal of this report is to assess the effect of aging and FR on endothelial functions, including the release of endothelial nitric oxide (NO) and the adhesion of mononuclear cells (MNCs) to endothelial cells (ECs). ECs were obtained from the aorta of young mice fed ad libitum (Y-AL), old mice fed ad libitum (O-AL), or a food-restricted diet (O-FR). When compared with those obtained from Y-AL and O-FR mice, ECs obtained from O-AL mice decreased the basal level of NO release and increased the basal level of peroxynitrite, superoxide, and hydrogen peroxide. In addition, ECs obtained from O-AL elevated the response to CuSO4-oxidized low-density lipoprotein (oxLDL). For example, incubation with oxLDL reduced NO release approximately 52% in ECs obtained from O-AL mice. In contrast, the same dose of oxLDL reduced NO release only approximately 40% in ECs obtained from Y-AL and O-FR mice. Moreover, the level of oxLDL-induced adhesion of MNCs and oxLDL-induced expression of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 was markedly higher in ECs obtained from O-AL mice as compared with those obtained from Y-AL and O-FR mice. These results suggest that aging increases the sensitivity of ECs in response to oxLDL-reduced endothelial NO release and oxLDL-increased adhesion of MNCs to ECs. FR attenuates age-related increase in the sensitivity of ECs to oxLDL, which might be responsible, at least in part, for the antiatherogenic action of FR. C1 Meharry Med Coll, Dept Pathol Anat & Cell Biol, Nashville, TN 37208 USA. Meharry Med Coll, Dept Physiol, Nashville, TN 37208 USA. Meharry Med Coll, Dept Internal Med, Nashville, TN 37208 USA. Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, Ctr Geriatr Res Educ & Clin, San Antonio, TX USA. RP Guo, ZM (reprint author), Meharry Med Coll, Dept Pathol Anat & Cell Biol, Nashville, TN 37208 USA. EM zguo@mmc.edu FU NHLBI NIH HHS [R15 HL071525, HL71525]; NIA NIH HHS [P03-AG13319]; NIGMS NIH HHS [S06 GM008037, GM08037] NR 32 TC 20 Z9 20 U1 0 U2 0 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD APR PY 2004 VL 59 IS 4 BP 316 EP 323 PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 812JM UT WOS:000220835800003 PM 15071074 ER PT J AU Barnes, DE Tager, IB Satariano, WA Yaffe, K AF Barnes, DE Tager, IB Satariano, WA Yaffe, K TI The relationship between literacy and cognition in well-educated elders SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article; Proceedings Paper CT 55th Annual Meeting of the American-Academy-of-Neurology CY APR 02-03, 2003 CL HONOLULU, HI SP Amer Acad Neurol ID ADULT READING TEST; NEUROPSYCHOLOGICAL TEST-PERFORMANCE; MINI-MENTAL-STATE; ALZHEIMERS-DISEASE; PREMORBID INTELLIGENCE; AFRICAN-AMERICAN; OLDER-ADULTS; DEMENTIA; ABILITY; COMMUNITY AB Background. Literacy is correlated with general intelligence and is often used to estimate premorbid intelligence in persons with dementia. However, little is known about the relationship between literacy and specific cognitive domains. Methods. Study participants were 664 community-living adults aged 65 years or older who were participating in a community-based study of health and function in Sonoma, California. Literacy was measured using the North American Adult Reading Test, which evaluates the ability to pronounce words with irregular spellings (such as indict). Cognitive function was assessed using a neuropsychological test battery that included the Mini-Mental State Examination and measures of attention and executive function (Trails B, Stroup, Digit Symbol), verbal learning and memory (California Verbal Learning Test), and verbal fluency (letter "s," animals). Results. The mean age of the participants was 76 years, 50% were women, 97% were white, and 92% had 12 or more years of education. A strong, linear association was observed between literacy and all cognitive measures (all p <.001). Results were similar after adjustment for age, sex, education, and health-related covariates and were consistent in subgroups of the study population (e.g., women vs men; English vs other native languages). Education was not associated with most cognitive measures after adjustment for literacy. Conclusions. Literacy is strongly associated with cognitive function across all cognitive domains in well-educated, elderly white persons. Future studies should determine whether interventions to improve lifetime literacy may help prevent cognitive deterioration with age. C1 Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. Univ Calif Berkeley, Dept Epidemiol, Berkeley, CA 94720 USA. Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. RP Barnes, DE (reprint author), San Francisco VA Med Ctr, 4150 Clement St,MC 181G, San Francisco, CA 94121 USA. FU NIA NIH HHS [K23-AG00888, R01-AG09389, T32-AG00212]; NIMH NIH HHS [F31 MH012665, F31 MH012665-02, F31-MH12665] NR 29 TC 31 Z9 34 U1 0 U2 3 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD APR PY 2004 VL 59 IS 4 BP 390 EP 395 PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 812JM UT WOS:000220835800013 PM 15071084 ER PT J AU Butt, AA Aldridge, KE Sanders, CV AF Butt, AA Aldridge, KE Sanders, CV TI Infections related to the ingestion of seafood Part I: viral and bacterial infections SO LANCET INFECTIOUS DISEASES LA English DT Review ID NORWALK-LIKE VIRUS; OYSTERS CRASSOSTREA-VIRGINICA; VIBRIO-VULNIFICUS INFECTION; GULF-COAST OYSTERS; AEROMONAS-HYDROPHILA INFECTION; POLYMERASE-CHAIN-REACTION; BOTULINUM TYPE-E; UNITED-STATES; LISTERIA-MONOCYTOGENES; SHELLFISH CONSUMPTION AB Foodbome diseases cause an estimated 76 million illnesses in the USA each year. Seafood is implicated in 10-19% of these illnesses. A causative agent can be traced in about 44% of seafood-related outbreaks, viruses accounting for around half of these illnesses. Although viruses are the most common cause of seafood-related infections, most hospitalisations and deaths are due to bacterial agents. A wide variety of viruses, bacteria, and parasites have been implicated in seafood-related outbreaks, which are reported worldwide. The factor most commonly associated with infection is consumption of raw or undercooked seafood. People with underlying disorders, particularly liver disease, are more susceptible to infection. The first part of this two-part review summarises the general incidence of seafood-related infections and discusses the common viral and bacterial causes of these infections. For each agent, the microbiology, epidemiology, mode of transmission, and treatment are discussed. In the May issue of the journal we will discuss parasites associated with seafood consumption, the safety of seafood, and the measures put in place in the USA to increase its safety. C1 Univ Pittsburgh, Div Infect Dis, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15213 USA. Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. Louisiana State Univ, Hlth Sci Ctr, Dept Med, Infect Dis Sect, New Orleans, LA USA. RP Butt, AA (reprint author), Univ Pittsburgh, Div Infect Dis, VA Pittsburgh Healthcare Syst, 3601 5th Ave,Suite 3A,Falk Bldg, Pittsburgh, PA 15213 USA. EM butta@msx.dept-med.pitt.edu NR 153 TC 100 Z9 102 U1 1 U2 11 PU LANCET LTD PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 1473-3099 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD APR PY 2004 VL 4 IS 4 BP 201 EP 212 DI 10.1016/S1473-3099(04)00969-7 PG 12 WC Infectious Diseases SC Infectious Diseases GA 809II UT WOS:000220630000021 PM 15050937 ER PT J AU Deininger, MWN McGreevey, L Willis, S Bainbridge, TM Druker, BJ Heinrich, MC AF Deininger, MWN McGreevey, L Willis, S Bainbridge, TM Druker, BJ Heinrich, MC TI Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography SO LEUKEMIA LA English DT Article DE BCR-ABL; mutation; imatinib; resistance; CML ID CHRONIC MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; GASTROINTESTINAL STROMAL TUMORS; BCR-ABL; IMATINIB MESYLATE; CHRONIC-PHASE; CYTOGENETIC RESPONSES; CLINICAL RESISTANCE; BLAST CRISIS; STI571 AB Mutations of the ABL kinase domain (KD) are common in patients with chronic myelogenous leukemia (CML) who develop resistance to imatinib. We developed an RT-PCR-based denaturing high-performance liquid chromatography (D-HPLC) assay to detect mutations of the ABL KD. Validation experiments using mixtures of wild type and mutant amplicons showed that the D-HPLC assay could detect mutant transcripts when they represented at least 15% of the total, and was thus twice as sensitive as automated sequencing. When D-HPLC was applied to 30 cDNAs from patients with imatinib resistance that had previously been characterized for KD mutations by direct sequencing of BCR-ABL RT-PCR products, there was concordance in 97% of samples. Resequencing confirmed the original mutations in all cases. In addition, sequencing of individual clones detected a mutation in one sample that had been mutation-positive by D-HPLC but wild type by conventional sequencing. In serial samples from the same individuals, D-HPLC detected mutations as early as 260 days before hematological relapse. D-HPLC is suitable for routine clinical monitoring of CML patients for emergence of KD mutations and may be useful for optimizing therapy. Early detection of emerging mutant clones may aid in guiding decisions regarding alternative treatment options. C1 Oregon Hlth & Sci Univ, BMT Leukemia Ctr, Inst Canc, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Portland VA Med Ctr, Inst Canc, Portland, OR USA. Howard Hughes Med Inst, Portland, OR USA. RP Deininger, MWN (reprint author), Oregon Hlth & Sci Univ, BMT Leukemia Ctr, Inst Canc, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA. EM deininge@ohsu.edu FU NCI NIH HHS [K24 CA82445, 1R01 CA65823] NR 27 TC 51 Z9 53 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0887-6924 J9 LEUKEMIA JI Leukemia PD APR PY 2004 VL 18 IS 4 BP 864 EP 871 DI 10.1038/sj.leu.2403307 PG 8 WC Oncology; Hematology SC Oncology; Hematology GA 811VS UT WOS:000220800000025 PM 14973502 ER PT J AU Glassman, PA Tanielian, T Harris, K Suarez, A Bradley, M Atkinson, SW Davies, W Williams, T AF Glassman, PA Tanielian, T Harris, K Suarez, A Bradley, M Atkinson, SW Davies, W Williams, T TI Provider perceptions of pharmacy management - Lessons from the military health system SO MEDICAL CARE LA English DT Article DE survey research; pharmacy benefits; physician attitudes; pharmaceutical care; formulary decision-making AB Objective: The objective of this study was to contrast experiences and opinion of providers in military treatment facilities, where a single formulary is used, with those of community providers where multiple formularies and preferred lists are commonly encountered. Study Design: We conducted cross-sectional surveys. Setting: The study was conducted at military and community practices that serve military beneficiaries. Participants: We studied randomly selected clinicians, stratified by military treatment facility (MTF) size or number of military beneficiaries served. The final samples included 566 eligible MTF and 557 private clinicians, with 69% and 38% response rates, respectively. Outcome Measures: We wanted to determine experiences with and opinions of formularies and/or preferred lists and related policies. Results: Sixty-three percent of military providers were very familiar with formulary content and 60% with nonformulary request procedures; 67% thought their formulary was up-to-date and 84% felt Pharmacy & Therapeutics (P&T) committees were responsive to providers. In contrast, 23% of community providers felt very familiar with (multiple) formulary content and 10% with nonformulary request procedures. Only 15% perceived that formularies were current and 34% thought P&T committees were responsive to providers. Statistically significant differences remained after analysis of potential bias. Conclusions: Community providers were less aware and less satisfied with pharmacy benefits management policies than military providers, likely as a result of their daily interactions with multiple, unrelated pharmacy management systems. Addressing the problems expressed by community providers is imperative for pharmacy benefits managers. C1 VA Greater Los Angeles Healthcare Syst, Div Gen Internal Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Los Angeles, CA 90024 USA. RAND Corp, Santa Monica, CA USA. RAND Corp, Arlington, VA USA. SAMHSA, Off Appl Studies, Rockville, MD USA. Brooke Army Med Ctr, Ft Sam Houston, TX 78234 USA. TRICARE Management Act, Pharm Program, Falls Church, VA USA. RP Glassman, PA (reprint author), VA Greater Los Angeles Healthcare Syst, Div Gen Internal Med, 111G,W Los Angeles Campus,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM Peter.Glassman@med.va.gov NR 14 TC 7 Z9 7 U1 2 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD APR PY 2004 VL 42 IS 4 BP 361 EP 366 DI 10.1097/01.mlr.0000118862.92043.9b PG 6 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 807BA UT WOS:000220475800009 PM 15076813 ER PT J AU Jasper, JD Nickerson, CAE Ubel, PA Asch, DA AF Jasper, JD Nickerson, CAE Ubel, PA Asch, DA TI Altruism incentives, and organ donation - Attitudes of the transplant community SO MEDICAL CARE LA English DT Article DE attitudes; decision-making; health policy; incentives; organ donation; survey research ID FINANCIAL INCENTIVES; PUBLIC-ATTITUDES; FUTURES MARKET; DONORS; POLICY; COMPENSATION; FAMILIES; PROPOSAL; CONSENT AB Objectives: This study investigated the attitudes of the transplant community toward the current policy of altruistic organ donation and 6 alternative policies offering incentives to the donor family. Methods: Two hundred forty-nine transplant surgeons, 143 transplant coordinators, and 134 critical-care nurses rated the moral appropriateness and success of the current policy of altruistic donation, rated the moral appropriateness of the alternative policies, judged whether donation would increase or decrease under each alternative policy, and decided whether each alternative policy,should be put into effect. Results: All 3 professions believed the current policy of altruistic organ donation to be morally appropriate and most of the alternative policies to be morally appropriate or morally neutral. All 3 professions believed the current policy to be at best only moderately successful and judged most or all of the alternative policies to be likely to increase donation. All 3 professions favored implementing a policy offering donor recognition; approximately one half of the surgeons and one half of the coordinators also advocated implementing a policy offering $1500 toward funeral expenses. In all 3 professions, respondents' decisions to implement the alternative policies were more frequently related to those policies' moral appropriateness than to their likelihood of increasing organ donation. Conclusions: Specific incentives varied in their acceptability to the transplant community Attitudes of the transplant community toward incentives were not in accord with published criticisms of incentives. C1 Univ Toledo, Dept Psychol, Toledo, OH 43606 USA. Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. Univ Penn, Sch Med, Ctr Bioeth, Philadelphia, PA 19104 USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. Univ Penn, Wharton Sch, Dept Operat & Informat Management, Philadelphia, PA 19104 USA. RP Jasper, JD (reprint author), Univ Toledo, Dept Psychol, 2801 W Bancroft St, Toledo, OH 43606 USA. EM jjasper@utnet.utoledo.edu OI Asch, David/0000-0002-7970-286X NR 47 TC 19 Z9 20 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD APR PY 2004 VL 42 IS 4 BP 378 EP 386 DI 10.1097/01.mlr.0000118863.47574.0f PG 9 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 807BA UT WOS:000220475800011 PM 15076815 ER PT J AU Rumbaut, RE Randhawa, JK Smith, CW Burns, AR AF Rumbaut, RE Randhawa, JK Smith, CW Burns, AR TI Mouse cremaster venules are predisposed to light/dye-induced thrombosis independent of wall shear rate, CD18, ICAM-1, or P-selectin SO MICROCIRCULATION LA English DT Article DE arterioles; microcirculation; phototoxicity; platelets ID HAMSTER-CHEEK POUCH; IN-VIVO; PLATELET-AGGREGATION; NITRIC-OXIDE; VESSELS; MUSCLE; MICE AB Objective: Microvascular adhesion of platelets to endothelium occurs in response to various inflammatory stimuli, and in venules is often accompanied by adherent leukocytes. In a light/dye injury model, platelet adhesion and thrombi occur preferentially in venules, though the reasons for this predisposition are unknown. The authors sought to determine whether lower wall shear rates or leukocyte endothelial interactions accounted for preferential platelet thrombi formation in venules relative to arterioles. Methods: A light/dye injury model of microvascular thrombosis was used in the mouse cremaster microcirculation. Results: In wild-type mice (n = 17), the time to form microvascular platelet aggregates was delayed in arterioles by 3.1-fold relative to venules (p < .0001). However, arterioles with spontaneously low wall shear rates, as well as arterioles manipulated to reduce wall shear rate to venous levels, still had delayed thrombosis as compared to venules. Similarly, in animals deficient in CD18, P-selectin, or ICAM-1, the time to form platelet thrombi in arterioles was >3.0-fold higher than in venules. Conclusions: Mouse cremaster venules are predisposed to light/dye-induced microvascular thrombosis. The data suggest that functional differences between arteriolar and venular endothelial cells ( independent of wall shear rate and of CD18, P-selectin, and ICAM-1) account for the venular predisposition to thrombosis. C1 Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA. Houston VA Med Ctr, Med Care Line, Houston, TX USA. RP Rumbaut, RE (reprint author), Baylor Coll Med, CNRC Room 6005,1100 Bates St, Houston, TX 77030 USA. EM rrumbaut@bcm.tmc.edu FU NHLBI NIH HHS [R01 HL064721, HL-42550, HL-64721]; NIAID NIH HHS [AI-46773] NR 20 TC 28 Z9 28 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1073-9688 J9 MICROCIRCULATION JI Microcirculation PD APR-MAY PY 2004 VL 11 IS 3 BP 239 EP 247 DI 10.1080/10739680490425949 PG 9 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 829XR UT WOS:000222085500003 PM 15280078 ER PT J AU Heidenreich, KA Linseman, DA AF Heidenreich, KA Linseman, DA TI Myocyte enhancer factor-2 transcription factors in neuronal differentiation and survival SO MOLECULAR NEUROBIOLOGY LA English DT Article DE neuron; apoptosis; brain; MADS-box; protein kinases; calcium signaling; muscle; development ID ACTIVATED PROTEIN-KINASE; CEREBELLAR GRANULE NEURONS; II HISTONE DEACETYLASES; CENTRAL-NERVOUS-SYSTEM; DNA-BINDING ACTIVITY; MADS-BOX GENE; FACTOR MEF2C; CARDIAC-HYPERTROPHY; FACTOR 2C; MUSCLE DEVELOPMENT AB Myocyte enhancer factor-2 (MEF2) transcription factors regulate genes that control critical cellular processes including proliferation, differentiation, and survival. Although MEF2 proteins were first identified as transcription factors that bound A/T rich DNA sequences and controlled muscle-specific genes during myogenic development, it is now apparent that MEF2 transcription factors are also highly expressed in neurons and are critical determinants of neuronal differentiation and fate. Here we focus our discussion on the role of MEF2 proteins in nervous tissue and the regulation of these transcription factors by calcium and phosphorylation signaling pathways. C1 Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA. Denver Vet Affairs Med Ctr, Denver, CO 80262 USA. RP Heidenreich, KA (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA. EM Kim.Heidenreich@UCHSC.edu FU NINDS NIH HHS [NS38619-01A1] NR 64 TC 56 Z9 58 U1 0 U2 4 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 0893-7648 J9 MOL NEUROBIOL JI Mol. Neurobiol. PD APR PY 2004 VL 29 IS 2 BP 155 EP 165 DI 10.1385/MN:29:2:155 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 822KB UT WOS:000221537000005 PM 15126683 ER PT J AU Raskind, M AF Raskind, M TI Cognition in AD: Long-term treatment benefits SO NEUROBIOLOGY OF AGING LA English DT Meeting Abstract CT 8th International Montreal-Springfield Symposium on Advances in Alzheimer Therapy CY APR 14-17, 2004 CL Montreal, CANADA C1 VA Puget Sound Healthcare Syst, Seattle, WA USA. EM murray.raskind@med.va.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD APR PY 2004 VL 25 SU 1 MA 77 BP S22 EP S22 PG 1 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 808SW UT WOS:000220589800078 ER PT J AU Tache, Y Perdue, MH AF Tache, Y Perdue, MH TI Role of peripheral CRF signalling pathways in stress-related alterations of gut motility and mucosal function SO NEUROGASTROENTEROLOGY AND MOTILITY LA English DT Article DE astressin; chronic stress; colonic motility; corticotrophin-releasing factor (CRF); CRF receptors; enteric nervous system; gastric motility; intestinal permeability; urocortin ID CORTICOTROPIN-RELEASING-FACTOR; IRRITABLE-BOWEL-SYNDROME; GASTROINTESTINAL-TRACT; RECEPTOR SUBTYPE-1; CONSCIOUS RATS; MOTOR-ACTIVITY; UROCORTIN; HORMONE; EXPRESSION; ANTAGONIST AB Central corticotrophin releasing-factor (CRF) signalling pathways are involved in the endocrine, behavioural and visceral responses to stress. Recent studies indicate that peripheral CRF-related mechanisms also contribute to stress-induced changes in gut motility and intestinal mucosal function. Peripheral injection of CRF or urocortin inhibits gastric emptying and motility through interaction with CRF2 receptors and stimulates colonic transit, motility, Fos expression in myenteric neurones and defecation through activation of CRF1 receptors. With regard to intestinal epithelial cell function, intraperitoneal CRF increases ion secretion and mucosal permeability to macromolecules. The motility and mucosal changes induced by peripheral CRF mimic those induced by acute stress. In addition, CRF receptor antagonists given peripherally prevent acute restraint and water avoidance stress-induced delayed gastric emptying, stimulation of colonic motor function and mucosal permeability. Similarly, early trauma enhanced intestinal mucosal dysfunction to an acute stressor in adult rats and the response is prevented by peripheral injection of CRF antagonist. Chronic psychological stress results in reduced host defence and initiates intestinal inflammation through mast cell-dependent mechanisms. These findings provide convergent evidence that activation of peripheral CRF receptors and mast cells are important mechanisms involved in stress-related alterations of gut physiology. C1 McMaster Univ, Intestinal Dis Res Program, Dept Pathol & Mol Med, Hamilton, ON L6J 3X6, Canada. Univ Calif Los Angeles, CURE Digest Dis Res Ctr, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Ctr Neurovisceral Sci & Womens Hlth, W Los Angeles Vet Affairs Med Ctr, Dept Med,Div Digest Dis, Los Angeles, CA 90024 USA. RP Perdue, MH (reprint author), McMaster Univ, Intestinal Dis Res Program, Dept Pathol & Mol Med, HSC-3 N5C,1200 Main St W, Hamilton, ON L6J 3X6, Canada. EM perdue@mcmaster.ca NR 44 TC 142 Z9 146 U1 0 U2 11 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 1350-1925 J9 NEUROGASTROENT MOTIL JI Neurogastroenterol. Motil. PD APR PY 2004 VL 16 SU 1 BP 137 EP 142 DI 10.1111/j.1743-3150.2004.00490.x PG 6 WC Gastroenterology & Hepatology; Clinical Neurology; Neurosciences SC Gastroenterology & Hepatology; Neurosciences & Neurology GA 810PA UT WOS:000220715000026 PM 15066020 ER PT J AU Cornia, PB Lipsky, BA Dhaliwal, G Saint, S AF Cornia, PB Lipsky, BA Dhaliwal, G Saint, S TI Red snapper or crab? SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID PHYSICAL-EXAMINATION; HISTORY; MESOTHELIOMA C1 Vet Affairs Puget Sound Hlth Care Syst, Primary & Specialty Med Care Serv, Seattle, WA 98108 USA. Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. Univ Calif San Francisco, Sch Med, San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA 94143 USA. Ann Arbor Vet Affairs Med Ctr, Ann Arbor, MI USA. Univ Michigan Hlth Syst, Dept Internal Med, Ann Arbor, MI USA. Univ Michigan Hlth Syst, Patient Safety Enhancement Program, Ann Arbor, MI USA. RP Cornia, PB (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Primary & Specialty Med Care Serv, 1660 S Columbian Way,S-111-GIMC, Seattle, WA 98108 USA. EM paul.cornia@med.va.gov OI Lipsky, Benjamin A./0000-0001-9886-5114 FU AHRQ HHS [P20-HS11540] NR 12 TC 2 Z9 2 U1 0 U2 0 PU MASSACHUSETTS MEDICAL SOC/NEJM PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD APR 1 PY 2004 VL 350 IS 14 BP 1443 EP 1448 DI 10.1056/NEJMcps032443 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 808IJ UT WOS:000220562500012 PM 15070795 ER PT J AU Russell, TV Crawford, MA Woodby, LL AF Russell, TV Crawford, MA Woodby, LL TI Measurements for active cigarette smoke exposure in prevalence and cessation studies: Why simply asking pregnant women isn't enough SO NICOTINE & TOBACCO RESEARCH LA English DT Review ID RANDOMIZED CONTROLLED TRIAL; LOW-BIRTH-WEIGHT; SELF-REPORTS; ANTISMOKING INTERVENTIONS; MATERNAL SMOKING; HEALTH-EDUCATION; CARE; PROGRAM; COTININE; THIOCYANATE AB Tobacco smoke exposure during and after pregnancy may cause maternal, fetal, and infant morbidity and mortality. The purpose of this review is to (a) describe existing methods of measuring active tobacco exposure among pregnant women and (b) illustrate the usefulness of these measures in validating self-reported smoking status among these women. Medline, PsycINFO, and Academic Search Elite were used to identify measures of cigarette smoking exposure, prevalence reports, cessation and validity studies, and research on deception about smoking during pregnancy. Review of the research on smoking cessation among pregnant women since 1966 revealed that 36% of studies (9 out of 25) located used only self-report to assess smoking status. The remaining 16 studies used either significant other reports or at least one type of biochemical test to confirm self-report. Deception rates were reported at baseline only, follow-up only, or both in 15 studies. Three federal agencies in the United States collect data on self-reported smoking during pregnancy. Smoking prevalence rates are inconsistent among these agencies. This article demonstrates that measuring smoking status during pregnancy via self-report alone leads to discrepancies in national prevalence rates, deceptions in clinical practice disclosure, and inconsistencies in research study results. Evaluation studies that confirm smoking status among pregnant women by biochemical methods provide more accurate prevalence rates and lead to the most effective behavioral interventions to achieve cessation. National statistics should carry a disclaimer indicating the likelihood of underestimation. Researchers and clinicians should be trained in best-practice, evidence-based behavioral methods to assess prenatal smoking status and to assist those who desire to quit. C1 Univ Alabama, Sch Med, Dept Family & Community Med, Div Res, Birmingham, AL 35294 USA. Birmingham VA Med Ctr, GRECC, Birmingham, AL 35294 USA. RP Russell, TV (reprint author), Univ Alabama, Sch Med, Dept Family & Community Med, Div Res, 930 20th St S,CH 371, Birmingham, AL 35294 USA. EM trussell@fms.uab.edu NR 76 TC 73 Z9 75 U1 1 U2 3 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1462-2203 J9 NICOTINE TOB RES JI Nicotine Tob. Res. PD APR PY 2004 VL 6 SU 2 BP S141 EP S151 DI 10.1080/14622200410001669141 PG 11 WC Substance Abuse; Public, Environmental & Occupational Health SC Substance Abuse; Public, Environmental & Occupational Health GA 823UY UT WOS:000221640100005 PM 15203817 ER PT J AU Pekary, AE Sattin, A Meyerhoff, JL Chilingar, M AF Pekary, AE Sattin, A Meyerhoff, JL Chilingar, M TI Valproate modulates TRH receptor, TRH and TRH-like peptide levels in rat brain SO PEPTIDES LA English DT Article DE valproate; TRH-like peptides; TRH receptors; depression; cortex; limbic system ID THYROTROPIN-RELEASING-HORMONE; PITUITARY RECEPTORS; MOOD STABILIZERS; DISORDERS; GLUTAMATE; LITHIUM; ACID; PROTECTION; EXPRESSION; DEPRESSION AB We have tested our hypothesis that alterations in the levels of TRH receptors, and the synthesis and release of tripeptide TRH, and other neurotropic TRH-like peptides mediate some of the mood stabilizing effects of valproate (Valp). We have directly compared the effect of 1 week of feeding two major mood stabilizers, Valp and lithium chloride (LiCl) on TRH binding in limbic and extra-limbic regions of male WKY rats. Valp increased TRH receptor levels in nucleus accumbens and frontal cortex. Li increased TRH receptor binding in amygdala, posterior cortex and cerebellum. The acute, chronic and withdrawal effects of Valp on brain levels of TRH (pGlu-His-Pro-NH2, His-TRH) and five other TRH-like peptides, Glu-TRH, Val-TRH, Tyr-TRH, Leu-TRH and Phe-TRH were measured by combined HPLC and RIA. Acute treatment increased TRH and TRH-like peptide levels within most brain regions, most strikingly in pyriform cortex. The fold increases (in parentheses) were: Val-TRH (58), Phe-TRH (54), Tyr-TRH (25), TRH (9), Glu-TRH (4) and Leu-TRH (3). We conclude that the mood stabilizing effects of Valp may be due, at least in part, to its ability to alter TRH and TRH-like peptide, and TRH receptor levels in the limbic system and other brain regions implicated in mood regulation and behavior. (C) 2004 Elsevier Inc. All rights reserved. C1 W Los Angeles Vet Affairs Med Ctr, Res Serv, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. VA Greater Los Angeles Hlth Care Syst, Psychiat Serv, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Inst Neuropsychiat, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Inst Brain Res, Los Angeles, CA USA. Walter Reed Army Inst Res, Div Neurosci, Dept Neurochem, Washington, DC 20307 USA. RP Pekary, AE (reprint author), W Los Angeles Vet Affairs Med Ctr, Res Serv, 11301 Wilshire Blvd,Bldg 114,Rm 229, Los Angeles, CA 90073 USA. EM epekary@ucla.edu NR 48 TC 23 Z9 23 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-9781 J9 PEPTIDES JI Peptides PD APR PY 2004 VL 25 IS 4 BP 647 EP 658 DI 10.1016/j.peptides.2004.01.016 PG 12 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA 829IA UT WOS:000222039800015 PM 15165721 ER PT J AU Morton, GJ Mystkowski, P Matsumoto, AM Schwartz, MW AF Morton, GJ Mystkowski, P Matsumoto, AM Schwartz, MW TI Increased hypothalamic melanin concentrating hormone gene expression during energy restriction involves a melanocortin-independent, estrogen-sensitive mechanism SO PEPTIDES LA English DT Article DE melanin-concentrating hormone; agouti; melanocortins; estrogen; hypothalamus ID MESSENGER-RIBONUCLEIC-ACID; ARCUATE NUCLEUS; NEUROPEPTIDE-Y; WEIGHT-LOSS; OBESITY; NEURONS; MICE; RNA; SYSTEM; MOUSE AB Increased expression of melanin concentrating hormone (MCH), an orexigenic neuropeptide produced by neurons in the lateral hypothalamic area (LHA), is implicated in the effect of energy restriction to increase food intake. Since melanocortins inhibit Mch gene expression, this effect of energy restriction to increase Mch signaling may involve reduced hypothalamic melanocortin signaling. Consistent with this hypothesis, we detected increased hypothalamic Mch mRNA levels in agouti (A(y)) mice (by 102%; P < 0.05), a model of genetic obesity resulting from impaired melanocortin signaling, compared to wild-type controls. If reduced melanocortin signaling mediates the effect of energy restriction, hypothalamic Mch gene expression in AY mice should not be increased further by energy restriction, since melanocortin signaling is impaired in these animals regardless of nutritional state. We therefore investigated the effects of energy restriction on hypothalamic Mch gene expression in both A(y) mice and in wild-type mice with diet-induced obesity (DIO). Responses in these mice were compared to those induced by administration of 17beta-estradiol (E2) at a dose previously shown to reduce food intake and Mch expression in rats. In both A(y) and DIO mice, energy restriction increased hypothalamic Mch mRNA levels (P < 0.05 for each) via a mechanism that was fully blocked by E2. However, E2 did not lower levels of Mch mRNA below basal values in A(y) mice, whereas it did so in DIO mice. Thus, the effect of energy restriction to increase hypothalamic Mch gene expression involves an E2-sensitive mechanism that is not altered by impaired melanocortin signaling. By comparison, impaired melanocortin signaling increases hypothalamic Mch gene expression via a mechanism that is insensitive to E2. These findings suggest that while both energy restriction and reduced melanocortin signaling stimulate hypothalamic Mch gene expression, they do so via distinct mechanisms. (C) 2004 Elsevier Inc. All rights reserved. C1 Univ Washington, Harborview Med Ctr, Dept Med, Seattle, WA 98104 USA. VA Puget Sound Hlth Care Syst, Geriatr Res, Educ & Clin Ctr, Seattle, WA 98108 USA. RP Schwartz, MW (reprint author), Univ Washington, Harborview Med Ctr, Dept Med, 325 9th Ave,Box 359757, Seattle, WA 98104 USA. EM mschwart@u.washington.edu RI Schwartz, Michael/H-9950-2012 FU NIDDK NIH HHS [DK52989, DK12829]; NINDS NIH HHS [NS32273] NR 21 TC 28 Z9 28 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-9781 J9 PEPTIDES JI Peptides PD APR PY 2004 VL 25 IS 4 BP 667 EP 674 DI 10.1016/j.peptides.2004.02.007 PG 8 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA 829IA UT WOS:000222039800017 PM 15165723 ER PT J AU Busti, AJ Murillo, JR Cryer, B AF Busti, AJ Murillo, JR Cryer, B TI Tegaserod-induced myocardial infarction: Case report and hypothesis SO PHARMACOTHERAPY LA English DT Article DE tegaserod; myocardial infarction; 5-HT; receptor agonist; migraine; triptans; cardiovascular adverse events; cardiovascular risk factors ID IRRITABLE-BOWEL-SYNDROME; SEROTONIN 5-HT4 RECEPTOR; CORONARY-ARTERIES; PARTIAL AGONIST; DOUBLE-BLIND; IN-VITRO; SUMATRIPTAN; 5-HYDROXYTRYPTAMINE; CONSTIPATION; TOLERABILITY AB Serotonin (5-hydroxytryptamine [5-HT])(1) receptor agonists, such as those used for treating migraine, can cause coronary artery contraction, coronary spasm, and even myocardial infarction. Tegaserod maleate is a relatively new 5-HT4 receptor agonist with moderate affinity for the 5-HT1 receptor. Currently, it is approved only for treatment of irritable bowel syndrome in women who have constipation as the primary symptom. However, it is also being administered as a promotility agent in patients with gastroparesis. Since tegaserod has affinity for the 5-HT1 receptor, it is plausible that tegaserod could cause the same types of cardiovascular adverse events seen with agents prescribed for management of migraine. We report the first case of a man who experienced a myocardial infarction after receiving only two 6-mg doses of tegaserod; we also provide a hypothesis regarding this event. When considering prescribing a drug with 5-HT1 receptor agonist activity, clinicians should review the patient's medical history specifically for the presence of underlying cardiovascular risk factors. C1 Texas Tech Univ, Hlth Sci Ctr, Dept Pharm Practice, Sch Pharm, Dallas, TX 75216 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX 78285 USA. Dallas Vet Affairs Med Ctr, Dallas, TX USA. Univ Texas, SW Med Ctr, Dept Med, Dallas, TX USA. RP Busti, AJ (reprint author), Texas Tech Univ, Hlth Sci Ctr, Dept Pharm Practice, Sch Pharm, Dallas Ft Worth Reg Campus,4500 S Lancaster Rd, Dallas, TX 75216 USA. EM anthony.busti@ttuhsc.edu NR 40 TC 40 Z9 40 U1 0 U2 1 PU PHARMACOTHERAPY PUBLICATIONS INC PI BOSTON PA NEW ENGLAND MEDICAL CENTER, 806, 750 WASHINGTON ST, BOSTON, MA 02111 USA SN 0277-0008 J9 PHARMACOTHERAPY JI Pharmacotherapy PD APR PY 2004 VL 24 IS 4 BP 526 EP 531 DI 10.1592/phco.24.5.526.33351 PG 6 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 809GG UT WOS:000220624600015 PM 15098809 ER PT J AU Weintraub, D AF Weintraub, D TI Diagnosing and treating depression in patients with Parkinson's disease SO PSYCHIATRIC ANNALS LA English DT Article ID QUALITY-OF-LIFE; MAJOR DEPRESSION; CONTROLLED TRIAL; RISK-FACTORS; FREQUENCY; SYMPTOMS; STIMULATION; PREVALENCE; DISORDERS; VALIDITY C1 Univ Penn, Parkinsons Dis Ctr, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Ctr, Philadelphia, PA USA. RP Weintraub, D (reprint author), 3535 Market St,Room 3003, Philadelphia, PA 19104 USA. NR 41 TC 7 Z9 8 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0048-5713 J9 PSYCHIAT ANN JI Psychiatr. Ann. PD APR PY 2004 VL 34 IS 4 BP 299 EP 304 PG 6 WC Psychiatry SC Psychiatry GA 811HN UT WOS:000220763100008 ER PT J AU Davalos, DB Compagnon, N Heinlein, S Ross, RG AF Davalos, DB Compagnon, N Heinlein, S Ross, RG TI Neuropsychological deficits in children associated with increased familial risk for schizophrenia SO SCHIZOPHRENIA RESEARCH LA English DT Article DE schizophrenia; genetic predisposition; neuropsychology; cognition; school-age children ID CHILDHOOD-ONSET SCHIZOPHRENIA; SHORT-TERM-MEMORY; WORKING-MEMORY; INDIVIDUAL-DIFFERENCES; EYE TRACKING; PSYCHIATRIC-DISORDERS; EMOTION RECOGNITION; PSYCHOTIC SYMPTOMS; INHIBITORY CONTROL; RELATIVES AB By studying neuropsychological performance in children genetically at-risk for schizophrenia, greater understanding may be obtained regarding the developmental processes of schizophrenia and associated cognitive weaknesses. A variety of cognitive deficits in genetically at-risk children have been reported. The present study was designed to examine cognitive tasks that have traditionally differentiated children genetically at-risk for schizophrenia (e.g. working memory) from normal children, while also assessing abilities that have received scant attention in this population. Aspects of emotional perception, verbal abilities, inhibition, visuo-spatial skills, and working memory were assessed in children of schizophrenic parents and normal children. Significant differences in performances were identified in at-risk children on measures of verbal skills, working memory and inhibition. Findings suggest that children genetically at-risk for developing schizophrenia exhibit neurocognitive weaknesses generally consistent with those noted in the literature. However, inhibition also appeared to be a cognitive process that significantly differentiated the groups. The possibility of a developmental expression of neurocognitive deficits is discussed. (C) 2003 Elsevier B.V. All rights reserved. C1 Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Denver, CO 80262 USA. Denver VA Med Ctr, Denver, CO 80220 USA. RP Davalos, DB (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Psychiat, 4200 E 9th Ave,Campus Box C268-71, Denver, CO 80262 USA. EM deana.davalos@uchsc.edu FU NIMH NIH HHS [MH15442, MH56539] NR 67 TC 29 Z9 29 U1 1 U2 8 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD APR 1 PY 2004 VL 67 IS 2-3 BP 123 EP 130 DI 10.1016/S0920-9964(03)00187-7 PG 8 WC Psychiatry SC Psychiatry GA 800CW UT WOS:000220007500002 PM 14984871 ER PT J AU Liu, HH Harker, JO Wong, AL MacLean, CH Bulpitt, KJ Mittman, BS FitzGerald, J Grossman, J Rubenstein, LZ Hahn, B Paulus, HE Kahn, KL AF Liu, HH Harker, JO Wong, AL MacLean, CH Bulpitt, KJ Mittman, BS FitzGerald, J Grossman, J Rubenstein, LZ Hahn, B Paulus, HE Kahn, KL TI Case finding for population-based studies of rheumatoid arthritis: Comparison of patient self-reported ACR criteria-based algorithms to physician-implicit review for diagnosis of rheumatoid arthritis SO SEMINARS IN ARTHRITIS AND RHEUMATISM LA English DT Review DE rheumatoid arthritis; agreement; reliability; algorithm ID PREDICTION AB Objective: To evaluate the interrater reliability of rheumatologist diagnosis of rheumatoid arthritis (RA) and the concordance between rheumatologist and computer algorithms for assessing the accuracy of a diagnosis of RA. Methods: Self-reported data regarding symptoms and signs for a diagnosis of RA were considered by a panel of rheumatologists and by computer algorithms to assess the probability of a diagnosis of RA for 90 patients. The rheumatologists' review was validated through medical record. Results: The interrater reliability among rheumatologists regarding a diagnosis of RA was 84%; the chance-corrected agreement (kappa) was 0.66. Agreement between the rheumatologists' rating and the best-performing algorithm was 95%. Using rheumatologist's review as a standard, the sensitivity of the algorithm was 100%, specificity was 88%, and the positive predictive value was 91%. The validation of rheumatologist's review by medical record showed 81% sensitivity, 60% specificity, and 78% positive predictive value. Conclusion: Reliability of rheumatologists' assignment of a diagnosis of RA by using self-report data is good. Algorithms defining symptoms as either joint swelling or tenderness with symptom duration greater than or equal to4 weeks have a better agreement with rheumatologist's diagnosis than do ones relying on a longer symptom duration. Relevance: These findings have important implications for health services research and quality improvement interventions pertinent to case finding for RA through self-report data. C1 Univ Calif Los Angeles, Dept Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Dept Med, Div Rheumatol, Los Angeles, CA 90095 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Olive View UCLA Med Ctr, Sylmar, CA 91342 USA. RAND Corp, Santa Monica, CA USA. RP Liu, HH (reprint author), Univ Calif Los Angeles, Dept Med, Div Gen Internal Med & Hlth Serv Res, 911 Broxton Plaza,Room 202,Box 951736, Los Angeles, CA 90095 USA. EM hhliu@ucla.edu FU NIAMS NIH HHS [P60 AR36834] NR 15 TC 8 Z9 8 U1 1 U2 1 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0049-0172 J9 SEMIN ARTHRITIS RHEU JI Semin. Arthritis Rheum. PD APR PY 2004 VL 33 IS 5 BP 302 EP 310 DI 10.1053/S0049-0172(03)00166-5 PG 9 WC Rheumatology SC Rheumatology GA 813UU UT WOS:000220932800003 PM 15079761 ER PT J AU Weeratunge, CN Bolivar, HH Anstead, GM Lu, DH AF Weeratunge, CN Bolivar, HH Anstead, GM Lu, DH TI Primary esophageal lymphoma: A diagnostic challenge in acquired immunodeficiency syndrome - Two case reports and review SO SOUTHERN MEDICAL JOURNAL LA English DT Review DE acquired immunodeficiency syndrome; esophagus; lymphoma ID ACTIVE ANTIRETROVIRAL THERAPY; NON-HODGKINS-LYMPHOMA; AIDS; PATIENT; PROGNOSIS AB Although extranodal presentation occurs in the majority of cases of acquired immunodeficiency syndrome-associated non-Hodgkin lymphoma, the esophagus is only rarely affected. We discuss two patients with acquired immunodeficiency syndrome who presented with dysphagia and weight loss, who were found to have human immunodeficiency virus-associated primary esophageal lymphoma. Both patients died within a few weeks of diagnosis, reflecting the poor prognosis associated with this malignancy. Primary esophageal lymphoma should be considered in the differential diagnosis in a human immunodeficiency virus-seropositive patient presenting with dysphagia. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Div Infect Dis, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Pathol, Div Infect Dis, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Weeratunge, CN (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Infect Dis, Mail Code 7881,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM cnamalw@hotmail.com NR 21 TC 12 Z9 13 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0038-4348 J9 SOUTH MED J JI South.Med.J. PD APR PY 2004 VL 97 IS 4 BP 383 EP 387 DI 10.1097/01.SMJ.0000100120.49153.3F PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 831DC UT WOS:000222172200015 PM 15108833 ER PT J AU Erkinjuntti, T Roman, G Gauthier, S Feldman, H Rockwood, K AF Erkinjuntti, T Roman, G Gauthier, S Feldman, H Rockwood, K TI Emerging therapies for vascular dementia and vascular cognitive impairment SO STROKE LA English DT Article DE carbamates; cognitive disorders; dementia; galantamine; memantine; nimodipine; piperidines; vascular diseases; donepezil; rivastigmine ID SCANDINAVIAN MULTIINFARCT DEMENTIA; PLACEBO-CONTROLLED TRIAL; LIPID-LOWERING AGENTS; ACUTE ISCHEMIC-STROKE; ALZHEIMERS-DISEASE; CLINICAL-TRIALS; CEREBROVASCULAR-DISEASE; MIXED DEMENTIA; DOUBLE-BLIND; RISK-FACTORS AB Background-Cerebrovascular disease (CVD) and ischemic brain injury secondary to cardiovascular disease are common causes of dementia and cognitive decline in the elderly. CVD also contributes to cognitive loss in Alzheimer disease (AD). Summary-Progress in understanding vascular cognitive impairment (VCI) and vascular dementia (VaD) has resulted in promising symptomatic and preventive treatments. Cholinergic deficits in VaD due to ischemia of basal forebrain nuclei and cholinergic pathways can be treated with cholinesterase inhibitors used in AD. Controlled clinical trials with donepezil and galantamine in patients with VaD, as well as in patients with AD plus CVD, have demonstrated improvement in cognition, behavior, and activities of daily living. The N-methyl-D-aspartate receptor antagonist memantine stabilized progression of VaD compared with placebo. Primary and secondary stroke prevention, in particular with control of hypertension and hyperlipidemia, can decrease VaD incidence. Conclusions-From a public health viewpoint, recognition of VCI before the development of dementia and correction of vascular burden on the brain may lead to a global decrease of incident dementia. C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX 78229 USA. Univ Helsinki, Cent Hosp, Helsinki, Finland. A Murphy Vet Adm Hosp, San Antonio, TX USA. McGill Ctr Studies Aging, Alzheimers Dis Res Unit, Montreal, PQ, Canada. Univ British Columbia, Div Neurol, Vancouver, BC V5Z 1M9, Canada. Dalhousie Univ, Queen Elizabeth II Hlth Sci Ctr, Geriatr Med Res Unit, Halifax, NS, Canada. RP Roman, G (reprint author), Univ Texas, Hlth Sci Ctr, Mail Code 7883,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM romang@uthscsa.edu OI Feldman, Howard/0000-0002-9258-4538 NR 87 TC 109 Z9 133 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD APR PY 2004 VL 35 IS 4 BP 1010 EP 1017 DI 10.1161/01.STR.0000120731.88236.33 PG 8 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 806RG UT WOS:000220450400038 PM 15001795 ER PT J AU Wierman, ME Pawlowski, JE Allen, MP Xu, M Linseman, DA Nielsen-Preiss, S AF Wierman, ME Pawlowski, JE Allen, MP Xu, M Linseman, DA Nielsen-Preiss, S TI Molecular mechanisms of gonadotropin-releasing hormone neuronal migration SO TRENDS IN ENDOCRINOLOGY AND METABOLISM LA English DT Review ID RECEPTOR TYROSINE KINASE; SIGNAL-REGULATED KINASE; NEURAL CELL-ADHESION; IDIOPATHIC HYPOGONADOTROPIC HYPOGONADISM; LINKED KALLMANN-SYNDROME; PROTEIN-KINASE; HYPOTHALAMIC NEURONS; GENE-EXPRESSION; LHRH NEURONS; FACILITATES MIGRATION AB Gonadotropin-releasing hormone (GnRH) neurons originate in the nasal compartment, migrate along olfactory nerves to the cribriform plate and then diverge caudally to the forebrain to reach their final destination in the hypothalamus. Here, GnRH neurons are dispersed in a network that synchronously releases GnRH in a pulsatile manner to activate pituitary gonadotropin production. Gonadotropins in turn promote gametogenesis and steroidogenesis from the gonad, ensuring reproductive competence. Failure of GnRH neurons to migrate normally results in deficient activation of the reproductive axis and delayed or absent pubertal maturation. The exact mechanisms that direct GnRH neuronal migration are under active investigation. This article will review new information concerning factors regulating GnRH neuronal migration and the intracellular signaling pathways involved in this process. C1 Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Physiol & Biophys, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA. Denver VA Med Ctr, Res Serv, Denver, CO 80220 USA. RP Wierman, ME (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Med, B151 Endocrinol,4200 E 9th, Denver, CO 80262 USA. EM Margaret.Wierman@uchsc.edu NR 72 TC 45 Z9 47 U1 0 U2 1 PU ELSEVIER SCIENCE LONDON PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 1043-2760 J9 TRENDS ENDOCRIN MET JI Trends Endocrinol. Metab. PD APR PY 2004 VL 15 IS 3 BP 96 EP 102 DI 10.1016/j.tem.2004.02.003 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 813GR UT WOS:000220896100002 PM 15046737 ER PT J AU Pajvani, UB Hawkins, M Combs, TP Rajala, MW Doebber, T Berger, JP Wagner, JA Wu, M Knopps, A Xiang, AH Utzschneider, KM Kahn, SE Olefsky, JM Buchanan, TA Scherer, PE AF Pajvani, UB Hawkins, M Combs, TP Rajala, MW Doebber, T Berger, JP Wagner, JA Wu, M Knopps, A Xiang, AH Utzschneider, KM Kahn, SE Olefsky, JM Buchanan, TA Scherer, PE TI Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID PPAR-GAMMA; GLUCOSE-PRODUCTION; DIABETES-MELLITUS; PROTEIN ACRP30; RESISTANCE; AGONISTS; OBESITY; TROGLITAZONE; ASSOCIATION; INDUCTION AB Adiponectin is an adipocyte-specific secretory protein that circulates in serum as a hexamer of relatively low molecular weight (LMW) and a larger multimeric structure of high molecular weight (HMW). Serum levels of the protein correlate with systemic insulin sensitivity. The full-length protein affects hepatic gluconeogenesis through improved insulin sensitivity, and a proteolytic fragment of adiponectin stimulates beta oxidation in muscle. Here, we show that the ratio, and not the absolute amounts, between these two oligomeric forms ( HMW to LMW) is critical in determining insulin sensitivity. We define a new index, SA, that can be calculated as the ratio of HMW/(HMW + LMW). db/db mice, despite similar total adiponectin levels, display decreased SA values compared with wild type littermates, as do type II diabetic patients compared with insulin-sensitive individuals. Furthermore, SA improves with peroxisome proliferator-activated receptor-gamma agonist treatment ( thiazolidinedione; TZD) in mice and humans. We demonstrate that changes in SA in a number of type 2 diabetic cohorts serve as a quantitative indicator of improvements in insulin sensitivity obtained during TZD treatment, whereas changes in total serum adiponectin levels do not correlate well at the individual level. Acute alterations in S-A (DeltaS(A)) are strongly correlated with improvements in hepatic insulin sensitivity and are less relevant as an indicator of improved muscle insulin sensitivity in response to TZD treatment, further underscoring the conclusions from previous clamp studies that suggested that the liver is the primary site of action for the full-length protein. These observations suggest that the HMW adiponectin complex is the active form of this protein, which we directly demonstrate in vivo by its ability to depress serum glucose levels in a dose-dependent manner. C1 Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA. Yeshiva Univ Albert Einstein Coll Med, Ctr Diabet Res & Training, Bronx, NY 10461 USA. Yeshiva Univ Albert Einstein Coll Med, Dept Med, Div Endocrinol, Bronx, NY 10461 USA. Merck Res Labs, Rahway, NJ 07065 USA. SGS Biopharma, B-12060 Antwerp, Belgium. Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA. Univ So Calif, Keck Sch Med, Dept Med, Los Angeles, CA 90033 USA. Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA. Univ Washington, Seattle, WA 98108 USA. Univ Calif San Diego, Dept Endocrinol & Metab, La Jolla, CA 92093 USA. RP Scherer, PE (reprint author), Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA. EM scherer@aecom.yu.edu OI Kahn, Steven/0000-0001-7307-9002 FU NIDDK NIH HHS [2R01 DK 46374, DK 02654, DK 17047]; NIGMS NIH HHS [T32 GM 07288] NR 29 TC 778 Z9 809 U1 4 U2 24 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD MAR 26 PY 2004 VL 279 IS 13 BP 12152 EP 12162 DI 10.1074/jbc.M311113200 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 804YV UT WOS:000220334900021 PM 14699128 ER PT J AU Chen, J McPherson, SA Zajac, A Hsu, HC Wu, Q Yang, P Zhou, JL Xu, X Mountz, JD AF Chen, J McPherson, SA Zajac, A Hsu, HC Wu, Q Yang, P Zhou, JL Xu, X Mountz, JD TI Quantification of E1Bp-specific CD8+ T lymphocytes in anti-adenoviral infection SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology 2004 Meeting CY APR 17-21, 2004 CL Washington, DC C1 Univ Alabama, CFAR, Birmingham, AL 35294 USA. Birmingham VAMC, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 24 PY 2004 VL 18 IS 5 SU S BP A803 EP A803 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 806ZB UT WOS:000220470700212 ER PT J AU Goncalves, RS Fernandez-Vina, M Lewinsohn, DM Sztein, MB AF Goncalves, RS Fernandez-Vina, M Lewinsohn, DM Sztein, MB TI Identification of a human HLA-E-restricted CD8(+) T cell subset in volunteers immunized with Salmonella enterica serovar Typhi strain Ty21a typhoid vaccine SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology 2004 Meeting CY APR 17-21, 2004 CL Washington, DC C1 Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA. Georgetown Univ, Naval Med Res Ctr, Bill Young DoD Marrow Donor Program, Kensington, MD, Australia. Oregon Hlth Sci Univ, Portland VA Med Ctr, Div Pulm & Crit Care Med, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 24 PY 2004 VL 18 IS 5 SU S BP A800 EP A800 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 806ZB UT WOS:000220470700195 ER PT J AU Hsu, HC Yang, P Wu, Q Zhou, JL Zhang, HG Mountz, JD AF Hsu, HC Yang, P Wu, Q Zhou, JL Zhang, HG Mountz, JD TI BXD2, a novel generalized autoimmune mouse model that develops both lupus and erosive arthritis SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology 2004 Meeting CY APR 17-21, 2004 CL Washington, DC C1 Univ Alabama, Birmingham, AL 35294 USA. Birmingham VAMC, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 24 PY 2004 VL 18 IS 5 SU S BP A836 EP A836 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 806ZB UT WOS:000220470700374 ER PT J AU Liu, ZY David, CS Liu, CR Xu, X Wang, JH Yang, P Yu, SH Hsu, H Mountz, JD Zhang, HG AF Liu, ZY David, CS Liu, CR Xu, X Wang, JH Yang, P Yu, SH Hsu, H Mountz, JD Zhang, HG TI Deletion of epitope specific T cells using CII peptide-DC-AdTRAIL results in the prevention of CII induced arthritis in DQ8 transgenic mice SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology 2004 Meeting CY APR 17-21, 2004 CL Washington, DC C1 Univ Alabama, Dept Med, Birmingham VAMC, Birmingham, AL 35294 USA. Mayo Clin & Mayo Fdn, Dept Med, Rochester, MN 55905 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 24 PY 2004 VL 18 IS 5 SU S BP A1173 EP A1174 PG 2 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 806ZB UT WOS:000220470701982 ER PT J AU Mountz, JD Zhou, T Yang, P Wu, Q Zhou, JL Zhang, Y Zhang, HG Hsu, HC AF Mountz, JD Zhou, T Yang, P Wu, Q Zhou, JL Zhang, Y Zhang, HG Hsu, HC TI The generalized autoimmune disease developed by the BXD2 mouse strain is associated with upregulation of BAFF receptor and increased B-cell response to both CD40 and IgM SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology 2004 Meeting CY APR 17-21, 2004 CL Washington, DC C1 Univ Alabama, Birmingham, AL 35294 USA. Birmingham VAMC, Birmingham, AL 35294 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 24 PY 2004 VL 18 IS 5 SU S BP A838 EP A838 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 806ZB UT WOS:000220470700381 ER PT J AU Rattan, R Giri, S Singh, A Singh, I AF Rattan, R Giri, S Singh, A Singh, I TI Rho A negatively regulates cytokine-mediated inducible-Nitric Oxide Synthase expression in brain derived transformed cell lines: Negative regulation of IKK alpha SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology 2004 Meeting CY APR 17-21, 2004 CL Washington, DC C1 Med Univ S Carolina, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 24 PY 2004 VL 18 IS 5 SU S BP A992 EP A992 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 806ZB UT WOS:000220470701110 ER PT J AU Young, MRI AF Young, MRI TI Tumor blood vessel development by vasculogenesis, not only angiogenesis SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology 2004 Meeting CY APR 17-21, 2004 CL Washington, DC C1 Ralph H Johnson VA Med Ctr, Res Serv 151, Charleston, SC 29401 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 24 PY 2004 VL 18 IS 5 SU S BP A1181 EP A1181 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 806ZB UT WOS:000220470702019 ER PT J AU Zhang, HG Hsu, HC Yang, P Wu, Q Yu, SH High, KA Mountz, JD AF Zhang, HG Hsu, HC Yang, P Wu, Q Yu, SH High, KA Mountz, JD TI Significant linkage of the anti-AAV immune response to loci on mouse chromosomes (Chr) 12 and 17 SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology 2004 Meeting CY APR 17-21, 2004 CL Washington, DC C1 Univ Alabama, Birmingham, AL 35294 USA. Birmingham VAMC, Birmingham, AL 35294 USA. Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 24 PY 2004 VL 18 IS 5 SU S BP A1142 EP A1142 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 806ZB UT WOS:000220470701829 ER PT J AU Rowe, S MacLean, CH Shekelle, PG AF Rowe, S MacLean, CH Shekelle, PG TI Preventing visual loss from chronic eye disease in primary care - Scientific review SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Review ID BEAVER DAM EYE; TREATMENT DIABETIC-RETINOPATHY; AGE-RELATED MACULOPATHY; RETINAL VEIN OCCLUSION; ATHEROSCLEROTIC CARDIOVASCULAR-DISEASE; ISCHEMIC OPTIC NEUROPATHY; CAUSE-SPECIFIC PREVALENCE; OPEN-ANGLE GLAUCOMA; RISK-FACTORS; MACULAR DEGENERATION AB Context Vision loss is common in the United States and its prevalence increases with age. Visual disability significantly impacts quality of life and increases the risk of injury. Although at least 40% of blindness in the United States is either preventable or treatable with timely diagnosis and intervention, many people with vision loss are undiagnosed and untreated. Objective To review the evidence regarding screening and management of eye disorders and visual disability among adults in the primary care setting. Data Sources and Study Selection MEDLINE, HealthSTAR, EMBASE, The Cochrane Database of Systematic Reviews, and the National Guidelines Clearinghouse were searched for articles and practice guidelines about screening and management of eye diseases and vision loss among adults in the primary care setting using key words and free-text terms, such as vision screening, glaucoma prevention and control, from 1985 to 2003. References in these articles and those suggested by experts in eye care, vision loss, and vision screening were reviewed as well. Data Extraction Articles were Searched for the most clinically important information and emphasized randomized controlled trials where available. Data Synthesis Most major guidelines recommend periodic referral of older adults to an eye care professional for comprehensive evaluation to detect eye diseases and visual disability. The value of routine screening for vision loss in the primary care setting has not been established. Timely identification and treatment of eye diseases can substantially reduce the incidence and prevalence of visual disability among-older adults. Optimizing management of systemic diseases, such as diabetes, hypertension, and hyperlipidemia, significantly reduces the risk of related eye disorders. Conclusions Primary care clinicians can play a vital role in preserving vision in their patients by managing systemic diseases that impact eye health and by ensuring that patients undergo periodic evaluations by eye care professionals and receive needed eye care. C1 Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02119 USA. RAND Hlth, Santa Monica, CA USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. Greater Los Angeles Vet Affairs Hlth Care Syst, Dept Med, Los Angeles, CA USA. RP Rowe, S (reprint author), Boston Univ, Sch Med, Dept Ophthalmol, Room L-907,720 Harrison Ave, Boston, MA 02119 USA. EM srowe@bu.edu NR 121 TC 47 Z9 49 U1 2 U2 5 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAR 24 PY 2004 VL 291 IS 12 BP 1487 EP 1496 DI 10.1001/jama.291.12.1487 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 805UI UT WOS:000220390800030 PM 15039416 ER PT J AU Goldzweig, CL Rowe, S Wenger, NS MacLean, CH Shekelle, PG AF Goldzweig, CL Rowe, S Wenger, NS MacLean, CH Shekelle, PG TI Preventing and managing visual disability in primary care - Clinical applications SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Review ID QUALITY-OF-LIFE; AGE-RELATED MACULOPATHY; SELF-RATED VISION; BEAVER DAM EYE; MACULAR DEGENERATION; DIABETIC-RETINOPATHY; FUNCTIONAL STATUS; RISK-FACTORS; CATARACT-EXTRACTION; SMOKING-CESSATION AB Clinicians in primary care settings are well positioned to participate in the prevention and management of visual disability. They can have a significant impact on their patients' visual health by screening for vision problems, aggressively controlling known risk factors for visual loss, ensuring adherence to ophthalmologic treatment and continuity of eye care, and by timely referral of specific patient populations to qualified eye care professionals (eg, ophthalmologists and optometrists). Using their knowledge about common ophthalmic medications, clinicians can detect adverse effects of these agents, including exacerbations of heart or lung disease. They can ensure that appropriate patients are screened for common serious eye diseases, such as glaucoma, and that patients with disabilities related to vision problems are assessed for treatable conditions, such as cataracts or refractive error. Finally, clinicians can direct patients with low vision from any cause to resources designed to help enhance patient function and emotional support. C1 Greater Los Angeles Vet Affairs Hlth Care Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA 90024 USA. Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA. RAND Hlth, Santa Monica, CA USA. RP Goldzweig, CL (reprint author), Vet Affairs W Los Angeles Healthcare Ctr, 111-G, Los Angeles, CA 90073 USA. EM goldzweig@med.va.gov NR 47 TC 17 Z9 18 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAR 24 PY 2004 VL 291 IS 12 BP 1497 EP 1502 DI 10.1001/jama.291.12.1497 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 805UI UT WOS:000220390800031 PM 15039417 ER PT J AU Birdsall, HH Green, DM Porter, W Lee, C Rubio, JA Trial, J Rossen, RD AF Birdsall, HH Green, DM Porter, W Lee, C Rubio, JA Trial, J Rossen, RD TI Impact of fibronectin fragments on the transendothelial migration of HIV-infected leukocytes and the development of subendothelial foci of infectious leukocytes SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology 2004 Meeting CY APR 17-21, 2004 CL Washington, DC C1 Houston VAMC, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 23 PY 2004 VL 18 IS 4 SU S BP A457 EP A457 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 806ZA UT WOS:000220470602203 ER PT J AU Kucik, DF Ni, N Kevil, CG Bullard, DC AF Kucik, DF Ni, N Kevil, CG Bullard, DC TI Avidity modulation by integrin rearrangement on leukocytes under shear stress SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology 2004 Meeting CY APR 17-21, 2004 CL Washington, DC C1 Birmingham VA Med Ctr, Res Serv, Birmingham, AL 35294 USA. Univ Alabama, Birmingham, AL 35294 USA. Louisiana State Univ, Hlth Sci Ctr, Shreveport, LA 71105 USA. RI Kevil, Christopher/G-9318-2011 NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 23 PY 2004 VL 18 IS 4 SU S BP A388 EP A388 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 806ZA UT WOS:000220470601866 ER EF